

00005170-24-12247310-Q STANDARD BIOTOOLS INC. 20241106241061717161717171717 0 0000950170-24-122473 10-Q 106 20240930 20241106 2024106 STANDARD BIOTOOLS INC. 0001162194 3826 770513190 DE 1231 10 3-Q 4001-34180 241432229 2 TOWER PLACE SUITE 2000 SOUTH SAN FRANCISCO CA 94080 650266600 2 TOWER PLACE SUITE 2000 SOUTH SAN FRANCISCO CA 94080 FLUIDIGM CORP 20011113 10 1-Q 1-lab-20240930.htm 10-Q 10-Q --12-31falseQ30001162194PY6110.3448276http://fasb.org/us-gaap/2024?PrimeRateMemberP3YP3Y0001162194us-gaap:FacilityClosingMember2024-01-012024-09-300001162194lab:InstrumentSupportServicesMember2024-07-012024-09-300001162194lab:ProteomicsMember2023-12-3100011621942024-01-062024-09-300001162194us-gaap:CommonStockMember2023-01-012023-03-310001162194us-gaap:LeaseholdImprovementsMember2024-09-300001162194lab:IlluminaAgreementMemberlab:IlluminaCambridgeLtdMember2021-12-310001162194us-gaap:ComputerEquipmentMember2023-12-310001162194us-gaap:CommonStockMember2024-03-310001162194us-gaap:EmployeeStockOptionMemberlab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember2024-09-300001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001162194us-gaap:RetainedEarningsMember2024-03-310001162194lab:CapitalizedSoftwareDevelopmentCostsMember2024-01-012024-09-300001162194lab:NewEnglandBiolabsIncMember2024-09-300001162194lab:NecCorporationMember2024-04-012024-04-3000011621942024-02-012024-02-290001162194lab:CollaborationAndOtherRevenueMember2024-01-012024-09-300001162194us-gaap:ServiceMember2024-01-012024-09-300001162194us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-3000011621942026-01-012024-09-300001162194us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001162194us-gaap:CommonStockMember2023-07-012023-09-300001162194srt:MinimumMemberus-gaap:ProductMember2024-01-012024-09-300001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001162194lab:TwoThousandAndSeventeenInducementAwardPlanMember2024-09-300001162194us-gaap:ConvertibleDebtMemberlab:SeniorConvertibleNotesDue2034Member2023-01-012023-09-300001162194us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001162194us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-09-3000011621942023-01-012023-09-300001162194us-gaap:OperatingSegmentsMemberlab:ProteomicsMember2023-07-012023-09-3000011621942024-05-310001162194srt:MaximumMember2024-09-300001162194lab:StandardBiotooolsMember2024-01-052024-01-050001162194us-gaap:ConvertiblePreferredStockMember2024-09-300001162194lab:ProductAndServiceMember2024-01-012024-09-300001162194lab:InstrumentsMember2023-07-012023-09-300001162194lab:GenomicsMember2024-01-012024-09-300001162194us-gaap:EmployeeSeveranceMember2023-12-310001162194us-gaap:CommonStockMembersrt:DirectorMemberlab:CmlsHoldingsILlcMember2024-01-050001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001162194lab:ProteomicsMember2023-01-012023-09-300001162194us-gaap:CommonStockMember2023-04-012023-06-300001162194us-gaap:OtherRestructuringMember2023-12-310001162194us-gaap:CostOfSalesMember2024-07-012024-09-300001162194lab:GenomicsMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-3000011621942025-01-012024-09-300001162194lab:IlluminaCambridgeLtdMember2023-12-310001162194lab:SeniorConvertibleNotesDue2024Memberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMember2019-11-012019-11-300001162194us-gaap:TreasuryStockCommonMember2023-12-310001162194us-gaap:TreasuryStockCommonMember2024-09-300001162194lab:SomaLogicPlansMember2022-09-012022-09-300001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001162194us-gaap:RetainedEarningsMember2024-01-012024-03-310001162194us-gaap:RetainedEarningsMember2023-01-012023-03-310001162194lab:GenomicsMemberus-gaap:OperatingSegmentsMember2024-01-012024-09-300001162194lab:SeniorConvertibleNotesDue2024CurrentMemberus-gaap:ConvertibleDebtMember2024-09-300001162194srt:MinimumMember2024-09-300001162194lab:IlluminaCambridgeLtdMembersrt:MaximumMember2024-03-310001162194us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001162194us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-3000011621942024-09-300001162194lab:TwoThousandAndElevenEquityIncentivePlanMember2024-09-300001162194us-gaap:RelatedPartyMember2024-09-3000011621942024-07-012024-09-300001162194lab:GenomicsMemberus-gaap:OperatingSegmentsMember2024-07-012024-09-300001162194us-gaap:AdditionalPaidInCapitalMember2024-06-300001162194us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001162194lab:LaboratoryAndManufacturingEquipmentMember2024-09-300001162194lab:IlluminaCambridgeLtdMember2024-03-310001162194us-gaap:EMEAMember2023-07-012023-09-300001162194us-gaap:SecuredDebtMember2024-09-300001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001162194lab:GenomicsMember2023-07-012023-09-300001162194lab:IlluminaCambridgeLtdMember2024-01-012024-09-300001162194us-gaap:ServiceMember2024-07-012024-09-300001162194us-gaap:FacilityClosingMember2024-09-300001162194lab:SomaLogicIncMembersrt:DirectorMember2024-01-052024-01-050001162194lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember2024-09-300001162194us-gaap:CommonStockMemberlab:StandardBiotooolsMember2024-01-052024-01-050001162194lab:CostOfCollaborationAndOtherRevenueMember2023-01-012023-09-300001162194srt:MinimumMember2024-01-012024-09-300001162194us-gaap:ConvertiblePreferredStockMember2024-03-182024-03-180001162194us-gaap:TradeNamesMember2024-09-300001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001162194us-gaap:RetainedEarningsMember2023-06-300001162194us-gaap:TreasuryStockCommonMember2023-09-300001162194us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001162194lab:GenomicsMember2023-12-310001162194us-gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandSeventeenEmployeeStockPurchasePlanMember2024-09-3000011621942023-09-3000011621942024-03-180001162194lab:ConsumablesMember2023-07-012023-09-300001162194lab:RoyaltiesMemberlab:IlluminaCambridgeLtdMember2024-03-310001162194us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001162194us-gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember2024-09-300001162194lab:CostOfCollaborationAndOtherRevenueMember2024-01-012024-09-3000011621942024-01-012024-03-310001162194lab:NecCorporationMember2023-12-310001162194us-gaap:ProductMember2024-01-012024-09-300001162194lab:TwoThousandSeventeenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockOptionMember2024-09-300001162194lab:SeniorConvertibleNotesDue2024CurrentMemberus-gaap:ConvertibleDebtMember2023-12-310001162194us-gaap:ServiceMember2023-07-012023-09-300001162194us-gaap:ComputerEquipmentMember2024-09-300001162194us-gaap:RestrictedStockUnitsRSUMember2024-09-300001162194lab:ProteomicsMember2024-07-012

[illegible]

compared to the net realizable value of the related product and the carrying value of the related assets are written down to the net realizable value to the extent the unamortized capitalized costs exceed such value. The net realizable value is the estimated future gross revenues from the related product reduced by the estimated future costs of completing and disposing of such product, including the costs of providing related maintenance and customer support. Revenue Recognition Revenues are recognized when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the products or services (the "transaction price"). Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue. The Company's contracts with customers typically include multiple distinct products and services, and the Company allocates transaction price to these performance obligations based on their relative standalone selling prices ("SSP"). The SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. SSPs are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product's SSP using a cost plus a margin approach. Payment terms may vary by customer, are based on customary commercial terms, and are generally less than one year. The Company does not adjust revenue for the effects of a significant financing component for contracts where the period between the transfer of the good or service and collection is one year or less. The Company expenses incremental costs to obtain a contract when incurred since the amortization period of the asset that would otherwise be recognized is one year or less. Product Revenue The Company generates product revenue from the sale of instruments and consumables, including Integrated Fluidic Circuits and reagents. The Company generally recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer's facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days. Revenue from the sales of certain instruments that involve significant customization, which primarily includes sales of the SomaScan® equipment bundle, is recognized over time as the Company's performance creates an asset that the customer simultaneously controls (the instrument installation and customization occurs at the customer site). Revenue is recognized based on the progress made toward achieving the performance obligation utilizing an input method of costs incurred relative to total estimated costs. The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations. Services Revenue The Company generates services revenue from the sale of lab services and field services. Lab services revenue is generated by performing the SomaScan® assay on customer samples to generate data on protein biomarkers. Lab services revenue is recognized at a point in time when the analysis data or report is delivered to the customer. SomaScan® services are sold at a fixed price per sample without any volume discounts, rebates, or refunds. The delivery of each assay data report is a separate performance obligation. A 9 A Field services revenue includes revenue from instrument service and support contracts. Revenue associated with these arrangements is recognized over time using a time-elapsed measure of progress, resulting in straight-line revenue recognition over the term of the agreement, which is generally one to four years. The Company measures progress using a time-elapsed measure of progress as the Company stands ready to provide service on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments collected in advance of service are reported on the Company's condensed consolidated balance sheets as deferred revenue. Collaboration and Other Revenue From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808, Collaborative Arrangements. With such collaborations, the Company determines if any obligations are an output of the Company's ordinary activities in exchange for consideration, and if so, the Company applies ASC 606, Revenue from Contracts with Customers ("ASC 606"), to such activities. For other payments received from collaborative partners for other collaboration activities, which primarily include research and development activities, the Company analogizes to ASC 606. Revenue from such activities is recognized as the Company satisfies its obligations. Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied. The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC 606, as the grant agreement is not with a customer. As there is no authoritative GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC 958, Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory. Warrant Liabilities In connection with the merger described in Note 2, Business Combination, the Company assumed warrant liabilities for the warrants issued in connection with the initial public offering CM Life Sciences II Inc ("CMLS II"), the predecessor company of SomaLogic, Inc. ("SomaLogic"). CMLS II issued 5,519,991 warrants (the "Public Warrants") to purchase shares of SomaLogic common stock, par value \$0.0001 per share ("SomaLogic Common Stock"), at \$11.50 per share. Simultaneously, with the consummation of the CMLS II initial public offering, CMLS II issued 5,013,333 warrants through a private placement (the "Private Placement Warrants", and together with the Public Warrants, the "Warrants") to purchase shares of SomaLogic Common Stock at \$11.50 per share. As of January 5, 2024 (the "Closing Date"), the Warrants converted into the right to receive, upon exercise of such Warrant, 1.11 shares of the Company's common stock for each share of SomaLogic Common Stock previously underlying the Warrants. The Public Warrants are no longer publicly traded and are now identical to the Private Placement Warrants. The Warrants are classified as liabilities on the condensed consolidated balance sheet as of September 30, 2024 as these instruments are precluded from being indexed to the Company's own stock given that the terms allow for a settlement adjustment that does not meet the scope for the fixed-for-fixed exception in ASC 815, Derivatives and Hedging. Since the Warrants meet the definition of a derivative under ASC 815-40, the Company recorded these warrants as long-term liabilities at fair value as of the Closing Date, with subsequent changes in fair value recognized within other income (expense), net in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Segment Reporting The Company manages its business through two reportable operating segments: proteomics and genomics. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses performance. The Company's chief operating decision maker ("CODM"), its chief executive officer, assesses performance of operating segments and determines the allocation of resources based primarily on segment operating loss. 10 A Recent Accounting Changes and Accounting Pronouncements Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures, which requires disclosure of more detailed information about a reportable segment's expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company expects to adopt ASU 2023-07 in its Annual Report on Form 10-K for the year ended December 31, 2024, and expects to include additional segment disclosures as a result of adoption. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the impact of adoption on its income tax disclosures; however, adoption will not impact the Company's results of operations. In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses. The new standard requires additional disclosure of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted, and may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement disclosures. 2. Business Combination On the Closing Date, the Company completed the merger (the "Merger") with SomaLogic. As a result, SomaLogic and its subsidiaries became wholly owned subsidiaries of Standard BioTools. Upon completion of the Merger, each share of SomaLogic common stock, par value \$0.0001 per share (the "SomaLogic Common Stock"), was exchanged for 1.11 shares of the Company's common stock, par value \$0.001 per share. The fair value of the Company's common stock provided in exchange for SomaLogic Common Stock was approximately \$419.2 million. A Purchase consideration also included replacement of equity awards attributable to pre-combination services. The acquisition-date fair value of consideration transferred in the Merger totaled approximately \$444.2 million, comprising the following: A A A SomaLogic Common Stock issued and outstanding as of January 5, 2024 A A 188,808 A Fixed exchange ratio A A 1.11 A Shares of Standard BioTools common stock issued to SomaLogic stockholders A A 209,577 A Standard BioTools common stock price at close of Merger A A \$ 2.00 A Fair value of Standard BioTools common stock issued to SomaLogic stockholders A A \$ 419,154 A Fair value of Standard BioTools replacement equity awards attributable to pre-combination service A A 26,923 A Less: Fair value of restricted shares subject to service conditions A A (1,858) Total consideration transferred A A \$ 444,219 A 11 A The Company accounted for the Merger as a business combination, using the acquisition method of accounting in accordance with ASC 805. The identifiable assets acquired and liabilities assumed of SomaLogic were recorded at their estimated fair values as of the acquisition date and consolidated with those of the Company. The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date: A A A Total consideration A A \$ 444,219 A A A Assets acquired A A Cash and cash equivalents A A 278,857 A Short-term investments A A 148,305 A Accounts receivable A A 16,430 A Inventory A A 14,642 A Prepaid expenses and other current assets A A 4,835 A Property and equipment A A 22,455 A Non-current inventory A A 12,208 A Royalty receivable A A 4,669 A Operating lease right-of-use assets A A 3,796 A Other non-current assets A A 1,590 A Intangible Assets A A 25,500 A Total assets acquired A A 533,287 A Liabilities assumed A A Accounts payable and accrued liabilities A A 20,660 A Operating lease liabilities, current A A 1,601 A Deferred revenue, current A A 3,522 A Operating lease liabilities, non-current A A 2,193 A Deferred revenue, non-current A A 30,667 A Warrant liabilities A A 906 A Other non-current liabilities A A 4,306 A Total Liabilities A A 63,855 A Total fair value of net assets acquired A A \$ 469,432 A Gain on bargain purchase A A \$ (25,213) A The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration transferred, resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, management reassessed the methods used in the acquisition accounting and verified that management had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. Management also reassessed the procedures used to measure amounts recognized at the Closing Date to ensure that the measurements reflected all consideration transferred based on available information as of the Closing Date. Management determined that the bargain purchase gain was primarily attributable to a rapid decline in the price of the Company's common stock in the days following the announcement of the Merger, which persisted through the close of the Merger. The bargain purchase gain is separately stated below income from operations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024. A The preliminary fair value estimates of the net assets acquired are based upon preliminary calculations and valuations and are subject to change as the Company obtains additional information during the measurement period (up to one year from the Closing Date). A The identifiable intangible assets acquired consisted of developed technology, customer relationships, and tradename. The fair values of the developed technology and customer relationships were estimated using variations of the multi-period excess earnings method, which isolates the net earnings attributable to the asset being measured. The fair value of the SomaLogic trade name was estimated using the relief-from-royalty method, which determines the present value of license fees avoided by owning the trade name. The useful lives of acquired intangibles was estimated based on the contractual terms or period over which approximately 85% to 90% of the cumulative discounted cash flows would be realized, depending on the nature of the asset. The valuation of the intangible assets acquired in connection with the Merger, along with their estimated useful lives, is as follows (in thousands): A 12 A A Fair Value A A Useful Life Developed technology A A \$ 20,000 A A 9 A years Trade name A A 2,750 A A 7 A years Customer relationships A A 2,750 A A 11 A years Total fair value of intangible assets acquired A A \$ 25,500 A A A As a result of the Merger, the Company incurred \$1.9 million of transaction bonuses recorded in selling, general, and administrative expenses on the condensed consolidated statement of operations. Additionally, the Company incurred \$12.3 million of acquisition-related transaction costs reflected in transaction and integration expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2024. A Unaudited Pro Forma Results The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and SomaLogic, as if the companies were combined as of January 1, 2023. A The unaudited pro forma financial information for the nine months ended September 30, 2024 combines the Company's financial results for the nine months ended September 30, 2024 and the historical results of SomaLogic for the 5-day period ended on the Closing Date. The unaudited pro forma financial information for the three and nine months ended September 30, 2023 combines the historical results of the Company and SomaLogic for their respective three and nine-month periods ended September 30, 2023. The pro forma financial information for the three and nine months ended September 30, 2023 has been adjusted to include certain nonrecurring impacts associated with the Merger, including the bargain purchase gain and transaction costs. These same impacts have been eliminated from the pro forma financial information for the nine months ended September 30, 2024. A The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from the Merger, mainly including adjustments to reflect additional amortization expense from acquired intangible assets, adjustments to stock-based compensation expense, and additional depreciation expense from the acquired property and equipment. The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023. A A Three Months Ended September 30, A A Nine Months Ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A Revenue A A \$ 44,969 A A \$ 47,415 A A \$ 128,359 A A \$ 141,047 A Net loss A A \$ (26,938) A A \$ (41,204) A A \$ (134,607) A A \$ (109,000) A 13 A The results of SomaLogic have been consolidated with the Company's results since the Closing Date. For the period of January 6, 2024 to September 30, 2024, SomaLogic contributed revenue and loss of \$61.5 million and \$30.6 million, respectively. For the three months ended September 30, 2024, SomaLogic contributed revenue and loss of \$22.9 million and \$1.6 million, respectively. 3. Revenue and Geographic Area Disaggregation of Revenue by Product Type and Geographic Area The following tables present the Company's revenue for the three and nine months ended September 30, 2024 and 2023, respectively, based on product type and the geographic location of customers' facilities (in thousands): A A Three Months Ended September 30, A A Nine Months Ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A Product revenue: A A A A A A A Instruments A A \$ 5,586 A A \$ 9,002 A A \$ 19,959 A A \$ 26,512 A Consumables A A 14,007 A A 9,709 A A 45,389 A A 31,302 A Total product revenue A A 19,593 A A 18,711 A A 65,348 A A 57,814 A Service revenue: A A A A A A A Lab services A A 18,247 A A 114 A A 40,780 A A 564 A Field services A A 6,191 A A 6,452 A A 18,738 A A 18,704 A Total service revenue A A 24,438 A A 6,566 A A 59,518 A A 19,268 A Product and service revenue A A 44,031 A A 25,277 A A 124,866 A A 77,082 A Collaboration and other revenue A A 938 A A 90 A A 2,848 A A 1,070 A Total revenue A A \$ 44,969 A A \$ 25,367 A A \$ 127,714 A A \$ 78,152 A A Three Months Ended September 30, A A Nine Months Ended September 30, A A 2024 A A 2023 A A 2024 A A 2023 A Americas A A \$ 23,751 A A \$ 10,865 A A \$ 68,241 A A \$ 32,975 A Europe, Middle East and Africa (EMEA) A A 16,057 A A 8,162 A A 39,108 A A 27,435 A Asia-Pacific A A 5,161 A A 6,340 A A 20,365 A A 17,742 A Total revenue A A \$ 44,969 A A \$ 25,367 A A \$ 127,714 A A \$ 78,152 A Illumina Cambridge, Ltd. In connection with the Merger, the Company assumed a multi-year arrangement with Illumina Cambridge, Ltd. ("Illumina"), originally entered into by SomaLogic and Illumina in December 2021 (the "Illumina Agreement"), to jointly develop and commercialize co-branded kits that will combine Illumina's Next Generation Sequencing ("NGS") technology with SomaScan® technology (the "Co-Branded Kits"). Pursuant to the Illumina Agreement, SomaLogic received a non-refundable upfront payment of \$30.0 million in January 2022. Subsequent to executing the Illumina Agreement, Illumina paid an additional \$0.5 million to purchase the equipment, supplies and training necessary to run the SomaScan® assay at their facilities, representing a modification to the Illumina Agreement. As of the Closing Date, the Company determined that the transaction price of the Illumina Agreement was \$30.5 million. Subsequent to commercialization of the Co-Branded Kits, the Company is entitled to receive \$124.5 million of minimum guaranteed royalties through the term of the Illumina Agreement. No royalties were included in the Illumina transaction price as probability of commercialization had not been achieved as of the Closing Date. Subsequent to commercialization of the Co-Branded Kits, Illumina has the right to purchase SOMAmer reagents below SSP through the remaining term of the Illumina Agreement, which will continue for approximately 8 years following commercialization. Illumina's option to purchase SOMAmer reagents below SSP for this period represents a significant material right (the "Material Right"). As of the Closing Date, the Company allocated \$30.4

million of the Illumina transaction price to the Material Right, which will be recognized as revenue as Illumina purchases SOMAmer reagents post commercialization. During the first quarter of 2024, the Company determined that commercialization of the Co-Branded Kits is probable due to the launch of an early-access program, and adjusted the transaction price to include \$127.9 million of royalties expected to be received from 2025 through 2032. The Company allocated \$0.4 million of the adjusted transaction price to satisfy performance obligations, and recognized that amount as revenue on a cumulative catch-up basis. The total transaction price of the Illumina Agreement as adjusted is \$158.4 million. Substantially all of the transaction price is allocated to the Material Right, which the Company expects to recognize as revenue over an 8-year period from 2025 through 2032. 14. A NEC CorporationAdditionally, in connection with the Merger, the Company assumed a joint development and commercialization agreement (the "JDCA") with NEC Solution Innovators, Ltd. ("NEC"), originally entered into by SomaLogic and NEC in March 2020, to develop and commercialize SomaScan® services in Japan. The JDCA is within the scope of ASC 808 as both companies are active participants and are exposed to significant rewards and risks dependent on commercial failure or success, and is accounted for by analogy to ASC 606. In connection with the Merger, the Company assumed certain contract liabilities and recorded \$1.8 million of deferred revenue as of the Closing Date. Under the JDCA, the Company was entitled to receive \$2.0 million in exchange for research and development services, which was received in April 2024. As of September 30, 2024, deferred revenue related to the JDCA was \$1.5 million, which is expected to be fully recognized by March 31, 2025. New England Biolabs, Inc.Also in connection with the Merger, the Company assumed a non-exclusive licensing agreement with New England Biolabs, Inc. ("NEB"), originally entered into by SomaLogic and NEB in September 2022 (the "License Agreement"), whereby the Company provides a license to use certain proprietary information and know-how relating to SomaLogic's aptamer technology. Under the License Agreement, the Company is guaranteed fixed minimum royalties of \$8.7 million to be received through September 2025. No revenue related to the guaranteed fixed minimum royalties will be recognized, as all revenue related to the receivable was recognized by SomaLogic prior to the Merger. Any revenue above the guaranteed fixed minimum royalties will be recognized in the period in which the subsequent sale or usage has occurred. As of September 30, 2024, royalties receivable related to this agreement were \$8.2 million, including a current and non-current portion of \$4.8 million and \$3.4 million, respectively. Unfulfilled Performance ObligationsA summary of the change in deferred revenue is as follows (in thousands):

	2024	2023
NEC	\$ 1,773	\$ 1,773
Other	\$ 1,773	\$ 1,773
Total	\$ 3,546	\$ 3,546

Deferred revenue assumed in connection with merger: \$ 1,773. Revenue deferred during the period, net of revenue recognized: \$ 1,000. Acquired intangible assets, net consisted of the following (in thousands):

	2024	2023
Acquired intangible assets	\$ 1,526	\$ 1,526
Deferred revenue	\$ 1,526	\$ 1,526
Total	\$ 3,052	\$ 3,052

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of September 30, 2024 in the following periods (in thousands):

Fiscal Year	Expected Revenue
2024	\$ 4,321
2025	\$ 9,002
2026	\$ 3,678
Thereafter	\$ 1,790

Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins. The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above. 4. Goodwill and Acquired Intangible Assets, netA The changes in the carrying value of goodwill by segment are as follows (in thousands):

	2024	2023
Goodwill	\$ 11,280	\$ 11,280
Acquired intangible assets	\$ 1,400	\$ 1,400
Total	\$ 12,680	\$ 12,680

Balance as of December 31, 2023: \$ 85,798. Foreign currency translation: \$ 27.4. Balance as of September 30, 2024: \$ 85,825. Acquired intangible assets, net consisted of the following (in thousands):

	2024	2023
Acquired intangible assets	\$ 1,526	\$ 1,526
Deferred revenue	\$ 1,526	\$ 1,526
Total	\$ 3,052	\$ 3,052

Gross Carrying Amount: \$ 1,400. Accumulated Amortization: \$ 1,400. Net: \$ 0. Developed technology: \$ 137,414. Customer relationships: \$ 119,081. Trade name: \$ 2,750. Other: \$ 1,773. Total: \$ 2,750. Restricted cash: \$ 51,704. Cash and cash equivalents: \$ 210,647. Total cash and cash equivalents and restricted cash: \$ 212,938. Restricted cash: \$ 1.3 million and \$0.8 million is included in other non-current assets on the condensed consolidated balance sheets as of September 30, 2024, and December 31, 2023, respectively. Accounts ReceivableAccounts receivable consisted of the following (in thousands):

	2024	2023
Accounts receivable	\$ 35,337	\$ 35,337
Royalty receivable	\$ 435	\$ 435
Other receivables	\$ 173	\$ 173
Total	\$ 35,945	\$ 35,945

Less: allowance for expected credit losses: \$ (628). Accounts receivable, net: \$ 35,317. InventoryInventory consisted of the following (in thousands):

	2024	2023
Inventory	\$ 60,593	\$ 60,593
Raw materials	\$ 42,644	\$ 42,644
Inventory, non-current	\$ 17,949	\$ 17,949
Total	\$ 121,186	\$ 121,186

The value of inventory that is not expected to be used within 12 months of the balance sheet date is classified as non-current inventory on the condensed consolidated balance sheets. The Company recorded charges for excess and obsolete inventory of \$0.1 million and \$0.4 million for the three months ended September 30, 2024 and 2023, respectively, and \$2.0 million and \$1.0 million for the nine months ended September 30, 2024 and 2023, respectively. Property and Equipment, netProperty and equipment, net consisted of the following (in thousands):

	2024	2023
Property and equipment	\$ 16,870	\$ 16,870
Leasehold improvements	\$ 17,400	\$ 17,400
Computer equipment	\$ 7,845	\$ 7,845
Internal-use software	\$ 6,232	\$ 6,232
Furniture and fixtures	\$ 3,482	\$ 3,482
Total	\$ 51,829	\$ 51,829

Less accumulated depreciation and amortization: \$ (69,623). Property and equipment, net: \$ (17,801). Construction-in-progress: \$ 6,223. Property and equipment, net: \$ 41,982. Depreciation and amortization expense was \$3.2 million and \$1.2 million for the three months ended September 30, 2024 and 2023, respectively. Depreciation and amortization expense was \$9.4 million and \$2.9 million for the nine months ended September 30, 2024 and 2023, respectively. Accrued LiabilitiesAccrued liabilities, which are included in current liabilities on the condensed consolidated balance sheets consisted of the following (in thousands):

	2024	2023
Accrued compensation and related benefits	\$ 14,390	\$ 14,390
Loss contingency accruals	\$ 4,262	\$ 4,262
Accrued warranties	\$ 1,874	\$ 1,874
Accrued restructuring	\$ 2,541	\$ 2,541
Uninvoiced receipts	\$ 1,354	\$ 1,354
Other	\$ 1,516	\$ 1,516
Total	\$ 27,937	\$ 27,937

Accrued liabilities: \$ 31,686. Refer to Note 16 for additional information on restructuring. Deferred Grant IncomeIn September 2020, the Company executed a contract with the National Institutes of Health ("NIH") under NIHâs Rapid Acceleration of Diagnostics program to support the expansion of the Company's production capacity for its COVID-19 test products. Under the now-completed contract, the Company received \$34.0 million of funding from the NIH and used \$22.2 million on capital expenditures for its Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was \$0.9 million for each of the three months ended September 30, 2024 and 2023, and \$2.7 million for each of the nine months ended September 30, 2024 and 2023. Cumulative amounts applied against depreciation expense for these assets placed in service were \$10.5 million and \$7.8 million as of September 30, 2024 and December 31, 2023, respectively, and the carrying values of these assets were \$11.7 million and \$14.4 million as of these same dates, respectively. The current portion of deferred grant income on the Company's condensed consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods. 6. DebtTotal carrying value of debt consists of the following (in thousands):

	2024	2023
Convertible notes	\$ 55,099	\$ 55,099
Term loan, non-current	\$ 3,414	\$ 3,414
Term loan, current	\$ 5,000	\$ 5,000
Total debt	\$ 55,212	\$ 55,212

Convertible NotesIn February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (the "2014 Notes"), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes beginning on February 6, 2029 at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. In March 2024, the Company repurchased \$0.3 million of the outstanding principal amount of the 2014 Notes. In November 2019, the Company issued \$55.0 million aggregate principal amount of 2019 Senior Convertible Notes (the "2019 Notes") and together with the 2014 Notes, the "Convertible Notes"). Net proceeds from the 2019 Notes issuance of \$52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but \$1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25% per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company's common stock per \$1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately \$2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include conversion of the 2019 Notes in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company's option in whole but not in part into shares of the Company's common stock upon certain conditions if the volume-weighted average price of the Company's common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days. Offering-related costs related to the Convertible Notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes. The carrying values of the Convertible Notes approximate fair values as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. The Convertible Notes are not regularly traded and there is no public market for the Convertible Notes. The estimated fair values for the Convertible Notes represent Level 3 valuations since the fair values for the Convertible Notes cannot be determined by using readily observable inputs or measures, such as market prices. Term Loan Facility, netOn August 2, 2021, the Company amended its revolving credit facility to, amongst other things, provide for a new \$10.0 million term loan facility (the "Term Loan Facility"). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of \$7.9 million and a carrying value of \$8.4 million. The interest rate on the Term Loan Facility was the greater of 4.0% per annum or a floating per annum rate equal to the prime rate plus 0.75%. Interest on any outstanding term loan advances was due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance was due the earlier of the maturity date or the date the advance is repaid. Principal balances were required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility was July 1, 2025. On March 4, 2024, the Company fully repaid all outstanding indebtedness owed pursuant to the Term Loan Facility and terminated the agreement. 7. LeasesIn connection with the Merger, the Company assumed three leases for office and laboratory space, with lease terms of three to five years. One of the assumed leases expired on June 30, 2024 and has not been renewed. The remaining leases require monthly lease payments that may be subject to annual increases throughout the lease term. The remaining leases also include renewal options at the Company's election to renew or extend the leases for additional periods ranging from three to ten years. Lease CostsLease costs for operating leases are recognized on a straight-line basis over the lease term. The total lease cost for the period, including the Company's historical leases and those assumed in connection with the Merger, was as follows (in thousands):

	2024	2023
Operating lease cost	\$ 2,386	\$ 1,994
Short-term lease cost	\$ 7,484	\$ 6,005
Variable lease cost	\$ 1,188	\$ 830
Less: Sublease income	\$ (1,076)	\$ (529)
Total lease cost	\$ 2,498	\$ 2,295

Lease MaturitiesThe table below reconciles the undiscounted lease payment maturities to the lease liabilities for the Company's operating leases:

	2024	2025	2026	2027	2028	Thereafter
Lease liabilities	\$ 46,023	\$ 11,761	\$ 34,262	\$ 34,262	\$ 34,262	\$ 34,262
Long-term operating lease liabilities	\$ 28,140	\$ 28,140	\$ 28,140	\$ 28,140	\$ 28,140	\$ 28,140
Weighted average remaining lease term	5.1	5.1	5.1	5.1	5.1	5.1
Weighted average discount rate	11.9	11.9	11.9	11.9	11.9	11.9

In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of September 30, 2024, the Company's open commitments totaled \$16.2 million. In connection with the Illumina Agreement, SomaLogic, and now the Company, is required to engage with two contract manufacturing organizations in order to ensure manufacturing capacity. In 2023, SomaLogic contracted with Integrated DNA Technologies, Inc. (IDT) to manufacture custom products. Under the contract manufacturing agreement with IDT, SomaLogic committed to minimum annual purchases of \$2.3 million, which obligation the Company subsumed in connection with the Merger. As the minimum contract term is three years, the total purchase commitment related to the Illumina Agreement is \$6.9 million. As of September 30, 2024, the Company had not yet began placing orders under the Illumina Agreement. The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year. IndemnificationIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. Legal ProceedingsFrom time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. These include disputes and lawsuits related to intellectual property, mergers and acquisitions, licensing, contract law, tax, regulatory, distribution arrangements, employee relations and other matters. Periodically, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and a range of possible loss can be estimated, the Company accrues a liability for the estimated loss. Stockholder LitigationOn December 12, 2023 two separate stockholder complaints were filed in the District of Delaware. The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. These complaints were voluntarily dismissed. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed business combination between SomaLogic and the Company, which was denied by the Court on January 4, 2024. An amended complaint was filed on June 20, 2024, containing primarily the same allegations, while removing some of the defendants. The remaining defendants filed a motion to dismiss on July 5, 2024, and served an opening brief on August 19, 2024. The Plaintiffs' opposition brief is due on November 1, 2024, and the defendants' reply brief is due on November 15, 2024.

September 30, 2024. No date for oral argument has been set. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs' claim is successful, this type of litigation may result in significant costs and divert management's attention and resources, which could adversely affect the operation of our business. 20. Between October 24, 2023 and January 3, 2024, SomaLogic received 18 letters from purported stockholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement. The Company has resolved fee disputes with all but two stockholders' counsel. In February 2024, the Company settled previously outstanding litigation with a former stockholder of SomaLogic, whereby the Company relinquished 422,048 shares of the Company's common stock that were subject to vesting conditions. In May 2024, the Company settled previously outstanding litigation with former stockholders of SomaLogic for \$6.2 million consisting of the repurchase of approximately 1.84 million shares of the Company's common stock from the stockholders at the market price of \$2.40 per share, and a cash payment of \$1.8 million. The Company recognized a litigation loss of \$0.6 million during the nine months ended September 30, 2024. On June 4, 2024, the Company received a demand pursuant to Section 220 of the Delaware General Corporation Law from a stockholder to inspect the Company's books and records relating to the prior conversion of the Company's Series B preferred stock. The Company has responded to the demand and has produced documents. Additional lawsuits against us and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, we will not necessarily announce such additional filings. In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, management currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based only on the best information available at the time. As additional information becomes available, the Company continues to reassess the potential liability related to pending claims and litigation and may revise estimates. Other Contingencies Following the Merger, the Company is responsible for SomaLogic's liabilities and obligations, including with respect to legal, financial, regulatory, and compliance matters. These liabilities and obligations will result in additional cost and expense by the Company and, if the Company has underestimated the amount of these costs and expenses or if the Company fails to satisfy any such liabilities or obligations, the Company may not realize the anticipated benefits of the Merger and there may be an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. Further, it is possible that there may be unknown, contingent or other liabilities, obligations or other problems that may arise in the future, the existence and/or magnitude of which the Company was previously unaware. Any such liabilities, obligations or other problems could have an adverse effect on the Company's business, financial condition, results of operations or cash flows. With respect to these additional matters, the Company is not able to estimate the possible loss or range of losses that could be incurred. 9. Fair Value of Financial Instruments Fair Value of Financial Instruments The following tables summarize the Company's financial instruments by significant investment category measured at fair value on recurring basis within the fair value hierarchy as of September 30, 2024 (in thousands):

Fair Value Measurements At Reporting Date Using	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Assets
Cash equivalents	\$185,227	\$185,227	\$0	\$0	\$185,227
U.S. treasury securities	\$155,683	\$155,683	\$0	\$0	\$155,683
Total assets measured at fair value	\$340,910	\$340,910	\$0	\$0	\$340,910

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

Fair Value Measurements At Reporting Date Using	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Assets
Cash equivalents	\$155,683	\$155,683	\$0	\$0	\$155,683
U.S. treasury securities	\$63,191	\$63,191	\$0	\$0	\$63,191
Total assets measured at fair value	\$218,874	\$218,874	\$0	\$0	\$218,874

There were no transfers within the hierarchy and no changes in the valuation techniques used during the nine months ended September 30, 2024. The following table summarizes available-for-sale securities (in thousands):

As of September 30, 2024	Maturity (in years)	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value	Assets
Cash equivalents		\$185,227	\$0	\$0	\$185,227	Short-term investments
U.S. treasury securities		\$155,683	\$0	\$0	\$155,683	U.S. treasury securities
Total assets measured at fair value		\$340,910	\$0	\$0	\$340,910	

As of December 31, 2023:

As of December 31, 2023	Maturity (in years)	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value	Assets
Cash equivalents		\$155,683	\$0	\$0	\$155,683	Short-term investments
U.S. treasury securities		\$63,191	\$0	\$0	\$63,191	U.S. treasury securities
Total assets measured at fair value		\$218,874	\$0	\$0	\$218,874	

As of September 30, 2024, none of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does not intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recorded. Liabilities measured at fair value on a recurring basis

The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs we utilized to determine such fair value:

As of September 30, 2024	Warrant liabilities	As of September 30, 2023	Warrant liabilities
Warrant liabilities	\$906	\$432	\$906

The Warrants were valued using Level 2 inputs as of the Closing Date as the Public Warrants were actively traded at that date. Therefore, the Company had directly observable prices for identical instruments as of the Closing Date. Following the Closing Date, and as of September 30, 2024, the Public Warrants were no longer publicly traded (see Note 1), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:

As of September 30, 2024	Volatility	Risk-free rate	Exercise price
Volatility	70.2%		
Risk-free rate		3.65%	
Exercise price			\$1.9

Mezzanine Equity Series B Redeemable Preferred Stock On March 18, 2024, the Company entered into an exchange agreement (the "Exchange Agreement") with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, "Casdin"), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, "Viking"), and collectively with Casdin, the "Investors"). Pursuant to the Exchange Agreement, the Investors exchanged (the "Exchange") an aggregate of (i) 127,780 shares of Series B-1 Convertible Preferred Stock, par value \$0.001 per share (the "Series B-1 Preferred Stock"), and (ii) 127,779 shares of Series B-2 Convertible Preferred Stock, par value \$0.001 per share (the "Series B-2 Preferred Stock"), and together with the Series B-1 Preferred Stock, the "Series B Preferred Stock"), representing all of the outstanding shares of Series B Preferred Stock, for an aggregate of 92,930,553 shares of the Company's common stock. The Exchange was completed on March 18, 2024. Following the closing of the Exchange, no shares of Series B Preferred Stock remained outstanding, and the Company had no amounts recorded in mezzanine equity. On June 18, 2024, the Company filed a registration statement on Form S-3 (File No. 333-280321), which became effective on June 27, 2024, registering the resale of 105,116,628 shares of common stock, including the shares of common stock which were issued upon conversion of the Series B Preferred Stock in the Exchange. The Exchange was considered to be an induced conversion of preferred stock as the Investors received a lower conversion price, and were issued more shares of common stock than provided under the original terms of the Series B Convertible Preferred Stock Purchase Agreement entered into with the Investors. The \$46.0 million difference between the fair value of the inducement and the carrying value of the Series B Preferred Stock was recognized to the Company's accumulated deficit during the nine months ended September 30, 2024.

11. Stockholders' Equity (Deficit) 2024 Stock Repurchase Program On February 6, 2024, the Company's board of directors authorized a share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company may repurchase up to \$50.0 million of shares of its common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate the Company to acquire any specific number of shares. During the nine months ended September 30, 2024, the Company repurchased 13,603,617 shares of its common stock for an aggregate of \$36.1 million under the 2024 Share Repurchase Program. Common Shares Reserved As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

Securities To Be Issued Upon Exercise Of Options	Number Of Remaining Securities Available For Future Issuance	2022 Inducement Equity Incentive Plan	2021 Equity Incentive Plan	2017 Employee Stock Purchase Plan	2017 Inducement Award Plan
Securities To Be Issued Upon Exercise Of Options	Number Of Remaining Securities Available For Future Issuance	2022 Inducement Equity Incentive Plan	2021 Equity Incentive Plan	2017 Employee Stock Purchase Plan	2017 Inducement Award Plan

Assumed through acquisition

As of September 30, 2024	Balance	As of September 30, 2023	Balance
As of September 30, 2024	\$2,970	\$2,970	\$2,970
As of September 30, 2023	\$2,436	\$2,436	\$2,436

As of September 30, 2024, unrecognized stock-based compensation expense related to outstanding unvested restricted stock units ("RSUs") under the Company's equity incentive plans was \$29.8 million. The Company expects to recognize the expense over a weighted-average period of 3.1 years. Stock Options

As of September 30, 2024	Balance	As of September 30, 2023	Balance
As of September 30, 2024	\$9,294	\$9,294	\$9,294
As of September 30, 2023	\$3,624	\$3,624	\$3,624

Assumed through acquisition

As of September 30, 2024	Balance	As of September 30, 2023	Balance
As of September 30, 2024	\$28,184	\$28,184	\$28,184
As of September 30, 2023	\$4,800	\$4,800	\$4,800

As of September 30, 2024, the Company's common stock on The Nasdaq Global Select Market on September 30, 2024, was \$1.93, and the

rate differences between the United States and foreign countries. The Company maintains a valuation allowance against its U.S. deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. 26

15. Segment ReportingThe Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. During the first quarter of 2024, the CODM began using operating income to measure the operating performance of the segments. The Company determines each segment's operating income by subtracting direct expenses, including cost of revenues, research and development expense, and sales and marketing expense, from revenues. Amortization, depreciation, and restructuring charges are included in each segment's operating expenses. Corporate costs, including general and administrative expenses for functions shared by both operating segments such as executive management, human resources, and finance, along with interest and taxes, and transaction and integration expenses are excluded from each segment's results, which is consistent with how our CODM evaluates segment performance. The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole. The Company's business segment information was as follows (in thousands):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024
Revenue	\$44,969	\$127,714
Proteomics	\$25,367	\$78,152
Genomics	\$19,602	\$49,562
Income (loss) from operations	\$1,210	\$4,848
Genomics	\$1,925	\$3,414
Proteomics	\$(716)	\$(1,566)
Corporate expenses	\$(16,013)	\$(49,217)
Restructuring and related charges	\$(2,341)	\$(1,998)
Transaction and integration expenses	\$(5,079)	\$(1,666)
Total loss from operations	\$(31,718)	\$(21,172)
Depreciation & amortization	\$3,420	\$9,932
Genomics	\$3,784	\$10,125
Proteomics	\$639	\$1,807
Corporate	\$1,540	\$4,590
Total depreciation & amortization	\$3,858	\$12,908
Restructuring and Related Charges	\$1,127	\$1,274

In April 2024, following a strategic review of the combined business after completion of the Merger, the Company announced a workforce reduction plan (the "Strategic Reorganization") to reduce operating costs and focus on long-term growth opportunities. Under this Strategic Reorganization, the Company reduced its workforce by approximately 10% of its total workforce, with the majority of these employees separating by July 2024. Employees who were impacted by the Strategic Reorganization were eligible to receive severance and other benefits contingent upon an impacted employee's execution of a separation agreement. Certain impacted employees were covered by employment agreements or existing severance plans that provided termination benefits. One-time termination benefits were recorded pursuant to ASC 420, Exit or Disposal Cost Obligations, while termination benefits under ongoing benefit arrangement were recorded pursuant to ASC 712, Compensation - Nonretirement Postemployment Benefits. The Company recognized restructuring charges of approximately \$2.3 million and \$12.4 million during the three and nine months ended September 30, 2024, respectively, related to a restructuring plan implemented after the Merger to integrate operations and realize synergies. For the three and nine months ended September 30, 2023, the Company recognized restructuring and related charges of \$2.0 million and \$5.4 million, respectively, related to a restructuring plan implemented in 2022 to improve the Company's operational efficiency. The Company also continues to recognize ongoing restructuring charges from its restructuring plans for facility-related costs, which will continue through the termination of the facility leases. The following table summarizes the change in the Company's restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

	September 30, 2024	September 30, 2023
Severance and other employee-related benefits	\$2,541	\$2,541
Facility Costs	\$4,744	\$4,744
Other	\$1,237	\$1,237
Total	\$8,522	\$8,522

December 31, 2023

	December 31, 2023	September 30, 2024
Severance and other employee-related benefits	\$825	\$2,541
Facility Costs	\$825	\$4,744
Other	\$825	\$1,237
Total	\$2,475	\$8,522

Cash payments

	September 30, 2024	September 30, 2023
Severance and other employee-related benefits	\$2,541	\$2,541
Facility Costs	\$4,744	\$4,744
Other	\$1,237	\$1,237
Total	\$8,522	\$8,522

Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.

Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets. The Company's restructuring and related charges by segment and corporate were as follows (in thousands):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024
Revenue	\$44,969	\$127,714
Proteomics	\$25,367	\$78,152
Genomics	\$19,602	\$49,562
Income (loss) from operations	\$1,210	\$4,848
Genomics	\$1,925	\$3,414
Proteomics	\$(716)	\$(1,566)
Corporate expenses	\$(16,013)	\$(49,217)
Restructuring and related charges	\$(2,341)	\$(1,998)
Transaction and integration expenses	\$(5,079)	\$(1,666)
Total loss from operations	\$(31,718)	\$(21,172)
Depreciation & amortization	\$3,420	\$9,932
Genomics	\$3,784	\$10,125
Proteomics	\$639	\$1,807
Corporate	\$1,540	\$4,590
Total depreciation & amortization	\$3,858	\$12,908
Restructuring and Related Charges	\$1,127	\$1,274

In April 2024, following a strategic review of the combined business after completion of the Merger, the Company announced a workforce reduction plan (the "Strategic Reorganization") to reduce operating costs and focus on long-term growth opportunities. Under this Strategic Reorganization, the Company reduced its workforce by approximately 10% of its total workforce, with the majority of these employees separating by July 2024. Employees who were impacted by the Strategic Reorganization were eligible to receive severance and other benefits contingent upon an impacted employee's execution of a separation agreement. Certain impacted employees were covered by employment agreements or existing severance plans that provided termination benefits. One-time termination benefits were recorded pursuant to ASC 420, Exit or Disposal Cost Obligations, while termination benefits under ongoing benefit arrangement were recorded pursuant to ASC 712, Compensation - Nonretirement Postemployment Benefits. The Company recognized restructuring charges of approximately \$2.3 million and \$12.4 million during the three and nine months ended September 30, 2024, respectively, related to a restructuring plan implemented after the Merger to integrate operations and realize synergies. For the three and nine months ended September 30, 2023, the Company recognized restructuring and related charges of \$2.0 million and \$5.4 million, respectively, related to a restructuring plan implemented in 2022 to improve the Company's operational efficiency. The Company also continues to recognize ongoing restructuring charges from its restructuring plans for facility-related costs, which will continue through the termination of the facility leases. The following table summarizes the change in the Company's restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

	September 30, 2024	September 30, 2023
Severance and other employee-related benefits	\$2,541	\$2,541
Facility Costs	\$4,744	\$4,744
Other	\$1,237	\$1,237
Total	\$8,522	\$8,522

December 31, 2023

	December 31, 2023	September 30, 2024
Severance and other employee-related benefits	\$825	\$2,541
Facility Costs	\$825	\$4,744
Other	\$825	\$1,237
Total	\$2,475	\$8,522

Cash payments

	September 30, 2024	September 30, 2023
Severance and other employee-related benefits	\$2,541	\$2,541
Facility Costs	\$4,744	\$4,744
Other	\$1,237	\$1,237
Total	\$8,522	\$8,522

Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.

Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets. The Company's restructuring and related charges by segment and corporate were as follows (in thousands):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024
Revenue	\$44,969	\$127,714
Proteomics	\$25,367	\$78,152
Genomics	\$19,602	\$49,562
Income (loss) from operations	\$1,210	\$4,848
Genomics	\$1,925	\$3,414
Proteomics	\$(716)	\$(1,566)
Corporate expenses	\$(16,013)	\$(49,217)
Restructuring and related charges	\$(2,341)	\$(1,998)
Transaction and integration expenses	\$(5,079)	\$(1,666)
Total loss from operations	\$(31,718)	\$(21,172)
Depreciation & amortization	\$3,420	\$9,932
Genomics	\$3,784	\$10,125
Proteomics	\$639	\$1,807
Corporate	\$1,540	\$4,590
Total depreciation & amortization	\$3,858	\$12,908</

primarily attributable to a rapid decline in our stock price in the days following the announcement of the Merger, which persisted through the close of the Merger. Results of Operations The following table presents our unaudited condensed consolidated statements of operations and as a percentage of total revenue for the three and nine months ended September 30, 2024 and 2023 (\$ in thousands):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Revenue	Cost of product revenue	Cost of collaboration and other revenue	Gross profit	Gross margin	Operating expenses	Research and development	Transaction and integration expenses	Product and service revenue	Total service revenue	Total revenue	Total gross profit	Total gross margin	Operating income	Income tax expense	Net income
Revenue	\$ 44,969	\$ 44,969	100 %	100 %	\$ 44,969	\$ 8,159	\$ 11,403	\$ 33,407	74 %	\$ 26,197	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 26,197	\$ (2,938)	\$ (2,938)
Cost of product revenue	\$ 8,159	\$ 8,159	18 %	18 %	\$ 8,159	\$ 11,403	\$ 11,403	\$ 22,862	51 %	\$ 21,708	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 26,197	\$ (2,938)	\$ (2,938)
Cost of collaboration and other revenue	\$ 11,403	\$ 11,403	25 %	25 %	\$ 11,403	\$ 11,403	\$ 11,403	\$ 22,862	51 %	\$ 21,708	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 26,197	\$ (2,938)	\$ (2,938)
Gross profit	\$ 33,407	\$ 33,407	74 %	74 %	\$ 33,407	\$ 33,407	\$ 33,407	\$ 33,407	74 %	\$ 26,197	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 26,197	\$ (2,938)	\$ (2,938)
Gross margin	74 %	74 %			74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %	74 %
Operating expenses	\$ 26,197	\$ 26,197	58 %	58 %	\$ 26,197	\$ 26,197	\$ 26,197	\$ 26,197	58 %	\$ 26,197	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 26,197	\$ (2,938)	\$ (2,938)
Research and development	\$ 13,156	\$ 13,156	29 %	29 %	\$ 13,156	\$ 13,156	\$ 13,156	\$ 13,156	29 %	\$ 13,156	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 13,156	\$ (2,938)	\$ (2,938)
Transaction and integration expenses	\$ 5,079	\$ 5,079	11 %	11 %	\$ 5,079	\$ 5,079	\$ 5,079	\$ 5,079	11 %	\$ 5,079	\$ 5,079	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 5,079	\$ (2,938)	\$ (2,938)
Product and service revenue	\$ 32,326	\$ 32,326	72 %	72 %	\$ 32,326	\$ 32,326	\$ 32,326	\$ 32,326	72 %	\$ 32,326	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 32,326	\$ (2,938)	\$ (2,938)
Total service revenue	\$ 57,814	\$ 57,814	128 %	128 %	\$ 57,814	\$ 57,814	\$ 57,814	\$ 57,814	128 %	\$ 57,814	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 57,814	\$ (2,938)	\$ (2,938)
Total revenue	\$ 44,969	\$ 44,969	100 %	100 %	\$ 44,969	\$ 44,969	\$ 44,969	\$ 44,969	100 %	\$ 44,969	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 44,969	\$ (2,938)	\$ (2,938)
Total gross profit	\$ 24,248	\$ 24,248	54 %	54 %	\$ 24,248	\$ 24,248	\$ 24,248	\$ 24,248	54 %	\$ 24,248	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	54 %	\$ 24,248	\$ (2,938)	\$ (2,938)
Total gross margin	54 %	54 %			54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %	54 %
Operating income	\$ (2,938)	\$ (2,938)	(7 %)	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)	\$ (2,938)	(7 %)	\$ (2,938)	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)
Income tax expense	\$ (2,938)	\$ (2,938)	(7 %)	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)	\$ (2,938)	(7 %)	\$ (2,938)	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)
Net income	\$ (2,938)	\$ (2,938)	(7 %)	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)	\$ (2,938)	(7 %)	\$ (2,938)	\$ 13,156	\$ 5,079	\$ 32,326	\$ 57,814	\$ 44,969	\$ 24,248	(7 %)	\$ (2,938)	\$ (2,938)	\$ (2,938)

Our growth in proteomics was driven by the acquisition of SomaLogic, which expanded our proteomics capabilities, products and services. Total genomics revenue decreased 8% for the three months ended September 30, 2024, compared to the three months ended September 30, 2023, and decreased 7% for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. The continued decline in the genomics segment was anticipated, and is a driver of our continued focus on growing the OEM business and managing this segment to sustainable positive contribution margin in the near-term. Cost of Revenue Cost of revenue, gross profit, and gross margin were as follows (\$ in thousands):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Revenue

Item 1. Controls and Procedures.

The Company's management, including its principal executive officer ("CEO") and its principal financial officer ("CFO"), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive officer and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that no controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37. Limitations on the Effectiveness of Controls Our systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

38. PART II. OTHER INFORMATION

Item 1. Legal Proceedings Information with respect to certain legal proceedings is included in Note 8 to the Condensed Consolidated Financial Statements (Unaudited) in Part I, Item 1 of this Quarterly Report on Form 10-Q. Item 1A. Risk Factors We operate in a rapidly changing environment that involves numerous uncertainties and risks. You should carefully consider the risk factors discussed in Part I Item 1A "Risk Factors" in our Annual Report, which could materially affect our business, financial condition or results of operations. The risks in our Annual Report are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employee relations, general economic conditions, global geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. If any of these risks occur, our business, results of operations or financial condition could suffer, the trading price of our securities could decline and you may lose all or part of your investment.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities and Use of Proceeds None. Issuer Purchases of Equity Securities On February 6, 2024, our board of directors authorized a share repurchase program (the "2024 Share Repurchase Program") pursuant to which we may repurchase up to \$50.0 million of shares of our common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate us to acquire any specific number of shares. As of September 30, 2024, we have repurchased 13,603,617 shares of our common stock under the 2024 Share Repurchase Program. The following table provides monthly information with respect to the shares of common stock repurchased by us during the three months ended September 30, 2024:

Period	Total Number of Shares Purchased	Average Price Paid Per Share
(1)	\$14.0 million	\$14.0 million
(2)	\$14.0 million	\$14.0 million
(3)	\$14.0 million	\$14.0 million

Item 3. Defaults Upon Senior Securities None.

Item 4. Mine Safety Disclosures None.

Item 5. Other Information 10b5-1 Trading Arrangements From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended September 30, 2024, none of our officers or directors adopted, modified or terminated any such trading arrangements.

Item 6. Exhibits The documents listed in the Exhibit List, which follows below, are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).

EXHIBIT LIST

Exhibit Number	Description
1	Incorporated by Reference from Exhibit Number 1
2	Date Filed 3.1
3	Eighth Amended and Restated Certificate of Incorporation of Standard BioTools Inc. Incorporated by Reference from Exhibit Number 3
4	Amended and Restated Bylaws of Standard BioTools Inc., as amended, dated April 1, 2022
5	As filed on January 4, 2024
6	As filed on January 4, 2024
7	As filed on January 4, 2024
8	As filed on January 4, 2024
9	As filed on January 4, 2024
10	As filed on January 4, 2024
11	As filed on January 4, 2024
12	As filed on January 4, 2024
13	As filed on January 4, 2024
14	As filed on January 4, 2024
15	As filed on January 4, 2024
16	As filed on January 4, 2024
17	As filed on January 4, 2024
18	As filed on January 4, 2024
19	As filed on January 4, 2024
20	As filed on January 4, 2024
21	As filed on January 4, 2024
22	As filed on January 4, 2024
23	As filed on January 4, 2024
24	As filed on January 4, 2024
25	As filed on January 4, 2024
26	As filed on January 4, 2024
27	As filed on January 4, 2024
28	As filed on January 4, 2024
29	As filed on January 4, 2024
30	As filed on January 4, 2024
31	As filed on January 4, 2024
32	As filed on January 4, 2024
33	As filed on January 4, 2024
34	As filed on January 4, 2024
35	As filed on January 4, 2024
36	As filed on January 4, 2024
37	As filed on January 4, 2024
38	As filed on January 4, 2024
39	As filed on January 4, 2024
40	As filed on January 4, 2024
41	As filed on January 4, 2024
42	As filed on January 4, 2024
43	As filed on January 4, 2024
44	As filed on January 4, 2024
45	As filed on January 4, 2024
46	As filed on January 4, 2024
47	As filed on January 4, 2024
48	As filed on January 4, 2024
49	As filed on January 4, 2024
50	As filed on January 4, 2024
51	As filed on January 4, 2024
52	As filed on January 4, 2024
53	As filed on January 4, 2024
54	As filed on January 4, 2024
55	As filed on January 4, 2024
56	As filed on January 4, 2024
57	As filed on January 4, 2024
58	As filed on January 4, 2024
59	As filed on January 4, 2024
60	As filed on January 4, 2024
61	As filed on January 4, 2024
62	As filed on January 4, 2024
63	As filed on January 4, 2024
64	As filed on January 4, 2024
65	As filed on January 4, 2024
66	As filed on January 4, 2024
67	As filed on January 4, 2024
68	As filed on January 4, 2024
69	As filed on January 4, 2024
70	As filed on January 4, 2024
71	As filed on January 4, 2024
72	As filed on January 4, 2024
73	As filed on January 4, 2024
74	As filed on January 4, 2024
75	As filed on January 4, 2024
76	As filed on January 4, 2024
77	As filed on January 4, 2024
78	As filed on January 4, 2024
79	As filed on January 4, 2024
80	As filed on January 4, 2024
81	As filed on January 4, 2024
82	As filed on January 4, 2024
83	As filed on January 4, 2024
84	As filed on January 4, 2024
85	As filed on January 4, 2024
86	As filed on January 4, 2024
87	As filed on January 4, 2024
88	As filed on January 4, 2024
89	As filed on January 4, 2024
90	As filed on January 4, 2024
91	As filed on January 4, 2024
92	As filed on January 4, 2024
93	As filed on January 4, 2024
94	As filed on January 4, 2024
95	As filed on January 4, 2024
96	

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

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Y0S+U'KDO<44/I>H5=VC&LRYKPK* MJKUJ>ZMPX>J>V\$F^>I10V-&UYT#4*NHTYUCAUQB\$F\$Y**.&MOU#PG@ /VE6&O # MONI=?'KA2HZ@ACS-WL#9F&OIP6-NU40-I>M@
Y45UTBF3@-NS<^85*^&E.L MW2I2@KN#*^*7I59KQ3-WUJ|=MVDI7\$WR&J IQVN.DI*^>@&L.MVCWU.L^M5YUN.L^>?>N2\$JOGAY"/.CYVU4I7=?>A1>2\$G7Z.K8)PU6ONR9MFAZAF< M6**
9G^E5\$D@I=PI6\$>59.^E.L MW6L9N9O/UYZK8^>3.32D.IVDI22 M&EU#JL^L^CZ^<@N^L^FC4T:R>+W3J^KY^>2Q^7FEYD4N&ATX&9N\$AFI-I> M.3X.T
[M6HT^63*N^<@D^72.^&CX^KJ7L4@=U2H^HJ=LRO0.M^E<^PC< MC80IYNJ.^*W^E2MR^J^I2V2V9 MGI6G DBDVL3\$=IJI#@&D@I13@:UL:JG:I>9=>.&S.I.MWIF<4:8D^V46.R1L\$2U>
L(YV4I27Z./AXB.8J>WXY/M^YQMC.I4D^>I B2@M&KPCVJZ&M.HU4<5.\$TWDW5H1D).DKI2DW1P\$BT136 M.@=(^S9FHLDF?G+&3<5\$RO/ (@=:AIC1DS0=I^<.<X.P#)H=Z.7\$IX?
LRF0B^&I68-VG7\$<(<X^D!>=M.4-MDQ/ONOI5I69Y^&OKNI-&S MZ00C4\$SM6RWI/13*

01:727444X6 MEWE = 34°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l=OR1T1.MNNL11%>+<9U456654S1\$TDR%3#<51=>J.G@3@=<Z1M1UOIMRR+3-O?<M1X5K?><37 XY1WXS001+<Z@<2+7+6 MOMY&EKFD51.10@C@<7TO1HWB1A1>TUIX"1%>W>F41?>1.NRI M%=>F=8\$U1UW1A1@<TRLXBW6GGV<?<C@.Q2 M1JE=>..?X5M911.O=<Z1FDHJ1L?<D?>1=0.VE(9VJ8KESJ1ZJ1#1JZ>W M&M1%*2>+<K%: M9YQ1=3E1(1.0 +<SFNI+<=ITVM&O1M&KPGPZC 4VU=<6<?>ZV2PLR+<XV MCO.Q.O."X?<7F&EASJ1P01ZBWFFH&amp

[illegible]

link:calculationLink link-definitionLink 996205 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details) link:presentationLink link:calculationLink link-definitionLink 996215 - Disclosure - Restructuring and Related Charges - Narrative (Details) link:presentationLink link:calculationLink link-definitionLink 996225 - Disclosure - Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) link:presentationLink link:calculationLink link-definitionLink 996235 - Disclosure - Restructuring and Related Charges- Restructuring and Other Efficiency Costs (Details) link:presentationLink link:calculationLink link-definitionLink 996245 - Disclosure - Related Parties Additional Information (Details) link:presentationLink link:calculationLink link-definitionLink Statement [Line Items]Statement [Line Items]Weighted- Average Remaining Contractual Life (in years)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]Operating lease right-of-use assetsBusiness Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Assets, Operating Lease Right Of Use AssetsBusiness combination recognized identifiable assets acquired and liabilities assumed, noncurrent assets, operating lease right of use assets,Debt Instrument [Axis]Debt Instrument [Axis]Accounts receivable, netIncrease (Decrease) in Accounts ReceivablePlan Name [Domain]Plan Name [Domain]Redeemable preferred stock, aggregate liquidation preferenceTemporary Equity, Liquidation PreferenceDenominator/Denominator Abstract/Denominator Abstract/Merger exchange ratio/Merger Exchange Ratio/Merger exchange ratio,Entity Address, Postal Zip CodeEntity Address, Postal Zip CodeBusiness CombinationsBusiness Combinations Policy [Policy Text Block]Other non-current liabilitiesBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other/Deferred grant income, current/Deferred Grant Revenue, Current/Deferred Grant Revenue, Current/Deferred grant income, current/Transaction price/Remaining performance obligation/Revenue, Remaining Performance Obligation, Amount/Office furniture and fixtures/Office Equipment [Member]Total/Weighted Average Number of Shares Outstanding, Diluted, Adjustment/Fair Value, Recurring and Nonrecurring [Table]Entity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeAcquisition-related transaction cost/Transaction and integration expensesBusiness Combination, Acquisition Related Costs/Transaction-related expenses/Total restructuring and other related costs/Restructuring and related charges/Restructuring and related charges/Restructuring Charges/Restructuring Charges, Total/Cost of revenue:Costs and Expenses [Abstract]/Revenue:Revenues [Abstract]/Cash paid for interest/Interest Paid, Excluding Capitalized Interest, Operating Activities/Non-current inventory/Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Non-current inventory/Business combination, recognized identifiable assets acquired and liabilities assumed, non-current inventory, Business Combination/Business Combination Disclosure [Text Block]2028/Finite-Lived Intangible Asset, Expected Amortization, Year Four/Fair Value Hierarchy and NAV [Axis]/Fair Value Hierarchy and NAV [Axis]/Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed/Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]/Temporary Equity, Shares Issued/Redeemable preferred stock, shares issued (in shares)/Level 2/Fair Value, Inputs, Level 2 [Member]Share-based Compensation Arrangement by Share-based Payment Award [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair ValueShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in Period, Weighted Average Grant Date Fair Value/Performance adjustment (in usd per share)/Amortization of acquired intangible assets,Amortization of Acquired Intangible Assets/Amortization of intangible assets/Long-term Debt, Type [Domain]/Long-Term Debt, Type [Domain]/Value of consideration transferred/Total consideration/Business Combination, Consideration Transferred/Less: term loan, current/Long-Term Debt, Current Maturities/Long-Term Debt, Current Maturities, Total/Term loan, current/Remainder of 2024/Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year/Maximum contract value/Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value/Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value/Leases/Lessee, Operating Leases [Text Block]Commitments and Contingencies/Commitments and Contingencies Disclosure [Text Block]/Schedule of Restructuring and Related Costs [Table]/Restructuring cost, net of shares withheld for taxes, and other/Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures/Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total/Schedule of Stock by Class [Table]/Stock, Class of Stock [Table]/Product and Service [Axis]/Product and Service [Axis]/Deferred tax liability per balance sheet/Deferred tax liability/Deferred Income Tax Liabilities, Net/Settled Outstanding Litigation/Settled Outstanding Litigation/Settled outstanding litigation,Finite-Lived Intangible Assets by Major Class [Axis]/Finite-Lived Intangible Assets by Major Class [Axis]/Depreciation & amortization/Depreciation, Depletion and Amortization/Depreciation, Depletion and Amortization, Total/Collaborative Arrangement and Arrangement Other than Collaborative [Domain]/Shares of common stock/Repurchase of common stock (in shares)/Repurchase of common stock (in shares)/Stock Repurchased During Period, Shares/Litigation Settlement, Loss/Litigation loss/Class of Treasury Stock [Table]/Maximum additional shares issuable (in shares)/Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum/Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum/2017 Employee Stock Purchase Plan/Two Thousand Seventeen Employee Stock Purchase Plan [Member]Two Thousand Seventeen Employee Stock Purchase Plan [Member]2017 Employee Stock Purchase Plan/Related Party Transaction [Line Items]/Schedule of Nonvested Performance-Based Units Activity/Schedule of Nonvested Performance-Based Units Activity/Schedule of Nonvested Performance-Based Units Activity [Table Text Block]2019 and 2014 Notes/Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities/Mezzanine Equity/Equity [Text Block]/Stockholders' Equity (Deficit)/Title and Position [Axis]/Class of Warrant or Right [Axis]/Revenue and Geographic Area/Revenue from Contract with Customer [Text Block]/Amortization on product-by-product basis using straight-line method over periods/Amortization On Product-By-Product Using Straight-Line Method Over Periods/Amortization on product-by-product using straight-line method over periods, Sale of Stock [Domain]/Cash and Cash Equivalents [Domain]/Cash and Cash Equivalents [Domain]/Total convertible notes, net/Long-Term Debt, Gross/Revenue From Contract With Customer, Terms Of Payment/Period Revenue From Contract With Customer, Terms Of Payment/Period/Terms of payment period/Entity Central Index Key/Entity Central Index Key/Cost of services revenue/Cost of services [Member]/Cost of services, Schedule of Common Stock Reserved for Future Issuance/Schedule of Stock-Based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]/Unvested awards/Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value/Share Based Compensation Arrangement By Share Based Payment Award, Options, Expected To Vest, Outstanding, Aggregate Intrinsic Value/Unvested awards/Restructuring Reserve [Roll Forward]/Restructuring Reserve [Roll Forward]/Cancelled (in shares)/Cancelled/Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period/Changes in assets and liabilities:Increase (Decrease) in Operating Capital [Abstract]/Proceeds from debt issuance/Proceeds from Issuance of Debt/Standard Bio/Tools/Standard Bio/Tools [Member]/Standard Bio/Tools, Common stock, shares issued/Merger consideration/Equity consideration transferred in connection with merger includes shares of common stock issued thereafter/Finite Lived Intangible Assets Amortization Expense After Year Four/Finite Lived Intangible Assets Amortization Expense After Year Four/Prepaid expenses and other assets/Increase (Decrease) in Prepaid Expense and Other Assets/Vested (in dollars per share)/Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price/Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price/Weighted-Average Grant Date Fair Value per Unit/Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]/Non-Cash Right-of-Use Assets and Lease Liabilities/Non-cash right-of-use assets and lease liabilities/Non-Cash Right-of-Use Assets and Lease Liabilities/Income Statement [Abstract]/Income Statement [Abstract]/Entity Address, State or Province/Entity Address, State or Province/Stock Issued During Period, Value, Employee Stock Purchase Plan/Issuance of common stock under ESP/Assets acquired/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]/Loss before income taxes/Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest/License agreement related accounts receivable current/License Agreement Related Accounts Receivable Current/License agreement related accounts receivable current, Assumed through acquisition (in dollars per share)/Stock Options Assumed Weighted Average Exercise Price/Stock Options Assumed Weighted Average Exercise Price/Purchases of short-term investments/Payments to Acquire Short-Term Investments/Trade receivables/Trade Receivables/Trade Receivables/Business Combination Consideration Transferred Equity Interests Issued/Business combination consideration transferred equity interests issued, Shares of Standard Bio/Tools common stock issued to Soma/Logic stockholders/Equity, Class of Treasury Stock [Line Items]/Loss/Contingencies/Table/Loss Contingencies [Table]/Repurchased outstanding principal amount/Debt Instrument, Repurchased Face Amount/2027/Finite-Lived Intangible Asset, Expected Amortization, Year Three/Lease, Cost [Abstract]/Equity Incentive Plan/Equity Incentive Plan [Member]/Equity Incentive Plan [Member]/Raw materials/Inventory, Raw Materials, Gross/Treasury stock, beginning balance (in shares)/Treasury stock, ending balance (in shares)/Treasury stock (in shares)/Treasury Stock, Common, Shares/Cover [Abstract]/Cover [Abstract]/Net loss per share attributable to common stockholders, basic/Net loss per share, basic (in dollars per share)/Earnings Per Share, Basic/Earnings Per Share, Basic, Total/Lessee, Operating Lease, Option to Extend/Lease option to extend/Unrealized Gains/Debt, Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax/Operating expenses/Operating Expenses [Abstract]/Revenue deferred during the period, net of revenue recognized/Contract With Customer Revenue Recognized Net/Amount of revenues recognized net in the period, Merger consideration (in shares)/Stock Issued During Period, Shares, Acquisitions/Other non-current assets/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets/Unvested awards/Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term /Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Weighted Average Remaining Contractual Term /Collaboration and other revenue/Collaboration and Other Revenue [Member]/Collaboration and Other Revenue, Contract with Customer, Liability, Current/Deferred revenue, current/Royalties/Royalties [Member]/Royalties, Consolidation Items [Domain]/Consolidation Items [Domain]/Schedule of Cash and Cash Equivalents/Schedule of Cash and Cash Equivalents [Table Text Block]Total stock-based compensation expense/Share-Based Payment Arrangement, Expense/Accounts receivable, net/Receivables, Net, Current/Schedule of the Acquisition-date Fair Value of Consideration Transferred/Schedule of Business Acquisitions, by Acquisition [Table Text Block]/Long-term debt/Long-Term Debt/Total debt/Internal-use software/Internal Use Software [Member]/Internal Use Software [Member]/Accumulated deficit/Retained Earnings (Accumulated Deficit)/Retained Earnings (Accumulated Deficit), Total/Plan Name [Axis]/Plan Name [Axis]/Segment Reporting [Abstract]/Segment Reporting [Abstract]/Beginning balance (in shares)/Ending balance (in shares)/Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number/Current assets:Assets, Current [Abstract]/Number of remaining securities available for future issuance (in shares)/Common Stock, Capital Shares Reserved for Future Issuance/Convertible notes, current/Convertible Debt, Current/Net cash used in operating activities/Net Cash Provided by (Used in) Operating Activities/Non Rule 10b5-1 Arr Modified Flag/Non Rule 10b5-1 Arr Modified [Flag]/Non-Rule 10b5-1 Arrangement Modified/Fair value stock and carrying value difference/Fair value stock and carrying value difference, Asset retirement obligations/Asset Retirement Obligations Incurred But Not Yet Paid/Asset Retirement Obligations Incurred But Not Yet Paid/Forfeited (in dollars per share)/Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value/Product and Service [Domain]/Product and Service [Domain]/Accumulated other comprehensive loss/Accumulated Other Comprehensive Income (Loss), Net of Tax/Accumulated Other Comprehensive Income (Loss), Net of Tax, Total/Lease, term of contract/Lessee, Operating Lease, Term of Contract/Weighted average remaining contractual terms/Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms/Debt Instrument [Line Items]/Debt Instrument [Line Items]/Property and equipment/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total/Total inventory/Inventory, Gross/Capital expenditures/Research and Development Arrangement, Contract to Perform for Others, Capital Expenditures/Research and Development Arrangement, Contract to Perform for Others, Plant and Equipment, Net/2028/Lessee, Operating Lease, Liability, to be Paid, Year Four/Other non-cash items/Other Operating Activities, Cash Flow Statement/Deferred revenue, non-current/Contract with Customer, Liability, Noncurrent/Operating activities/Net Cash Provided by (Used in) Operating Activities [Abstract]/Type of Restructuring [Domain]/Type of Restructuring [Domain]/Fair Value, Recurring/Fair Value, Recurring [Member]/Restructuring and Related Activities [Abstract]/Common stock, par value (in dollars per share)/Common Stock, Par or Stated Value Per Share/Securities To Be Issued Upon Exercise Of Options/Redeemable preferred stock, \$ 0.001 par value: zero and 256 shares authorized and issued and outstanding at September 30, 2024 and December 31, 2023, respectively: aggregate liquidation preference of zero and \$255,559 at September 30, 2024 and December 31, 2023, respectively/Total Series B Redeemable Preferred Stock/Temporary Equity, Carrying Amount, Attributable to Parent/Goodwill and Acquired Intangible Assets, net/Intangible Assets Disclosure [Text Block]/Measurement Input Type [Domain]/Deferred revenue at December 31, 2023/Deferred revenue/Contract with Customer, Liability/Contract with Customer, Liability, Total/Deferred revenue at June 30, 2024/Total fair value of intangible assets acquired/Intangible Assets/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill/Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total/Statement of Cash Flows [Abstract]/Statement of Cash Flows [Abstract]/Counterparty Name [Axis]/Counterparty Name [Axis]/Payment for litigation settlement/Payments for Legal Settlements/Non-refundable upfront payment, Non-refundable Upfront Payment/The amount that is non-refundable upfront payment, Warrant to purchase common stock/Initial public offering warrants issued/Class of Warrant or Right, Number of Securities Called by Warrants or Rights/Selling, general and administrative expense/Selling, General and Administrative Expenses [Member]/Entity [Domain]/Acquired Finite-Lived Intangible Assets [Line Items]/Balance Sheet Related Disclosures [Abstract]/Balance Sheet Related Disclosures [Abstract]/Equity Components [Axis]/Equity Components [Axis]/Entity Address, Address Line One/Entity Address, Address Line One/Schedule of computation of loss per share/Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]/Accrued compensation and related benefits/Accrued compensation and related benefits/Employee-related Liabilities, Current/Severance and other employee-related benefits/Employee Severance [Member]/Related Party Transaction [Table]/Granted (in shares)/Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period/Schedule of Finite-Lived Intangible Assets [Table]/Intangible Asset, Finite-Lived [Table]/Computer equipment/Computer Equipment [Member]/Property, Plant and Equipment [Line Items]/Property, Plant and Equipment [Line Items]/Proteomics/Proteomics [Member]/Proteomics/Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders/Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]/Uninvoiced receipts/Accrued Uninvoiced Receipts Current/Amount of accrued uninvoiced receipts current, Warrant Liabilities/Warrant Liabilities [Policy Text Block]/Disclosure of accounting policy for warrant liabilities, Beginning balance (in shares)/Ending balance (in shares)/Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number/Warrants/Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants/2026/Finite-Lived Intangible Asset, Expected Amortization, Year Two/Amendment Flag/Amendment Flag/Illumina/Illumina Cambridge, Ltd/Illumina Cambridge, Ltd [Member]/Illumina Cambridge, Ltd, Operating lease liabilities/Increase (Decrease) in Operating Lease Liability/Long-term operating lease liabilities/Long-term operating lease liabilities/Operating lease liabilities, non-current/Operating Lease, Liability, Noncurrent/Debt Instrument, Name [Domain]/Debt Instrument, Name [Domain]/Restructuring Plan [Domain]/Net loss/Net loss/Lessee, Lease, Description [Table]/Inventory, non-current/Inventory, Noncurrent/Inventory, Noncurrent, Total/Exercised (in shares)/Issuance of common stock from option exercises (in shares)/Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period/Exercise of stock options (in shares)/Research and development expense/Research and Development Expense [Member]/Revenue/Business Acquisition, Pro Forma Revenue/Schedule of Total Carrying Value of Debt/Schedule of Debt [Table Text Block]/Number of installments/Debt Instrument, Periodic Payment, Number Of Installments/Debt Instrument, Periodic Payment, Number Of Installments/Accounts receivable, net of current portion/Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Receivables/Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent receivables, Equity Component [Domain]/Equity Component [Domain]/Statistical Measurement [Domain]/Statistical Measurement [Domain]/Net change in unrealized gain on investments/Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent/Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total/Balance Sheet Details/Supplemental Balance Sheet Disclosures [Text Block]/Other income (expense), net/Other Nonoperating Income (Expense)/Other Nonoperating Income (Expense), Total/Treasury Stock/Treasury Stock, Common [Member]/Disaggregation of Revenue [Table]/Disaggregation of Revenue [Table]/Vested/Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One/Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One/Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]/Preferred stock, shares issued (in shares)/Preferred

Stock, Shares IssuedPrivate Placement WarrantsPrivate Placement Warrants [Member]Private Placement Warrants.Proceeds from Stock Options ExercisedProceeds from exercise of stock optionsAssumed through acquisition (in dollars per share)Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Assumed Through Acquisition, Weighted Average Grant Date Fair ValueShare-based compensation arrangement by share-based payment award, equity instruments other than options, assumed through acquisition, weighted average grant date fair value2011 Equity Incentive PlanTwo Thousand And Eleven Equity Incentive Plan [Member]Two Thousand And Eleven Equity Incentive Plan [Member]Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]Finite-lived intangible assets acquiredFinite-Lived Intangible Assets AcquiredStock Issued During Period, Shares, Employee Stock Purchase PlansIssuance of common stock under ESPP (in shares)Consolidation Items [Axis]Consolidation Items [Axis]Granted (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of ForfeituresShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, TotalPrepaid expenses and other current assetsPrepaid Expense and Other Assets, CurrentCancelled (in dollars per share)Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceAssumed through acquisitionShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Assumed through acquisitionShare-based compensation arrangement by share-based payment award, equity instruments other than options, assumed through acquisition.Non-current restricted cashRestricted Cash, NoncurrentCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Class of Stock [Domain]Class of Stock [Domain]Schedule of Acquired Intangible AssetsSchedule of Finite-Lived Intangible Assets [Table Text Block]Comprehensive LossComprehensive Income (Loss), Net of Tax, Attributable to ParentCommon stock, shares outstanding (in shares)Beginning balance (in shares)Ending balance (in shares)Common Stock, Shares, OutstandingFinite-Lived Intangible Assets, Major Class Name [Domain]Finite-Lived Intangible Assets, Major Class Name [Domain]Number of OptionsShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]Fair value of Standard BioTools replacement equity awards attributable to pre-combination serviceBusiness Combination Consideration Transferred Fair Value Of Replacement Equity Awards Attributable To Pre-combination ServiceBusiness combination consideration transferred fair value of replacement equity awards attributable to pre-combination service.Fair Value Measurement, Policy [Policy Text Block]Fair Value MeasurementsVestedShare Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic ValueShare Based Compensation Arrangement by Share Based Payment Award, Options, Vested, Aggregate Intrinsic ValueVestedUseful Life (Years)Acquired Finite-Lived Intangible Assets, Weighted Average Useful LifePreferred stock, par value (in dollars per share)Preferred Stock, Par or Stated Value Per ShareCasdin Partners Master Fund, L.P.Casdin Partners Master Fund, L.p [Member]Casdin partners master fund, lp.CasdinCasdin [Member]CasdinRoyalty Receivable CurrentRoyalty Receivable CurrentRoyalty Receivable CurrentStandard BioTools common stock price at close of MergerBusiness Combination Consideration Transferred Equity Shares Issued Price Per ShareBusiness combination consideration transferred equity shares issued price per share.Capitalized Software Development CostsCapitalized Software Development Costs [Member]Capitalized software development costs.Finite-Lived Intangible Assets [Line Items]Finite-Lived Intangible Assets [Line Items]Entity Interactive Data CurrentEntity Interactive Data CurrentCash acquired in mergerCash Acquired from AcquisitionCash and restricted cash acquired in MergerProduct revenueProduct [Member]Cost of product revenueCost of Sales [Member]SomaLogic Inc.Somalologic Inc [Member]SomaLogic Inc.Liabilities assumedBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]Debt instrument redemption priceDebt Instrument, Redemption Price, PercentageOptions in exchange of common sharesOptions In Exchange Of Common SharesOptions in exchange of common shares.Document Quarterly ReportDocument Quarterly ReportSettlement of outstanding litigationSettlement of Outstanding LitigationSettlement of outstanding litigation.Goodwill [Line Items]Released (in dollars per share)Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair ValueTotal cash, cash equivalents and restricted cashTotal cash, cash equivalents and restricted cashCash, cash equivalents and restricted cash at beginning of periodCash, cash equivalents and restricted cash at end of periodCash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsRelated PartiesRelated Party Transactions Disclosure [Text Block]Balance Sheet Location [Axis]Statement of Financial Position Location, Balance [Axis]2014 NotesSenior Convertible Notes Due 2034 [Member]Senior Convertible Notes Due 2034 [Member]Statistical Measurement [Axis]Statistical Measurement [Axis]Total cost of revenueCost of Goods and Services SoldCost of Goods and Services Sold, TotalOperating lease costOperating Lease, CostTotal assets measured at fair valueAssets, Fair Value DisclosureConvertible DebtConvertible Debt [Member]Related and Nonrelated Parties [Domain]Total lease costLease, CostProceeds from sales and maturities of investmentsProceeds from Maturities, Prepayments and Calls of Other InvestmentsSchedule of Disaggregation of RevenueDisaggregation of Revenue [Table Text Block]Schedule of Operating Lease Undiscounted Lease Payment Maturities to the Lease LiabilitiesLessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Redemption, Period ThreeDebt Instrument, Redemption, Period Three [Member]Eli CasdinDirector [Member]Gross Carrying AmountFinite-Lived Intangible Assets, GrossFinite-Lived Intangible Assets, Gross, TotalBasis of Presentation and Summary of Significant Accounting PoliciesBasis of Presentation and Significant Accounting Policies [Text Block]Granted (in dollars per share)Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValuePurchase commitment due in the next yearPurchase Obligation, to be Paid, Year OneEffect of foreign exchange rate fluctuations on cash and cash equivalentsEffect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing OperationsIncome Statement Location [Axis]Statement of Income Location, Balance [Axis]Cash and Cash Equivalents [Axis]Cash and Cash Equivalents [Axis]Total assetsAssetsLicense agreement related accounts receivable non-current,License Agreement Related Accounts Receivable Non-currentLicense agreement related accounts receivable non-current,Restructuring Type [Axis]Restructuring Type [Axis]Transaction price royalties expected to be receivedTransaction Price Royalties Expected To Be Received PeriodTransaction price royalties expected to be received period.Schedule of Long-term Debt Instruments [Table]Schedule of Long-Term Debt Instruments [Table]Vested (in shares)Vested (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodBusiness Acquisition [Line Items]Accrued restructuringRestructuring Reserve, CurrentOtherOther [Member]Other Recent Accounting Changes and Accounting PronouncementsNew Accounting Pronouncements, Policy [Policy Text Block]Entity Address, City or TownEntity Address, City or TownAccum. Other Comp. LossAOCl Attributable to Parent [Member]Equity [Abstract]Equity [Abstract]Segments [Axis]Segments [Axis]Soma Logic PlansSoma Logic Plans [Member]Soma logic plans.Forfeited (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodSchedule of Supplemental Lease InformationSchedule of Supplemental Lease Information [Table Text Block]Schedule of supplemental lease information.Cash paymentsPayments for RestructuringTransaction bonuses incurredBusiness Combination, Transaction Bonuses IncurredBusiness combination, transaction bonuses incurred.Face amountDebt Instrument, Face AmountRestructuring Cost and Reserve [Line Items]Restructuring Cost and Reserve [Line Items]Share price (in dollars per share)Share PriceMarket priceSchedule of Segment Reporting Information, by Segment [Table]Schedule of Segment Reporting Information, by Segment [Table]Stock-based CompensationShare-Based Payment Arrangement [Text Block]Securities to be issued (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedRoyalty receivableBusiness Combination Recognized Identifiable Asset Acquired And Liabilities Assumed Royalty ReceivableBusiness combination recognized identifiable asset acquired and liabilities assumed royalty receivable,Debt Securities, Available-for-Sale, Allowance for Credit Loss, Sell before RecoveryAmortization cost before recoveryWeighted average discount rateOperating Lease, Weighted Average Discount Rate, PercentFair Value Disclosures [Abstract]Fair Value Disclosures [Abstract]New England Biolabs, Inc.New England Biolabs, Inc. [Member]New England Biolabs, Inc.Deferred revenue, currentBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred RevenueRevenueBusiness Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, ActualFacility CostsFacility Closing [Member]2017 Inducement Award PlanTwo Thousand And Seventeen Inducement Award Plan [Member]Two Thousand And Seventeen Inducement Award Plan [Member]Schedule of Unaudited Pro Forma Financial InformationBusiness Acquisition, Pro Forma Information [Table Text Block]Purchase Commitment AgreementPurchase Commitment AgreementPurchase commitment agreement.Exercise of stock optionsIssuance of common stock from option exercisesStock Issued During Period, Value, Stock Options ExercisedLessee, Lease, Description [Line Items]Lessee, Lease, Description [Line Items]Current liabilities:Liabilities, Current [Abstract]Debt redemption conditioned upon common stock value exceeding a percentage of the conversion priceDebt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion PriceDebt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion PriceCash paid for income taxes, net of refundsIncome Taxes Paid, NetIncome Taxes Paid, Net, TotalCash and cash equivalentsCash and Cash Equivalents [Member]Document TypeDocument TypePerformance adjustment awards (in shares)Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in PeriodShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Adjustment in PeriodPerformance adjustment (in shares)Title of 12(b) SecurityTitle of 12(b) SecurityCash and cash equivalentsCash and cash equivalentsCash and Cash Equivalents, at Carrying ValueCash and Cash Equivalents, at Carrying Value, TotalBalance Sheet Location [Domain]Statement of Financial Position Location, Balance [Domain]Schedule of Lease CostLease, Cost [Table Text Block]Debt Instrument, Redemption, Period [Axis]Debt Instrument, Redemption, Period [Axis]Statement of Stockholders' Equity [Abstract]Statement of Stockholders' Equity [Abstract]Fair value of warrant liabilities as of Closing DateFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability ValueFair value of warrant liabilities as of June 30, 2024Document Fiscal Period FocusDocument Fiscal Period FocusResearch and development servicesResearch and developmentResearch and Development ExpenseResearch and Development Expense, TotalPayments for taxes related to net share settlement of equity awards and otherPayment, Tax Withholding, Share-Based Payment ArrangementTerm loan, non-currentLong-Term Debt, Excluding Current MaturitiesLong-Term Debt, Excluding Current Maturities, TotalSchedule of the Changes in the Carrying Value of Goodwill by SegmentSchedule of Goodwill [Table Text Block]Warrant liabilitiesBusiness Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Warrant LiabilitiesBusiness combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, warrant liabilities.Indefinite-Lived Intangible Assets [Axis]Property and equipment, grossProperty, Plant and Equipment, GrossProperty, Plant and Equipment, Gross, TotalProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, Ending BalanceRedemption, Period TwoDebt Instrument, Redemption, Period Two [Member]Measurement Input, Expected Term [Member]Warrant TermForeign currency translation adjustmentOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to ParentOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, TotalOperating segmentsOperating Segments [Member]Schedule of Restructuring LiabilitiesSchedule of Restructuring Reserve by Type of Cost [Table Text Block]Schedule Of Significant Accounting Policies [Table]Schedule Of Significant Accounting Policies [Table]Schedule Of Significant Accounting Policies [Table]Mezzanine equity.Mezzanine Equity [Text Block]Mezzanine EquityPublic WarrantsPublic Warrants [Member]Public WarrantsFixed exchange ratioExchanged common stockBusiness Acquisition, Share PriceExercise price of warrantsPurchase shares of Common StockClass of Warrant or Right, Exercise Price of Warrants or RightsFinancial Instruments [Domain]Financial Instruments [Domain]SomaLogic Common Stock issued and outstanding as of January 5, 2024Amount of common stockBusiness Combination, Consideration Transferred, Equity Interests Issued and IssuableTransaction price royalties expected to be receivedRemaining performance obligation, expected timing of satisfactionRevenue, Remaining Performance Obligation, Expected Timing of Satisfaction, PeriodSale of Stock [Axis]Investing activitiesNet Cash Provided by (Used in) Investing Activities [Abstract]Repurchase of common stockShare repurchase amountPayments for Repurchase of Common StockAmericasAmericas [Member]Illumina AgreementIllumina Agreement [Member]Illumina Agreement, Schedule of Activity Under Restricted Stock UnitsSchedule of Nonvested Restricted Stock Units Activity [Table Text Block]Total revenueRevenue from Contract with Customer, Excluding Assessed TaxStatement of Comprehensive Income [Abstract]Statement of Comprehensive Income [Abstract]Income TaxesIncome Tax Disclosure [Text Block]Term loan, non-currentSecured DebtSecured Debt, Total2022 Inducement Equity Incentive PlanTwo Thousand And Twenty Two Inducement Equity Incentive Plan [Member]Two Thousand And Twenty Two Inducement Equity Incentive PlanSchedule of Expected Timing of Revenue RecognitionRevenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]TotalFinite Lived Intangible Assets Future Expected Amortization ExpenseFinite lived intangible assets future expected amortization expense.InstrumentsInstruments [Member]Instruments [Member]Other Restructuring [Member]OtherSelling, general and administrativeSelling, General and Administrative ExpenseSelling, General and Administrative Expense, TotalSeries B Preferred StockSeries B Preferred Stock [Member]Repurchase of common stockStock Repurchased During Period, ValueTotalFinite-Lived Intangible Assets, NetFinite-Lived Intangible Assets, Net, Beginning BalanceFinite-Lived Intangible Assets, Net, Ending BalanceIncrease (Decrease) in Stockholders' Equity [Roll Forward]Increase (Decrease) in Stockholders' Equity [Roll Forward]TradenameTrade NameTrade Names [Member]Depreciation, Depletion and Amortization, Nonproduction, TotalDepreciation, Depletion and Amortization, NonproductionDepreciation and amortization expenseOther Other Accrued Liabilities, CurrentAccounts payableIncrease (Decrease) in Accounts PayableIncrease (Decrease) in Accounts Payable, TotalEntity Address, Address Line TwoEntity Address, Address Line TwoLIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)Liabilities and Equity [Abstract]Document Period End DateDocument Period End DateNet cash used in financing activitiesNet Cash Provided by (Used in) Financing ActivitiesNet cash used in financing activitiesBeginning balanceEnding balanceRestructuring ReserveRestructuring Reserve, TotalStock-based compensation expenseAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionAPIC, Share-Based Payment Arrangement, Increase for Cost Recognition, TotalAccrued liabilitiesAccrued liabilitiesAccrued Liabilities, CurrentRule 10b51 Arr Modified Flag,Rule 10b51 Arr Modified [Flag]Rule 10b5-1 Arrangement ModifiedIncome tax expenseIncome tax expense (benefit)Income Tax Expense (Benefit)Income Tax Expense (Benefit), TotalTrading SymbolTrading SymbolBusiness Combinations [Abstract]Total stockholders' equity (deficit)Beginning balanceEnding balanceEquity, Attributable to ParentExchange Convertible Senior Notes due 2034Exchange Convertible Senior Notes due 2034 [Member]Exchange Convertible Senior Notes due 2034 [Member]Number of Nonvested and Outstanding UnitsShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]Impairment of intangible assetsImpairment of goodwill, long-lived assets or intangible assetsImpairment of Intangible Assets, Finite-LivedProperty, Plant and Equipment, Type [Axis]Long-Lived Tangible Asset [Axis]2019 Notes2019 Convertible NotesSenior Convertible Notes Due 2024 [Member]Senior Convertible Notes Due 2024 [Member]EMEAEMEA [Member]Other non-current liabilitiesOther Liabilities, NoncurrentDeferred revenue assumed in connection with mergerContract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business CombinationRestricted Stock Units (RSUs)Restricted Stock UnitsRestricted Stock Units (RSUs) [Member]Shares sold (in shares)Sale of Stock, Number of Shares Issued in TransactionRelated Party Transactions [Abstract]Redeemable preferred stock, shares authorized (in shares)Temporary Equity, Shares AuthorizedVariable lease costVariable Lease, CostSchedule of Property, Plant and Equipment [Table]Property, Plant and Equipment [Table]GoodwillGoodwill, TotalGoodwill, Beginning BalanceGoodwill, Ending BalanceTotal unrecognized compensation cost related to stock-based compensation arrangementsShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, AmountShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, TotalShare Repurchase Program [Axis]Schedule of Stock-Based Compensation ExpenseShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Schedule of Accounts ReceivableSchedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]Measurement Input Type [Axis]Term loan advances percentageDebt Instrument, Incremental Payment, PercentDebt Instrument, Incremental Payment, PercentGenomicsGenomics [Member]GenomicsGeographical [Axis]Geographical [Axis]Unrealized LossesDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before TaxLeases [Abstract]Provision for excess and obsolete inventoryInventory, LIFO Reserve, Period ChargeUse of EstimatesUse of Estimates, Policy [Policy Text Block]Unvested options (in shares)Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding NumberShare Based Compensation Arrangement by Share Based Payment Award Options Expected To Vest Outstanding NumberConversion of redeemable preferred stockStock Issued During Period, Value, Conversion of Convertible SecuritiesRelated PartyRelated Party [Member]Class of Stock [Line Items]Class of Stock [Line Items]VolatilityMeasurement Input, Price Volatility [Member]Schedule of Business Acquisitions, by Acquisition [Table]Royalty receivable, non-currentRoyalty Receivable Non CurrentRoyalty receivable non current,Summary of the Change in Deferred RevenueContract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]Security Exchange NameSecurity Exchange NameIndefinite-lived intangible assets acquiredIndefinite-Lived Intangible Assets AcquiredSchedule of Available-for-Sale Securities ReconciliationSchedule of Available-for-Sale Securities Reconciliation [Table Text Block]Counterparty Name [Domain]Counterparty Name [Domain]Business Acquisition, Acquiree

[Domain]Business Acquisition, Acquiree [Domain]Total operating expensesOperating ExpensesRisk-Free RateMeasurement Input, Risk Free Interest Rate [Member]Term loan, currentSecured Debt, CurrentTransaction and integration expensesTransaction And Integration Expenses [Member]Transaction and integration expenses, Schedule of Valuation of the Intangible Assets Acquired in Connection with the MergerFinite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]Property, Plant and Equipment, Type [Domain]Long-Lived Tangible Asset [Domain]Class of Stock [Axis]Class of Stock [Axis]Term loan, non-currentSecured Long-Term Debt, NoncurrentLess accumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceLegal Entity [Axis]Secured DebtSecured Debt [Member]Fair Value of Financial InstrumentsFair Value Disclosures [Text Block]2027Lessee, Operating Lease, Liability, to be Paid, Year ThreeCommon stock relinquished in litigation settlementCommon Stock Relinquished In Litigation SettlementCommon Stock Relinquished In Litigation SettlementMaximumMaximum [Member]Restructuring and Related ChargesRestructuring and Related Activities Disclosure [Text Block]Total liabilities, mezzanine equity and stockholders' equity (deficit)Liabilities and EquityRestructuring and Related Cost, Number of Positions Eliminated, Period PercentPercentage of reduction in workforceOperating lease right-of-use asset, netOperating Lease, Right-of-Use AssetVested (in shares)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of SharesSupplemental disclosures of cash flow informationSupplemental Cash Flow Information [Abstract]Net loss per share attributable to common stockholders, dilutedNet loss per share, diluted (in dollars per share)Earnings Per Share, DilutedEarnings Per Share, Diluted, TotalLeasehold improvementsLeasehold Improvements [Member]Total LiabilitiesBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, LiabilitiesTotal liabilitiesLiabilitiesFair Value Hierarchy and NAV [Domain]Fair Value Hierarchy and NAV [Domain]Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair ValueFair value of Standard BioTools common stock issued to SomaLogic stockholdersTotal current assetsAssets, CurrentNet cash provided by investing activitiesNet Cash Provided by (Used in) Investing ActivitiesReceived aggregate sharesReceive aggregate sharesStock Issued During Period, Shares, New IssuesLessee, operating lease, existence of option to extend [true false]Lessee, Operating Lease, Existence of Option to Extend [true false]Schedule Of Significant Accounting Policies [Line Items]Schedule Of Significant Accounting Policies [Line Items]Schedule Of Significant Accounting Policies [Line Items]Schedule Of Significant Accounting Policies [Line Items]Instrument support servicesInstrument Support Services [Member]Instrument Support ServicesInterest income, netInterest Income, OperatingInterest Income, Operating, TotalEntity Filer CategoryEntity Filer CategoryStock-based compensation expense due to acceleration of awardsStock-Based Compensation Expense Due to Acceleration of AwardsStock-based compensation expense due to acceleration of awards, Debt conversion, converted instrument, shares issued (in shares)Debt Conversion, Converted Instrument, Shares IssuedDeferred revenue, non-currentBusiness Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Noncurrent Liabilities, Deferred RevenueBusiness combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, deferred revenue, Debt Instrument, Redemption, Period [Domain]Debt Instrument, Redemption, Period [Domain]Current Fiscal Year End DateCurrent Fiscal Year End DateFair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]Less: amount of lease payments representing interestLessee, Operating Lease, Liability, Undiscounted Excess AmountSeries B Preferred StockIncremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred StockRedeemable preferred stock, par value (in dollars per share)Temporary Equity, Par or Stated Value Per ShareStock-based compensation expenseShare-Based Payment Arrangement, Noncash ExpenseShare-Based Payment Arrangement, Noncash Expense, TotalOutstandingShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueRelated and Nonrelated Parties [Axis]Foreign currency translationGoodwill, Foreign Currency Translation Gain (Loss)Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]Entity Registrant NameEntity Registrant NameIndefinite-Lived Intangible Assets, Major Class Name [Domain]Unvested awards (in dollars per share)Share-Based Compensation Arrangement By Share-Based Payment Award Options Expected To Vest Weighted Average Exercise PriceShare-Based Compensation Arrangement By Share-Based Payment Award Options Expected To Vest Weighted Average Exercise PriceLess: allowance for expected credit lossesAllowance For Expected Credit LossesAllowance For Expected Credit LossesGross profitGross ProfitNumber of reporting segmentsNumber of Reportable SegmentsSchedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Net Loss Per ShareEarnings Per Share [Text Block]Entity Emerging Growth CompanyEntity Emerging Growth CompanyCarrying value of assetsResearch And Development Arrangement, Contract To Perform For Others, Property and Equipment, NetResearch And Development Arrangement, Contract To Perform For Others, Property and Equipment, NetCarrying value of property and equipment, netMoney market fundsMoney Market Funds [Member]Weighted-average shares outstanding during the period, basicShares used in computing net loss per share attributable to common stockholders, basic (in shares)Weighted Average Number of Shares Outstanding, BasicWeighted Average Number of Shares Outstanding, Basic, TotalCommon stock, shares authorized (in shares)Common Stock, Shares AuthorizedShare Repurchase Program [Domain]Less: Sublease incomeSublease IncomeLevel 1 Fair Value, Inputs, Level 1 [Member]Aggregate intrinsic value, vested and releasedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, VestedOperating lease liabilities, currentBusiness Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Operating Lease Liabilities, CurrentBusiness combination recognized identifiable assets acquired and liabilities assumed, current liabilities, operating lease liabilities, Debt Disclosure [Abstract]Debt Disclosure [Abstract]Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option ExercisedProceeds from ESPP stock issuanceDebtLong-Term Debt [Text Block]Granted (in dollars per share)Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceAmortization of acquired intangible assetsAmortization of intangible assetsAmortization of Intangible AssetsShort-term investmentsBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short-term InvestmentsBusiness combination, recognized identifiable assets acquired and liabilities assumed, short-term investmentsFinancial Instrument [Axis]Financial Instrument [Axis]Asia-PacificAsia Pacific [Member]Prepaid expenses and other current assetsBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other AssetsShare-based Payment Arrangement [Abstract]Share-Based Payment Arrangement [Abstract]Accrued warranties currentAccrued Warranties CurrentAccrued warrantiesDepreciation expensesResearch And Development Arrangement, Contract To Perform For Others, Depreciation ExpenseResearch And Development Arrangement, Contract To Perform For Others, Depreciation ExpenseNet lossBusiness Acquisition, Pro Forma Net Income (Loss)Impairment of goodwillGoodwill, Impairment LossMerger considerationStock Issued During Period, Value, AcquisitionsTreasury stock at cost: 18,580 and 3,132 shares at September 30, 2024 and December 31, 2023, respectivelyTreasury Stock, Common, ValueRestructuring Plan [Axis]Operating lease liabilities, non-currentBusiness Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Non-current Liabilities, Operating Lease LiabilitiesBusiness combination recognized identifiable assets acquired and liabilities assumed, non-current liabilities, operating lease liabilities, Short-term investmentsEstimated Fair ValueDebt Securities, Available-for-SaleDebt Securities, Available-for-Sale, TotalAccounting Policies [Abstract]Accounting Policies [Abstract]Schedule of Activity Under Stock OptionsShare-Based Payment Arrangement, Option, Activity [Table Text Block]Income Tax Disclosure [Abstract]Income Tax Disclosure [Abstract]Minimum Annual PurchaseLong-Term Purchase Commitment, AmountStockholders' equity (deficit):Equity, Attributable to Parent [Abstract]Corporate Corporate Segment [Member]Statement [Table]Statement [Table]Segment ReportingSegment Reporting, Policy [Policy Text Block]Schedule of Property and Equipment, NetProperty, Plant and Equipment [Table Text Block]Bargain purchase gainBargain purchase gainGain on bargain purchaseBusiness Combination, Bargain Purchase, Gain Recognized, AmountPayment of term loan feePayments of Loan CostsContractual termShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermAccounts payable and accrued liabilitiesBusiness Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued LiabilitiesBusiness combination recognized identifiable assets acquired and liabilities assumed accounts payable and accrued liabilities, Weighted-Average Exercise Price per OptionShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]Initial conversion price of stock (in usd per share)Initial Conversion Price Of StockInitial Conversion Price Of StockPreferred stock, shares authorized (in shares)Preferred Stock, Shares AuthorizedChange in fair value of warrantsFair Value Adjustment of WarrantsEntity File NumberEntity File NumberSegment ReportingSegment Reporting Disclosure [Text Block]Net increase in cash, cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectRevenue from Contract with Customer [Abstract]Revenue from Contract with Customer [Abstract]Earnings Per Share [Abstract]Warrants and Rights Outstanding, TermVikingViking [Member]VikingFair Value, Assets Measured on Recurring Basis, Unobservable Input ReconciliationFair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]Equity consideration transferred in connection with mergerEquity consideration transferred in connection with mergerEquity consideration transferred in connection with MergerStatement of Financial Position [Abstract]Statement of Financial Position [Abstract]Loss from operationsOperating Income (Loss)Income (loss) from operationsDeferred grant income, non-currentDeferred Grant Revenue, NoncurrentDeferred Grant Revenue, NoncurrentCorporate expensesSegment Reporting, Reconciling Item, Corporate Nonsegment [Member]Entity Shell CompanyEntity Shell CompanySchedule of Warrants LiabilitiesFair Value Measurement Inputs and Valuation Techniques [Table Text Block]Entity Tax Identification NumberEntity Tax Identification NumberASSETSAssets [Abstract]Class of Warrant or Right [Domain]Construction-in-progressConstruction in Progress, GrossEntity Current Reporting StatusEntity Current Reporting StatusRestricted cashRestricted Cash and Cash Equivalents, CurrentRestricted Cash and Cash Equivalents, Current, TotalNet loss attributable to common stockholdersNet loss attributable to common stockholdersNet Income (Loss) Available to Common Stockholders, BasicSchedule of Liabilities Measured at Fair Value on a Recurring BasisFair Value, Liabilities Measured on Recurring Basis [Table Text Block]Induced conversion of redeemable preferred stockPreferred Stock Conversions, InducementsAggregate Intrinsic ValueShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]Long-term Debt, Type [Axis]Long-Term Debt, Type [Axis]Revenue RecognitionRevenue from Contract with Customer [Policy Text Block]Deferred revenueIncrease (Decrease) in Contract with Customer, LiabilityTotal assets acquiredBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, AssetsGeographical [Domain]Geographical [Domain]Document Fiscal Year FocusDocument Fiscal Year FocusFocusNotes Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]Restructuring and Related Charges2019 Notes, currentSenior Convertible Notes Due 2024, Current [Member]Senior convertible notes due 2024, currentInventoryBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, InventoryPreferred stock, \$0.001 par value, 10,000 and 9,744 shares authorized at September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023Preferred Stock, Value, IssuedAccumulated AmortizationFinite-Lived Intangible Assets, Accumulated AmortizationCascin Private Growth Equity Fund, L.P.Cascin Private Growth Equity Fund, L.P [Member]Cascin private growth equity fund, L.P.Business Acquisition [Axis]Business Acquisition [Axis]City Area CodeCity Area CodeWarrants and Rights Outstanding, Measurement InputLaboratory and manufacturing equipmentLaboratory And Manufacturing Equipment [Member]Laboratory And Manufacturing Equipment [Member]Total current liabilitiesLiabilities, CurrentThereafterLessee, Operating Lease, Liability, To Be Paid, After Year FourAmount of lessee's undiscounted obligation for lease payment for operating lease due after four fiscal year following current fiscal year.Inventories, netInventories, netInventory, NetFinished goodsInventory, Finished Goods, GrossEffective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, PercentFederal statutory tax rateConversion of redeemable preferred stock (shares)Exchange of common stockStock Issued During Period, Shares, Conversion of Convertible SecuritiesLocal Phone NumberLocal Phone NumberPreferred Stock, Shares OutstandingPreferred Stock, Shares OutstandingPreferred Stock, Shares Outstanding, Beginning BalancePreferred Stock, Shares Outstanding, Ending BalanceAntidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]Additional paid-in capitalAdditional Paid in CapitalAdditional Paid in Capital, TotalCommitments and Contingencies Disclosure [Abstract]Commitments and Contingencies Disclosure [Abstract]Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]Mezzanine equity:Temporary Equity [Abstract]Series B Preferred StockConvertible Preferred Stock [Member]Convertible Preferred StockAmortized CostDebt Securities, Available-for-Sale, Amortized CostAssumed through acquisition (in shares)Stock Options Assumed Through AcquisitionStock Options Assumed Through AcquisitionAssumed lease expiredLessee Operating Lease, Assumed Lease ExpiredLessee operating lease, assumed lease expiredCumulative discounted cash flow percentageAcquired Intangibles Cumulative Discounted Cash Flow PercentageAcquired intangibles cumulative discounted cash flow percentage, Less: current operating lease liabilitiesOperating lease liabilities, currentOperating Lease, Liability, CurrentDeveloped TechnologyDeveloped Technology Amortization ExpenseDeveloped Technology Rights [Member]Strategic reorganization, Strategic Reorganization MemberStrategic Reorganization [Member]Interest rate on notesDebt Instrument, Interest Rate, Stated PercentageConvertible Aggregate Common StockConvertible Preferred Stock, Shares Issued upon ConversionAccum, DeficitRetained Earnings [Member]Purchase to equipment supplies and trainingPurchases of property and equipmentPayments to Acquire Property, Plant, and EquipmentPayments to Acquire Property, Plant, and Equipment, TotalAccounts receivableBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, ReceivablesDocument Transition ReportDocument Transition ReportNo of leases for office and laboratory spaceNumber Of Leases For Office And Laboratory SpaceNumber of leases for office and laboratory space, Stock repurchase program, authorized amountShare Repurchase Program, Authorized, Amount2026Lessee, Operating Lease, Liability, to be Paid, Year TwoSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]Antidilutive Security, Excluded EPS Calculation [Table]License agreement related royalties receivableLicense Agreement Related Royalties ReceivableLicense agreement related royalties receivable, NECNEC CorporationNEC Corporation [Member]NEC Corporation, Exercised (in dollars per share)Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price2024 remainder of the yearFinite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal YearMinimumMinimum [Member]Common StockCommon Stock [Member]2024 Share Repurchase ProgramTwo Thousand Twenty Four Share Repurchase Program [Member]Two thousand twenty four share repurchase program, Cash and cash equivalentsBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and EquivalentsEnding balance (in dollars per share)Beginning balance (in dollars per share)Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueAdditional Paid-in CapitalAdditional Paid-in Capital [Member]Loss contingency accrualsLoss Contingency AccrualsLoss Contingency AccrualsShort-term investmentsDebt Securities, Available-for-Sale, CurrentAmortizes internal-use software costs using the straight-line method over the estimated useful life of assetAmortizes Internal-Use Software Costs Using Straight-Line MethodAmortizes internal-use software costs using straight-line methodAdjustments to reconcile net loss to net cash used in operating activitiesAdjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Short-term investmentsShort-Term Investments [Member]Assay servicesAssay Services [Member]Assay Services, Other comprehensive income (loss), net of tax:Other Comprehensive Income (Loss), Net of Tax [Abstract]Income Statement Location [Domain]Statement of Income Location, Balance [Domain]2025Lessee, Operating Lease, Liability, to be Paid, Year OneOther non-current assetsOther Assets, NoncurrentRepurchase of common stock shares for litigation settlementRepurchase of Common Stock Shares for Litigation SettlementRepurchase of common stock shares for litigation settlement, Segments [Domain]Segments [Domain]Revenue From Contract With Customer, Performance Obligation PeriodRevenue From Contract With Customer, Performance Obligation PeriodPerformance obligation periodNon-cash lease expenseNon-cash Lease ExpenseNon-cash lease expenseOther liabilitiesIncrease (Decrease) in Other Operating LiabilitiesIncrease (Decrease) in Other Operating Liabilities, TotalPerformance SharesPerformance Shares [Member]Schedule of InventoriesSchedule of Inventory, Current [Table Text Block]Goodwill and Intangible Assets Disclosure [Abstract]Goodwill and Intangible Assets Disclosure [Abstract]Entity Common Stock, Shares Outstanding (in shares)Entity Common Stock, Shares OutstandingInitial conversion rate of notesDebt Instrument, Convertible, Conversion RatioDisaggregation of Revenue [Line Items]Disaggregation of Revenue [Line Items]Basis of PresentationBasis of Accounting, Policy [Policy Text Block]2025Finite-Lived Intangible Asset, Expected Amortization, Year OneDepreciation and amortizationDepreciation, Amortization and Accretion, NetDepreciation, Amortization and Accretion, Net, TotalTitle and Position [Domain]Customer RelationshipsCustomer Relationships [Member]Allowance for credit lossDebt Securities, Available-for-Sale, Allowance for Credit LossDebt Securities, Available-for-Sale, Allowance for Credit Loss, TotalDebt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning BalanceDebt Securities, Available-for-Sale, Allowance for Credit Loss, Ending BalanceSoftware Development CostsSoftware Development Costs [Policy Text Block]Disclosure of accounting policy for software development costs, Less: Fair value of

restricted shares subject to service conditionsBusiness Combination Consideration Transferred Fair Value Of Restricted Shares Subject To Service ConditionsBusiness combination consideration transferred fair value of restricted shares subject to service conditions.Common stock: \$0.001 par value, 600,000 shares authorized at September 30, 2024 and 400,000 shares authorized at December 31, 2023; 390,841 and 83,364 shares issued at September 30, 2024 and December 31, 2023, respectively; 372,261 and 80,232 shares outstanding at September 30, 2024 and December 31, 2023, respectivelyCommon Stock, Value, IssuedRecognition of revenue from beginning or assumed deferred revenue balancesContract With Customer Revenue RecognizedAmount of revenues recognized in the period,Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized LossAvailable-for-sale securities heldSchedule of Future Expected Amortization Expense of Acquired Intangible Assets, NetSchedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]Cash and cash equivalentsCash and Cash Equivalents, Fair Value DisclosureFair Value, Assets Measured on Recurring Basis [Table Text Block]Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value HierarchyLossBusiness Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, ActualPresent value of future minimum lease paymentsPresent value of future minimum lease paymentsOperating Lease, LiabilityRevenue receive minimum guaranteed royaltyRevenue Receive Minimum Guaranteed RoyaltyRevenue receive minimum guaranteed royalty.Measurement Frequency [Axis]Measurement Frequency [Axis]Accrued LiabilitiesSchedule of Accrued Liabilities [Table Text Block]Commitments and contingencies (Note 8)Commitments and ContingenciesRevenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]Weighted-average shares outstanding during the period, dilutedShares used in computing net loss per share attributable to common stockholders, diluted (in shares)Weighted Average Number of Shares Outstanding, DilutedWeighted Average Number of Shares Outstanding, Diluted, TotalConvertible notes, non-currentConvertible Debt, NoncurrentSchedule of Business Segment InformationSchedule of Segment Reporting Information, by Segment [Table Text Block]Accounts receivable, netAccounts Receivable, after Allowance for Credit Loss, CurrentAccounts Receivable, after Allowance for Credit Loss, Current, TotalRenewal termLessee, Operating Lease, Renewal TermTotalLessee, Operating Lease, Liability, to be PaidIncrease (Decrease) in InventoriesIncrease (Decrease) in Inventories, TotalInventoryCMLS Holdings II LLCCLMS Holdings II LLC [Member]Cmls holdings ii llc.Product and service revenueProduct And Service [Member]Product And ServiceEntity Small BusinessEntity Small BusinessSegment Reporting Information [Line Items]Segment Reporting Information [Line Items]Additional interest rateDebt Instrument, Basis Spread on Variable RateNumerator:Numerator AbstractNumerator AbstractU.S. treasury securitiesUS Treasury Securities [Member]Total fair value of net assets acquiredBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, NetIssuance of restricted stock, net of shares withheld for taxes, and other (in shares)Stock Issued During Period, Shares, Restricted Stock Award, Net of ForfeituresStock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, TotalOther receivablesAccounts and Other Receivables, Net, CurrentAccumulated depreciation expensesResearch And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation ExpensesResearch And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation ExpensesCumulative amounts applied against depreciation expense for assets placed in serviceCumulative amounts applied against depreciation expense for assets placed in serviceService revenueService [Member]Accretion of discount on short-term investments, netAccretion (Amortization) of Discounts and Premiums, InvestmentsFinancing activitiesNet Cash Provided by (Used in) Financing Activities [Abstract]Beginning balance (in dollars per share)Ending balance (in dollars per share)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceRSUs, PSUs, stock options, restricted shares and ESPP sharesIncremental Common Shares Attributable to Dilutive Effect of Share-Based Payment ArrangementsAcquired intangible assets, netIntangible Assets, Net (Excluding Goodwill)Intangible Assets, Net (Excluding Goodwill), TotalMeasurement Frequency [Domain]Measurement Frequency [Domain]Change in fair value of warrant liabilitiesChange In Fair Value Of Warrant Liabilities, Recurring BasisChange in fair value of warrant liabilities, recurring basisChange in fair value of warrant liabilitiesRemained outstanding sharesRedeemable preferred stock, shares outstanding (in shares)Temporary Equity, Shares OutstandingWork-in-processInventory, Work in Process, GrossOther comprehensive income (loss), net of taxOther comprehensive income (loss), net of taxOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to ParentSignificant Unobservable Inputs (Level 3)Fair Value, Inputs, Level 3 [Member]Fair Value, Level 3 InputsWeighted average remaining lease termOperating Lease, Weighted Average Remaining Lease TermCost of collaboration and other revenueCost Of Collaboration And Other Revenue [Member]Cost of collaboration and other revenue,ConsumablesConsumables [Member]Consumables [Member]Inventory CurrentInventory CurrentAccounts payableAccounts Payable, CurrentAccounts Payable, Current, TotalRepayment of term loan and convertible notesRepayment of term loan and convertible notesRepayments of Long-Term Lines of CreditAccrued liabilitiesIncrease (Decrease) in Accrued Liabilities, TotalShort-term lease costShort-Term Lease, Cost XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended	
	Sep. 30, 2024	Nov. 01, 2024
Cover [Abstract]		
Document Type	10-Q	
Document Quarterly Report	true	
Document Period End Date	Sep. 30, 2024	
Document Transition Report	false	
Entity File Number	001-34180	
Entity Registrant Name	STANDARD BIOTOOLS INC.	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	77-0513190	
Entity Address, Address Line One	2 Tower Place	
Entity Address, Address Line Two	Suite 2000	
Entity Address, City or Town	South San Francisco	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	94080	
City Area Code	650	
Local Phone Number	266-6000	
Title of 12(b) Security	Common Stock, \$0.001 par value per share	
Trading Symbol	LAB	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding (in shares)		372,258,798
Amendment Flag	false	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q3	
Entity Central Index Key	0001162194	
Current Fiscal Year End Date	--12-31	

XML 10 R2.htm IDEA: XBRL DOCUMENT

Condensed		
Consolidated Balance		
Sheets - USD (\$)	Sep. 30, 2024	Dec. 31, 2023
\$ in Thousands		
Current assets:		
Cash and cash equivalents	\$ 210,647	\$ 51,704
Short-term investments	155,683	63,191
Accounts receivable, net	35,317	19,660
Inventories, net	42,644	20,533
Prepaid expenses and other current assets	9,316	3,127
Total current assets	453,607	158,215
Inventory, non-current	17,949	0
Royalty receivable, non-current	3,388	0
Property and equipment, net	41,982	24,187
Operating lease right-of-use asset, net	30,264	30,663
Other non-current assets	4,640	2,285
Acquired intangible assets, net	23,367	1,400
Goodwill	106,342	106,317
Total assets	681,539	323,067
Current liabilities:		
Accounts payable	10,926	9,236
Accrued liabilities	31,686	21,019
Operating lease liabilities, current	6,122	4,323
Deferred revenue, current	13,436	11,607
Deferred grant income, current	3,532	3,612
Term loan, current	0	5,000
Convertible notes, current	54,913	54,530
Total current liabilities	120,615	109,327
Convertible notes, non-current	299	569
Term loan, non-current	0	3,414
Deferred tax liability	841	841
Operating lease liabilities, non-current	28,140	30,374
Deferred revenue, non-current	32,682	3,520
Deferred grant income, non-current	8,119	10,755
Other non-current liabilities	1,510	1,065

Total liabilities	192,206	159,865
Commitments and contingencies (Note 8)		
Mezzanine equity:		
Redeemable preferred stock: \$0.001 par value; zero and 256 shares authorized and issued and outstanding at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and \$255,559 at September 30, 2024 and December 31, 2023, respectively	0	311,253
Stockholders' equity (deficit):		
Preferred stock: \$0.001 par value, 10,000 and 9,744 shares authorized at September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023	0	0
Common stock: \$0.001 par value, 600,000 shares authorized at September 30, 2024 and 400,000 shares authorized at December 31, 2023; 390,841 and 83,364 shares issued at September 30, 2024 and December 31, 2023, respectively; 372,261 and 80,232 shares outstanding at September 30, 2024 and December 31, 2023, respectively	390	83
Additional paid-in capital	1,688,398	860,816
Accumulated other comprehensive loss	(1,409)	(2,221)
Accumulated deficit	(1,151,579)	(1,000,752)
Treasury stock at cost: 18,580 and 3,132 shares at September 30, 2024 and December 31, 2023, respectively	(46,467)	(5,977)
Total stockholders' equity (deficit)	489,333	(148,051)
Total liabilities, mezzanine equity and stockholders' equity (deficit)	\$ 681,539	\$ 323,067

XML 11 R3.htm
IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets	Sep. 30, 2024 Dec. 31, 2023	
(Parenthetical) - USD (\$)		
\$ in Thousands		

Statement of Financial Position [Abstract]		
Redeemable preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Redeemable preferred stock, shares authorized (in shares)	0	256,000
Redeemable preferred stock, shares issued (in shares)	0	256,000
Redeemable preferred stock, shares outstanding (in shares)	0	256,000
Redeemable preferred stock, aggregate liquidation preference	\$ 0	\$ 255,559
Preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	9,744,000
Preferred stock, shares issued (in shares)	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Common stock, shares authorized (in shares)	600,000,000	400,000,000
Equity consideration transferred in connection with merger includes shares of common stock issued	390,841,000	83,364,000
Common stock, shares outstanding (in shares)	372,261,000	80,232,000
Treasury stock (in shares)	18,580,000	3,132,000

XML 12 R4.htm
IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD (\$)	3 Months Ended		9 Months Ended	
shares in Thousands, \$ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Revenue:				
Total revenue	\$ 44,969	\$ 25,367	\$ 127,714	\$ 78,152
Cost of revenue:				
Total cost of revenue	21,708	14,213	65,357	41,059
Gross profit	23,261	11,154	62,357	37,093
Operating expenses:				
Research and development	13,156	6,370	48,358	19,039
Selling, general and administrative	34,403	22,292	119,020	66,187
Restructuring and related charges	2,341	1,998	12,374	5,415
Transaction-related expenses	5,079	1,666	25,024	1,666
Total operating expenses	54,979	32,326	204,776	92,307
Loss from operations	(31,718)	(21,172)	(142,419)	(55,214)
Bargain purchase gain	0	0	25,213	0
Interest income, net	3,941	340	13,559	656
Other income (expense), net	957	(115)	(865)	292
Loss before income taxes	(26,820)	(20,947)	(104,512)	(54,266)
Income tax expense	(118)	(50)	(301)	(614)
Net loss	(26,938)	(20,997)	(104,813)	(54,880)
Induced conversion of redeemable preferred stock	0	0	(46,014)	0
Net loss attributable to common stockholders	\$ (26,938)	\$ (20,997)	\$ (150,827)	\$ (54,880)
Net loss per share, basic (in dollars per share)	\$ (0.07)	\$ (0.27)	\$ (0.44)	\$ (0.69)
Net loss per share, diluted (in dollars per share)	\$ (0.07)	\$ (0.27)	\$ (0.44)	\$ (0.69)
Shares used in computing net loss per share attributable to common stockholders, basic (in shares)	371,538	79,152	346,093	78,967
Shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	371,538	79,152	346,093	78,967

Product revenue				
Revenue:				
Total revenue	\$ 19,593	\$ 18,711	\$ 65,348	\$ 57,814
Cost of revenue:				
Total cost of revenue	8,159	11,403	33,142	33,276
Service revenue				
Revenue:				
Total revenue	24,438	6,566	59,518	19,268
Cost of revenue:				
Total cost of revenue	13,536	2,810	32,115	7,783
Collaboration and other revenue				
Revenue:				
Total revenue	938	\$ 90	2,848	\$ 1,070
Cost of revenue:				
Total cost of revenue	\$ 13		\$ 100	

XML 13 R5.htm
IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD (\$)	3 Months Ended		9 Months Ended	
\$ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Statement of Comprehensive Income [Abstract]				
Net Income (Loss)	\$ (26,938)	\$ (20,997)	\$ (104,813)	\$ (54,880)
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustment	(304)	(403)	540	(560)
Net change in unrealized gain on investments	395	5	272	507
Other comprehensive income (loss), net of tax	91	(398)	812	(53)
Comprehensive loss	\$ (26,847)	\$ (21,395)	\$ (104,001)	\$ (54,933)

XML 14 R6.htm
IDEA: XBRL DOCUMENT

Condensed

Consolidated Statements of Stockholders' Equity (Deficit) - USD (\$) \$ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accum. Other Comp. Loss	Accum. Deficit	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2022		79,904,000				
Beginning balance at Dec. 31, 2022	\$ (81,467)	\$ 80	\$ 847,008	\$ (1,896)	\$ (926,096)	\$ (563)
Treasury stock, beginning balance (in shares) at Dec. 31, 2022						(422,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)		420,000				
Issuance of restricted stock, net of shares withheld for taxes, and other	(93)		(93)			
Stock-based compensation expense	3,148		3,148			
Repurchase of common stock (in shares)						(1,250,000)
Repurchase of common stock	(2,466)					\$ (2,466)
Net Income (Loss)	(16,843)				(16,843)	
Other comprehensive income (loss), net of tax	568			568		
Ending balance (in shares) at Mar. 31, 2023		80,324,000				
Ending balance at Mar. 31, 2023	(97,153)	\$ 80	850,063	(1,328)	(942,939)	\$ (3,029)
Treasury stock, ending balance (in shares) at Mar. 31, 2023						(1,672,000)
Beginning balance (in shares) at Dec. 31, 2022		79,904,000				
Beginning balance at Dec. 31, 2022	\$ (81,467)	\$ 80	847,008	(1,896)	(926,096)	\$ (563)
Treasury stock, beginning balance (in shares) at Dec. 31, 2022						(422,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Repurchase of common stock (in shares)	(2,634,594)					
Net Income (Loss)	\$ (54,880)					
Other comprehensive income (loss), net of tax	(53)					
Ending balance (in shares) at Sep. 30, 2023		82,527,000				
Ending balance at Sep. 30, 2023	(131,720)	\$ 82	856,926	(1,949)	(980,976)	\$ (5,803)
Treasury stock, ending balance (in shares) at Sep. 30, 2023						(3,057,000)
Beginning balance (in shares) at Mar. 31, 2023		80,324,000				
Beginning balance at Mar. 31, 2023	(97,153)	\$ 80	850,063	(1,328)	(942,939)	\$ (3,029)
Treasury stock, beginning balance (in shares) at Mar. 31, 2023						(1,672,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)		1,410,000				
Issuance of restricted stock, net of shares withheld for taxes, and other	(36)	\$ 1	(37)			
Issuance of common stock under ESPP (in shares)		268,000				
Issuance of common stock under ESPP	326		326			
Stock-based compensation expense	3,114		3,114			
Repurchase of common stock (in shares)						(1,209,000)
Repurchase of common stock	(2,375)					\$ (2,375)
Net Income (Loss)	(17,040)				(17,040)	
Other comprehensive income (loss), net of tax	(223)			(223)		
Ending balance (in shares) at Jun. 30, 2023		82,002,000				
Ending balance at Jun. 30, 2023	(113,387)	\$ 81	853,466	(1,551)	(959,979)	\$ (5,404)
Treasury stock, ending balance (in shares) at Jun. 30, 2023						(2,881,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)		482,000				
Issuance of restricted stock, net of shares withheld for taxes, and other	(11)	\$ 1	(12)			
Exercise of stock options (in shares)		43				
Exercise of stock options	86		86			
Stock-based compensation expense	\$ 3,386		3,386			
Repurchase of common stock (in shares)	(175,910)					(176,000)
Repurchase of common stock	\$ (399)					\$ (399)
Net Income (Loss)	(20,997)				(20,997)	
Other comprehensive income (loss), net of tax	(398)			(398)		
Ending balance (in shares) at Sep. 30, 2023		82,527,000				
Ending balance at Sep. 30, 2023	\$ (131,720)	\$ 82	856,926	(1,949)	(980,976)	\$ (5,803)
Treasury stock, ending balance (in shares) at Sep. 30, 2023						(3,057,000)
Beginning balance (in shares) at Dec. 31, 2023		80,232,000	83,364,000			
Beginning balance at Dec. 31, 2023	\$ (148,051)	\$ 83	860,816	(2,221)	(1,000,752)	\$ (5,977)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023		(3,132,000)				(3,132,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Conversion of redeemable preferred stock (shares)		92,931,000				
Conversion of redeemable preferred stock	\$ 311,253	\$ 93	357,174		(46,014)	
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)		1,733,000				
Issuance of restricted stock, net of shares withheld for taxes, and other	(18)	\$ 2	(20)			
Exercise of stock options (in shares)		47,000				
Exercise of stock options	72		72			
Stock-based compensation expense	11,611		11,611			
Repurchase of common stock (in shares)						(4,119,000)
Repurchase of common stock	(11,051)					\$ (11,051)
Common stock relinquished in litigation settlement	1,009		1,009			
Merger consideration (in shares)	[1]	209,577,000				
Merger consideration	[1] 444,219	\$ 209	444,010			
Net Income (Loss)	(32,157)				(32,157)	
Other comprehensive income (loss), net of tax	429			429		
Ending balance (in shares) at Mar. 31, 2024		387,652,000				
Ending balance at Mar. 31, 2024	\$ 577,316	\$ 387	1,674,672	(1,792)	(1,078,923)	\$ (17,028)
Treasury stock, ending balance (in shares) at Mar. 31, 2024						(7,251,000)
Beginning balance (in shares) at Dec. 31, 2023		80,232,000	83,364,000			
Beginning balance at Dec. 31, 2023	\$ (148,051)	\$ 83	860,816	(2,221)	(1,000,752)	\$ (5,977)
Treasury stock, beginning balance (in shares) at Dec. 31, 2023		(3,132,000)				(3,132,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Exercise of stock options (in shares)	573					
Repurchase of common stock (in shares)	(15,448,533)					
Net Income (Loss)	\$ (104,813)					
Other comprehensive income (loss), net of tax	\$ 812					
Ending balance (in shares) at Sep. 30, 2024		372,261,000	390,841,000			
Ending balance at Sep. 30, 2024	\$ 489,333	\$ 390	1,688,398	(1,409)	(1,151,579)	\$ (46,467)
Treasury stock, ending balance (in shares) at Sep. 30, 2024		(18,580,000)				(18,580,000)
Beginning balance (in shares) at Mar. 31, 2024		387,652,000				
Beginning balance at Mar. 31, 2024	\$ 577,316	\$ 387	1,674,672	(1,792)	(1,078,923)	\$ (17,028)
Treasury stock, beginning balance (in shares) at Mar. 31, 2024						(7,251,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Issuance of restricted stock, net of shares withheld for taxes, and other (in		1,384,000				

shares)							
Issuance of restricted stock, net of shares withheld for taxes, and other	(326)	\$ 1	(327)				
Issuance of common stock under ESPP (in shares)		202,000					
Issuance of common stock under ESPP	425		425				
Exercise of stock options (in shares)		465,000					
Exercise of stock options	981	\$ 1	980				
Stock-based compensation expense	6,730		6,730				
Repurchase of common stock (in shares)						(11,329,000)	
Repurchase of common stock	(29,439)					\$ (29,439)	
Net Income (Loss)	(45,718)					(45,718)	
Other comprehensive income (loss), net of tax	292			292			
Ending balance (in shares) at Jun. 30, 2024		389,703,000					
Ending balance at Jun. 30, 2024	510,261	\$ 389	1,682,480	(1,500)		(1,124,641)	\$ (46,467)
Treasury stock, ending balance (in shares) at Jun. 30, 2024							(18,580,000)
Increase (Decrease) in Stockholders' Equity (Roll Forward)							
Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)		1,102,000					
Issuance of restricted stock, net of shares withheld for taxes, and other	(70)	\$ 1	(71)				
Exercise of stock options (in shares)		36					
Exercise of stock options	68		68				
Stock-based compensation expense	5,921		5,921				
Net Income (Loss)	(26,938)					(26,938)	
Other comprehensive income (loss), net of tax	\$ 91			91			
Ending balance (in shares) at Sep. 30, 2024		372,261,000	390,841,000				
Ending balance at Sep. 30, 2024	\$ 489,333	\$ 390	\$ 1,688,398	\$ (1,409)		\$ (1,151,579)	\$ (46,467)
Treasury stock, ending balance (in shares) at Sep. 30, 2024	(18,580,000)						(18,580,000)

[1] Merger consideration included 26,367 shares of common stock that were issued to a related party

XML 15 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
(Deficit)			
(Parenthetical) - shares			
Merger consideration	390,841,000		83,364,000

Related Party

Merger consideration	26,367	26,367

XML 16 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD (\$)	9 Months Ended	
\$ in Thousands	Sep. 30, 2024	Sep. 30, 2023
Operating activities		
Net loss	\$ (104,813)	\$ (54,880)
Adjustments to reconcile net loss to net cash used in operating activities:		
Bargain purchase gain	(25,213)	0
Stock-based compensation expense	24,262	9,648
Amortization of acquired intangible assets	3,533	8,400
Depreciation and amortization	9,375	2,874
Accretion of discount on short-term investments, net	(6,303)	(321)
Non-cash lease expense	4,348	2,885
Provision for excess and obsolete inventory	1,991	963
Change in fair value of warrants	(474)	
Other non-cash items	1,111	611
Changes in assets and liabilities:		
Accounts receivable, net	2,272	677
Inventory	(14,910)	(3,258)
Prepaid expenses and other assets	(2,718)	749
Accounts payable	(12,887)	(484)
Accrued liabilities	3,450	5,448
Deferred revenue	(3,572)	218
Operating lease liabilities	(4,414)	(2,802)
Other liabilities	(4,433)	46
Net cash used in operating activities	(129,395)	(29,226)
Investing activities		
Cash and restricted cash acquired in Merger	280,033	
Purchases of short-term investments	(226,612)	(55,857)
Proceeds from sales and maturities of investments	289,000	91,964
Purchases of property and equipment	(4,973)	(2,753)
Net cash provided by investing activities	337,448	33,354
Financing activities		
Repayment of term loan and convertible notes	(8,192)	(833)
Payment of term loan fee	(545)	
Repurchase of common stock	(40,490)	(5,240)
Proceeds from ESPP stock issuance	425	326
Payments for taxes related to net share settlement of equity awards and other	(414)	(139)
Proceeds from exercise of stock options	1,120	80
Net cash used in financing activities	(48,096)	(5,806)
Effect of foreign exchange rate fluctuations on cash and cash equivalents	(518)	(196)
Net increase in cash, cash equivalents and restricted cash	159,439	(1,874)
Cash, cash equivalents and restricted cash at beginning of period	52,499	82,324
Cash, cash equivalents and restricted cash at end of period	211,938	80,450
Supplemental disclosures of cash flow information		
Equity consideration transferred in connection with Merger	[1] 444,219	
Cash paid for interest	1,644	2,171
Cash paid for income taxes, net of refunds	407	629
Non-cash right-of-use assets and lease liabilities	183	226
Asset retirement obligations	\$ 777	\$ 739

[1] Equity consideration transferred in connection with the Merger included 26,367 shares of common stock that were issued to a related party. See Note 17, *Related Parties*

XML 17 R9.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Parenthetical) - shares	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Equity consideration transferred in connection with merger includes shares of common stock issued	390,841,000		83,364,000
Related Party			
Equity consideration transferred in connection with merger includes shares of common stock issued	26,367		26,367

Pay vs Performance Disclosure - USD (\$) \$ in Thousands	3 Months Ended			9 Months Ended				
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023

Pay vs Performance Disclosure

Net Income (Loss)	\$ (26,938)	\$ (45,718)	\$ (32,157)	\$ (20,997)	\$ (17,040)	\$ (16,843)	\$ (104,813)	\$ (54,880)

Insider Trading Arrangements	3 Months Ended Sep. 30, 2024

Trading Arrangements, by Individual

Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended Sep. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

1. Basis of Presentation and Summary of Significant Accounting Policies

Description of the Business

Standard BioTools Inc. ("Standard BioTools" or the "Company") is a Delaware corporation headquartered in South San Francisco, California. The Company has an established portfolio of essential technologies that assist biomedical researchers develop medicines faster and better. The Company has created high resolution instruments designed to provide reliable and repeatable insights in health and disease, through the use of proprietary mass cytometry and microfluidics technologies, which are useful in proteomics and genomics, to help transform scientific discoveries into better patient outcomes. Additionally, the Company has an integrated proteomics platform ("SomaScan® Platform"), capable of robust, high throughput proteomics analysis with broad proteome coverage, low limits of detection, and high reproducibility.

The Company works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding financial reporting. All intercompany transactions and balances have been eliminated in consolidation. These interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying financial statements contain all adjustments of a normal and recurring nature, necessary for a fair statement of the Company's financial position as of September 30, 2024, results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Certain prior period amounts have been reclassified to conform to the current period presentation.

Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 ("2023 Financial Statements") included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 1, 2024.

Interim results are not necessarily indicative of the results to be expected for the full year ending December 31, 2024.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.

Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.

Restructuring and Related Charges

Restructuring and related charges include employee separation costs, contract termination costs, and other costs associated with implementing restructuring plans. Employee separation costs principally consist of one-time termination benefits and contractual

termination benefits for severance, other termination benefit costs, and stock-based compensation expense for the acceleration of equity awards.

The Company records restructuring charges based on whether the termination benefits are provided under an ongoing benefit arrangement or under a one-time benefit arrangement. The Company accounts for ongoing benefit arrangements, such as those documented by employment agreements, in accordance with ASC 712, *Compensation - Nonretirement Postemployment Benefits* ("ASC 712"). Under ASC 712, liabilities for post-employment benefits are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC 420, *Exit or Disposal Cost Obligations*. One-time termination benefits expenses are recorded at the date the entity notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

- Level 1 - Quoted prices in active markets for identical assets or liabilities.
- Level 2 - Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
- Level 3 - Unobservable inputs that reflect the Company's own assumptions incorporated into valuation techniques. These valuations require significant judgment.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. When there is more than one input at different levels within the hierarchy, the fair value is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assessment of the significance of a particular input to the fair value measurement in its entirety requires substantial judgment and consideration of factors specific to the asset or liability. Level 3 inputs are inherently difficult to estimate. Changes to these inputs can have significant impact on fair value measurements.

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting in accordance with ASC 805, *Business Combinations* ("ASC 805"). Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. When the fair value of net assets acquired and liabilities assumed exceeds the purchase price, the Company records a gain on bargain purchase in earnings in the period of acquisition. Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Transaction costs, including legal, accounting, and integration expenses, are expensed as incurred and are included in operating expenses in the Company's condensed consolidated statements of operations.

Software Development Costs

Internal-Use Software

The Company capitalizes certain internal and external costs related to the acquisition and development of internal-use software or cloud computing arrangements during the application development stages of projects. The costs incurred for development of software intended for internal use and cloud computing arrangements are capitalized in accordance with authoritative accounting guidance. These costs are included in property and equipment, net of accumulated depreciation and amortization in the condensed consolidated balance sheets.

When the software is ready for its intended use, the Company amortizes these costs using the straight-line method over the estimated useful life of the asset, typically three years, or, for cloud computing service arrangements, over the term of the hosting arrangement. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred.

Software Developed for Sale

The costs incurred for the development of computer software to be sold, leased, or otherwise marketed are capitalized in accordance with authoritative accounting guidance, when technological feasibility has been established. Technological feasibility generally occurs when all planning, design, coding and testing activities are completed that are necessary to establish that the product can be produced to meet its design specifications, including functions, features and technical performance requirements. The establishment of technological feasibility is an ongoing assessment of judgment by management with respect to certain external factors, including, but not limited to, anticipated future revenues, estimated economic life and changes in technology.

Capitalized software costs include direct labor and related expenses for software development for new products. Capitalized software costs are included in other long-term assets in the condensed consolidated balance sheets. Amortization of capitalized software development costs begins when the product is available for general release. Amortization is provided on a product-by-product basis using the straight-line method over periods of three years. Unamortized capitalized software development costs determined to be in excess of the net realizable value of the product are expensed immediately. Capitalized software costs are subject to an ongoing assessment of recoverability based on anticipated future revenues and changes in software technologies at each balance sheet date. In the event of impairment, unamortized capitalized software costs are compared to the net realizable value of the related product and the carrying value of the related assets are written down to the net realizable value to the extent the unamortized capitalized costs exceed such value. The net realizable value is the estimated future gross revenues from the related product reduced by the estimated future costs of completing and disposing of such product, including the costs of providing related maintenance and customer support.

Revenue Recognition

Revenues are recognized when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the products or services (the "transaction price"). Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

The Company's contracts with customers typically include multiple distinct products and services, and the Company allocates transaction price to these performance obligations based on their relative

standalone selling prices ("SSP"). The SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. SSPs are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product's SSP using a cost plus a margin approach.

Payment terms may vary by customer, are based on customary commercial terms, and are generally less than one year. The Company does not adjust revenue for the effects of a significant financing component for contracts where the period between the transfer of the good or service and collection is one year or less. The Company expenses incremental costs to obtain a contract when incurred since the amortization period of the asset that would otherwise be recognized is one year or less.

Product Revenue

The Company generates product revenue from the sale of instruments and consumables, including Integrated Fluidic Circuits and reagents. The Company generally recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer's facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days.

Revenue from the sales of certain instruments that involve significant customization, which primarily includes sales of the SomaScan® equipment bundle, is recognized over time as the Company's performance creates an asset that the customer simultaneously controls (the instrument installation and customization occurs at the customer site). Revenue is recognized based on the progress made toward achieving the performance obligation utilizing an input method of costs incurred relative to total estimated costs.

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Services Revenue

The Company generates services revenue from the sale of lab services and field services. Lab services revenue is generated by performing the SomaScan® assay on customer samples to generate data on protein biomarkers. Lab services revenue is recognized at a point in time when the analysis data or report is delivered to the customer. SomaScan® services are sold at a fixed price per sample without any volume discounts, rebates, or refunds. The delivery of each assay data report is a separate performance obligation.

Field services revenue includes revenue from instrument service and support contracts. Revenue associated with these arrangements is recognized over time using a time-elapsed measure of progress, resulting in straight-line revenue recognition over the term of the agreement, which is generally one to four years. The Company measures progress using a time-elapsed measure of progress as the Company stands ready to provide service on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments collected in advance of service are reported on the Company's condensed consolidated balance sheets as deferred revenue.

Collaboration and Other Revenue

From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808, *Collaborative Arrangements*. With such collaborations, the Company determines if any obligations are an output of the Company's ordinary activities in exchange for consideration, and if so, the Company applies ASC 606, *Revenue from Contracts with Customers* ("ASC 606"), to such activities.

For other payments received from collaborative partners for other collaboration activities, which primarily include research and development activities, the Company analogizes to ASC 606. Revenue from such activities is recognized as the Company satisfies its obligations.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC 606, as the grant agreement is not with a customer. As there is no authoritative GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC 958, *Not-for-Profit Entities* by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Warrant Liabilities

In connection with the merger described in *Note 2, Business Combination*, the Company assumed warrant liabilities for the warrants issued in connection with the initial public offering CM Life Sciences II Inc ("CMLS II"), the predecessor company of SomaLogic, Inc. ("SomaLogic"). CMLS II issued 5,519,991 warrants (the "Public Warrants") to purchase shares of SomaLogic common stock, par value \$0.0001 per share ("SomaLogic Common Stock"), at \$11.50 per share. Simultaneously, with the consummation of the CMLS II initial public offering, CMLS II issued 5,013,333 warrants through a private placement (the "Private Placement Warrants", and together with the Public Warrants, the "Warrants") to purchase shares of SomaLogic Common Stock at \$11.50 per share. As of January 5, 2024 (the "Closing Date"), the Warrants converted into the right to receive, upon exercise of such Warrant, 1.11 shares of the Company's common stock for each share of SomaLogic Common Stock previously underlying the Warrants. The Public Warrants are no longer publicly traded and are now identical to the Private Placement Warrants.

The Warrants are classified as liabilities on the condensed consolidated balance sheet as of September 30, 2024 as these instruments are precluded from being indexed to the Company's own stock given that the terms allow for a settlement adjustment that does not meet the scope for the fixed-for-fixed exception in ASC 815, *Derivatives and Hedging*. Since the Warrants meet the definition of a derivative under ASC 815-40, the Company recorded these warrants as long-term liabilities at fair value as of the Closing Date, with subsequent changes in fair value recognized within other income (expense), net in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024.

Segment Reporting

The Company manages its business through two reportable operating segments: proteomics and genomics. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses performance. The Company's chief operating decision maker ("CODM"), its chief executive officer, assesses performance of operating segments and determines the allocation of resources based primarily on segment operating loss.

Recent Accounting Changes and Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued *ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures*, which requires disclosure of more detailed information about a reportable segment's expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company expects to adopt ASU 2023-07 in its Annual Report on Form 10-K for the year ended December 31, 2024, and expects to include additional segment disclosures as a result of adoption.

In December 2023, the FASB issued *ASU 2023-09, Improvements to Income Tax Disclosures*, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the impact of adoption on its income tax disclosures; however, adoption will not impact the Company's results of operations.

In November 2024, the FASB issued *ASU No. 2024-03, Disaggregation of Income Statement Expenses*. The new standard requires additional disclosure of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. *ASU 2024-03* is effective for fiscal years beginning after December 15, 2026, with early adoption permitted, and may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement disclosures.

[XML 21 R13.htm IDEA: XBRL DOCUMENT](#)

Business Combination
[Business Combinations \[Abstract\]](#)
[Business Combination](#)

**9 Months Ended
Sep. 30, 2024**

2. Business Combination

On the Closing Date, the Company completed the merger (the "Merger") with SomaLogic. As a result, SomaLogic and its subsidiaries became wholly owned subsidiaries of Standard BioTools. Upon completion of the Merger, each share of SomaLogic common stock, par value \$0.0001 per share (the "SomaLogic Common Stock"), was exchanged for 1.11 shares of the Company's common stock, par value \$0.001 per share. The fair value of the Company's common stock provided in exchange for SomaLogic Common Stock was approximately \$419.2 million.

Purchase consideration also included replacement of equity awards attributable to pre-combination services. The acquisition-date fair value of consideration transferred in the Merger totaled approximately \$444.2 million, comprising the following:

SomaLogic Common Stock issued and outstanding as of January 5, 2024	188,808
Fixed exchange ratio	1.11
Shares of Standard BioTools common stock issued to SomaLogic stockholders	209,577
Standard BioTools common stock price at close of Merger	\$ 2.00
Fair value of Standard BioTools common stock issued to SomaLogic stockholders	\$ 419,154
Fair value of Standard BioTools replacement equity awards attributable to pre-combination service	26,923
Less: Fair value of restricted shares subject to service conditions	(1,858)
Total consideration transferred	\$ 444,219

The Company accounted for the Merger as a business combination, using the acquisition method of accounting in accordance with ASC 805. The identifiable assets acquired and liabilities assumed of SomaLogic were recorded at their estimated fair values as of the acquisition date and consolidated with those of the Company. The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date:

Total consideration	\$ 444,219
Assets acquired	
Cash and cash equivalents	278,857
Short-term investments	148,305
Accounts receivable	16,430
Inventory	14,642
Prepaid expenses and other current assets	4,835
Property and equipment	22,455
Non-current inventory	12,208
Royalty receivable	4,669
Operating lease right-of-use assets	3,796
Other non-current assets	1,590
Intangible Assets	25,500
Total assets acquired	533,287

Liabilities assumed		
Accounts payable and accrued liabilities		20,660
Operating lease liabilities, current		1,601
Deferred revenue, current		3,522
Operating lease liabilities, non-current		2,193
Deferred revenue, non-current		30,667
Warrant liabilities		906
Other non-current liabilities		4,306
Total Liabilities		63,855
Total fair value of net assets acquired	\$	469,432
Gain on bargain purchase	\$	(25,213)

The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration transferred, resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, management reassessed the methods used in the acquisition accounting and verified that management had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. Management also reassessed the procedures used to measure amounts recognized at the Closing Date to ensure that the measurements reflected all consideration transferred based on available information as of the Closing Date. Management determined that the bargain purchase gain was primarily attributable to a rapid decline in the price of the Company's common stock in the days following the announcement of the Merger, which persisted through the close of the Merger. The bargain purchase gain is separately stated below income from operations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.

The preliminary fair value estimates of the net assets acquired are based upon preliminary calculations and valuations and are subject to change as the Company obtains additional information during the measurement period (up to one year from the Closing Date).

The identifiable intangible assets acquired consisted of developed technology, customer relationships, and tradename. The fair values of the developed technology and customer relationships were estimated using variations of the multi-period excess earnings method, which isolates the net earnings attributable to the asset being measured. The fair value of the SomaLogic trade name was estimated using the relief-from-royalty method, which determines the present value of license fees avoided by owning the trade name. The useful lives of acquired intangibles was estimated based on the contractual terms or period over which approximately 85% to 90% of the cumulative discounted cash flows would be realized, depending on the nature of the asset. The valuation of the intangible assets acquired in connection with the Merger, along with their estimated useful lives, is as follows (in thousands):

	Fair Value	Useful Life
Developed technology	\$ 20,000	9 years
Trade name	2,750	7 years
Customer relationships	2,750	11 years
Total fair value of intangible assets acquired	\$ 25,500	

As a result of the Merger, the Company incurred \$1.9 million of transaction bonuses recorded in selling, general, and administrative expenses on the condensed consolidated statement of operations. Additionally, the Company incurred \$12.3 million of acquisition-related transaction costs reflected in transaction and integration expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2024.

Unaudited Pro Forma Results

The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and SomaLogic, as if the companies were combined as of January 1, 2023.

The unaudited pro forma financial information for the nine months ended September 30, 2024 combines the Company's financial results for the nine months ended September 30, 2024 and the historical results of SomaLogic for the 5-day period ended on the Closing Date. The unaudited pro forma financial information for the three and nine months ended September 30, 2023 combines the historical results of the Company and SomaLogic for their respective three and nine-month periods ended September 30, 2023. The pro forma financial information for the three and nine months ended September 30, 2023 has been adjusted to include certain nonrecurring impacts associated with the Merger, including the bargain purchase gain and transaction costs. These same impacts have been eliminated from the pro forma financial information for the nine months ended September 30, 2024.

The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from the Merger, mainly including adjustments to reflect additional amortization expense from acquired intangible assets, adjustments to stock-based compensation expense, and additional depreciation expense from the acquired property and equipment. The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenue	\$ 44,969	\$ 47,415	\$ 128,359	\$ 141,047
Net loss	\$ (26,938)	\$ (41,204)	\$ (134,607)	\$ (109,000)

The results of SomaLogic have been consolidated with the Company's results since the Closing Date. For the period of January 6, 2024 to September 30, 2024, SomaLogic contributed revenue and loss of \$61.5 million and \$30.6 million, respectively. For the three months ended September 30, 2024, SomaLogic contributed revenue and loss of \$22.9 million and \$1.6 million, respectively.

[XML 22 R14.htm IDEA: XBRL DOCUMENT](#)

Revenue and Geographic Area
Revenue from Contract with Customer [Abstract]
Revenue and Geographic Area

9 Months Ended Sep. 30, 2024

3. Revenue and Geographic Area

Disaggregation of Revenue by Product Type and Geographic Area

The following tables present the Company's revenue for the three and nine months ended September 30, 2024 and 2023, respectively, based on product type and the geographic location of customers' facilities (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Product revenue:				
Instruments	\$ 5,586	\$ 9,002	\$ 19,959	\$ 26,512
Consumables	14,007	9,709	45,389	31,302
Total product revenue	19,593	18,711	65,348	57,814
Service revenue:				
Lab services	18,247	114	40,780	564
Field services	6,191	6,452	18,738	18,704
Total service revenue	24,438	6,566	59,518	19,268
Product and service revenue	44,031	25,277	124,866	77,082
Collaboration and other revenue	938	90	2,848	1,070
Total revenue	\$ 44,969	\$ 25,367	\$ 127,714	\$ 78,152

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Americas	\$ 23,751	\$ 10,865	\$ 68,241	\$ 32,975
Europe, Middle East and Africa (EMEA)	16,057	8,162	39,108	27,435
Asia-Pacific	5,161	6,340	20,365	17,742
Total revenue	\$ 44,969	\$ 25,367	\$ 127,714	\$ 78,152

Illumina Cambridge, Ltd.

In connection with the Merger, the Company assumed a multi-year arrangement with Illumina Cambridge, Ltd. ("Illumina"), originally entered into by SomaLogic and Illumina in December 2021 (the "Illumina Agreement"), to jointly develop and commercialize co-branded kits that will combine Illumina's Next Generation Sequencing ("NGS") technology with SomaScan® technology (the "Co-Branded Kits"). Pursuant to the Illumina Agreement, SomaLogic received a non-refundable upfront payment of \$30.0 million in January 2022. Subsequent to executing the Illumina Agreement, Illumina paid an additional \$0.5 million to purchase the equipment, supplies and training necessary to run the SomaScan® assay at their facilities, representing a modification to the Illumina Agreement. As of the Closing Date, the Company determined that the transaction price of the Illumina Agreement was \$30.5 million. Subsequent to commercialization of the Co-Branded Kits, the Company is entitled to receive \$124.5 million of minimum guaranteed royalties through the term of the Illumina Agreement. No royalties were included in the Illumina transaction price as probability of commercialization had not been achieved as of the Closing Date.

Subsequent to commercialization of the Co-Branded Kits, Illumina has the right to purchase SOMAmer reagents below SSP through the remaining term of the Illumina Agreement, which will continue for approximately 8 years following commercialization. Illumina's option to purchase SOMAmer reagents below SSP for this period represents a significant material right (the "Material Right"). As of the Closing Date, the Company allocated \$30.4 million of the Illumina transaction price to the Material Right, which will be recognized as revenue as Illumina purchases SOMAmer reagents post commercialization.

During the first quarter of 2024, the Company determined that commercialization of the Co-Branded Kits is probable due to the launch of an early-access program, and adjusted the transaction price to include \$127.9 million of royalties expected to be received from 2025 through 2032. The Company allocated \$0.4 million of the adjusted transaction price to satisfy performance obligations, and recognized that amount as revenue on a cumulative catch-up basis. The total transaction price of the Illumina Agreement as adjusted is \$158.4 million. Substantially all of the transaction price is allocated to the Material Right, which the Company expects to recognize as revenue over an 8-year period from 2025 through 2032.

NEC Corporation

Additionally, in connection with the Merger, the Company assumed a joint development and commercialization agreement (the "JDCA") with NEC Solution Innovators, Ltd. ("NEC"), originally entered into by SomaLogic and NEC in March 2020, to develop and commercialize SomaScan® services in Japan. The JDCA is within the scope of ASC 808 as both companies are active participants and are exposed to significant rewards and risks dependent on commercial failure or success, and is accounted for by analogy to ASC 606.

In connection with the Merger, the Company assumed certain contract liabilities and recorded \$1.8 million of deferred revenue as of the Closing Date. Under the JDCA, the Company was entitled to receive \$2.0 million in exchange for research and development services, which was received in April 2024. As of September 30, 2024, deferred revenue related to the JDCA was \$1.5 million, which is expected to be fully recognized by March 31, 2025.

New England Biolabs, Inc.

Also in connection with the Merger, the Company assumed a non-exclusive licensing agreement with New England Biolabs, Inc. ("NEB"), originally entered into by SomaLogic and NEB in September 2022 (the "License Agreement"), whereby the Company provides a license to use certain proprietary information and know-how relating to SomaLogic's aptamer technology. Under the License Agreement, the Company is guaranteed fixed minimum royalties of \$8.7 million to be received through September 2025. No revenue related to the guaranteed fixed minimum royalties will be recognized, as all revenue related to the receivable was recognized by SomaLogic prior to the Merger. Any revenue above the guaranteed fixed minimum royalties will be recognized in the period in which the subsequent sale or usage has occurred. As of September 30, 2024, royalties receivable related to this agreement were \$8.2 million, including a current and non-current portion of \$4.8 million and \$3.4 million, respectively.

Unfulfilled Performance Obligations

A summary of the change in deferred revenue is as follows (in thousands):

	NEC	Illumina	Other	Total
Deferred revenue at December 31, 2023	\$ -	\$ -	\$ 15,127	\$ 15,127
Deferred revenue assumed in connection with merger	1,773	30,418	1,998	34,189
Recognition of revenue from beginning or assumed deferred revenue balances	(1,247)	(406)	(10,899)	(12,552)
Revenue deferred during the period, net of revenue recognized	1,000	—	8,354	9,354
Deferred revenue at September 30, 2024	\$ 1,526	\$ 30,012	\$ 14,580	\$ 46,118

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of September 30, 2024 in the following periods (in thousands):

Fiscal Year	Expected Revenue ⁽¹⁾
2024 remainder of the year	\$ 4,321
2025	9,002
2026	3,678
Thereafter	1,790
Total	\$ 18,791

(1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above.

[XML 23 R15.htm IDEA: XBRL DOCUMENT](#)

[Goodwill and Acquired Intangible Assets, net](#)
[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)
[Goodwill and Acquired Intangible Assets, net](#)

9 Months Ended
Sep. 30, 2024

4. Goodwill and Acquired Intangible Assets, net

The changes in the carrying value of goodwill by segment are as follows (in thousands):

	Proteomics	Genomics	Total
Balance as of December 31, 2023	\$ 85,798	\$ 20,519	\$ 106,317
Foreign currency translation	27	(2)	25
Balance as of September 30, 2024	\$ 85,825	\$ 20,517	\$ 106,342

Acquired intangible assets, net consisted of the following (in thousands):

	September 30, 2024			December 31, 2023		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Developed technology	\$ 137,414	\$ (119,081)	\$ 18,333	\$ 117,354	\$ (115,954)	\$ 1,400
Trade name	2,750	(294)	2,456	—	—	—
Customer relationships	2,750	(172)	2,578	—	—	—
Acquired intangible assets, net	\$ 142,914	\$ (119,547)	\$ 23,367	\$ 117,354	\$ (115,954)	\$ 1,400

Total amortization expense of the Company's acquired intangible assets was \$0.7 million and \$2.8 million for the three months ended September 30, 2024 and 2023, respectively. Total amortization expense of the Company's acquired intangible assets was \$3.5 million and \$8.4 million for the nine months ended September 30, 2024 and 2023, respectively. There were no indicators of impairment of goodwill, long-lived assets or intangible assets during the nine months ended September 30, 2024.

As of September 30, 2024, future expected amortization expense of acquired intangible assets, net was as follows (in thousands):

Fiscal Period	
2024 remainder of the year	\$ 711
2025	2,844
2026	2,844
2027	2,844
2028	2,844
Thereafter	11,280
Total	\$ 23,367

[XML 24 R16.htm IDEA: XBRL DOCUMENT](#)

[Balance Sheet Details](#)
[Balance Sheet Related Disclosures \[Abstract\]](#)
[Balance Sheet Details](#)

9 Months Ended
Sep. 30, 2024

5. Balance Sheet Details

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Cash and cash equivalents	\$ 210,647	\$ 51,704
Restricted cash	1,291	795
Total cash, cash equivalents and restricted cash	\$ 211,938	\$ 52,499

Restricted cash of \$1.3 million and \$0.8 million is included in other non-current assets on the condensed consolidated balance sheets as of September 30, 2024, and December 31, 2023, respectively.

Accounts Receivable

Accounts receivable consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Trade receivables	\$ 35,337	\$ 19,972
Royalty receivable, current	435	—
Other receivables	173	—
Less: allowance for expected credit losses	(628)	(312)
Accounts receivable, net	\$ 35,317	\$ 19,660

Inventory

Inventory consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Raw materials	\$ 49,953	\$ 12,140
Work-in-process	1,558	282
Finished goods	9,082	8,111
Total inventory	60,593	20,533
Inventory, current	42,644	20,533
Inventory, non-current ⁽¹⁾	\$ 17,949	\$ —

(1) The value of inventory that is not expected to be used within 12 months of the balance sheet date is classified as non-current inventory on the condensed consolidated balance sheets.

The Company recorded charges for excess and obsolete inventory of \$0.1 million and \$0.4 million for the three months ended September 30, 2024 and 2023, respectively, and \$2.0 million and \$1.0 million for the nine months ended September 30, 2024 and 2023, respectively.

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

	September 30, 2024		December 31, 2023	
Laboratory and manufacturing equipment	\$	59,785	\$	35,563
Leasehold improvements		17,400		13,785
Computer equipment		7,845		6,232
Internal-use software		16,870		—
Office furniture and fixtures		3,482		1,762
Property and equipment, gross		105,382		57,342
Less accumulated depreciation and amortization		(69,623)		(35,489)
Construction-in-progress		6,223		2,334
Property and equipment, net	\$	41,982	\$	24,187

Depreciation and amortization expense was \$3.2 million and \$1.2 million for the three months ended September 30, 2024 and 2023, respectively. Depreciation and amortization expense was \$9.4 million and \$2.9 million for the nine months ended September 30, 2024 and 2023, respectively.

Accrued Liabilities

Accrued liabilities, which are included in current liabilities on the condensed consolidated balance sheets consisted of the following (in thousands):

	September 30, 2024		December 31, 2023	
Accrued compensation and related benefits	\$	14,390	\$	12,052
Loss contingency accruals		4,262		—
Accrued warranties		1,874		2,593
Accrued restructuring		2,541		825
Uninvoiced receipts		1,354		1,516
Other		7,265		4,033
Accrued liabilities	\$	31,686	\$	21,019

Refer to [Note 16](#) for additional information on restructuring.

Deferred Grant Income

In September 2020, the Company executed a contract with the National Institutes of Health ("NIH") under NIH's Rapid Acceleration of Diagnostics program to support the expansion of the Company's production capacity for its COVID-19 test products. Under the now-completed contract, the Company received \$34.0 million of funding from the NIH and used \$22.2 million on capital expenditures for its Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was \$0.9 million for each of the three months ended September 30, 2024 and 2023, and \$2.7 million for each of the nine months ended September 30, 2024 and 2023. Cumulative amounts applied against depreciation expense for these assets placed in service were \$10.5 million and \$7.8 million as of September 30, 2024 and December 31, 2023, respectively, and the carrying values of these assets were \$11.7 million and \$14.4 million as of these same dates, respectively.

The current portion of deferred grant income on the Company's condensed consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods.

[XML 25 R17.htm IDEA: XBRL DOCUMENT](#)

Debt

[Debt Disclosure](#)
[\[Abstract\]](#)
[Debt](#)

**9 Months Ended
Sep. 30, 2024**

6. Debt

Total carrying value of debt consists of the following (in thousands):

	September 30, 2024		December 31, 2023	
Convertible notes:				
2014 Notes	\$	299	\$	569
2019 Notes, current		54,913		54,530
Total convertible notes, net		55,212		55,099
Term loan, non-current		—		3,414
Term loan, current		—		5,000
Total debt	\$	55,212	\$	63,513

Convertible Notes

In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (the "2014 Notes"), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes beginning on February 6, 2029 at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. In March 2024, the Company repurchased \$0.3 million of the outstanding principal amount of the 2014 Notes.

In November 2019, the Company issued \$55.0 million aggregate principal amount of 2019 Senior Convertible Notes (the "2019 Notes" and together with the 2014 Notes, the "Convertible Notes"). Net proceeds from the 2019 Notes issuance of \$52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but \$1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25% per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company's common stock per \$1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately \$2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include conversion of the 2019 Notes in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company's option in whole but not in part into shares of the Company's common stock upon certain conditions if the volume-weighted average price of the Company's common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days.

Offering-related costs related to the Convertible Notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes.

The carrying values of the Convertible Notes approximate fair values as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. The Convertible Notes are not regularly traded and there is no

public market for the Convertible Notes. The estimated fair values for the Convertible Notes represent Level 3 valuations since the fair values for the Convertible Notes cannot be determined by using readily observable inputs or measures, such as market prices.

Term Loan Facility, net

On August 2, 2021, the Company amended its revolving credit facility to, amongst other things, provide for a new \$10.0 million term loan facility (the "Term Loan Facility"). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of \$7.9 million and a carrying value of \$8.4 million. The interest rate on the Term Loan Facility was the greater of 4.0% per annum or a floating per annum rate equal to the prime rate plus 0.75%. Interest on any outstanding term loan advances was due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance was due the earlier of the maturity date or the date the advance is repaid. Principal balances were required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility was July 1, 2025.

On March 4, 2024, the Company fully repaid all outstanding indebtedness owed pursuant to the Term Loan Facility and terminated the agreement.

[XML 26 R18.htm IDEA: XBRL DOCUMENT](#)

Leases

[Leases \[Abstract\]](#)
[Leases](#)

**9 Months Ended
Sep. 30, 2024**

7. Leases

In connection with the Merger, the Company assumed three leases for office and laboratory space, with lease terms of three to five years. One of the assumed leases expired on June 30, 2024 and has not been renewed. The remaining leases require monthly lease payments that may be subject to annual increases throughout the lease term. The remaining leases also include renewal options at the Company's election to renew or extend the leases for additional periods ranging from three to ten years.

Lease Costs

Lease costs for operating leases are recognized on a straight-line basis over the lease term. The total lease cost for the period, including the Company's historical leases and those assumed in connection with the Merger, was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Operating lease cost	\$ 2,386	\$ 1,994	\$ 7,484	\$ 6,005
Short-term lease cost	—	—	—	—
Variable lease cost	1,188	830	3,781	2,417
Less: Sublease income	(1,076)	(529)	(3,228)	(1,978)
Total lease cost	\$ 2,498	\$ 2,295	\$ 8,037	\$ 6,444

Lease Maturities

The table below reconciles the undiscounted lease payment maturities to the lease liabilities for the Company's operating leases:

	September 30, 2024
Remainder of 2024	\$ 2,419
2025	9,789
2026	8,800
2027	7,428
2028	7,362
Thereafter	10,225
Total	46,023

Less: amount of lease payments representing interest	(11,761)
Present value of future minimum lease payments	34,262
Less: current operating lease liabilities	(6,122)
Long-term operating lease liabilities	<u>\$ 28,140</u>

Supplemental Lease Information

Supplemental information related to the Company's operating leases was as follows:

	September 30, 2024
Weighted average remaining lease term	5.1
Weighted average discount rate	11.9%

[XML 27 R19.htm IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies

[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

**9 Months Ended
Sep. 30, 2024**

8. Commitments and Contingencies

Other Commitments

In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of September 30, 2024, the Company's open commitments totaled \$16.2 million.

In connection with the Illumina Agreement, SomaLogic, and now the Company, is required to engage with two contract manufacturing organizations in order to ensure manufacturing capacity. In 2023, SomaLogic contracted with Integrated DNA Technologies, Inc. ("IDT") to manufacture custom products. Under the contract manufacturing agreement with IDT, SomaLogic committed to minimum annual purchases of \$2.3 million, which obligation the Company subsumed in connection with the Merger. As the minimum contract term is three years, the total purchase commitment related to the Illumina Agreement is \$6.9 million. As of September 30, 2024, the Company had not yet began placing orders under the Illumina Agreement.

The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.

Legal Proceedings

From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. These include disputes and lawsuits related to intellectual property, mergers and acquisitions, licensing, contract law, tax, regulatory, distribution arrangements, employee relations and other matters. Periodically, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and a range of possible loss can be estimated, the Company accrues a liability for the estimated loss.

Stockholder Litigation

On December 12, 2023 two separate stockholder complaints were filed in the District of Delaware. The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. These complaints were voluntarily dismissed. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed business combination between SomaLogic and the Company, which was denied by the Court on January 4, 2024. An amended complaint was filed on June 20, 2024, containing primarily the same allegations, while removing some of the defendants. The remaining defendants filed a motion to dismiss on July 5, 2024, and served an opening brief on August 19, 2024. The Plaintiffs' opposition brief is due on November 1, 2024, and the defendants' reply brief is due on December 13, 2024. No date for oral argument has been set. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs' claim is successful, this type of litigation may result in significant costs and divert management's attention and resources, which could adversely affect the operation of our business.

Between October 24, 2023 and January 3, 2024, SomaLogic received 18 letters from purported stockholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement. The Company has resolved fee disputes with all but two stockholder's counsel.

In February 2024, the Company settled previously outstanding litigation with a former stockholder of SomaLogic, whereby the Company relinquished 422,048 shares of the Company's common stock that were subject to vesting conditions.

In May 2024, the Company settled previously outstanding litigation with former stockholders of SomaLogic for \$6.2 million consisting of the repurchase of approximately 1.84 million shares of the Company's common stock from the stockholders at the market price of \$2.40 per share, and a cash payment of \$1.8 million. The Company recognized a litigation loss of \$0.6 million during the nine months ended September 30, 2024.

On June 4, 2024, the Company received a demand pursuant to Section 220 of the Delaware General Corporation Law from a stockholder to inspect the Company's books and records relating to the prior conversion of the Company's Series B preferred stock. The Company has responded to the demand and has produced documents.

Additional lawsuits against us and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, we will not necessarily announce such additional filings.

In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, management currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based only on the best information available at the time. As additional information becomes available, the Company continues to reassess the potential liability related to pending claims and litigation and may revise estimates.

Other Contingencies

Following the Merger, the Company is responsible for SomaLogic's liabilities and obligations, including with respect to legal, financial, regulatory, and compliance matters. These liabilities and obligations will result in additional cost and expense by the Company and, if the Company has underestimated the amount of these costs and expenses or if the Company fails to satisfy any such liabilities or obligations, the Company may not realize the anticipated benefits of the Merger and there may be an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. Further, it is possible that there may be unknown, contingent or other liabilities, obligations or other problems that may arise in the future, the existence and/or magnitude of which the Company was previously unaware. Any such liabilities, obligations or other problems could have an adverse effect on the company's business, financial condition, results of operations or cash flows. With respect to these additional matters, the Company is not able to estimate the possible loss or range of losses that could be incurred.

[XML 28 R20.htm IDEA: XBRL DOCUMENT](#)

Fair Value of Financial Instruments

[Fair Value Disclosures \[Abstract\]](#)
[Fair Value of Financial Instruments](#)

**9 Months Ended
Sep. 30, 2024**

9. Fair Value of Financial Instruments

Fair Value of Financial Instruments

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of September 30, 2024 (in thousands):

	Total	Fair Value Measurements At Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash equivalents—money market funds	\$ 185,227	\$ 185,227	\$ —	\$ —
Short-term investments—U.S. treasury securities	155,683	—	155,683	—
Total assets measured at fair value	<u>\$ 340,910</u>	<u>\$ 185,227</u>	<u>\$ 155,683</u>	<u>\$ —</u>

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

	Total	Fair Value Measurements At Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash equivalents—money market funds	\$ 35,385	\$ 35,385	\$ —	\$ —
Short-term investments—U.S. treasury securities	63,191	—	63,191	—
Total assets measured at fair value	<u>\$ 98,576</u>	<u>\$ 35,385</u>	<u>\$ 63,191</u>	<u>\$ —</u>

There were no transfers within the hierarchy and no changes in the valuation techniques used during the nine months ended September 30, 2024.

The following table summarizes available-for-sale securities (in thousands):

As of September 30, 2024					
	Maturity (in years)	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value
Assets:					
Cash equivalents—money market funds		\$ 185,227	\$ —	\$ —	\$ 185,227
Short-term investments—U.S. treasury securities	1 or less	155,335	348	—	155,683
Total assets measured at fair value		<u>\$ 340,562</u>	<u>\$ 348</u>	<u>\$ —</u>	<u>\$ 340,910</u>
As of December 31, 2023					
	Maturity (in years)	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value
Assets:					
Cash equivalents—money market funds		\$ 35,385	\$ —	\$ —	\$ 35,385
Short-term investments—U.S. treasury securities	1 or less	63,169	22	—	63,191
Total assets measured at fair value		<u>\$ 98,554</u>	<u>\$ 22</u>	<u>\$ —</u>	<u>\$ 98,576</u>

As of September 30, 2024, none of the available-for-sale securities held have been in an unrealized loss position for greater than 12 months. The Company does not intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis. No allowance for credit losses was recorded.

Liabilities measured at fair value on a recurring basis

The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs we utilized to determine such fair value:

Fair value of warrant liabilities as of Closing Date	\$ 906
Change in fair value of warrant liabilities	(474)
Fair value of warrant liabilities as of September 30, 2024	<u>\$ 432</u>

Warrant liabilities

The Warrants were valued using Level 2 inputs as of the Closing Date as the Public Warrants were actively traded at that date. Therefore, the Company had directly observable prices for identical instruments as of the Closing Date. Following the Closing Date, and as of September 30, 2024, the Public Warrants were no longer publicly traded (see [Note 1](#)), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:

	September 30, 2024
Volatility	70.2 %
Risk-free rate	3.65 %
Warrant term	1.9

[XML 29 R21.htm IDEA: XBRL DOCUMENT](#)

Mezzanine Equity

[Equity \[Abstract\]](#)

[Mezzanine Equity](#)

**9 Months Ended
Sep. 30, 2024**

10. Mezzanine Equity

Series B Redeemable Preferred Stock

On March 18, 2024, the Company entered into an exchange agreement (the “Exchange Agreement”) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, “Casdin”), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, “Viking” and, collectively with Casdin, the “Investors”). Pursuant to the Exchange Agreement, the Investors exchanged (the “Exchange”) an aggregate of (i) 127,780 shares of Series B-1 Convertible Preferred Stock, par value \$0.001 per share (the “Series B-1 Preferred Stock”), and (ii) 127,779 shares of Series B-2 Convertible Preferred Stock, par value \$0.001 per share (the “Series B-2 Preferred Stock” and, together with the Series B-1 Preferred Stock, the “Series B Preferred Stock”), representing all of the outstanding shares of Series B Preferred Stock, for an aggregate of 92,930,553 shares of the Company’s common stock. The Exchange was completed on March 18, 2024. Following the closing of the Exchange, no shares of Series B Preferred Stock remained outstanding, and the Company had no amounts recorded in mezzanine equity.

On June 18, 2024, the Company filed a registration statement on Form S-3 (File No. 333-280321), which became effective on June 27, 2024, registering the resale of 105,116,628 shares of common stock, including the shares of common stock which were issued upon conversion of the Series B Preferred Stock in the Exchange.

The Exchange was considered to be an induced conversion of preferred stock as the Investors received a lower conversion price, and were issued more shares of common stock than provided under the original terms of the Series B Convertible Preferred Stock Purchase Agreement entered into with the Investors. The \$46.0 million difference between the fair value of the inducement and the carrying value of the Series B Preferred Stock was recognized to the Company’s accumulated deficit during the nine months ended September 30, 2024.

[XML 30 R22.htm IDEA: XBRL DOCUMENT](#)

**Stockholders’ Equity
(Deficit)**

[Equity \[Abstract\]](#)

[Stockholders’ Equity
\(Deficit\)](#)

**9 Months Ended
Sep. 30, 2024**

11. Stockholders’ Equity (Deficit)

2024 Stock Repurchase Program

On February 6, 2024, the Company’s board of directors authorized a share repurchase program (the “2024 Share Repurchase Program”) pursuant to which the Company may repurchase up to \$50.0 million of shares of its common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate the Company to acquire any specific number of shares. During the nine months ended September 30, 2024, the Company repurchased 13,603,617 shares of its common stock for an aggregate of \$36.1 million under the 2024 Share Repurchase Program.

Common Shares Reserved

As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

	Securities To Be Issued Upon Exercise Of Options	Securities To Be Issued Upon Release Of Restricted Stock	Number Of Remaining Securities Available For Future Issuance
2022 Inducement Equity Incentive Plan	7,320	898	454
2011 Equity Incentive Plan	7,929	12,781	23,584
2017 Inducement Award Plan	59	—	2
2017 Employee Stock Purchase Plan	—	—	1,379
SomaLogic Plans	24,920	757	—
Total common stock reserved for future issuance	<u>40,228</u>	<u>14,436</u>	<u>25,419</u>

[XML 31 R23.htm IDEA: XBRL DOCUMENT](#)

**Stock-based
Compensation**

[Share-Based Payment
Arrangement
\[Abstract\]](#)

[Stock-based
Compensation](#)

**9 Months Ended
Sep. 30, 2024**

12. Stock-based Compensation

The Company has various stock-based compensation plans, which are more fully described in our 2023 Financial Statements.

Upon completion of the Merger, the Company assumed SomaLogic’s stock incentive plans. In addition, all outstanding options to purchase SomaLogic Common Stock and all restricted stock units in respect of shares of SomaLogic Common Stock that were outstanding immediately prior to the completion of the Merger were automatically adjusted by the exchange ratio of 1.11 and converted into an equity award of the same type covering shares of the Company’s common stock, on the same terms and conditions (including any continuing vesting requirements), under the applicable Company plan and award agreement in effect immediately prior to the completion of the Merger.

During the three and nine months ended September 30, 2024, the Company recorded nil and \$6.2 million, respectively, of stock-based compensation expense due to the acceleration of awards for certain SomaLogic executives in connection with the Merger.

Restricted Stock Units

	Number of Units (in thousands)	Weighted-Average Grant Date Fair Value per Unit
Balance at December 31, 2023	6,933	\$ 2.46
Assumed through acquisition	2,970	2.00
Granted	10,263	2.21
Vested	(4,002)	2.34
Forfeited	(1,728)	2.30
Balance at September 30, 2024	<u>14,436</u>	<u>\$ 2.24</u>

As of September 30, 2024, unrecognized stock-based compensation expense related to outstanding unvested restricted stock units (“RSUs”) under the Company’s equity incentive plans was \$29.8 million. The Company expects to recognize the expense over a weighted-average period of 3.1 years.

Stock Options

	Number of Options (in thousands)	Weighted-Average Exercise Price per Option	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value ⁽¹⁾ (in thousands)
Balance at December 31, 2023	9,294	\$ 3.62	8.5	
Assumed through acquisition	28,184	4.80		
Granted	6,697	2.50		
Exercised	(573)	2.12		
Cancelled	(3,374)	3.92		
Balance at September 30, 2024	40,228	\$ 4.26	6.2	\$ 196
Vested at September 30, 2024	28,006	\$ 4.76	5.1	\$ 93
Unvested options at September 30, 2024	12,222	\$ 3.10	8.7	\$ 103

(1) Aggregate intrinsic value as of September 30, 2024 was calculated as the difference between the closing price per share of the Company's common stock on The Nasdaq Global Select Market on September 30, 2024, which was \$1.93, and the exercise price of the options, multiplied by the number of in-the-money options.

The total intrinsic value of options exercised during the three and nine months ended September 30, 2024 was nil and \$0.6 million, respectively. The total intrinsic value of options exercised during each of the three and nine months ended September 30, 2023 was immaterial. As of September 30, 2024, the aggregate unrecognized compensation costs related to outstanding unvested options under the Company's equity incentive plans were \$22.5 million. The Company expects to recognize those costs over a weighted-average period of 2.6 years.

Performance-based Awards

In July 2023, the Company granted performance-based restricted stock units ("PSUs") to certain executive officers that vest based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive's continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service period, as it is deemed probable the Company will satisfy the performance measures. Certain of the specified revenue and EBITDA targets were met and the PSUs vested and were released from restriction in April 2024.

Activity under the performance-based awards was as follows:

	Number of Units (in thousands)	Weighted-Average Grant Date Fair Value per Unit
Balance at December 31, 2023	309	\$ 2.42
PSU granted	100	2.25
Performance adjustment	(26)	2.42
PSU released	(383)	2.38
Balance at September 30, 2024	—	\$ —

Stock-based Compensation Expense

Stock-based compensation expense is reported in the Company's condensed consolidated statement of operations as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Cost of product revenue	\$ 136	\$ 151	\$ 441	\$ 524
Cost of services revenue	228	37	455	122
Cost of collaboration and other revenue	—	—	1	2
Research and development expense	724	459	4,480	1,241
Selling, general and administrative expense	4,833	2,739	18,885	7,759
Total stock-based compensation expense	\$ 5,921	\$ 3,386	\$ 24,262	\$ 9,648

[XML 32 R24.htm IDEA: XBRL DOCUMENT](#)

Net Loss Per Share

[Earnings Per Share](#)
[\[Abstract\]](#)

[Net Loss Per Share](#)

9 Months Ended
Sep. 30, 2024

13. Net Loss Per Share

The Company's basic and diluted net loss per share is calculated by dividing net loss less any redemption or induced conversion on the Series B Preferred Stock by the weighted-average number of shares of common stock outstanding for the period. RSUs, PSUs, options to purchase the Company's common stock, restricted stock, Employee Stock Purchase Plan ("ESPP") shares pending issuance, Series B Preferred Stock and Convertible Notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented.

As described above, on March 18, 2024, the Company consummated the Exchange in which all outstanding Series B Preferred Stock were exchanged for an aggregate of 92,930,553 shares of the Company's common stock. This transaction was determined to be an induced conversion due a reduction in the original conversion price. The excess of the fair value of the common stock issued over the fair value of shares issuable under original terms represents an in-substance distribution to the Investors, and was included as a reduction to the numerator in calculating earnings per share.

Computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands, except per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Net loss from operations	\$ (26,938)	\$ (20,997)	\$ (104,813)	\$ (54,880)
Induced conversion of redeemable preferred stock	—	—	(46,014)	—
Net loss attributable to common stockholders	\$ (26,938)	\$ (20,997)	\$ (150,827)	\$ (54,880)
Denominator:				
Weighted-average shares outstanding during the period	371,538	79,152	346,093	78,967
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.07)	\$ (0.27)	\$ (0.44)	\$ (0.69)

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

	Nine Months Ended September 30,	
	2024	2023
RSUs, PSUs, stock options, restricted shares and ESPP shares	54,664	16,872
Series B Preferred Stock	—	75,164
2019 Notes ⁽¹⁾	18,966	18,966
2014 Notes	5	10
Warrants	11,692	—
Total	85,327	111,012

(1) The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes prior to the Company's exercise of the Issuer's Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company's common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of the Company's common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to [Note 6](#) for additional information on the 2019 Notes.

The 175,910 shares of the Company's common stock that were repurchased during the three months ended September 30, 2023, and the 15,448,533 and 2,634,594 shares repurchased during the nine months ended September 30, 2024 and 2023, respectively, have also been excluded from the Company's net loss per share and diluted net loss per share calculations.

[XML 33 R25.htm IDEA: XBRL DOCUMENT](#)

Income Taxes

[Income Tax Disclosure](#)
[\[Abstract\]](#)
[Income Taxes](#)

14. Income Taxes

The Company's quarterly provision for income taxes is based on an estimated annual effective income tax rate. The quarterly provision for income taxes also includes discrete items, such as changes in valuation allowances or adjustments upon finalization of tax returns as well as infrequently occurring items, if any, such as the effects of changes in tax laws or rates, in the interim period in which they occur.

The Company recorded income tax expense of \$0.1 million in each of the three months ended September 30, 2024 and 2023, and income tax expense of \$0.3 million and \$0.6 million in the nine months ended September 30, 2024 and 2023, respectively. The decrease in the Company's tax provision reflects the effect of the Company's foreign operations, which reported lower pre-tax income in the first nine months of 2024 compared to the same period in 2023.

The Company's effective tax rates for both periods differ from the 21% U.S. Federal statutory tax rate primarily due to valuation allowances recorded against deferred tax assets on domestic losses and the tax rate differences between the United States and foreign countries. The Company maintains a valuation allowance against its U.S. deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.

[XML 34 R26.htm IDEA: XBRL DOCUMENT](#)

Segment Reporting

[Segment Reporting](#)
[\[Abstract\]](#)

9 Months Ended
Sep. 30, 2024

15. Segment Reporting

The Company operates in two reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.

During the first quarter of 2024, the CODM began using operating income to measure the operating performance of the segments. The Company determines each segment’s operating income by subtracting direct expenses, including cost of revenues, research and development expense, and sales and marketing expense, from revenues. Amortization, depreciation, and restructuring charges are included in each segment’s operating expenses. Corporate costs, including general and administrative expenses for functions shared by both operating segments such as executive management, human resources, and finance, along with interest and taxes, and transaction and integration expenses are excluded from each segment’s results, which is consistent with how our CODM evaluates segment performance.

The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies as the Company as a whole.

The Company’s business segment information was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenue:				
Proteomics	\$ 34,565	\$ 14,008	\$ 98,954	\$ 47,296
Genomics	10,404	11,359	28,760	30,856
Total revenue	<u>\$ 44,969</u>	<u>\$ 25,367</u>	<u>\$ 127,714</u>	<u>\$ 78,152</u>
Income (loss) from operations:				
Proteomics	\$ (10,210)	\$ (7,106)	\$ (48,485)	\$ (16,297)
Genomics	1,925	301	2,681	41
Corporate expenses	(16,013)	(10,703)	(59,217)	(31,877)
Restructuring and related charges	(2,341)	(1,998)	(12,374)	(5,415)
Transaction and integration expenses	(5,079)	(1,666)	(25,024)	(1,666)
Total loss from operations	<u>\$ (31,718)</u>	<u>\$ (21,172)</u>	<u>\$ (142,419)</u>	<u>\$ (55,214)</u>
Depreciation & amortization:				
Proteomics	1,940	3,420	\$ 7,193	\$ 9,932
Genomics	378	373	1,125	703
Corporate	1,540	193	4,590	639
Total depreciation & amortization	<u>\$ 3,858</u>	<u>\$ 3,986</u>	<u>\$ 12,908</u>	<u>\$ 11,274</u>

[XML 35 R27.htm IDEA: XBRL DOCUMENT](#)

Restructuring and Related Charges
[Restructuring and Related Activities](#)
[\[Abstract\]](#)
[Restructuring and Related Charges](#)

9 Months Ended
Sep. 30, 2024

16. Restructuring and Related Charges

In April 2024, following a strategic review of the combined business after completion of the Merger, the Company announced a workforce reduction plan (the "Strategic Reorganization") to reduce operating costs and focus on long-term growth opportunities. Under this Strategic Reorganization, the Company reduced its workforce by approximately 10% of its total workforce, with the majority of these employees separating by July 2024. Employees who were impacted by the Strategic Reorganization were eligible to receive severance and other benefits contingent upon an impacted employee's execution of a separation agreement. Certain impacted employees were covered by employment agreements or existing severance plans that provided termination benefits.

One-time termination benefits were recorded pursuant to ASC 420, *Exit or Disposal Cost Obligations*, while termination benefits under ongoing benefit arrangement were recorded pursuant to ASC 712, *Compensation - Nonretirement Postemployment Benefits*.

The Company recognized restructuring charges of approximately \$2.3 million and \$12.4 million during the three and nine months ended September 30, 2024, respectively, related to a restructuring plan implemented after the Merger to integrate operations and realize synergies.

For the three and nine months ended September 30, 2023, the Company recognized restructuring and related charges of \$2.0 million and \$5.4 million, respectively, related to a restructuring plan implemented in 2022 to improve the Company's operational efficiency.

The Company also continues to recognize ongoing restructuring charges from its restructuring plans for facility-related costs, which will continue through the termination of the facility leases.

The following table summarizes the change in the Company’s restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

	Severance and other employee-related benefits ⁽¹⁾	Facility Costs	Other ⁽²⁾	Total
Balance at December 31, 2023	\$ 825	\$ —	\$ —	\$ 825
Restructuring and related charges	9,522	2,108	744	12,374
Cash payments	(7,806)	(2,108)	(744)	(10,658)
Balance at September 30, 2024	<u>\$ 2,541</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,541</u>

- (1)

Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.
- (2)

Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets.

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Restructuring:				
Proteomics	\$ —	\$ 213	\$ —	\$ 691
Genomics	—	70	—	629
Corporate expenses	2,341	1,715	12,374	4,095
Total restructuring and related charges	<u>\$ 2,341</u>	<u>\$ 1,998</u>	<u>\$ 12,374</u>	<u>\$ 5,415</u>

[XML 36 R28.htm IDEA: XBRL DOCUMENT](#)

Related Parties
[Related Party Transactions](#)
[\[Abstract\]](#)
[Related Parties](#)

9 Months Ended
Sep. 30, 2024

17. Related Parties

In connection with the Merger, Eli Casdin, a member of the Company’s board of directors and the Company’s principal stockholder, and the former principal stockholder of SomaLogic, was issued 3,807 shares of common stock, 3,807 RSUs vesting in equal annual installments beginning on March 17, 2024, and 144,088 options in exchange for his shares of SomaLogic Common Stock and SomaLogic equity awards. In addition, Casdin Partners Master Fund, L.P. and Casdin Private Growth Equity Fund, L.P. received 11,246,525 and 2,744,219 shares of common stock, respectively, in exchange for their shares of SomaLogic Common Stock, which shares may be deemed to be indirectly beneficially owned by Mr. Casdin. Additionally, in connection with the Merger, Warrants held by CMLS Holdings II LLC ("CMLS LLC") converted into the right to receive, upon exercise of such warrants, 4,824,802 shares of the Company’s common stock and CMLS LLC also received 7,548,000 shares of common stock in exchange for its SomaLogic Common Stock, all of which may be deemed to be indirectly beneficially owned by Mr. Casdin. In total, Mr. Casdin may be deemed to have beneficially received 26,515,248 shares of common stock in the Merger, including the shares of the Company's common stock issuable upon the vesting of RSUs and exercise of options and warrants.

On March 18, 2024, Casdin and its affiliates entered into the Exchange Agreement with the Company whereby all of the outstanding shares of the Series B-1 Preferred Stock held by Casdin and its affiliates were converted into an aggregate of 46,465,458 shares of the Company's common stock.

[XML 37 R29.htm IDEA: XBRL DOCUMENT](#)

Basis of Presentation and Summary of Significant Accounting Policies (Policies)
[Accounting Policies](#)
[\[Abstract\]](#)
[Basis of Presentation](#)

9 Months Ended
Sep. 30, 2024

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding financial reporting. All intercompany transactions and balances have been eliminated in consolidation. These interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying financial statements contain all adjustments of a normal and recurring nature, necessary for a fair statement of the Company's financial position as of September 30, 2024, results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Certain prior period amounts have been reclassified to conform to the current period presentation.

Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 ("2023 Financial Statements") included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 1, 2024.

Interim results are not necessarily indicative of the results to be expected for the full year ending December 31, 2024.

Use of Estimates

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.

Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.

Restructuring and Related Charges

Restructuring and Related Charges

Restructuring and related charges include employee separation costs, contract termination costs, and other costs associated with implementing restructuring plans. Employee separation costs principally consist of one-time termination benefits and contractual termination benefits for severance, other termination benefit costs, and stock-based compensation expense for the acceleration of equity awards.

The Company records restructuring charges based on whether the termination benefits are provided under an ongoing benefit arrangement or under a one-time benefit arrangement. The Company accounts for ongoing benefit arrangements, such as those documented by employment agreements, in accordance with ASC 712, *Compensation - Nonretirement Postemployment Benefits* ("ASC 712"). Under ASC 712, liabilities for post-employment benefits are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC 420, *Exit or Disposal Cost Obligations*. One-time termination benefits expenses are recorded at the date the entity notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

- Level 1 - Quoted prices in active markets for identical assets or liabilities.
- Level 2 - Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.
- Level 3 - Unobservable inputs that reflect the Company's own assumptions incorporated into valuation techniques. These valuations require significant judgment.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. When there is more than one input at different levels within the hierarchy, the fair value is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assessment of the significance of a particular input to the fair value measurement in its entirety requires substantial judgment and consideration of factors specific to the asset or liability. Level 3 inputs are inherently difficult to estimate. Changes to these inputs can have significant impact on fair value measurements.

Business Combinations

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting in accordance with ASC 805, *Business Combinations* ("ASC 805"). Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. When the fair value of net assets acquired and liabilities assumed exceeds the purchase price, the Company records a gain on bargain purchase in earnings in the period of acquisition. Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Transaction costs, including legal, accounting, and integration expenses, are expensed as incurred and are included in operating expenses in the Company's condensed consolidated statements of operations.

Software Development Costs

Internal-Use Software

The Company capitalizes certain internal and external costs related to the acquisition and development of internal-use software or cloud computing arrangements during the application development stages of projects. The costs incurred for development of software intended for internal use and cloud computing arrangements are capitalized in accordance with authoritative accounting guidance. These costs are included in property and equipment, net of accumulated depreciation and amortization in the condensed consolidated balance sheets.

When the software is ready for its intended use, the Company amortizes these costs using the straight-line method over the estimated useful life of the asset, typically three years, or, for cloud computing service arrangements, over the term of the hosting arrangement. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred.

Software Developed for Sale

The costs incurred for the development of computer software to be sold, leased, or otherwise marketed are capitalized in accordance with authoritative accounting guidance, when technological feasibility has been established. Technological feasibility generally occurs when all planning, design, coding and testing activities are completed that are necessary to establish that the product can be produced to meet its design specifications, including functions, features and technical performance requirements. The establishment of technological feasibility is an ongoing assessment of judgment by management with respect to certain external factors, including, but not limited to, anticipated future revenues, estimated economic life and changes in technology.

Capitalized software costs include direct labor and related expenses for software development for new products. Capitalized software costs are included in other long-term assets in the condensed consolidated balance sheets. Amortization of capitalized software development costs begins when the product is available for general release. Amortization is provided on a product-by-product basis using the straight-line method over periods of three years. Unamortized capitalized software development costs determined to be in excess of the net realizable value of the product are expensed immediately. Capitalized software costs are subject to an ongoing assessment of recoverability based on anticipated future revenues and changes in software technologies at each balance sheet date. In the event of impairment, unamortized capitalized software costs are compared to the net realizable value of the related product and the carrying value of the related assets are written down to the net realizable value to the extent the unamortized capitalized costs exceed such value. The net realizable value is the estimated future gross revenues from the related product reduced by the estimated future costs of completing and disposing of such product, including the costs of providing related maintenance and customer support.

Revenue Recognition

Revenue Recognition

Revenues are recognized when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the products or services (the "transaction price"). Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

The Company's contracts with customers typically include multiple distinct products and services, and the Company allocates transaction price to these performance obligations based on their relative standalone selling prices ("SSP"). The SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. SSPs are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product's SSP using a cost plus a margin approach.

Payment terms may vary by customer, are based on customary commercial terms, and are generally less than one year. The Company does not adjust revenue for the effects of a significant financing component for contracts where the period between the transfer of the good or service and collection is one year or less. The Company expenses incremental costs to obtain a contract when incurred since the amortization period of the asset that would otherwise be recognized is one year or less.

Product Revenue

The Company generates product revenue from the sale of instruments and consumables, including Integrated Fluidic Circuits and reagents. The Company generally recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer's facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in 30 to 60 days.

Revenue from the sales of certain instruments that involve significant customization, which primarily includes sales of the SomaScan® equipment bundle, is recognized over time as the Company's performance creates an asset that the customer simultaneously controls (the instrument installation and customization occurs at the customer site). Revenue is recognized based on the progress made toward achieving the performance obligation utilizing an input method of costs incurred relative to total estimated costs.

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Services Revenue

The Company generates services revenue from the sale of lab services and field services. Lab services revenue is generated by performing the SomaScan® assay on customer samples to generate data on protein biomarkers. Lab services revenue is recognized at a point in time when the analysis data or report is delivered to the customer. SomaScan® services are sold at a fixed price per sample without any volume discounts, rebates, or refunds. The delivery of each assay data report is a separate performance obligation.

Field services revenue includes revenue from instrument service and support contracts. Revenue associated with these arrangements is recognized over time using a time-elapsed measure of progress, resulting in straight-line revenue recognition over the term of the agreement, which is generally one to four years. The Company measures progress using a time-elapsed measure of progress as the Company stands ready to provide service on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments collected in advance of service are reported on the Company's condensed consolidated balance sheets as deferred revenue.

Collaboration and Other Revenue

From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808, *Collaborative Arrangements*. With such collaborations, the Company determines if any obligations are an output of the Company's ordinary activities in exchange for consideration, and if so, the Company applies ASC 606, *Revenue from Contracts with Customers* ("ASC 606"), to such activities.

For other payments received from collaborative partners for other collaboration activities, which primarily include research and development activities, the Company analogizes to ASC 606. Revenue from such activities is recognized as the Company satisfies its obligations.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC 606, as the grant agreement is not with a customer. As there is no authoritative GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC 958, *Not-for-Profit Entities* by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Warrant Liabilities

Warrant Liabilities

In connection with the merger described in *Note 2, Business Combination*, the Company assumed warrant liabilities for the warrants issued in connection with the initial public offering CM Life Sciences II Inc ("CMLS II"), the predecessor company of SomaLogic, Inc. ("SomaLogic"). CMLS II issued 5,519,991 warrants (the "Public Warrants") to purchase shares of SomaLogic common stock, par value \$0.0001 per share ("SomaLogic Common Stock"), at \$11.50 per share. Simultaneously, with the consummation of the CMLS II initial public offering, CMLS II issued 5,013,333 warrants through a private placement (the "Private Placement Warrants", and together with the Public Warrants, the "Warrants") to purchase shares of SomaLogic Common Stock at \$11.50 per share. As of January 5, 2024 (the "Closing Date"), the Warrants converted into the right to receive, upon exercise of such Warrant, 1.11 shares of the Company's common stock for each share of SomaLogic Common Stock previously underlying the Warrants. The Public Warrants are no longer publicly traded and are now identical to the Private Placement Warrants.

The Warrants are classified as liabilities on the condensed consolidated balance sheet as of September 30, 2024 as these instruments are precluded from being indexed to the Company's own stock given that the terms allow for a settlement adjustment that does not meet the scope for the fixed-for-fixed exception in ASC 815, *Derivatives and Hedging*. Since the Warrants meet the definition of a derivative under ASC 815-40, the Company recorded these warrants as long-term liabilities at fair value as of the Closing Date, with subsequent changes in fair value recognized within other income (expense), net in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024.

Segment Reporting

Segment Reporting

The Company manages its business through two reportable operating segments: proteomics and genomics. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses performance. The Company's chief operating decision maker ("CODM"), its chief executive officer, assesses performance of operating segments and determines the allocation of resources based primarily on segment operating loss.

Recent Accounting Changes and Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued *ASU 2023-07, Segment Reporting - Improvements to Reportable Segment Disclosures*, which requires disclosure of more detailed information about a reportable segment's expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company expects to adopt *ASU 2023-07* in its Annual Report on Form 10-K for the year ended December 31, 2024, and expects to include additional segment disclosures as a result of adoption.

In December 2023, the FASB issued *ASU 2023-09, Improvements to Income Tax Disclosures*, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the impact of adoption on its income tax disclosures; however, adoption will not impact the Company's results of operations.

In November 2024, the FASB issued *ASU No. 2024-03, Disaggregation of Income Statement Expenses*. The new standard requires additional disclosure of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories. *ASU 2024-03* is effective for fiscal years beginning after December 15, 2026, with early adoption permitted, and may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement disclosures.

XML 38 R30.htm IDEA: XBRL DOCUMENT

Business Combination (Tables)

9 Months Ended Sep. 30, 2024

Business Combinations [Abstract] Schedule of the Acquisition-date Fair Value of Consideration Transferred

The acquisition-date fair value of consideration transferred in the Merger totaled approximately \$444.2 million, comprising the following:

SomaLogic Common Stock issued and outstanding as of January 5, 2024	188,808
Fixed exchange ratio	1.11
Shares of Standard BioTools common stock issued to SomaLogic stockholders	209,577
Standard BioTools common stock price at close of Merger	\$ 2.00
Fair value of Standard BioTools common stock issued to SomaLogic stockholders	\$ 419,154
Fair value of Standard BioTools replacement equity awards attributable to pre-combination service	26,923
Less: Fair value of restricted shares subject to service conditions	(1,858)
Total consideration transferred	\$ 444,219

Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed

The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date:	
Total consideration	\$ 444,219
Assets acquired	
Cash and cash equivalents	278,857
Short-term investments	148,305
Accounts receivable	16,430
Inventory	14,642
Prepaid expenses and other current assets	4,835
Property and equipment	22,455
Non-current inventory	12,208
Royalty receivable	4,669
Operating lease right-of-use assets	3,796
Other non-current assets	1,590
Intangible Assets	25,500
Total assets acquired	533,287
Liabilities assumed	
Accounts payable and accrued liabilities	20,660
Operating lease liabilities, current	1,601
Deferred revenue, current	3,522
Operating lease liabilities, non-current	2,193
Deferred revenue, non-current	30,667
Warrant liabilities	906
Other non-current liabilities	4,306
Total Liabilities	63,855
Total fair value of net assets acquired	\$ 469,432
Gain on bargain purchase	\$ (25,213)

Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger

The valuation of the intangible assets acquired in connection with the Merger, along with their estimated useful lives, is as follows (in thousands):	
	Fair Value Useful Life
Developed technology	\$ 20,000 9 years
Trade name	2,750 7 years
Customer relationships	2,750 11 years
Total fair value of intangible assets acquired	\$ 25,500

Schedule of Unaudited Pro Forma Financial Information

The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023.	
	Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023
Revenue	\$ 44,969 \$ 47,415 \$ 128,359 \$ 141,047
Net loss	\$ (26,938) \$ (41,204) \$ (134,607) \$ (109,000)

XML 39 R31.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area (Tables)

9 Months Ended Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following tables present the Company's revenue for the three and nine months ended September 30, 2024 and 2023, respectively, based on product type and the geographic location of customers' facilities (in thousands):	
Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023	
Product revenue:	
Instruments	\$ 5,586 \$ 9,002 \$ 19,959 \$ 26,512
Consumables	14,007 9,709 45,389 31,302
Total product revenue	19,593 18,711 65,348 57,814
Service revenue:	
Lab services	18,247 114 40,780 564
Field services	6,191 6,452 18,738 18,704
Total service revenue	24,438 6,566 59,518 19,268
Product and service revenue	44,031 25,277 124,866 77,082
Collaboration and other revenue	938 90 2,848 1,070
Total revenue	\$ 44,969 \$ 25,367 \$ 127,714 \$ 78,152
Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023	
Americas	\$ 23,751 \$ 10,865 \$ 68,241 \$ 32,975
Europe, Middle East and Africa (EMEA)	16,057 8,162 39,108 27,435
Asia-Pacific	5,161 6,340 20,365 17,742
Total revenue	\$ 44,969 \$ 25,367 \$ 127,714 \$ 78,152

Schedule of Expected Timing of Revenue

The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of September 30, 2024 in the following periods (in

Recognition

thousands):

Fiscal Year		Expected Revenue ⁽¹⁾
2024 remainder of the year		\$ 4,321
2025		9,002
2026		3,678
Thereafter		1,790
Total		\$ 18,791

(1) Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

Summary of the Change in Deferred Revenue

A summary of the change in deferred revenue is as follows (in thousands):

	NEC	Illumina	Other	Total
Deferred revenue at December 31, 2023	\$ -	\$ -	\$ 15,127	\$ 15,127
Deferred revenue assumed in connection with merger	1,773	30,418	1,998	34,189
Recognition of revenue from beginning or assumed deferred revenue balances	(1,247)	(406)	(10,899)	(12,552)
Revenue deferred during the period, net of revenue recognized	1,000	—	8,354	9,354
Deferred revenue at September 30, 2024	\$ 1,526	\$ 30,012	\$ 14,580	\$ 46,118

XML 40 R32.htm IDEA: XBRL DOCUMENT

Goodwill and Acquired Intangible Assets, net (Tables)

9 Months Ended Sep. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract] Schedule of the Changes in the Carrying Value of Goodwill by Segment

The changes in the carrying value of goodwill by segment are as follows (in thousands):

	Proteomics	Genomics	Total
Balance as of December 31, 2023	\$ 85,798	\$ 20,519	\$ 106,317
Foreign currency translation	27	(2)	25
Balance as of September 30, 2024	\$ 85,825	\$ 20,517	\$ 106,342

Schedule of Acquired Intangible Assets

Acquired intangible assets, net consisted of the following (in thousands):

	September 30, 2024			December 31, 2023		
	Gross Carrying Amount	Accumulated Amortization	Net	Gross Carrying Amount	Accumulated Amortization	Net
Developed technology	\$ 137,414	\$ (119,081)	\$ 18,333	\$ 117,354	\$ (115,954)	\$ 1,400
Trade name	2,750	(294)	2,456	—	—	—
Customer relationships	2,750	(172)	2,578	—	—	—
Acquired intangible assets, net	\$ 142,914	\$ (119,547)	\$ 23,367	\$ 117,354	\$ (115,954)	\$ 1,400

Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net

As of September 30, 2024, future expected amortization expense of acquired intangible assets, net was as follows (in thousands):

Fiscal Period		
2024 remainder of the year		\$ 711
2025		2,844
2026		2,844
2027		2,844
2028		2,844
Thereafter		11,280
Total		\$ 23,367

XML 41 R33.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables)

9 Months Ended Sep. 30, 2024

Balance Sheet Related Disclosures [Abstract] Schedule of Cash and Cash Equivalents

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Cash and cash equivalents	\$ 210,647	\$ 51,704
Restricted cash	1,291	795
Total cash, cash equivalents and restricted cash	\$ 211,938	\$ 52,499

Schedule of Accounts Receivable

Accounts receivable consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Trade receivables	\$ 35,337	\$ 19,972
Royalty receivable, current	435	—
Other receivables	173	—
Less: allowance for expected credit losses	(628)	(312)
Accounts receivable, net	\$ 35,317	\$ 19,660

Schedule of Inventories

Inventory consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Raw materials	\$ 49,953	\$ 12,140
Work-in-process	1,558	282
Finished goods	9,082	8,111
Total inventory	60,593	20,533
Inventory, current	42,644	20,533
Inventory, non-current ⁽¹⁾	\$ 17,949	\$ —

(1) The value of inventory that is not expected to be used within 12 months of the balance sheet date is classified as non-current inventory on the condensed consolidated balance sheets.

Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Laboratory and manufacturing equipment	\$ 59,785	\$ 35,563
Leasehold improvements	17,400	13,785
Computer equipment	7,845	6,232
Internal-use software	16,870	—
Office furniture and fixtures	3,482	1,762
Property and equipment, gross	105,382	57,342
Less accumulated depreciation and amortization	(69,623)	(35,489)
Construction-in-progress	6,223	2,334
Property and equipment, net	\$ 41,982	\$ 24,187

Accrued Liabilities

Accrued liabilities, which are included in current liabilities on the condensed consolidated balance sheets consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Accrued compensation and related benefits	\$ 14,390	\$ 12,052
Loss contingency accruals	4,262	—
Accrued warranties	1,874	2,593
Accrued restructuring	2,541	825
Uninvoiced receipts	1,354	1,516
Other	7,265	4,033
Accrued liabilities	\$ 31,686	\$ 21,019

XML 42 R34.htm IDEA: XBRL DOCUMENT

Debt (Tables)

9 Months Ended Sep. 30, 2024

Debt Disclosure [Abstract]

[Schedule of Total Carrying Value of Debt](#)

Total carrying value of debt consists of the following (in thousands):

	September 30, 2024		December 31, 2023	
Convertible notes:				
2014 Notes	\$	299	\$	569
2019 Notes, current		54,913		54,530
Total convertible notes, net		55,212		55,099
Term loan, non-current		—		3,414
Term loan, current		—		5,000
Total debt	\$	55,212	\$	63,513

XML 43 R35.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended
Sep. 30, 2024

[Leases \[Abstract\]](#)
[Schedule of Lease Cost](#)

The total lease cost for the period, including the Company's historical leases and those assumed in connection with the Merger, was as follows (in thousands):

	Three Months Ended September 30, 2024		September 30, 2023		Nine Months Ended September 30, 2024		September 30, 2023	
Operating lease cost	\$	2,386	\$	1,994	\$	7,484	\$	6,005
Short-term lease cost		—		—		—		—
Variable lease cost		1,188		830		3,781		2,417
Less: Sublease income		(1,076)		(529)		(3,228)		(1,978)
Total lease cost	\$	2,498	\$	2,295	\$	8,037	\$	6,444

The table below reconciles the undiscounted lease payment maturities to the lease liabilities for the Company's operating leases:

	September 30, 2024	
Remainder of 2024	\$	2,419
2025		9,789
2026		8,800
2027		7,428
2028		7,362
Thereafter		10,225
Total		46,023
Less: amount of lease payments representing interest		(11,761)
Present value of future minimum lease payments		34,262
Less: current operating lease liabilities		(6,122)
Long-term operating lease liabilities	\$	28,140

[Schedule of Supplemental Lease Information](#)

Supplemental information related to the Company's operating leases was as follows:

	September 30, 2024	
Weighted average remaining lease term		5.1
Weighted average discount rate		11.9%

XML 44 R36.htm IDEA: XBRL DOCUMENT

Fair Value of
Financial Instruments
(Tables)

9 Months Ended
Sep. 30, 2024

[Fair Value Disclosures \[Abstract\]](#)

[Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy](#)

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of September 30, 2024 (in thousands):

	Total	Fair Value Measurements At Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash equivalents—money market funds	\$ 185,227	\$ 185,227	\$ —	\$ —
Short-term investments—U.S. treasury securities	155,683	—	155,683	—
Total assets measured at fair value	\$ 340,910	\$ 185,227	\$ 155,683	\$ —

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

	Total	Fair Value Measurements At Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash equivalents—money market funds	\$ 35,385	\$ 35,385	\$ —	\$ —
Short-term investments—U.S. treasury securities	63,191	—	63,191	—
Total assets measured at fair value	\$ 98,576	\$ 35,385	\$ 63,191	\$ —

[Schedule of Available-for-Sale Securities Reconciliation](#)

The following table summarizes available-for-sale securities (in thousands):

	Maturity (in years)	Amortized Cost	As of September 30, 2024		
			Unrealized Gains	Unrealized Losses	Estimated Fair Value
Assets:					
Cash equivalents—money market funds		\$ 185,227	\$ —	\$ —	\$ 185,227
Short-term investments—U.S. treasury securities	1 or less	155,335	348	—	155,683
Total assets measured at fair value		\$ 340,562	\$ 348	\$ —	\$ 340,910

	Maturity (in years)	Amortized Cost	As of December 31, 2023		
			Unrealized Gains	Unrealized Losses	Estimated Fair Value
Assets:					
Cash equivalents—money market funds		\$ 35,385	\$ —	\$ —	\$ 35,385
Short-term investments—U.S. treasury securities	1 or less	63,169	22	—	63,191
Total assets measured at fair value		\$ 98,554	\$ 22	\$ —	\$ 98,576

[Schedule of Liabilities Measured at Fair Value on a Recurring Basis](#)

The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs we utilized to determine such fair value:

Fair value of warrant liabilities as of Closing Date	\$	906
Change in fair value of warrant liabilities		(474)
Fair value of warrant liabilities as of September 30, 2024	\$	432

[Schedule of Warrants Liabilities](#)

Following the Closing Date, and as of September 30, 2024, the Public Warrants were no longer publicly traded (see [Note 1](#)), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:

	September 30, 2024	
Volatility		70.2%
Risk-free rate		3.65%
Warrant term		1.9

XML 45 R37.htm IDEA: XBRL DOCUMENT

Stockholders' Equity
(Deficit)) (Tables)

9 Months Ended
Sep. 30, 2024

[Equity \[Abstract\]](#)
[Schedule of Common Stock Reserved for Future Issuance](#)

As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

Securities To Be Issued Upon Exercise Of Options	Securities To Be Issued Upon Release Of Restricted Stock	Number Of Remaining Securities Available For Future Issuance

2022 Inducement Equity Incentive Plan	7,320	898	454
2011 Equity Incentive Plan	7,929	12,781	23,584
2017 Inducement Award Plan	59	—	2
2017 Employee Stock Purchase Plan	—	—	1,379
SomaLogic Plans	24,920	757	—
Total common stock reserved for future issuance	40,228	14,436	25,419

XML 46 R38.htm
IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)
[Share-Based Payment Arrangement \[Abstract\]](#)
[Schedule of Activity Under Restricted Stock Units](#)

9 Months Ended Sep. 30, 2024

Restricted Stock Units

	Number of Units (in thousands)	Weighted-Average Grant Date Fair Value per Unit
Balance at December 31, 2023	6,933	\$ 2.46
Assumed through acquisition	2,970	2.00
Granted	10,263	2.21
Vested	(4,002)	2.34
Forfeited	(1,728)	2.30
Balance at September 30, 2024	14,436	\$ 2.24

[Schedule of Activity Under Stock Options](#)

Stock Options

	Number of Options (in thousands)	Weighted-Average Exercise Price per Option	Weighted-Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value ⁽¹⁾ (in thousands)
Balance at December 31, 2023	9,294	\$ 3.62	8.5	
Assumed through acquisition	28,184	4.80		
Granted	6,697	2.50		
Exercised	(573)	2.12		
Cancelled	(3,374)	3.92		
Balance at September 30, 2024	40,228	\$ 4.26	6.2	\$ 196
Vested at September 30, 2024	28,006	\$ 4.76	5.1	\$ 93
Unvested options at September 30, 2024	12,222	\$ 3.10	8.7	\$ 103

Aggregate intrinsic value as of September 30, 2024 was calculated as the difference between the closing price per share of the Company's common stock on The Nasdaq Global Select Market on September 30, 2024, which was \$1.93, and the exercise price of the options, multiplied by the number of in-the-money options.

[Schedule of Nonvested Performance-Based Units Activity](#)

Activity under the performance-based awards was as follows:

	Number of Units (in thousands)	Weighted-Average Grant Date Fair Value per Unit
Balance at December 31, 2023	309	\$ 2.42
PSU granted	100	2.25
Performance adjustment	(26)	2.42
PSU released	(383)	2.38
Balance at September 30, 2024	—	\$ —

[Schedule of Stock-Based Compensation Expense](#)

As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

	Securities To Be Issued Upon Exercise Of Options	Securities To Be Issued Upon Release Of Restricted Stock	Number Of Remaining Securities Available For Future Issuance
2022 Inducement Equity Incentive Plan	7,320	898	454
2011 Equity Incentive Plan	7,929	12,781	23,584
2017 Inducement Award Plan	59	—	2
2017 Employee Stock Purchase Plan	—	—	1,379
SomaLogic Plans	24,920	757	—
Total common stock reserved for future issuance	40,228	14,436	25,419

[Schedule of Stock-Based Compensation Expense](#)

Stock-based compensation expense is reported in the Company's condensed consolidated statement of operations as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Cost of product revenue	\$ 136	\$ 151	\$ 441	\$ 524
Cost of services revenue	228	37	455	122
Cost of collaboration and other revenue	—	—	1	2
Research and development expense	724	459	4,480	1,241
Selling, general and administrative expense	4,833	2,739	18,885	7,759
Total stock-based compensation expense	\$ 5,921	\$ 3,386	\$ 24,262	\$ 9,648

XML 47 R39.htm
IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)
[Earnings Per Share \[Abstract\]](#)
[Schedule of computation of loss per share](#)

9 Months Ended Sep. 30, 2024

Computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands, except per share data):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Numerator:				
Net loss from operations	\$ (26,938)	\$ (20,997)	\$ (104,813)	\$ (54,880)
Induced conversion of redeemable preferred stock	—	—	(46,014)	—
Net loss attributable to common stockholders	\$ (26,938)	\$ (20,997)	\$ (150,827)	\$ (54,880)
Denominator:				
Weighted-average shares outstanding during the period	371,538	79,152	346,093	78,967
Net loss per share attributable to common stockholders, basic and diluted	\$ (0.07)	\$ (0.27)	\$ (0.44)	\$ (0.69)

The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):

	Nine Months Ended September 30,	
	2024	2023
RSUs, PSUs, stock options, restricted shares and ESPP shares	54,664	16,872
Series B Preferred Stock	—	75,164
2019 Notes ⁽¹⁾	18,966	18,966
2014 Notes	5	10
Warrants	11,692	—
Total	85,327	111,012

(1) The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes prior to the Company's exercise of the Issuer's Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company's common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of the Company's common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to [Note 6](#) for additional information on the 2019 Notes.

XML 48 R40.htm
IDEA: XBRL DOCUMENT

Segment Reporting (Tables)
[Segment Reporting \[Abstract\]](#)
[Schedule of Business](#)

9 Months Ended Sep. 30, 2024

[Segment Information](#) The Company’s business segment information was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Revenue:				
Proteomics	\$ 34,565	\$ 14,008	\$ 98,954	\$ 47,296
Genomics	10,404	11,359	28,760	30,856
Total revenue	<u>\$ 44,969</u>	<u>\$ 25,367</u>	<u>\$ 127,714</u>	<u>\$ 78,152</u>
Income (loss) from operations:				
Proteomics	\$ (10,210)	\$ (7,106)	\$ (48,485)	\$ (16,297)
Genomics	1,925	301	2,681	41
Corporate expenses	(16,013)	(10,703)	(59,217)	(31,877)
Restructuring and related charges	(2,341)	(1,998)	(12,374)	(5,415)
Transaction and integration expenses	(5,079)	(1,666)	(25,024)	(1,666)
Total loss from operations	<u>\$ (31,718)</u>	<u>\$ (21,172)</u>	<u>\$ (142,419)</u>	<u>\$ (55,214)</u>
Depreciation & amortization:				
Proteomics	1,940	3,420	\$ 7,193	\$ 9,932
Genomics	378	373	1,125	703
Corporate	1,540	193	4,590	639
Total depreciation & amortization	<u>\$ 3,858</u>	<u>\$ 3,986</u>	<u>\$ 12,908</u>	<u>\$ 11,274</u>

[XML 49 R41.htm](#) IDEA: XBRL DOCUMENT

**Restructuring and
Related Charges
(Tables)**

**[Restructuring and
Related Activities
\[Abstract\]](#)**

**[Schedule of
Restructuring Liabilities](#)**

The following table summarizes the change in the Company’s restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

	Severance and other employee- related benefits ⁽¹⁾	Facility Costs	Other ⁽²⁾	Total
Balance at December 31, 2023	\$ 825	\$ —	\$ —	\$ 825
Restructuring and related charges	9,522	2,108	744	12,374
Cash payments	(7,806)	(2,108)	(744)	(10,658)
Balance at September 30, 2024	<u>\$ 2,541</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,541</u>

- (1) Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.
- (2) Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets.

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Restructuring:				
Proteomics	\$ —	\$ 213	\$ —	\$ 691
Genomics	—	70	—	629
Corporate expenses	2,341	1,715	12,374	4,095
Total restructuring and related charges	<u>\$ 2,341</u>	<u>\$ 1,998</u>	<u>\$ 12,374</u>	<u>\$ 5,415</u>

[XML 50 R42.htm](#) IDEA: XBRL DOCUMENT

**Basis of Presentation
and Summary of
Significant
Accounting Policies -
Narrative (Details)**

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Amortizes internal-use software costs using the straight-line method over the estimated useful life of asset](#) 3 years

[Number of reporting segments | Segment](#) 2

[Common stock, par value \(in dollars per share\)](#) \$ 0.001 \$ 0.001

[Standard BioTools | Public Warrants](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Initial public offering warrants issued | shares](#) 5,519,991

[Standard BioTools | Private Placement Warrants](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Initial public offering warrants issued | shares](#) 5,013,333

[Common Stock](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Exercise price of warrants](#) \$ 1.11

[Common Stock | SomaLogic Inc.](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Common stock, par value \(in dollars per share\)](#) 0.0001

[Common Stock | Public Warrants | SomaLogic Inc.](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Common stock, par value \(in dollars per share\)](#) \$ 0.0001

[Common Stock | Standard BioTools](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Common stock, par value \(in dollars per share\)](#) \$ 0.001

[Common Stock | Standard BioTools | Public Warrants](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Exercise price of warrants](#) 11.5

[Common Stock | Standard BioTools | Private Placement Warrants](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Exercise price of warrants](#) \$ 11.5

[Product revenue | Maximum](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Terms of payment period](#) 60 days

[Product revenue | Minimum](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Terms of payment period](#) 30 days

[Service revenue | Maximum](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Performance obligation period](#) 4 years

[Service revenue | Minimum](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Performance obligation period](#) 1 year

[Capitalized Software Development Costs](#)

[Schedule Of Significant Accounting Policies \[Line Items\]](#)

[Amortization on product-by-product basis using straight-line method over periods](#) 3 years

[XML 51 R43.htm](#) IDEA: XBRL DOCUMENT

**Business
Combination -
Schedule of the
Acquisition-date Fair**

**9 Months Ended
Sep. 30, 2024**

**9 Months Ended
Sep. 30, 2024
Segment
\$ / shares
shares****Jan. 05, 2024****Dec. 31, 2023**
\$ / shares**\$ / shares**

Jan. 05, 2024

Value of
Consideration
Transferred (Details)
- Standard BioTools
\$ / shares in Units, \$
in Thousands

USD (\$)
\$ / shares

Business Acquisition [Line Items]

SomaLogic Common Stock issued and outstanding as of January 5, 2024	\$ 188,808
Fixed exchange ratio \$ / shares	\$ 1.11
Shares of Standard BioTools common stock issued to SomaLogic stockholders	\$ 209,577
Standard BioTools common stock price at close of Merger \$ / shares	\$ 2
Fair value of Standard BioTools common stock issued to SomaLogic stockholders	\$ 419,154
Fair value of Standard BioTools replacement equity awards attributable to pre-combination service	26,923
Less: Fair value of restricted shares subject to service conditions	(1,858)
Total consideration	\$ 444,219

XML 52 R44.htm IDEA: XBRL DOCUMENT

Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed (Details) - USD (\$) \$ in Thousands	3 Months Ended	9 Months Ended
	Jan. 05, 2024	Sep. 30, 2024
	Sep. 30, 2023	Sep. 30, 2024
	Sep. 30, 2023	Sep. 30, 2023

Liabilities assumed

Bargain purchase gain	\$ 0	\$ 0	\$ (25,213)	\$ 0
Standard BioTools				

Business Acquisition [Line Items]

Total consideration	\$ 444,219			
Assets acquired				
Cash and cash equivalents	278,857			
Short-term investments	148,305			
Accounts receivable	16,430			
Inventory	14,642			
Prepaid expenses and other current assets	4,835			
Property and equipment	22,455			
Non-current inventory	12,208			
Royalty receivable	4,669			
Operating lease right-of-use assets	3,796			
Other non-current assets	1,590			
Intangible Assets	25,500	\$ 25,500	\$ 25,500	
Total assets acquired	533,287			
Liabilities assumed				
Accounts payable and accrued liabilities	20,660			
Operating lease liabilities, current	1,601			
Deferred revenue, current	3,522			
Operating lease liabilities, non-current	2,193			
Deferred revenue, non-current	30,667			
Warrant liabilities	906			
Other non-current liabilities	4,306			
Total Liabilities	63,855			
Total fair value of net assets acquired	469,432			
Bargain purchase gain	\$ (25,213)			

XML 53 R45.htm IDEA: XBRL DOCUMENT

Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger (Details) - Standard BioTools - USD (\$) \$ in Thousands	9 Months Ended
	Sep. 30, 2024
	Jan. 05, 2024

Acquired Finite-Lived Intangible Assets [Line Items]

Total fair value of intangible assets acquired	\$ 25,500	\$ 25,500
Trade Name		

Acquired Finite-Lived Intangible Assets [Line Items]

Indefinite-lived intangible assets acquired	\$ 2,750
Useful Life (Years)	7 years
Developed Technology	

Acquired Finite-Lived Intangible Assets [Line Items]

Finite-lived intangible assets acquired	\$ 20,000
Useful Life (Years)	9 years
Customer Relationships	

Acquired Finite-Lived Intangible Assets [Line Items]

Finite-lived intangible assets acquired	\$ 2,750
Useful Life (Years)	11 years

XML 54 R46.htm IDEA: XBRL DOCUMENT

Business Combination - Schedule of Unaudited Pro Forma Financial Information (Details) - USD (\$) \$ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
	Sep. 30, 2024	Sep. 30, 2023
	Sep. 30, 2024	Sep. 30, 2023

Business Combinations [Abstract]

Revenue	\$ 44,969	\$ 47,415	\$ 128,359	\$ 141,047
Net loss	\$ (26,938)	\$ (41,204)	\$ (134,607)	\$ (109,000)

XML 55 R47.htm IDEA: XBRL DOCUMENT

Business Combination - Narrative (Details) - USD (\$) \$ / shares in Units, \$ in Thousands	3 Months Ended	9 Months Ended
	Jan. 05, 2024	Sep. 30, 2024
	Sep. 30, 2023	Sep. 30, 2024
	Sep. 30, 2024	Sep. 30, 2023
	Sep. 30, 2023	Dec. 31, 2023

Business Acquisition [Line Items]

Revenue	\$ 22,900	\$ 61,500
Loss	1,600	\$ 30,600

Acquisition-related transaction cost	\$ 5,079	\$ 1,666		\$ 25,024	\$ 1,666	
Common stock, par value (in dollars per share)	\$ 0.001		\$ 0.001	\$ 0.001		\$ 0.001
Minimum						
Business Acquisition [Line Items]						
Cumulative discounted cash flow percentage				85.00%		
Maximum						
Business Acquisition [Line Items]						
Cumulative discounted cash flow percentage				90.00%		
Selling, general and administrative expense						
Business Acquisition [Line Items]						
Transaction bonuses incurred				\$ 1,900		
Transaction and integration expenses						
Business Acquisition [Line Items]						
Acquisition-related transaction cost				\$ 12,300		
Common Stock SomaLogic Inc.						

Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \$ 0.0001

Standard BioTools	
Business Acquisition [Line Items]	
Exchanged common stock	\$ 1.11
Amount of common stock	\$ 188,808
Value of consideration transferred	444,219

Standard BioTools Common Stock	
Business Acquisition [Line Items]	
Amount of common stock	\$ 419,200
Common stock, par value (in dollars per share)	\$ 0.001

XML 56 R48.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) - USD (\$) \$ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Disaggregation of Revenue [Line Items]				
Total revenue Americas	\$ 44,969	\$ 25,367	\$ 127,714	\$ 78,152
Disaggregation of Revenue [Line Items]				
Total revenue EMEA	23,751	10,865	68,241	32,975
Disaggregation of Revenue [Line Items]				
Total revenue Asia-Pacific	16,057	8,162	39,108	27,435
Disaggregation of Revenue [Line Items]				
Total revenue Assay services	5,161	6,340	20,365	17,742
Disaggregation of Revenue [Line Items]				
Total revenue Instrument support services	18,247	114	40,780	564
Disaggregation of Revenue [Line Items]				
Total revenue Service revenue	6,191	6,452	18,738	18,704
Disaggregation of Revenue [Line Items]				
Total revenue Instruments	24,438	6,566	59,518	19,268
Disaggregation of Revenue [Line Items]				
Total revenue Consumables	5,586	9,002	19,959	26,512
Disaggregation of Revenue [Line Items]				
Total revenue Product revenue	14,007	9,709	45,389	31,302
Disaggregation of Revenue [Line Items]				
Total revenue Product and service revenue	19,593	18,711	65,348	57,814
Disaggregation of Revenue [Line Items]				
Total revenue Collaboration and other revenue	44,031	25,277	124,866	77,082
Disaggregation of Revenue [Line Items]				
Total revenue	\$ 938	\$ 90	\$ 2,848	\$ 1,070

XML 57 R49.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area - Narrative (Details) - USD (\$) \$ in Thousands	1 Months Ended			3 Months Ended		9 Months Ended					
	Apr. 30, 2024	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Jan. 31, 2022	Mar. 31, 2020
Disaggregation of Revenue [Line Items]											
Deferred revenue				\$ 46,118		\$ 46,118			\$ 15,127		
Transaction price	[1]			18,791		18,791					
Purchase to equipment supplies and training						4,973	\$ 2,753				
Research and development services				13,156	\$ 6,370	48,358	\$ 19,039				
Illumina Cambridge, Ltd.											
Disaggregation of Revenue [Line Items]											
Deferred revenue				30,012		30,012			0		
Transaction price			\$ 30,400					\$ 400			
Non-refundable upfront payment										\$ 30,000	
Purchase to equipment supplies and training			500								
Revenue receive minimum guaranteed royalty			124,500								
Transaction price royalties expected to be received								8 years			
NEC Corporation											
Disaggregation of Revenue [Line Items]											
Deferred revenue				1,526		1,526			\$ 0		\$ 1,800
Research and development services	\$ 2,000										
New England Biolabs, Inc.											
Disaggregation of Revenue [Line Items]											
Revenue receive minimum guaranteed royalty		\$ 8,700									
License agreement related royalties receivable				8,200		8,200					
License agreement related accounts receivable current				4,800		4,800					
License Agreement Related Accounts Receivable				\$ 3,400		\$ 3,400					

Non-current					
Soma Logic Plans					
Disaggregation of Revenue [Line Items]					
Revenue receive minimum guaranteed royalty	\$ 0				
Maximum Illumina Cambridge, Ltd.					
Disaggregation of Revenue [Line Items]					
Transaction price royalties expected to be received				2032 years	
Minimum Illumina Cambridge, Ltd.					
Disaggregation of Revenue [Line Items]					
Transaction price royalties expected to be received				2025 years	
Illumina Agreement Illumina Cambridge, Ltd.					
Disaggregation of Revenue [Line Items]					
Transaction price	\$ 30,500			\$ 158,400	
Transaction price royalties expected to be received		8 years	8 years		
Royalties Illumina Cambridge, Ltd.					
Disaggregation of Revenue [Line Items]					
Transaction price				\$ 127,900	

[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company’s condensed consolidated financial statements and are subject to change if the Company’s customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

XML 58 R50.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area - Summary of the Change in Deferred Revenue (Details)	9 Months Ended Sep. 30, 2024 USD (\$)
\$ in Thousands	

Disaggregation of Revenue [Line Items]	
Deferred revenue at December 31, 2023	\$ 15,127
Deferred revenue assumed in connection with merger	34,189
Recognition of revenue from beginning or assumed deferred revenue balances	(12,552)
Revenue deferred during the period, net of revenue recognized	9,354
Deferred revenue at June 30, 2024	46,118

NEC	
Disaggregation of Revenue [Line Items]	
Deferred revenue at December 31, 2023	0
Deferred revenue assumed in connection with merger	1,773
Recognition of revenue from beginning or assumed deferred revenue balances	(1,247)
Revenue deferred during the period, net of revenue recognized	1,000
Deferred revenue at June 30, 2024	1,526

Illumina	
Disaggregation of Revenue [Line Items]	
Deferred revenue at December 31, 2023	0
Deferred revenue assumed in connection with merger	30,418
Recognition of revenue from beginning or assumed deferred revenue balances	(406)
Revenue deferred during the period, net of revenue recognized	0
Deferred revenue at June 30, 2024	30,012

Other	
Disaggregation of Revenue [Line Items]	
Deferred revenue at December 31, 2023	15,127
Deferred revenue assumed in connection with merger	1,998
Recognition of revenue from beginning or assumed deferred revenue balances	(10,899)
Revenue deferred during the period, net of revenue recognized	8,354
Deferred revenue at June 30, 2024	\$ 14,580

XML 59 R51.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area - Performance Obligations (Details)		Sep. 30, 2024 USD (\$)
\$ in Thousands		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 18,791	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 4,321	[1]
Remaining performance obligation, expected timing of satisfaction	6 months	
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 9,002	[1]
Remaining performance obligation, expected timing of satisfaction	1 year	
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 3,678	[1]
Remaining performance obligation, expected timing of satisfaction	1 year	
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 1,790	[1]
Remaining performance obligation, expected timing of satisfaction		

[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company’s condensed consolidated financial statements and are subject to change if the Company’s customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

XML 60 R52.htm IDEA: XBRL DOCUMENT

Revenue and Geographic Area - Performance Obligation (Details1)		Sep. 30, 2024 USD (\$)
\$ in Thousands		
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]		
Remaining performance obligation	\$ 18,791	[1]

[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company’s condensed consolidated financial statements and are subject to change if the Company’s customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

XML 61 R53.htm IDEA: XBRL DOCUMENT

Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment (Details)	9 Months Ended Sep. 30, 2024 USD (\$)
\$ in Thousands	

Goodwill [Line Items]	
Goodwill, Beginning Balance	\$ 106,317
Foreign currency translation	25

[Goodwill, Ending Balance](#) 106,342

[Proteomics \[Member\]](#)

[Goodwill \[Line Items\]](#)

[Goodwill, Beginning Balance](#) 85,798

[Foreign currency translation](#) 27

[Goodwill, Ending Balance](#) 85,825

[Genomics \[Member\]](#)

[Goodwill \[Line Items\]](#)

[Goodwill, Beginning Balance](#) 20,519

[Foreign currency translation](#) (2)

[Goodwill, Ending Balance](#) \$ 20,517

[XML 62 R54.htm IDEA: XBRL DOCUMENT](#)

Goodwill and		
Acquired Intangible		
Assets, net - Schedule		
of Acquired		
Intangible Assets		
(Details) - USD (\$)		
\$ in Thousands		
Sep. 30, 2024 Dec. 31, 2023		

[Finite-Lived Intangible Assets \[Line Items\]](#)

Gross Carrying Amount	\$ 142,914	\$ 117,354
Accumulated Amortization	(119,547)	(115,954)
Total	23,367	1,400

[Tradename](#)

[Finite-Lived Intangible Assets \[Line Items\]](#)

Gross Carrying Amount	2,750
Accumulated Amortization	(294)
Total	2,456

[Customer Relationships](#)

[Finite-Lived Intangible Assets \[Line Items\]](#)

Gross Carrying Amount	2,750
Accumulated Amortization	(172)
Total	2,578

[Developed Technology](#)

[Finite-Lived Intangible Assets \[Line Items\]](#)

Gross Carrying Amount	137,414	117,354
Accumulated Amortization	(119,081)	(115,954)
Total	\$ 18,333	\$ 1,400

[XML 63 R55.htm IDEA: XBRL DOCUMENT](#)

Goodwill and		3 Months Ended		9 Months Ended	
Acquired Intangible					
Assets, net -					
Narrative (Details) -		Sep. 30, 2024 Sep. 30, 2023		Sep. 30, 2024 Sep. 30, 2023	
USD (\$)					

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)

Impairment of goodwill				\$ 0
Impairment of intangible assets				0
Amortization of intangible assets	\$ 700,000	\$ 2,800,000	\$ 3,500,000	\$ 8,400,000

[XML 64 R56.htm IDEA: XBRL DOCUMENT](#)

Goodwill and	
Acquired Intangible	
Assets, net - Schedule	
of Future Expected	
Amortization Expense	
of Acquired	
Intangible Assets, Net	
(Details)	
\$ in Thousands	
Sep. 30, 2024	
USD (\$)	

[Finite-Lived Intangible Assets \[Line Items\]](#)

2024 remainder of the year	\$ 711
2025	2,844
2026	2,844
2027	2,844
2028	2,844
Thereafter	11,280
Total	\$ 23,367

[XML 65 R57.htm IDEA: XBRL DOCUMENT](#)

Balance Sheet Details	
- Summary of Cash	
and Cash Equivalents	
(Details) - USD (\$)	
\$ in Thousands	
Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022	

[Balance Sheet Related Disclosures \[Abstract\]](#)

Cash and cash equivalents	\$ 210,647	\$ 51,704		
Restricted cash	1,291	795		
Total cash, cash equivalents and restricted cash	211,938	52,499	\$ 80,450	\$ 82,324
Non-current restricted cash	\$ 1,300	\$ 800		

[XML 66 R58.htm IDEA: XBRL DOCUMENT](#)

Balance Sheet Details	
- Accounts Receivable	
(Details) - USD (\$)	
\$ in Thousands	
Sep. 30, 2024 Dec. 31, 2023	

[Balance Sheet Related Disclosures \[Abstract\]](#)

Trade receivables	\$ 35,337	\$ 19,972
Royalty Receivable Current	435	0
Other receivables	173	0
Less: allowance for expected credit losses	(628)	(312)
Accounts receivable, net	\$ 35,317	\$ 19,660

[XML 67 R59.htm IDEA: XBRL DOCUMENT](#)

Balance Sheet Details	
- Inventory (Details) -	
USD (\$)	
Sep. 30, 2024 Dec. 31, 2023	
\$ in Thousands	

[Balance Sheet Related Disclosures \[Abstract\]](#)

Raw materials	\$ 49,953	\$ 12,140
Work-in-process	1,558	282
Finished goods	9,082	8,111
Total inventory	60,593	20,533
Inventory Current	42,644	20,533
Inventory, non-current	\$ 17,949	\$ 0

[XML 68 R60.htm IDEA: XBRL DOCUMENT](#)

Balance Sheet Details	
- Property and	

Equipment (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024 Dec. 31, 2023	
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	\$ 105,382	\$ 57,342
Less accumulated depreciation and amortization	(69,623)	(35,489)
Construction-in-progress	6,223	2,334
Property and equipment, net	41,982	24,187
Laboratory and manufacturing equipment		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	59,785	35,563
Leasehold improvements		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	17,400	13,785
Computer equipment		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	7,845	6,232
Internal-use software		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	16,870	0
Office furniture and fixtures		
Property, Plant and Equipment [Line Items]		
Property and equipment, gross	\$ 3,482	\$ 1,762

XML 69 R61.htm
IDEA: XBRL DOCUMENT

Balance Sheet Details - Accrued Liabilities (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024 Dec. 31, 2023	

Balance Sheet Related Disclosures [Abstract]		
Accrued compensation and related benefits	\$ 14,390	\$ 12,052
Loss contingency accruals	4,262	0
Accrued warranties	1,874	2,593
Accrued restructuring	2,541	825
Uninvoiced receipts	1,354	1,516
Other	7,265	4,033
Accrued liabilities	\$ 31,686	\$ 21,019

XML 70 R62.htm
IDEA: XBRL DOCUMENT

Balance Sheet Details - Narrative (Details) - USD (\$)	1 Months Ended Sep. 30, 2020	3 Months Ended Sep. 30, 2024 Sep. 30, 2023	9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023

Balance Sheet Related Disclosures [Abstract]					
Maximum contract value	\$ 34,000,000				
Capital expenditures	\$ 22,200,000				
Provision for excess and obsolete inventory		\$ 100,000	\$ 400,000	\$ 1,991,000	\$ 963,000
Depreciation and amortization expense		3,200,000	1,200,000	9,400,000	2,900,000
Depreciation expenses		900,000	\$ 900,000	2,700,000	\$ 2,700,000
Accumulated depreciation expenses		10,500,000		10,500,000	\$ 7,800,000
Carrying value of assets		\$ 11,700,000		\$ 11,700,000	\$ 14,400,000

XML 71 R63.htm
IDEA: XBRL DOCUMENT

Debt - Schedule of Carrying Value of Debt (Details) - USD (\$)	Sep. 30, 2024 Dec. 31, 2023	

Debt Instrument [Line Items]		
Total debt	\$ 55,212	\$ 63,513
Convertible Debt		
Debt Instrument [Line Items]		
Total debt	55,212	55,099
Secured Debt		
Debt Instrument [Line Items]		
Term loan, non-current	0	3,414
Term loan, current	0	5,000
2014 Notes Convertible Debt		
Debt Instrument [Line Items]		
Total debt	299	569
2019 Notes, current Convertible Debt		
Debt Instrument [Line Items]		
Total debt	\$ 54,913	\$ 54,530

XML 72 R64.htm
IDEA: XBRL DOCUMENT

Debt - Narrative (Details)	1 Months Ended Nov. 30, 2019 USD (\$) \$ / shares shares	Feb. 28, 2014	9 Months Ended Sep. 30, 2024 MonthlyInstallment	Mar. 31, 2024 USD (\$)	Dec. 31, 2023 USD (\$)	Aug. 02, 2021 USD (\$)
Secured Debt						
Debt Instrument [Line Items]						
Face amount					\$ 7,900,000	\$ 10,000,000
Interest rate on notes			4.00%			
Term loan, non-current					\$ 8,400,000	
Additional interest rate			0.75%			
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]			us- gaap:PrimeRateMember			
Term loan advances percentage			6.50%			
Number of installments MonthlyInstallment			24			
2014 Notes Convertible Debt						
Debt Instrument [Line Items]						
Proceeds from debt issuance	\$ 52,700,000					
Total convertible notes, net	1,100,000					
2014 Notes Convertible Debt Redemption, Period Three						
Debt Instrument [Line Items]						
Debt instrument redemption price		100.00%				
2019 Convertible Notes Convertible Debt						
Debt Instrument [Line Items]						
Face amount	\$ 55,000,000					
Interest rate on notes	5.25%					
Initial conversion price of stock (in usd per share) \$ / shares	\$ 2.9					
Repurchased outstanding principal amount					\$ 300,000	
2019 Convertible Notes Convertible Debt Redemption, Period Two						

Debt Instrument [Line Items]	
Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price	130.00%
Exchange Convertible Senior Notes due 2034 Convertible Debt	
Debt Instrument [Line Items]	
Debt Conversion, Converted Instrument, Shares Issued shares	344.8276
Initial conversion rate of notes	0.3448276

[XML 73 R65.htm IDEA: XBRL DOCUMENT](#)

Leases - Schedule of Lease Cost (Details) - USD (\$) \$ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Lease, Cost [Abstract]				
Operating lease cost	\$ 2,386	\$ 1,994	\$ 7,484	\$ 6,005
Short-term lease cost	0	0	0	0
Variable lease cost	1,188	830	3,781	2,417
Less: Sublease income	(1,076)	(529)	(3,228)	(1,978)
Total lease cost	\$ 2,498	\$ 2,295	\$ 8,037	\$ 6,444

[XML 74 R66.htm IDEA: XBRL DOCUMENT](#)

Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024		Dec. 31, 2023	

Leases [Abstract]		
Remainder of 2024	\$ 2,419	
2025	9,789	
2026	8,800	
2027	7,428	
2028	7,362	
Thereafter	10,225	
Total	46,023	
Less: amount of lease payments representing interest	(11,761)	
Present value of future minimum lease payments	34,262	
Less: current operating lease liabilities	(6,122)	\$ (4,323)
Long-term operating lease liabilities	\$ 28,140	\$ 30,374

[XML 75 R67.htm IDEA: XBRL DOCUMENT](#)

Leases - Schedule of Supplemental Lease Information (Details)	Sep. 30, 2024

Lease, Cost [Abstract]	
Weighted average remaining lease term	5 years 1 month 6 days
Weighted average discount rate	11.90%

[XML 76 R68.htm IDEA: XBRL DOCUMENT](#)

Leases - Narrative (Details)	9 Months Ended Sep. 30, 2024 Office

Lessee, Lease, Description [Line Items]	
No of leases for office and laboratory space	3
Assumed lease expired	Jun. 30, 2024
Lease option to extend	extend the leases
Lessee, operating lease, existence of option to extend [true false]	true
Maximum	

Lessee, Lease, Description [Line Items]	
Lease, term of contract	5 years
Renewal term	10 years
Minimum	

Lessee, Lease, Description [Line Items]	
Lease, term of contract	3 years
Renewal term	3 years

[XML 77 R69.htm IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies - Narrative (Details) - USD (\$) \$ / shares in Units, \$ in Millions	1 Months Ended	9 Months Ended
	May 31, 2024	Feb. 29, 2024
	Sep. 30, 2024	

Lessee, Lease, Description [Line Items]		
Purchase commitment due in the next year		\$ 16.2
Settlement of outstanding litigation	\$ 6.2	
Repurchase of common stock shares for litigation settlement	1,840,000	
Payment for litigation settlement	\$ 1.8	
Settled Outstanding Litigation		422,048
Litigation loss		\$ 0.6
Market price	\$ 2.4	\$ 1.93

Illumina Agreement	
Lessee, Lease, Description [Line Items]	
Purchase Commitment Agreement	\$ 6.9
SomaLogic Inc.	

Lessee, Lease, Description [Line Items]	
Minimum Annual Purchase	\$ 2.3

[XML 78 R70.htm IDEA: XBRL DOCUMENT](#)

Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) - USD (\$) \$ in Thousands	Sep. 30, 2024		Dec. 31, 2023	

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Short-term investments	\$ 340,910	\$ 98,576
Fair Value, Recurring		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Total assets measured at fair value	340,910	98,576
Fair Value, Recurring Level 1		
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]		
Total assets measured at fair value	185,227	35,385
Fair Value, Recurring Level 2		

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Total assets measured at fair value	155,683	63,191	
Fair Value, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Total assets measured at fair value	0	0	
U.S. treasury securities Fair Value, Recurring			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Short-term investments	155,683	63,191	
U.S. treasury securities Fair Value, Recurring Level 1			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Short-term investments	0	0	
U.S. treasury securities Fair Value, Recurring Level 2			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Short-term investments	155,683	63,191	
U.S. treasury securities Fair Value, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Short-term investments	0	0	
Money market funds Fair Value, Recurring			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Cash and cash equivalents	185,227	35,385	
Money market funds Fair Value, Recurring Level 1			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Cash and cash equivalents	185,227	35,385	
Money market funds Fair Value, Recurring Level 2			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Cash and cash equivalents	0	0	
Money market funds Fair Value, Recurring Significant Unobservable Inputs (Level 3)			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Cash and cash equivalents	\$ 0	\$ 0	
XML 79 R71.htm IDEA: XBRL DOCUMENT			
Fair Value of			
Financial Instruments			
- Summary of			
Available-for-Sale			
Securities (Details) -			
USD (\$)			
\$ in Thousands			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Amortized Cost	\$ 340,562	\$ 98,554	
Unrealized Gains	348	22	
Unrealized Losses	0	0	
Estimated Fair Value	340,910	98,576	
Money market funds Cash and cash equivalents			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Amortized Cost	185,227	35,385	
Unrealized Gains	0	0	
Unrealized Losses	0	0	
Estimated Fair Value	185,227	35,385	
U.S. treasury securities Short-term investments			
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]			
Amortized Cost	155,335	63,169	
Unrealized Gains	348	22	
Unrealized Losses	0	0	
Estimated Fair Value	\$ 155,683	\$ 63,191	
XML 80 R72.htm IDEA: XBRL DOCUMENT			
Fair Value of			
Financial Instruments			
- Schedule of			
Liabilities Measured			
at Fair Value on a			
Recurring Basis			
(Details)			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Fair value of warrant liabilities as of Closing Date	\$ 906		
Change in fair value of warrant liabilities	(474)		
Fair value of warrant liabilities as of June 30, 2024	\$ 432		
XML 81 R73.htm IDEA: XBRL DOCUMENT			
Fair Value of			
Financial Instruments			
- Narrative (Details)			
USD (\$)			
Fair Value Disclosures [Abstract]			
Available-for-sale securities held	\$ 0		
Amortization cost before recovery	0		
Allowance for credit loss	\$ 0		
XML 82 R74.htm IDEA: XBRL DOCUMENT			
Fair Value of			
Financial Instruments			
- Schedule of			
Warrants Liabilities			
(Details) - Fair Value,			
Level 3 Inputs			
Volatility			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Warrants and Rights Outstanding, Measurement Input	70.2		
Risk-Free Rate			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Warrants and Rights Outstanding, Measurement Input	3.65		
Warrant Term			
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]			
Warrants and Rights Outstanding, Term	1 year 10 months 24 days		
XML 83 R75.htm IDEA: XBRL DOCUMENT			
Mezzanine Equity -			
Narrative (Details) -			
USD (\$)			
\$ / shares in Units, \$			
in Millions			
Debt Instrument [Line Items]			
Preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001	
Remained outstanding shares	0	256,000	
Series B Preferred Stock			
Debt Instrument [Line Items]			

Conversion of redeemable preferred stock (shares)	105,116,628	92,930,553		
Remained outstanding shares			0	
Fair value stock and carrying value difference			\$ 46.0	
Series B Preferred Stock Casdin				
Debt Instrument [Line Items]				
Preferred stock, par value (in dollars per share)		\$ 0.001		
Shares sold (in shares)		127,780		
Series B Preferred Stock Viking				
Debt Instrument [Line Items]				
Preferred stock, par value (in dollars per share)		\$ 0.001		
Shares sold (in shares)		127,779		
<i>XML 84 R76.htm IDEA: XBRL DOCUMENT</i>				
Stockholders' Equity	3 Months Ended	9 Months Ended		
(Deficit) - Narrative	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Feb. 06, 2024
(Details) - USD (\$)				
Equity, Class of Treasury Stock [Line Items]				
Repurchase of common stock (in shares)	175,910	15,448,533	2,634,594	
Share repurchase amount		\$ 40,490,000	\$ 5,240,000	
2024 Share Repurchase Program				
Equity, Class of Treasury Stock [Line Items]				
Stock repurchase program, authorized amount				\$ 50,000,000
Repurchase of common stock (in shares)		13,603,617		
Share repurchase amount		\$ 36,100,000		
<i>XML 85 R77.htm IDEA: XBRL DOCUMENT</i>				
Stockholders' Equity				
(Deficit) - Schedule of				
Shares Reserved for				
Future Issuance				Sep. 30, 2024
Under Equity				shares
Compensation Plans				
(Details)				
shares in Thousands				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			25,419	
2022 Inducement Equity Incentive Plan				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			454	
2011 Equity Incentive Plan				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			23,584	
2017 Inducement Award Plan				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			2	
2017 Employee Stock Purchase Plan				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			1,379	
Soma Logic Plans				
Class of Stock [Line Items]				
Number of remaining securities available for future issuance (in shares)			0	
Securities To Be Issued Upon Exercise Of Options				
Class of Stock [Line Items]				
Securities to be issued (in shares)			40,228	
Securities To Be Issued Upon Exercise Of Options 2022 Inducement Equity Incentive Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			7,320	
Securities To Be Issued Upon Exercise Of Options 2011 Equity Incentive Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			7,929	
Securities To Be Issued Upon Exercise Of Options 2017 Inducement Award Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			59	
Securities To Be Issued Upon Exercise Of Options 2017 Employee Stock Purchase Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			0	
Securities To Be Issued Upon Exercise Of Options Soma Logic Plans				
Class of Stock [Line Items]				
Securities to be issued (in shares)			24,920	
Restricted Stock Units				
Class of Stock [Line Items]				
Securities to be issued (in shares)			14,436	
Restricted Stock Units 2022 Inducement Equity Incentive Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			898	
Restricted Stock Units 2011 Equity Incentive Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			12,781	
Restricted Stock Units 2017 Inducement Award Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			0	
Restricted Stock Units 2017 Employee Stock Purchase Plan				
Class of Stock [Line Items]				
Securities to be issued (in shares)			0	
Restricted Stock Units Soma Logic Plans				
Class of Stock [Line Items]				
Securities to be issued (in shares)			757	
<i>XML 86 R78.htm IDEA: XBRL DOCUMENT</i>				
Stock-based			9 Months Ended	
Compensation -			Sep. 30, 2024	
Narrative (Details)			USD (\$)	
\$ in Millions				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Stock-based compensation expense due to acceleration of awards			\$ 6.2	
Merger exchange ratio			1.11%	
Equity Incentive Plan				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Aggregate intrinsic value, vested and released			\$ 0.6	
Total unrecognized compensation cost related to stock-based compensation arrangements			\$ 22.5	
Weighted average remaining contractual terms			2 years 7 months 6 days	
Restricted Stock Units (RSUs)				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				

Total unrecognized compensation cost related to stock-based compensation arrangements\$ 29.8

Weighted average remaining contractual terms3 years 1 month 6 days

XML 87 R79.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Restricted and Performance Stock Units (Details) shares in Thousands	9 Months Ended Sep. 30, 2024 \$ / shares shares
Restricted Stock Units (RSUs)	
Number of Nonvested and Outstanding Units	
Beginning balance (in shares) shares	6,933
Assumed through acquisition shares	2,970
Granted (in shares) shares	10,263
Vested (in shares) shares	(4,002)
Forfeited (in shares) shares	(1,728)
Ending balance (in shares) shares	14,436

Weighted-Average Grant Date Fair Value per Unit

Beginning balance (in dollars per share) \$ / shares	\$ 2.46
Assumed through acquisition (in dollars per share) \$ / shares	2
Granted (in dollars per share) \$ / shares	2.21
Released (in dollars per share) \$ / shares	2.34
Forfeited (in dollars per share) \$ / shares	2.3
Ending balance (in dollars per share) \$ / shares	\$ 2.24
Performance Shares	

Number of Nonvested and Outstanding Units

Beginning balance (in shares) shares	309
Granted (in shares) shares	100
Performance adjustment (in shares) shares	(26)
Vested (in shares) shares	(383)
Ending balance (in shares) shares	0

Weighted-Average Grant Date Fair Value per Unit

Beginning balance (in dollars per share) \$ / shares	\$ 2.42
Granted (in dollars per share) \$ / shares	2.25
Performance adjustment (in usd per share) \$ / shares	2.42
Released (in dollars per share) \$ / shares	2.38
Ending balance (in dollars per share) \$ / shares	\$ 0

XML 88 R80.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock Option Activity (Details) - USD (\$)	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023	May 31, 2024
Number of Options			
Beginning balance (in shares)	9,294		
Assumed through acquisition (in shares)	28,184		
Granted (in shares)	6,697		
Exercised (in shares)	(573)		
Cancelled (in shares)	(3,374)		
Ending balance (in shares)	40,228	9,294	
Vested (in shares)	28,006		
Unvested options (in shares)	12,222		
Weighted-Average Exercise Price per Option			
Beginning balance (in dollars per share)	\$ 3.62		
Assumed through acquisition (in dollars per share)	4.8		
Granted (in dollars per share)	2.5		
Exercised (in dollars per share)	2.12		
Cancelled (in dollars per share)	3.92		
Ending balance (in dollars per share)	4.26	\$ 3.62	
Vested (in dollars per share)	4.76		
Unvested awards (in dollars per share)	\$ 3.1		
Weighted- Average Remaining Contractual Life (in years)			
Contractual term	6 years 2 months 12 days	8 years 6 months	
Vested	5 years 1 month 6 days		
Unvested awards	8 years 8 months 12 days		
Aggregate Intrinsic Value			
Outstanding	\$ 196		
Vested	93		
Unvested awards	\$ 103		
Share price (in dollars per share)	\$ 1.93	\$ 2.4	

XML 89 R81.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD (\$)	3 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	\$ 5,921	\$ 3,386	\$ 24,262	\$ 9,648
Cost of product revenue				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	136	151	441	524
Cost of services revenue				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	228	37	455	122
Cost of collaboration and other revenue				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense			1	2
Research and development expense				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	724	459	4,480	1,241
Selling, general and administrative expense				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	\$ 4,833	\$ 2,739	\$ 18,885	\$ 7,759

XML 90 R82.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Narrative (Details) - shares	3 Months Ended Mar. 18, 2024	9 Months Ended Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Repurchase of common stock (in shares)		175,910	15,448,533	2,634,594

Series B Preferred Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Exchange of common stock92,930,553

XML 91 R83.htm IDEA: XBRL DOCUMENT

Net Loss Per Share -	3 Months Ended			9 Months Ended				
Schedule of computation of loss per share (Details) - USD (\$)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ / shares in Units, shares in Thousands, \$ in Thousands								

Numerator:

Net Income (Loss)	\$ (26,938)	\$ (45,718)	\$ (32,157)	\$ (20,997)	\$ (17,040)	\$ (16,843)	\$ (104,813)	\$ (54,880)
Induced conversion of redeemable preferred stock	0			0			(46,014)	0
Net loss attributable to common stockholders	\$ (26,938)			\$ (20,997)			\$ (150,827)	\$ (54,880)

Denominator:

Weighted-average shares outstanding during the period, basic	371,538			79,152			346,093	78,967
Weighted-average shares outstanding during the period, diluted	371,538			79,152			346,093	78,967
Net loss per share attributable to common stockholders, basic	\$ (0.07)			\$ (0.27)			\$ (0.44)	\$ (0.69)
Net loss per share attributable to common stockholders, diluted	\$ (0.07)			\$ (0.27)			\$ (0.44)	\$ (0.69)

XML 92 R84.htm IDEA: XBRL DOCUMENT

Net Loss Per Share -	9 Months Ended	
Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) (Details) - shares	Sep. 30, 2024	Sep. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

RSUs, PSUs, stock options, restricted shares and ESPP shares	54,664,000	16,872,000
Series B Preferred Stock		75,164,000
Warrants	11,692,000	
Total	85,327,000	111,012,000
Maximum additional shares issuable (in shares)	4,741,374	

2019 Notes | Convertible Debt

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

2019 and 2014 Notes	18,966,000	18,966,000

2014 Notes | Convertible Debt

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

2019 and 2014 Notes	5,000	10,000

XML 93 R85.htm IDEA: XBRL DOCUMENT

Income Taxes -	3 Months Ended		9 Months Ended	
Narrative (Details) - USD (\$)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				

Income Tax Disclosure [Abstract]

Income tax expense (benefit)	\$ 118	\$ 50	\$ 301	\$ 614
Federal statutory tax rate			21.00%	21.00%

XML 94 R86.htm IDEA: XBRL DOCUMENT

Segment Reporting -	9 Months Ended
Narrative (Details)	Sep. 30, 2024
Segment	

Segment Reporting [Abstract]

Number of reporting segments2

XML 95 R87.htm IDEA: XBRL DOCUMENT

Segment Reporting -	3 Months Ended		9 Months Ended	
Schedule of Business Segment Information (Details) - USD (\$)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				

Segment Reporting Information [Line Items]

Total revenue	\$ 44,969	\$ 25,367	\$ 127,714	\$ 78,152
Income (loss) from operations	(31,718)	(21,172)	(142,419)	(55,214)
Restructuring and related charges	(2,341)	(1,998)	(12,374)	(5,415)
Transaction and integration expenses	(5,079)	(1,666)	(25,024)	(1,666)
Depreciation & amortization	3,858	3,986	12,908	11,274
Corporate expenses				

Segment Reporting Information [Line Items]

Income (loss) from operations	(16,013)	(10,703)	(59,217)	(31,877)
Restructuring and related charges	(2,341)	(1,715)	(12,374)	(4,095)
Proteomics				

Segment Reporting Information [Line Items]

Total revenue	34,565	14,008	98,954	47,296
Depreciation & amortization	1,940	3,420	7,193	9,932
Proteomics Operating segments				

Segment Reporting Information [Line Items]

Income (loss) from operations	(10,210)	(7,106)	(48,485)	(16,297)
Restructuring and related charges	0	(213)	0	(691)
Genomics				

Segment Reporting Information [Line Items]

Total revenue	10,404	11,359	28,760	30,856
Income (loss) from operations	1,925	301	2,681	41
Depreciation & amortization	378	373	1,125	703
Genomics Operating segments				

Segment Reporting Information [Line Items]

Restructuring and related charges	0	(70)	0	(629)
Corporate				

Segment Reporting Information [Line Items]

Depreciation & amortization	\$ 1,540	\$ 193	\$ 4,590	\$ 639

XML 96 R88.htm IDEA: XBRL DOCUMENT

Restructuring and Related Charges - Narrative (Details) - USD (\$)	3 Months Ended		9 Months Ended	
\$ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

Restructuring Cost and Reserve [Line Items]

Restructuring and related charges	\$ 2,341	\$ 1,998	\$ 12,374	\$ 5,415

Strategic Reorganization [Member]
Restructuring Cost and Reserve [Line Items]

Percentage of reduction in workforce10.00%

XML 97 R89.htm IDEA: XBRL DOCUMENT

	3 Months Ended		9 Months Ended	
Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) - USD (\$)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				

Restructuring Reserve [Roll Forward]

Beginning balance			\$ 825	
Restructuring and related charges	\$ 2,341	\$ 1,998	12,374	\$ 5,415
Cash payments			(10,658)	
Ending balance	2,541		2,541	
Severance and other employee-related benefits				

Restructuring Reserve [Roll Forward]

Beginning balance			825	
Restructuring and related charges			9,522	
Cash payments			(7,806)	
Ending balance	2,541		2,541	
Facility Costs				

Restructuring Reserve [Roll Forward]

Beginning balance			0	
Restructuring and related charges			2,108	
Cash payments			(2,108)	
Ending balance	0		0	
Other				

Restructuring Reserve [Roll Forward]

Beginning balance			0	
Restructuring and related charges			744	
Cash payments			(744)	
Ending balance	\$ 0		\$ 0	

XML 98 R90.htm IDEA: XBRL DOCUMENT

	3 Months Ended		9 Months Ended	
Restructuring and Related Charges- Restructuring and Other Efficiency Costs (Details) - USD (\$)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
\$ in Thousands				

Restructuring Cost and Reserve [Line Items]

Total restructuring and other related costs	\$ 2,341	\$ 1,998	\$ 12,374	\$ 5,415
Corporate expenses				

Restructuring Cost and Reserve [Line Items]

Total restructuring and other related costs	2,341	1,715	12,374	4,095
Proteomics Operating segments				

Restructuring Cost and Reserve [Line Items]

Total restructuring and other related costs	0	213	0	691
Genomics Operating segments				

Restructuring Cost and Reserve [Line Items]

Total restructuring and other related costs	\$ 0	\$ 70	\$ 0	\$ 629

XML 99 R91.htm IDEA: XBRL DOCUMENT

Related Parties	9 Months Ended			
Additional Information (Details) - shares	Jan. 05, 2024	Sep. 30, 2024	Mar. 18, 2024	Dec. 31, 2023

Related Party Transaction [Line Items]

Common stock, shares issued		390,841,000		83,364,000
Convertible Aggregate Common Stock			46,465,458	

Eli Casdin

Related Party Transaction [Line Items]

Common stock, shares issued	3,807			
Received aggregate shares	26,515,248			

Eli Casdin | Casdin Partners Master Fund, L.P.

Related Party Transaction [Line Items]

Common stock, shares issued	11,246,525			
Eli Casdin Casdin Private Growth Equity Fund, L.P.				

Related Party Transaction [Line Items]

Common stock, shares issued	2,744,219			
Eli Casdin CMLS Holdings II LLC				

Related Party Transaction [Line Items]

Warrant to purchase common stock	4,824,802			
Eli Casdin CMLS Holdings II LLC Common Stock				

Related Party Transaction [Line Items]

Warrant to purchase common stock	7,548,000			
Eli Casdin SomaLogic Inc.				

Related Party Transaction [Line Items]

Options in exchange of common shares	144,088			
Restricted Stock Units (RSUs)				

Related Party Transaction [Line Items]

Vested (in shares)	4,002,000			
Restricted Stock Units (RSUs) Eli Casdin				

Related Party Transaction [Line Items]

Vested (in shares)	3,807			

EXCEL 100 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L#!0 ("2*9ED'0AUB@0 +\$ 0 9&IC4'O<'O87!P+GAM M:\$V./0L".1!\$ \IQO=!'P4)B0-!2L+ (/>QLOD&1#LD)^OCG|CVX>:QA&WPIG M*N*I#BV&5(C(I//!47BK9.7:=N')=H!6-Y #OGDK7A.YNJO<&4GPZ4A!0W]=0UIR:UEA 6!#MI7E!+ P04 M " DBF99?P.4\| K @ \$0 &1Q8UIR-W!S+V: O&ULS9+! M3L,P#(9?!>7>NNE8#U&7"XC3)B\$Q"<0M2KPMHFFBQ*C=VY.6K1."!^ 8^ \ G MSY):'83V\$9^C#QC)8KH.7= \.SS=C/;. ."2:4@|<R@LX!- ^PZ^77U!+A 8K*NZON"VZ]JG4M>"!6Z. ?J8??3=AY8P V M'QM?'!64+O^Y"?@%02P.\$% @)(IF69E&UL[5!:<JHX%'OK]!X9_9M"!8V@::T\$W-I=MNTF83M M3A^%\$5B-:EDD81 OTV23;j/ 0LZ? Q.14ZGZ#AY!^XN8NB&B)3R M> +!O6N!U3+ MUES@6OHQ(!JM-O=5H!L.*\$81V1@25XL.\$#05%::U!@M.42. @5RU2-9:.! M\$U=)KF(M/+Y:.7VVMX^9<_LATR@6XP&U@@? !YO!^1.6HCA5.+SP&IG/U9K MOI'22('"RV4!;!U)I/3%0@R#3LZG5C.=GSVQ.V2C.K:=#1M&N#C!7@XMLQ2.MBW A!5M>5 TR M6!VULS2 Y9>*? !UE!K9':O=05SP6.XYB1'^OL4\$UFG2&98TIG*=D 4. #?*\$ MT4Q0?'!IMHK@PI+27)6SRFU4!H(FLB)!4>"(<7K.YH! M5Z%82=J\$^!|&&N*^<<^9ST6S!|Z5&T795O-RCEU@5 9<8WS2J!- 25%UGB5P&M MG#P=P=\$Q+-E L&08:7)"82J3E^34@3 BNEVOZKR2.FJW"\$2M'/F(9 M-AIRM1:IMG&IA&!:\$L:1>\$!2M!'6:PUDSY@R.S-D77 UI\$. \$9!>-T(^8LZ+ MD!& "H8X2IKMHG%8!V>7L- !P>B"RV:IN'Z&U3-L+((W1!072N0!))< Z3(T MUZ:.60F!A%9JGZ]'-#ZH'C(*!?'&Y'CIE>G@*Y:&O%N@GL! !:-!*K^! (+ M.7!N?<^E!|IGT/:2MSAD6R4)RU3393>* M\$!Y"~V!U4_5*E=? EKIDHN#Q.Y.FOH70^+. Y/% GM.T+.T.WF)&Y M"M-2D& #^>G%>IKB.=D\$N7V85VWGV-'1^>?!4."CISR6'<>|J(AJ!&&F. # M0X=Y>U^89Y7&4#04:6RL)"O&MVXU \$L% !D8"V@!X.O40+R4E5@.5O& RN0 MHGO.C\$7H<.>77% CT9+CVZ9EM6ZO*7<9:2)2.<0!F!-G!K>9:'!51W/55OR ML+XJ.053L ^6:W(GPP13A8+\$DACE!>F2I+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X\$G:V#P(RN:LYJ7IE.6>FMM# DL6XA9\$N)-7>W5YYNTB42%(P# 4A M%W+CI^<3:G>_U_HL@6V\$5#JDU1?2*OXG/I/3-R0IA4)? NVB8+A=OB5.VI&XXF M8\$O#>FZ=+22_VU!4:07/4.SHYG@'K.'MYA.L0Z1^P7V*BH 1JV*^N!/^26<_J!|8\$@F.S6VZ3VW>_? .2K6J5D*O\$ M2P=!'Y!&XO;!#1?CQ1BK::QK<::0OY@%CS#*F.-'^19H..!6+K#F.'F! MU4#E/IQ4#6CV#30.9FV-J/D3@H!W!O#;:#"O(IA8N_5!+ P04 M" DBF991M|PF/D% #>'P &_AL+W=OP)

[illegible]

QGNR=LJYAM9"<& 5G+TGY1Y+15ECP+DFF(NE,3+0Q(6BH7FX)@B+=Y"? MKRD5IXUX@.PQG=G 4SL#/'!0 "2*9EGXW/(N!@&4> 9 > &PO M=VJR-W-H965TS317 M R?>H'W"?CQ3UPY&A>0+G? P77TM:0+IG*2ELUA!&0?)WHJ5S(S\$Q) M!H-TA.1BL.5NE@G3N-73K87VJ|@E YYZH7!>YXXW\$W\$TG8UR/%1."YJR+?" M>XMQ9G<*M Q&=8"/YB!/@9:=(0B6)/7CZ&@/J |6C12>0 R6L WGN8 MHSAT-X3JLY4WK |ZL-?K(YG) 095=BC7F/C27LR68|ZR/M!F| MF&?"SS<|J MZP V3

(C=AS:;#1, L E8P;3S71?7?7PVGU04;P-WUEOW":;#=:YEC A,7222SD75F MH106N,KE#5M, #4:,231AN":; #WI#AP+1)960K6C* "H, *T2H:YH21 43S? M.P;#-8T#P#,10 /YK(PW-
 GZ=AS:;#1, M6K1L7(PECD+;UHAH;16F%Z3J2JWJ,MI) @JVSU05,B-#*Z1 DK -WB#OT 7W%GK/=> QON(H#E)+D2516GHWWUOUB @XOS?O*=>IASO? CG1GKXZ72G/L @/OQOZ?O/L-
 NCX/L ^ _6C@&(B MDIR)B@/Z<3X7DJOW^6=7OVO&H)MIWW^#4>(\$1L:ZO 3P%5CIVS?NP/G<5>QC MDL7")L>B6RO+4;^EN O @J8M4K4%-FH"/5NSH"/@LC3KI4; /#IJ?S*G+=
 MLJ>[5;2J4 2V7>+GKXCCKRO,WWJ,W^#UF/L:;J5V?^HJ@2X#A0F92<B? MC1U)IT7+YU-YF5B/LC5;W,^JII+>I2:P5D 2-P2R=<8;XD5?<#BJ4T, N.H.N:U?^TW
 MDI5FN,R95?+>#JUNO<=>ZCG"/L>J.#MI 76I02P.\$% @J(F69=1 L MQ-L< @ 100 ID IX:"I;W;WUB/LC53;CM.P,MS/T5RT0/OC2+>M#?T5N?E85=5^>^!> FDI1.7X+M-.O?<
 XTL:BM2M;L21 MIJPS9R8SS@;T:G4+8- 39T+GN#6G6T1+>EO@L,IDI+>2%)QBJRIFDFA"DCE M090%21Q21YQO@8O.GVU4D, @J(HY#N,22J1QI8"1QI)>+>#6U:XPZB(NM(M
 SPL7N-LE8T1524@/U4?2@SOQJIOERGSMI?P2J,1L#A H.G.VN=M<ID3#C632:67;+ J?C: MLQLY7 8SY7C?43/O&HO&F4IMH/H*M DY#6,G36<30)I,TA&O.)U
 MATI>Y2TQI,B4?JRWI;-7RJFW4%>^RLXH?>TLMSA0I&R#=#I?Y6AHDO? MT0-IBKABH5>W8 AE^C46&10.O.R)R#X'XN09X@ H7@K3:0151%IBX^LRSE?<
 MQ52IA@==<?2J5VVB+;+5,1W18T01 L.M:H6.NB.EY<@.B09U #RI?&# CCI>I2L6M-41;S15% >@D*SMI/552J?2GL;.
 MY^XIFQOQOY?>D1?>32.AQ4XP=SHU+VPHONFDGZ&5R%UOOK@:XGJB#H78 MU18;S9N"H,13"/JPI60>+VYK7U'O'D'>U1+;8Z&"S"3,424\$1#10 M ("29EGJL_RM8 8-
 &PO=VIR:W-H96513=>1 ML:;%YPM<S+2WD-RM6YHF0E^S2RK-XTS@)BIE5M1+>NBN&C=SI:FMY2157R3;.)M05H2K2KIE>L;CVI&#.)2J1I#W6512AC15EU<+<
 <IG3CACFEM&%"I2>=>^ M7M(LJYCD/I?22?>F78.NE=ID'U>+>"GF+NTDF6.ITN0,9\$SI?DIJ2V7B1OY,MI-M;D5W5YEOX@+^EJL P&+^1.X;H&M?21I1HU72I9+XKV0,H*
 1DIJS4WT^M, 2HEHH MMZ4WZ;23LQOZ5J&78;NF6E2(LU, 6W@5=%LSJK M1)\$5?^IQM1)JHZ^W\$3AY1PZ1 6D1OFS8CB?%D^FL P&DZ&FJZ;"=TT4P(9@O MIIJ9(384IG
 L<_O, YH:J31@OEE1B6P0C(=%B)C8YU^82?#P>JIL>Z.MF7FU>L2Y+V=,T8A%M?O\$16-41#Y1B16#R&L^0?T48<=>."4I
 MH:Y1Z2G08D?P)QGC.O^L2I8#N7N614+JIV&SMV;Q2F&@>P4Y1H8@M%W'BGO-M#1)SH+(6<S7;3GHWHXKO/O<774"?W4+LRNHIE(E61CQ+1%VY0281IU3K M\$^C#1.HZ>
 >@8J?7JHIT"(1I-2GFSN@IQ20=>^)IQ(ODXQJ;GTAI>=>#H.LF.MI(C^E44U@OW-9-Q?7E:U#0SI%QO:P:#W1#&#_O, 13:0W3Z Z^B,JI4L@; MP6>3?/L1)F5C2^I;^FDI2-YX,153IX&%
 J#&#(HMJ1I<+F&L X^L^I?2' M1MV7K2I;CESEOB@.8I=8VR213;8DMDD@T1 RI:G5,UD^Z>CPV23+;+MMB&X;IJBND1,IOKX=74C
 M0@/JH<YT&#&41V,1"1PUORB&I9X8RS051\$#(6)"K+U@, =FH^C604Z16 MX=>31+R R OA=U18X,C<5/M#A849F-CWWZK+>51MEB6VS#(2I)4#OF^21
 ML75Z.DPVV2?K+;#MBF4&8^OX+P7NOZROUGY043G\$(6I.T, @=D,1U^8Q4*Y1" M46I(8P1 3N74; M^8L1;59QJMLL2VY863Z,@YKDI6&UUK+)%5MEB6VS#/_6M#C# S7E9^3E^
 MP3(JI<@04U)M, FMY4ILG0?P?2?U@JIV6,5J1ES6A62F?K+>#MMN&ACKY, MP_Y@>31,28ICE2VRRRA;8AN&J6^W/L+G=>D%U2I(SF.XHY I="CUII=(RN MJ.8)YA12=>I&A?<
 BQ/GNGW+>9Y=0(CR4# "A#& M.O.M AL+W@O?#>FUR:;I=&=<=<K,21K+&8LZ2?2VIGGN3?IENN:B3 MS8 B#VGV,Y(B-E,H.3%&L,14=O&&Y9<9%2A5.O-N5&
 U4J)8CF7U5)3& MSN@/A16&9 JYI78P40F:41%3O(-;D6;KSX5YO(Z47C#PPU=PP+V4S68F M<9&6+&&L1O9T3.F1+&F TY,K<818VB1((%M, @>K'B:0)H(S?A1-;^@YI
 2IUS@EP'D,UX) MN?7 J5;#5P185T2T?NNEGXG@?P.IXJ.AXIOB=&2R^8>?1S, 8K9GP+&I3 MKS^B+U@4HDL4(F(V9IO%IYQ)12^1821%6N0X1WY3@>I.D.U)=%X2?^P=6;
 M4413Z0SQ(SIB7BF42T)H^K=>+<9E1<=>E8XQ@C@4NN.5.1)1,60E8P7Y0Q MYPUX14L+>A394>32.21E17IS; #JIBV1'63J5J+D-7G&11G^>@.%;U2D>SEFODKNOXIK
 MY41S@>3X7L1 _SOR& 1LAQ^JZAU/215->#>RO/NH^X^CI27^88" ML21R^N2?>1LAJ38H^HW9^"I" =D&V2'6V2351L@A+K1+I^W^6CZ2&6J3 DMH<5&H<3-;
 H2V4&&E6&^HTG9P8B,?P#R1A>4BS(QN&2IRW=9AIOE 76H:65? MFC;., @=O<^C-5Y5 ^F+6DLOF(N15PIB)W5S;XD<8^?I7:k7IIR-R,O+1M^J4JF@UZS1VWT6I (>^>:-
 ZOL:S3)(\$5C^Z03QM(NB(2XFBE,RCF)%2;1/2#3^?P@06@ "KSA7NXE64/V5C#4\$1#10 (@^29EDG&PO=VIR:W-H965T,KK.@+*2)XPSLB:Q-9MDYOIS; @J@QBIB:0
 M@>^U.IB1ZLV61MYSIY-2I@U1^DE9IO&C+DX^2+>U@/IWSBI@9B+>2+>DQ, M.J.TE?7GW?^WJ=3RTI0F(5L5,S5;>^VR7R&4I2U _%2?^?G&G@Z><?^?>I>1
 M?>67,DB91LMS, @I7<3,V1A>9LOP@2,3^WU414:"@XYR145I+>8Z%FH=LFEC M(CEA=0133-6 ZOI1B&S:QV@&@&4#1?2?2I?>Z-E&T?P@0 2#&J1D125NIY5G
 MPGE4TMSL",226A4%2SID7F12I)@3A?0@OKU;."@BFI15<5I@>@GB+&+M&CERRDDJW1?2?#EAB4W;@&O<OW2.Y8>CY6YU50HRI@>9#J+V14^#M1,109A(\$,M5.AICTD:A,D'=
 (^&RST.MT1^X% ,GCAT3?A@A-JH+22I-710^W>0?DIP?T MT<=>RUV" C-UUBVQGC#;(BWE9BEHNI1?T7MB1)I8.A:UG@Q<4B,Y7KFEX?W.MVLIY6W;U=DU,7KEINIEO-
 Y+CTL=,?S^T^?/1R1M/5'S, 9OSG-IOI2B/ MSIMSD1A:LJFG8:T9C .A.Z.KVV"0I(2)@/I-.FIEJ,1#ZGVS;1#^Z0L M:4CC%6M@;I.R.BZSO PKP<-
 LA@Z5 #JIF(N1/215=H2O:Q&XIKYN4M E^<43,M<94 6-OD=AM%5D5XZU7?FX-P>#S2IWGY(/=TS,D-^S6IFBBWCRL5M<C9>#& M^8N%SPKSOGCZK:D^Y%FD,
 IJF(&@>H^";#78;D;@R:RBGINZT5=H5%2IEI3S MRPX;1" W1L8,2,K^=DE&R&R&C)MJJH+&U%&G&WGIA(IIS=IUR4;^#SB8&P33YFA,P@FE3@YWM^#ADIPQZ.C*Y3
 4&3"IIK;I:~4NHBG@Q@O-1QDFE=18>D>07M52Q2TA==:" MNND141VBC51TOQW=6&)&1P%32M80G.G\$&#^8^DNL251I&W+IUF(SCOMYC2= MM;LDIO?54Y>NFC8:-
 (^T57ZSY-G,2)Y8YG34I17@>I-^?DI?Y>=>Y4& M1M18N<@)@I1YH

<C>F1PFV07P00IRWIL/IWO_MZ3C9{YL1}+:\$+^ZAVPRJ=X\VSRL5BJKOR^8(2S/L49RJIXS-HD9JIZMC8AKF=/0.-/RO(E(8TGYSU^UTJ^FY(LG<3
MCMG_#G@YL7).MGYSN_T&ZW:6V:L7ILX^4_M3Z:QN^1#7V7GHJ>G4J8:MZ3_.'N-SK2(ZGEU_L M9%UHSI_B6V(L2?IV>_T&IO97IWA^CVI_Sl-Gi/NR.2YQW6_T/IBS@?120
M/B2DC0+2AX+Th2%15^'U^'I^A6E58JH.874G&J)3DSUIZB:4UC-^:FM%AS MBJR'QJN@R^HHL@'^*K(BJZ@'CBBR'HJL@B^KH4:4&K0M^*+6%>D+BJP^1=:'
M(M(EID:6@R%09{THLDI^K)(BJZ3^BFR7HJLDB^KLJ.@)^:BJR2(EID:6D MR%129^TIL1846AN^K^%5UI(WB:TF1M:3^4(JBBR^HJLB&^KHLBJ+^)(BJR^)(JNB MR^HHLBJ^K)HBJZ:
(JBFR:HJLFB^KILBJ^:)(JBJR:(INFR%119^THLE8462N^ MK15%UHHB:T61M:+(6E%DK2BRKBFRKO^GK-.'W/YG_ZW/Ps_M4\$!_A0#%@) (IF60=136*!_L0 ! (! M
&108UBR:WIS+V%P<^YX:Q002P\$%^_4^ DBF99?P.A1_K @ M\$0 @ &O 9&IC4^O<^,OBVIR92YX:G002P\$%^_4 M^ DBF99F5R<(Q &^<^P \$P @^ - 0 > &PO=&AE:640
M=&AE:640+GAM:~+ 04_Q0 ("2*9EE&WW^8^04_X2^8 M^) @0X1X:'JW:WK&PO=VJR:W-H M965T&UL4\$!_A0#%@) (IF62_>85CV_P001!_M ("JAB^'AL+W=OS@LZD\$^_1^
M0#0 @ (&@P>+&PO=VJR:W-H965T&UL M4\$!_A0#%@) (IF65^&SOU1^ 3N<_!@ C^'IBB< M^'AL+W=ODI_IX:'JW:WK&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF M677/8NB*^@
G0<_!@ C^'1^<^<^'AL+W=O&UL4\$!_A0#M^@) (IF66)9IMU@ @ P<@< ID C^'1^VD?T^'AL+W=OMM_IX M:'JW:WK&UL4\$!_A0#%@) (IF6<6%NDIA9 M\$ J2 ID C^'107H
'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF63C^'A18 ID M ("I19.'AL+W=O&PO=VJR M:W-H965TVRC X^PF M 9^) @?A_IX:'JW:WK&UL M4\$!_A0#%@) (IF6:JR2A?@
IA_ID C^'1IN M^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@ @ M(IF65^?Z&F^&^ RQ4 ID C^'1B_5^'AL+W=O&PO=VJR:W-H965T+@0_P) 9^) @&UL4\$!_A0#%@) (IF6:3CX0%!@ M\$
X ID C^'1M8^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF62^VIA P&^&^ W% @ ID M ("JZ<^<^'AL+W=O&PO=VJR:W-H M965T&UL4\$!_M A0#%@) (IF68:.'C! MOH ID C^'1ZAS!
'AL M+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF6 M67B^!_L H ID C^'1A1^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF672^ICZ:.'@ &S M ID C^'1^RT!
'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF63'D9(!_W0 ID M ("13T1^'AL+W=O&PO=VJR:W-H965T M&UL4\$!_A0# M% @) (IF6112&Y_LIP 2S ID C^'1J\$T!^'AL+W=O
M^002&PO=VJR:W-H965TQ8 M 0!X:'JW:WK&UL4\$!_A0#%@) (IF6=R MC1-F1P)DP ID C^'15P1^'AL+W=O8Ps >&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF6>IK^K E8! I10 ID M
C^'1IWB1^'AL+W=OPS >&PO M:VJR:W-H965TE_0!X:'JW:WK&UL4\$!_A0#%@) (IF62^0P:Y1_P 00L ID C^'1M6H1^'AL+W=O&PO=VJR:W-H965T^* 0!X:'JW:WK&UL4\$!_A0#% M
) (IF67IB>URN @ +0< ID C^'1!CX1^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF68^FOKX3 M^@ P@ @ P@ @ C^'1O&PO=VJR:W-H965T_0!X:'JW:WK&UL4\$!_A0#%@)
(IF6>/OMVY+14 ID M ("IS^!^'AL+W=O&PO=VJR M:W-H965T&UL M4\$!_A0#%@) (IF616CID@ P 8@L ID C^'1C:.\$ M^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@ @ M)
(IF64!>L:P1_P B@L ID C^'1+L1^'AL+W=O&PO=VJR:W-H965T@?:_?_8% 9^) @=G/O_IX:'JW:WK&UL4\$!_A0#%@) (IF63L1^#17 @ K@D ID M ("1C:.'1^'AL+W=O^& @ (&:U0\$
>&PO=VJR:W-H M965T&UL4\$!_M A0#%@) (IF66ZM^&^9!0 9B< ID C^'1-X1^'AL M+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF M62_B@!'K10 LB_ID C^'1!@>P!
'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF68Y0T13>_1AP M ID C^'1IOH1^'AL+W=O&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF69=L^O!< @ 100 ID M ("IV 8^"
'AL+W=O&PO=VJR:W-H965T M&UL4\$!_A0# M% @) (IF62=RPL(H10 IB8 ID C^'1A_1^'AL+W=O M\$P\$M(# \$ M% &0 @ (%&I^ (>&PO=VJR:W-H965T&UL4\$!_A0#%@) (IF68^K
MH%1G P G1< T^'HBB^'AL+W=T>6QE&PO=VJR:VJO:VLN> &UL4\$!_A0#%@) (IF65J_Z@F M @ F#4 IH ("1CBT^'AL+UIR960S+W=O XML 101 Show.js IDEA: XBRL
DOCUMENT /_Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope
of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null;Show.showAR=function(a,r,w)
fif(Show.LastAR)Show.hideAR()var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if((e.nodeName!='TABLE')fvar ref=(window)?
w.document.document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}
if(e.style.display='block';Show.LastAR=e);Show.hideAR=function()f(Show.LastAR.style.display='none');Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if((e.style){e.style.display}=e.style){e.style.display='none'}d='block';p='t'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML 102 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { font-size: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a: hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */.pl a .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th,td { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { font-size: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td,td a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td,td,td a: hover {
background-color: #ffc; } /* Header rows... */.report tr,th { background-color: #acf; color: black; font-weight: bold; } .report .rc { background-color: #f0f0f0;
} /* Even rows... */.report .re .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */.report .ro .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */.report .num .report .num { text-align: right; white-space: nowrap; } .report .num { padding-left: 2em; }
.report .num { padding: 0px 0.4em 0px 2em; } /* styles for text types */.report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 104 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 360 441 1 true 94 0 false 7 false false R1.htm 100000 -
Document - Cover Sheet http://www.standardbio.com/20240930/taxonomy/role/Cover Cover Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance
Sheets Sheet http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false
R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet
http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements
3 false false R4.htm 100050 - Statement - Condensed Consolidated Statements of Operations Sheet
http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false
false R5.htm 100060 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet
http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss
Statements 5 false false R6.htm 100070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) Sheet
http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders'
Equity (Deficit) Statements 6 false false R7.htm 100080 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) Sheet
http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical Condensed Consolidated
Statements of Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 100090 - Statement - Condensed Consolidated Statements of Cash Flows Sheet
http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false
false R9.htm 100100 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet
http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash
Flows (Parenthetical) Statements 9 false false R10.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs
Performance Disclosure Notes 10 false false R11.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements
Insider Trading Arrangements Notes 11 false false R12.htm 995455 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of
Significant Accounting Policies Notes 12 false false R13.htm 995465 - Disclosure - Business Combination Sheet
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombination Business Combination Notes 13 false false R14.htm 995475 - Disclosure - Revenue and
Geographic Area Sheet http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicArea Revenue and Geographic Area Notes 14 false false R15.htm 995485 -
Disclosure - Goodwill and Acquired Intangible Assets, net Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNet3
Goodwill and Acquired Intangible Assets, net Notes 15 false false R16.htm 995495 - Disclosure - Balance Sheet Details Sheet
http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetails Balance Sheet Details Notes 16 false false R17.htm 995505 - Disclosure - Debt Sheet
http://www.standardbio.com/20240930/taxonomy/role/Debt Debt Notes 17 false false R18.htm 995515 - Disclosure - Leases Sheet
http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeases Leases Notes 18 false false R19.htm 995525 - Disclosure - Commitments and Contingencies Sheet
http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 995535 - Disclosure -
Fair Value of Financial Instruments Sheet http://www.standardbio.com/20240930/taxonomy/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 20
false false R21.htm 995545 - Disclosure - Mezzanine Equity Sheet http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquity Mezzanine Equity Notes 21 false
false R22.htm 995555 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficit
Stockholders' Equity (Deficit) Notes 22 false false R23.htm 995565 - Disclosure - Stock-based Compensation Sheet
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensation Stock-based Compensation Notes 23 false false R24.htm 995575 - Disclosure - Net Loss Per
Share Sheet http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShare Net Loss Per Share Notes 24 false false R25.htm 995585 - Disclosure - Income Taxes Sheet
http://www.standardbio.com/20240930/taxonomy/role/IncomeTaxes Income Taxes Notes 25 false false R26.htm 995595 - Disclosure - Segment Reporting Sheet
http://www.standardbio.com/20240930/taxonomy/role/SegmentReporting Segment Reporting Notes 26 false false R27.htm 995605 - Disclosure - Restructuring and Related
Charges Sheet http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedCharges Restructuring and Related Charges Notes 27 false false R28.htm
995615 - Disclosure - Related Parties Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedParties Related Parties Notes 28 false false R29.htm
995625 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary
of Significant Accounting Policies (Policies) Policies
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 29 false false R30.htm 995635 - Disclosure
- Business Combination (Tables) Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationTables Business Combination (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombination 30 false false R31.htm 995645 - Disclosure - Revenue and Geographic Area (Tables)
Sheet http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaTables Revenue and Geographic Area (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicArea 31 false false R32.htm 995655 - Disclosure - Goodwill and Acquired Intangible Assets, net
(Tables) Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetTables Goodwill and Acquired Intangible Assets, net
(Tables) Tables http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNet3 32 false false R33.htm 995665 - Disclosure -
Balance Sheet Details (Tables) Sheet http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetails 33 false false R34.htm 995675 - Disclosure - Debt (Tables) Sheet
http://www.standardbio.com/20240930/taxonomy/role/DebtTables Debt (Tables) Tables http://www.standardbio.com/20240930/taxonomy/role/Debt 34 false false R35.htm
995685 - Disclosure - Leases (Tables) Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeases 35 false false R36.htm 995695 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet
http://www.standardbio.com/20240930/taxonomy/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/FairValueofFinancialInstruments 36 false false R37.htm 995705 - Disclosure - Stockholders' Equity (Deficit)) (Tables)
Sheet http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables Stockholders' Equity (Deficit)) (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficit 37 false false R38.htm 995715 - Disclosure - Stock-based Compensation (Tables)
Sheet http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables Stock-based Compensation (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensation 38 false false R39.htm 995725 - Disclosure - Net Loss Per Share (Tables) Sheet
http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShare 39 false false R40.htm 995735 - Disclosure - Segment Reporting (Tables) Sheet
http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingTables Segment Reporting (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/SegmentReporting 40 false false R41.htm 995745 - Disclosure - Restructuring and Related Charges (Tables) Sheet
http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesTables Restructuring and Related Charges (Tables) Tables
http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedCharges 41 false false R42.htm 995755 - Disclosure - Basis of Presentation and Summary of
Significant Accounting Policies - Narrative (Details) Sheet
http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and
Summary of Significant Accounting Policies - Narrative (Details) Details

[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies 42 false false R43.htm 995765 - Disclosure - Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies 42 false false R43.htm 995765 - Disclosure - Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred \(Details\) Details 43 false false R44.htm 995775 - Disclosure - Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred (Details) Details 43 false false R44.htm 995775 - Disclosure - Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed \(Details\) Details 44 false false R45.htm 995785 - Disclosure - Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed (Details) Details 44 false false R45.htm 995785 - Disclosure - Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger \(Details\) Details 45 false false R46.htm 995795 - Disclosure - Business Combination - Schedule of Unaudited Pro Forma Financial Information \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger (Details) Details 45 false false R46.htm 995795 - Disclosure - Business Combination - Schedule of Unaudited Pro Forma Financial Information (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfUnauditedProFormaFinancialInformationDetails Business Combination - Schedule of Unaudited Pro Forma Financial Information \(Details\) Details 46 false false R47.htm 995805 - Disclosure - Business Combination - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfUnauditedProFormaFinancialInformationDetails Business Combination - Schedule of Unaudited Pro Forma Financial Information (Details) Details 46 false false R47.htm 995805 - Disclosure - Business Combination - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails Business Combination - Narrative \(Details\) Details 47 false false R48.htm 995815 - Disclosure - Revenue and Geographic Area - Schedule of Disaggregation of Revenue \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 47 false false R48.htm 995815 - Disclosure - Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleOfDisaggregationOfRevenueDetails Revenue and Geographic Area - Schedule of Disaggregation of Revenue \(Details\) Details 48 false false R49.htm 995825 - Disclosure - Revenue and Geographic Area - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleOfDisaggregationOfRevenueDetails Revenue and Geographic Area - Schedule of Disaggregation of Revenue (Details) Details 48 false false R49.htm 995825 - Disclosure - Revenue and Geographic Area - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails Revenue and Geographic Area - Narrative \(Details\) Details 49 false false R50.htm 995835 - Disclosure - Revenue and Geographic Area - Summary of the Change in Deferred Revenue \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails Revenue and Geographic Area - Narrative (Details) Details 49 false false R50.htm 995835 - Disclosure - Revenue and Geographic Area - Summary of the Change in Deferred Revenue (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails Revenue and Geographic Area - Summary of the Change in Deferred Revenue \(Details\) Details 50 false false R51.htm 995845 - Disclosure - Revenue and Geographic Area - Performance Obligations \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails Revenue and Geographic Area - Summary of the Change in Deferred Revenue (Details) Details 50 false false R51.htm 995845 - Disclosure - Revenue and Geographic Area - Performance Obligations (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails Revenue and Geographic Area - Performance Obligations \(Details\) Details 51 false false R52.htm 995855 - Disclosure - Revenue and Geographic Area - Performance Obligation \(Details\)1 Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails Revenue and Geographic Area - Performance Obligations (Details) Details 51 false false R52.htm 995855 - Disclosure - Revenue and Geographic Area - Performance Obligation (Details)1 Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1 Revenue and Geographic Area - Performance Obligation \(Details\)1 Details 52 false false R53.htm 995865 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1 Revenue and Geographic Area - Performance Obligation (Details)1 Details 52 false false R53.htm 995865 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDet Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment \(Details\) Details 53 false false R54.htm 995875 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDet Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment (Details) Details 53 false false R54.htm 995875 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets \(Details\) Details 54 false false R55.htm 995885 - Disclosure - Goodwill and Acquired Intangible Assets, net - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets (Details) Details 54 false false R55.htm 995885 - Disclosure - Goodwill and Acquired Intangible Assets, net - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails Goodwill and Acquired Intangible Assets, net - Narrative \(Details\) Details 55 false false R56.htm 995895 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails Goodwill and Acquired Intangible Assets, net - Narrative (Details) Details 55 false false R56.htm 995895 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangible Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net \(Details\) Details 56 false false R57.htm 995905 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangible Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net (Details) Details 56 false false R57.htm 995905 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryOfCashandCashEquivalentsDetails Balance Sheet Details - Summary of Cash and Cash Equivalents \(Details\) Details 57 false false R58.htm 995915 - Disclosure - Balance Sheet Details - Accounts Receivable \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryOfCashandCashEquivalentsDetails Balance Sheet Details - Summary of Cash and Cash Equivalents (Details) Details 57 false false R58.htm 995915 - Disclosure - Balance Sheet Details - Accounts Receivable (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccountsReceivableDetails Balance Sheet Details - Accounts Receivable \(Details\) Details 58 false false R59.htm 995925 - Disclosure - Balance Sheet Details - Inventory \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccountsReceivableDetails Balance Sheet Details - Accounts Receivable (Details) Details 58 false false R59.htm 995925 - Disclosure - Balance Sheet Details - Inventory (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails Balance Sheet Details - Inventory \(Details\) Details 59 false false R60.htm 995935 - Disclosure - Balance Sheet Details - Property and Equipment \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails Balance Sheet Details - Inventory (Details) Details 59 false false R60.htm 995935 - Disclosure - Balance Sheet Details - Property and Equipment (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails Balance Sheet Details - Property and Equipment \(Details\) Details 60 false false R61.htm 995945 - Disclosure - Balance Sheet Details - Accrued Liabilities \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails Balance Sheet Details - Property and Equipment (Details) Details 60 false false R61.htm 995945 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails Balance Sheet Details - Accrued Liabilities \(Details\) Details 61 false false R62.htm 995955 - Disclosure - Balance Sheet Details - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails Balance Sheet Details - Accrued Liabilities (Details) Details 61 false false R62.htm 995955 - Disclosure - Balance Sheet Details - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails Balance Sheet Details - Narrative \(Details\) Details 62 false false R63.htm 995965 - Disclosure - Debt - Schedule of Carrying Value of Debt \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails Balance Sheet Details - Narrative (Details) Details 62 false false R63.htm 995965 - Disclosure - Debt - Schedule of Carrying Value of Debt (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails Debt - Schedule of Carrying Value of Debt \(Details\) Details 63 false false R64.htm 995975 - Disclosure - Debt - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails Debt - Schedule of Carrying Value of Debt (Details) Details 63 false false R64.htm 995975 - Disclosure - Debt - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails Debt - Narrative \(Details\) Details 64 false false R65.htm 995985 - Disclosure - Leases - Schedule of Lease Cost \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails Debt - Narrative (Details) Details 64 false false R65.htm 995985 - Disclosure - Leases - Schedule of Lease Cost (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails Leases - Schedule of Lease Cost \(Details\) Details 65 false false R66.htm 995995 - Disclosure - Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails Leases - Schedule of Lease Cost (Details) Details 65 false false R66.htm 995995 - Disclosure - Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities \(Details\) Details 66 false false R67.htm 996005 - Disclosure - Leases - Schedule of Supplemental Lease Information \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities (Details) Details 66 false false R67.htm 996005 - Disclosure - Leases - Schedule of Supplemental Lease Information (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalLeaseInformationDetails Leases - Schedule of Supplemental Lease Information \(Details\) Details 67 false false R68.htm 996015 - Disclosure - Leases - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalLeaseInformationDetails Leases - Schedule of Supplemental Lease Information (Details) Details 67 false false R68.htm 996015 - Disclosure - Leases - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails Leases - Narrative \(Details\) Details 68 false false R69.htm 996025 - Disclosure - Commitments and Contingencies - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails Leases - Narrative (Details) Details 68 false false R69.htm 996025 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative \(Details\) Details 69 false false R70.htm 996035 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 69 false false R70.htm 996035 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy \(Details\) Details 70 false false R71.htm 996045 - Disclosure - Fair Value of Financial Instruments - Summary of Available-for-Sale Securities \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details) Details 70 false false R71.htm 996045 - Disclosure - Fair Value of Financial Instruments - Summary of Available-for-Sale Securities (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails Fair Value of Financial Instruments - Summary of Available-for-Sale Securities \(Details\) Details 71 false false R72.htm 996055 - Disclosure - Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails Fair Value of Financial Instruments - Summary of Available-for-Sale Securities (Details) Details 71 false false R72.htm 996055 - Disclosure - Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis \(Details\) Details 72 false false R73.htm 996065 - Disclosure - Fair Value of Financial Instruments - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 72 false false R73.htm 996065 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative \(Details\) Details 73 false false R74.htm 996075 - Disclosure - Fair Value of Financial Instruments - Schedule of Warrants Liabilities \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 73 false false R74.htm 996075 - Disclosure - Fair Value of Financial Instruments - Schedule of Warrants Liabilities (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails Fair Value of Financial Instruments - Schedule of Warrants Liabilities \(Details\) Details 74 false false R75.htm 996085 - Disclosure - Mezzanine Equity - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails Fair Value of Financial Instruments - Schedule of Warrants Liabilities (Details) Details 74 false false R75.htm 996085 - Disclosure - Mezzanine Equity - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails Mezzanine Equity - Narrative \(Details\) Details 75 false false R76.htm 996095 - Disclosure - Stockholders' Equity \(Deficit\) - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails Mezzanine Equity - Narrative (Details) Details 75 false false R76.htm 996095 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails Stockholders' Equity \(Deficit\) - Narrative \(Details\) Details](http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails Stockholders' Equity (Deficit) - Narrative (Details) Details)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables 76 false false R77.htm 996105 - Disclosure - Stockholders' Equity \(Deficit\) - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables 76 false false R77.htm 996105 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails Stockholders' Equity \(Deficit\) - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans \(Details\) Details](http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetails Stockholders' Equity (Deficit) - Schedule of Shares Reserved for Future Issuance Under Equity Compensation Plans (Details) Details)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables 77 false false R78.htm 996115 - Disclosure - Stock-based Compensation - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables 77 false false R78.htm 996115 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative \(Details\) Details 78 false false R79.htm 996125 - Disclosure - Stock-based Compensation - Restricted and Performance Stock Units \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 78 false false R79.htm 996125 - Disclosure - Stock-based Compensation - Restricted and Performance Stock Units (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails Stock-based Compensation - Restricted and Performance Stock Units \(Details\) Details 79 false false R80.htm 996135 - Disclosure - Stock-based Compensation - Stock Option Activity \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails Stock-based Compensation - Restricted and Performance Stock Units (Details) Details 79 false false R80.htm 996135 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity \(Details\) Details 80 false false R81.htm 996145 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 80 false false R81.htm 996145 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-Based Compensation Expense \(Details\) Details 81 false false R82.htm 996155 - Disclosure - Net Loss Per Share - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-Based Compensation Expense (Details) Details 81 false false R82.htm 996155 - Disclosure - Net Loss Per Share - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails Net Loss Per Share - Narrative \(Details\) Details 82 false false R83.htm 996165 - Disclosure - Net Loss Per Share - Schedule of computation of loss per share \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails Net Loss Per Share - Narrative (Details) Details 82 false false R83.htm 996165 - Disclosure - Net Loss Per Share - Schedule of computation of loss per share (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails Net Loss Per Share - Schedule of computation of loss per share \(Details\) Details 83 false false R84.htm 996175 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails Net Loss Per Share - Schedule of computation of loss per share (Details) Details 83 false false R84.htm 996175 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedtoCommon Net Loss Per Share - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders \(Details\) Details 84 false false R85.htm 996185 - Disclosure - Income Taxes - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedtoCommon Net Loss Per Share - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details) Details 84 false false R85.htm 996185 - Disclosure - Income Taxes - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails Income Taxes - Narrative \(Details\) Details 85 false false R86.htm 996195 - Disclosure - Segment Reporting - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 85 false false R86.htm 996195 - Disclosure - Segment Reporting - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative \(Details\) Details 86 false false R87.htm 996205 - Disclosure - Segment Reporting - Schedule of Business Segment Information \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 86 false false R87.htm 996205 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails Segment Reporting - Schedule of Business Segment Information \(Details\) Details 87 false false R88.htm 996215 - Disclosure - Restructuring and Related Charges - Narrative \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails Segment Reporting - Schedule of Business Segment Information (Details) Details 87 false false R88.htm 996215 - Disclosure - Restructuring and Related Charges - Narrative (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails Restructuring and Related Charges - Narrative \(Details\) Details 88 false false R89.htm 996225 - Disclosure - Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails Restructuring and Related Charges - Narrative (Details) Details 88 false false R89.htm 996225 - Disclosure - Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities \(Details\) Details 89 false false R90.htm 996235 - Disclosure - Restructuring and Related Charges- Restructuring and Other Efficiency Costs \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails Restructuring and Related Charges- Summary of the Changes in Our Restructuring and Other Related Liabilities (Details) Details 89 false false R90.htm 996235 - Disclosure - Restructuring and Related Charges- Restructuring and Other Efficiency Costs (Details) Sheet)
[http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails Restructuring and Related Charges- Restructuring and Other Efficiency Costs \(Details\) Details 90 false false R91.htm 996245 - Disclosure - Related Parties Additional Information \(Details\) Sheet](http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails Restructuring and Related Charges- Restructuring and Other Efficiency Costs (Details) Details 90 false false R91.htm 996245 - Disclosure - Related Parties Additional Information (Details) Sheet)

<http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd>, <http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd>, <http://www.xbrl.org/2006/ref-2006-02-27.xsd>, <http://www.xbrl.org/ir/arcrole/esma-arcrole-2018-11-21.xsd>, <http://www.xbrl.org/ir/role/negated-2009-12-16.xsd>, <http://www.xbrl.org/ir/role/net-2009-12-16.xsd>, <http://www.xbrl.org/ir/role/reference-2009-12-16.xsd>, <https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd>, <https://www.xbrl.org/2023/calculation-1.1.xsd>, <https://www.xbrl.org/dtr/type/2020-01-21/types.xsd>, <https://www.xbrl.org/dtr/type/2022-03-31/types.xsd>, <https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd>, <https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd>, <https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd>, <https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd>, <https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd>, <https://xbrl.sec.gov/country/2024/country-2024.xsd>, <https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd>, <https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd>, <https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd> } } } . "keyStandard": 355, "keyCustom": 86, "axisStandard": 33, "axisCustom": 0, "memberStandard": 50, "memberCustom": 41, "hidden": { "total": 15, "http://fasb.org/us-gaap/2024": 10, "http://xbrl.sec.gov/dei/2024": 4, "http://www.standardbio.com/20240930": 1, "contextCount": 360, "entityCount": 94, "elementCount": 791, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1097, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1, "report": { "R1": { "role": "http://www.standardbio.com/20240930/taxonomy/role/Cover", "longName": "100000 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b


```

"reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R19": { "role": "http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingencies", "longName": "995525 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R20": { "role": "http://www.standardbio.com/20240930/taxonomy/role/FairValueofFinancialInstruments", "longName": "995535 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R21": { "role": "http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquity", "longName": "995545 - Disclosure - Mezzanine Equity", "shortName": "Mezzanine Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "lab:MezzanineEquityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "lab:MezzanineEquityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R22": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficit", "longName": "995555 - Disclosure - Stockholders' Equity (Deficit)", "shortName": "Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R23": { "role": "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensation", "longName": "995565 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R24": { "role": "http://www.standardbio.com/20240930/taxonomy/role/IncomeTax", "longName": "995575 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R25": { "role": "http://www.standardbio.com/20240930/taxonomy/role/IncomeTaxes", "longName": "995585 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R26": { "role": "http://www.standardbio.com/20240930/taxonomy/role/SegmentReporting", "longName": "995595 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R27": { "role": "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedCharges", "longName": "995605 - Disclosure - Restructuring and Related Charges", "shortName": "Restructuring and Related Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R28": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedParties", "longName": "995615 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R29": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ] }, "reportCount": 1, "baseRef": "
```

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R37": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitTables", "longName": "995705 - Disclosure - Stockholders' Equity (Deficit) (Tables)", "shortName": "Stockholders' Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:DisclosureOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R38": { "role": "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables", "longName": "995715 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R39": { "role": "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareTables", "longName": "995725 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R40": { "role": "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingTables", "longName": "995735 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:SegmentReportingDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SegmentReportingDisclosureTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R41": { "role": "http://www.standardbio.com/20240930/taxonomy/role/RestructuringAndRelatedChargesTables", "longName": "995745 - Disclosure - Restructuring and Related Charges (Tables)", "shortName": "Restructuring and Related Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R42": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "995755 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:AmortizesInternalUseSoftwareCostsUsingStraightLineMethod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "lab:SoftwareDevelopmentCostsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:AmortizesInternalUseSoftwareCostsUsingStraightLineMethod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "lab:SoftwareDevelopmentCostsPolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R43": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitionDateFairValueOfConsiderationTransferredDetails", "longName": "995765 - Disclosure - Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred (Details)", "shortName": "Business Combination - Schedule of the Acquisition-date Fair Value of Consideration Transferred (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_9949ce98-a4f6-4ffd-bcd1-da5df96326e2", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9949ce98-a4f6-4ffd-bcd1-da5df96326e2", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssued", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationDisclosureTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "R44": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "longName": "995775 - Disclosure - Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed (Details)", "shortName": "Business Combination - Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "R45": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails", "longName": "995785 - Disclosure - Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger (Details)", "shortName": "Business Combination - Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_2cf849d7-d822-465a-b0a0-d3c73e6f9ced", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets

http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails", "longName": "995845 - Disclosure - Revenue and Geographic Area - Performance Obligations (Details)", "shortName": "Revenue and Geographic Area - Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C ad0e5827-50c5-4931-8392-74fd0ab7ba61", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true }, "R52": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "longName": "995855 - Disclosure - Revenue and Geographic Area - Performance Obligation (Details1)", "shortName": "Revenue and Geographic Area - Performance Obligation (Details1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe", "longName": "995865 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment (Details)", "shortName": "Goodwill and Acquired Intangible Assets, net - Schedule of the Changes in the Carrying Value of Goodwill by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C d28544d3-be12-4e79-80cf-265e3b8a108", "name": "us-gaap:Goodwill", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:Goodwill", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true }, "R54": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails", "longName": "995875 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets (Details)", "shortName": "Goodwill and Acquired Intangible Assets, net - Schedule of Acquired Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R55": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails", "longName": "995885 - Disclosure - Goodwill and Acquired Intangible Assets, net - Narrative (Details)", "shortName": "Goodwill and Acquired Intangible Assets, net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R56": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibl", "longName": "995895 - Disclosure - Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net (Details)", "shortName": "Goodwill and Acquired Intangible Assets, net - Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R57": { "role": "http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails", "longName": "995905 - Disclosure - Balance Sheet Details - Summary of Cash and Cash Equivalents (Details)", "shortName": "Balance Sheet Details - Summary of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true }, "R58": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccountsReceivableDetails", "longName": "995915 - Disclosure - Balance Sheet Details - Accounts Receivable (Details)", "shortName": "Balance Sheet Details - Accounts Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "lab:TradeReceivables", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "lab:TradeReceivables", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "R59": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails", "longName": "995925 - Disclosure - Balance Sheet Details - Inventory (Details)", "shortName": "Balance Sheet Details - Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:InventoryRawMaterials", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "div", "body", "html"] }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation",

LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails", "longName": "995995 - Disclosure - Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities (Details)", "isDefault": "false", "groupName": "Leases - Schedule of Operating Lease Undiscounted Lease Payment Maturities To The Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalLeaseInformationDetails", "longName": "996005 - Disclosure - Leases - Schedule of Supplemental Lease Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeaseInformationTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeaseInformationTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails", "longName": "996015 - Disclosure - Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "lab:NumberOffLeasesForOfficeAndLaboratorySpace", "unitRef": "U Office", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "lab:NumberOffLeasesForOfficeAndLaboratorySpace", "unitRef": "U Office", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.standardbio.com/20240930/taxonomy/role/CommitmentsAndContingenciesNarrativeDetails", "longName": "996025 - Disclosure - Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails", "longName": "996035 - Disclosure - Fair Value of Financial Instruments - Summary of Recurring Basis within the Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_67d392bf-0ea2-4e1a-9106-cdc3b3cbd02", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableForSaleSecuritiesDetails", "longName": "996045 - Disclosure - Fair Value of Financial Instruments - Summary of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "longName": "996055 - Disclosure - Fair Value of Financial Instruments - Schedule of Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_d28544d3-be12-4e79-80cf-265e3bd8a108", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d28544d3-be12-4e79-80cf-265e3bd8a108", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "longName": "996065 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_aa12961e-0a7a-435c-bf46-6c8607a189f9", "name": "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr",

```


Standard Disclosure - Restricted and Performance Stock Units (Details)", "shortName": "Stock-based Compensation - Restricted and Performance Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "C_458f1a91-faae-45bc-82f8-9124071b9112", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_458f1a91-faae-45bc-82f8-9124071b9112", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails", "longName": "996135 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)", "shortName": "Stock-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "C_d28544d3-be12-4e79-80cf-265e3bd8a108", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "lab:StockOptionsAssumedThroughAcquisition", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true } }, "R81": { "role": "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails", "longName": "996145 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)", "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails", "longName": "996155 - Disclosure - Net Loss Per Share - Narrative (Details)", "shortName": "Net Loss Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "C_e5f809f-515b-4403-a23d-f0d186673ff2", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2fd5a678-13f6-47d5-9a6e-09e1822a674", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:EarningsPerShareTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true } }, "R83": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails", "longName": "996165 - Disclosure - Net Loss Per Share - Schedule of computation of loss per share (Details)", "shortName": "Net Loss Per Share - Schedule of computation of loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2fd5a678-13f6-47d5-9a6e-09e1822a674", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true } }, "R84": { "role": "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedToCommonStockholders (Details)", "shortName": "Net Loss Per Share - Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureIncomeTaxNarrativeDetails", "longName": "996185 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "unique": true } }, "R86": { "role": "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingNarrativeDetails", "longName": "996195 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:SegmentReportingPolicyTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_226ec9df-d3c0-4a2f-b914-c00b99b43411", "name": "us-gaap:SegmentReportingPolicyTextBlock", "div": "ix:continuation", "div", "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "R87": { "role": "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails", "longName": "996205 - Disclosure - Segment Reporting - Schedule of Business Segment Information (Details)", "shortName": "Segment Reporting - Schedule of Business Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "lab-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3175a3da-92dc-45d0-bb63-bc7f1602050a", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals


```


"localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" I, "lang": { "en-us": { "role": { "negatedLabel": "Accretion of discount on short-term investments, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth ref": I "r116" I }, "us-gaap AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": I "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": I "r80" I }, "lab AccruedUninvoicedReceiptsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AccruedUninvoicedReceiptsCurrent", "crdr": "credit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Uninvoiced receipts", "label": "Accrued Uninvoiced Receipts Current", "documentation": "Amount of accrued uninvoiced receipts current." } } }, "auth ref": I I },
"lab AccruedWarrantiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AccruedWarrantiesCurrent", "crdr": "credit", "presentation": I "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" I, "lang": { "en-us": { "role": { "documentation": "Accrued warranties current.", "label": "Accrued Warranties Current", "terseLabel": "Accrued warranties" } } }, "auth ref": I I }, "us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails" I, "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth ref": I "r40", "r214", "r752" I }, "us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" I, "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth ref": I "r23", "r24", "r101", "r224", "r748", "r788", "r789" I }, "us-gaap AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" I, "lang": { "en-us": { "role": { "verboseLabel": "Accum. Other Comp. Loss", "label": "AOCL Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth ref": I "r4", "r13", "r24", "r593", "r598", "r655", "r784", "r785", "r1128", "r1129", "r1130", "r1140", "r1141", "r1142", "r1143" I }, "us-gaap AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails" I, "lang": { "en-us": { "role": { "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": I "r399", "r400", "r401", "r403", "r912" I }, "us-gaap AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Useful Life (Years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth ref": I "r401", "r912" I },
"lab AcquiredIntangiblesCumulativeDiscountedCashFlowPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AcquiredIntangiblesCumulativeDiscountedCashFlowPercentage", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Cumulative discounted cash flow percentage", "label": "Acquired Intangibles Cumulative Discounted Cash Flow Percentage", "documentation": "Acquired intangibles cumulative discounted cash flow percentage." } } }, "auth ref": I I }, "ecd Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth ref": I "r1047" I }, "us-gaap AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" I, "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "totalLabel": "Additional Paid in Capital, Total", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth ref": I "r92", "r982", "r1298" I }, "us-gaap AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": I "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" I, "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth ref": I "r801", "r1140", "r1141", "r1142", "r1143", "r1236", "r1299" I }, "ecd AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth ref": I "r1060" I }, "ecd AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth ref": I "r1060" I }, "ecd AdjToNonPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth ref": I "r1060" I }, "ecd AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } }, "auth ref": I "r1060" I }, "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": I "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" I, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth ref": I "r57", "r58", "r519" I }, "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" I, "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth ref": I I }, "ecd AggtChngPnsnValInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth ref": I "r1093" I }, "ecd AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth ref": I "r1019", "r1029", "r1039", "r1071" I }, "ecd AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": I "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" I, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth ref": I "r1022", "r1032", "r1042", "r1074" I }, "ecd AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth ref": I "r1094" I }, "ecd AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth ref": I "r1060" I }, "ecd AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": I "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth ref": I "r1067" I }, "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": I
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" I, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth ref": I "r1023", "r1033", "r1043", "r1067", "r1075", "r1079", "r1087" I }, "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": I "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" I, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth ref": I "r1085" I }, "us-gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth ref": I "r549", "r555" I }, "lab AllowanceForExpectedCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AllowanceForExpectedCreditLosses", "crdr": "debit", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccountsReceivableDetails" I, "lang": { "en-us": { "role": { "terseLabel": "Less: allowance for expected credit losses", "label": "Allowance For Expected Credit Losses", "documentation": "Allowance For Expected Credit Losses" } } }, "auth ref": I I },
"dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": I
"http://www.standardbio.com/20240930/taxonomy/role/Cover" I, "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth ref": I I }, "srt AmericasMember": { "xbrltype":

"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]", "documentation": "Continents of North and South America." } } }, "auth_ref": ["r1110", "r1111", "r1112", "r1113", "r1301", "r1302", "r1303", "r1304"] }, "lab_AmortizationOfAcquiredIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AmortizationOfAcquiredIntangibleAssets", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amortization of acquired intangible assets.", "label": "Amortization of Acquired Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "verboseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r9", "r398", "r405", "r940"] }, "lab_AmortizationOnProductByProductUsingStraightLineMethodOverPeriods": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AmortizationOnProductByProductUsingStraightLineMethodOverPeriods", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization on product-by-product basis using straight-line method over periods", "label": "Amortization On Product-By-Product Using Straight-Line Method Over Periods", "documentation": "Amortization on product-by-product using straight-line method over periods." } } }, "auth_ref": [] }, "lab_AmortizesInternalUseSoftwareCostsUsingStraightLineMethod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AmortizesInternalUseSoftwareCostsUsingStraightLineMethod", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortizes internal-use software costs using the straight-line method over the estimated useful life of asset", "label": "Amortizes Internal-Use Software Costs Using Straight-Line Method", "documentation": "Amortizes internal-use software costs using straight-line method" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r589"] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Asia-Pacific", "label": "Asia Pacific [Member]", "documentation": "Region of Asia Pacific." } } }, "auth_ref": ["r1110", "r1111", "r1112", "r1113", "r1301", "r1302", "r1303", "r1304"] }, "lab_AssayServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AssayServicesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Assay services", "label": "Assay Services [Member]", "documentation": "Assay Services." } } }, "auth_ref": [] }, "lab_AssetRetirementObligationsIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "AssetRetirementObligationsIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Asset retirement obligations", "label": "Asset Retirement Obligations Incurred But Not Yet Paid", "documentation": "Asset Retirement Obligations Incurred But Not Yet Paid" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r144", "r155", "r218", "r246", "r289", "r297", "r322", "r326", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r590", "r592", "r628", "r741", "r838", "r931", "r932", "r982", "r1010", "r1202", "r1203", "r1253"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r210", "r226", "r246", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r590", "r592", "r628", "r982", "r1202", "r1203", "r1253"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r606", "r607", "r969"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r341"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r342"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r338", "r375", "r740"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Short-term investments", "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r339", "r375", "r606", "r733", "r969", "r973", "r1156", "r1240", "r1241", "r1242"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r336", "r375"], "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r1082"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r1083"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r1078"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r1078"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r1078"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r1078"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimallItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"]

l,"lang":{ "en-us":{ "role":{ "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth ref": ["r1081"] } } ,
"ecd_AwardsCloseToMnpiDiscIndName":{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang":{ "en-us":{ "role":{ "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name" } } }, "auth ref": ["r1080"] } } , "ecd_AwardsCloseToMnpiDiscTable":{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang":{ "en-us":{ "role":{ "label": "Awards Close in Time to MNPI
Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth ref": ["r1079"] } } , "ecd_AwardsCloseToMnpiDiscTableTextBlock":{ "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang":{ "en-us":{ "role":{ "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }, "auth ref": ["r1079"] } } , "us-gaap_BalanceSheetLocationAxis":{ "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"] , "lang":{ "en-us":{ "role":{ "label": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of
financial position where disaggregated cumulative balance has been reported." } } }, "auth ref": ["r416", "r1265", "r1266"] } } , "us-gaap_BalanceSheetLocationDomain":{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"] , "lang":{ "en-us":{ "role":{ "label": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial
position where disaggregated cumulative balance has been reported." } } }, "auth ref": ["r73", "r74", "r416", "r1265", "r1266"] } } , "us-gaap_BalanceSheetRelatedDisclosuresAbstract":{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BalanceSheetRelatedDisclosuresAbstract", "lang":{ "en-us":{ "role":{ "label": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related
Disclosures [Abstract]" } } }, "auth ref": [] } } , "us-gaap_BasisOfAccountingPolicyPolicyTextBlock":{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"] , "lang":{ "en-us":{ "role":{ "label": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or
basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth ref": [] } } , "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock":{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"] , "lang":{ "en-us":{ "role":{ "label": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
"documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used
to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe
all significant accounting policies of the reporting entity." } } }, "auth ref": ["r117"] } } , "us-gaap_BusinessAcquisitionAcquireeDomain":{ "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of
individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth ref": ["r399", "r400", "r401", "r402",
"r403", "r585", "r963", "r964"] } } , "us-gaap_BusinessAcquisitionAxis":{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of
individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth ref": ["r399", "r400", "r401", "r402",
"r403", "r585", "r963", "r964"] } } , "us-gaap_BusinessAcquisitionLineItems":{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails",
"http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth ref": ["r60", "r62", "r399", "r400", "r401", "r402", "r403", "r585", "r963", "r964"] } } , "us-gaap_BusinessAcquisitionLineItems":{ "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r585"] } } , "us-gaap_BusinessAcquisitionProFormaInformationTextBlock":{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationTables"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Pro Forma Information [Table Text
Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions
that are material in the aggregate." } } }, "auth ref": ["r1100", "r1101"] } } , "us-gaap_BusinessAcquisitionSharePrice":{ "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net income or loss for the period as if the
business combination or combinations had been completed at the beginning of a period." } } }, "auth ref": ["r583", "r584"] } } , "us-gaap_BusinessAcquisitionsProFormaRevenue":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfUnauditedProFormaFinancialInformationDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net income or loss for the period as if the
business combination or combinations had been completed at the beginning of a period." } } }, "auth ref": ["r583", "r584"] } } , "us-gaap_BusinessAcquisitionsProFormaRevenue":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfUnauditedProFormaFinancialInformationDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Acquisition", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or
combinations had been completed at the beginning of the period." } } }, "auth ref": ["r583", "r584"] } } , "us-gaap_BusinessCombinationAcquisitionRelatedCosts":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Combination, Acquisition Related Costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "In a business combination in which the amount of net identifiable assets acquired and
liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity." } } }, "auth ref": ["r67", "r68", "r69", "r70", "r71", "r72"] } } , "us-gaap_BusinessCombinationConsiderationTransferred1":{ "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Combination Consideration Transferred Equity Interests Issued", "label": "Business Combination Consideration Transferred Equity Interests Issued", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and
equity interest issued by the acquirer." } } }, "auth ref": ["r1", "r2", "r12"] } } , "lab_BusinessCombinationConsiderationTransferredEquityInterestsIssued":{ "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssued", "crdr": "credit",
"presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Combination Consideration Transferred Equity Interests Issued", "label": "Business combination consideration transferred equity
interests issued." } } }, "auth ref": [] } } , "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable":{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails"] , "lang":{ "en-us":{ "role":{ "label": "Business Combination Consideration Transferred Equity Interests Issued and Issuable", "label": "SomaLogic Common Stock issued and outstanding as of January 5, 2024", "terseLabel": "Amount of common stock", "label": "Business
Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or
interests issued or issuable in consideration for the business combination." } } }, "auth ref": ["r1", "r2"] } } ,

"lab_BusinessCombinationConsiderationTransferredEquitySharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationConsiderationTransferredEquitySharesIssuedPricePerShare", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Standard BioTools common stock price at close of Merger", "label": "Business Combination Consideration Transferred Equity Shares Issued Price Per Share", "documentation": "Business combination consideration transferred equity shares issued price per share." } } }, "auth_ref": I }

"lab_BusinessCombinationConsiderationTransferredFairValueOfReplacementEquityAwardsAttributableToPreCombinationService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationConsiderationTransferredFairValueOfReplacementEquityAwardsAttributableToPreCombinationService", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair value of Standard BioTools replacement equity awards attributable to pre-combination service", "label": "Business Combination Consideration Transferred Fair Value Of Replacement Equity Awards Attributable To Pre-combination Service", "documentation": "Business combination consideration transferred fair value of replacement equity awards attributable to pre-combination service." } } }, "auth_ref": I }

"lab_BusinessCombinationConsiderationTransferredFairValueOfRestrictedSharesSubjectToServiceConditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationConsiderationTransferredFairValueOfRestrictedSharesSubjectToServiceConditions", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Less: Fair value of restricted shares subject to service conditions", "label": "Business Combination Consideration Transferred Fair Value Of Restricted Shares Subject To Service Conditions", "documentation": "Business combination consideration transferred fair value of restricted shares subject to service conditions." } } }, "auth_ref": I }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": I "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombination" }, "lang": { "en-us": { "role": { "terseLabel": "Business Combination", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": I "r136", "r586" }

"us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Loss", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": I "r61" }

"us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": I "r61" }

"lab_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilitiesAssumedRoyaltyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilitiesAssumedRoyaltyReceivable", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable", "label": "Business Combination Recognized Identifiable Asset Acquired And Liabilities Assumed Royalty Receivable", "documentation": "Business combination recognized identifiable asset acquired and liabilities assumed royalty receivable." } } }, "auth_ref": I }

"lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Liabilities", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed accounts payable and accrued liabilities." } } }, "auth_ref": I }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, current", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": I "r64" }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilitiesCurrent", "crdr": "credit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Operating Lease Liabilities, Current", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed, current liabilities, operating lease liabilities." } } }, "auth_ref": I }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "verboseLabel": "Total fair value of intangible assets acquired", "terseLabel": "Intangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": I }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcquired": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": I "r64" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": I }

l, "lang": { "en-us": { "role": { "terseLabel": "Liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "totalLabel": "Total fair value of net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r63", "r64"] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentInventory", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Non-current inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-current Inventory", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, non-current inventory." } } }, "auth_ref": [] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentLiabilitiesOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentLiabilitiesOperatingLeaseLiabilities", "crdr": "credit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-current Liabilities, Operating Lease Liabilities", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed, non-current liabilities, operating lease liabilities." } } }, "auth_ref": [] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsOperatingLeaseRightOfUseAssets", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets, Operating Lease Right Of Use Assets", "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed, noncurrent assets, operating lease right of use assets." } } }, "auth_ref": [] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesDeferredRevenue", "crdr": "credit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, non-current", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Deferred Revenue", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, deferred revenue." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r64"] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesWarrantLiabilities", "crdr": "credit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Warrant liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Warrant Liabilities", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, warrant liabilities." } } }, "auth_ref": [] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentReceivables", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of current portion", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Receivables", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent receivables." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r64"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r63", "r64"] }, "lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShortTermInvestments", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Short-term Investments", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, short-term investments." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitionDateFairValueOfConsiderationTransferredDetails", "lang": { "en-us": { "role": { "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Fair value of Standard BioTools common stock issued to SomaLogic stockholders", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": ["r17"] }, "lab_BusinessCombinationTransactionBonusesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "BusinessCombinationTransactionBonusesIncurred", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Transaction bonuses incurred", "label": "Business Combination, Transaction Bonuses Incurred", "documentation": "Business combination, transaction bonuses incurred." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r137", "r138", "r139", "r140"] }, "lab_CapitalizedSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CapitalizedSoftwareDevelopmentCostsMember", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Capitalized Software Development Costs", "label": "Capitalized Software Development Costs [Member]", "documentation": "Capitalized software development costs." } } }, "auth_ref": [] }, "lab_CasdinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CasdinMember", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Casdin", "label": "Casdin [Member]", "documentation": "Casdin", "auth_ref": [] }, "lab_CasdinPartnersMasterFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CasdinPartnersMasterFundLPMember", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Casdin Partners Master Fund, L.P.", "label": "Casdin Partners Master Fund, L.p [Member]", "documentation": "Casdin partners master fund, lp." } } }, "auth_ref": [] }, "lab_CasdinPrivateGrowthEquityFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CasdinPrivateGrowthEquityFundLPMember", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Casdin Private Growth Equity Fund, L.P.", "label": "Casdin Private Growth Equity Fund, L.p [Member]", "documentation": "Casdin private growth equity fund, l.p." } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Cash acquired in merger", "label": "Cash Acquired from Acquisition", "verboseLabel": "Cash and restricted cash acquired in Merger", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."} } }, "auth_ref": ["r26"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryOfCashAndCashEquivalentsDetails", "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r28", "r212", "r917"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r1212"], "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1238", "r1239"], "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails", "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Total cash, cash equivalents and restricted cash", "totalLabel": "Total cash, cash equivalents and restricted cash", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r114", "r244"], "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r114"], "lab_ChangeInFairValueOfWarrantLiabilitiesRecurringBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ChangeInFairValueOfWarrantLiabilitiesRecurringBasis", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liabilities", "label": "Change In Fair Value Of Warrant Liabilities, Recurring Basis", "documentation": "Change in fair value of warrant liabilities, recurring basis", "negatedLabel": "Change in fair value of warrant liabilities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r1058"], "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r1055"], "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r1053"], "normalizedStringItemType": { "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r166", "r221", "r222", "r223", "r246", "r271", "r276", "r281", "r283", "r291", "r292", "r367", "r437", "r440", "r441", "r442", "r446", "r447", "r468", "r469", "r472", "r475", "r483", "r628", "r792", "r793", "r794", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r826", "r847", "r870", "r892", "r893", "r894", "r895", "r896", "r1097", "r1137", "r1144"], "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r221", "r222", "r223", "r291", "r468", "r469", "r470", "r472", "r475", "r481", "r483", "r792", "r793", "r794", "r795", "r951", "r1097", "r1137"], "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": ["r50", "r51", "r52", "r53"], "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r54"], "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price of warrants", "terseLabel": "Purchase shares of Common Stock", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r484"], "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Warrant to purchase common stock", "terseLabel": "Initial public offering warrants issued", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r484"], "lab_CmlsHoldingsIIlCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "CMLS Holdings II LLC", "label": "CMLS Holdings II LLC [Member]", "documentation": "Cmls holdings ii llc." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r1059"], "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r1059"], "lab_CollaborationAndOtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CollaborationAndOtherRevenueMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration and other revenue", "label": "Collaboration and Other Revenue [Member]", "documentation": "Collaboration and Other Revenue." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r86", "r147", "r744", "r825"], "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r124", "r429", "r430", "r899", "r1188", "r1196"], "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail"]

l, "lang": { "en-us": { "role": { "terseLabel": "Number of remaining securities available for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r90" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r999", "r1000", "r1001", "r1003", "r1004", "r1005", "r1006", "r1140", "r1141", "r1143", "r1236", "r1296", "r1299" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r90" } }, "lab_CommonStockRelinquishedInLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CommonStockRelinquishedInLitigationSettlement", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock relinquished in litigation settlement", "label": "Common Stock Relinquished In Litigation Settlement", "documentation": "Common Stock Relinquished In Litigation Settlement" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r90", "r826" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"] }, "lang": { "en-us": { "role": { "verboselabel": "Common stock, shares issued", "label": "Merger consideration", "terseLabel": "Equity consideration transferred in connection with merger includes shares of common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r90" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit"] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r14", "r90", "r826", "r844", "r1299", "r1300" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, 0.001 par value, 600,000 shares authorized at September 30, 2024 and 400,000 shares authorized at December 31, 2023; 390,841 and 83,364 shares issued at September 30, 2024 and December 31, 2023, respectively; 372,261 and 80,232 shares outstanding at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r90", "r746", "r982" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r1064" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r1063" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r1065" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r1062" } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofComprehensiveLoss"] }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r25", "r229", "r231", "r235", "r734", "r758", "r759" } }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r153", "r167", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r252", "r289", "r299", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r931", "r932", "r1114", "r1115", "r1202", "r1203" } }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": { "r153", "r167", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r252", "r289", "r299", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r437", "r438", "r439", "r440", "r442", "r443", "r444", "r445", "r446", "r931", "r932", "r1114", "r1115", "r1202", "r1203" } }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Construction-in-progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": { "r120" } }, "lab_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ConsumablesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Consumables", "label": "Consumables [Member]", "documentation": "Consumables [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Summary of the Change in Deferred Revenue", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": { "r1207" } }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"] }, "lang": { "en-us": { "role": { "periodStartLabel": "Deferred revenue at December 31, 2023", "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "totalLabel": "Contract with Customer, Liability, Total", "periodEndLabel": "Deferred revenue at June 30, 2024", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r486", "r487", "r506" } }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": { "r486", "r487", "r506" } }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue assumed in connection with merger", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination." } } }, "auth_ref": { "r952" } }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, non-current", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": { "r486", "r487", "r506" } }, "lab_ContractWithCustomerRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ContractWithCustomerRevenueRecognized", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Recognition of revenue from beginning or assumed deferred revenue balances", "label": "Contract With Customer Revenue Recognized", "documentation": "Amount of revenues recognized in the period." } } }, "auth_ref": [] }, "lab_ContractWithCustomerRevenueRecognizedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ContractWithCustomerRevenueRecognizedNet", "crdr": "credit", "presentation": [

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Revenue deferred during the period, net of revenue recognized", "label": "Contract With Customer Revenue Recognized Net", "documentation": "Amount of revenues recognized net in the period." } } }, "auth_ref": [] |, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, current", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r79"] |, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedtoCommon" |, "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r126", "r448", "r449", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r463", "r46", "r47", "r48", "r49", "r50"] |, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Convertible notes, non-current", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r20"] |, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails" |, "lang": { "en-us": { "role": { "verboseLabel": "Series B Preferred Stock", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": ["r468", "r469", "r472", "r1003", "r1004", "r1005", "r1006"] |, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Convertible Aggregate Common Stock", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": ["r21", "r46", "r89", "r130", "r478"] |, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r1147"] |, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Corporate expenses", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r19", "r321", "r322", "r323", "r324", "r327", "r1150"] |, "lab_CostOfCollaborationAndOtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CostOfCollaborationAndOtherRevenueMember", "presentation": ["http://www.standardbio.com/20240930", "localname": "CostOfCollaborationAndOtherRevenueMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Cost of collaboration and other revenue", "label": "Cost Of Collaboration And Other Revenue [Member]", "documentation": "Cost of collaboration and other revenue." } } }, "auth_ref": [] |, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations" |, "lang": { "en-us": { "role": { "terseLabel": "Total cost of revenue", "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of Goods and Services Sold, Total", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r104", "r105", "r698"] |, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Cost of product revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] |, "lab_CostOfServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "CostOfServicesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Cost of services revenue", "label": "Cost Of Services [Member]", "documentation": "Cost of services." } } }, "auth_ref": [] |, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations" |, "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Costs and Expenses [Abstract]", "documentation": "Costs associated with exit or disposal activities or restructuring policies." } } }, "auth_ref": [] |, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" |, "lang": { "en-us": { "role": { "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "terseLabel": "Restructuring and Related Charges", "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": ["r121", "r122"] |, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r202", "r203", "r250", "r251", "r451", "r470", "r662", "r680", "r739", "r919", "r921"] |, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] |, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover" |, "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] |, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r66", "r1175", "r1176", "r1177", "r1178", "r1180", "r1182", "r1185", "r1186"] |, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)", "label": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. [Part noncash] refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r30", "r31"] |, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]", "documentation": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] |, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedtoCommon" |, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r20", "r79", "r80", "r145", "r146", "r252", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r46", "r47", "r48", "r49", "r50", "r980", "r1138", "r1189", "r1190", "r1191", "r1246", "r1247"] |, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Additional interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] |, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "verboseLabel": "Total convertible notes, net", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r20", "r146", "r465"] |, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Initial conversion rate of notes", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": ["r46", "r83", "r130", "r131", "r450"] |, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r448", "r636", "r637", "r947", "r948", "r980"] |, "lab_DebtInstrumentIncrementalPaymentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DebtInstrumentIncrementalPaymentPercent", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Term loan advances percentage", "label": "Debt Instrument, Incremental Payment, Percent", "documentation": "Debt Instrument, Incremental Payment, Percent" } } }, "auth_ref": [] |, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Interest rate on notes", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r82", "r449"] |, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r252", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r46", "r47", "r48", "r49", "r50", "r980", "r1138", "r1246", "r1247"] |, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [

"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails",
"http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedFromComputationsOfNetLossPerShareAttributedtoCommon",
l, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r252", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r946", "r947", "r948", "r949", "r950", "r980", "r1138", "r1189", "r1190", "r1191", "r1246", "r1247"] }, "lab_DebtInstrumentPeriodicPaymentNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DebtInstrumentPeriodicPaymentNumberOfInstallments", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Number of installments", "label": "Debt Instrument, Periodic Payment, Number Of Installments", "documentation": "Debt Instrument, Periodic Payment, Number Of Installments" } } }, "auth_ref": [] },
"lab_DebtInstrumentRedemptionConditionStockValueExceedingPercentageOfConversionPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DebtInstrumentRedemptionConditionStockValueExceedingPercentageOfConversionPrice", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Debt redemption conditioned upon common stock value exceeding a percentage of the conversion price", "label": "Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price", "documentation": "Debt Instrument, Redemption Condition, Stock Value Exceeding Percentage of Conversion Price" } } }, "auth_ref": [] },
"-us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": ["r151"] },
"-us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r151"] },
"-us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodThreeMember", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Redemption, Period Three", "label": "Debt Instrument, Redemption, Period Three [Member]", "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r151"] },
"-us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Redemption, Period Two", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r151"] },
"-us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument redemption price", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r151"] },
"-us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchasedFaceAmount", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Repurchased outstanding principal amount", "label": "Debt Instrument, Repurchased Face Amount", "documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] },
"-us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails",
"http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r20", "r46", "r49", "r77", "r129", "r131", "r252", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r946", "r947", "r948", "r949", "r950", "r980", "r1138", "r1246", "r1247"] },
"-us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSelfItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" l, "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r738"] },
"-us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit loss", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r340", "r375", "r379", "r381"] },
"-us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Sell before Recovery", "terseLabel": "Amortization cost before recovery", "documentation": "Amount of decrease in allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) from intent to sell or more likely than not will be required to sell before recovery of amortized cost basis." } } }, "auth_ref": ["r380"] },
"-us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails" l, "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss", "terseLabel": "Available-for-sale securities held", "documentation": "Amount of cumulative unrecognized loss on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1157", "r1158"] },
"lab_DeferredGrantRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DeferredGrantRevenueCurrent", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" l, "lang": { "en-us": { "role": { "terseLabel": "Deferred grant income, current", "label": "Deferred Grant Revenue, Current", "documentation": "Deferred Grant Revenue, Current", "terseLabel": "Deferred grant income, current" } } }, "auth_ref": [] },
"lab_DeferredGrantRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DeferredGrantRevenueNoncurrent", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" l, "lang": { "en-us": { "role": { "terseLabel": "Deferred grant income, non-current", "label": "Deferred Grant Revenue, Noncurrent", "documentation": "Deferred Grant Revenue, Noncurrent" } } }, "auth_ref": [] },
"-us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" l, "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax liability per balance sheet", "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r559", "r560", "r742"] },
"lab_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "DenominatorAbstract", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Denominator Abstract", "documentation": "Denominator Abstract" } } }, "auth_ref": [] },
"-us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" l, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Amortization and Accretion, Net", "totalLabel": "Depreciation, Amortization and Accretion, Net, Total", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r9"] },
"-us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails" l, "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r9", "r39"] },
"-us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Depreciation & amortization", "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r289", "r302", "r326", "r931", "r932"] },
"-us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Developed Technology", "label": "Developed Technology, Member", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r142", "r1175", "r1176", "r1177", "r1178", "r1180", "r1182", "r1185", "r1186"] },
"srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Eli Casdin", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": ["r1116", "r1154", "r1297"] },
"-us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/RevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails",
"http://www.standardbio.com/20240930/taxonomy/role/RevenueAndGeographicAreaNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/RevenueAndGeographicAreaScheduleOfDisaggregationOfRevenueDetails" l, "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r505", "r953", "r954", "r955", "r956", "r957", "r958", "r959"] },
"-us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": },
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails",
"http://www.standardbio.com/20240930/taxonomy/role/RevenueAndGeographicAreaNarrativeDetails",

"http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth ref": ["r505", "r953", "r954", "r955", "r956", "r957", "r958", "r959"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth ref": ["r1208"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Text Block]", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth ref": ["r517", "r522", "r550", "r551", "r553", "r966"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth ref": ["r11", "r55"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-T statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth ref": ["r11", "dei_DocumentFiscalYearFocus"] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth ref": ["r11", "dei_DocumentPeriodEndDate"] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth ref": ["r1046"] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth ref": ["r1014"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth ref": ["r1046"] }, "dei_DocumentType": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth ref": ["r11", "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRflctdInTtlCompForCvrdYrMember"] }, "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth ref": ["r1057"] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "EMEA", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth ref": ["r1301", "r1302", "r1303", "r1304"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]", "documentation": "The entire disclosure for earnings per share." } } }, "auth ref": ["r236", "r258", "r259", "r260", "r261", "r262", "r263", "r268", "r271", "r281", "r282", "r283", "r287", "r581", "r588", "r603", "r604", "r735", "r760", "r923"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, basic", "label": "Net loss per share, basic (in dollars per share)", "documentation": "Net loss per share attributable to common stockholders, diluted", "label": "Net loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r236", "r258", "r259", "r260", "r261", "r262", "r263", "r268", "r271", "r281", "r282", "r283", "r287", "r581", "r588", "r603", "r604", "r735", "r760", "r923"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth ref": ["r267", "r284", "r285", "r286"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rate fluctuations on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": ["r629"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureIncomeTaxNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "label": "Federal statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."} } }, "auth ref": ["r247", "r562", "r572", "r968"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Accrued compensation and related benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."} } }, "auth ref": ["r80"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized compensation cost related to stock-based compensation arrangements", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth ref": ["r552"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and other employee-related benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth ref": ["r11", "us-gaap_EmployeeStockOptionMember"] }, "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "label": "Employee Stock Option", "documentation": "Securities To Be Issued Upon Exercise Of Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth ref": ["r11", "dei_EntityAddressAddressLine1"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth ref": ["r11", "dei_EntityAddressAddressLine2"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth ref": ["r11", "dei_EntityAddressCityOrTown"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth ref": ["r11", "dei_EntityAddressPostalZipCode"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth ref": ["r11", "dei_EntityAddressStateOrProvince"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth ref": ["r11", "dei_EntityCentralIndexKey"] }, "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": {

"role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. } } }, "auth_ref": ["r1012"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains. } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria. } } }, "auth_ref": ["r1012"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. } } }, "auth_ref": ["r1012"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation. } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). } } }, "auth_ref": ["r1096"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. } } }, "auth_ref": ["r1012"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. } } }, "auth_ref": ["r1012"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC). } } }, "auth_ref": ["r1012"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. } } }, "auth_ref": ["r1012"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r1051"] }, "ecd_EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtInSummaryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r1092"] }, "ecd_EqtyAwrdsAdjMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r1092"] }, "ecd_EqtyAwrdsInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r1092"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc. } } }, "auth_ref": ["r14", "r207", "r232", "r233", "r234", "r253", "r254", "r255", "r257", "r262", "r264", "r266", "r290", "r368", "r369", "r413", "r485", "r570", "r571", "r579", "r580", "r582", "r587", "r588", "r594", "r595", "r596", "r597", "r598", "r599", "r602", "r630", "r631", "r632", "r633", "r634", "r635", "r638", "r640", "r655", "r756", "r784", "r785", "r786", "r801", "r870"] }, "lab_EquityConsiderationTransferredInConnectionWithMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "EquityConsiderationTransferredInConnectionWithMerger", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "label": "Equity consideration transferred in connection with merger", "documentation": "Equity consideration transferred in connection with merger", "terseLabel": "Equity consideration transferred in connection with Merger" } } }, "auth_ref": [] }, "lab_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "EquityIncentivePlanMember", "presentation": ["http://www.standardbio.com/20240930", "localname": "EquityIncentivePlanMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan", "label": "Equity Incentive Plan [Member]", "documentation": "Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r1061"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r1019", "r1029", "r1039", "r1071"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r1016", "r1026", "r1036", "r1068"] }, "lab_ExchangeConvertibleSeniorNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ExchangeConvertibleSeniorNotesDue2034Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exchange Convertible Senior Notes due 2034", "label": "Exchange Convertible Senior Notes Due 2034 [Member]", "documentation": "Exchange Convertible Senior Notes Due 2034 [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } }, "auth_ref": ["r1067"] }, "us-gaap_FacilityClosingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FacilityClosingMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Facility Costs", "label": "Facility Closing [Member]", "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan. } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrants", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability. } } }, "auth_ref": ["r0", "r9"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } }, "auth_ref": ["r606", "r607", "r620", "r969"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis. } } }, "auth_ref": ["r606", "r607", "r620", "r969"] }, "us-

gaap FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/FairValueOfFinancialInstrumentsTables"] }, { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Liabilities", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r608", "r609", "r973"] }, { "us-gaap FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/FairValueOfFinancialInstrumentsTables"] }, { "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Company's Financial Instruments by Significant Investment Category Measured at Fair Value on a Recurring Basis Within the Fair Value Hierarchy", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1238", "r1239"] }, { "us-gaap FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r611", "r612", "r613", "r614", "r615", "r616", "r621", "r971"] }, { "us-gaap FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r611", "r612", "r613", "r614", "r615", "r616", "r621", "r971"] }, { "us-gaap FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r456", "r509", "r510", "r511", "r512", "r513", "r514", "r605", "r607", "r608", "r609", "r610", "r619", "r620", "r622", "r667", "r668", "r669", "r947", "r948", "r960", "r961", "r962", "r969", "r973"] }, { "us-gaap FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r606", "r607", "r608", "r610", "r969", "r1241", "r1244"] }, { "us-gaap FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": ["r456", "r509", "r514", "r607", "r620", "r667", "r960", "r961", "r962", "r969"] }, { "us-gaap FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/FairValueOffFinancialInstruments"] }, { "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r615", "r617", "r618", "r619", "r622", "r623", "r624", "r625", "r626", "r731", "r969", "r974"] }, { "us-gaap FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r456", "r509", "r514", "r607", "r620", "r667", "r960", "r961", "r962", "r969"] }, { "us-gaap FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r456", "r509", "r514", "r607", "r620", "r668", "r947", "r948", "r960", "r961", "r962", "r969"] }, { "us-gaap FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Fair Value, Level 3 Inputs", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r456", "r509", "r510", "r511", "r512", "r513", "r514", "r607", "r608", "r609", "r610", "r620", "r669", "r947", "r948", "r960", "r961", "r962", "r969", "r973"] }, { "us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/FairValueOfFinancialInstrumentsTables"] }, { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liabilities Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": ["r1238", "r1239"] }, { "us-gaap FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r606", "r607", "r608", "r610", "r969", "r1241", "r1244"] }, { "us-gaap FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"] }, { "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": ["r456", "r509", "r510", "r511", "r512", "r513", "r514", "r605", "r607", "r608", "r609", "r610", "r619", "r620", "r622", "r667", "r668", "r669", "r947", "r948", "r960", "r961", "r962", "r969", "r973"] }, { "us-gaap FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, { "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r969", "r1238", "r1239", "r1240", "r1241", "r1242", "r1244"] }, { "lab FairValueStockAndCarryingValueDifference": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "FairValueStockAndCarryingValueDifference", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails"] }, { "lang": { "en-us": { "role": { "label": "Fair value stock and carrying value

"difference", "documentation": "Fair value stock and carrying value difference." } }], "auth ref": [] }, "us-gaap FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth ref": ["r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r464", "r481", "r600", "r627", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r757", "r738", "r669", "r971", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r983", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1159", "r1160", "r1161", "r1162", "r1237", "r1240", "r1241", "r1242", "r1243", "r1244"] }, "us-gaap FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Valuation of the Intangible Assets Acquired in Connection with the Merger", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination." } } }, "auth ref": [] }, "us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth ref": ["r216", "r382", "r404", "r940"] }, "lab FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Assets Amortization Expense After Year Four", "documentation": "Finite Lived Intangible Assets Amortization Expense After Year Four" } } }, "auth ref": [] }, "us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth ref": ["r406", "r912", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "2024 remainder of the year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth ref": ["r1306"] }, "us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth ref": ["r406", "r912", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth ref": ["r406", "r912", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth ref": ["r406", "r912", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails" "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth ref": ["r397", "r399", "r400", "r401", "r403", "r404", "r408", "r409", "r699", "r700", "r912"] }, "lab FiniteLivedIntangibleAssetsFutureExpectedAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "FiniteLivedIntangibleAssetsFutureExpectedAmortizationExpense", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibleAssets"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets Future Expected Amortization Expense", "documentation": "Finite lived intangible assets future expected amortization expense." } } }, "auth ref": [] }, "us-gaap FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth ref": ["r382", "r404", "r700", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r397", "r404", "r408", "r409", "r411", "r699", "r912", "r940"] }, "us-gaap FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails" "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth ref": ["r397", "r399", "r400", "r401", "r403", "r404", "r408", "r409", "r912"] }, "us-gaap FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth ref": ["r699", "r1182"] }, "us-gaap FiniteLivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth ref": ["r399"] }, "ecdd ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": []
"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth ref": ["r1023", "r1033", "r1043", "r1075"] }, "ecdd ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": []
"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth ref": ["r1023", "r1033", "r1043", "r1075"] }, "ecdd ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": []
"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth ref": ["r1023", "r1033", "r1043", "r1075"] }, "ecdd ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": []
"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth ref": ["r1023", "r1033", "r1043", "r1075"] }, "ecdd ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "ForgoneRecoveryIndName", "presentation": []
"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth ref": ["r1023", "r1033", "r1043", "r1075"] }, "ecdd FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": []
"http://xbrl.sec.gov/ecdd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth ref": ["r1056"] }, "lab GenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "GenomicsMember", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe" "http://www.standardbio.com/20240930/taxonomy/role/RestructuringAndRelatedChargesRestructuringAndOtherEfficiencyCostsDetails",

"http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Genomics", "label": "Genomics [Member]", "documentation": "Genomics" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets",

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe", "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r215", "r383", "r732", "r932", "r939", "r970", "r982", "r1165", "r1172"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe", "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r391"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r9", "r384", "r390", "r395", "r939", "r970"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe", "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r939"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r102", "r106", "r154", "r246", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r628", "r925", "r931", "r1146", "r1149", "r1151", "r1152", "r1153", "r1202"] }, "lab_IlluminaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "IlluminaAgreementMember", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails",

"http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Illumina Agreement", "label": "Illumina Agreement [Member]", "documentation": "Illumina Agreement." } } }, "auth_ref": [] }, "lab_IlluminaCambridgeLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "IlluminaCambridgeLtdMember", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails",

"http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Illumina", "terseLabel": "Illumina Cambridge, Ltd.", "label": "Illumina Cambridge, Ltd [Member]", "documentation": "Illumina Cambridge, Ltd." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFiniteLived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFiniteLived", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Impairment of intangible assets", "terseLabel": "Impairment of goodwill, long-lived assets or intangible assets", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": ["r398", "r1135", "r1187"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r103", "r149", "r154", "r736", "r754", "r925", "r931", "r1146", "r1149", "r1151", "r1152", "r1153"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails",

"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r414", "r416", "r421", "r612", "r616", "r621", "r781", "r783", "r855", "r912", "r972", "r1267"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails",

"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r416", "r421", "r612", "r616", "r621", "r781", "r783", "r855", "r912", "r972", "r1267"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r247", "r358", "r562", "r563", "r564", "r565", "r566", "r567", "r573", "r575", "r376", "r577", "r797", "r968"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations",

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureIncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "verboseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r156", "r164", "r265", "r266", "r289", "r305", "r326", "r361", "r562", "r574", "r761", "r968"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes, net of refunds", "label": "Income Taxes Paid, Net", "totalLabel": "Income Taxes Paid, Net, Total", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r29", "r243", "r568", "r569"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r697", "r1134"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r1102", "r1134"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": []

"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofStockholdersEquityDeficit" }, {"lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, {"auth_ref": ["r397", "r402", "r407", "r940"] }, {"us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon"], {"lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, {"auth_ref": ["r272", "r273", "r274", "r283"] }, {"us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon"], {"lang": { "en-us": { "role": { "terseLabel": "2019 and 2014 Notes", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, {"auth_ref": ["r277", "r278", "r283"] }, {"us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon"], {"lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } }, {"auth_ref": ["r277", "r278", "r283"] }, {"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon"], {"lang": { "en-us": { "role": { "terseLabel": "RSUs, PSUs, stock options, restricted shares and ESPP shares", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, {"auth_ref": ["r272", "r273", "r275", "r283", "r521"] }, {"us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"], {"lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, {"auth_ref": ["r397", "r402", "r407", "r940"] }, {"us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"], {"lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, {"auth_ref": ["r397", "r402", "r407", "r940"] }, {"us-gaap_IndefiniteLivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets acquired", "label": "Indefinite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, {"auth_ref": ["r402", "r1184"] }, {"ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCom Disclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], {"lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual", "documentation": "Initial conversion price of stock (in usd per share)", "label": "Initial Conversion Price Of Stock", "documentation": "Initial Conversion Price Of Stock" } } }, {"auth_ref": ["r1023", "r1033", "r1043", "r1067", "r1075", "r1079", "r1087"] }, {"lab_InitialConversionPriceOfStock": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "InitialConversionPriceOfStock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Initial conversion price of stock (in usd per share)", "label": "Initial Conversion Price Of Stock", "documentation": "Initial Conversion Price Of Stock" } } }, {"auth_ref": ["r1023", "r1033", "r1043", "r1067", "r1075", "r1079", "r1087"] }, {"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", {"lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements", "documentation": "Insider Trading Policies ProcLineItems", "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures", "documentation": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "label": "Insider Trading Policies and Procedures Not Adopted", "documentation": "Insider Trading Policies and Procedures Not Adopted" } } }, {"auth_ref": ["r1015", "r1091"] }, {"lab_InstrumentSupportServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "InstrumentSupportServicesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Instrument support services", "label": "Instrument Support Services [Member]", "documentation": "Instrument Support Services" } } }, {"auth_ref": ["r397", "r402", "r407", "r940"] }, {"us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNet3"], {"lang": { "en-us": { "role": { "terseLabel": "Goodwill and Acquired Intangible Assets, net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, {"auth_ref": ["r396", "r410", "r412", "r911", "r912"] }, {"us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], {"lang": { "en-us": { "role": { "terseLabel": "Acquired intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, {"auth_ref": ["r397", "r1182", "r1184"] }, {"us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOperating", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations"], {"lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "label": "Interest Income, Operating", "totalLabel": "Interest Income, Operating, Total", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, {"auth_ref": ["r300", "r848", "r886", "r887", "r931", "r1007", "r1008", "r1131", "r1305"] }, {"us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"], {"lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, {"auth_ref": ["r239", "r241", "r242"] }, {"lab_InternalUseSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "InternalUseSoftwareMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Internal-use software", "label": "Internal Use Software [Member]", "documentation": "Internal Use Software [Member]" } } }, {"auth_ref": ["r1126"] }, {"us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "label": "Inventory Current", "documentation": "Inventory Current" } } }, {"auth_ref": ["r225", "r918", "r982"] }, {"us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, {"auth_ref": ["r1123"] }, {"us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "totalLabel": "Total inventory", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, {"auth_ref": ["r1126"] }, {"us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Provision for excess and obsolete inventory", "label": "Inventory, LIFO Reserve, Period Charge", "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period." } } }, {"auth_ref": ["r119"] }, {"us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"], {"lang": { "en-us": { "role": { "totalLabel": "Inventories, net", "label": "Inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, {"auth_ref": ["r225", "r918", "r982"] }, {"us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "label": "Inventory, Noncurrent", "totalLabel": "Inventory, Noncurrent, Total", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, {"auth_ref": ["r1119"] }, {"us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, {"auth_ref": ["r1125"] }, {"us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsInventoryDetails"], {"lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be

completed within one year or operating cycle, if longer." } } } , "auth_ref": ["r1124"] } } , "lab_LaboratoryAndManufacturingEquipmentMember": { "xbrltype": "domainItem", "nsuri": "http://www.standardbio.com/20240930", "localname": "LaboratoryAndManufacturingEquipmentMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Laboratory and manufacturing equipment", "label": "Laboratory And Manufacturing Equipment [Member]", "documentation": "Laboratory And Manufacturing Equipment [Member]" } } } } , "auth_ref": [] } , "us-gaap_LeaseCost": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails"] , "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } } , "auth_ref": ["r645", "r981"] } , "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Lease Cost [Abstract]" } } } } , "auth_ref": [] } , "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost", "label": "Lease Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } } , "auth_ref": ["r1249"] } , "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } } } , "auth_ref": ["r120", "r653"] } , "us-gaap_LeasesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } } } , "auth_ref": [] } , "dei_LegalEntityAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"] , "lang": { "en-us": { "role": { "label": "Legal Entity Axis", "documentation": "The set of legal entities associated with a report." } } } } , "auth_ref": [] } , "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "verboseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } , "auth_ref": ["r643", "r654"] } , "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } } } , "auth_ref": ["r643", "r654"] } , "lab_LesseeOperatingLeaseAssumedLeaseExpired": { "xbrltype": "dateItem", "nsuri": "http://www.standardbio.com/20240930", "localname": "LesseeOperatingLeaseAssumedLeaseExpired", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Assumed lease expired", "label": "Lessee Operating Lease, Assumed Lease Expired", "documentation": "Lessee operating lease, assumed lease expired" } } } } , "auth_ref": [] } , "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, existence of option to extend [true false]", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } } } , "auth_ref": ["r644"] } , "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Undiscounted Lease Payment Maturities to the Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability, includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } } } , "auth_ref": ["r1250"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } } } , "auth_ref": ["r1250"] } , "lab_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItem", "nsuri": "http://www.standardbio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after four fiscal year following current fiscal year." } } } } , "auth_ref": [] } , "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails"] , "lang": { "en-us": { "role": { "negatedLabel": "Less: amount of lease payments representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } } } , "auth_ref": ["r652"] } , "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Lease option to extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } } } , "auth_ref": ["r644"] } , "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days." } } } } , "auth_ref": ["r1248"] } , "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDnHnMnS' format, for example, 'PIY5M13D' represents reported fact of one year, five months, and thirteen days." } } } } , "auth_ref": ["r1248"] } , "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeases"] , "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } } } , "auth_ref": ["r639"] } , "us-gaap_Liabilities": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } } } , "auth_ref": ["r20", "r79", "r80", "r81", "r84", "r85", "r86", "r87", "r246", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r591", "r592", "r593", "r628", "r824", "r924", "r1010", "r1202", "r1253", "r1254"] } , "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, mezzanine equity and stockholders' equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } } , "auth_ref": ["r96", "r148", "r750", "r982", "r1139", "r1163", "r1245"] } , "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "label": "LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)", "label": "Liabilities and Equity [Abstract]" } } } } , "auth_ref": [] } , "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } } , "auth_ref": ["r81", "r211", "r246", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r591", "r592", "r593", "r628",

```

98282, "r1202", "r1253", "r1254" ] }, "us-gaap:LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" ] }, "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [ ] }, "lab_LicenseAgreementRelatedAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "LicenseAgreementRelatedAccountsReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "License agreement related accounts receivable current", "label": "License Agreement Related Accounts Receivable Current", "documentation": "License agreement related accounts receivable current." } } }, "auth_ref": [ ] }, "lab_LicenseAgreementRelatedAccountsReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "LicenseAgreementRelatedAccountsReceivableNonCurrent", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "License agreement related accounts receivable non-current", "label": "License Agreement Related Accounts Receivable Non-current", "documentation": "License agreement related accounts receivable non-current." } } }, "auth_ref": [ ] }, "lab_LicenseAgreementRelatedRoyaltiesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "LicenseAgreementRelatedRoyaltiesReceivable", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "License agreement related royalties receivable", "label": "License Agreement Related Royalties Receivable", "documentation": "License agreement related royalties receivable." } } }, "auth_ref": [ ] }, "us-gaap_LitigationSettlementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementLoss", "crdr": "debit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "label": "Litigation Settlement, Loss", "terseLabel": "Litigation loss", "documentation": "Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r197" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/Cover" ] }, "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "totalLabel": "Total debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r146", "r453", "r466", "r947", "r948", "r980", "r1263" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Less: term loan, current", "label": "Long-Term Debt, Current Maturities", "totalLabel": "Long-Term Debt, Current Maturities, Total", "verboseLabel": "Term loan, current", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r219" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Term loan, non-current", "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r220" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/Debt" ] }, "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r125" ] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Minimum Annual Purchase", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [ ] }, "us-gaap_LongTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTypeAxis", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" ] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon", "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20", "r189", "r190", "r191" ] }, "us-gaap_LongTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTypeDomain", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails" ] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails", "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon", "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r42", "r189", "r190", "r191" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "verboseLabel": "LossContingenciesTable", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r431", "r432", "r433", "r436", "r556", "r945", "r1198", "r1199" ] }, "lab_LossContingencyAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "LossContingencyAccruals", "crdr": "credit", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accruals", "label": "Loss Contingency Accruals", "documentation": "Loss Contingency Accruals" } } }, "auth_ref": [ ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r168", "r170", "r172", "r173", "r175", "r205", "r206", "r432", "r433", "r434", "r435", "r516", "r556", "r610", "r696", "r780", "r782", "r790", "r816", "r817", "r878", "r880", "r882", "r883", "r885", "r909", "r910", "r937", "r951", "r965", "r973", "r974", "r978", "r979", "r993", "r1204", "r1253", "r1256", "r1257", "r1258", "r1259", "r1260" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure" } } }, "auth_ref": [ "r1059" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1059" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails" ] }, "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Warrant Term", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1240", "r1241", "r1242" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantsLiabilitiesDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r973", "r1240", "r1241", "r1242" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "
```

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r1060"] }, "lab_NecCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "NEC", "terseLabel": "NEC Corporation", "label": "NEC Corporation [Member]", "documentation": "NEC Corporation." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r240"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r114", "r115", "r116"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r107", "r116", "r150", "r209", "r227", "r230", "r234", "r246", "r256", "r258", "r259", "r260", "r261", "r262", "r265", "r266", "r279", "r367", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r581", "r588", "r604", "r628", "r755", "r846", "r868", "r869", "r1008", "r1202"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "terseLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r237", "r258", "r259", "r260", "r261", "r268", "r269", "r280", "r283", "r388"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Changes and Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "lab_NewEnglandBiolabsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NewEnglandBiolabsIncMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "New England Biolabs, Inc.", "label": "New England Biolabs, Inc. [Member]", "documentation": "New England Biolabs, Inc." } } }, "auth_ref": [] }, "lab_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NonCashLeaseExpense", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Non-cash Lease Expense", "documentation": "Non-cash lease expense" } } }, "auth_ref": [] }, "lab_NonCashRightOfUseAssetsAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NonCashRightOfUseAssetsAndLeaseLiabilities", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Non-Cash Right-of-Use Assets and Lease Liabilities", "terseLabel": "Non-cash right-of-use assets and lease liabilities", "label": "Non-Cash Right-of-Use Assets and Lease Liabilities" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r1059"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs", "label": "Non-NEOs", "documentation": "The amount that is non-refundable upfront payment." } } }, "auth_ref": ["r1049"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r1050"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r1049"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r1067"] }, "lab_NonRefundableUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NonRefundableUpfrontPayment", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable upfront payment", "label": "Non-refundable Upfront Payment", "documentation": "The amount that is non-refundable upfront payment." } } }, "auth_ref": [] }, "lab_NonRule10b51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NonRule10b51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Non Rule 10b5-1 Arr Modified Flag", "label": "Non Rule 10b5-1 Arr Modified [Flag]", "terseLabel": "Non Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r1086"] }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r1086"] }, "lab_NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleOfPotentialCommonSharesExcludedfromComputationsOfNetLossPerShareAttributedtoCommon"], "lang": { "en-us": { "role": { "terseLabel": "Maximum additional shares issuable (in shares)", "label": "Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum", "documentation": "Number Of Additional Shares Issuable Under Make-Whole Premium, Maximum" } } }, "auth_ref": [] }, "lab_NumberOfLeasesForOfficeAndLaboratorySpace": { "xbrltype": "integerItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NumberOfLeasesForOfficeAndLaboratorySpace", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "No of leases for office and laboratory space", "label": "Number Of Leases For Office And Laboratory Space", "documentation": "Number of leases for office and laboratory space." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r926", "r936", "r1148"] }, "lab_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "NumeratorAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfLossPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Numerator Abstract", "documentation": "Numerator Abstract" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Office furniture and fixtures", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Operating income loss", "label": "Operating Income Loss", "documentation": "Operating income loss" } } }, "auth_ref": [] }] }

[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations](#) ",
"[http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails](#)"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "verboseLabel": "Income (loss) from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth ref": ["r154", "r925", "r1146", "r1149", "r1151", "r1152", "r1153"] }, "us-gaap OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Cost", "crdr": "debit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth ref": ["r646", "r981"] }, "us-gaap OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Liability", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails](#)"], "lang": { "en-us": { "role": { "totalLabel": "Present value of future minimum lease payments", "terseLabel": "Present value of future minimum lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth ref": ["r642"] }, "us-gaap OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Liability Current", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets](#)", "[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails](#)"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current operating lease liabilities", "terseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth ref": ["r642"] }, "us-gaap OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Liability Noncurrent", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets](#)", "[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseUndiscountedLeasePaymentMaturitiesToTheLeaseLiabilitiesDetails](#)"], "lang": { "en-us": { "role": { "totalLabel": "Long-term operating lease liabilities", "verboseLabel": "Long-term operating lease liabilities", "terseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth ref": ["r642"] }, "us-gaap OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Right Of Use Asset", "crdr": "debit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets](#)"], "lang": { "en-us": { "role": { "totalLabel": "Long-term operating lease liabilities", "verboseLabel": "Long-term operating lease liabilities", "terseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth ref": ["r642"] }, "us-gaap OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Weighted Average Discount Rate Percent", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalLeaseInformationDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth ref": ["r651", "r981"] }, "us-gaap OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Lease Weighted Average Remaining Lease Term 1", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfSupplementalLeaseInformationDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDThHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth ref": ["r650", "r981"] }, "us-gaap OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Operating Segments Member", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails](#)", "[http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth ref": ["r320", "r321", "r322", "r323", "r324", "r327", "r931", "r932"] }, "lab OptionsInExchangeOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "[http://www.standardbio.com/20240930](#)", "localname": "Options In Exchange Of Common Shares", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Options in exchange of common shares", "label": "Options In Exchange Of Common Shares", "documentation": "Options in exchange of common shares." } } }, "auth ref": [] }, "us-gaap OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Accrued Liabilities Current", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities, current", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth ref": ["r80"] }, "us-gaap OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Assets Noncurrent", "crdr": "debit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth ref": ["r217"] }, "us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Comprehensive Income Available for Sale Securities Adjustment Net Of Tax Portion Attributable To Parent", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfComprehensiveLoss](#)"], "lang": { "en-us": { "role": { "terseLabel": "Net change in unrealized gain on investments", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth ref": ["r6", "r13", "r143"] }, "us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfComprehensiveLoss](#)"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth ref": ["r6", "r13", "r143"] }, "us-gaap OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease Abstract", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfComprehensiveLoss](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth ref": [] }, "us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfComprehensiveLoss](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other comprehensive income (loss), net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth ref": ["r6", "r13", "r143", "r228", "r231", "r262"] }, "us-gaap OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Liabilities Noncurrent", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth ref": ["r85"] }, "lab OtherMember": { "xbrltype": "domainItemType", "nsuri": "[http://www.standardbio.com/20240930](#)", "localname": "Other Member", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaSummaryOfTheChangeInDeferredRevenueDetails](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other." } } }, "auth ref": [] }, "us-gaap OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "[http://fasb.org/us-gaap/2024](#)", "localname": "Other Nonoperating Income Expense", "crdr": "credit", "presentation": ["[http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations](#)"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth ref": ["r109"] },

of common stock", "terseLabel": "Share repurchase", "label": "Label", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r112"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails"] , "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r420", "r1133"] }, "us-gaap_PaymentsOffLoanCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOffLoanCosts", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "negatedLabel": "Payment of term loan fee", "label": "Payments of Loan Costs", "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow." } } }, "auth_ref": ["r27"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards and other", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r238"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "terseLabel": "Purchase to equipment supplies and training", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r111"] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of short-term investments", "label": "Payments to Acquire Short-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": ["r110"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r1058"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r1058"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r1050"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r1067"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r1060"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r1049"] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail"] , "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail"] , "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235"] }, "ecd_PnsnAdjsPrsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r1031"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r1095"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r1050"] }, "us-gaap_PreferredStockConversionsInducements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConversionsInducements", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofOperations"] , "lang": { "en-us": { "role": { "negatedLabel": "Induced conversion of redeemable preferred stock", "label": "Preferred Stock Conversions, Inducements", "documentation": "The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period." } } }, "auth_ref": ["r288"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r89", "r468"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r89", "r826"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r89", "r468"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParentetical"] , "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Outstanding", "label": "Preferred Stock, Shares Outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r89", "r826", "r844", "r1299", "r1300"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.001 par value, 10,000 and 9,744 shares authorized at September 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r89", "r745", "r982"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1127"] }, "lab_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "PrivatePlacementWarrantsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Private Placement Warrants [Member]", "documentation": "Private Placement Warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt issuance", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r1132"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from ESPP stock issuance", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r5", "r18"] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsofCashFlows"] , "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales and maturities of investments", "label": "Proceeds from Maturities, Prepayments and Calls of Other Investments", "documentation": "The cash inflow associated with the maturity

(principal being due), prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy." } } } , "auth ref": ["r1098"] } , "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } } , "auth ref": ["r5", "r18"] } , "lab_ProductAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ProductAndServiceMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Product and service revenue", "label": "Product And Service [Member]", "documentation": "Product And Service" } } } , "auth ref": [] , "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } } , "auth ref": ["r953"] } , "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product And Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } } , "auth ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r204", "r330", "r698", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r914", "r953", "r992", "r993", "r994", "r997", "r998", "r1117", "r1200", "r1201", "r1208", "r1264", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295"] } , "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } } , "auth ref": ["r177", "r178", "r179", "r180", "r181", "r182", "r204", "r330", "r698", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r914", "r953", "r992", "r993", "r994", "r997", "r998", "r1117", "r1200", "r1201", "r1208", "r1264", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295"] } , "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } } , "auth ref": ["r10", "r653"] } , "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } } , "auth ref": ["r120", "r213", "r753"] } , "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth ref": ["r653"] } , "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } } , "auth ref": ["r10", "r653", "r737", "r753", "r982"] } , "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } } , "auth ref": ["r10"] } , "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } } , "auth ref": ["r120", "r653"] } , "lab_ProteomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ProteomicsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Proteomics", "label": "Proteomics [Member]", "documentation": "Proteomics" } } } , "auth ref": [] , "lab_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "PublicWarrantsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Public Warrants", "label": "Public Warrants [Member]", "documentation": "Public Warrants" } } } , "auth ref": [] } , "lab_PurchaseCommitmentAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "PurchaseCommitmentAgreement", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment Agreement", "label": "Purchase Commitment Agreement", "documentation": "Purchase commitment agreement." } } } , "auth ref": [] } , "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Purchase commitment due in the next year", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth ref": [] } , "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } } , "auth ref": ["r1048"] } , "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } } , "auth ref": ["r1048"] } , "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } } , "auth ref": ["r168", "r170", "r172", "r173", "r175", "r205", "r206", "r432", "r433", "r434", "r435", "r508", "r516", "r545", "r546", "r547", "r556", "r610", "r670", "r679", "r696", "r780", "r78

label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other party for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r335", "r515", "r659", "r660", "r743", "r751", "r819", "r820", "r821", "r822", "r823", "r843", "r845", "r877"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"] }, "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r248", "r249", "r659", "r660", "r661", "r662", "r743", "r751", "r819", "r820", "r821", "r822", "r823", "r843", "r845", "r877"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r335", "r851", "r852", "r855"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r656", "r657", "r658", "r660", "r663", "r798", "r799", "r800", "r833", "r854", "r855", "r874", "r876"] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "terseLabel": "Repayment of term loan and convertible notes", "negatedTerseLabel": "Repayment of term loan and convertible notes", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r113"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r202", "r203", "r250", "r251", "r451", "r470", "r662", "r680", "r739", "r920", "r921"] }, "lab_RepurchaseOfCommonStockSharesForLitigationSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RepurchaseOfCommonStockSharesForLitigationSettlement", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock shares for litigation settlement", "label": "Repurchase of Common Stock Shares for Litigation Settlement", "documentation": "Repurchase of common stock shares for litigation settlement." } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation expenses", "label": "Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Accumulated Depreciation Expenses", "negatedTerseLabel": "Cumulative amounts applied against depreciation expense for assets placed in service", "negatedLabel": "Cumulative amounts applied against depreciation expense for assets placed in service" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Capital Expenditures" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation expenses", "label": "Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Depreciation Expense" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Maximum contract value", "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Contract Value" } } }, "auth_ref": [] }, "lab_ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsNarrativeDetails"] }, "lang": { "en-us": { "role": { "verboseLabel": "Carrying value of assets", "label": "Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net", "documentation": "Research And Development Arrangement, Contract To Perform For Others, Property and Equipment, Net", "totalLabel": "Carrying value of property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "verboseLabel": "Research and development services", "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r557", "r912", "r931", "r1261"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date", "documentation": "Date of restatement." } } }, "auth_ref": ["r1017", "r1027", "r1037", "r1069"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r1018", "r1028", "r1038", "r1070"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require recovery" } } }, "auth_ref": ["r1025", "r1035", "r1045", "r1077"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsSummaryofCashandCashEquivalentsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r28", "r212", "r244"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r212"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role

"RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedCharges", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r9", "r417", "r418", "r420", "r423", "r428"] }, "us-gaap_RestructuringAndRelatedCostNumberOFPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOFPositionsEliminatedPeriodPercent", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost. Number of Positions Eliminated. Period Percent", "terseLabel": "Percentage of reduction in workforce", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails", "lang": { "en-us": { "role": { "verboseLabel": "Total restructuring and other related costs", "negatedTerseLabel": "Restructuring and related charges", "terseLabel": "Restructuring and related charges", "label": "Restructuring Charges", "totalLabel": "Restructuring Charges. Total", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r9", "r424", "r425", "r1193"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r419", "r420", "r425", "r426"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r419", "r420", "r421", "r422", "r425", "r426", "r427"] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "totalLabel": "Restructuring Reserve. Total", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r420", "r426"] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Accrued restructuring", "label": "Restructuring Reserve. Current", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": ["r1120", "r1194", "r1195"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherRelatedLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit). Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r93", "r132", "r749", "r787", "r789", "r796", "r827", "r982"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "terseLabel": "Accum. Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r207", "r253", "r254", "r255", "r257", "r262", "r264", "r266", "r368", "r369", "r413", "r570", "r571", "r578", "r579", "r580", "r582", "r587", "r588", "r594", "r596", "r597", "r599", "r602", "r638", "r640", "r784", "r786", "r801", "r1299"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r152", "r153", "r289", "r298", "r299", "r320", "r326", "r330", "r332", "r334", "r504", "r505", "r698"] }, "lab_RevenueFromContractWithCustomerPerformanceObligationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RevenueFromContractWithCustomerPerformanceObligationPeriod", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Performance Obligation Period", "label": "Revenue From Contract With Customer, Performance Obligation Period", "terseLabel": "Performance obligation period" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r163", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r913"] }, "lab_RevenueFromContractWithCustomerTermsOfPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RevenueFromContractWithCustomerTermsOfPaymentPeriod", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Terms Of Payment Period", "label": "Revenue From Contract With Customer, Terms Of Payment Period", "terseLabel": "Terms of payment period" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicArea", "lang": { "en-us": { "role": { "terseLabel": "Revenue and Geographic Area", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r163", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r507"] }, "lab_RevenueReceiveMinimumGuaranteedRoyalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RevenueReceiveMinimumGuaranteedRoyalty", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Revenue receive minimum guaranteed royalty", "label": "Revenue Receive Minimum Guaranteed Royalty", "documentation": "Revenue receive minimum guaranteed royalty." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Transaction price", "terseLabel": "Remaining performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r162"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationDetails1", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails", "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails", "lang": { "en-us": { "role": { "verboseLabel": "Transaction price royalties expected to be received", "terseLabel": "Remaining performance obligation, expected timing of satisfaction", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as

revenue, in 'PnYmMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. } } } , "auth_ref": ["r163"] } , "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of remaining performance obligation, in YYYY-MM-DD format." } } } , "auth_ref": ["r163"] } , "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRevenueAndGeographicAreaPerformanceObligationsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } } , "auth_ref": [] } , "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Timing of Revenue Recognition", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } } , "auth_ref": ["r1099"] } , "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]" } } } , "auth_ref": [] } , "lab_RoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RoyaltiesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalties [Member]", "documentation": "Royalties." } } } , "auth_ref": [] } , "lab_RoyaltyReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RoyaltyReceivableCurrent", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBalanceSheetDetailsAccountsReceivableDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Royalty Receivable Current", "label": "Royalty Receivable Current", "documentation": "Royalty Receivable Current" } } } , "auth_ref": [] } , "lab_RoyaltyReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "RoyaltyReceivableNonCurrent", "crdr": "debit", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "terseLabel": "Royalty receivable, non-current", "label": "Royalty Receivable Non Current", "documentation": "Royalty receivable non current." } } } , "auth_ref": [] } , "lab_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "Rule10B51ArrModifiedFlag", "presentation": []
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "documentation": "Rule 10b51 Arr Modified Flag.", "label": "Rule 10b51 Arr Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } } , "auth_ref": [] } , "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } } , "auth_ref": ["r1086"] } , "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": []
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] , "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } } , "auth_ref": ["r1086"] } , "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails"] , "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } } , "auth_ref": [] } , "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } } , "auth_ref": ["r91", "r97"] } , "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"] , "lang": { "en-us": { "role": { "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } } , "auth_ref": ["r399", "r400", "r401", "r403", "r912"] } , "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareShareNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareScheduleofPotentialCommonSharesExcludedfromComputationsofNetLossPerShareAttributedtoCommon"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } } , "auth_ref": ["r32"] } , "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Common Shares Excluded from Computations of Net Loss Per Share Attributed to Common Stockholders", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } } , "auth_ref": ["r32"] } , "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/FairValueofFinancialInstrumentsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-Sale Securities Reconciliation", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq"] , "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination, includes, but is not limited to, recognized asset and liability." } } } , "auth_ref": ["r60", "r62", "r585"] } , "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Acquisition-date Fair Value of Consideration Transferred", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } } , "auth_ref": ["r60", "r62"] } , "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Carrying Value of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/NetLossPerShareTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of computation of loss per share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } } , "auth_ref": ["r145"] } , "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } } , "auth_ref": ["r56"] } , "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfAcquiredIntangibleAssetsDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfFutureExpectedAmortizationExpenseOfAcquiredIntangibl"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } } , "auth_ref": ["r397", "r404", "r408", "r409", "r411", "r699", "r912", "r940"] } , "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": []
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } } , "auth_ref": ["r940", "r1181"] } , "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": []

[["http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetTables"](http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetTables)] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Changes in the Carrying Value of Goodwill by Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollover schedule." } } } , "auth_ref": ["r939", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174"] } , "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } } , "auth_ref": ["r22", "r98", "r99", "r100"] } , "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Performance-Based Units Activity", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } } , "auth_ref": ["r134"] } , "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Under Restricted Stock Units", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } } , "auth_ref": ["r134"] } , "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetailsPropertyAndEquipmentDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } } , "auth_ref": ["r10", "r633"] } , "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Preliminary Allocation of Consideration Transferred to the Identifiable Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } } , "auth_ref": ["r141"] } , "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails>] , "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } } , "auth_ref": ["r75", "r76", "r851", "r852", "r855"] } , "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails>", "<http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesSummaryoftheChangesinOurRestructuringandOtherEfficiencyCostsDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } } , "auth_ref": ["r419", "r420", "r421", "r422", "r425", "r426", "r427"] } , "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Liabilities", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } } , "auth_ref": ["r41", "r123"] } , "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } } , "auth_ref": ["r36", "r37", "r38"] } , "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Segment Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } } , "auth_ref": ["r36", "r37", "r38"] } , "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails>", "<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails>", "<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } } , "auth_ref": ["r518", "r520", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548"] } , "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Under Stock Options", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } } , "auth_ref": ["r15", "r16", "r133"] } , "lab_ScheduleOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "<http://www.standardbio.com/20240930>", "localname": "ScheduleOfSignificantAccountingPoliciesLineItems", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Significant Accounting Policies [Table]", "label": "Schedule Of Significant Accounting Policies [Table]", "documentation": "Schedule Of Significant Accounting Policies [Table]" } } } , "auth_ref": [] } , "lab_ScheduleOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "<http://www.standardbio.com/20240930>", "localname": "ScheduleOfSignificantAccountingPoliciesTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Significant Accounting Policies [Table]", "label": "Schedule Of Significant Accounting Policies [Table]", "documentation": "Schedule Of Significant Accounting Policies [Table]" } } } , "auth_ref": [] } , "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfStockByClassTable", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } } , "auth_ref": ["r44", "r45", "r46", "r47", "r48", "r49", "r127", "r129", "r131", "r132", "r221", "r222", "r223", "r291", "r468", "r469", "r470", "r472", "r475", "r481", "r483", "r792", "r793", "r794", "r795", "r951", "r1097", "r1137"] } , "lab_ScheduleOfSupplementalLeaseInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://www.standardbio.com/20240930>", "localname": "ScheduleOfSupplementalLeaseInformationTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Lease Information", "label": "Schedule of Supplemental Lease Information [Table Text Block]", "documentation": "Schedule of supplemental lease information." } } } , "auth_ref": [] } , "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetTables>] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Expected Amortization Expense of Acquired Intangible Assets, Net", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } } , "auth_ref": ["r940", "r1183"] } , "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "SecuredDebt", "crdr": "credit", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Term loan, non-current", "label": "Secured Debt, Total", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } } , "auth_ref": ["r20", "r146", "r1263"] } , "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "SecuredDebtCurrent", "crdr": "credit", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets>] , "lang": { "en-us": { "role": { "terseLabel": "Term loan, current", "label": "Secured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } } , "auth_ref": ["r79", "r145"] } , "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "SecuredDebtMember", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails>", "<http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } } , "auth_ref": [] } , "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "SecuredLongTermDebt", "crdr": "credit", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets>] , "lang": { "en-us": { "role": { "terseLabel": "Term loan, non-current", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } } , "auth_ref": ["r20"] } , "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname": "Security12bTitle", "presentation": ["<http://xbrl.sec.gov/dei/2024>", "localname": "SecurityExchangeName", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/Cover>] , "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } , "auth_ref": ["r1011"] } , "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "<http://xbrl.sec.gov/dei/2024>", "localname": "SecurityExchangeName", "presentation": ["<http://www.standardbio.com/20240930/taxonomy/role/Cover>] , "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } , "auth_ref": ["r1013"] } , "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "SegmentDomain", "presentation": []

<http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails>] , "lang": { "en-us": { "role": { "terseLabel": "Revenue and Geographic Area Schedule of Disaggregation of Revenue Details" } } } , "auth_ref": ["r152", "r153", "r154", "r155", "r289", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r334", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r411", "r422", "r427", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r928", "r931", "r932", "r939", "r996", "r1264", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295"] } , "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } } , "auth_ref": ["r169", "r171", "r174", "r176", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r332", "r333", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r813", "r814", "r815", "r879", "r881", "r884", "r888", "r898", "r900", "r901", "r902", "r903", "r904", "r905", "r907", "r908", "r915", "r954", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r995", "r1001", "r1208", "r1264", "r1268", "r1269", "r1271", "r1272", "r1273", "r1274", "r1275", "r1276", "r1277", "r1278", "r1279", "r1280", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1290", "r1291", "r1292", "r1293", "r1294", "r1295"] } , "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } } , "auth_ref": [] } , "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/SegmentReporting"] , "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } } , "auth_ref": ["r155", "r289", "r293", "r294", "r295", "r296", "r297", "r309", "r311", "r312", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r334", "r926", "r929", "r930", "r931", "r933", "r935", "r936"] } , "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleofBusinessSegmentInformationDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "us-gaap_SegmentReportingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"] , "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } } , "auth_ref": ["r313", "r314", "r315", "r316", "r317", "r318", "r319", "r329", "r332", "r927", "r928", "r934"] } , "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } } , "auth_ref": ["r108"] } , "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } } , "auth_ref": [] } , "lab_SeniorConvertibleNotesDue2024CurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SeniorConvertibleNotesDue2024CurrentMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureDebtScheduleOfCarryingValueOfDebtDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2019 Notes, current", "label": "Senior Convertible Notes Due 2024, Current [Member]", "documentation": "Senior convertible notes due 2024, current." } } } , "auth_ref": [] } , "lab_SeniorConvertibleNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SeniorConvertibleNotesDue2024Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2019 Notes", "label": "Senior Convertible Notes Due 2024 [Member]", "documentation": "Senior Convertible Notes Due 2024 [Member]" } } } , "auth_ref": [] } , "lab_SeniorConvertibleNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SeniorConvertibleNotesDue2034Member", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DebtNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "2014 Notes", "label": "Senior Convertible Notes Due 2034 [Member]", "documentation": "Senior Convertible Notes due 2034 [Member]" } } } , "auth_ref": [] } , "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Series B Preferred Stock", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } } , "auth_ref": ["r1121", "r1122", "r1205"] } , "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "terseLabel": "Service revenue", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } } , "auth_ref": ["r953"] } , "lab_SettledOutstandingLitigation": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SettledOutstandingLitigation", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Settled Outstanding Litigation", "label": "Settled Outstanding Litigation", "documentation": "Settled outstanding litigation." } } } , "auth_ref": [] } , "lab_SettlementOfOutstandingLitigation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SettlementOfOutstandingLitigation", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Settlement of outstanding litigation", "label": "Settlement of Outstanding Litigation", "documentation": "Settlement of outstanding litigation." } } } , "auth_ref": [] } , "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"] , "lang": { "

"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": "I http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during
the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } },
"auth_ref": ["r537"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": {
"periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding
stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r534", "r535"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Number of Nonvested and Outstanding Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },
"auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Number of Nonvested and Outstanding Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },
"auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": {
"periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "label": "Share-Based Compensation Arrangement
by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-
average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r534", "r535"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
"presentation": "I http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted
average remaining contractual terms", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options,
in PnYnMnDnTnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r135"] },
"lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriod", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Performance adjustment awards (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options,
Performance Adjustment in Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options,
Performance Adjustment in Period", "verboseLabel": "Performance adjustment (in shares)" } } }, "auth_ref": [] },
"lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriodWeightedAverageGrantDateFair"
{ "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceAdjustmentInPeriodWeightedAverageGrantDateFair"
"presentation": "I http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": {
"periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)", "label": "Share-Based Compensation Arrangement
by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-
average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r534", "r535"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": "I http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails",
"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": { "verboseLabel":
"Vested (in shares)", "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other
than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting
period." } } }, "auth_ref": ["r538"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": "I http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Released (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other
than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain
shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r538"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails",
"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails",
"http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-
based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line
Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": ["r518", "r520", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533",
"r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail",
"lang": { "en-us": { "role": { "terseLabel": "Securities to be issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of
Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r967"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average
Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } },
"auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested awards",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value", "documentation": "Share
Based Compensation Arrangement By Share Based Payment Award, Options, Expected To Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Unvested awards" }
} }, "auth_ref": [] }, "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType",
"nsuri": "http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested options (in
shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number", "documentation": "Share Based
Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number" } } }, "auth_ref": [] },
"lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested awards (in
dollars per share)", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price",
"documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price" } } }, "auth_ref": [] },
"lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm": { "xbrltype":
"durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unvested awards",
"label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term",
"documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Weighted Average Remaining Contractual Term" } } }
}, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled (in
shares)", "terseLabel": "Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The
number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements
pertaining to the stock option plan." } } }, "auth_ref": ["r532"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": "I
http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)",

"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "documentation": "Net number of share options (or share units) granted during the period." } } } . "auth_ref": ["r1217"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } } , "auth_ref": ["r55"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } , "auth_ref": ["r526", "r527"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } , "auth_ref": [] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } } , "auth_ref": ["r526", "r527"] } , "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price per Option", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } } , "auth_ref": [] } , "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Aggregate Intrinsic Value", "verboseLabel": "Vested" } } } , "auth_ref": [] } , "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Exercise Price", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Exercise Price" } } } , "auth_ref": [] } , "lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "verboseLabel": "Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Remaining Contractual Term One", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Remaining Contractual Term One" } } } , "auth_ref": [] } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail", "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"] , "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } } , "auth_ref": ["r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548"] } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } } , "auth_ref": ["r531"] } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } } , "auth_ref": ["r532"] } , "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } } , "auth_ref": ["r530"] } , "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "verboseLabel": "Share price (in dollars per share)", "label": "Share Price", "terseLabel": "Market price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } } , "auth_ref": [] } , "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } } , "auth_ref": ["r1206"] } , "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails"] , "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } } , "auth_ref": ["r1206"] } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]" } } } , "auth_ref": [] } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, vested and released", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } } , "auth_ref": [] } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationRestrictedandPerformanceStockUnitsDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value per Unit", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } } , "auth_ref": [] } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } , "auth_ref": ["r542"] } , "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails"] , "lang": { "en-us": { "role": { "terseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "documentation": "Number of options vested." } } } , "auth_ref": [] } , "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [] }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfAvailableforsaleSecuritiesDetails",
"http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r889", "r890", "r891", "r916"] }, "us-gaap ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r647", "r981"] }, "lab SoftwareDevelopmentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "Software Development Costs Policy Text Block", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Software Development Costs", "label": "Software Development Costs [Policy Text Block]", "documentation": "Disclosure of accounting policy for software development costs." } } }, "auth_ref": [] }, "lab SomaLogicPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SomaLogicPlansMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfSharesReservedForFutureIssuanceUnderEquityCompensationPlansDetail", "http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Soma Logic Plans", "label": "Soma Logic Plans [Member]", "documentation": "Soma logic plans." } } }, "auth_ref": [] }, "lab SomaLogicIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "SomaLogicIncMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CommitmentsandContingenciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "SomaLogic Inc.", "label": "SomaLogic Inc [Member]", "terseLabel": "SomaLogic Inc.", "auth_ref": [] }, "lab StandardBiToolsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "StandardBiToolsMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfPreliminaryAllocationOfConsiderationTransferredToTheIdentifiableAssetsAcq", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfTheAcquisitiondateFairValueOfConsiderationTransferredDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails"], "lang": { "en-us": { "role": { "terseLabel": "Standard BioTools", "label": "Standard BioTools [Member]", "documentation": "Standard BioTools." } } }, "auth_ref": [] }, "us-gaap StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureGoodwillAndAcquiredIntangibleAssetsNetScheduleOfTheChangesInTheCarryingValueOfGoodwillBySegmentDe", "http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesRestructuringandOtherEfficiencyCostsDetails", "http://www.standardbio.com/20240930/taxonomy/role/SegmentReportingScheduleOfBusinessSegmentInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r208", "r289", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r328", "r334", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r411", "r415", "r422", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r446", "r447", "r468", "r469", "r472", "r475", "r483", "r628", "r792", "r793", "r794", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r826", "r847", "r870", "r892", "r893", "r894", "r895", "r896", "r1097", "r1137", "r1144"] }, "us-gaap StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r90", "r94", "r95", "r207", "r232", "r233", "r234", "r253", "r254", "r255", "r257", "r262", "r264", "r266", "r290", "r368", "r369", "r413", "r485", "r570", "r571", "r578", "r579", "r580", "r582", "r587", "r588", "r594", "r595", "r596", "r597", "r598", "r599", "r602", "r630", "r631", "r632", "r633", "r634", "r635", "r638", "r640", "r655", "r756", "r784", "r785", "r786", "r801", "r870"] }, "srt StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaScheduleofDisaggregationofRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r169", "r171", "r174", "r176", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r332", "r333", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999"] }, "us-gaap StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations", "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParentetical", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParentetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r253", "r254", "r255", "r290", "r640", "r698", "r791", "r812", "r818", "r819", "r820", "r821", "r822", "r823", "r826", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999"] }, "us-gaap StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]", "documentation": "Statement of cash flows [Abstract]", "auth_ref": [] }, "us-gaap StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]", "documentation": "Statement of financial position [Abstract]", "auth_ref": [] }, "us-gaap StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]", "documentation": "Statement of comprehensive income [Abstract]", "auth_ref": [] }, "us-gaap StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]", "documentation": "Statement of stockholders' equity [Abstract]", "auth_ref": [] }, "us-gaap StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfOperations", "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParentetical", "http://www.standardbio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParentetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r253", "r254", "r255", "r290", "r335", "r640", "r698", "r791", "r812", "r818", "r819", "r820", "r821", "r822", "r823", "r826", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999"] }, "us-gaap StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r1020", "r1030", "r1040", "r1072"] }, "us-gaap StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "lab StockBasedCompensationExpenseDueToAccelerationOfAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "StockBasedCompensationExpenseDueToAccelerationOfAwards", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense due to acceleration of awards", "label": "Stock-Based Compensation Expense Due To Acceleration of Awards", "documentation": "Stock-based compensation expense due to acceleration of awards." } } }, "auth_ref": [] }, "us-gaap StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "terseLabel": "Merger consideration (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": ["r89", "r90", "r132"] }, "us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.standardbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNarrativeDetails", "http://www.standardbio.com/20240930/taxonomy/role/MezzanineEquityNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of redeemable preferred stock (shares)", "terseLabel": "Exchange of common stock", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r14", "r46", "r90", "r94", "r132", "r458"] }, "us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under ESPP (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r14", "r89", "r90", "r132"] }, "us-gaap StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [] }

"http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Received aggregate shares", "verboseLabel": "Receive aggregate shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r89", "r90", "r132", "r792", "r870", "r893"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "terseLabel": "Issuance of restricted stock, net of shares withheld for taxes, and other (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r14", "r89", "r90", "r132"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r14", "r89", "r90", "r132", "r531"] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "terseLabel": "Merger consideration", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r14", "r90", "r94", "r95", "r132"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "terseLabel": "Conversion of redeemable preferred stock", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r14", "r90", "r94", "r95", "r132"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r14", "r89", "r90", "r132"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r14", "r132"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options", "terseLabel": "Issuance of common stock from option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r14", "r90", "r94", "r95", "r132"] }, "lab_StockOptionsAssumedThroughAcquisition": { "xbrltype": "sharesItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "StockOptionsAssumedThroughAcquisition", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Assumed through acquisition (in shares)", "label": "Stock Options Assumed Through Acquisition", "documentation": "Stock Options Assumed Through Acquisition" } } }, "auth_ref": [] }, "lab_StockOptionsAssumedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "StockOptionsAssumedWeightedAverageExercisePrice", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/StockbasedCompensationStockOptionActivityDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Assumed through acquisition (in dollars per share)", "label": "Stock Options Assumed Weighted Average Exercise Price", "documentation": "Stock Options Assumed Weighted Average Exercise Price" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficitNarrativeDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1206"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "verboseLabel": "Shares of common stock", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r14", "r89", "r90", "r132", "r795", "r870", "r895"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r14", "r89", "r90", "r132", "r801", "r870", "r895", "r1009"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r90", "r94", "r95", "r118", "r828", "r844", "r871", "r872", "r982", "r1010", "r1139", "r1163", "r1245", "r1299"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity (deficit)", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureStockholdersEquityDeficit" |, "lang": { "en-us": { "role": { "terseLabel": "Mezzanine Equity", "label": "Equity [Text Block]", "verboseLabel": "Stockholders' Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r128", "r245", "r467", "r469", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r480", "r482", "r485", "r601", "r873", "r875", "r897"] }, "lab_StrategicReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "StrategicReorganizationMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RestructuringandRelatedChargesNarrativeDetails" |, "lang": { "en-us": { "role": { "documentation": "Strategic reorganization", "label": "Strategic Reorganization Member", "terseLabel": "Strategic Reorganization [Member]" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetails" |, "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r649", "r981"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffinancialInstrumentsScheduleOfLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" |, "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/BalanceSheetDetails" |, "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Details", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r1118"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" |, "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1066"] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAbstract", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Mezzanine equity", "label": "Temporary Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "terseLabel": "Redeemable preferred stock; \$0.001 par value; zero and 256 shares authorized and issued and outstanding at September 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of zero and \$255,559 at September 30, 2024 and December 31, 2023, respectively", "verboseLabel": "Total Series B Redeemable Preferred Stock", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r437", "r440", "r441", "r442", "r446", "r447", "r554", "r747"] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" |, "lang": { "en-us": { "role": { "terseLabel": "Redeemable preferred stock, aggregate liquidation preference", "label": "Temporary Equity, Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of

shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "lang": { "en-us": { "role": { "terseLabel": "Redeemable preferred stock, par value (in dollars per share)", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": ["r21", "r43"] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "lang": { "en-us": { "role": { "terseLabel": "Redeemable preferred stock, shares authorized (in shares)", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r88"] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "lang": { "en-us": { "role": { "label": "Redeemable preferred stock, shares issued (in shares)", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r88"] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "lang": { "en-us": { "role": { "label": "Redeemable preferred stock, shares outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r88"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": ["r1154", "r1251"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1058"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1065"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationScheduleOfValuationOfTheIntangibleAssetsAcquiredInConnectionWithTheMergerDetails": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangements [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": ["r1085"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1087"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/Cover"] }, "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "lab_TransactionAndIntegrationExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "TransactionAndIntegrationExpensesMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureBusinessCombinationNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Transaction and integration expenses", "label": "Transaction And Integration Expenses [Member]", "documentation": "Transaction and integration expenses." } } }, "auth_ref": [] }, "lab_TransactionPriceRoyaltiesExpectedToBeReceivedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "TransactionPriceRoyaltiesExpectedToBeReceivedPeriod", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/RevenueandGeographicAreaNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Transaction price royalties expected to be received", "label": "Transaction Price Royalties Expected To Be Received Period", "documentation": "Transaction price royalties expected to be received period." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfAvailableForSaleSecuritiesDetails"] }, "http://www.standardbio.com/20240930/taxonomy/role/DisclosureFairValueOffFinancialInstrumentsSummaryOfRecurringBasisWithinTheFairValueHierarchyDetails": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1088"] }, "ecd_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1089"] }, "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1089"] }, "ecd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1087"] }, "ecd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1087"] }, "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1090"] }, "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1088"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"] }, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"] }, "http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1088"] }, "ecd_TrdrArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1089"] }, "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1089"] }, "ecd_TrdrArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1087"] }, "ecd_TrdrArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1087"] }, "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1090"] }, "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1088"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.standardbio.com/20240930/taxonomy/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit"] }, "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r50"] }, "r53", "r94"] }, "lab_TwoThousandAndElevenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.standardbio.com/20240930", "localname": "TwoThousandAndElevenEquityIncentivePlanMember", "presentation": [] }


```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

0120WAX829JMC44ZHO5SB80V7/7,D=F9D,BP<7*%X9W@RINNRR%=>R=R=X-D:\$!@<=,WHY(6-M)?2-A@A^>^BL:"<S@SAI5PDWJHB6VW>^QM7NU20VNJZ^Z4ED(B+#G^1M^W
MIP_-8H<+<1,3RB@<@<^1^3351+3G#=>1^K^55DIDM2>?=>90K^UHYH,TF-<=>M<=<5HQ^U5<6;WX^H^<S^K)7^A/0?R8^<+<=,16I1MOSKO=12@<SUE,1,QEJ?
MCA6E+24EBB^X4,)=Xl@74^LHFV53QINNMT7Y2Q^<=>=WOX^M1609?QV?>#UO MJX^<=DC1G49M8^<OYM,1^<=,141702^<@<?<=,T+1N4KM12^<?<=4Xl0J2X,
M9K1Z<@<5\$>^#IT7^AX1^L1N819W167^P52W1M3^<LX%6B>95+1(L^S MP,YP2B>^<O^M,^F^SEW,SE%N^M,HP^5D6V1^<ESREFM9^<B551^>7^UW,1HF M5^BY5^V^H K17-
(4SA=YZ,2=W^A1H1M^<GLG<F8I5^S)=13L1<3^<ZG,MJH<=>SS\$1=NL-6O^AB15^M0XQQ^<60^10^P^TEW^<^S11OU^P\$8CK3^A>@<1972^61^<F8Z1^1AD3^S1
M16WG<8V<^,QPD<5^,OGP8W1^1^B<1^UNL>1F^<F^<66LSCA4^43^H^BCOO MQO16AY4>B^<B0013S,=^M,^1OIPP^HS^=>M=,Z-9Z5^?D3&SZ91^,11^#1M-ZR5^4%>Q<C/K+R_-0C0-
9P4P^1J^W9>GJYIV7AS(G=>+1^1JR2^%M^1G29U^0^UW,^WFAZCM^<P^<RQKW,6^?<FZ1D^M^Y1F^K^>=>MS9+CPQD^2GP2=5!@<9Q^ML^W48CU^9C,XH&11^U^:C?7
FUZ0G6M6SU+1U4M=YK MY9Y6OXZ1UW^R8T7PM^N^P=TF1R2,S10^>O=>12FBR_0P^YV16TKGQ2@<L
MGHHM16F0=1X21=KK4 E=0,1^?7#1UN=>Y^VAXI<@<K^#B3^D^XV,8(1T19,8FKF(UNO^1W M^,A2N9QBMH^1V^<6M9>X^N:01^<?Z4^WWOS12+1^F,GKS#<2FKL^>WKRM>S_9Y
M(W8M13^VPZ4K1<=>E,OG D=IMV^FVSQ^>9M&L=C,D,1^BHXO^G61G^1F^M^<BG<S^1D17G&UL&A+^N^?413TJF P3,3^RMJ,^<S0S1NEW1^4+^SNV>ZW^,%>9(G+<
<3QOE8Y87H^,004F2U5=L62T6,2^131C G M61^+U^,^H=1^#^PNVY,TF,MOZ,UD7>)>6&ZIE(CPZ2&PBI>? G^G4N7SMBZ MROOJOU^IAM UAM^P^<@<+1J7OFMUW1^0PP^<PN-
36KJ M^?7^6)>=>406JY24PM M02=E9^<F^?#<1^1^JEYTF3>^<PHY(BG11H^1^PEF3^9X^<1^<6Z,6AOGQFWD MOZU1^<W1G1Z^W7D19A^E^<S^RJC1U^R^M^1^NBF^ZC^JBOH36^19-
56J M^=>S>=H:78^A3U^06,120X8V^XN6^8H6>XIV<,<1^J JX1?RB1?^<S^<78FIU^MAG9GLB^,^SB#<WL6O>?UEY1^<S^EZZ-2%SL8 O<SM>=>G21E.YD(> A1B B5
M^>31N^,3&Q8XWYFS^>7FHSUK Q^O^Q^K^<R^<JCYBD8C^LN^<S^<A141QV M^T^WBL+206S^H1^?^<@>TEP_2^<8&8HJZ>^<=>4-25E<4C^KHINKO^?GV5&C1^>>4>=>:,S^U+4
M2059^<@<2DDBBY9^,C9N1GS<18-2P>Z^=>=,SW5751380),M6TFN^F MFSU6^<D0B7R1^9L1U^C^<P30^<VW,2=2^V5%ZBM,R^<J6C^NP2A0+^<E^<PH+R
M0IY(83E^M^U)HKAY1T^SDJ^PPU^<MS21D8(K8J^TF>)>1H^<D3,D+V%>S^<J^<JW^<DSZ^0^4ZPF M4ZU^<4RS<HFFROSLM5<ON^<MNR#^,33GLJF<3MA_G^?2^1QO+?<
UYV1^<1^LMC^>5^<FLBR^<C^<1^GH^,E0^A^4^,VR592^W^<9J^<H^?<W^UE^<ZU^H^1^TK94^<=>OFED&^?0 M^U<3^<^AA9-
Z81K4=2,4UZVS=1AN+^<+XOGX^<UO_OHEYZ>C6Q<1\$@<U8TIS2 M^O>H<@>BK^<E^M^O4M^UZRGZ^%HJVGS\$5_4X4^18:5+<F&U+2F4=5^2/T+Y8 Y
M1V1YHJZ,S^<0(S<JNTRY2J^>L>GMS5GRO^4XC^M725Q(S1^Z2^ SX14P+=A^LG1S^,^>U^E^1^R1Q1Q2TTEE3WV1^V5^
M^<719^>AYON<X3^Y(2^0^69P2^<3F52^<C@<L@<=>M^<C3C1H^<L^<=>1^JHOGEL^MYXR,1^<H^<JH,8^<4&=<RFGXVYP^BRQ^TF3>3IOPB1^L408P^T^=>T^GB^44MS,M^#FX9?
YZSN^<CEG0QI06_<=>0CB<21V7Y^<X&^<@>ALW=EL^1KN^<=>=>8C^?T^MY^?7^1KH<=MM9W^FCGM^1^02^UHLTOSG^<VY^M,913H18E58W^<0F>BA9+8G^BS^<^
^HYU_10Z>17^<G04X^<1^C^1^92^F^M^<P8H^P^<=>=>8^HFK Y^<GONB<S^PLB^K^<48^<PKD7^P^H^1^M^9<@>76^1^01^<M^<AMS^F6^V04^1W1@<8H<@<IN6^<N1^Z^?<
MECG^+1^BYV1B1G^<MOZ^W&2^O^XZ1^2,02146N41Q+<SZVJ^<AB^HDS&A^<A^<97H6J^<1^MH2F^<B1^USK^?QOO>E5B1=RI-G6^<1^2K^O^Z^<=>510X1^U^US^<A^1P+1M^<Y6^B1M^<8^?<
(TF6>K7,1Y1UT0P6^F21^<F1B7^M08E,1=1,2^N1ZNSM^7Z:M^<=>4=R,E,1O1&^<=<6&0^<=>GGG^78,NBOH1U^W+^<H1&Z5:6^<=>S^<=>WQP MW1>S6=>,<1^JTSRF?^<H^<14PL^<SVFN^<1,0M>^<
(EG9)^<D^<S^<W0&1@_M42Y8(MXA^<O^<M^EYB^<A1YCA6S19M^<=>1^D1B^<7DDW41@_TGX_<=>DKH19^<Z^<N1K^<SU2^<P^<M^<15^<7OE^<T^<3OKINIA^<ROZH8<74L^<U^<1TFB
<Z,2H1S<1R\$1^<D^Y>_<MNFCS13^<H^<P^<41^,MEPMQO>=>W>?<PJKR1Z+1553H1463Z^<Z^<TW&1^<H^<1NOU^<P^<MMY1^<1070^GA8Z^<A1NMP^2>1F^<
1^T^<D14IBGX^<1^<P3^<PEF^<1^<LQ3^<EJWL^<MSQ^<1KR^<=>R13^<1^<O1Z^<P1UGNX^<D9S^<DK1^<2^<G5A^<1^<F=^<672^<EHL^<N^<MOP5^<CDH^<A^<XHX86^<6^<H^<=>
15X^<=>ZFFC^<N1T^<K^<G^<NO^<B^<XO^<HA^<TF^<Y4S^<S^<W^<M^<L^<L^<1O18^<1+1^<7D^<1Q9R5^<QHS1H^<1^<ZRX^<=>1HXK^<B9^<KM^<5H^<1F^<F>S^<12(B^<M^<S^<C^<P1@<Q&D2^<VE^<EF^<5^<JH1^<1^<F^<G1-
R^<OQ^?7^<RHKQ&G1<1^<E^<2^<W1MW^<N^<H^<78^<Q^<F^<C^<=>S^<F^<H^<O^<MOH^K^<L1^<70^<Z^<B^<F^<SK^<

[illegible]

[illegible]

[illegible]

EDJ.FMSXF8PW52+FAF#D.V22.M (E=3M.#1514566B+Q*026T.UH.X7C<JL+MC9.1.DJY4P.CCXLD)S<^5HYA9IO.<46&6AY.MO(1Y.#10IN.A9U2H1G.U7JB<9R.R.YNO-70%<#>+>1H4VKT>SYSO<X7P>WT<^UI<U<MWL0P<R<9D)>UMWEXIM&Q/SIN0>6#>1XE.5T5 MQ-U*0MHDQ4A=SU(MCk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~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f..<UWFGXSVY.E20K<VAA1E&#JR=>#T>VG<K/NL-AD1PH<V/VR5FDX<f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

X.V.S;2AE2F1)BKR;TO;D)W/v+~7MF)>ITRX7 M5(I #6@.TW**E^4Z?(V:B06K7&~[TH-08>IWRYW]IMJ=7%F>PYJO>P.MPJ^U3YR5>5BJO^F)FMVLIS7-8-5/-
8^CQJ5RLZ4TU<^<9^>U7XKEKU6ZCNX8H8RUEFM(I&M%EWML8;@QNTCS^X1#N8JD=>A^S^4U^SJS&9^HEC(^(^HJ&67^ZJHJG6 MLU5QTO7Z9.D0#?2
Y+Z6/D1F^=A1^=>M90V7S^QWMOZ5^#UF.GG5)G.GC1MA2^T.CS;RDP-TULF7^HHRP.M5(S8J3.36ZXS.XD^?#C^ZYFEWHRH6F7K.
M.MIV4XB=>P^N^T43^IWXQ^WMO=>7L75^XSRM6^7FD9.12%TJB.MIDPUE.Y>.&.;IMN;IGUMH8E5IVG<=>47^6FY.(5.=>G30)5Y;H(N5)J>L>; M0B^MMW^M^H0^T0G6MK^Y5(O-
^T1PP^H4B;LAVIX^&VYU&1W6^*t~>W.MI>NB.W+JF.U?>I0-6^&^ZTDPZGY>N99QJ-50.^U^>0%BO#5C^9DIH^K\$R
M.&.%AVH^>0&W&V&JEHO^<S.ZFTO>.>4H(S^EQ;0^SN1LE5E=2%N.3:QM^MUU^>=>8-V83CS2^?0R7REMBAA0J^?#D<^V)^7=>DRH512RT:D.\$G.7^LPI^YMG2-B^2WC?>
GGU^L^>M&S^UK1+OP9-U^>T7@Z^N^D5C>V1.3FC^#HJBYLT^M^X(C^>+>W.NCGG;L&0^QO^PXRKK^>790;6V9&3FU1WLMDCM04JB29^H180623IE.M%>K.N^T^T8C3?>
2IAIY^S01^EH3.N.Y19-KB#>GTS52(0)3.-LE-0>=>U&H\$1 M878^..MN75(16^>@VN;31UYE^?^PZGP>3MLLWE>N.E0&^>3N^2K0^MH0>VF7C0^MG97F3C0A^#4%1^L#Y^T^>=>71^>V^>@
(#K^1+0\$A.0R&4^?D0.DHRH85HIDIOB^D.MCXB1^V.N.#H(BK;1^?R7BLWIC0^J0EK17^L&2^GHJG6ZKN^S.ECN<4(MU+>@^42472^HJENGJCS&C)6I2W+>7^7KY<O^YQ>0>4&
t^UKIUXENM(1BAJH^*MP0%YSPS6^3I^>P%)(G.B\$15#M+BAH&>WQ);.IEU;J3;MD.E7.MAV(866^7+(E^XIOVAV>R;BVH)J;L:5ZH7X7C;L.FD4IW+SI)BD6<6^*(8!=M.R.^>
S1PTP^%CZS>.>CFV.RH5U5.CF=>JG&9J.B;MK51H+>=>9^>M;H&AG99^DRM71C=ZC^Y3J6AHU+EX&G^>I=JNQ5.5D^W1DP.M&>?>?Q(A^31^Z3DTHF7^&V1.ZN
MPH^F8;F1^OPX^Y^>H1THHHH^Q>S>JG(P23C^>XW6B3/B0@>HJ2J5GDK^>M^X&9R^1^5C.N^>M^>L^T(FD^2%OB#^>A2^>=>SCA.0^9VB;7^N2)4X..D.M^C0^>P
>#>W.FY7OEX7^>UO.XB3UR1^OV&YK7P3H\$^>B7^>S;U.O>+>6^>?M00I^>792IB^>6-N\$5.^>QKIC5Q.F10MB.V13^>EWB.F3^>Z6^>9A1H^SEZ^6
M630G&G>GX\$10Q20B=>C^>F-07)Q.HJH^>1^>F&P\$IL755XCI^>IZI.MK&KA^>2XHPMH1^?7^>R>U^>1^>J^>U2ZFTN^Z5L&X&Y<E<08(I\$0^>1RB-FM.EI.AI?N^*A9Q;
MY\$::HB\$U%KH%&IR596\$1.031;.%O^T^>=>PE34R.2Q.K72=-MHKV^R.^>9/M.Y4>+>8IOI/K\$%<^?Y)IE)WEA0H/N)I^PB\$%X16>#G.^/J(FB;.%7HJ3YI.MT8MX&P;S^>ROH88E>
<=>3B1L4=52PPQ^<=>J03J00^>M^C3P^>BBD3H^DY.M^>35Y3)1^>S4^>1^>P7=6C.CJ.KJBKJ80^>2W(I\$0.1G9^>E^>7XIZ;A(ZY.MH^>4P?>@E301^>A.OH)0^>2IMV9MWR.
Q10=>6WE^YV1XX^>=>P60.F7E&E.MGQC>Q04A10^>+>J^>WTF&Z^>L^>S8YT7D)Q9)7^>1J^>#6.NL.Y>+>6)P^>MN025F\$A)D14M^>3^>GZCRIF)J12I<^>W4=1^>IYV64%7^>
WHH^1^>Z7%(HKBDDM^>@>WMF14^>FU^>H3XWWM7F@J^>A^>8-E<=>^>DJH.E9<^>2^>277IT^>4^>3YZGA5M^>=O^>9L.OZ^>4^>7^>8ARCAYUOIT^>67P15)C^>I&CH&X^>P.NEY#6#=>HYV
MGXIZ&1^>MH.K\$12H(2L1C^>FPQ^>RP0T^>I.W^>Q^>VS96FW0256=>X1.QR)M.ZP9W7.M-3%>HD.D9Z415^>1FEW+>#BKN175I^>0.MR<4^>L^>B26X118;JDF^>0%>#&^>LCC57.28A9(6
)0F^>9HIU4F>+>+>Q>@15.K.MYD.Q6A^>QB^>6^>YX^>Q>1.NI.T.MN^>%\$AE2106C\$7P+HP>ZOI91^>AU\$>@JP^>K.E\$6HGV.YFM2&I2BP.K%>GL^>1.M7N^>T+>%M.^>=7T^>27^>OUY18TB)04.
JH5^>9K0V^>4YSK^>H\$JC^>810P^>M.FTHK>@>9.YW<=>E^>2^>11DBS^>F7S.FM^>+>8^>0^>%P7=^>@JBM+M^>9^>3LY.SH6^>K2/HN.IF6^>=>VZM^>UOZK914^>+>5>^>^>+>RALE^>=>DW^>RY0.
M>=>YF^>E2X&S^>6^>9^>H1.N^>+>1A^>W\$>G.P150.(0K057Y4.N\$;7A3X&F^>J)0.M^>R^>H3N&B^>H+>W^>10^>MFA4I6F7^>FP6^>W^>3=>7BKY3T^>3G4I^>P6P^>M^>K&Z.MG2&G30^>I3^>R^>G1
M^>UL<=>+>YZF55K^>W&B;89ZDL.M^>#>WU^>DGK;J^>HHR90FEIH^>KN.EA+>+>JZG2.E^>9.Y6K^>RQPN^>88Z\$X%>B.M^>J+>PUZC^>2^>=>V1X^>J.6^>6^>0O4T^>=>M54.
9575%>^>U24Y^>3%>2DU&A^>+>ML61&1^>9R5G31^>#(O.H^>X^>G^>1^>U^>VBF\$1^>X6E9^>HNGM<=>9FG^>IX^>GZ^>IP64^>@5B)G^>F45DI+>+>H2;UMWJ5)0+>G8.M^>NGYI^>
>642^>8&1@F1Y33&^>Y.M@BYQ.TUCA^>1VM2A.#.4.#.7.^>L@RPGH.M21L5ND=U^>T.3SQ2.76180^>Y>S)6.1^>D^>ZRYJ^>F<59TKK^>@A6RC^>U(6OHU)^>M^>@B1K^>PPW&EDW5.2166-
C@A^>FAYB^>JF>+>8H2QE^>7^>2H3JF^>M^>Q>B.#.%Q>@>HCTI.MAU^>V^>D3>1%>W.\$>T^>2F&0^>#>BZJ&C16L^>@4U6E9^>2^>6^>#>Y0L^>UINWM+BEH^>+>5ZKZC^>D0I6^>K&3^>F^>^>P^>M.
MAQ0^>7^>L^>S^>AF\$1^>3^>H^>U^>X^>HJ.D^>E^>C^>D^>VCLL.O^>TOYNH^>K^>MKM^>7^>3^>D^>M18^>L^>7<=>64&XCI2^>@BATZIHFTU^>F2)SVIA2ICYP^>#^>BBHJVG&K^>U^>2BQ.M<=>3P1P24^>
>C)01.H^>C^>K3C^>1^>0Y^>=>88U^>L4H1G^>@R4>B>ZLUMV1L1W6\$11MGB.MP.KJ^>^>3^>J&L^>HUT&^>Q^>2^>#>B^>80Z19T^>CDN<^>@Y^>V9DI^>F7^>KT.54^>X08
M^>T^>J^>E1^>A^>6V.P2X^>2H^>I3^>+>AC9^>1^>D^>M^>4^>L&4.44&8&3&X1Z^>J^>^>MWA0&I^>HFW^>2>VFM^>A^>+>1MFC&I^>N1^>3^>2^>CIUO&S^>1^>Q.WGR<^>U5I7A.94R6)MW5^>
<2^>#>TIT<^>6^>3P>T^>S780/QEX4<^>#6PYBD^>@%>2UIH^>+>OD2S4G^>FDY@0I^>MU:0^>?R^>F8)H^>70^>N12^>IP&K^>L^>7%>KHD^>@Y^>V&JS82A^>0O&K^>A^>2W&6K>@>@P^>M^>W2.7&
/IR13101MR1^>=3S^>926^>?2^>Y^>6^>F^>H^>J^>T^>C^>+>HESB0H^>M^>4^>NOM1^>CMYUJ0087^>LRB5^>1^>70515^>60I^>A^>#>W^>@>9^>V3Y.M^>2/FOXZU.677^>F^>H^>W^>2^>ISOK1&L^>E^>
/P3^K1^>7^>L^>F^>C^>#>YENW&U^>X^>MB8F12^>P4^>#>61^>#>Z^>+>F^>XJ^>H^>=>H^>5^>6^>T^>9^>+>I480<^>C%>=>S<=>I^>L^>@1^>5RYLO.M^>V207(2=>G+>1^>8^>W^>F^>M^>BUV\$)^>Q@>7^>YONN6^>
2V3G90M^>Q^>@PL^>H^>S^>4^>W&R.M6R^>C^>L\$O=>=>TYV^>7V2>^>1^>37AR7^>@R^>C^>VMD3P^>577^>2^>3^>3E58&4^>M^>M^>D^>F^>@X617KM\$=>GLD9Q^>X1^>C^>K&G&T9ISA>F7129.FAF^>#>CEZ^>^>
QY2X80>2^>2V.M.NQ1B^>+>H6KU>2^>F3AKB&S^>QV\$1H^>I^>C449>8^>P.O^>X^>I^>R^>S^>VMD9E^>B^>K6H.M.O\$<=>#>I^>T^>L^>68X)7^>F0F0G^>+>I^>^>^>^>Y^>I^>C^>S^>MPEFG^>@>P^>OC@>CDM^>M^>?
G7K^>#>EMU00I^>4U(1^>G^>A6&S^>WH\$^>9C(1^>D^>)C4.^>J0&J^>EAB^>F3(1^>G^>O&L^>M^>(C^>MFJ^>+>+>IP>=>EX0N1^>B^>C^>#>+>+>Y>31^>A^>5^>N)J^>C^>+>F^>C^>L4^>1^>WBL^>E^>M\$>M^>?I+
(H^>B^>MVR5^>9^>F^>J^>AFIN^>J4^>0CZ^>+>CFNAI^>#>KJLJ3T^>F4A5A<^>A.MN19^>820^>X^>SKA6&4&DBL5^>5Y1^>7^>ES.HA3^>B^>JWDC4&Q2^>53L^>T0^>P^>#>APBQ&1&J^>JL+>=GJF?>
#>YTTI2C4.7AY6H^>27I^>P&S2^>L5^>P+R^>O&D^>MH5^>A^>U^>H^>7H3^>7EC^>E05024X9^>4IG^>G33^>@>GPKL&6^>UKH.M^>A^>11^>#>=>HQS^>A^>M^>32^>1^>S0510MA.I&M&K^>
P^>VY6M^>5^>XJ1D227^>=>1^>G&30.P8@>1^>8VM7^>DUB>P901QW6V5^>M^>1G1^>M1AYOH3^>C2>F5^>41SI^>TW^>CBOLV18K^>Z^>O^>FLX0H1^>BW^>VRN1^>P^>
I^>O10^>L^>7^>W25.^>1WT^>7^>VGL^>M.^>J^>K^>R^>25I^>P^>AVH1^>6S61CN7^>J^>B^>U^>N^>T^>M^>3^>W^>9^>Y^>449R1D^>2I^>QMNMXX^>2I<^>+>9.X5RN^>1^>1^>86P61^>3^>U1^>C^>N^>=>ZJ^>^>06\$>7(V84NOP6^>L^>M^>?U
D^>D<=>@J7J^>N^>K^>7^>D^>I^>W^>T^>B4.M^>89^>AA@E^>T^>7V.5S(0EAP^>IY6<4H^>0^>33RTM.NFLRY(IQO^>XEWB9>5BR^>M^>M^>#>TP?SEP4KI)^>E^>IS0JLZ?>
X^>R^>W^>K^>+>H^>T^>G^>CB9>=>X2A^>1^>+>6>=>XV6\$2L\$^>MGR>R^>QO<^>?>D^>Y^>Z^>7661L^>ETD^>#^>+>@1N\$8^>7^>U^>T^>C^>S90^>LN^>Z^>4^>L^>7^>MBF^>ZG9^>I^>E^>C^>#>BR^>#^>^>45^>M^>XO\$=>VBHJM^>?>
K^>M^>=>C^>B^>J51<@>B^>PA0^>648^>400W^>3^>=>EAYM^>ZL8I^>H8I^>BZ^>1^>HJ^KJ8I^>ZW.M1^>B^>B^>3^>H^>76^>132^>YD@>149C2&^>4Z^>W@>I6^>A44(I^>G1^>P^>M^>J0D)7^>L^>6^>M^>+>=>UEA&W\$?>
F^>V^>J^>6M^>5^>XJ1D227^>=>1^>G&30.P8@>1^>8VM7^>DUB>P901QW6V5^>M^>1G1^>M1AYOH3^>C2>F5^>41SI^>TW^>CBOLV18K^>Z^>O^>FLX0H1^>BW^>VRN1^>P^>
MHLJ5^>=28I>2>=>2EGNE^>G0&66G^>66P^>ZP8^>#>S^>S^>=>E0AR.FY10J1Z0^>MDE^>C1G^>I^>T0L^>V4NK^>1^>H^>96C5^>U^>E^>BIO2&4^>A^>N^>K^>416F^>W^>+>E^>W^>M^>M^>27^>M^>J^>E5^>S2654_9^>
(E^>S^>G^>I3V^>5^>2^>16BR(C^>#>M^>OY1E^>7GB^>FF^>X^>808(2^>WP^>A3>1^>+>17>K^>2^>+>GOBK.0.0^>V1WR=QC^>172@M.A^>A^>H^>F^>3L^>GU^>4X5D6B>W+JVN0J^>P4V^>VUIT>Y^>A^>IXTGC
FV&^>#>FX^>6M78.M19C9.4IR8^>1^>MR^>+>1P^>45G^>+1^>P^>S^>U^>YEO&N16D.CD0\$W\$S(MXEN9)G^>#>M^>8^>#>@BHK0&30F^>F^>8^>N^>X1^>H1^>#>Y1R+>N^>KU^>W^>E5N0H^>#>KH10^>7D1S^>I^>
MYR3L^>9^>1^>6^>7B8I4H<5CDS9R1^>4P^>NH^>^>JFYNR^>J2H29^>3^>+HHEFG61AIATR^>J^>Q08UB^>H^>M(SLM^>Z^>1^>D1S1^>P^>W^>K^>H1^>IBRR^>FFM^>=>00YV^>6^>ONEF418&IBQ_5^>@QH^>W>
<9.R^>/4X^>I^>X^>C^>TN1^>P2^>MJ^>XF^>#^>AAL8.S^>TBK^>H10^>G^>00&K^>S^>S^>?PQIU^>R>@>25Y^>1^>=>ZM^>Q^>L^>M^>+>MKO.M^>Z^>W^>=QV^>1^>E^>+>MUD4V4&4^>P9L3^>ETRD^>10G5^>8^>YU^>7^>K&KBR
M&A^>9^>1^>Q^>7^>278H^>M+M7X^>R^>F3^>9^>49B19I^>=>X>0ML1^>?^>Y^>X^>YJ^>A1^>OHH^>MHINO^>JM^>5.8C^>#^>T^>H1HM.O92CAK^>1^>4^>T^>Y^>Z^>F^>T^>QED8^>XYI8W^>MA4B^>#>Z^>
Y\$F^>H^>I^>V^>Z^>A1^>+>+>EC2WW^>5^>1^>+>Q.3ZOY4^>84^>)&^>S^>X^>=^>E^>M^>+>+>3^>+>6I@&^>+>P^>HY^>G^>V^>7H^>S^>D.COY^>9^>R8.N36^>Z^>FIR3^>3^>3N1^>G^>Y1^>M^>3^>171^>=>TX.FVG^>I9S^>L15I0KM^>
#BS<=>S^>RCB7^>PTRM>5^>5M^>MA38^>T^>H^>7HVIZ^>=>#>XP5G244K^>A^>CZ80(QC2W6I^>E^>L^>+>K&7ZH^>H^>H^>B0^>I^>F^>M&V^>I54^>APX4^>4^>0^>0^>=>N^>9M^>+>V55^>2^>G^>X^>J^>X^>FBI^>9@>
@JW6A^>A^>NBU>1^>L^>4^>9N^>.%>I@>J0LS0.020XZ^>A^>M^>4^>20Y^K^>R^>P^>B.M^>JOVYV&+GJ7A1^>6SA&C1^>G^>=>75.G0^>AWYY1DL^>CM42^>W^>249^>YHBBP^>MPI^>1^>N^>@>
^>J^>+>M^>0.D8^>F&P^>J^>+>H^>C^>P77^>?^>W^>L^>YUM\$>C^>L^>LISF57C.M9I^>@>0\$^>Y^>C^>1^>Y^>W3A>TORC^>Q^>Y^>O^>B^>#>M^>@>UV1L^>UVB.M1H8^>33>Y^>F^>A^>XTTELX^>JH^>S^>Q^>82LD4R^>+>
VR1^>@>H^>+>U^>L^>K5B^>N^>OOPE.M05^>8&6MD2^>L^>X^>Q.Y1WTG^>7^>^>S^>NN^>3^>32X^>2^>K\$S9NDK^>M^>0^>#>+>L^>N^>J^>V1D^>+>I^>Z^>T^>R^>3^>NMB&+>N7^>I^>Z^>L^>K^>JH^>+>H^>S^>1^>Y^>K\$SOM^><
M1HZAY..&2Y^>#>G\$>P4NS^>=>XK^>N3I^>P&G3A8R^>00.22Y2.GY11^>1^>S^>W^>=>3MV8.MCJ&F&ZW^>N0JW^>IUB8GB6N^>#>H^>M^>I^>8D9^>S8)0^>4^>A^>H^>D^>GF4X0ZD^>#^>W209FL^>2^>JX^>^>UH>(>5^>F3
X^>Y^>2^>P^>U^>=>MIVL4B8V^>=>S3YV344^>.%>Y^>E^>W^>#>G^>W^>P^>MB@G5^>+>E3D^>=>IS^>T^>M^>+>=>TY^>MHS^>IVR\$>2^>L^>+>+>J^>F5)0^>O^>L^>P^>OQ^>C^>AW236W^>1^>W15^>+>V0Z>=>MMWV.91%JNA<@>D^>I^>
<=>Q527R^>M9TD8H^>A^>Q.Z1^>QK5M1BXW0^>X\$>M^>Z^>0^>1^>J^>T^>M^>C^>45^>N^>1A^>N^>V8^>I^>VXD)2^>M^>I^>K^>+>K^>+>H^>+>D^>+>UE@>E^>R&XG^>MU?>
<UO22^>ZL1P^>@W4.W+U>3W+>B7K^>20Y^>P^>Z^>P10^>1^>3P7^>1^>M^>K&6^>+>Q96X^>1^>M^>S^>+>I^>E1GZ^>Q105W^>3^>HLHS^>8LZ16576^>ZBAAVZP^>M^>I^>X^>Y^>CZ^>Y^>W^>+>
+Y6S&50^>Y^>6S6^>K^>W8^>6^>#>RISRKNOZ^>U^>7&QM^>8ZD^>MOK7Y^>=>1^>W6.M1ZYQ9K^>@DIF^>H1^>G6H4KL^>#>^>EF^>S158(1^>#>W1^>+>5.M^>9^>C.GP5N1M^>^>7^>E^>H066)JQ&1^>FB?>
Z2I8>@>0.N^>T^>H^>I^>KWIDW^>#>X.4M6.M^>D14N4N^>2^>S^>K.R4GYH.M.FAP.P^>Z^>EL0F^>Z8OUW7^>R6@1^>=J3D92^>M4IK.E<9I^>W6PW.O1+>SYDZDYH@S?=>PI9^>T^>G^>V^>D8^>V43U1FF=>9
MMS(4F8M^>C^>YX^>4M^>+>O^>S^>+>M^>C^>K9^>Q0^>D^>329^>6^>V2^>S^>NWO^>=>UO9H.M11^>+>V7L9^>Y1JZ.M^>5V19ZE07^>=>S^>L\$>B&K^>L^>M^>+>H^>YD^>Z^>N1^>YD2?>
Y^>+>W^>J^>0^>A^>06N^>=>P.BK<G12<8^>F1J3KA^>I^>AW.HO^>#>45X2P^>V^>VP7^>#>M^>M^>X^>Y^>L^>I^>SP52^>FJ^>7^>5B^>MAQJ2B^>U70A0^>+>YVGC6D^>P1^>M^>H^>E1EY7^>M^>
C^>YH^>#>=>9YBG^>=>=>0M&T^>Z^>S^>W^>1^>4^>U^>+>6^>S43NWA^>M^>9^>C^>3B^>UM^>R^>3Y1JX.MO.FU1^>4^>I^>M^>+>V.HVBPBR1C1S^>7N^>U^>8&L^>2MY1104^>P1^>4VRM923^>=>D07&18C^>M4T^>L07
>@>ABJEU^>G6UN8^>EHOI^>Z^>1^>2PSN^>C04^>M0&4^>+>VZ^>1^>E^>S^>M1.N\$G^>4^>MH9Q1SN^>P9Y2^>IT^>N^K^>H^>^>CM^>+>J^>+>DK41GLXG^>4^>Q^>T8^>+>1^>BQ&E^>E2Z0I^>W^>V^K13
M1B1^>K^>B^>F^>2^>6TFV^>+>HBT8A2^&gt

[illegible]

[illegible]

M/_7@/!%;<=,6B)*GPU%;BPUA+AUMOW(5LY#KZC.4F,>\$Y8(1/@\O9O.^0/2
MU\8N2BDC7T#YC!6,64NQFYTOWZ>;L4=XH1?LJC-UFR_I6GV0IE#+FGG
BT<8LF^N8T,7GB_C?T&8/D4LM#?"EG4>0.T19UC MWE0@PYP/!4T>F94_-M+GWA'(<|-
NL2_GZ!'<42G69-4MIB(:/=)J/I9B>X;A M40I%=KMY\$=9@,K-WSLAKOT^P6SG642 J?
SBG4!WF!16NM.7BOB;=-@9<09K M+.NV?"3-HUV6H*1W,K^(>:.\$?#HNGP2UM'"_Q\$?
HCG\$%("JR M3RU =@=8E1KP9J^5Q89O:D#8/H@C,&8!!?I9RVH5M#VEAH,|:(?TS1Z\$
M>_HJG?(R1-2)H%T%MVLJ/\$_SX>PP+)R).>IX(-VASN-+@T&,^|3 LO'
MO^=^ORWL#J!/NYY>9U33U)>SNLO>ZH,C\MO0\OF(BXFH!\$!!!;VR089_1/
MH+BC,WF@4V:P/S!F)UNW_B6/(3=OT7*C&:|P*3A((ONX5|WGY1|O.2NUH
M,AN@SKCR:'Q*Z&_'N1^D-FD.X.MR=OZJ?WT0.'8_LL&GK MJ>ZU:D|(>-
R>96PK^Y6/68)PV2_MH|: #IGJED'#8G=9Y|U6_-J.\$PR_1+8N|#Z/H1S<+|\$I>&,X:R^?
@&JMj+ V. MR,X=2|+)_@ JU =|^S%,C6+^+";
ID9K5:2D/OK!L/N|\$#;\$^|5_E'6JX>"!K9X,/IGJ"JK0(ADVQE+-9: M&--
QMXWV2B|?'XS;_%E\$|O/-A'./%%%@
MX\$Z^4_5YH!Z>EERI00609|+D|@*4B^EW);!L(H9S|U"AS6U45L?C-P#Z-
*D>X|HKS16'1^M.A.E+^%|L"%Q9" M) (F|L@5.)2FO_R99/#|TBZCP2RD4B|&N|K4-
_D65RS|0NY!"#|S?,W^,G/MQOV@S.-
U827Q\$Y#^_N|7_+:O,_EG4(>R#V&I=^,.E*DBD<+^)^3:;#;F#S=J(M,PN+-
(ASC\$_E0E&_.D#"7TZEBJV-!YQ9CW6V-YV=RR8|_6L,QZ|= &IT=(>:;! MG+V
VIR6O+Z+E#SA|: OD/R\$^5+|_BZ|"H|L?"N|\$JY&=I8JDZ9/SK1/ND M?Q:H#-
IC,IVF:S+FB.Z#LR(YO"C2FVAF_)AG|H3W)\\$0-'N|).)=',.6XT
M._21HXUA/R#P:C+=:TEU/9^;#D!<@:X3|0CMI"E6>I78U.*I,J?'#K:"9 ME0P||FY-
X"3@,0IV0*X9C8)><@29FDOY@T*S/|@M|E?A|5IB0|807|V|AC=
MP2IMT|#4Y|C|2"3|:&=Z)|E+67FX@6|VY1@7&2Q>> M T(9WRBX99GQC>>&
1=L:=FU<_?SOK_8U-"6|G&^07?)Z00*/H)_5SD"% M|1:|CR&,3Z M!KACE'PFF<|9V=+-
#P<:_|Q1(V|NX9M):\$%VXJHP!?'K->|T<>P-,4/&1C\$%(MCPL?
HMA&BPGVP0##U_6W@!GTP//QP>"I" XXG1;)J(:3#"QRO)-T!*WAM
MM2#DWEW8U\$KR""OF7O|V98(R-?FS?ES@?|O(_K;VWP|02P,\$% @) (IF M69J /?!7SP(
PV,O ! _L86(M,C R-# Y,S N:'1M|+UYV;BG83:%|H/WZ|H.(>X=,, /'DX/GM-B.9G/_OPG?
5W|Z8:F==XFLZ=_M.M MQ|?OW?O3_ GI?_WXOP\$.?
KE|H>#W^C%P:VZFCRG7R;+.ITOCQ=T|\$^/?_WG M@WNSZ61&!_Q|Z/H!
|_Z_\$AS58'>/_&BQ-O>G|=9|_O^5NJG4N:- MCUXM)D^?K0|^J?|S@7R+
|SV;T71*KP|N3F8XJQ.<'CP^N^N_|&/6ZP>WIM.#
M1_*UY<\$C6M+B.;7K)Q=|MN+UX#69+?|H|=RCOI#7YXNG-W3.^<9+.>?:R4DW
M7Y;%M\$U>GRM_KL|T2H4;)PMJ>0PAN5#|/39?/8;4WXQJ>_M6ELM;JQ>='-\$-
/A%F)V>^?JKEY'W/Q&^@;_S'K_7K&5_6 MK'Z|H|!<^(XL8|_%*Y/YFA?E(56VZ@WE5|O
%>EP^NCAR|N/8O5^|_N8_=5=|6@_YG%UDN5N|2FC^|N"56 MBP|2.-
_@H|=^E|/SXC;/SSX,?59#6EG|2"?_WQOLGO\NDAK7 MY8#^WCR
M_,7;L|G3,85/&\$Z7#NH)W_|^=J*J7MC+3INR%5OG%|VQS)OKPZ6JU=3^O.U
M0UP\GO'?_IK+*Z+!# M2"Z"2M8.J5,FY..NT0083@#:|7Z|<>'1WO^D
M(>KD70D0*E5^TNBAF.2|M(LN-5^L4N>?|!8KHR8*Z>X4GW|1XQV<;+8_7^/=M>;-
/7E*#CE,6J3^M?USJH9MO(55>5=|HJ>-AX2*H"G;NTJVVY;/_69%CU9
MX(=|H7F|RY|MOVR!_|5>ZBE))95-+D"U,54#%"4BE_2+ZRO/9(NYY_RSHQY MX=5M?
LX%3N_-&KW|O_3JRY0L:C7P>CL/O"D=Q=8URCAY%\$+YNY#<8 F\$;AB
M\$4HU#4SOH22TMI=T|JBG4O|F|?GAX60ER|J-6O"J|Q9#'DF|,ZR(FJ3@R90 M&!&
<|15*=|+I4E_1=_?|X%Q8MR|G-V63*#+|X)N;U|S|Z M<|I'ICX@":|_%ZR#;0*"M-
|ZDE&JR7_'HC;F!&=A"(>8J1S%#4K6#"9YL:0FU M2I=^|+=VL3RA4Q5J8:'K?
&4I\$4J\$&\$|LJD:G*)X|>N^!-Y'D315.@ M|"VAZ.0Z2RN-KEW|Z:'^STOM<|J96'\$6A-?S:
<.V5_!WH2*C\$?K2;U-@=-W M><1_9#+CQ7_OP|HY>41U1>W)Y)!/>=?Z?+?D+|DQ?
3|^PTEJ|^FOA>50|N M6PW)9@/|1::PQ(+AH@@2S7RS'2|. ^3+/_KOT4+O7&F>6ZHEI8X
3><|3LG0(O M8BRJ,/5|C?;;O;%2K?5@ (3#F9 FN&W-""!"9L3)2|M'A>|_X%>N9:S|=3DT4
M@Y54M+Q5?6_2NP(84X'LC.*N4E\$H(-1D-KO,+%^L;J)Q|9)9! MJIM7O| #3+\$1T,N S67
!^84+|^E_&3M%G77HW^J%8RC=1\$L0D66FBST!.D>0 M>BLQ=UM2ILM*2Q^+-
|CK5@-?ACF_4.4S\$!%1|?'.G|H^|U^H;*ZQ|;"8JU# M6?
2PE;L2;'WRJOB|C^3=WGGPEI(V+!M D^_M26@@|"T|(%))6)T03GR@79><0V
M|+6#1G5RR#C@S|=8_(G"YF=1%W\$#8WIHQ6O?<'5#-: MLJ0S=-
+JFN&PBJ9|;;1RE55\$=_1=Q>7X=|P,4%>@WO|P@M:KG@%2'#JG=>6
MQYTWAL<|C=8SYK)|-KSGG*LT!D:=@*3.R7E32^E7/OI8^;5/SQ<3 Y);OHK

M'19:7&I3JYB,J3E!:HT5COQ6E.[0&4:%SDK!V?CV6]^GY9+HP='Z369/IQ-;
MOTIH5\N\|R/:\$80<"J/OKD'OG'1#EA0Y|W|+
|Z4'N\WNVD*=@_0YG=N\UE\LF# 'SCK4NN M_US.CQ?K0|:>C9NG;|>K-
M_2|Q6SML&#.5\$;BG>5XV7K3NLP:4>>&M=._LJ MK>'FV5^3)G_W"2T.UD|
|S57;|_|OQ?|Y=M?/KOS6@|:;=
|;VE)V3GL):=76|8)+=GB|7C,Q.74JW7DZ6UWXZ._\$NULE4@/)T
MON13S_>V_TT|D3OGZ>&^|H^.:UX'W|H"MFHJ,663(R*FY&54"VW8N;IL@_M7R9ZPK?
>NBY7OM,1.F|5<.,IY,0L|M-B:95576|[#;|T|_WTL&F)^>#2?O=FZ
MY|W_ ^>SQ:E|_OF7I8R^O/>R)DWDC)&3SON:J09?.2,FPA<306\$%G,Z*PL1AM
M'Q8&L&CA5UV|>CAE5F<((0\6DNC5P*O+Q)RC>R>S:~MWN'18OY\3?KMBJ2W
M&.VK1%),(.I'3941N.I>\$A%|4@JB9NB|J&U1%"B@?|UF*!LZ?K53^GZ*?3
M8S9M|=;3!:T/?8(>E|HGF3JZ57E+++"=B5|U|U|MX6!:3|I3NK|H6-X+>H&Y*
MT5#.#%.L\$O|99;"GO#BN(B,|ZKYU/^I&^"QV%7E|S.;RZY/V!CVD9(LE-ENJ
MN+^T8RXU;\$=7--UIGWP;#HZ/I.LO"E"|*J@2CHB7|Z'*G8|,=|DIGFN*7D;
MD|5Z5*K<>H&+|BZ'W#D\FLY?\$.W|L.!(9-RFQ*=PZ&|X>,XD>_)B_N39_'B)ML|:
<^0%O|K_NS>C\$VX*%=FS-(L05&^@VL1^3=7^>IL_M?87:>8,,*U,OR;&W:CT^/)
|RN>W!ZADMY+P%/9.K/2@#4#8UFEQB3%LWY;9,VD>T0L8Z|0XN))"P=4B|,8E<;7-('FI)
MFFU'50"3DUAU(^4*F|YV6-
OQ4DA&Q.9M/)JL<#KY'VJ/YWW%@IQ^H>6VS!!10!)5O)4@H4L@1.7;|LK/2@Q7T+6G7)-
MSY,Y?|!DX;DW>JZQ=.:|C!A6,1"R2@M)#@JRBPM84YCZL,/P\$4>KM^>)H?A)
MVS#N28JQ"G'&*++X-YP>T|^O7O_Z5|XB+NJS5_<%K;T=4SX|Z=|L_MZ'BU7)^A-
V5YGWN87PFESF.=B|J@_SZF67WU@2|MP)))+MY6CM9.J("D;
|6!;"5^9P/3YCSA.R_KB="U|O<|F.4"V<"8?MWNGUGCNW@\$-M MN\$;))
(N^UF"7@SIHE:8R@M=+&D|J#AOR^BZL=NO=S|HV-E-I%:| ^)\$1,!!# MS-
@|V8P=L|O*>|=N.;.^/??"S|9K'?*J|>R2=CD^V3^SY7;N)L4_M>KIYZJ4_10#1RE!;L5
M|9(0)EOR,MN0|A|;=3-2|KS+8;|-G&MLPX&T*S_M#9R-
#G(("7R*KB9EFU'#D5#,HD<2^#|AE?SY*R.-P^/#K^7E3QMOIL%F
M0E..>"|D6N"RG'BN!TCN@;JIB'=".'+.Z*'S#IH2O#2U\$K:|G)MFZD@)5_MZ>
|TBJDG;#.30N&PM^+";\$BFCV)A;#ECO4P0X^VJ+(P6Y"GUR02A&>PA8_MI?2".:L/Ys-
|G=)02D|>ET;SN@)'3M@4@+I8W_)F:SRFV62^.'?3_MW^8K6OYR3\$99-U3^Y,8\$HM;
QJ5*%0LY"M;5VBAB"HE&WSE &P6U<
M/L,"6_XA>N\$Y3M|5";^RGGCU*R|^3JN|Q|VW1|X"l\$758_!=|@M|!FWDD/8
M%6#JQ62LC974|WU|B89_MZE+F&@"SU-GEXA7#3F7JUG.0|T0GQ.:Q4_SF?
3MK:ZWN/;?I;XO=UE>19E<^F>&C'940CV/9)EYZ3@N1)\KHCB^/2
M+5@TQC32/MD1XOL7)8O?E%.5-8|SJ*\$4Q_QB6X?2=86*F@VCA\$;YY!_GV,#
M7U|"L3&./^S9TL#0(Z(X#>&Q3ID|/0MYZ#-8';*M^J72@QZ<|MGZ>S%?S_M^?3;9-
CY2SJ_S|_Z50(C>X/4,I0<61NCDGX)K')*L_)R:4,IV/>\$?>W|A<
M/NAKE^T'|=:Z|KV!;5O4G"P.>ZJ(=?LH_:3P36Q"|7K(*V73'9>5S.<2^C
M:4BG1|8NGRN3:*2&,IYBZ1|S'C?M'MC9_FBD(GC\$YG_M-!"Z(G"&(3=3*D+";A-:|A|A?
\$GX8>#|%YH|"|B|*VX3CVLQ8\$*/S&W=2"2|M@,V2IHG-
8AJ6=I=N00*Z4(M8I4EJS=XD.Y24@O21,DF2CM&M&Z0YZ"P0&;J7_MIM*P67T;CQE?
2@H_D0:E#_J|69L|G|1CG+ZQ#GZ9+*BNYHNOO8UT?|Q/3W%Z_M9|W@Y|*\$#Z?
+O|ZGTK-T>6|JR?|KUNH3S4;KMEE%"H8"Z)8-L.YEV>U#A\$K5_ME:RS#VDXIV?
8IEOZ^;+EBW8BX'/KY+OE76R9'1ZVQD%FXZ_V7B@I_K&X+QJ_MP_8M&,PIM0L_9@L)
<^(|)I7_56GXJW(&;76W5AG#'PU/O8%RAG;|!@*VZ9AN3
ML\$8&QYU0ZM|9IO%,Q%Q"K6|8|.2E=9I0J;W+#-
(D|4UFL^NS^O^,8/|X:_EBO)&|>T>9MN5BLNU8)Y)QOFRE6|^._5+NL-H4E
M:HRYG62*RE"!;4\$FX-5/767AU4Q8|7QVJ#>1^54PUJ_*6%D,H,TWXT:@D|I
M515RR&E4HGQ|H_Y5.|?%|H|\$34Z/'K3#OVB0OGXN4|>S#?U4)M,P?Q*K;:S
M>H#79;3:R:D;TFJ2VB+YY|TV!4Z;?8S=@|:LI.D981|?SO^XI?BZ&DELQ1.S_M<6^DC7&;
<:B"V(VT:~4*BO\$(1L=\$S;N0_7"QR,&ILTD%;;P)&0/H(&4|SD;(-M+C2PP4N)-
ETAAIMQ6I2MGG?XY+?F(Z|Z3V.M44)|'4'Y(JV;:("478'4(S9,NE,>
|29=|&.T394&*K*2==95*!@(-M9+B52E\$3Q;ME-I.^|PBANJ6V.E1C*
M2F^N"Q^H%7WW?<4F/=D"FA CJZ6H_M4("M2;H|5K&U<&;=BM^\$;F_3;'
IKKULBT3:V3_W'PG&4_1H,@H76^|K2%D_ME>JP7N21\$O5&4**Y5+(IBY04U-
6M^!L"5!;ZJH2L>C;UU0U5^?D'K|J^U'#F
M+>^=';Y|R|V5"A9;8<9A:9BJ%X^/"5|:L>0RK+/G4UT|DPE-KK'0QRP5%2^
M(5@C_-V*S(^M6GK^L|KR1KND AO7M/*U>^TAB_J73UCQ+\$^BS^WC-.S|HW-

4DS\$5\4K\NM7G!T+=EB! M7;f-&,-0@>&I*YT@:F&)-00 \$M1@"UA490;N3^,?
W,8+V117I56\$9K3PD3D MH.C"?RJ533>J.C5J^2IT?IK HV>3BF)VSN WKEU)1/>BRG%
(E7H M'JVD-S'-,A66K*A4#*8K.QS-+AA+Q:JQA3:ASR7G7>VV)'8 MLOBS-
0&2K9\$MR40LJE*4D+SH445QVTI/!^&"!.5GS(&9F"YJ1=OL&,#C> M2J5J)J"W50_?'0--
(=N\IZ;X5BE6#35'!\$SK!LDPZ(C>-)6=B8F&H!AG!ZGO M8EVWC;TIG2_W*)88NR)X02
MV?HIZ: ^78MFO;QNS&1\K9L8EN0[8=-03.9-(=,>4\3*2M)8--*X8%BO
ZI43J4AX>+^HS7.Y57+6D:#\["AB+),YC@%Q2AL@85.9U5XWC%[A_
MLOY0W_N3OMDWJ4>=OA(TBV|= \$C!>=#4&AJMK+DXF\TM5BAW-Y
M=J,/B/F>R.@N8VPL.!T(LLV%:0(%;QEJL8@8C::?,M-V!*,EJ90RRV>*6F(-
MD=FNAP:F9:MR\$CH-F\PW5EO@MXEIO:+= \$O\J5J%3-2QEA8A)>,E9B3-F!*
M5"WIKI3XV'F-S*46=&6\IR7-JIV:L)X*W6XME\1: OSJ5 RO^6)-Z;:&1
*LMZ,4M0:3"5\$DF0"VO)WQC%=D5D^-N7B?08JT=:6X.YUC?
#.D/>@B8XY#8VB=LH*:LR&3 MJXEUZUZDSZ;\>?OJU\>AA)K)@A9>O=F5QFH@!D?
2:C2@QAN&KWCX\BD23S MXT, LV^|\&NYN@?
PVJ=^F5+15A,L@L02&7^1\F4JHOD106Z2GR^T& M5B(LTR^
M^X9LC^:O<+J:?)HEH\7 D&VTE0K\$&'CDH0'6,ZY\F,2=ZS0-AL:"F9/7W ML>P#43?
=/9L(G6BIHHU;=B:TO% C6+L)D-2H"8G)60Q)5I<)-M4(I28%A9HV.U\;<_WVVI*
I6HEPUZ11JC&"CM/P@OG!N;)NFXJMK(?+_PT8? M/@HP?J-Z>[XX.MWT>^,@2
E#KD\F2V07(I8JB+TPRFK3ZPN\;
M2XX\,F:&V\L"WMJ\U%QKZ%TRH8++@*D8T#%&S0*8^A\DH#(015(.2)Y-%/%G
M&XV04R9@X9942\6F.FPEZ"4BCM\JL&.1NBFMJJRSQ4@ KH*N@YL*G2E('O-B+3\$!
/&7LQP1L.EO=/GVB R&>_Q>S\=O&Y1-UM^ MBVFBN_ 8\1R#<@4Z56%%5K3HK
'50U*^_VWC.59FX MF3I\$AS\$7VUJ,PV6!C.*IWTUA6\;
(%5GDHK>6;1N6P*6D"BJ58@(921(8C6)C M-
O::S'!6)SA\VTU|=L+OCU\GP\$OWI,DFLXK^@%T%FZZAI99!\;*IP6\$I#')
M'%G>Q0X3:Z%1-^|\&JL_EBJ;4P\Z74;D(.B&K "\EMX_CBVJF,0YK*K=7V1^
MDC=RJB*N**33K2=R%9JQ;%EA1L#<+%\J&*=:Z;4,!^G6,/P9+N@1'9T%8A<"
MQ@_?"^Y.\$K7NSH\7\ 2MK\$6VS1A(ZQFC"U.XF7!20<1,H!=)?#6E%8DI<\, M9S%=
(N/V+?VUM,%T26B+I>^YY7-O&TF>>>820NQ=G44I0BW=C#!DRTMH59;
M3Y;?'0RPH5MG,C3KI=E<,Y#74VE)!LQA^B'PZA?=^&J P8\7,YK2;&0"-8+8
M>P97C(Q/8XT34S*4C5)ATVN&J8IBT2K(IB2@GGML/N;@AVTB^%'M
MO@YO7DVAGI(VE=@*EF(K1S+[B6J3X*8R,9K@W+!-;SZ44W?G)<-QQH7G,MI.
MTNS>Y-99=T62ZLYO(A3I'YH-1FV\TRH/ MAZ
N9;* (>+;,:=04GJY"Q=NL2XJZHRH97)/D#+IS((@!K;F6\54QIUJ.4JU
MPB9C(\$WU2GQ%KR3WW?L;(:%K?8T15?QBT>N?LE::MN'R\7S(6+J5P^&=fW
M;'+T;>IE=J).INK^\$9H4Q=\$+3-T4D)&&6SM_X.Z4:TK"#SX0X7SX9@+?
MV@=W10G7&8%YJ8%W,OX8I@LC=JX6V8\55J MH;NHHR%8MQ1VE0ARC
VJ4S'HYHW/PV8@#M-\;01_1T^N;5LG+4%!EX%)-T% M;-8I%VNZ\U\!RE-PG!9 M>(-
BATZBVJ3#*PUZJX3!J1\H\Z7RT:(=-(O@B9\4ODO0W/Z+V MA.JSV7PZ?
_KJT>3ILVW\$6K<3"8;O"i5^@)*E US JS\6\ \$>Q6\$;XKA6Y=#A MT\|#-YMJ-
4.V^X9L%JH\$BAG0\$IL3H8,UR806E2.2=U4W\CD9<'WM?\$\
(CEJGC#&G,&P;ZL;J#RY\QW>K+F2>V'V9)R:' M\@?W\F.I3P%T#HQ\>ZXL?
YN'CEDUG2AY&JX_Z6CEI/M*^:AJD>R,7D1>HT1+
M65Z\'+6QL9(;L,V'WKEI)H:!"\$#\$KI7,P,3.5D".TD)Q%99C/AJ//\|=CLMW;)K.'O+%G
MM%C^BLL5+<1&O?_P:P7ISH9E7J3Z^2%Y7T7U".HVI_T 7/(U\YD/"37M*N
MNUR'35H8S8S9DA"49XSC9>1=L'QUM)%",X\4<(:F<(*\$,^;325L\ MRN\QH=YQZ)VDE-
!O\JEI*YLK&7XFC*E:HX&M2\=Z#R50%1/X8/E3++\4?<.H
MWR!O8\$ LZ#LDKGRQ8*TG2KDA'+JF0UBTD,BVK<<<[#1>"VH657Y1*@1(\$(_03
MAL(8"5JWVA2?*J%>RL('O A\;TK?*7ILRH\TW#J.E,75IBN"*%J25_1A+J MW\G;=:
I9H3Y+6\SUP\&<5'+61,58+O:GXSC2H5A3"RNVT*VF#QLPN3'4Y76 MA2\4JJD?*
I7N6G8=#'K&Y:9\IR#:RS&/ T\$U,Q83QU\6QA%#%YW\$^U5^7IH8M72O ML9"U-
)O'PL#,44GC!D/W)=M@@J E*Y(R;0^6&!BY5!!R8).TUZ!35:57'#8' M\IF)&\!-
J=+@.C3UQ*Z@Z.28#;1&-QP!1<4_DAX*;P+\$OTYFD\ C3W4W^PKP\&UGW^QH
M+P25&D4VB7J24GNLD,7H-%CD\I5QOK1\H+(I2B;M"V#="D\$!-E+%&4)B@R
MXM+\$VDM#KVL:%M'\D8VX\01<>\ ^I60@.9EU2C7+C <"DSLEY4TO95@W\@YC M"D.
(6-:WFB^GJR9P4IM26HA0+"HIV?7TJY:I(V22O9=M\ADZ=>8U MUH*2RD502\;AAN*
I'Y;7WDU+WN.AW1V-L0XU\@"A9Y,9I%JGH757551\$;ON- M0+^8\$*-
FNFX2HC0VF8OI4*UET>8,0JFA@LW\$IB#VCG58B')OUJA_J^Y XW!4

M=|FVU*#I+JU6;ZE1!9R:\$XI%FR)A@U8?.^QO,&-H%17Y)QB<|+*|. (4 4L(
M\$*LMR9GJ(@V7I#|*8)/=>/B5SE@KL3)TTAY=R6PW5S7\$0%A3D%;#PYKJW^W!
M3:M>930K7Y0\$7(O@):.RD?P*NK0):%3#:.=ZAYJK,("UJ SJ*)67!IFDKCIB M0U&"\$1I
;^N6I9)02;50&\$M/B&6Z/>|G=8N4AIV22\$?3).|E*Z%;<19 M@"TG:*XYF<;D6Q\|V(7I\$*-;
(Q*^BC1!&86I W8R,N/"2N,'Q40BU(2Q>S5B
M:N|E\QXN(.ZO0F:1\$A%+_)A*EDU<('6;H9F<48;|V?'*NO=#S&PJAT?%;IM+
MO)=|E@%B;|PC.C:8*U)W/HK+=I/ZSDC6Q*(Z^):DR1I|#7>RV,I-Y MFWIU.*PKLF1\N-&
(&7Q&+KKH%1OX-0Z6)T1NC>Q1E7YZ' 91E?8AJRIY5 M MU-8KN)@CH!0I>+1%?:
2*:34:-3I5X'G*/T|'-.R:M?4XI\$?B7#B^FMG=JK\$Q MX|BPL2P\$I363!RS,53EXGYP.3,GQ-
=L@V.,KG'R;2J%5+2FK.7)4/-JV'86NQ@4 MMZ68!N4(VIK&ZL;J@=(N0-
K!57#Y4&L2B8)\L5ALH&A" S&|2AE8^Z,6LK MKP/S(AG(&1G1=TO1-
V;3,%P;WP\VL9.G%/IS,F409+<)>DW/J?K*=VYL<"5& MIYE,EZK-5
.FZNUPDG,=#3|CL;^0A'2/GDWJ^1Z MY83?(B5;_-R+8+)M,4 M;
@>K\$P|=ST71O2H@3)1|UF9&H?%@9=6>*|M9|;/%M+L;%| H;8&FR2>5I(> M6=)I)(<>
(\$H7I.:M3*H=E3KG>C&|_06O?\$5O|DN"|@?;.=R;'1VOENLS MS*;"|002&&*C>|>E|EV
D,1@+|T"H08_IA^ M:Q5R&@ZVCIF@(:U'-F37:V=|#|F
J4\$JQG6&;+H#VU7TN5F3XKXG:'RKH5H; M|'B@7:K&DP>O=
=G8@%TS#FU%A5|/3&,5P;^/9_X_&|8Y#17|1V24|P'4A= _M#3%|.H5@;|\$S8"0G'|==<-
L)0Z_'A\93//0D8R7D+>B97>TXG/I^AG.;BC9H MCI|F;6J\$EC^"DY7FB2\$S;.)H.R:4T;/:5(-
/SOMM0.P@'Z(BDQ,W@>9_ROHT1 M2@P\$NJ8>:|SIT'!!F6&Q^"YLJ=1=R8SSE*
<(+MH"180,6- CFI((I6CT&R)W M?03:Y6"UEFDF4F/DL%AI-
X\$0@E;K628I#^=00E3XYDW7B>F492\$3D07ZE%7, MK<;FU60I77D9#MQY><270:+-
_W5.73*RH6-EK*?8*"NM&,AD2VJZ1#MNC=%K
MLJXKLO_TMG8&*RUIM;:KFW8T,/0&46|8NE.3KK*1,,(R46J MD HVL+\$9FI*/9;SFDI(
+Z.'_UZY|90=MG&:(.:%|1&"-9+|XPH#4&= Y|P MW8FOI#%;|:|=API??IL^?_
^LN'\7>Z\$X*21T4(Q,W0TQ0#;92SN5%A0F4VE| MK#R@^ ^6BZW1315.ZU!QUJ^
#7|/5|RLP^S93D/7U%36E*T;N:(-K(&"Y5#TFY#B\$ILE9C"&%8
M,VI'K0)'0%O=Z!1S@9BSS",B)0W0F/>,MJD:E7'I89?L%*7'67G-C?*CE?*<
MMIX"U.XMN*PK(*M4",UIZSP#51HV=C28@-K55K>VL17!1J:J4E7+6SV:"C84
M7ZL*&G%8#?/'\ _6|O6'.>_L^&2W6&QD I'MC5.(C6"<=X8UJ4*3M.'FBJ),M M=HA!&-
O)B3%*U99EMD5F6|P91#;(NX2LC\$6L<9J@D-;@<#W0BG=VZS:FX%W"
<>=_;L(|LYLRS|X96NO+ MO^L|>/L,V59U)7W
%UMHUK<=BXS!'|7L,A14TB"W&DA5NN1&8TCU9IS=|RX4 M.ZNTW@%^-
=ID5F25#3(G8YT:0M9D6*H7E="V7,8UL,>%/I=QV29;|W^QJ5"G M83/<2/M\$C+&!JIE
3C&"5JWW0-AC'M9&'R G_ (7;_'97HZ+|>9;:QG=DJ+\$
M5JC#S\$+9\$:"DDAN+I>026ALW6+WG.OS19/GWNPOBIV%10,O5(|S&5+0MZ7(3
M8LV)(+VN1-C2&XD;:L:?'6IW. 'O A\:/;T+|T4Y)_I/Z".^(7 M9X-RC!|:R-
(C@63SR&@G&29D?\$DF#=_N_:TJZ@DHV&MT0?9, M4EU+T*7:Y/1PN/
R;2|.>0TJ7LW&,D8HXW(!X4:F6?208UY/,RP>M59A^_ZX MSU5;^OS>_BJU%9:0-
PO>\$8+K1% PK/MBYZI\$,+GOE;"7!A.;2NOLBX74 MNB
IWHVY10W4E;75^>^|&*_K_1+02=7>6B3A?UY3X?399+1|_GT3;J\$GDI64
M'O1|LS9Y/FG'YP77+Y,%U=5|"PWGWH,?"4%U_E3OTIP18UHM *V*HO,7V+H
MD+R'BN(6CJA5&FX8X?:J,Z6QX=8ODERSB|@07*
Z&P#0#,_OF&*P;M@0|^:J\$G=BK.ZI%\$G=&M4|A-P9LU%D
MK\$HM04*5>W'4=1DN(CA;|U=F/L958LU02^UBH?(-D-LXC|SI%)5"# Y;A0
M^SR(^BKIFZNU8@"5;)DJE3Q@9, *V9"/U1F*.%S-TQ\W'CM .AIOF&"|KA(
M/3C+9ED.)0.95))REEP:MB_-!@<6CQ-3PZ8M2F?N4!IKPY8AI>Z!&*[N4E5<5
M>@_2!R->>7&X16C)2V^L1BD(E\$>YH?*1< M:5C,|I^|V;*66.1^O-
DOIK/TWLSQ=4T3|@8"\$AEALW&|+|APM2?8?0^ MYJ6@Y<^?9?
#NIS%JE=4AU|@<|5EQ&|F66VL'DQA.Y^2MCL.AYTM|M^HGJ&Q M;0|V5)M+
N/E|F@EI=^T"LXW)0T&A2:Q:YEK|+<_D7<_(*@UQ3JV|H M=YD? MR#B4-
8B,._N\$&7NV;L2"9W_YE?:(2C7GE<)6DX.6&|-X#PE2#N)%#D|Q9Q7-
M<%'|>_6Q|N(-0CF4Y4= SW""^8P!5F U1.OX@9FTN9|?/XBGB \$<,7Q@1L#-U:
MFXW5KD,*U3-JA*N1PW5|^AJM26W85V|@U)G@SVOK"O5)!T@6U&V78KH:D)0
MJE6B4H-7X|?-/TZ=1|1"QDCM#BYF+*_ _@R|;\$6DW5Q%I'752QHB-!D\$|: &
M**18P35341,E:X=U?@P6%|V@96|=0_K!2P#6?:5('V\$4-
13<0S7R'G*06D+BI<02AD4G|V:-.HA%=UGB-_NS7@5GDJ2
MPJWEDE;+GU_|BO\U7ZP|/&_C%6PDN08;|KN.*

P!"MWAQ@495#T:\%KNCV(JET4B/*6RUIWX:YD1;6.A2E)1;ISLD
MXR)0\2U;K4K'(3,>/EQJ\29 ^OCXZ&B^6'VCX?&[HE^,(1."+]*00YJML,9# M8-
M29V6#Y(Z-1K^MJ;A+W_DTPQ;O*F#O(D>39X^,YK3CM,U3I@>E8^\$.2%N\$|4J986U-
J6'?^N_ UYGIR8/WDV/UXR M+6I-VI,7?+U7_!G#^ ^-
Z;LJNN8'OMB@5NNML5:&.;% ^IY*%0(VB)"AE?8C+# ME5FLM\$[*%#.OB^YI?
O9MN>I|P2<_FTW;/X=?\6VI,<=Y8,0KZA*%F)K'ISO"C#;P'C=43'65_3# M^J"^8
RW<9MB^QU/SQE!E1#U%E-@8|P:<+UD**5T,%B\|1?J\X|KZE@67.9UL(4EOA")-;'G?&Y
<@ _&RIJP\J51|0.*3R4LN0G"YPML0H:9G!^ _LC;F390-MCFR;1|0*-
G8^=8U90T=&N=>7K=IP1+JB>0JY
MQK)0ZU%#2;V!ZM|5C(6T&ZX6>92.3+NQ&5TPE'Q64)N5RCOO(=48(633?&PQ_M|
| ^C46SW@8%-^AHN?=-/12.. "U_@DC&
(P@V=H9.J4%"M(RDK*'66W)ZWW/'MYKR|+;FWL\$@_M'9=KY<5U4()?9ZTU0-5\$D>N.%
(B*&E9S#|)|>S=.8.?&C(DF@(^)28JQ :V M;RBID@H6%_6PRG"3Z&0G.&P<2%0R=8L--
%J|):Z\$\$45FNNZ=)M+M*Q8P;TI*-H7>C0 M=21PV1O S.9|C-
6@Z<4Y&JY689S!LCNBF0_D4RE0D*6M"XE_*|:|":HH)ID-MXX:>OZ?
N|5OJWB;U!6|G13*%T**2*=86,E%>=XH)K2;EZG#"YN,0|JMPUC?=
MMYOKE+PG^W;3.#1|JA@S|)*DY@|@Y!(3V\$B1S9-"=;R61F,W#-M-Y=G90BE M!-
^QI>F";Y!K|1"TY1|^Z43#!H@V6:YQZ9M^08&* _52!RE=N'9TOSK#|R-8Y
M.7536Z>%TDL\$Y2N",U@A.|MR(*#3UL>: _7"FS@>|Y2=#EDZKV/^RF+|8/3N1
M#J*U|C_ |VMVSL|&JV_ '3^Z(2%<^7HQ|!U>8D'8N G,*2N0%YO)#FR"D_GY&L
MNZF,.E|"(H_2|HZRE:MZA62|AJ(|6|FVA.;&=^8/\$&H9(#G2U|R|_0IBBHVO M6"%
:Q\$P)=;J1?JG#ZO#1S%^ _S"XO:'RJ5I@V|)(&V8%Z^\$5L0?&\|F3L,I
M|>|M=+:Y'XIMJG3H7M1_9'6.S210W>IHF8|<+3|).GV::='KV80EPQZ2W)G
M::2NHHR^30:*MTC&V13JL)T9AHT ;9*C>O2YF S=49\$Q3@|@E4P+30|*&=*UI M?
&"U^2&XWQ8E;XS9>J1\$3\$)56A-B,I^%6*%J;%V;;MRX)44?U5=G(VIOXV%9 M3-
I3NK|JFS|RW^|D/9EMIY/W=JJ_@TK68\$)P268'FG4AO>E0>W36=N;E,KY= M.T#6|&Z8-;
12XD-6CI^@8GV/07OOH_@5|ZW7IGBG&\$2.5XCW|8RP6|LE
MOOI&+:YWT'9LMS5Z!"R::6S*"HIEM4.Y, ^U489 X7.^1_2Y|N;PHO8J=*X(S
M);KLH6%);'SXP@|@G60B&@4ZNF\$;- M5|K\$R<|^&\$;|QOF^ ^F9ZBU&W"U.!:4
MCL#4@#;8'\$/=NLGUN9|H8_50P2@UU!41JT0Q^7:|XSR M;5&@+UVWCJ"
|%+5Z%O)M@+DE3B<\$EH_:(QVL-JYW?33",WY!(KYE2E--4@_M_X8(+3"
UTS;UH<,E'UJUM&7X|_A|/E7^?Y=G3Y;W)_>G>U"&'D*M)(4%M
MR;%D|P3)M0H^R*>|H++ #5ED-D|UZ4>EN#" \$5+J1;C;%,%1&VR&1S'%W3;-
M;3;EK8<_/U=BK7M47TYBJ0U*K-AL-J6#(F1L1AHA:P8_M=5BBZVEJ6%;FNX+
M0M@DE(ZD2DD&&#PR0B#+6|R*#8B4C:V|J?'ZG0XNHZF
M0TG5@&|LZ|14D)7%GI/FFZ:|@*^Y6Q2E32,H)J,76;XY@00!*-4348'&C9Z ML
D/B_UNNWTY^V<,3>\$ZV2I+C0SOG<:VFZG*>%=C:FG8N/+(J=*7+7>RFRMW
M"JB|DP|OP08&|BS%H?|GK&15P9RS3^)G&" ;NH0Y,F.Z-
AYRU!93\$,,!H@<34TVQ)S'_3\$ _|@>*J1"DOQ.3/R|2X-9X| #C1\$2)|HS20JZ#0R"2\$FA0%30
MC_J^MI#"|OTN>R^%M|P,Q#_KQG4|"*34FIGKF:8 YB)D6G33>U!7|Y/M'5K
M;9W&AM.'&GW9K?Q:++ "Z=Y8\$-WVZER%JHH&9Y6%DB;.\$9B=;;852T.J00%& MWN|
(^'57@U2Y&R4MH4PCP.0BA\$9H)5;0^OAYX0-8@%O*VN|I40P>J)|@_#DV\$ M'
1B2CEZ,Q2S&@|50*|6_E|NIU9B"-JF6J).C|XL=T=\$N1H2+H>U8J|9MP#
M%;6;PHHM11MZ;;T|OR:8|'VIBHWJ|!/:9I&2P6(0A^T|-31FV*!4:XD"9S|Z>FTJMBLJFHJ0.
O+&|4Z:+9\$|YOQ M*0VG<(?RT^W_OQ.95K95#5BD*4Q\$PV:(|F!T-:|F;%H;-
H"YZ5K)KY,B>G.6 M1U0YL:2O;|NV(@F:59(9"!09@U0*-
*XC3&_|_?;*6:|JCNL;+3&P*:.NP.%0%TNJ24/G_ J5TEI
MW;%1|U"::S62X>D<^\$;D"^_5\$EAV"*\$L0VYC=DR-M0<9/R>83(Y9:+4R#3P
M|1.JSDPX7HNESV|8<_J|D1;|H8K/^A5GQQU/)JZ^ _LK>B\$>OE+6E0.K2!*18
M8DW*"#I4%0VZ5\$ L9SE?UB?|_UJV11;0TGDR SA\$KW59B|K;DO".N6S&P:1|FW^GH
MHT=TB!-) \$WE(BSY?'JXLP=E.GFZ|MLD/9GJBMJ3R2&?PF8*?|H42#21)/O3
M:3ZA^H_ ;N?#U-I?K"-7BF4K>|HU>;|!S"SA0Q"M&UU+K)!W=FHR5|9|C"!|-MR)Y:
L8.&5+82?KA>|R/_I(B_ORI7R4@ (ADMTRE12<%M(@LYL;#09%N(,3!*
M'19L&MG|^#9I=S!TA\$G;;U_56O.6+6(M&=U14M<8JEMJUM3A\$=G->H3-,I
M"|V_T(QA_)0MXEN-A>ADN9(I>L_IM&/?U48CDK78G9L2<#+IMU#_
*!A4L:UJW=EA_|=CA.O6)=2V MDY1|
(6"K\$BBS\$9B"NNM@"R@;@A2;R0CTJ"\$47TU.V<8^K&S|J&6SUG#|DAX5
M2|V,"J4#EW09T%5!"2V"-=W"%&((?C@A=J6|?|:J0G>2;=;=^5(+L%V38A3>G:F)

I3\$'0K'L,DR M4X)?4_&;G-"9>5IN^%S&S7R*DI=^@%LO6#*_BV(>\$4N!B?
ABUKOGHEDM7ST M^/>|T:4M>;8(GCK2;,\$
NR.H!4J)7BI.1PV,^4#%#GG,'O!#!?:\$;M;BG60 M8BLL.X:31BSO|B!
IFZ!C*KK5905XI1*O<0U.3Q:^^S8:)|@ZT+;2*1IH-!;'92|"0M"M0NZI)55-
K'!;N_I'K@K=3304I M>(NE /JL3R+J.*7QOLJQ9*ML-
|/"L>|"8GMZO+N4;,'VYDT@F14:4#D#XO\H
MT9NLQAT=^(F8:SWK73H9#)9_N85US"AQ3;C?_W9TO'BCU |/4C5^..KT&_WIV
M@;,'C9W_+%=YSM>4;!'S@>B<|/_.*F@%V_++1_1_TTSRE7^;3*2Z6:WCU^F;K
M\$!B=O!1OS&3KO+.WGV>RG+,A&9GC?OG8X|SS??GP%YK-I>#C/9>|H&M>N,2-
MBT_|=7XE>GX;/I*) A.II+)WEEKV;3OGO:9J_Z@|TE|=U^L777K0Y|YO=,J
MR/=>|/38Y^Z+Q|^|<|5+DO6G'R,\$K9&PL^?\$/..NW: B|KX^,FG9|R0B#CT^7PU8WAQ|6
U?T1|^>=K=W|I M|C=;=>#_&%_96UF/DH6\$J,%WZVS+(?EHKAWTQ?SP|_#M_XX|;1500
502;DII?)AF%4%WMXGB@PN;+A17-V89,/D)TRH/+5\$5|&8@%,|HW|ZJZ M05ZN*
D):5X;UK4H9.|F H|0OYW07R?;,&O?BRRFF6K0F0|"-7RYJ#X6A.I2F M@G?
|UJH)G#U/E/1""\$SL%|W%LW)&U"!CV@92ZGEM%BZZ;4CD&|2GZD19!>B
MU&A3C+;%\$C9U;ZK4U"G*L/?&IR6^J>;M8G1CTQXU6PS\$I_-'>YL7F|4DFR,)>7
MMC25=V!CE0PMSQ1\$6?@;ZY5?SH|7E98G?SXC;&M5RP+SI_|U3V0__Y-
9HY>D0P\$.3UV-#_1|:>T?4X_ME/E+6\$|^AR|QL|P7?!O@3WY@,7-
T=H=#7#SEZTRIKV|;Z|::?_RALZR5;|%- MK8Y6/YR>L7Z\$DV,=#R?
35S>?;/!8'00&+PX>S0|Q=G9BF;|6|T,^|_300?H)
M3Z|M.AMP.GDZNRFE\$=9'N'L|&E>/&/_="/Q)I9M""X(7"SQZ^WD^^@A|OQ>3
MMGIVLT|6L,8(|G)_X5Q6E&B|=?LLZG M||7-?
U#K_W|X|_N_.%MF4;^34P7|@&O_IV|F=7PX>|GUY,|CNSMT'CWX|
M.'OY|_S&=>^M@8=L_EL;8),ZAKTLK+.VO;B"A33I+_|.GVF9="5%7=W-OG.
MN.'4V&, @O:Y,8%J;AV:K4H:X'0H63NH2I6M|P|>LJ#;|C?
WP<&ONZU|Q>^|3D)U>W!@OG|X=>M?_W8@L)F*X9AU|ED^,6F43PU4V
MO%#2HFPCRCW:'&S=%O|ZS\$N6)Y-7STBZ9|&N%|B2:L_7YOPJRVI,O'FT|*6_M_7S%
'6C*N!D#3X,#'-TX8/3EX^/NCQ|_?^NW)P9,'|PRIGC|N.M#VX,&C^W_MJ?WSP8.
|!T_>N?@-'IZC;1NW7XBAW6V;M_UZ9>"T+OSO<'J&1W|QE7')PX M-
P^(A4K|E*;|U%T_P.XED30T-4 |%V;=R*P;H@;M&>)7M^I?MD2*:G(C(_GE)7EP
MA0P4LBA%|*T\$;?+=<%DN#M95IS^)_R_Q7?YD.<8BB|?_\$R)W^|_#H2Q_>6|*B
MH<36?""\$5&F%GI2&D*5&AS""I@Q1|=25\$ZGUCOL@"9R?>NB\$AD?L.B3|.
M#\$|>W?KM|;TU|F.B3:(B5:O^>(.%\$D(X.#"?ZOYWJS2^EG25KU25|0Y|;4; M1|*+)TO)?
SCHDRD=S(X%O=W<%HK.Q7J5/9CF#3B9?YQS*Q"|M4\$ELAM T7?6
MR15W^65^6|_+&.NL6"_RDR9U)1&.^|2M+L,-D|.G|M%915^>^2G:'(*P?Q-M7?^OHZ?
7#G"Z>O^!L|_#7^D78&CMZ^<-I5\$^KQ'^LPX;|8NIO%I#;S>N|N9'Y M0H&006L|(8L!
L;,"BF0?7'@4GMW|Y=:C7PY^OO?@R8,'|Q|?W|OM|O5O)B&^^+GWQX;|C;|ISLOL;|6
M6^E@W@|6K|?0_2X/ED=4)=&P'4QF|Y/5|_>6_NCWG9|K|P7GU/O@>K^8_MG.85R+-
+F@&_NIP.4WPU/U|QX|RD|L.I;%|JNOK'LR|4R7@|6M+-)1VAS%&-
MF""^POO8UN3|_P.+L|L|GRTF93)D;|Y|_0D/JM=%*4N7P_N|^G0)RNRTD.
MQ(T/?_U<|Y_)1>OI_"IK_UX8|5X^X5.);T@O/?N@1>|6%-6A'^_N?X7Y(W
MO/(Z;KB|'3A89|GY&|2P\$KK_A!4&64C/1A*!4L@RK2D\$IRT)N5#MO)H8V M(T.E-
O%UZNLZ!/?V_'BV6KRZ/6_TK@F^E#..%O/G"@_Q*B_T!1?H&2G M?
MPK)IDKJ_8H|_0YP,43|L-V5U&)'_&.^|/+D^,!GO/'@I%WK',5)H6H-' MP|#!E6J-V|PN?
X(O|YUFD9^4!&S.CO@0|6(\$Y;75^5/6P7GB?D-Y^%F;Y2T&
M^23&V(+J_R#>\$H%T,%|XFSR/^N_MMRA#OF*)|DF*#+PQ|EU_=|WQ|8,|AT?
3^2O>&1?Y_>"W^?7+DQSZE>SQ_=5V^6J CZI4A0(AQJ>A0()A2P3G%4#NE-
DZ;UL+H=%7 MA|A.0,BMUA92@G;RX_YD1GJ+,_0GS,WSXP?%+H,1!&8A"
M4DFJC'K_,O8I(|3=%328G>J9Q7R1FESFW|JL.#=O4WS|_>|7LX#%?_.Y" M2GJ7=;
|O3.1,HMQ9TA5M"KC.*Y|SN)G4V&+\$E|T08)M<;F#Q8/%/_GC,,W
MX:#|8,CKUIZ|";X9AMD?Q1(^G^*Q7> MF1?=>|0@-|D/>V0BU+??HK5OR6NJ|?
G'@M#A#D1H6:5O|U|H\$D=1%29:I(D61 MV-EP4SRJ"DCD|IR42>>1(>
(V5E*1=7/DPR*FT_||L;UQ?RUNLAN/OGAF^!.NM M+7UH?>LWE6?>_YV/
7FZY|97Q6_1CW,*(+R=LYOK @V;)750W"IK|D,J|/_-
M9S\$OX81KT1"9JT/1_,OFA+UNJY&L1?/3P?|62A()|O%>N,<85990 < T1#O
MC@|YNB&ST""=|VVU*I\$%&6(33L*-C41T(0,RH9*W&DY,GR
MSB6&>A^R;BTA,FG1^\$<)^N.1%43O9F/>G+S|7#<2(F#N=;?_^F|3=|;_X;2V1_/5%V:?
GU<|C*.UH|6/KZ|_S. U9:Y9/_9/;?|SO-&OX"KPSA6(

M+M>'T(I:YVBL'Y#).KBC&%B&1!"6.04<>(.EP%L"N%X3X2Q>230:=33KP@
MU#5HL4R/5."O&H*2G>J/A'T8U(!T55?&5)V!+'HZZV'6Q_8&MSQ;W.Z/P5WE8A|QM(!
/^D|?VO4|V.^FO'ZW+,MRJJ4|:1N3V_+Y'(+F+BI_M&OT_JK-<+>7K:6SBT?
*6Y5J,^4_DY^K4UDU>5JALKPY'0K=&T'-5M0>7N4/YYDU5HVF|W7X4!^|@85X16
M3:V!NOH)K@=+KZK'8#W4N2@R/|TPW|T:D>WG_VKQ?F436Y9|^/I&'IN5+8?
MJH_H9(P.%C!|OZ>5Q5|O_DJ_"@_Q?0Z3>WEYB&A|3UJ#*X"O:BWFDPP9QE>MH2@5-
E+DDH2\$(2X<199YAJ3!1J4@F\$FRG6.E-^/A\$8XR6;.D#ZRH7K#3QI_MD?X/?&M9V#?
F:@MWD45@8TOJH_A,E=ZY=8O;4C6^7|R=LX5Y31G>DW1J?=-)E/F/&?
+!MU)@|!"2:Q_GEY4&:X=JY&,P^)^D'!TFLD86%M9&)>RRJ*:(L?
AX.OH=/:Q#M@KL7FV\$%.WWQ0T:(H|S\$EQ:_O>|+F8_)Z|K7O?N'^YMY|M,1LITR_?
|ZRS;W;|S\$RC;|5)T9G9=MI5V6EF#RP|7N+HW:S;|N2W/NUZIXYV:M';F
QSX3B@=5_L7G3'+)"IR7;H_H_(|Y9X&>+S@=|RAD\$H3M4/#7H::W|MOBVG_|R_&U9?
M&M|15%2+VX.GK!,YDVJS9B2LBS*'#PUFK1@9UD@"V+GB|1D_M5E2)|J'0?
VN8|M\$AA6-\$G'J'G"<>,46UEMC&%%HJ#)!|8L,WH-N?|!+.XYB_MFB|U6N^G7UKD5.;>
(_V|-MG+=+<|V+9.(4NH/9T4).;-R5E690Y>*)J'_G_M85P0H@LHK|W*>WX3*!E&J=
(\$225TSJJ6"(PB,(\$((3%I9I(1|9A_S7*>|<=M_MO>CVT|J,O'A;NBA3F8,R|V4.RARLO5FW?
_=9<#|J-F7=/:|1AS7'T3&>*^0+MQ!;)"*P@BW"0P2F+8VS+J)LMYE^;M?
QFLI17:|Q|MV%*"2*^#.A)#P3.Y&S|M.^|NNFNJ,
F%C"&JCIH0OG&|23H!D8YZ:5V1SN1P;"Y5^|BW_QK%VX-MZWZ_M|-
B#O,O|TJT;WV0_UT&R07R8G\$L\$YR_7(|L/=ACJ*M<\$|H;L,CC93_;G.^-G
M2BS7C|=RU:>QUYNMCMNHGD'D3436I6OYPO-(D6#*'||F?A93MZ18:~J%)P2V
MKI@AJA\$#FN-=+3:|V4"CVUM8O..Y>06@ZU9/D^~AHG8M^|TF
M|J|P|&7269!TJMP!KY,7|!#|67_3UN13V"OZ5)^UP3D_GI-F|-29:DP'#E/
M(^)&&N0X@7^"5TQ82K":SP^2Q'EN'&(2/71>-0+2#NJVK<|TXN_NG)D&O?
@7JHMGL,#_~NK@|-W-U=|?MGZ\$P&*I5U|H&U.T0X7N**-GBW\$VT&>,|)V,9(98P_D2-
GZ2KEA_+UVQ4PVN_M)NMV=&H?IGD76<#|W-\$_4&(LZ<L>>|IZ/^HU&^;|N(O4Z|^-
V%|G!"93FZ_M<'S6?QVZ|7G/7NSF3R|MT)F&|8CN9*Q3|H3DC;^/ZU\$W7_/A|,
M^'AW&'.@_9=X/3QN&A391,==LVJO!UN2RVEOPFR17LU2>' +M19_4&
<5P>@_&J:WW7Z30MC(KC>577TINV8O!39Y
MYK2S:/OY4Z"XV:Z(JKT|4CF0,CA9)_3J#|Q,O*S_M^\$FR\$DR3_6*|O28E_/9^-
R^|4^6\$XP>F*C_4=\$KS)G)6MA&N.IW>CKT42Z,M<)>G
|=O|H|_MUGX|:7^8GW:O;WL7=;9PTBZAW9ED@|^Y_ZDD=O7AS/@9|'X<38<,<
"4W3PG.3LFSV3>2X|'XSQ>M6Y|6J3?XVLF|_|@?@_E2PV_|Q|2:OM<|X?
#J"0>73|B!>|6C29G+01B#T*_M9|/;>1,*)U@5A3)^H&<_D_MLO-3-STSK+*M-
@*+5|GZB;(|^O9_(APB^QPF+3CR!>8_2S|-|S>C2925@Q_MS3=#|QT0(
"/&!>IYW)I1H_Q*(LTP\$HRMFTOTCG*NY^.O)U:|_3/YO.%\$S_P_Q|VI;Z;)|82|P\$SX
MT^M?SFOUTU4)QZD0X6MY6J|L.F,"S/&@|Z7YW>4|ZS&L1PM2^_Q#_Y'W|+I
M#::=,2;7S_>M8XN|F/*M#>OR=|N_XI^OYKR9UIP|>O/V?QE_M"-!S\$O|F\$O*P
WG=633%C_~E^"PA(^<(UO2MS+@&T|_O^'|XUZ82Z.+M1|SWX1U"+O(.RX|)\$-:OW=
|<);_>^&).4_8U|MEFU>5BPI?LEY=;AWYN;/OICG60?:Q9_M&/>F
JYO(7V_I>N:FD@/+O&.;'Z1W_P=4*PX_|D|!;_Z,AFZFJ3Z#WBH_R_MBA|,IOH!RP06?
G9@9P6\$3|:V-R/"3M|R-YP+EYIDGOK3O+HOV034)2_5W-@=MC_A_K!2SF3)IGIT=IU,2?
MP%IZL@VTS#JGMVWIOIX(-6S4|U7|&!;.'|E.?<|1)B(WLS*F:
|&C_"MZMUD,F9KC\$85Q/5:R#M/+<@@>^\$<9|N7G="*/?/C|H19WZ36F8O/R
MVOU!8WW0ST;YI5LM-)W2IO4:'MS<|.0E\$,^;GJB7Q1=@M?M,PR:PZ;SYA|?
DVNC7C>^#G>Q=8.P-|2|JAIJKS7U;E1X@GP7A%>F"K1=^Z=M3>1|=I_/MZ|:|2Z"79#
M06|JJ,^|7?4&GP>=ZEUOW_W=SV?_YU^(X|G|WYV|_T*USM|HYX%R"6"P5=R
MZA<@|HYP:"|NWPM?8,G96W|6^WO'^Y?O7;|&/\$7>6MSZL_KOV1M3QA|EV_9Y
M,4R699T|PV|/;HI3BE@|L,WY/(5+(=L+U|^#5LV=|#V|L^+DZ-WL_\$V?U3_M?3+L
(|_IMYT_&_9|_.WL0>#^A7,ZLMW&A?XU5^?N|!UN#DU;R_Z-AO|H<
M_W#YM/O_7OU|FH(|WKQ6W7<_7;U|^!KLST?9_!>G?X_MG.6_P7RA#_"\$W8:MC-
PQ,C_~8'1Q#K-Z^;63@VLO_~EZXOF*+Q_~^++QS|
MIN;RY9EMY/0;@#"#,7|ZFPE|SZM.S<3|6'X:#::6KO;J^FHO_-^Y?BNHW"|O=
MX4PXO|VY%-IOQ^|G|O|_B?\$|P^H*7K5W?C|H^X,=G=9Q!+AP^N?
C5|HV|C=_D://NX9Z^~@X=5IM+W1_MZ:U5_M|F|@J
%19:|H4J#^;XH@8HAX|ABO>N'F>V)9M-77|C&+9-EW?;9W_M%HUSH(=P!ULYO.!G;>
M|J:L07FS.>/AW_O=3/*;_QR"S_9-S0!*4.P/7>JH^:~.@Z_='ULO#J9%ZYN_MW.SAI-
N6NV;X!*H6EFAM|E|2;(3;EK;)+;70QM:~Z>:BY@_RDRC:20=GH3!-<>)<_%UA?

X*:T11VSPT+:\$ _BA9 M!;(O!+=Z^OM4C\Y&GP;ITU6"US/RW[5]W8VLN,OX\A&,9))HUH?
+S]H[30+. M\^')M:.?&=F'A":O("RL65BRL^#U6Y#M/KOI:6^&M6/\$,AGX*=-3!\$C_U!O7Z
M,.;ZX]6O8='*TRX"B9DA0D+\$Q8F+\$RX74S8%#H\]>0DG?I3SL<7:P-%1Y? M>
I9I#FJUWSQB]=:/F+J^ _JYD.,JR)\$7V>'XNE!VH4%IPK??\;EBFIP4TBO/Y@%.M/H\'-
M6)G+V,]3?#G*K@PEZUM:CK<0XIWO87N%FYIS-)5A=L*MO5N6P6WO13\;PE9
MFCP(NBYYS.VQ8I,"03^=!:L*ZEMBI>E"D(^*B3&%(0M#%H8L# +D0>6A% MIXK-
K1L^ '!YZI4FO*=7>"C,JP+I88.'MBW,]W*JR*:^)JH\;YXV=I4+UO;
M>3HZ^=O^OZ<7+LT1]5U]OQ,JED(J1#2%A)2V8JH\')F+3LIR:=>_&Q[DTU8 M;#K=KV
3]C[?<[+[:NY9ME\ _N/TJ1W*%[0K;%;9;.%MOM;2K=V4^Y\$>BTW>DJ
MJ.YZ1]"4*RVUG:..X?I7\;Q4D\ _NU^U7MC=IT#[I-3;_5 MY/KWNFF&/-
W\%4XLG+AVQ+!0RN<6#AQ.X,Q0TPVIP!\&I/\^I JV.\.AO"? M&3>M@B;?3A^A^AT>
7@QA(U>BQ46*APW?AB@X=6J+!0X19&7W[BGV#8\5-M M4QQ=? I7:0
KR>;+Q5F.FUM?ST HU%>H;]WX88.'5JBO4-I#U"4;UH=7-VTT-
V/E=O\$A>X*W16Z*W2W'+J3&TIW\EA M=MIUW=4TI-N?WJN0VX^1VRH\|
<%SYGOH15]5=A@P]G@*=67[U@G+PX"II CW MJ=>M1RO!O _^V\\$_O:R?
5^X/CDX*!!0,+!A8,?&X,K.%=.UJ5<_XX-?#09/? M/^X?%_SL?Q[L.\D_-
>Z7FO>KGIK=7\.\M6\]IS=8]4Y#RYTOU2^9^LZ+X\/-M\$24'(I&; M/HUM1-%\;-
C\%L1]>GP_JH#D[C#VFMI9K]W@ M6QX_7!-6Z!#4 B\|
I<JFTYSL\;)GDU2" *: _CW3!"KN4X1GD>* _@6\$/TW M2_1T>&M"NOV;
(*@>V>%HUXY'@]ZHA+J2]=V-P,IT<X=OISZ^K7XY.#HY.GI_#*OZS+S_MH)7QT?O#JN
MG< ?O^R\!W38KX\ _MK\ _V'NE/%;SZ>CRJ ^J+ M]8WCST\!@Z<I6?
5B1/*X<4Z^FJ^VQW!;?W\,OF\;|
IFVJIN^QR^=.NNZ_:ZHXO=V>_O.%^;W\$[*'6/8GZ_;GM.:3HS/
MO]SS.]B)T@5^M3@8]P.:HD-J_N\ _%+S M.O>44WV]5 A\YI"%ES.X)WJBESO0-FO3W6C
N)VRWNC!;8*.BP5'2I=KS,W/>PJ&S=!=/>EXX?N??P8HO@@;F9J!EF+WZA%"W8&BU@
M100:8%@(TZ^U4AWF)W\IK Y\G_&(-Y+'["X^.;IMFGX\Q2Q_XL.//8\GV
MAK\,**#V8IXV9;QE(6^H8#=#KO"O85;YDSKOW@(',*KRM9UO-[K04#\$YJO;
MMD%\$67A6_?@G< M.:O3IM:HSR_BA?+=+I9W*Q#LSC7XF.G:\$,2YXY+IP9J-I^82N&^@?
VI1JHNF M%+2+-K?GIPF\]*_=;R#7_KNA;+<CFS"=Y^4%UY@QA"/C"(N*47.4X\XT2X*
M)K40XE757.7;Z&./)'GSR5I"C2018:LLXDQXY!*72'HML;)\$FV1>57U\!@,8 MU^BSM>>
I61'W^B'_9_]*" =&;^QP>-'M?_/'["VJAKWNY._/H\^ WP(@ M%[@*>U6%Z+MGME?
_J16"OR8APW\HU?TVVNV/SU_8- DJ^1NO_HT2W)%<=>M? M;H\XWUZT\K2GW_7.GGV\!1
MVSE66<1(WOMBNIT2=8@AVPYGQ<&|\$_GMY MSWN8Q%%=#.:/L
^\$Q=ZI^G%4&&;#|:LPS\$,DI1G7\$J%1)# %LQQ9+'W*!AM M8\(^\$NU;L9BGZO?
Q4OL.XZA=.F&BPTAQ)A?LVGIA;@EV&>RD2M*#D4LUXE03
M9!)L_I6@WANA0S2Z%>MX^=A%3\$=*O.W855S'JRF@W?\"+P;#B\(?&ZY0A3|>
MX@^J>'<@;K24)<*. / 800J-6&.L*5F^./16S?2WT#VFB)+SCM2+IUIXT%
MJXHPMP2K'(W&!(UIX(D@3D1\$AGF.C')6,*UHLG/H]\$5LW25@%<4=P;;^U*JX
M>5=BVWX8QG/;#57\=H+%M9-3"30:SR-J)O"ILK'+9[NOF4HN*.IO#W]+ M.\$F:Q#_1
L6D9.87A\1+!CD6'0N"!SH?PI>(_3S5Z?V)2N_U0\.<;Z]1XW;=
M,*,#B%P>4SVA%.)FJ\$Y!RH*4VXB4-#D3\$C.(.*T1"-&VG.'F-(Z1J.I=JH-MZWUU2,DZA"
IQK&USD'+9/NU%S/P78,>?#\$.V5TSV|=HC%Q?00R2BL754,HNT M3CD#4\$>DHZ)@20?
E-:..MY*J,82Z((+UH\$;KL3J*!5\$>:6H!6AP4AJ J*8 M\$4 K!
IAE&47\$24RMIOH+TDIPOA+0B@C=H41L.UHMMV6IH;KY1%*IX+%@Z8V
M;*&##=>60@Q29PEWFGLEYC)9GA9K,>C|=DE! M=0PWV\X)!;*,+
<\$LH3B0A,J\$&RRP1J%#3>R4A&4?\$_C!2L9MB.V&7#P1LIKE
M6.B\!ODH6M*Z.MMAZOB?5U((3X.+FOO='\$S5ZI8LENC-H48'JPRP6GD4E*4 MM_:I5
'2.T\$E\$I\$*Y8WGB;NGV+(JZW:G&G@MY630;_L\$CVFH?Q04*L(NLCI(K#=#B'M.(+5:4?
=_N>J%VT=JT8;T2"A.?S1 M1,62W<;U*>PQ8,1M-
S%*QV@3@,5BNFR+F83P#X/WCC;AJ5]J8WOLS)^
MS&,J2K_7L8E5:\M]BSM4E@H0\;RV7IA; EZ1J1"2MBC;?H4;4+6*HEHHI@D M\?A3N
U3=T7@)64I"5\$|N0O9NDTUAVOA""4\;#OTI?##@PD720N<.\$76.X*X
M\$!&P/D:4L,#9P/4;>FOKXJH=K4H\!PU1S.B P\$26X\XBE\;AG8J3%(0'W*E9(MU>>=*=^4
M(N)H_YOOC4.W_ G7P2!\I?9Z;9\$%ZS"YI8=!\<.*,+<\$PP1-AGMD1\$DUT@4
M\$AE"\$C*46)-]9)2V8N&N\$,-(A^MWZ07W^U"2C);BH452DW)4E/R2G=&0!Q*(!1 ?#8C*
MN>"H("@)Y"C@4=%SS!DU@8Y0***0+2 M62:19L0C\YO+DA+A)&VO""!;P:Z>_').\N=O7
MR7RX02_SCW\ZN_NX,W!R<_?6Z*;254@A_S)7U\!ECPX MT,>B;GM#OQ-
VET#39;QE(6^P8#=#KO N\L;:#,^ ^;T&DAL:K7M;\;ZXZZL=XM M.+%%>K-

M.%%\$6\M8*=K/&6WJ?KRB;P.,DCNKJW%IDXIO%F_FB@A!7IZG<\$B^D M)=
!%1#12D.,62I'S/B*?&SE\$Z3"6".+)8F2\$"CH@ EUQDC12O/PI<*7Z5"V!>BU
M/BE8@?/4.#A.(:KCJ+)"1NN6H5""J(09B5+ H,-JY4':S8%9 F+*E.F),1
M!\%: LH"SYKV_4KR6>1:0CM1;3R,%N(HPMP2X/.)>)B^@0=D8@[H-%5GN%,('Y
M9(D28ULI>KALX**D@IG6-XIM?NIG*09^S0IN5*6%XW;H6N&5!|LR..=,A:% M(,"X-
9\$CDI1&2C)B!;*4*WF^_\$OB,7B!:)1?9(0TO2G@M?7"W!+PXC\$F 1MZ
M1+EBB&NPC!US%JDD+-&12MD^Y7 EP1>O,-HJ01>'.K,(S?QA2'N=SB,'Z)
M_7\$LUO"V%*@AE(<(10=K,, 4F>CS"2.%5RHW58O&.9.(3W+NA'\$1:._@-7""?
M^;^ZHJ,WXQI&'X+=+HA7".KP<.:!8,*|+<\$@R3%O;TR3NDE\$A@X(: 8(L?4&"4
M&TIA7YIX&T;Q*C&,=!*MQW#BM-XM;:QYZ'MCZINW\/*+@;RMFA9(9>'R(5(
MX3@U\$2D<,>)&):1M8HC\$I!0U28?TI%J+!>MV9PKX:1: CY,-:LO1\$QW!BI^X MH;-6"W-
+4,N)%\$0 D|B;(!"76B'#X)\DG%1<&L%P>HD)O"K4DF3K4:LXB%=3
M*3\$.SZK>P/:+X;LMFE4HY,'RAEQ:P7)5<9: #@(P@1:)(&JPI59Q,&-;2IY M'\$'?
8G@;W>A)I)&ZWV) ?3A(M<4T)?;SMU%+0JPMP2M(K.8REI0%9FXS4D
MAXPS8/I&Y9G55M T5XQU\$1IP6V@U9^N*#BZM=8K#=#S7EE ;I9HRYZF1,"JQ
MP:47Q9/%77I1S*VG3)>J 1)ASBSCND'14HA."PX-3:=LJ"7U/B); 1HQB RMQ-
B|S6E,4="QH&-!Q!?:C 25&0<*< VQ(G3R!B;4)(ZLN"=P"FV%*NQ5'04 M;
(G&^N:@8VG;|X2V/7Z^ZFEAH W? 1'B*BY<\$C:5)"/'&&C;!@6R70"X ?G9!P M-G
OJ*=R[AAM\$8-W>9""38?1\$HMY@R1Q2
M#X!+_M4C4M%2=^)8SY'#0|^V6.#);7|^HH%81YI:@EF148,1N|;2K=;*FH)N?
6H5=RS3XT5+L;LJFA+H84'ZW5J M(7VT% GG
^(F*&0))T@0&YUT.A'<2B6):03>^T' <|;#3 TE8+A8L06N"ES|
MD!7KK/#&*2"58@KCY%-U,\$KP6.P*7'72B!:".W!U1W8<)WS;\$:NX99|6|F%D
MOUW&%UP42MAP;2F4! E!&R3,8\$CYQ1&G*2\$= @&V1"(4H;Y1)Y4ZF%&"3/E
M.V@*K9S8;|?..f@YC6_2@.=EVG3!<"*,+<\$P\$3023,E\$=,>P(AP M@30S\$@7K"(W!TL#F
S%1ABM QC#':.-I=X<|MI;E\$LW>U1FD(4#U;"C;0S
M;BT*|_%\$N<7("F1H9)0%TV*>*Z-:L-+MJG"J1>NM+8Q88*|+<\$ACSG!OM M@T-
..=BP1Y' BF4,86I|\$LD;&UOIAKQB&.L(NO6|N+I;:-K1;%|MT=S"F4| MF'F,?
>8,CHC,\$6Y"1V0"ML5*(LE2C;*[X0\$Y\$Q)RUU*W5Z&SV^'B77.LMT M!"G%*(L)70"R &2;
F|LRPR@C"S"Z\$F3D_D0D3GF.3*##-C;B"F6&\$U\$)-)VM*>&V,%&8CBXV^%*|Y7>MK|
<:YH^VP5O3H+LFZ|90;GV,ZNA1|QLZ|880^|OO M/CEKDI".
(TMU1#R7)'2>!D13DDY;QI+3WJU(X%@H;3&RD>#H1U>
|#=6P@<|/!H>C^PHAO^TO7!\$(?'IW88;JIM MX&4,S;?JH|1W%H>P5MX.>CT|K*??
OG)E'1R^~XXOZYZ8U;B|Y4HB9Q-""># M=(H2AB4MIDP+IUHBK &\$X!W,+ZK/-
<|OKTEZ< \$D|ML/J2!_ZZ>I9U;|2) M1#.,**4@=AH)-U.J|>AT,(31A1OBKIL/|;4WI9N
M=H=E"6?XK6/_OF\$JQ@75RH%Z>X)XKI-LE:'(4Q4(-L(+/>=Y;FV8!W4|7OX0 MK>
(NZ8A1)#+"\$(5\$6L _SLE(X+W 8ROA@'<.16@|JD>V'[K]S^V-,U>V?XR: M/H?>9M?
G|Q"5)B)&G8L)!"9,|2J>20,F=I8#@EBX!IUM3V,?R482!2,4"
M"C@ZQ(70R#@<\$2&&8J!G@NGRQOE\$C7WL&#V)RGH#MF4"@?)\$/(("M%&*;75
M*277RGG8TE3VCCIFXJ| @;50V!SIP2,IJE5#\$2H.-*PC2) D4DU B1\$RMF5.I%ACB_=4L?
+B< MA(7.91_+\$"O"_^?9J5#'I(P C!;.,|2EYAR1A#ED3NM@K2VE:C6I4GQ+M 0
M'2'NSY!=KB07U?02\$+3A>7\ER?5!0S1A%6CDL',6RJ:.*|R&)#\$A+C + "9+
MV5*|L%O+6"W:SQEGB'YXAW M^+ F00I8\$^DH;-FMDHACH'V2B'+C>
(:S%416|E)O!QN8SBL3XP#(T9J|L.(MEC&PV E8^<0X!;|MLE9(D4K-6B??
_QK&>+0>9YC#^\$544H:))D.B&OXQR;! M\$/968F*T.UDXMZ4^A(3 GNP-
1LV;DWCM1H1Q@RV(>4B&0"P&C -=WW-BD M26A?=Y (9 M|I 16A%D
+&1D\$Y1N#K%J946%W<-X7(|J)S:40(06DE6\$Y4"U'GSA@
M7|UYM%%R|>>"PY|.T,UNJ9SFEM/< E<%KGX(KA2)R6F'HG0"X HK9*Q)B&\$5
M.)A;8#K/A<(_W=HJ<+461|7%4?T\$LSE7=QGTG|=+#7M=#YLE##MZ"9IH,&QZ
M:8"JO1"@A|+ YZJ=AH=YK&OFHG,*S"TI!++>YK2'H)&C1J'H)%'4>LYQ|US^:48) M\$?
FD%><-LTP2&1 Q K/%8ZDU-FH.QEO1Z1|T|GT_<-#@CN9W0?4F'S91|R)7
M6B"!F0<3!)3/2I8W\$-PXIZ2S611+4-VQ:=9A|GG/66:..5|?V F3Y6|D<3!
MALJ.+JIA#ZD<0R1ZA5F""|NY-*M6-'B1Z,0,6!H*4:4-ZVDRJU&AAIW*+N_9?HJ=+F5#-
GBG-QPUTUQ3C|HWM 8 M!|LPBL\$!*#FG 6 P6!G<X)F|RR#<=M=D :LBS&T;JYAD
MR">|+.7BXEI*I',RIZ1JU.UMBYLFA/M*#;:"M=,MXV*MY_3/D|D+HYN5E
M>|6Y|09X|LK|^|(|@J|;+B&%0)YB\$!DU;C|E;!B-.E0)^
/T|Z+^9:%|K#1BEUAUF|+;324&N(LQM02X?.9&/83"%CV'.2*#
M"4:4!T,)|MC+5D|BEXM<@)@=39;8S.|E+|7-BB9:7S/8^-'9N)=#2:I|HH, M^G\$&OSJ-

-,Kf)5:J05UZRVZZKKUH6FGQY.2GYXDP"8\$DG;,C.2&(&!:0-SFJ0#;SZKD7. M?T%
(U^DIMU<"O=) ->>"GR/*J@4 7Q9^F439SXBL-CSH9S02/,048I81^,E
MH^U4@GMF_*0=2N\!WF1F08\$ "Q>\I50#Z9UXPJ;02@=*VSVLMB,>FZC,QZQ
M)G%7&XU<(!P%(96VQE+!6LDM^!A'MMN/8=|. ^|W^Y J:IK^=*K/!&P B2\$>H
ML@DHL+GV4BVP^,;),PF>E* <4><|3XIY*Y'Q2B.F@N84=,;M; *> S9ABCI* MW!|' -
(5;)6V_UH?#;R41.,3F+)Z/+RHFE3C'\$SN!_5H|YGR!"@-U(&2;X/! MXC&"
(D,51U0HL)&4PL2V\$J0P&W03YS8->9MF!+25)\$!T1^AMJPV8O'6:TY1+
M>@+T)H61%E\$CP9(\$F!|LLVP M;BX|7*KE6; /K,>)|8?92|-R"Q 7("Y O#9 3+%G022/)(!H-
EL)')8&1|!\$U_!=_I0%?(KY+?9Y+=| MT/M.DPML3|+-):"6*H1_!,1)U@@*R5!.,@8534R)DU;J
SX%>A|YT,AU M!XLEAABN*P:O|5'D1F|. >EWKNKWNJ!OK3G46__C#|KO|.-L?
Y/+.LGU8(4?2 M'9HU,@S&KA>?E24?
IY!_6AI=WCT3ZT&82R'^E_7O|L+2=A=2D(|@28PX?7#IE;U%PL^#F5N"FB%H%:8|
MX4(!;L:(#&4<4:6TUF)LODJ@8ML!%:\$FXRR#E|=D>W+QLW9-@#^: ^YFY?+
M7.&!/L1;|W|P=H|=|;('=P42"SL*%A|L<8R5|;D\$@NU?Y)JY_<\$HUK<&'H? M*M^S-:C1N?
T<47|0XNP:|3YX^E#_|\$?';1>QUZL50*'2'L5&C71C.^*S_M.G3K|YZ|V,V?OCZW(=?
IO;9!|DZ>=+JCG+SQ|W\$|ZJ:+V0V;GZ+8#Z_!W53
MEF1W&'LV!WB!BGW+|P'7W+W4MF^/1%_YO1E<3P&2&^H)HIC^F^5V>KE%GSY|
MM|^#2>J1W8XVK7CT>#US0|@5B=O-V*>;-1M@K'MVMY7>U&_?O67RP4QO?),
MAHT&-/*ZM@;F9-FNR,SB(GM60+F2T/K"RM>)V!PP;2LX<|)W^';OX|OJEX.C MDZ.C|?<
5P>&;G6<V<9X@><*L5_!E>-1XY^ZD>G8T^#=*GP7DR<|*POAD);GL?<
#OK5Z'0PKFT_U)TJ?O,1+#U85E43OUS9L|&X/ZI_?C'S M|CIF'PU7WDW5P?<
K^OLGZ/>^'0>X6UCE'#R|#=F8RG>ERS24.V6__"R9#.'1 M|<
<1&\$N#|;3|XNO)K0C&._C/LQ_XW.'LO(ZI=3RW@%QO-@?-KG!R|5>W7?9? MNG6WV51=
|,Y^?Y N?R=T%?GKEMW|YJQI,8J|_@|L.ZVH?-0;B98;;8 GG"^?^+641%<
M0|9#0PYSI\$)1D-64|"W\$7& GPP|=>MC)F=T%6XH6;+T6L*(%10NV7@L*%Q0M<
M*%I0N.'=UO-.<|HBJ=KU#LJTC-6P^\$;3_-CANB'.(29F;_"J"<
MK\$H<6;2|#!..'*. \$54L:(ZT0M9)B91GN0JUYRK: ^4+_C9*|&P|. MWL#%|DA5W=T^F974?<
X_!#';A>KL-A.L(LL132,ZS^ M9|Y\$+D!6@&SM@ PKSAEG&E (-<
(PWU=L2QHAQ'+TFCL!\$;P.9"(X%|!)*PD< ML@1_%JA&.#&B&"8DY#IO:P-DNJ/(REL6%B<
K0%:;(5_%J2@"=, <;#B MN%?P2B>DN%4&C+6@%%T?(!.JHPG?"M_0,>.X_!+U/-<
B|MR&|2J<
M4.EU*\$^&!DL1HY9BKC)5*)\$0,ECH105%%SFTJM#)91W."LV<<&O|1;EAN)7L)'J:<
4GEPNZ@O6+C%5@_23+\$G6& M!C97U=Q|*FC\$!BGG%.(Q9H_9\$=(6>"KP-<
=6BW)#X20"DPFWA4P;&X/OA%3(?*;<>O\$C>Y\$D_DFUS2SPTF M94R;OC*#T6D<%L?<
D<_586S,U+"W6?HR=;'12>4)A>O|=, WF2#,@'I\$C_0SQ M6,FY W_L=3#2,^1#|F! =&X6<
XC02ECE,K,V_V9=V,DLT|Y>-|Q9NA-!&=EHA9#|:3\$);<8R(M3|&RQ*1.:HU<
\$A>,+!A9,+)|@Y,(!5|HX1H(\$4S!BQ*GVR#\$G463,D_E,(1X2P9@BQ35!W,6 G(1_,!BAP7*X<
MD%RCTRS2P:I8DVL0NKJ(?WC|'<"3=N/%W5OHI|#/C|./BCP*SBTR1_#|4.|R<
MOKU"AFFOG0E.9RJY=1A)%CB_7Y#@P?*CF80C+DO\$H@%XH%7J.,>|X|1JZL M1?<
@+YI^"DP4G"TI>%|3|J/*!2\$0I93F #.#.Y.A93Z@S6#FGYV)F8Q))8Y.0 M:+"58X8L90\$E' C<
JF(HK5'Z&!4=MKJ6X 4G"TYNL+"W%B<-ID83@I'&8\$5R MJA7204E\$HA%\$&<&##<
|=ODE(9OE &3VGSCJ*,"\$TIUS99!/FR ;!DR1:2SQW/&84|=QRAC3! M"7%D);(Y^Y0);S<
Q"LAV?7V 4ND.\$;3@Y!(CA;>ZF<;03VJ!FGF^BU-'1X< MYWK:."G!7<
J)EU5<5G%9Q5LDUBT;EG%&RG6C1N*9.VTBW*>6GNL\$69OR7= M_4.U-<
JPYEPB+YQ&W&"!K&4>*>Z(8E9I*>9R91;IZ9!U|2C|AB\$>J!9@4* MCP>|T)(_*<
INSEAA'LLE+NZ#4QHAROU&*4""X.;I&M'*4(Z')<&,P6FMEN4&PI3U!K&E<=<
(FAQZ2SE!.B.:DE;>,A&# ML*VT8U@Z3#'6(7R)AX.;O+8+3&V,*#<4IK@BA'N3\$(ZJR?<
T%M*&<(NF\$PEH1 M"E93&|T65@%35&U|)=E2R6RESL*ZI%;8)NTJS'\$CSX(X\$1@3R-%<
<2LP2@YQT M% 46E#'.2*G.L NTEMA^?MPUA%LVYFCP-2VBW)#82I1&27%!*F4A=PR.<
\$%JM7|P7_%FBAL'28HAU-FEB<89.7=D&IC1'EAJ*4T4)9"MOPJ(6% M;7@BR<
B;JU^P2/N#%?@?2^9M.;D+%!8H?,QZT930 ME2R8@@|%'S9+V%N_#_<5<
M<"E/7;"P8&'!PF(KK7&4X":7K_M04A1^J7#H10=)DJ/C@*!0X+'!X>X|(-Q4%;)\$V4B<.<
M&U|2 XJ6*)T EBE(N+*6Z0%9DBHY(W!444YESBTB#NU4;/C7ZU MY3|E'2K)EL?<
@%US:=E%N*"Y%AA6QOB.F>;.8:)&5R2,B)9BM.DE#?1M^S?9Q MB9<
.\$4ML&K?)B|G@TL:(X/S M,_BH.*@V>D|?'%0WZB@+\$02W#FGO68|A5 M7JG:_L0|T%<
I%=R)*Q?>"5-LMR@U%*A:X=R(Y1#"7N2ZR02XHDFN_4ZV38I2T MDE*U"J22':9*T?<"5-<
LMR@T%*%@%(15)T2+\$H0QY9'&0*V(&TQ&%14<
MV+DH|T6B\$U:R^3,=S):8BO0BEG=I%+D2S^%Q|/6Z_<^=ZG/LQZ'M-1Y\$&^#K<

MW7J4(Q^E)2FZUHA4=N|_QTGCI\$Z)\$, +!X(T7:2HILC)(SK(43L0TGXE30 M?
IUH',#)W@V=:Y=0&_IPO.T!< 6RMEV4&PI9@0?C/0Y(OB1RFUN-#(L*86DL
M<8RI.:?3"SB35PI9%':H886R"J0M=6BW%#(8L(:X1)%OF8X<P#3>\$&903!2M
MK3UZ!VSN+>>.@D_:+LH-Q2>6L-8T<.2(58ACP"<=" \$%*&BPX=UPEWE*,XK+P
MB72,*0\$!9^V6Y0;BD^:!!^("C)W)8"&X\$T;8(4,694:V9P*W78EXE/8\$"I M4L>M
-1VBW)# %\$ M;#D^E3C\$U;2N' I^/=6?I!KLP@>?L<;_IY57BKTL:BFE>83E\$5HS-
N+OYA\$=_N90.,:>):!RY8"X SH@\$_.6ZF DN2P49+3#:#&W"PH6%"PHN'BHF3:\$FNR,P\$PB
M#F8ATM\$JE#1E|\$<4V+<2"LL%*28=Y0|,%A@L,!@@<'%M1*<@&'QAVU,#V M5L/-
G"!9(B*"2|MEZP-G^RR8-"_8B7F(R_2BX)CW|:4C)JFD[%4PL&\$!2V /)3S&G%L!;)8!B
D0M5D51PL"%@0L"+CL M7FZ6&:(M\HH;Q)/ 2*M0A(..UPLEF-1PH\$%@@L\$+A<
M".1&F^2#0I39;-!&#K!\$R+):.45I*W\$@N|_@@4HD/9I5D>0("EAC7A;3D M%
|B3|?:K|_'0G|HZ5OFOPC O2&<*PSR-\$2+W!FOA43(*,#TX@C15'F&+%672
M66+|D@H/3)7OPU3W?H77'Z,??| #-(;|,P"KT6+'=:G|+0;T1QP.|CK0E-#7
M&|43)1BAP%>!KP:^(F\$D(\$CJ90\$*"(>6>|HDA83);4D+|,59FZLD"!KW5? MAP6^
D:4&PI?05'B9&X(EW)I>3\)!TU@6%'&;T,QW/65TNI^TN#K|O2^"DI M/2T+A&VW*#
<5PH+57F.%.\$T4|0BOC-.##*=",>.X/F>EBVEUQ<+K,1QKK=_ M2#K>:Q'5;?Q@W>J?
AP5=MAH32GL<./,7=G 922(> 4&KI4.V<0E"BDX2WFB
MRL|5IEK\$03A3M,EYT^7Q4UNYGQU3VB<5B-IR46XH1\$EGF,3<(.QS8KH%8|0P M%Y
01HL4>63.M.%"7#)\$|=+.N #4=HMR0P&*:R:BM@*LH.SP8V!#:2H-DD9X
M^"1.:|_|JWP.BZ5#8"01 M&@DG/,S5M5C\$"[A@T#J=.ONJG.:7.GXN|K|0& M*:5!?
I1*1&Y>S&U"4=F.!\$<3%?XTS,5*,#_N!FK/JT M4DA;A4)\$J1)2S.*"AP4/UR8'2!-B0^
1:9';,3MFD>;1(:PU)U*9Q'QJ)1&+M)7Q|9\$;D,MN?KBG0EHS)@K@%
<=)J61"W(&Y!W(*X+=BD7CMA|Z|=1IUM4H.T!-P3048BP/:T90'MEOI2O3AI_+;.MIXXH
MXWG#58P62:8|T_F2\$?.D;*">14,=6&N,M1B4;JS:BCOAH.S-W"|;G\,+1T M6>3WET:S)|H
|R7J|_VTM !PW;X=7AR,XED-|)6?9#CH|1H"FQR(MEYC3W8T
MW:R0LF*|%R0M2+KD_B;6)TDY!1AD!%"11F1#D,AS'556\$?;4C#MRT%2W-%V
M*4A:D'2M95J0=+V05#C+%)<.22LIXH;|_| 2&C+A7!4Z8#;B?H|,4A*,|(
M4@H_%RA=;YD6*%TO*,4QD13B7.G|Q8*37PR4 M"MZA4:6,=_
_(>8*2B|N^%X6P*#|QOA!6\$+PA:\$+0B|:-.\$ M(&/4DB++2<@|7W"N.LX!O!Q+R@1-
YRN>+>X/7Q;"RF5V_HHA"WQU@MIT&\$< M5;U!7>*K-
^|HZ\$ _E);ESI,@M%\$JEXAG.=#:@)TN=\$#,|>!UY";,9T(NXIX&
MK5UB^W'9,6R)#NJU59ABN6^>3 L(KKX/>12<_.A|\$_.N<\$0-TI1@E#C-(J&!
MJH!*C/1R01!WC"E1S04\$-T&F!017#H(J%PRU B,N"06K+A(-,U0L\$)HFZ2* M<:
|*VR)>WJ6"8 Y(UAO6VJR@8\$'!@H*K2I<37B1'-);:2\$ TV I;026B)F@=
ML#:&T#8|L4M%00\$@J\$N|<(DE?EHL<1C|&):A|'4644&J1K&\$..9=;U8P152 M';(
<+.!_T?AGW*(6 X1?Z3\$4L3>\$)5+|FL%M %FM)4Q(L^!@9@16)(YK\B MKM4?JVE2H
6ED=E@D M@VP0'FD5M!;4JVCFG!R+N'J7!D)S+@|N.|B\$GQ7?<\$'<@KAM'(9I#E:G"\$A:
MGLL?8P7@:#G2AD;XGQ+.|#;QH-.RZ!AQ\$(|&H"%G M9X/^Q\$%|_NC!
(BEQNRUI&=VA6)DI(# M7|D(_U!#D/4;:'M@,A)PY;|UN_|H|8;B|Q;G@30,0Q|?
PX1=;=_U+BQ!^ M<\$66#4(!Y?64>P'EM01EIC6)T08D!ZZ,4ZTXS9\9E(G '4T+
M*A=4+JA<4'GM49E'XL%*QH@8 :8RC@\$Y;QA*SGLJ?/!@/+<>K|UZ5%YV1/_4|F|
|BO;#U7H|L:C& I1%J(L1+DN1)F28SI% MAKQU;V3!:29RHY^S:26D2?
52K3YOAWVN_W/|8V=Q"()_.^CU|+!N?G))EO@Z6=+'"(L5R'P#,#N|/H M4\$R Q-
0!|NJYBE2+"ZL*U%ASYW,5,-
MLHA'GY#!..22N|;ZE)2D&H)%&V=DZTI4!Z<1&\$0=LX@|JQ_VD:-
M*/\$N8!;YGZ|QW;XGX>H|E\$5>KRK_|#X>@3I4_7*@ M6*R*=8D=DTA|/M5I?Y-SKOQJ\$
MC&\$|&_QV/QF80#HS1!A:/QJ|Z!);@_-RDK%
<2+*SI5|:'0R^<,93I\$T\$(9A3(*913*:+N/F).\$Q2 1PQK0DV") MC,41>>F8IM)BC>F:L|
ML|BYS%IQAC.26.;@V0V%+0.6&&FJ\$O+*:.L.CL;D69'#KW@->
|K&C7O;@KJ#R!U&LA<\$>QUA9G|_;/^B.00; MC&)|:_"A^Z7R/5N#5IV#BJ+^(-,39->"H|?
3A_X#=?LA?MM%|'7JQ6|H=(>Q MT:)=&|XKAZ=.OSGKW8S9^~/KH(HIO|F
MN9U>'@M/'H|:|W7|!|0C.QSMVO%H\KF|S"KD|<;,4_.AFV"L>W:WE=|4;|^ M|9?
+!3&|DR&C08T|KJV!N9DV:|S.(B>U9 N9+0^L+*UXG8W* 76L&9D|W# MMWL?
WU:_'R=|V|ZX.#M_|/(-M9-QKMA/(W|&L;@IWSFOQZS|;H|.W^
MX?'^VPI>'1^|/WB|8-S5,AYN|P2>"^1XLO_ N')<77T#HRMP|?|_|&CWSP
MG_O5^Z/CXQ=#FRU/SD|_6IT.AC78*76/|^867C|8|@MO|^:?B|
M;+W3J'L(S*#!>%K_ ^O7D5@3C M'?SGV0|CK8|K^N'<_MT(|B;
Z:7>_DVJIN!X|JZ=9=U^UU1Q>|L|_?%=G5 MW\$|@':_?)V" I^.<&MQ|#

M>R#"4S\8X'D7^-T=|3D/H|>?|4>|OWJIK+8\$|^|F#@Y60_|DKZ_DJX<'NFC7
MD.5.Q2(VW'TS=7(ZC+'Z#?X^K:MI)V)B&ZCB>CV+V,E8,=Q9;((OWD7@YBZAH
MR'9HR&&W7Q2DO?8KA9@+|'P?='NC6PP|%E!='L*5JP|5K_BA84+=AZ+2A<4+2@
M:\$'A@E(@N_4"V27F=|&(O6>7|RH*V+SXH-T5-!4BAJ= \$|,3KM6W".#E42.
M4)*X#U|;N>(T3VY^+=+2ZZMPI1*7YLGTP**P=|;:Q5)G&4\$L.(Z^B0TT2B
M\$(PF,8"=25O)/5XN""ZYG>/:*DP!P|!#4I2\$RT*U *@)4V1=DDC
M32DW@#)T*UU9A6BXH^OBPEN^&L;P|/^O1Z#0.JOLY M156W6;+53|G_ ^G.G*2TZ2-
7(?MMM|YCGQ1#-HT|YU@-|5W9ZMV7#+:MX(6Z
M9<,MJW@CQ;IEPRVK>"/%NE'#77K@1S..7*ZB|/WB(I\$@UQ-^FXM& 1.4PPPL%)0X-
_GLWU|EDD?*1Q1KRY|HN8>, ^F.OYF MJN(G6<,G#[C7#R=7^KYWJ>Z'<7243NRW#X-
A|!&U5B@G@P|VF(L_M>R.8_BN MYG4O5PG+@40!U@*L2P962X)T22*K<@L5_9>|?F-
I(D7?.OP&JGUV;X*JX M7Z2>8Z92J?;H;+6DE32SMI_&/'(1/2! !8 JJ3Y|1N9I&X\$5:(H@
0RO<>& M19\$D)E0OD|X>'TXN 96DR10REE|2@'S5EW>34I2CAJL|0P9K S6@|:4P?IC
M(#19FUBC 8G>M&C11\$!R"(1(+;XTY,-RE.(% (3?>,X|K(>|W.2=L3LFW'#XNDA|++>H/
MBQGS"2Y>=|4U|6YN5VS>CK=,7F|/=^?>Q5LZ|P,O>-S1% @777V0|C!'RVV=_
M|&/HU6.>SS*EB C96=^F#C5 *HJ@2HQ%):.4W1KS=IF|_C |QD!EH X?J;+%V&)_!Z:-
@TH0@*F MD\$ KS\$9I*=)N|F@|!#J R3AFGC%/&ZPSM7U8.%7^JLVQ&:,@.5 8J
_5Z26Z,2HJ@&@IM\$WZ12IN|PM.^!PK69|, M|C?)5A M6*/W4 & U3NPK?_U:\$|D/%
Q@/9=PODU\$8=A0:|R+:AR!0-,08' MF:JR%LD\$D_:9N>Z:\$MS>0!4ECU,
<^# ,OF9>'4BWCMI:(X)U799%V0RAR/9= MD6A|08MF*S.SRT3WSOE|S84J<8|-5
^4Q%QSS4AF).|E%U.RI@BU-(X:GR,\$ M:PI\$4BY'M%Z&K1!VE|GMVPUA@^3D-
<>P#\$P&YL'\$L,H%=\$4AR"A"BUR5ABA2 M "%|%5%9|%;O,QE^1S&LW>.2P
_,%|2&7>0|S^_W%|S05.J>ZEQ5EF>- M\$7^ZY762-C#D\$|("DD&&,3H.)N)3*)PKM?
SNI_+YBV/LP MY.UACYM@;NV!|J6|TA'-P8P Y@!?!<-C98C|9"BMU\$0F
%I\$IM(A%TSO)/|^|UO'YQB*>TS/WOT M-#L_THN'-><-Z-
:8S.K|!#Q_80Q1H41Z<+M>S_KU7U+59>DO-:N^ZZI'>|_Y'
MU|V|HK7G7Q<'|UO,9XMV%:M<;>|CV6;YX,M? MM*MZ_N->YO-'8%C;N=W'^9_X?
OW@IY|_WA 7|_Q:P|X!O5Z?W0-;6NY6LGAS MR>X4*)|4.ERL 'DN6UK.RTXX|^KATU|?
00AU|LN39Z^>/?O|Y>3)TT?W|@|"R M?1RSWBSS_S|HT:K|7_1'V>SS?
O#N\$R/GCW|H?'3EX|_G;3O7CH_ ^/QTUS1_T_G_W^Z^,7+/_R,HZ1|,'O|_M_'DU?
|W^==?'_VY-&35_|V-"/ICJ_4OSY93#8GR|,U+LKZ>*|'|4|Z_\$^|M=
|X_V|2/S5^_#|^OP+|2/JWWBWSX?EB|.I'Q<_ODKKY.WA)WSTA_MJ=W@Y?
8>S&&0STX|A!GH^U0SH?YL%AGX^|I^P^|/F+ D^_HIVOMV.)@|BJ M|>K8;B@;4>
|_|#YN1>F^L17E3=^;Y6+RLIL+W^QNN'GE M^'ZOTAW;X7A.|MH;LQ|HO?ZPE#
|OB/_H7/_^,YS@K,%N,4?=-G-YX|.N>S M_?ZN|E?JS1.N0=|9C|,G^BOEAN<
MG|_J%X|9+YX.|@+'X_Z)Z^AN HLSS@Z8B.,W @|6V8?L |XMLP^8!_TBW\$N(|_
O=M48I17^X@%-N/M-T)A M=HW|!>>XR#3!:=;|;?6#OTPFJU|
M>5%WWBJE^."BU1*P=IW_?"F B EDK_O>E>\$'JIG=E?EY0! MW^VW?VKCPM;M-
Y0:|;|8072XZ&KW5+3EIH4IM89O4M@5|VA% @ M, Z:W|/(62;=AK 7;-
+_52I|;9/(E0_|_W,1.2"3EB0CH7J%'-@LI=BJZ2 M@M3-
68TQ*FMOHY+F,B&K\$Z&0UR!K>Z%QF"\$6HT&YBLX|892VMT|(.6V79.KM
M'C=L/51-/26/1|&1/6\$X:CA*A5)3C.!S-Z'VPD|HS /=)MH1G4HM0KP,1Y35 MD
H>:BZBA8|U OIJ06(4U4A+&+=:O7|8&=M#|N)AQL63BET|O-!3J9F,3,:C M5Y3CQX-
")86,B(1),IMMJ0*FV\$KK\$#MIXV:)(O;FF'?!)|CO_M-/H|L-Y MJ'YB0@Y-
42;D81%2Z)*3|R"RE&VV' (\$GQ-8Y8.EHGVH6WL6%Q6L,44WJLI& M5?(1@LBUS;
MZ50"2K'3IS+7G&&,:!66LY W+)7|T,OBFI62_9%W^X@L-N?V MNDGMY,7EZ-
NN|V_R^;N*RZXYO-+*1|M%.-UYZ9EG:RH\$+WIVJW5U9:M1|, MUM?|L0UEH?
CN9%E0!:=P#4VMU\$B00G:@8G60/)=/M<(U|P2113|A O!BDPB4 MK
1!U8/)Q4",D8",P!2JLI'PRN'ER7|1N77LJ5L|?HYK6;+U!C\$)0(-
@;,%MA2|6V(M|7%S56#,2UNCE4;
M\$(H*IFC5W6/8/M/G)_1|W'MYH5/D>LT&6@C%G(40\$-A1.TV7R^E UJM D(-M"%8)
(I=|4L9>|HH K,) G3QL45WW@*F'"\$Z:X.1#G6Z.E5ZQT#3UD^EY|4R
M3+41"WE=jNWJ9'>|GWK?L%:QU.S9.S_:@_L/_#X:IRC@JTDR #6T\$W<'\$)
MVRW|H38Y*5"9|4?"VOO2?@Y&40:3O(+80AL@X:2-,=1JFKB=KUG(9-A1Q4
MO,./CQFB'/BPU.S940C)GAV-U.S9@0AY&).5/4|GLG5M4H *!.4*)L@"H>8" M0AB?
0XC6&W%Y.I&|)"3=U:)2 J.5@Y2\$ *5+0*.^IVKSG7| M_&N|HR<;?;\$?
KZ0079;*|SEZ<7(|US |EX>HOZK%(15&"@UAE&ZYT&ZE2B1ZR
M|!%+U='GLO=ZK!TN99_6VYJC3;G.UT;9F<>CWR,8LC|7\$+

M.0JTZ9RR5S6"S*I%U4F);MT_KYY*RP9&93?=T76=Y/MYL'XH);+,M(8:<>(MM*
^\$NL,"0E|54:8T(!E+&|L5YBC"ZMW>*/YV"OK-JL20T(G/PAEAO)#M%9:/3L*
(=FSHY&:/3L0(=FSHY&:/3L0(=FSHY&:/3L0(3DG^,,YP1"%4UH2MD#
\$1J.'E((('8(0)%*.U>6M9^Z|+F>XB)R@#YP2Y;|1ME3<|?D>K/%OWY4U|M3=-D>=K=
<|<")P+DP|'9",;U08|1%1/J+R3H*UN@PB1AUBB@VQ0"C3.Q|RU
M.|3."Y/Z7SX|M^('CY;=52*9035PY?B<0<9S:I;Z0\$Z-/V@YV)!AMB(A>38S12LV<'
M(B1|=C12LV<'(B1|=C12LV<'(B1|=C12LV<'(N0HDG)5VIQ|54#=#HC2C@X94
MC0.AJ@BQ)%VV&Y+ONA2%DW+|N->YDN^M)RXX&,+%. "1DJ3DD'(60|
G12,V>'8B0XYC&45*8:P:7C #C2X'H@H02LU&B
MAFKEUHJ'F|16/"S_/ %MOWK1#6;|:/BOEUAT#SI_CK#Q9/;+3V0;G?95G'PP_M^BP6?
D%_G.W6|41?TNKM+-/Y_.| %Y>7K1?|N_51P1L,^*:.|@:AS+T1"|FQ
MRFBDD9L|.1\$CV|&BD9L|.1\$CV|&BD9L|.1\$CV|&BD9L|.1,A1Y/%<%B0KF2Z%
MAV"LS)!4L4#=#FBF9C(C|!:(<@_X1V,7|A5R"Q4<+^CT;)5A+Q;2%Z^>;/L MWG:9_S?
7;@S97!P_LM06?BY:4J)),XQTY""9)""%)83YZZ#6SWS<@=/U(6=E"/E)F/MS\$?
FXYWQ,523=(Y@M91@@K\$0L@R0I;124I7:|FXO'^;C@>_3P|U3OM|7CSZK
MMIFL:#Y;=|5F)U0FL|5D/MO,7HW4UG39C.GKF:-.W*.QWT'-Y9Q#O/HI>;X M^3Q>|?
8|Z7'T/>79<^R
M9|FS+"||=CQ2LV<'(B1|=C12LV<'(N0H\G%HE8TN&0BU5C!);!,!0\$)2IWCf+M!>U6I>
|W5%EP/H|FPRYQN(?M'I-J|X@ZUFAU7E!Q;_*_1<%MY"C@!@JEYRHC5H!M6UCL7N0?
2+P+N22")4,:8|0Z^N.O|PFT?%:NPQ,<-KW\$*.E|:NY(*.E!%
MB1:|M3E|K+9T_U12%E|DV9K3WV3/HEN&ES%F*J1@@#'|QBLD/T@8C=3LV8\$(
MR9X=C=3LV8\$(R9X=C=3LV8\$(R9X=C=3LV8\$(.8J\$G-&E9\$0!/I:N'1X52"E\$M4-
*C*EBD*WEGK40N-R&GAM42|Q:J;+B3R?;ZBEM)O/E>LU5-4.V\$H=|+ #6'
M?;0DCT|&JG9LP,1DCT|&JG9LP,1DCT|&JG9LP,1C!2HD?=.YHL^21*@\$!|(
M8"16"#IH2)F"K+EB0;J<<\$7M?5%&=JWX,YCD%42=\$I|PTL88:C5;""=>GM'FR
MR,LW|MR_1U9U76|ZNV|;Z17M9I*.ZC%)MQ0GZ'(@0Q+S9X=A9#LV=%(S9X=MB)|^?
CAR8>O\$IWH2C6PFWSD(@!KU2_\$HL|B:U6V)A|WJ?;@R<=M33ZXD|HM
MU'@|VYSTC53>M+||H<5ZH8FL_|^GDX6M)DLZV2#|@|Y*:.2^W>H|7'0|UG
M3S>3|7(^*Y|/<@UX6/OVR7.P>NTK=DXWH8=|PXPKH&4V;!N8#SDN(K9P&Q@-C;F
W,!F8#LX'9P&Q@-G^YIK=
MGV4I/F3P669)KCN2H_@:M|,M%R.E%"&:Y".IZZ0Y&5SNYY=\$E6J)A3;0.+H_8E:4@:
M0QLXL)|@V2L0J|>71)82@DR8"G;(#8Z6!(%2D%%5(VVP7?NS+T>7S_8;/-1
MZ=G99KW!19DM7N|N0R<=-19:0R5XZLF5O,K2UNN0:<*GV\$F(0\$XVL!#*&
M55XEH:SW2NR"6SVQ3L;S%C>N'_IQ-MN|WU&@VU#%F&),C5?(46J9VE<#00B
M10&&K_849""KY%%J@63,UM9-G@*1#N!#BFWRKA.\$JB,4%2/Z4'1|V:UA2DZ=M-
^W_..9B6(U8R,.U5\$OH|3.-JRA@H5G|?,%\$@Z&|LJ,&2"=M-LYUT%84&
M881I\$5M%" +8Q5\$H7&B8I:"EVB<+KK:644Q|'Q4/NX|)|@9##>%1@M)BME%1",MKF"
H?W%!.!DQ*QS^V'9>L_3DE-!(8%*KIR#,:%U0%%EKV+R/OB|_*/P81J5-M9C@R'|748;C|
<#1-|Y5(ZE-@46#H_&EP=%D(="=)%A|DE:T)M&M_X&Q&4"U&M!*,*0;CP15"|6)6I6Y-
H%^M"-=GJ_<|)"|>5EP|B=C5PPD_558R&9F,AZLH
MD_%XR&B#=8JR:2CLFIPF)0%5PZ/-Y"AZFVQ,NR#C+82-?BI48#(R&0|7T9&1
M<=_LT@H-V0EHP#C789(7H(H+B)2EG*|I9I209-V'DAZW;5A: ^RR%\$|J+WT5
MZ+3;Z93W+Y%EO9|JZ8;\$K%LH0^0V:M|OH&|H|Q|YN<5DG;>ZQ6_H7/%
|H|_K7=T5W+-5I|)|@HDV57|M#T(-RD/0MUX>@V&T/H',&|!"*
H2@A>&RHBC))78P7N%7X:*(-V7L+3OL*QH8"5&W,|.*M2BW!2'O-/5S/DPLO/AJZ_|.'?
^*J|+7VORU7E6::LYTF(.14!S/N(801-FXA
M1X&V:J()G<=B|JL|4|HG|=)\$B%F'*A4YN=W!98=HZ|>G_FZR_4")\$B_-D39>M(0|#:
<>=2JVN%+0)T.D6"P;C(LU8)50.@?,4MNM=(2(5**)D%"H%CIF!2'7MU()
(I4C4HHR.=P?,ZS:%'U0-.F==&:*|M0U+S9X=A9#LV=%(S9X=B)#LV=%(
MS9X=B)#LV=%(S9X=B)"<%/SAI&P;I<)5_U!8RH&F(R!E!T&T(&J8W;ZC_A
MJY+!QP0^MB_&D(#H2H*HI_Y9B8C^")*"@RIKNLUM(K^SS1K7-UVJ;AK|NHOS
MVJ9V5Q=:31Z_?/ZZ|1>OSF=+Y3|3_T?.S53|!-3V?XV'*E4E*#&H|8|/4!W)H%D:
M06|<9U'6ZH*UH'PR;4:KJ84328*6,4EGLQ#5|;LTYJL1R,YZCEN./ADXQ62
MHX_12,V>'8B0|-G12,V>'8B0|-G12,V>'8B0|-G12,V>'8B0H|C,"6.EB|)
M+6C|Y)|@=@/UP:A+H22@=Y:BM5W7IW|F;L|&X!8|MU""|O@=K?)LW9>@G->>
M+\$^|6VW-8|N_K<5CR|?'EC:8I&I+-M#|2-
4AB@, @HUDE9)|JFZW8@0K)G1R,U>W8@0K)G1R,U>W8@0K)G1R,U>W8@
M0HXB*T>R"B4E@?,1P5B#D\$A;0"M4UED+@UM=|G==?|/?K-S(GRUP^Y=;J+WI M|V|!

(V./;KOW+*2W6V)N,WG7?P\O W88AX0L-7MV%\$*R9TK^*5!TE5XVX2Z**QZ6?YZM-
V.;H:Q?+1^6,NN. >?/ M<5:>+!IAZ6R#|
HNM8^%'WT6"K^@AYFZW:B+VGU=L;I?/IW@O+R|.)_EWXJ
MN*-9GYMZS=48C+T1"|FARFBD9L|.1\$CV|&BD9L|.1\$CV|&BD9L|.1\$CV|&BD
M9L|.1.A1H/%2|DJED,\$C.C"Q2H@F&;I2&M5I4LZSQO4HW!.;QC<0NW3KF%
M\HT7='K1|>?R_CT|\$@W86QP\LM3LV5\$(R9X=C=3LV8\$(R9X=C=3LV8\$(R9X=
MC=3LV8\$(R9X=C=3LV8\$(>1A/0ZYAVDO7_2O7YU_7)I;?-"&86/6*"ZE,"(M*
"#CU"%R<96JV0QEY^U%)>4)>4@BNC!^H@)&O I.12+%G*K@_G%2M?/V68
MKV@1?.UNP\$^>_O:M1HRJE4I>AX+'5P Q1G)H|>
M:O;L0(1DSXY&:O;L0(1DSXY&:O;L0(1DSXY&:O;L0(3DA.L/)UQU\$)5DL8"D
M)9@(@%40C")0L43@;E*6M1F?62\K8/=I/P8'Q6"\$F'T|/IA2HFS2Y83K4|H|
M6>3E&_H5Y?/IFZ;E>|??>M37OMU,O 65:&XN\$J>G!0Y\$#FZ*5FSPY\$2;/I
M:*1FSPY\$2)Y_/#DP^M@DY "I.G:LRB? */4\$)U007EA-B:?.RDVH,G'P=; MXL'M5;|?3,|V)
I3J|59T0DMUK.WU)=|3!:TZ1JN;/=#U@W=%MJJQVM/AH
M/7NZF:R7\UF9?)!JP\$/:MT^> |5K7|%SL@D|Y!N&VDJX:R%
<3*7MO\U;JRW M2TK<_1Y\$KF\$: M8C 9*NGBO'=6B*WG|'UNX-'GJ8%/F: ^GM'E67^&
IY|M5=V0/-Y05+)UM,,WI MU?(YKMKQ|VS9D|H?
0HS9R>QD=G)ZIS5%F>-2Z,;X2Z^O1',48E
M%ZA:CR"++6"40D@*J7MF\$%;AV3\$Y3%*M9^B+!JL(013B2"A\U"EC5D4%TOW
MFB_'J\$?|FUI2|3S|KK/SC;K#2|*|/ZVKUTOSD&Z1"G7NC;&H2"2E%#
(A'IKC|>;4++GX\ERWJHZ^O\$? M9|/-^QT%YPV,#\$6&
(D.1H;@S*"I#H013P>3JP1@5(7@A03D;I'0A)9400Q&K M+EY"">2B;2_,!::++"9(7*04?
0Q7VUJ_HIRZHJ0E|W*Z:T'AJ/>DEK M"RP%V5+
&2L:1*V&4*P!A;,%J55&Z>ME\;\$EBC"DP\$628"*V"%:AFT9/=K2
M::NSTVCT>NM:Y=2*\$=*7.^|PAAG#1X_A+(-/F\$!YGQM(75=N30Z<%5'%F%3(
M\C*&A76J=.%RE=WN.EH38(D!BBD&8|&VU*OWV=DSAJ4R4VR1?/-+ZONT@OYV4"%;
IQHP\$@YA!S" ^>A#7XKR-77LM MF5I|2Z9!-60();5WS:XZMU5.9PZ/D\Y)633:ZH*\$
M&+4%4TN\$J,"*MDHHT6I3E\FI:LED#;|4J9&2FT;6(U%D#5)G=H09_ZW|O3;
M2C%5;H0I@UNH^N6.A=|OLR?K|5E?)KRLDS;|VJOF>4/=-)6KW_1#V|+SJ=GD
MS|GFY(3FY>|H?%;H|;?=|U^"0UM,)+LIDV=77|X!W0QL?@T&NCWOOE>Q
M2*F|0013I)C7 %,3D,Q46ME"L48MP:J(%!UXQI9UP8JKRJT68 "6|2A!'KP MU-4#56?
B+W=*/L^OO/AHZ/H/OZ)H(O;?EMN:HTVYSM-@,5\C"0=M3I72R)I"\$/N0K7-L*8
6U)@(4(T2A5ZE9ZMVA/4A0"7VL\$DY2' M)\$P&'X*BJ(0(>'7)PZT
|WK)8#|H="**EQG*FTBQU.S940C)GAV-U.S9@0C) MGAV-U.S9@0C)GAV-U.S9@0C).<\$?
+_DDH5SIEO3",!8I2|VY4E4@|85\$EI
M:S6JEMZB+@A1E=Q>4P2D|IERRKXVA96PW::L!YX3W&.1_E'E!/?=TY"KFRY5 M-
^5^X6+%=(6)WT:=|2W&GBY(8TV"*@S MO7ARS5(?R*FQ9SGBN&G\$88JLP6;!(J/1(N09
F@A>W7ZD23T|Y+8KX=<-R|M:-%#CP88N,5D@./T4C-GAV(D.S9T4C-GAV(D.S9T4C-
GAV(D.S9T4C-GAV(MD*-(RL7DC4TU@Y#&@<&<(\$3I('F;DW
B6MKJ6;#KFA1.RNWOWN>&.K=05G7TL_.BS4/@%_7\$V6|<3?4FKM|_
YI.%Y27KQ?|N_0SP5TU M7)U&-:@^)(P|QAZ'*BSU@9P:>Y8|RYYES|*0|-GQ2,V>'8B0|_
G12,V>'8B0 MHTCC(4E2I!W40*);(14A*@K@==7!""CM+LHQN
TWK&XA3N&W\$+YQE/:3.;+ M-?<"&.*3.%9DJ=FSHQ"2/3L:J=FS Q&2/3L:J=FS
Q&2/3L:J=FS Q'R,/*H M1|W&F4R@I%, \$I:0!\$VJ
0&0@9BFD2T:7+:*+:OQTBL"C#:#R400O2^0C?!. M%JMLMS7PEUG:|H1YLLC+-_3|U-
HXWJN-HTR8?L)A^J??\$A%XO:>V&W)A|W*1'AR<=M
M33ZX0|0Y4KWW%SLDF|)!O&&8#LX'9P&Q@-C;F W;
M!F8#LV%O;#CJU5|2Z4#):I"Z2W79&"&4Z"#9DI,F:Y+?2G4%5#4539"\$K6"*
MQ_.F1EK\$FERN(5A|.=75YP8>?9X: ^)3YZK=&?H7OGB|7W9\$|W&Q6LW2VP32G
M5|OGN&K'OZ/%3G&/*YT8G8Q.1B>'5UQM08QD
M1C(C#YB11|W@E6K51=@ "V4H!QI."Z-%#B\$YKTX|JTU9:K5LX)8>B|J&3?2 MT&
<+RB:R7@952|HE@: ^WZE5.C8CCPS#WY6\$>,X|'P^,H342%AS:|C%@"")"I
MM>"M5|84|740EWE,0J:"GD!'|\$HE2%T(-=%1F|\$T5'O-
"*^+H^EE5/KF*!\$EK9DBZ9#L\$A@7*01+40',E&9<14TRZ(O/_@V+BI<9Z!S\$!F(4;R'M&
MH>9C#,>BA4:C%0.0FA!+&9G8|J9|8M9*)4T4D"@1H!:)LA5>/Y>"\$1QEB
MW2DR_YJ4(4ZUUN-#Y<|W^|_)EW6*K|Y>URDY/_5_EODP^GWFO0E|O-
8KFA\$DV>=M:3?KKW"WG^E|T;W^^VC|EKU_: %Q=7ZWF|6C-: MWYG&|
|Y&Z\$\$/WQR1W9R9?9VDN>X;AP|Q=<\$BV6A#Z|IQ|7|^N*P_KOOPOSN

M/N@'=4/OH,Q6U/T?O/3V90%@S);G/H/Q?WNMP/L73K\$SY;>S8/[/*+=50G
M/^AVAY_5IQ|^L^IT*(L.%VN^UW>|_?PFIVE%IR^ZIZ_O>?ICW^JNVO.4IRW MKMC7!?
HT^HQ06XLV)=+M)H4%U|W4Y6ER*^V6(^6/2CV#3NW<>SS?+!E|H
M5_7IQ/W,Y|OAL+9SNX_S/_|^L%//W^|(2|>^8.&_1W>Z_79/;"EY6XEBS>7 M|\$X|H4FA?
N9Q55C>JW!Q0;HCZJY/X^NSZ^Y9WG6?#!|1^7!^0=*(>Z)OWUX M0;OSYGBZIOMK:0%
&^D^7(E^2GW^WC|=7BOY=K:>I=F|347O?WC|5:L@^X_3 MZEX(_F^?BW=QNN?J_?
R5U|E;>8F|YV4XU(.|T?FHR.?#Y|GP^'^U
M7W0\$|^'^YE|E5<<#5;0*V(XK+Q_H|CUG|CB8,5|>C>WC0,LR3:W=#|YM_|G|M|-M-&
/N|%->==_QY;H6TG)>O7JGS9-NDS|;=|&X>7N1X|EAQN\$&|0TW M'/N|_K!-9+NY*
<|_GE8_X_G."MM)CM.T0=|W.OOY0|/E;CE'00 M)S>V>WF4(@_ZY#C:_GBE/I2V<|S-?
A@^T5|M-Q>A|N?5<'UG8/^@_EY9=SH
M;@/.6S\$Y|D|X8^DYY5A/(R#|;M@X=OVCBQ81^P#|;M@T=XVM6\$LA'8""W MPO+-
Z;U)MWL!>X&|&XO_\$IUFE<<';\$11FX\$GBVS#|@/'%MF'|/^@74%Y'1 M-QN+C-(*O-
'8#=:;?|G1V*^4+_89D_T^8XH|V'S|?/^R'<P|YN,T"K_YC,#OML96T-KJC4*?@DIJW&E
G4=L\$RR#E+0\$DAX254V4(FM MK|WX=?
>&F;ML|KXXIQQ;@Z)%P9*XDL50@F=WNQV!9XA8:>JFTC5A\$UX/9^M
=%'EV77G|H|,*@,1%*VO461-IMH8M|H_BU_C2OCIT+L@2V:"I/H=5XN&
(&37|C2V2\$QEE,5M-XE.E\$EVO?W(@ZDH(\$9G@%"U MR6R@ZK6|BQU40G1# B-W?
V9",B'OG).K;&Q:DC6BS9=C0%04@39M8^E)\$P+ M|B|3TI&M,071
DL7P;38\$K"T5QM_FUN0@26= UIQ|>X7;|0ZRCT'N=XNZ0S74E8C|A+)
M#QTLKEDBV1|YUV5^L3EWUTUJ)B|N1|HNO7^3S|H57#;-X954=OO>|#65RSII M|Y|:-I:
|/4WZ76*FDP5MNE|<:"+SYVQ\$X M*)/E=9K%|=!W.&<|LI3)GLD|VK?CU;S1:OG|
JMBSGB8T7 M'PW=_|G#/W%5GM+F6?UMN:HTVYSM./G!55,MA\$+>5VPI>ID;OK)?
_V'!"45 M2|V>O?.S/3CA03|JZ&.-M%H*A6"|4.)@W!H0(NYU)E%(+JUO;TLZ*E"W(
M9\$U|3?W8@0K)G1R,U>W8@0K)G1R,U>W8@0K)G1R,U>W8@0G).|.@
::V@92BF)H01.:/3L0 M(=FSHY&:/3L0(0|C\$KGG:1YEHX(V&0QV3?A"E-
#F;@Y*M5U//^&KV.Z\$=8/2 MCX?EGV?KS9MV*.M7RX>ES+ICP/ESG)4GBXMMF?
J2USX6?019*/R"_CB;K=N) MOJ35VUFF|_GA"|K+UXO^7?J|XH|Z:NFI-Q5B|\$W8B\$Y5!F-
U.S9@0C)GAV-MU.S9@0C)GAV-U.S9@0C)GAV-
U.S9@0@YBC1>,KY:R@&J\$@Z,JK5K4ZH@N^J5 MREAP>P773:HU.(UW+&|AWBNW4+
|Q@DI/50FDW>M=DY7<=Z2<|)U7>"0:L+F2IV;.C\$)
(|.QJIV;.#\$9(|.QJIV;.#\$9(|.QJIV;.#\$9(|.QJIV;.#\$?(P MGH8<|RG#/.5W8&OW?GWR=/?
OKEKIK*#:O|+W?"8D|T;N|H&RFAK'&V8R'@|84<;C|>#1HA2E M%A9|
R&84A5\$'0U8%WPT 75496?-51B/W#=#E:(4W3VDSF2_7:QZ?CL92|S<^
M<5KRZ*5FSPY\$2/L:*1FSPY\$2/L:*1FSPY\$2/L:*1FSPY\$2,ZW_G"^U=52
M#%8/QE4+1@<%T0<'5H<<44I+=>MQ%%HA3;\$>? GMA2\$0(%*|'7&K\$+445_.
MMSZES9-%7KZAWY?KG7>FEFX:#'>G9B@>L*('!T4.9(Y>:O;L0(1DSXY&O;L
M0(3DR<U;Y|ARK7ON*G<--Z'?",P&9@.S@=G; & V;!N8# MV'#4G8AE-
4|G7\$|JDKKG|0)0"PU>D3-"&N&W'|4;H1,28'/3H'1R4(2&\$!; M%:HU.20<60G9IP<>?
9X=^)|3|ZO>(?H7OGB|7W9\$|W&Q6LW2VP32G5|OGN&K' MOZ.%3|;MLSDN(K9P&Q@-C
:F W;|F8#LX'9P&Q@-G ^YEKY&"|5
M3=9JD#)5.)0|A.!C^|X9;V.R189=5|H|Q/N9HV+GO#C4WJ58Z^'^*D7W".BTP3 M7'>51_
53Z9:#F=**\$T#U!'4_4WLL+9/0|NJ=3D0BX0DA=@2I2 !A.0KL4)
M5ZR4='EPD4;7ZH("E9T#8V6\$J*H!744;CTK7-5)<'EP>|3NK|=W,SCO?/CO;
MK#>X*+/%ZVLWP?WFX!'\$5"LSI!H7CJL'|JWK%2O_"_/K._LP.AE|M+ZQ2+9 MMV2"&
(H\$X65,H|*=BOOF_"K)|?) M:=HBHA?
58#890#,>C(DMZ%.BA7^J"&.2#K7Z71+QF@LLV|QS4%O6WWYSEX-X MUL?
09&@>.#13B"1:5P!C3"V,|!6"M|;-8+W/-4E%>CN,|!12:K->ET0&0SH! MYJ#!(46EV5.
(XZ9E-+;6U*"G@FPA9M40 MK;1@I4:O4U1)VNT'Z*E8)00(ZK8(5.TUZ'.&")A-
K44B|3|M6*<'VV>M|3 M|^*!Q_?M|O?-Z;><J8ECP+AW9%.:|*\$0J*;Q5LH)HH2"88"0@=
<0TR463 M.T;4NT#D @-*/16*PTDFY-\$KRHO|*\$(60|T468&)2;?I-/ESMCDYH7GY>UK|?
(ZS|^V.|MK M&D?KZ0079;+L;I9YZ#L;|XXL;,+O3@U"6^%4)_:T&)*31"4+\$#):.S.;J7R
MY3\$I%AY|<>/'1T/V?/?P3 M5Z5?+O#;240>>0P(AL
%\$7|/4F3V1TW<(S&OF>_VOT,G)7F;H M,1>!'%"?C % +S9X=B)#LV=%(S9X=B)#LV=%
(S9X=B)#LV=%(S9X=B)"<\$_SQ MM95(&
(@('&\$%4X2\$0,*)5VDD+F**B|G!*G(2#5X2*:KAIBQ-V(A.509C=3LV8\$(R9X=C=3LV8\$(
MR9X=C=3LV8\$(R9X=C=3LV8\$(.8HTGG4EVY LZ&R|S=AM!HPHNZTE8M\$JM>_E
M+BHR.(UW+&|A#B*W4+|O@DXO*H|N|O#AD6C WN+HD:5FSXY"2/L:*1FSPY\$

M2/L:*1FSPY\$2/L:*1FSPY\$2/L:*1FSPY\$R,-X&G+4S=F+B&AEJB!SD&!D M3I",BX
>=2:~?T9ET^5F+B^B*0 M&^ C&68102@*5A;(F^V|9|D)6K7S|EF* H
MCWOM+KA/GO|VS>VYE8A#>F+"&S(R(YF1=|5(1=EEI5WW%|H;|SP-!*|HC9"
MFQB4*/MFY"X?~*NIH;QR'@|7\$49C|>#1T*?!%8";U4"8|.-%-H75QH?LTXR
M5+^S!BJ,QV/>NH?|HGR_K9|29C)?KM<|AV-I0YN?.*TY-%+S9X=B)#LV=%(
MS9X=B)#LV=%(S9X=B)#LV=%(S9X=B)"<;WA?~N1)GNT\$H+)"8PK"6)! H\5 MK?
=>FF0NYUNU25D%Z2#JDL%44H!R0!"B9**4G>UVP/TRW_J4-D|6>?F&?E^N M=
|XYNO13801G61F*AZOHP4&1 YFCEYH|.Q AV:~CD9H|.Q A>?+OPY./1+7- M&4R
7!,"1XAD&HS\$J:2.BBQ~DXR;%'CSY.-@2#^ZM|OUF>K8YH56_*SF=E\D&K 8H
MWSYYCE2O?<7,J|>\$'O(-PVQ@-C;F W,|F8#LX'9P&Q@-NR-#9Q)^VHF+:#W
MKEH!'D6W65F2D I*4"(:)V.0T=;+F;28D9PB|!)\$!<8D#|S\$Z#YFR2;&|PH5Z M.9/6IQX>?
9YY^)^18>TJ;9_450GN^7'5'IG"S6|C^5 MN\$7W_7=N4HMU|,56O^<
M%YDFN.XJJ_|7V8(F6DPG2G2W'H^'.W"6NJ;^C7IA!,AP9C@Q'AN/NX9BUKU9F#R\$)"29Z
)2/U|_M7E8!418'->HBL|*F6'F9OS*94\$HVC;^A|=?Y-OU7T4+*KCB!0672N^3O-=?S
M3JT=8:~!Z^W6%!_%(F!'~B!X)HJO7E8*Q(\$A1PVT+=Z.5"%"(&C~5Z.16B)QR
M"X253.!X*1M#FB%|T)#F9U7#8G-6 MAKP4'D(#*AB?5>-L-
"!D#*E0|B~%K=RNCDI+4R&X;+O7:\$""\$K*MWN2L4RQ;
M|I1NO5H3KL|7|GM\$7C|6^<|/;|^QX%,:8Z.5U.6/D, ?+ P6R*HVAW;I('OE;
ML%PM1\$P2R%0EI--5.=P%D/*683H MNPQ&3XUG/PYVYR<73J, @7'/0Q=559QO@X|7.8.)
MV*W-,1Z2DLHEXRC9O-6;119+-26@;A9A*0(*BFH6B>=2J!HRY5#5V?B+W>S
M/L_OO/AHZ/|/'OZ)J|OV/EMN:HTVYSM-=DPA|KH ?L!P;;0(09JF@/J@C-@J=FS
Q&2/3L:J=FS Q&2 M/3L:J=FS Q&2/3L:J=FS Q&2|K07J0M-#R@D.ZG*7=EY-JF2|5-N5_V
MZH_-=R\$:Z/8|%,5<5* @ 74U0
MK<>0G,S2;748VWFE4O_+9|TCUX|O"%FN+\$WZ-.RC|4C|;%-|(!O>J;70(3D MN?
5HI&;/#D3(440<2:,S1480J5OW;@@A=C-9%Z/(-CI90MIW1V8Z7X)A.X|1=ECW,H?>
|%GV+'N6L;|H M4V//LF?9L^Q9%G(<*2ZD;|/KI=C46|LC!"|(\7^>"VIR.KTO@L.,6UOWN?
M>|/<00U&?P-#PG;;=O4;H18XT7-1O<|EVP,V6\$<\$;+4|E1",F>'8W4|F! M"#F*61R)-
A.CZJ"FZ,"\$-AE+W5;5Q::JLC'5AZU9W\$T*%1Z6?YZM-V_:H:Q? M+1^6,NN. >?/<5:>+!
|AZ6R#|Y.LH^%"WT6"K^@AYFZW:B+VGU=I;I?/KW M@O+R|;)~EWXFN*~
)7|?"=.3S/L;>N(7D4&4T4K-G!R(D>W8T4K-G!R(D>W8T M4K-G!R(D>W8T4K-G!R+D*~
)X7G4;_U"&F*H!DXJ%&!. "%:6B|%):M|4^|DV* M,3B-=RQNX?8;MU"~^|8).SU;YI-
WKEQMP|\$@T8&|Q|A2LV='(21|=C12LV<'
M(B1|=C12LV<'(B1|=C12LV<'(B1|=C12LV<'(N1A/ TYZL|F6N48O:E@T2HP
MR4E(0FM0EK356!U2O?RL182J?!+M-240F*(=8-490K4ZU%2H^'CEPM=/&>8K
M6LI>>V/K)T|_^U;,%XN(HR'(|'CHE0!UT2."DB&(H\$ 4W|3@1G:@V*,">E
M.@S'@|_QACNF?+^IGM)F,E^NUSPZ'8VE#FYTXH3DT4O-GAV(D.S9T4C-GAV(
MD.S9T4C-GAV(D.S9T4C-GAV(D)QM_>%L*RIR*OL*TB""L48!9M1@+0IKC')I
MNTNUPQBK5=T22JG!!"00O+801%2HBB/1/>#_MOZE#9/%GGYAGY?KG>^H@2
MTQ@|9UD9BH>KZ,%!D0.9HY>;/3L0(=FSHY&;/3L0(7GR|<.3#RE%,&@T")\M M&*T"))
<,R(I=M8=+U;I=E'KPY.-@2SRXJ|KWF^G9YH16_78X*SJAQ7KVEQJ2
MC^ED09NNTKCH=ZSIYO)>CF?E;T\$.^89@-S 9F|.!V=|AK1|IQ_YR:U6
=?:/4+SG&1:8+KKK+J)9UN MZ\$VBU42+Z40)I7E0W(FIU#W5^:LLSQHNQCNA|UN_|U
M7=_.NP,_.JNL-|@HL|7K:S<* F:WMZ"F5NVQ&O@O;QN>.3 D#R<&^1>FY1X>
M|%:M33 *=~"0-1@+@+4:,#BBK;Z#1&)79!RYZ3)|MYN^KKOW^C"\$
M!*AD:G#TFJ*PI9*Y/3A:-XUJCSM,"&9D\$S(R;D<6>AT>EH54-O5AF,B@5" M31+
(*W(^)IOLULX_*:&(03FHI!M_:XH01+=Y4"l:E1P(\$^V2O|=++MI-'ML
MVWZH&;B0N8Q|W@P/ YH%:)+H,@WMOJB6CPL-3@?DL>HI(|F|F;BUD%%R"7 M8,#
(2A!,R6!=|H/::*VWFKOMG|)O*K%>'Z
M;/6^)/%DZ_OVQ+SV_L:384=X8,N!C(#F8\$|&!"!KDA0P\$AAA2X.KDQ!"2N"2 MJ;J6U
+/K>=I-P'R_D-D.PU",X^9Q|QCYO'1MB|2,G' *A2X|&4 H((\$J0@
MBUK5:K8+F;/2AB@FD%56,,JVU|1N77N7|E|0M"-Z7#CDWU)-,DV!+R|U*%F|NV9T"Y9-
"AXN5A|E2VWDW0EG M7CU|^NO#%|I.?GGR|_6S9|^_G#QY^NC>'4"V#UARKD_^J|Z7?
ZX/X^H|>O;T MU|=/7S|^==*^>_GLIR>_/GS5_O'RU56!W1T=8SNB?SQ^~^NKEY-
EODT&EX:=OY-V/+Q>HIPZQ(W|P^|/H44&R|,VPL_>47EP
M_GE2B'OB;Q|>T,YSCJ=KNK^F4USAACY/UU>.O=VMIZEV;Q->Y_
M>/U5B^+ZCW/N7HSZ;Y|2Q=G>SXN_?R5U|E|3MW@53=XB;H7@A:~?G>3|QC|
M^=VX^_U5QKIZU>5VK"Y6.|B:74U/?;0MAKFR;6|H?O-O_D?OKK\$|WK1@*|
M&RN_=J6>MOG"Y!_MGR?KR>,6|Y|/ZX^Y7<>|V'&#N,G1_"CAH|=I10 MAMG"+AB|"

[[9SV*4+OB+\$;?][7Z]=+@M3RE&.I4+168!!52'%]A99B!1C,MK(MK;*PO>X4+
(69!KG'&MV#=#YVW,12%'!.'2 L509&QM39?1"Y72K%+0-@F&/9;\$':YCO[-Y61%]5=Y-
J=^!_0N[-Y^VGW?E61-SM94)K/%9'E% M^ND^S]Q',Y4=VBMB_R>?O*BY7
M21[[@B/I+^R1L8^3IV2J?X)HFW;|XVG9\$4>BM]5\#>P<_&Q-*^N*[QHT%]/F
M6\%J2"4*D#J3,=);=&D7.:M?SM:S!;W7CY9OTFR!W1%] MU2^ZAX1=,J9;&TR+=3I
<3>A=]STQ4@?MLK\$B]>KPL&H2TAN"2J& 28H 2T(@ MA>2%
(Y7U3L+ #ON_ ;+YWG'GUFN5V%?V;JW!YW!|CR?9T!K7.0?7))!H.HM_JYW^1YXUX1%?:
!&7T*.XK3F'>CM/)=]T6]^-
M]WE,NZP3S'^L@NY)1RU#*\$742ZG|OO67WRT7,/>|OM:#C14ZN'E>_D@)=)Q:3J225+
M\$:\$Z JD)M9 5-41?+01OE(SHB|JTBX#W5D@5ID8,J|Z.\$[L'&OC^2NU/ANP\ M\,5%F>!G-
SB/((.V&(!@7XP@#JGDFB!BUQO>F0A1>P-)15.5"=\$XMXM8|W/' M?
3Z:/%R4ASF0J/O^*>WJ*7^<:F!|I0PLL8NY4"1A5@5VMCFXT5+,*VZ7EI
M46QT028A:LQD)T'O[2)+3500/G)D<=KW=M*^'^[>+N=:9NO(09M//&.L+<3F6MB)6*
(@,ZQ6|T,0%230&.=L(+ MBH7T3H+LC\;^,E_SZX7%UVWD>KZB-[-S-^LGG_R|HP',3?
4^|W/BPEI&(Z-Q M>&@L+0(GX|\$T>]-AQ T%="FD)14;
(OQ=Y+!ODLT:B49C)S@OLUN3LL%|S\$O) MY|2MC>-ZY>,S&8|4/S:R&&6L2:Z K=&";3)
L"* 3%W"6R53A?^1H'N.Z7ZS MV:/FLM|DST^|HB.A@PSU:;O
F0TC5W*@(+:)J:A!;D&OU*A;V.H2!'06-#K5
M)M%HH|4_\$O3N%TUJ&L+8'ZYQIOI6PMCGJV6W:U4S3KLC6Q2;::WNZS66;:V<
MTX;Z//5BLUR|YP%DT(C>2+OGI!;I=5:0,(R1:G^@0HD0"%J?|_>V->W#:2 MY8O^?
S\%PG?Z=E4\$4PTD\$DO;S="Y:6?|ZVR_2S7=+R_*A*Y2.BF"#9 RE9|
M^G=.)@""FRQ+E\$21V3'CHD@LN9P|S_D=&;P98G:14#Y?<==O|Y_|&S;G1|
MI3_INJS4ZPM8@UUIE&C\$^6%%2+RQZV65EU4NPALF(5=A09)"BS*2TF>Y8+D
M:2R%"<-8)VN'7W>)\#Z2K.+I81UR^1SE;/5]|@6HGYVC@!D:4=7 EQG.-"1M?
M15V+B2).W N.U8E|CC'CJK@E'::\$/QF#!0,Z0 DYAH55A(LXQ&:"<9&>^ M=?
|:7\$!ZO(3
9CZN^E"VY>GORL#GK6,7H9OLOT:\$P\$1>DR!\$I**22",Y#HL(RW*6JDRM=2:YB_UG
M&:WO(GK:=W' H|EWX^KKV4P[-^F=P=M&HRCRD500M(Y|*P|4;G4I%FF-*&)
M9H1H4G.DHSP-.5%J-)0ZIWDRCZVT\$J/7F3YKDKW")\$V&"-U,&4V-
V!QZKXMM6.6'C05U>B6*L?57WX9N5WGT:ND|4 MQ3R1A2%QFA2\$A6\$.KE
(GI%*"ZY4IG(J=Y,T)VO,NGZCW7_?3SKV^|QSWZZ/ M_NB(9A|6W@NNX|H*
Q5<(9,B8:0@('\$482H'(906FBC)RH3O^+?6N4#DB-
N+180%.^XPY+P*|'"S@VCNJ0R\$%B#,J4 3& M,>%)\$1(*)GI><,ECL59|MQMK?)R?
(,K1W*|IN%PC/&#|HB>8#X7MJ?_>Y(%-QC22|Y MR*/K>'CY(_=I6NNE|J9O&IZ1ASF5=,|
(IG:Q:6M_(\$.-4.7P2C\$19KK11 M.@HCC!;-Z@2Y+Q?
%XRWL^-6EAQ6PHG/TO;RRLK5UXB8U4H7I!);6#&FC0D
M0C!*"BUC5H1%GH7%@YF^#R.ODA\$|^B8D/BK|*-9N=|82U/I*3^8^*GW87'6L
MJN.14A23).1)')("6J*)&\$ITE"l,P%J*&8/Q"l?-PJP(J4F4+\$@1|92P4\$>)\$RHGC";
M9T5JP\$Q^&+MZ1+LYE2V TMD\Q @>VI@|WAN;4M8'U8^%@8|5G7R6!D@ (9,R
MUB2-4R\6 M|TLL"L-%;)0B- HCL;153+C2FBA#LUQRJFF^\$ZS;)Q.+=)2'/OC@@@^2/W|!;
M6^X|X*|"Z\$S7_5!/DNDL:*IQJ8)N9PY9B7U_|E|-W4K-F3C-=,0\$5\$5*"J9^&
MC.0)RT@L4VUTF\$=4/E"2RC)(^YW.?F|M_|H, L.(C.J" %S1.9IV&>+|\$?
ML.YS&5.2LRAE":@Z*NDNG &0!MB*Z5-=795*JU^N?P>L, A|+3HVL;XJE|B
MGAR=HO/>@)? 7@+OOP061G(!0IC\$&0=I6H01\$;\$&@:P*;),&Q/O!"G|Z20P M"&!0&5X
A:9Q"9Z/+C>>O9M7|UZ%-58W0B@WOR@RW&0NLTW)O/3|51|J-MZ M4-/UX;:
|I97%4!O"\$M>@|>I2SK1RX3"^TW7Y|KV+M|SRG#Q26+W M3A*"S(8^U#IFXOJ
YF*Y^|H/I?_S.G\$3VRS7|P=,O#-.L^S6MY(;#E1&6"
MYJ*J9P0H_A*.,8QL7,)%_@SUL!GG6*7DXT3?8|&9R65,*(U#/-2-B\$A,3HQ,
M5&P,5;18R_F_BWGX25Q:9OU2M4;B&?+R%V#E|PM.WI6A2--1&OE\$?R|+JWM/
MO2S<,UF82I%Q@|TKDI@PSL!5EEE.M&\$R\$EF!X 6|.(E\3%F8)*,|I9C@/K9Z
MO_9OE=1;-8&I|N@ 3)T">" |:U/51\$Z|R;Y,^3G|P:NI_-T#2F2@C0&"K, M"3-
@">BW&X^:CL7GS
M#V!8YWP\$BW90VL1'8+T@|X+,%48R'6/+!R*9P>9M4A*A\$D5HKD6:&IFP;VH
MZ\$|V|Y,+,AZ->'I8 "D^(OT4\$>EIC54|LVMK#FMPYJ9(IEYK^)QRGU/^A)&<
M1(8%4V!9AWG&\$'62\$F%21A(3Q:E(#*BSG7147HOD?&KEP:>QF,Q C;WM1,*N
M"E9//.%_3|X|<6N%|O|)W93&86Q%IH8< H(*R@#L2M3PIGB)DUCE>VFE.?1
MQ2X=98D7NS|0_FB8 =.V2BTHKMNXNL<-*K,J|H|^GS/(U2K4B8@*YA(H|C M
08|B73&0&<5)N,|:;^QI0<:Q)^+2<:_GQ=:U7NZCPE'T7^JEX'Y)P2(U M49XF&0K E+";,

<+S/"3@@<&9K+/S:@.TP#_M,G|-E| M-?,V,:KF?U2,V%H#)>&\$RFI
..9&!)YF!\$M,TE5K%E8)+M,'D4E(R:OJV9W M1;-L
>'>GUQ">N/:2|UCDGH>+LM'9\|@(MN6)Z%-**O+RPH?6\E_>>%XT/OR
MK,+QD5J&&I9RPPM2Z,P0EFCGXP%G4:9Y%/#0D327(09X5A&.68)S)'>4A;F
MNRSP>7 YF(Q@R%X,^B#LSM"OWIY|^N0L|J|LKF82!^-.?4|XU7_.50\$52;-
MTB@BDD>(AE5((DPDB4GBO&"<"A'NI-!F""+SOF6TC^;L0M2Z^7VB\$#4&E|6|
MTJ<39;_!72(A4RU9-&X(BQ6G1GG:3I885HEF)%H5140 B))\$
M@C!-.8US4&SV+;%JFL<)-MUV#GKRC-&"D,YX2Q#)26D@41!14QE7\$DV\$YAL#X|-O|2?
1'?_E'+BZJL2HG MY^^J>K.ZVI7M'1T6E*./9'O1Z\$7C Y_HZ2Q-BXB2-)0@&E-
&2:%X3E02AX7@ MF8K61>-I(ME/)!JCF'O1Z*/;.XMNZV^ZEJ7++G%!|FJ*1.7+^SS@B@=
<^1\$%_MQ)(LS@P8XX4P8&='AA&1*DERK@N3FZC0L=IUG-
R>G'YT#/NVY62U*TTSTBN@#_MCJ0>#,_R*%XI>*JAN*W.&&&*IFRG.?Y6H=?4/M
M#RD4):D62A(@IDPS-"8 M\ 3!T9-4Z(3SK&/B3O;@|'=!5>Q@66'3|^+ON>CD#_@4?
&>ZCD?|/<"V O@_M_1?_D6&9X5%!3!;!2Q%'\$2DR9HC65.@HD5R&.W\$IGDX
)Z,|/|+7GP0|M,/Q MUA@M;:X.D",LUR30W^2%F)SKH!8S'9CQ7,|F|O2J'8#_K'-BL0#Q
^;W7 &9 M^^|07B=ZG?BT.I\$SR>."981F"27@3<18QA42)11GH>*),3M!.'\$2XZ-YV|J|
MSR F/DY03>+_OUU(A,^ZF=6EG&F%/YQ.U/(7@RMWKCRCXVN=X5T7+Z:|F-Y-
M;:T+\$*N&:1(: "LZ'E@7A,&1VX;H\ S\$=^0C3PWHX1W6D8M|V MFUX>>,923B2L1*/QB
4|F=&:/V.=G+IG!/?N|5Y|/*00)^?>|Y CS7E"12 T M3!."Q_0D#PM*),V-
\$(SJB*_!0MS%G|B72Q|DZ|)2|UMN?J|/?^O\1PS<8?*MSRG\$725&)7S\$#BP-
UZ<|>=EW=++O<8S^/,IY\$8+93FG,"8LXF/(9_)DE"Z)
M:5K(M0/CNQC|^RI+;^D/C/+,%WWY|XS|_|K6QOS@9@%A89A33"|JC+!U-*
MUW,^0.8#9#^2WAM%>;JC C1:J@E#+2>P'IE&)HJC4-,4,?YEW:9HGC"F8E+H
MB!*F,PZ^A32\$IHf."Y6+""G=JC;=H4L1T>./Z#5OZ=!*"^|9>(G|>;NC@_4 M_(F@NCO)"
Q643RO\$|P-9JH)-7*B+6VW\$S&N1(&C+THRT|BZI044B /5:D*\$<:K #XAH;
@36H!6,P4I"A4:EL3Y|CA|(+*TTB3 M4&2"L#B1H#L):G,TS 34M1J-HQ-
'2S):H:/GI=B\|42U\$O06YT2 MJ#A2W*0D3|@D8/\$;4N@|(I\$,)9>19H1GJQ)4TAB<
0Y2UT0@=6D2(H0IV(@9
M+Y*\$)V&F=WOBNK,BZA%+'JV0^ED+T\$V>P79O8!,9WM9%V |OX '\$|\$&J&-AX
M_.6_7M 7-|SA3EHVWKD4W74_%;!NM!3??NA|G/7YWM,KAU-H.';JV& >J M;:2X:N8UC
H0F)(RXRKKTY<:87&%1>I|P-CQV92/%4?*3;>E#3|:<^=ZM: M=WTEX(NF!#??
JKI@5HM)8W1=.^0L^'&B77CE:SF|'|3|;FN@Y|B7P-Y>"F4 MNXO |H> V7U|;
(|3KI,9"Q,.-:.\$E%P2K)"|%1QL+,MP7Y+?=J@069D>N\$+QL.O:M/%#9E'
>Y0D58*\$6G##-0I S('9 RF1Q MPFB6LK5ZS;09J@|DFU)Z|,2PI|J-5+,*
<<*-3PK#S.\$|9)S+-C%)A4B0QO>^1.K @ MNHR?<4(?S>^_
/K7<=SI1OR+O_!|@O5V%7?/XR)6%EU?'O14'*J|,G:99PC(2 M928G+,|CA"%DI
@%F+8JCU+|V/(|HF\ H%ZY/+*1V+OQ".6,(-:S|K:EE0\$ M50&O<:V.O%Hx:
(|Q:F&|HCP6B2YB1BA3E#"94E)\$(B)QFK B+K*0IVLM*7|4
MC+7,|KGGM8|+5GL_D7/,#OUE/OM0S?X_;8_J=J0;LLP'9;W0.NZM/%"A%4>Z
M4#H,2993#KXW#4EA4DYTI"-#L;E.NN9|_Z@M^T1"Z^C|"G0&+?Q7%&-M/^Z%
M.%IY|XVON^VLER;7#A('|#(|2=/L+ZOO?.HR93N2_(Z3_RGZ.>BF#A1NJFHV MJ6;:L?
2'+W^DC\$K*0TVB">+&\$HT21G(:"2":-S*341:A?|-|NQR_'8G+^7R_T
MA/Q^|A03N4L|VNQ"=T5HI075A|LV=1^X_>AV'R!(I @51@1DA %-)\$:YSF\$| M&)B
/(U3G1=K&&X%W),H06(J8|R'\$BXC15@BLRRA\$5L.S627_M=78A:MV;YJY7A:@C?
UA*#G??WCWO5A .HK3|2;?HY-)X"9AR_/ME.'M,&<@ M!3\$+ONH.*
|.)/A5@0!7="P0G'(JZMGU27"F=? !N2/*1@|^ W0GPL|ZNDUQJ-|X=V|
G3F5|.7JFRF8|%|40|)=54*.QT,D 3+MU(VVB.^>^?V96FNON MA?96HB?
JU;1J2OMLR|CEE7Y55-|P/>"9+WM LF^WM,'2|ZW@?FY@NF30P5:T
M_^^^7=0K=DXY&9<3&,4,1,E+,9|5KY9_@%5U7|MM=C%*86!N+|7XJ|HAN7KWX
M6T|0|9.|/0<8/=K0-K>|G;+>-WW|(G-4\$7.|2_8F4(C|,+.?/E|.;T|O M@E_>?
_SR|>.09|'|#Z^?0H=8R|L*N3|FU1|H4")Z.2K8/TPY\$1-9BO\$?P" S
MO1|+|^'CE|=GP9>/P>N/'|Z|_7#V|DWP^C|6R8Z'|_#V<=?W|Y_0+C>O?^ MP^F'U^|/?
PU@M|^|>WMAR|GST;-|HK>|72F+POP/>)P%-0,?E7=6KG%'R8
M7^JZE%UF;J&D02<@HU00EH.1GZ=4\$A,67,D0_#5Q+|R SB?X131E|!%| GL9
M|:U0*I|.U!FL9&E**2:S4S +Y|,92.9/P"(23,|O|,9?QF!0OPAT(44GC:K
MYVU)6SD|P_IT=MLI_!|=3L9'|+Y"ON=X^|HH(WH9*,?^D2C^66/QH(DB<|;
MD"AMWMO9_!+V^1H_&U!HL"#1H*/1H9H|%)ZU(6|O=OX|CBT+J=V!6'5,!CR MR|P!
(Z|Y+DMT3P\$| |H1M0I^*.LO535N@O<3>1+|J&+MAQ=!5=OU>?':N4\$O M?@Z

#\$7P!FS4KZ+6(-[J:=4&G2ZT4/^>@_VLV|#3636?701G,+|W-9H/C:Q&
MP6N8OJGJ22E.@B_PZ/;)P87 /\$Z0GA AH+9L+C#Y4|8PLQ5;@=35-MM"
|U#+G|J\$88R&N@ (CV#/_'6RU+6E1G/2YA5L|0HHP!(1\(+:OLL,Q_C6^%Q
M,UU=XL5X^|F>V#|&./H+/9ZV0<.JO@P:\$!>PUB!*++1C=05*6./0X5*W8,\$4
M|MQF*LQGF^K>G-2GX.W@\$HGQ^IDY|&RM0A|<%Z|N-)B+.#SSNO+@?Z:;|
M>H%7D+%7P:?VEQ<_8Q>5J5U&K\$FK"G:|1VYGVF6;SF?+|Q/C:Q28-MI9U)7H
M7XDD"!.)VX4(\$+EN+PL9U:R*CUS#OG(KD^|7";FLO29@I=G_R@?+B'X_QT
MXF'("5^K^E_M*HZ!NU&,"F4AE4>|>>XD!-DA5\$PO1#U)8QD;@|Z1LB*/44" M-<F
ZW@LHH)QD=|_G1K+<%'MFP|@%5*D|J2&|Q|K&"\$L%.FDBBASP.,;C15O?@*+I?5*2|'
QM#SO!,YW"?ELE4L_Q
ME4Y!G|^=O&@Z4_#WDS,|)|#SVJ:&VLNZAM,H%RI|+\$#KPS)^L773V|C6,!X#_M9A-:?
%^6_(P7^|T(SCL1M@&TQVN_IP MC|56&MU/^DSMPs#|QF\$C?
0JD)EA*H3#N|;Z'AXE@@AL|M;J>&V1!6*8@93_PKV6%=&
|2AD\$X\$V'YEO7ARM^NMPOMK,WA|Y%'2;)WM1:W_M&*%6F8_=,*H>_C:V!?
A0|\$XT!Q#-BNSBZ'05CK\$C|B*VRN#&Q|>_|T(-R/PKCK5G%5.@|WP|\$3B.(^V!) M
&V3+#<)?934@TU:4"5L)9CLX%&H\$QNRL%*T|1^:K>2|?W-134?HT,'-""Z
M,?|S/EG)>UAP^D#?'4|H.D\$S43TK7H,OV?+@.NO|L+^YUW_J|/+^4>A_#U9U
M>4"GC0X_6|V|PO8=4FX4DO_ ;O|>4F,AUX^O:6B|!\$, _8|!1^+?#T/P-W\$7L
M1XG|21.:3FM8Q!X0|K#S/A=L.|H5MMW.@|QYPF?/-VK@Z4CR277K3M*WJDCF!I&
M&4T5X5F>\$A9A8BAEDH2ISG-C1&CRG9QL_ -|HC^9M,P,??(893=|AZ|?|=Q=T
MZQ=GCP7DZN&^EX^=X^IL\$-&%)C2VN7,|Y0M-H-G=!"O,I;5T M5_FOK0,<%Q(
B/_DFX&(WY6FO|N>2.'2=/#\$|WM-.BB_<|N>@|_R&B*1NUKWT+<|_%2|LIM@
M&70Q1'LYS.&|M=+3;)M&+%+G|1'C-B'FZ!P1T<|+9\$VP>GK3_C8O|AB7M M_%9C%|
|&|!L:SB|QR22>^%R4#8;-T3E(Z|N-7R/@7.8|YVJ4YXN.C"%=B+
MU1P>C3'N=8%6SL!:)>P@IWE"&O35!-6W=UR|:=W,I,VVQR::H4\$R8C1<8+PF@<
MDD*F!3%9Q(I\$QXG0:TW" |V)RO:Z:67/-!5P%LP*NTV|_5;./M9ORF9:-6C;
MLKV|LK'&C|7M=3L'88|AK,;%Y|^347*;>=PZH^10C;NE=;5DUZ6.O|Z*?VP-MM?B?
KRLFT9B.^OET:#!X0@="=|N>W%W5F#-%'OKTMC8+>@*G)#+PVG-MT!-
MRDY.M@,&^VFO_HP,2U._;#3_2S7_#^+^F|+V4+H:<'D5U1|9URX M-<6CF
OM=N)BF|JN=9=/IX(YB#-,U8,|SRM|7K=IHJ|Q3-Z=XM;==0N+8,-U
MRZY+FXG@Z.2&IP-E-',|T/GJ(24)6T&8:XD'K=&DMV&.*|UMTM&|),IV>O
M@RRBHWOE..:-'X|)'(2?*@F_QRB3|_8@_G|TNW0TUE2/|UH5_-'SR?|IW;/
M^V4=@'_:/05|-R.#X2|1F"-6/,|V@3MG15XLARM:2BRZW,-"(XV4+>1">TX_M6?
*/KWM/5MU(;BV5K@|OB?2VD1&CX7Z1\$?JTR(:=5QN@WQM|7,>Q>H)SL.#C
MC5Y"*|DWDP6&QNP'=%M_OD|J#-'1IE_2^4DCD#YCC.L,OPPNYS9)T>4%FSFF MHX
ZJH|*5\$;EI W;282MM6&| (76V8P(7S>8/7P>8:|F>V T?U"8RP!2|0\$|G M<;4N6-
T'P/YJJ0^:-6X3VV8/7O=Q(.#|\$>O,L:>E7+(8) MHO_U/_.(LU>D_>_.Z|
<688|;,\$VATTB<9OM3!9WR('#.W)!GPWL+@VNSS' MLJ|T94?6|+L?6_/?)-
TZT8!+6FLS|H|G6V/<=N_-7@-\$-?YTLG7|A&9^K:+/6TD)HL04M MY;_GNND2L/O?
FBY|(&@&)|_G*MSZW8>@Y)Z/^E/Z|D;<5XNP;Y3"0_S7|MZ3+DJS:G-17(&#>Y/_D=W-
#K@Y/@'Q?:&K06O2BXX&KM6-U/D.V;43.M/1*=Mj-
80|AU6GV+5;3.7;#YTLTB_1WT\$KAX|FGM:|RA;:T^VW&|>:C2^1_ZWM,MT-
=&C"5\$^&N:84|ZXF%2NT1WIW3G8U%W|_V1=RPR7)IY@0?'MIJR(|+NL&2 M(F;ULYQ5-
=PQU=+6_|9O|*V)WG0X"5JV|/8<)5DYN;|+Y(+MP";@?=N<@G
M>/XV.7>GS+.VJ,'>C6ZU31@>+FD)S"MM9NSW#H3W|HAGIY*HI-
I"RL/%@>I|V|.7BW69'<-E.:QOS7"
MM3'7)7!5G"Y^#L*H+;!O1KN5<8OJL"V1KSQ,|BORM7'KGSQ""LN\$\$=)35_6V MP#I
/EIM7O=8%793^7/25*7V)3,|-BBG;INK7|IY|=&%*/#='A?
3^5,&P;@ON&*?'=M=,Y:'CT0)VKW\$?2 M,.5K)7OKIBE0FT>Q%&&#(9Y7E?
I:CL<+^V3E-?CBVsx=IX+5S>L36:ZO|Y> M1"".)A@Z|"
N,;%4=Q=|UJ*>8&;12B#0DD*_H"?!F|;RZ7AU>?BW'3HR|\$8Q ML"W5%G\$/-MG/|@U|?
M@(|J(U8DG'BH7:2C%SB64K|>F^B"(T1|T+8AWK,^Q
M7'W!"&W|=PM5,#CXP_/!86!6+**D+B'3FCN+TIZV'A#>T<>7UPI^MB1B#M(O
MEPH+|HZZV6RIF#Q)DCQ4)! =11EBF4U*8) ?3(FC-1|I CO"^I_5ID9 I*| M<5@?N'@V|>
|F@.KJ|?UM1GKTN73=4@>#M;:G/0=E|HQ^/6Q=UD2,"5:0=(MS
M2\$MQ&|/F,HN\$X9F95|CZA;&B>|O|1_N7&J0X|NJSFU1Q("T7%:U6V*K(3KZ M-R-
3CJNYR|.86U&|= '2J7/Z!??| #|H^&R3MN4LOG|;5/T&'-%W9=#,;R'>T
M9U>&U("QV8+,7L8 IRE;4YT|4=N&*%4.H7;C:-PAQLM;JQ-

CHP:'G4!4CD)+&7'1+B\$!I4P<|T#:YAU6=7\Y;2 0-@|\(3
MU!XVXA)1'/YLDZUNK)I8*JK_X12@YXDEUENX"WYH;/VU@ULH+1>U##)O5FS6
M=FW=:4Z_>PL7L9G5PG9!'5O@@|9MZ|7&'|SM>HHG%F H MW@QQ?|
<@C#92IDREA"9:\$,9B37*N.1\$RS>*41CD-TWOW*^I6J5,TH&=^NGP
M|FSF4|N;X7/WWH_8*"UW&/W4UL5?2;&1V.=;3!C:\$|3LBGC M:|WHN9?AKN0+-)L:N;
|:;F21.O"HY6O9=&>66NW\$A\$&X0CT9(!CB&;!U|:H M>Q8_T&\$B+<
AP4|;>OTBLE2!;|J|W|8|(RDXGUAUV(|:Sj*X:9J9;|NT+ MLMST*N1#:ZQV!
|0+3"%WEN\$&Y7Y065+-@27;W\$#WIU9|;YOR;#R%2C|78&2 M^PJ4(ZY
H7>K0(EW7X&RR|9L|2W-KM!SZS+XY1+?VCN HK?#L+-I8:G@2U!< M,X?
9U40HB@/AL6N+?A\A8(|8OS?9S.Z?;%MBK#LAD63XBE+(, ^P%Y<#T/Q
MJT'U+J#3QW#:K(|C!P^P"HV*888(Z@11=P>Y|'9 ML\$F;%5_.S((?1M_=;T-
V:SW&P)KJ#;+>D+/EN4ZK.K#_J3!5CYU-P_-M/?QA F-H+13\$U=O^OK4C#9N+-
JY0W*/;TQX\$ _5!4)#@=|E30^MST_N&0W5@* M?5Y.6DMN:&(A>5^)
(AH^.;CX^KLBH)D7_VPU MP59-@L?/6&C9*IT^7^X&#;_JZ!?
>YQ#?'SPJ+>3%"F*IRRYO@67Q>>Z8X'(J MRMK%=N??6^;%_ %Q2^N(PXJ;%
|!LC=HO:HL!(4=<6L&GCU=V).;SL:XUHEY- M8>;I32|L?T.=.W%>Y;8IN9FX1 %7J6B?
X"R%C<|NFY4(|KLUYW75-(L-ZH%9 M5V<-BX7^+)-H-
&Y_C1M2&%L|W|COL980#6GP>.|+VB4|;:'8Q>(3UBY!Q8WA M4MB LB4&2T\$M?E
)+.&";.E;&BSP(WS5#"*)FC!+&34'RI)"\$1U\$42I;)- MG/)=9-5|=FO\#E;X=>4 *A
9YG4|F1|MK|-H(-^V+I=|>#S_@|J&,* GWMH
MNUP)V|M2@VR4#HFK!75RT"G5N.7#RQ)E.B8WV=*/-B|>5CI/6K"QI8S|HK,+
MAYV)!^<_#HW4YOZV%4NM9G-@ZUVXLK-5AV|MX=>'!4HV*0ISWC#"|_J4!4
M&@+36/ N&-)X|'!087 =M%;K|=CE:FW!#=% &)VSAZUP;"|_#L_DR|5*|M)&
M&+?!F5OGKUS.QS.\$^4?Y#W)+SA9;;B\$7>DKJM&E_0#@&Z6I\$PO@UJ
M;IBS7|9!%W&Z_67NIQ=G9Y^0@G"F'|&E"\$#,%NA', L|H0^)^2P=X/I^J+JFA
M|SGH)NN>F|+ Q9NS9;)6#L;/C>(:WZ"@W/?+4+=@X&VK5(6U3 P+-\$1K+3F MQ*
!@;6C;;D&#L/;>YBI7|95?**;7>|F+1_B#F)NVWMJVMP# =U@A%7IP70| MQ^L<>6-
61EV!<7<<(|/-)N#)_W*;&EKU|G&7Z@A^5W|1-Z>,1.RFJ+8=IV5!AF8;;PD(CD M
8^"A|=AA(\$ L&0SR"?MJ-T>D'9E|JU-C ID(C;LA;KCUL'O1N_+2^!62W/ M8Y!.*5U,K\$|J
KYK-9=8;)IEK?X(K\$&^ZX!:%V&|11|LHKA E4%*|./A:30;= M--
B#HN7;FU=MN"!H|8UC,*V&5.GX\$*7@PD=J^:MSHAHQ;B%"%QWDNIJK^24* MUJ40?<
M%M|H1WKLE;|HA/SM<.W#JSA5QH#SHR71|2-TD)?COMDC,0F-8
M/AE8?!VOPNW6U5|TT.B%U8JV|CKX(;:GU*[3#AKUMCV>\$WXXV+)9/Z!MRUPW M1?
>:BW(Z|>PMY+;UCBU"=JGG5?L,AZ)27NF^KT;=J^;VKNN1\O%?0.X0"=K
M3X+7O6FC*BM!;5V: '|^|1)?4!AN|>=8:'.#)P+|!TS/0S6,82WV-JO;JLK;& MLO NFV;N+
R<;@=IA(),777E?T!.66@+1;OFUF)^F-BC\$9R'A>\$)2(G+:: M!P<0IR5C,"5.)(2(Q&&)6
MS!@C%4OT*D%\$@L%D94;2.-&\$L2PF(F,")\$.3.L;::@""+=0X* M3@.0+K/
MFU2NBT/V*>D+W>MJMD\$>CU>JC)VJ:\$W#KL;&|YNOQ!U+LMC,MF:/7A;99X+?
T*4;+L&>)|K68Z&K>.&Q< MU.!M@&0Q7_L1=,TBLWEIFTB7G_Z3(-
#W*WL|B26%">HO'-LR F>C4+O"\$0 M
W#N2GW5)SON=&Z#^0P4|9|N1MS6M2|*%%=2V'HO'JV1"DW_1?#97KHO-5+/
MW02_C=7;8#MB>U^|MZ,Z/O,,|HVOGX6)%QF <"|/8S,>F'(|=I>'B"K"|>^P6N+I%I-
X:HCDH M"?L#6;9=0;H';|^+-W5|P,#9W&5|297ZO\$B_GD2_#JH%|(W.XE|L2ML;|
MJ*XH'N @<;V(|J\$(%Y>VQ2IP1/<<%)>KVH|@V)BBK&Q*;WW#():KLL4F|H\$&
M3|K>V^X==L9PL52K1NT.&E=|2\$29^R?
#@IR|RG+|#|##MQ5RG)\MY1EMON4Y9VF33Q+6_|=DOVQ4/:= MA|MDR0Q|R6\$HLNO?
U!|+;S%U?XOK1&^!&^|Q2ON3@WQ#P*, -T5/LT./<_D(
MUMOL6G"W@\$'+J9H;H!M+MSK<=L|;W|H1GW_-KP3HQ0D?;N2B5TL.7|_Y0
M<4(3%DHB"PIDF,B(%&F1D2Q+,Q/*C(4Z>OKRJ"8+|VUN|= QZ^"%\$X&IV|J4E9"
<2QCHMKO+*N% M=.^DH,64N'2G874U/H/>^R%81|TSH,V'/C97_1*F>H'-T?
H!VL(\$9KQ\$,|V M# ??QF;9\$'L6;3/83X(V3#
L=|HRI&1SP|HFD=4M48J6\$ _MQT90VNHW2'6!;
MU.UC(|JAN;\$V8Q%K=>C|=PN1|/>J;#4M;/##|ERH%KTU^B0.|#X:|_DJEU=K MI?
F%T|J1)<5OK2R MS7*^69_G!AMN M>="=#E/#E.@YC;|1EA+%0#%Z?
6!G>U933I7S5%@X.|7Y6 ML\$LO40CNQOU-PW2_JG?H(*RS.-I\$S44VPU-#5,*RO?
AY9'L4V/9*_98|HXC: M,Q7.'9A#EY?3+%I&6)J12P('I>P\$*
<;T|ZT(|7|KMAZ7HI^F\$6H|#=|K>/,2 MATT\$U@#|Z4+7+<\$LG\$L|SA7"60U3K|AQ?<
ZL:Z^|Z>C&T|O#S-*9/YT|+EW| M5JMH08K9KGI6_U;78FQARMOP

7QW7EL=W=J32P;^(,%M*4[1/I)OQK8XG.A^M*YL^+W7#<<2BJJOI
L\,.)^M!2EU*5BN6U=_RM,^R1XMY0)IOAHB\$Z,S^EKBZJS4;8WQ/U&!
<+^35X/SOY^>?NJ1>US!M9N;7SI>F^Q0(:Y(YN(99IW&:*M6@/*\5G_/+##%
<-0\V3.#^4,%#X%9?7*S>MO.Z@GU1M\$IR.NE)P-^;JJ4?&^
MR!X"E/YL\$=DMK2SZP+7;^54/FW#:C%?+19>Z!HL"V QILV^N*%L!7!#N(NJ
MOKYM;>;NHGN&&W/6S,(F_:CA/(L1<:XR5H*A M!08KBM_7OP\$!&1V<8=4>1I;?
OP->3V3PTX070_UZ!G!9/I M!3BJ+76=-5#<^M,/.T\$_'OZK82M.N\$S\$!4R
M\$2C>M28LC33)XT@2);5.9*0,+ =2JC&>"1S1#)4L-R#CLX*(E\$=\$YV&1%Z)@
M692OUNR_QGR2CZ858!_KSRAY0-T4NOYHSC08WG937X/ZU>J7Z_:ZIKVP>8\$%
M(^HO_17(!JA*!@-!1'C?_!2)<.NIY.9E?@\$@561WO!B_ ^=C)*(CSB/N@.7
M;A6>|E2NIUN;8RU-31\H*-S|EVC/5CE;=%-0F2,,M.K0EW/^Q;P0G,YI%L8D)HG5.F,S
GHB!_G(E)-4TTCs+5PDNC4TLLT00440)M89J'I(@C(#AN8"1A\$5,1KQ&<79
S7(I/HOY8GV%?"&5[H'!2!1DNX1)1_3Y! MY"UI%=#IJ;6#Q!N,U-1-
>_6"WMY->/<=B@M/8+WVBMQLSA!_9"BA K=,@5TG
M%'1@X^X=R3"5)#P6\$8E%AJ?,\$810!36"JC6@:;)92G2= *%+%\$=;;
M)"2764923E62J8S#O!>246^_8?%PHS|AXF3_8R^8HA|E(C!F<3W#(3G1/Q!3
M%)TDX5!2TDEPME1",5KH6U>:>3EHGZ07RG"S+A|MN|:DH"4_YEA1OAD*+T.\$
M9)0DC(LLIQ)\HK5\AT2),,%[E,P+PC)PBT2;Y20S:28,B!G1Z;YIRS"*1W\$<
M!Q/)I=JRS1.PB_GEE4TM'L/;,%1F29.VOW|J?UU1JFT1;G6N7?UL1|@K*M@9_M?^U#?
U@O#^7K7@I77D1NR2B@ (64M?_,KL4,# M>P/KT;DHW0+B?
EWINN_#:T/2BS)K&WP=!?;H=#EMJ!'"%6N?L3F&^)24FL>@_MT+61A',P&EDH-"DH&
(5.*)H8)2)6)&OA*"Y"E|6HP;5AU?-U5Z72+ M|8ZP5L2SPY2O++(JGLG:7^\$9LUJH07>Y2?
5UT(2!98GM*L*?:C|'":=#2%MJ" MDQ*/P_#
(91CGJ6X/D=LVN3S3TYE&8RF(PU9FBjY/SA*"B_W3ZR\$H6:%=-K32_MWQ9GFX,\GVU)
(^53I/9N,VDLJA!#L (;^CAA"SH
M!2+EJ8MHV5(M>V;BBK80GG+;-5&R25'1G05Q?;M*SG0\$&"Y_T&F3J'NY*T9A!Z19'MH
ML_ZU=^LT86-Q_>^YA:Y=(+L.|AXB\$+IL.9=/A/%\$^B?6G2GGUUSKIN1?LV MFL)|?
N3.X7&6%DRHC* @8H?JC&\$M> M5-TV9:N@#?0EZ|,OE;|Y ?4_0P'C9N;=K(O79T\MJAP
MIL&YMOTJP)KO.+:!MBEL/*WL)M6@P0:Z"?JKR|KIR'P\$%_S+ZLNK MK@^5S4EOJGF-
)1HN^P8&V*4Y^H;=/R%Q.P>/%N M7AU,ZR)?
%+VN=E\$7#P9+H|F%FO0%X<^R(#P*E|:65X0?5T7X?4N|UPQ<="HQ_MBUA"M%+8-
27+"\$<,PIQ\$S!BI*?:K4;:|J\$?|H;1'(!45Q/XZ((PC;=UOU^C
M8I&H%PL8O&X|1E0>@Z^7%_81(TNMT-Z7JL+U!;O7RMQ#5SS*PMR0J?;ANG*^
M_CML0MNO#L|^6F\$|>GVK33L|_M*\$F8C8(UIRX@P?M+3+)MZQ1F5; PM?O+
MWY2-!,(BYF2;J?-10BWO>@:B|!#D1H7VW&5E.Q?-1#FV!S8+:U@4%IH:&&W
M|ET/Q=M!>G<=:|ZV&VU1=AVP.1HB6)@QY1X|.JT%U3,)N |&#EW@"+6,*(
MW#E3|*KWT+(I+_MN7=^|B|EQ@*B?*+(S.V^QGJC|ZHN M6|. @. #1.|+BY345I
O'_Z)1I?71=BY"-@@#<3V4!=-.A)'_8<_<1#A@|< UI MQM>MOIV=(6)I
|G\$ER@82@>/VB|+D)M?8=A!7UG7O;OA:SD>VV;:|F'+1T.. M|YOE>/H1,?_0L&#|S_P?JA
|4A*"IJSQD^M"#CKCTG>MGKVJ2%;EMBS%P@#_MU;1L6^
V3&R3W.Z080^0OCNI2Y"W4^Y/AH8-%=8%SN!1V%#/G1Y-L4YO,@!" MP?
S<|NK5Y|O4E*|/IT!;G>P=L;2\$|H0QUOL)XK0|8ER1I+T8=7)V13BOR&(4_MSTOR^@;9J'_
TD4?EX70#M8|.3;2N"V20Z:53UM#\$3QO6.7FP,=81*GALN;
M)\$VA\$68(:Q%1)1DG,8R946|5OEPET!'5UXSJ*Y9&!6W|5)XF|'>%FIOWD\$1
MNX"@!_4?|'\$#)-NX@YZT14Q/4 RW;4R;ZZD..J?GXV1#;L,P>Z+M;-H6+K?U_M<2Z;13?
|QXN?G9SJ4|1L"F3G58T&J6/6H_79@4D3I2J%M7(+ +86%4ZYL>YRO_M\$|O3=7
!Y@9UPN>7LOI256/0-K|C'F37;76AW=R01ENSUYR-R0T3*=0&;NPH,B,"0@=IE"2(L|B
MP1)-1%9\$(&I%2GB1_MV_C,Z43A!SOB6&:2LS>|&\$V'#\$&2|_
#B_@)W2=^@*O'SZOE1/(@DQL>>V:/_MU(*X*_-;PK@,@!FJ12BMUHM B1.R,8EG-
P3MA+OBL+HOYK\$-#P|)!;A.>MD, M271S|(7.J2P|\$3F!H'/PY"
2F185<|2EF8J,|5.A#EA5;SL?YH-AAFS2_7 M@|HN&|NXS=!M+;-
IM)58S(A@KOR*^EK>_2\$07AM&=6ZC:I"&Q2S|K9_R@J3
M/'L|C\$.&Z3Y8Q4D5B/&;9;&*J1!K43#.&9>:YT0PDQ)FC"*%5!&L5J(C3V,@
M,WH/_13M2@\$QMI<*:&1C#779GTV9"LN&, 'N.|#P*%QWW,?CULQXL.KJ?P3V M?
9IERE+=-ZY5X7A>)_*6|P6*| M3AO|LFN\$U:V#<+<=USW|1C0\$&T2=L7@%|V"JBZY?
=,P87PI6J7RG|VCP|2=A? MAMF4|9Q=.N7?;K@U.N%WO/&.MR4G2?J;_S/O|WJ34M: "/FO|
|J:3Q1I.=|8_M_VWF>,RV=QFP+UT>+'ZQ@6HW#19KK|'0M+W2T?R6G-
9!1TRT.0GYAU3\$ACS5_MF3JR"0)EX*|V3G3PDSWD"6Z3_FTZNE4@ZQ)!&A;N87YM|C?

36->65)8JENF MM#^V9[2UG&YSR*7-YL#C%U\|B37'CMO
JFX#>G=90%:>MPPU^=,G|M685+=ML_9/0\$.JG=WM|WBQ_0|Y8VN&|9!M-
GM9H0"O)-4%#%#A#\$5\$ZZRF&2%HBDV
MS\$OX6@C|@;VL.T:4J>C_(PW^J&'1=7W\$TG=5;JT>ND=QT:ACL9
ML#2|8P&T+Y|N(^J4ONJN*|*YSM
M3JN|GCE()VJ9D+;MOG|X;VHW2BN.\$YU)KDBFDQS/TADHH(21-&,B%R8O@ZDR&
<:Q5EA(161|LU(2GF+^>|U@47"9)N!8QPF7WZ_W\$ M_E1KC0QOZSNVIPS^F" _&
(CZ*\$N9|>^+/:PZ&N:*WRE1W*NHHV0%%KYF&FBE+MHCB7:4HXE8(P
8X6N\$H)">,D,W\$N,A/J1XP.JFK(@CUW/.V4UJGEZ-;!0W^I M/M5ZJ.L<,^JFIB..-
W>N.NXN;:/4_ =BOE^!_%|&RVH, #;"ZE+:%A#OE:N;%
M/|6TG:5:033HD.Y5U\$&&%GUVQF|5W\$|WK\$KZ,-;69%D(9*4.2,*4)DS\$G/(D+
M\$@DJ3:%XD:|7XC^6VNRDB@M7GCF9|J5JE>/K7J#L*BUQE"0G<9L7X|GKSLVZ3J5Q;|2-
M29%I3E@*:JZ(0.N%B0A#HV*5FGLED.RTKOD'@Y2,C6C\$'U-[K9#.1SY9@|_H
MA^~);'P0!(XM>)B:T3-|AY|H_3^0X_SY%:'|'AYY:HKG<"@Z7|8OQYB*\$| M=7,4KE5-
BP8Y):Q;2;Z_HZ#8Z%1,|A108@-L&EGEU4RD+?+|K?E!|/5ZUI
M(SH+NFI|WH:)|@W5VO;)-:8^@\$H?&|.Y8U=7_04Y+9I0*.H97C4K|K6BWZY
MKDUR60?8G^_2MJ!=X.HT@|:XPY%;^!U|F1RVKK6#A2DUJW!RM|%- \$CPVW*24
M,)8KX!TCB4BSE.0F9R940@!/|18WZ7/?M?=|NZ; QW9!VV-LK+K|=;&:IVXQ
MO|BS@EM"*MUF5D|(J=0#W_3N2+/6H.%MB:V^/3?H|8AEO'+!7S;9GB>X>*^N
5H3|2RI|H#0*HJ,N_CAJ8*FG@MX>;55N2>V^|YX>#;T|BNJ#\$G_*
|0.'=&N,EI|"0%NGC,FP^%_|-80-W<|>WI>MRW'7)?A.%.39+((_)!;DX@?
B/'|N/Y!'H/O0U3_(_#M|371+&6A)@Z:9|Z%R=Y M&,VU#QD^-5R-
XN|A6MQKT5RX@Q|@,505V!\$3V8^?_QXBC5|B=-2|_W*9). M*LGRF!\$6IYKD&?
XCDDQ2'4H1FETB|PU|W?4#2SP*NL61)7(Q_!|VP;Z|*FK* M|E&>>(BD71BY7C?|,)A?5<|
(") ;+H)Q9?I M|=72J_F|P.NEHF,WKI*0%.TAFG%,Q;DALA5,49\$D<1:"B(LZ2_MCO?.69K7-
=S@KOS<|_#.=%,Z8O\$#8^|&V|Q'M.CJB:TM".SJK|V"NEH
M6,PKI*5^3|FB@L<@2G08@9,D8I++4),HIW"!TY1'Q4|H:NO"(?5@VU
M=+ZDBRS5)B\$|T^@R@;+)C4R)*AC+,ATJFMXKC/?@+E/+XF|=A|U'Y&|W6^|
M2LH55(\$;'|\$JR?07SV!>OI0
M34CG2)4^VG=TI.:UTU)=6@*:)DHYR8LT!E|JBPG/M2\$ZTI32(HEE?*|HWZY3 M(H!
|6U=JYS\$ _J^*V;MWF9Y")WVKNL48/"?:#W&\$O.85TE);=YY*HUA\$,L\$, M.\$E,DCQ-
A+&89HI+D#;L,=52#?JHY9S%TD0.XO?I>D#EU0&P;Q#M*C*J./
M4XL5,#D/QEHT.K|3RI#YHWV1T_'OGQ>.RUED\$N>F%3F1&^8NR>')4|_OR)K?
|8U^VA^;_1.SY|B4<93K|N|(_4\$NLOF24P&
M(3ZOL(Z,X|S"&B|JL0HLX*DQ.3,0CPG+\$D\$H+272:FB*+=!0E>Y?-9YEX57/M
MK'E2PGUJN?>KGB2U?"8FYR4B&9|ZI72XR(J^P>!C*#:>"294COJ)IN")*4I\$
M+@WA)L!|U&"JZ+Q=B|O>J4E_+|7A7Z17)*D?6,L= M!2#C@WH!=!>:D#Y'3>A0AL6/
|1Y;7@0AJ=WT982!'5\$)9.4J+! N"3)B9|2 M\$2:+6&M%F>1JWS393GVR)(Y'-
/<02;OPRCP.Z%HG^/4^AX+U&.!L>4G^;X
M(=E%B"=YAH9M#VPS%=>NL===\$8: ^Z>JZ7&GIY6_ =HU+FW=9?.S|-(8+L+DC,%
MMJZ! ?W+*&=%AFL51#)9@<2|HT%V?GW<,_0IR1,38R,C!3Z98*1@3"O)A
2EMF|G8!N5GA41.|5BQ|: MT_G*T/LZ;'07VI ^1VWH*D_?6P-
&#VV!AP^_Z^OX>:B+O|Z:L2D(8VN2^~5 MI%>1CX\$.Q\$4A*,^(YL*"K6I2R#@B+*%
<.:%"2O<.1&'WOE|C_*|D;AE>)=M7,2|Z,#GHN2,*.O@2HSG.JA,,-
&SIP%\$|*IOWU3?,F5M6XW_|#IP-SI0I:F* MJ(@)-=B5J8A2(B3-
B,PUY46DTHSOG0|H'>5L|/2/F+Q R=#>N5W%X_P>2N_ M6^,S_%V4DP"XL8 AX,?
IO)87HGFD#AA>_?5|24|P9!"H:HZ5ZT>N #)3%DC!T|"O)\$FGU)U MWHY%?|Z-#H7:/7|;
|N2>&|YF8MV*55Y-9C;,)B9GJ1H|H<;(IH|_DHLGSQ M|AM?
=VNIOJ^_Z_'|S_*A5SS>V85>|7@M7,K@^+|/ #:PKT-ZFU@@^SC8^!US2E_MLBG7((-F-
2A3E|DV"FK=S,>VW@),_|%F9_3XUTGPBP96UJA^RTH*O%S8G|P
M6;|K%,|4Q;G&CJAP\$|X" _L^-[E+|+BK5!'A_NZQT|3Y-:4=G7"(\$085,-LK
MU/FE05?AH^|/\$"!|ZQ7@RHS'-RW:X.<-ZS>RU|@WX%&2#K|B/YJ\$ \$K942W0
M&*MZZ0&S*B@6ZZO52?#;8H@(@)ZO5Z4_K2FHUAV5W*P/N(0KX(M_7#ILG+J7
MOX\$;4/|Z7#6X(&_\$3,=>F)OZ ;L9:S=DVV;CUL&KX?5_Q*E&.+
MQE-.G\$2W^|T"S9|_|+|E_8-#P2M%VNWF8""K _T:0UZH0:>@%G-ZK*86|&&
MTQ\$!;!\$X.Z_ZOO"TCBK@!MF3,*@PX,GKOS8PH|O+"KFSDO_J+E7BN@%M-!Y7
M7W&DE@HF\$UA.Z4;:/N0W79_K>A0_\$|N+8*KKIFQF=O3@BYQ?.%Z|V>KE&TZ"
M+UMG5C9!HZ<"UE?#S)J9P.<5&@8"8X.A CO6U6503=LM.:8T+|V4<,"P2PI;

MW2N[7^CYV>?8Q[E=A0\$-G@';9!\RP>6"U9A=-\$ 4* #.!\1N*70=Q.\$HH"%E M)W(JU?
(\SOB5<(.KKH5K1S0QX>:9!\$;\$A.AN(6KVL R+?X(80_D \#8Y1[D^E 1!5 EI:!
=4Q1)6EY,8"!GE\ C5 ,HNTLOZ! MU^>4U()>!
I<!\\$Q\Z^';.MNGXW!\@7LL.5Z"Y6P9M'WN)9B-IV0GMSP94D*A! M(YTWK9'7*=H2-
)J5%IVHZ*!;M01Z\PU4*+ZVY5RU.KEN\$&>P#;!6YZ5TZV#=- M7VMLK(X?+T8:H
U!5B=UVU\ V>:"\0=.T!HAN4&;TKQR#00):.C ::<>KJD2-M6X
H^CKI7K(8AQLS&'EF/H8[K]R.)\N^((EF9<2]8=::[C-TG><@WG!PU@)M
M5[T"X]@\=N9B"8?G-/@#;D\$UBZP?(>N?Q#I.'2::5(C'#(P0649+33!*5:A&;
M(D\+N8;@7.1<:QK! ?G\$=\$Q:EFO"8%X07.DWBG(JLB(:IU=UYP**0/-Z?FFU
MS)5^4S;6J\#JM6@NWH%UIDG7&*"\$4W8IW '&G>[C'80. Q\T. &.?/L)^>-+MH+|\@-
^T=&<2J4(+&)#&&\$<8+200U@A0BD3J7453D\2H9I"/;=98F1! ?8QD+0 MC/"4"
<(T"X6B.N.AWBLRN*%[TE.001=Y!_1DUDCO8'=[X-%@DXJ'#S1#06_5K.+I:<9S&N
M@"2ZKT\$C#W7M0MF-T#46G5?>!#\90\>:-V\Z-#^ _[(W)8I9B@[\X.9*S/' M2
I6^TZ;1/>E"N!!#.YM0>0MW_ ^/(\! ".08J.2_7DQ\4)))I73WCA=VF\H
M_&FCS\]>DOB5&>M01 \$!62J"1X_GEY-7('NF8W'\\$G\]-47/;7(^./8NW4S:
MDV+WQ3_!2BW-=?=">RL!N?1J6KF(X4MGOEH5T7U#=<+GOFR/QCX=LOH_SW"
MX8N3KL?G\8@N::\;RF\ C+OJS\W;TY03C:Z29@:SZM7R#\['L\FN\ S^X
M7AB8W\$LO_BJNFUX&4 5N'EQ,0'=4<1\$#Y3:M7;JGA\2?A7\H;@.G&8MKHEUU,
MMJ,!>T\LG OUB4W+*5=F4_JA_);I\QK:L\$ _O:-#\I)_C(DWG:\?'?7^[88\HY.4
MW0'..JY&3S@+!\^[\ZW,>?;I\Q27RK6\]^3<90_9D.8@ZLD_&X->#>6#?/-=S3=
MS1KVR1J_ %JZ),MSRYST-YAY.V_0QV=Y*Y39+C/JR;YZ.'G/#Q\<[OSBG^MM31;F\ID
M&?_::<&.7N/("H>^%5;:!%S?=K*WSX\PR\$U>+^VS/'XP*RP2A=8RBDDE,T\$8
MHP4H1)23@L5"JDS24&5K(CU189*,C%#-)&%QDH%",(SD*A_ZUGB\;
#H'=OAVVRPQ3P:4ZDI0)8\$"5A:3(TI"E?- \$ D>KL-@% MT^ZY'98\ PZY+8I4G48-
TP=;A\O\2QU<+=0>!\NOV,,_3!\@%U+*S3 M*N\-\$#ZC=(TT5/?FVSXIRP3%GG&5!R"
I:X%)XR#_Y1G6A*99"(M4IXE\7J' MXT P;F8:2*(7.6ABE<\$\&GR2/9*Q53*7^3B.N+XB-Y
;R2S69-IYWR\15L65 M+BFNY#N**SKA>U0:';#5XZX@=#'UH'!SMRA4M7+EH(V&2R?
GH^!\<3\#Y'#OH M":'@\V64SJUU=L?XV17"\$9H!\<<".FT3*DT4EPVN.XC*^?"ZDR\$6T2Y-
2&-M0F*B%(\$I"(S!0U08:>= M+C#3/E,07Z0753/;#OG_@[\1*3\9#-SXML0\I
XDCM9KY\$P!*788""5DZ6?D;* M!1=6G\>0:/@*"3%J&I?ZP#:OP_LSV^C\H(
MK*B)O:@Y&@K\ \$0W44-PLWV@.5Z_D"BT!NM'(9Z&PYT%LWH\5R!)=
(U(BMAC%8Q^L+0M M&C#,5LXL0FX%HA!\;UH!\@W,ZY+/-
^*@\M1MVR=6;G"EE"7&DWR!8H M\$M_9XS+ND@N\I
<#PJX8@PR!WWM9!\UBVPU_8OFCHJU88B%4D:FV,EM:KZ-"R M>|+LF.\$2J'U\>
)QVH.O7=6=0\)\$J3T957/RC^7_!\#WX TH@>UAVVCUN18' MF3C,0#01X"%+^Q\I?
ZM2L,BR'+#6WLH\|MJM+"S:S_D\#5\!96WP?O2@K\$T
MC6.2,!IB)DP!#FXB"%4J\$5&H(A;GN\#I ZISB@2<,AKBUP\O2."V %ZW&?43 M
GC=GN3%D,I)&JGSP=7P3T@IZ>5!F*!;B?SL,N84<%_*BU%=
(Q685YKVQ^.TS\2^X;#H6B/,IV6\#WH@1=H:+TD2%Y_!3\!/=NBH\X\0N:>|+
MZ_0L81\.=X(JCE-Z;QRCYXX\|6&"7YS\O#;=7?X8=&<#H&8/+<<#|=|P-B1
M9Y9\IQ1YY>W%T1Z, #YW<82A:B\ S/\$=XCAAP1.PYPG.\$YPBO(SQ')>(\P.F+W
MGIJ'3KEY<3_K*SVY'0ZZKW7=,SPO#R>|P\H';M(X82(EK. 980DS).=Y3B(3
M*YKG)@ZC< T3*\H2\$2M!.%4(C:!"4A1I3 J9&2 P&B:AN\$6:1\|E>;3,N*/_M4L9&/-U>H_
UHGRO5>T'F M!9D79-L%F5*)CGEJ2!IB96E>9&"1J9C\$-
%&ACDEF5)RF26&TT*N2C&>19(+% M)(I"0U@*GJG@N>TSGX01ST(JU_I>/*
(D8\ \$H9)F79/>(0?HV&EVBDIX%XZKQ M@,W/D6.\HK@3S?
^T8ZC1S8K'D)HF,>>EXYXG!\^<&KH=4_WL!>;!\JT7F\$B,&.E M#?
Q_3G@4@=4M8I"5J0%9F(5QD84BUWH-IG\7P=,'%9A@M\I.0>8'I!>:!\T7
MF\$B,+ 'S4YH:2I2(4\+"4) \8X(4@F=*)=0DE#YTD/9!!684LU\$:'EZDPTM,
M+S&IQ'P"B2E5DL0TUH1&24)8FDD B4(\&6C.:FER'4?+0P>""E9@A\@VYO>4
MF!M1RO="&#X\$ \I6_/4MW\/"6/0;18-4-M4G&LRJ93NWO%B"1SG3\MUYYM+
M\$K\IR8_V-J++6EL@03F5^_7FERF8Z%M;EL8IT#IYAS
1XAEIE1"C&20J7AT6J(JR6X#);!#- M:X^_YJVZ8\^PZT:V\$X4:=R-
A?;&_O\&.9\&IULSUE\?"KO,>>1:/:6_05 M.DZI)"G%S@,RSHE@24C27.A(F((9NM8DX^&
(Y:VH)\|S<<:\>-T)DX/\$GW MD&9& SC@|\?5"G#G8WN_
TSYK(1:F2O(BE,08D1%&=4H*%H9\$*IV% X'6%,EL\ M#\C/ >J^"3%*!
I/+RUX*L8@F2584@A11_994#KN?LY22PA0FQ\ "F46N>_<,1 MRY,)L>@YR+!;N*I#NWD-
%5AE*@D-S4@LX@0\$P_ /WILVMW%DZ<+?|Z\! :9G MI @<3NX+-

=T1LKR\$|^N6::FWKB?.G(5T0T";!0@B?WKWY,%@%N1\$I<"0))M.R@00%7E*Y7^<34_?
%O#\$!^R_J'^^N M.H?MQSP?89|WTJPU#O5RV_7<#*=H:N>Q-7\$V=|H%(^-\$_%_H1-
KS@"XD MXT|H^@\$? T@?-<@W4H&'(*G*=.MM-5C.,'Z|'_
J|F_+R|!NP!AE\GEZ>9|GH|'TT|MZX:R"!5'M3P8MF1I%2"N"|SAH-EG7SD@+,5S<_7-
%^F|^&2|H\$B+E@EK&1^|O_—M9AC5KP?
9A57OV\W;0.@Z:++!>S3?'A|\$9XD|J1\$NR1\$WCZV|S!Y;7OQQE|DC
M:@2Y_'EL">*WNOM/<I5XK>Z^T|P"E7BM[K|=V|_M*3|_=%V3B7K=K*ZZV,*DEX-
K6MO5EN*!B3_?|C12D0|*9I\$OX?W|O//=6ZED-H|LYH>JE,4&OV5URK MN/:%C'1*N5">
XO.@6!*@I\$R0++4LA"UEM%WRC0Y:940'CO3!\$24!)PW&9+D M+I\$0I;:=9,
fMX5J|TL0JKE5 MI"6=)\$5M7'9!9V#)YE+*Q8,-20*.->6
ZAJW<7=PC=JAK4V6*K#M_I968.L1 MV'QT-E.?0+M4LJ|+KXO(+2@26+1,4L
|E8B3THA|1 #)'A4VZQ1XJ1#BK*., MZY"\$?VA%A@T"&U-#2:O&|A2?YR/ZOE>?
9|D/DGJS.&V3ZZNH>2J3/3;"; ?9 M\)&;_O45V%.;IQ;GDDKH\$7&E4OXG08(KW-
!G.O/1,F6Z|_)@-RB\$205K*4?TF M'HQ#'#9Q.;JSG+,N<=D=*43\$DFZZ7_@00/UAH8J;%3
MBPJ;%38K;!X2;#*E0HA4@,P254=4&,'(\$\$'0+&GRED?343>%(MDH&R QCM=D
M3<&;'(%D*8)U/E'!=P3FGD+0
M*:@;=C(!*=T|Y:NHT1=:Z2\$X\$B.3#N*JNONX":G0|H|X_^|PLVM M!-FR/AS.f"4ZG-
/YVY|4==TE4E89=K!G._4P\UK>KQD7F8OP?K\$0"27P&5=M.J7D*#E%4=5MID-
()DD(E\$>:MU\$;&IQ7"G3@W@.@6A\$X|%(U&|5!;7@|W*Y|5 M+=U_/(N1>,N9!!5*VY-
@%=AL#80LB?_D6J?233R3T7.|+\$.6(2&>Y=+OB1D@_MF5/-
":7XX0|AF1EJ2BN>53RK6WH >\$:9D(1Q<*GT";/:@K4R@,|1!(&&=K:B M*
(+&5R:;%DY;5-VBUFQW M|\$SJH:&BXMD3?)NUWMEJ|!3KE2|!YO|P%.
MN5+T7F_OWDVYUCM|5O/F%^<'S=+\$J/QE M5#+)!6*1.5CB)VZ&8HH*|*"E+D&
(8T%Z|(';;B(7"N:|'"XE|HDA\$QM.W-MW MXJ|XMG=;NJ=XI@+-E/H,Q
C\$)H:PY&/T0'FR1E(I\$-\$Z>\$:X|:2\$7(@D\$,5 M|^.#@,B|EC(R:%;QK&|I_N.9EB3F
M8F*&A-.C*/5B'(WX)XE">|<28E<'SOPJ;0Z_J_|@JRID)X/\$14(YX9ZV5ANT0-MGDE5E;.G.#-
K(;-',MR/HS2.U9U9DZ1KDO13I91PAA))!=#20\$\$\$*L%K0B + MEA5/UF73*25L&&/4|
(E))24H;YAE/L*FY6W*RX>4BX MR:7DJ#"*HBLF\$-%IL()J.#9X+W)IQ=@I'<,-R|PS
277#X2@&0P3&I*7T7)*M?'9DMW"3;-B=O%>X64N9;:&467,|2;#*M"K3JDQ|:'HZ\$2BBC
>?15L.S:!*M3PF\$S&FD*-(8)3=EFI?*6L<4))\$|V@*:@5,HTX@/5\$4M>:|5-:8B:&HMD"U
M:2IN5MSL;:XD&^|=ZDROEX#U8S15D3SS17(:<.W\$E(3#)\$K&@O=>(M4F
MS4ZA5:"T2H)'FG?(%E!#J3;AH@1/?==R;^M^F&X2:P.Y9HL| MW5,IP|/6 M/G.-
EA9\$E|L>.ID M(SB246NF%.'/A(AXEJ7UPIA4'+N|@F=,#IFNE68JGM4M/0
|HV@A4U.Z"\$M7 M#NLI!:-94=*X3)9(G46^B6?6:H7JG("@"|)LBEF1F*C(0XBVS0M+|.
|@&65B-M:#9H+3OU%|!;>^V=\$|!C5#A*=<:E\$4|2WAEP!!K<+R2>TT0FU*GV@SEPF0I
M%"BC\$=|!#N",,:|LP\$O|\$K04/,RK8?;\$#B#Z|40_|-R^ZGR_+M=#QV?CIS
M+0<5Q^5T?D)FU6U9#|CJ_=M34XF==)PI#9&6-DTL9E23 P6G?-R\$*(BZ|0%
M#B9:%3B\$B\$)(.*OOZ|H WLD3ZB1Q*N^.)+(U"+JWA4T*VCV|YJJ^!|"S\$!3 M 4V*
&B8"*!U*G48&&)GY|PHQ""3-PJX"QY\$M"6F01"@ (4?',UJA0Q4T(8:&\$H")|B>(6_B DB.D%*
(YK=@4TZ)+JFS7^ M|5E+*537|498BQVQPEMQNO#CM\$WA=)U |EJ?|I^HE+H,?
943@EOB,X^E9 M@#!|@XG&00"\$S\$|4=_M,YT>14HPX?5@6
P@92X*;XH"F0D9"924U;G?DE!!# MJ^QS"JH;:/3R1%6%T0JC%48? J-2"YM5XD!#R*54
JK|"?|TP@7'K)&&=B+= M4L;9\$)M!4NE!";,+,1XADTB-4IKGO\$,E*ID<,(QJ)3E3
MC()TFH\$@B:(VR@3^:2+1(NK8|9HPIE*P,4/D@8!P+(-W5\$-H\$M/M*2N.5ARM.'K
.&JH""PSU#|32B_82XBCFD!(26F=;+2;=Q(O-W"
M";R&\$E1AE5/|K|\$@K)>\$6DU8V*4X93.DS|MIXL7#Z%4'+YV.(T=0<@;S_|B-MX^X|)?
5\$VWE>+-QRL&U!8;>83|=;7;#9%J&7|X.8W<^7>>7C+K-'U AR^?/(VSSVLCK=
M.MV7.=VO' V:;Z:9W :HMQ|7=J'YMG\$_1)DV/4F*2|WK&;3I_9T@4D;Y|,^O
MU*LO3_:Q@2F;78Y|J.'MSXMV<)/Q_'NX^*364J#O^+?)\W@ATE,4QP8TS7 "30W3>
(\$%L+83@K&G MX17\$D!2XLI S3R_DY^#;6#7!.(I.!MM)TQ-2IH,#4_5R"196-\$4"#5|0'
M;@05NQ->P?A0RUIWO +;SF|H;8^JXH9*3WA#+(R\$001#)Q.MC3.I51FF87K
MQ(TQ3T(@S(|L<"9H*9"3E(;=,|&:8\$?|PZP43(T2E9@J"VZUM:@:U/C4TG
MYI5SH\$,IK1"S|B<9!;5\$Y)P%|+AN9X5LM2+"0TZA=%8('IQ;:"0(CD3F2)G8
MH<0"988XG@IL%=AV?4LKL/4(;*5OMTF>(*;"UC\$EB"EJFTE(;|
VR<#:VN&MM37)BU(OEJ<7|8S*9G M:3CXZRC&<1K|X)IE0|4WN7@V|!|H-RQE"!%
(1YB*C=M@N!9@/>Q9-)J\$QPC/ IU2_:M#M:@U(FE99DH4L6G#,%GFH2WF?L=JBE.U9#(
MVGZLXEG=T@/,QMHSI(IB)YX\$(8P|(H&A-OI6<.|=Q.N6|/)/\$Q.(B"HM&? M\$V(@|?
@G(99E1H(@.X1G9DA5;=93X:QNZ0' F.=;OF=DC)ADMQISOQ

M5SS;NRW=4SS+0@3&N0 I6:E_EPUX%B)8SW-PAB4F.YT%I\$B:"X482#7BF94,
MG'4(SHPQI(7(NU29P\$!%+RZ+I_BNJS1E^OHRV;DX#<71GD4JLBHG1EJ9X;'
MEFI51\$JA!7"?&(@@ CCB\$B041T('L/H!&J2ZF@*,@ "A,8(PVH!-+ /GU 3E
M3)!A/P"!I+IT1/:*2,YJWX%-DSDC48*RY9JD+;@4#1B"".I%RM30 MDI.##/FF(^HK;E;,\$
T!<<1 ZAE81PDB*,TQ*BN"IL0B<:M% M-J0<=KG2A\$4P,*7T-7Y9%
Q6SN|2_T0|U.)9*UB_<-RLL: ^U@>*NRJ;::N%0 M6RTX\$UE@SD 04H (DH'W/
ABFLDR:YXTZN#13WO-5"A=\$*HQ5&'Y1|+\$+A/ M.@K(J:B757#@E8U@B1EN.
I0P8'U@).P|2 M94TLZ|0FUP;*>PZCMS907"W@NT5;'17_CJ./IYH095|K==B|:-C&8+
|T|.57 MRYV/1W-|: +B3@7X>CQ?XF1N|=:=^ -HH?TG#PRSP>75W%%|I<=TY^4D!@DI;8
M|0E9=S_28_ IMF' -!NVKH|.3W%8YP/7-\$@C<> &IXOQ? 3GR*>_3_&&>/N("#6>GK4W
M"!3I/(PPE7_5|*_P./H2|>@?XSF#4|6E4F,Q^5|OG046M_ \AM2?IX?DJ3 M-
/M4OV1_KE(D)T\$V?V|J<_7GT|F*=P,L%=^W"^7(HRD3^"FR!3:G'!E,^_
MQU<'MERTMU/X;C7S_P|G_NK;H%OBUFS<+B+N'3E.JUU'5|9F1GNQ.AC2PR(
M'3|!>3&);./2Q5F>X9,'9^Z|)8H'OS|;5- P+SZ-S(2\$3YG!;H5;JEZ,\$)9
M<\$Q3E'4T9M)-1!2\$ \$LX5T!0\B%)@PB?&@*(0DID298U>"|>Q||?OH/?+U;E M?
Y: +|MMR3>X4@J:)1?2S8D1W='^VV!RO#;XW:-)X/_|28+-SLO?J:|G|L M?--
R2TMI""CL;S,*):U)+0&D|
M|>&@69R=C4=XNP+UJ(J.)H7*4+:AYEFH\$2^=+2;M56MHWMZ\$MBX44)P|%.KS
MLAZCV2"|4+HZX_(-\$=WQ20U^KZP?BOMI+\$E;2|EWTW@X&KQI"MJW*L-XVI1K
MOW?S=%V)B F%/5Z(HJ,5M^4SW*|)LV*|,|1!T_HVW8<./KEF|S!_O*C0N_K@
MLRK'H4&#)3Q!H)H9IC@Q5M|S *_LDE3X K,F&|1.-.*#%\$:.^4)X'<96S|
MGDZ7M/U;FK4L/ GI5X^*9+M#_4F77>3_F|+DJD:W)- U"5Y7<:Y3X:@I6N=H
M/BYD.%UK,|M'6%J*H%00P+*%<%16CA45| Z(46D6GJMGR)MTO?RV=8Q_E
MW(>B@>&JCZ>?!G_||=LUHIBM4?DKY#\$)-N(|JZ' BJ%0B*^Z29!>(I!T\$33#+?@G
M:EZX84F2GO,+YN.|Q7R1=M?:E3C-(B+"WH:N|4\$"0@OPGDCV(_/P87B*RC?
M_C!SI/6D>#BWQ?-O'WH;:8JWFREW.T>C&7F@|7EU,|1M\$NM*O5P=6F.\$Y@G MAG-
A.K75@R(Y&Q+!,B71Y(@&H4|8_(4V10K:)%73-JSP!AE^NCN6-[MXMBE
MTH|6FDXACR4X+=WE>38|W9!F9YW4/"M7O X)4&,KFITUX+BPC\$O+;>XD:I;X
M;E3>'JY4A:\$V%)@5->|A8N9LLR\$,Y00|(INM17\$0521NZ?3K\$VQ"!L2KGCG7*F-
_LR"G(T2\$R1: _!\$>9!"9),#M|JR M/2,,SG:.,(X&
IU^&OBP4B;L";AHG"?)QB2VJB_ OMKI|J97XL+' M!UR,?
K2#WGPCLE9>*D@^%&|^<6C(60J4.^*TM,+R3@AJ9(O|D00BJS#(F-
MOTP,2,Z0^@5!|=+DK!/5YM"9I=I*^ -O:|.)=DX"K_UA&|3;F4T,%?
=2C0I5=I&|1UO+6B@!E\XHHWRW
M4\$#5VW>".#;LMZ.@H8*CZ>V|6H;C&N\$%T*BR)%PGZSN\$4?7V72":T=NM|;7
M_J!X+_QWT\$8NP;E|YGI|D& RC6E|SUS+|O%JU/^"T22FS|? 7^=Q^@QQ-%L& M;!
|C?|:GD|=QU)R-W?EQ^?3U60F7FGRX4C1CM!SJJL|\$HVB@(WR^?J|!60
M)O'UV;1I@ZV.9VFHKWVT|JE0?">QQ=E^0Z7<7+;OS) MG3>O7_W7!46L|KS>O#9RO-
VP*T30V8_35S5CWJZSU6|Q>'H8L_. MILMXZ(XKWAS\$8GKF/2E.7PC+GU)>.["7%X>L?
|O||^ ^ M>?7M|BEEZ?| X&^ ^/-D,OWHYM-9/16?IDT/C9>G7 M:.'#X9PBL;03ZY,KX!|F-
Q@NT11!?->|RR|(<6X#*%X0(J:'C_%97*X M>B5H'A|61JR(JD>"&Y|E(_)10IK-
W9(9V_RSP7BT#)Y:AP(7LW|6=I%OFC,S M1-L(*6>T_8@WX R-
@\$ (EZQP5S=UH'\$XX539HH\$Q2%\$.FE-T)&9B1AE@C.=7A MIJOIMM2|7U:K=-
Z7B^GH|L9_V_67QI33K,#?E:B VP+E!O^#@#%KWR_@=9W;
M2N#QBX@99:@5)7,V&XW;4(=UR-3V9O='.ILOL^LX*@!E3-L;
MR|#+|LZUE<^GW;;6+G4P&H(P+SB,'YLM1@#0,C\$;64HP(&GD*BG62RTHM94U2
M!DYM*1XD"1CK&&@5:8R!)|J-!G@>3-_%6.TU-XTZ<19Y4;3=*P=;J,0MU5I. M6YJ658%!?
DL1K_EA|F%

=FC0@V"/M)P^EL9NDBYE,Z^JJ5!HC M)R5&BMLV'U-
XBOT3|D.R;G!=8*'|L#!X!3A|F(LR@GG4U?S

9_WI!.^& MM|DZ@|/9|.,H%MU|>CV2'J|_ZPU=?P&"KXT+TEYH|D2@5JC%X?PC|GT\$YQ;
M/RT!OPT/G%Z.|C_QKF=S5X(W+Y.:KRING5%V\$G^N9'?DT6?|O4|IN(S>VL6< M96I-
S#EZ|+\$41K)"@16) O\$^,Z|TK13T\$,KXKP*%I(3.%XDUR8%,"Z-)3F
M,2E.MY<*9(|N+B;W1>7N1L3>^HSG&D_(HZ>>^?1O2J(A21V/X'B)|231E%@\$
M"UHBX42C+ O=@V8FF;). 55XH1!<(TVI"%Q)C=2&-D&2FZ,/U3U)0AJY.(1^ M-
|TEZKA##;T'F'0#U(=M",QX?=-E|37ABNO#(8KZLPE8". \$EJR-Z151@E;\$

MY/S2S/73C^GQPUSGJJV.P/&OR^"YC+=JL&M+=ZT1>/0""H5-,0%D5WKS;-M=90FA-%
M=Q>2VJ.=L\PL6&;AMSRU.B\HJN'Z\H/L)W\L'/\$XB.+P8@.3J\|H2B>(H2 M%1#A2"
QITSXAHCES=*9?X56WBX7K">2\$;OHBS4L7-DD)WTRG!1^IJ4(#B5
MP;MD@4MMK2'&IUOJ(VR*#-Y_) U2 M_)R,I2Q;ISA'4U;G+|GM8;9CYG|:
M!E3XZ3ANO@_R/Y.1&&?<'93V5V)!Y?|OLW5I7I*#\$,GEDSRA':!++E<)4#? M4-
3TF4<3,BJ3A/'3=>!K^|6J0D.W.
M!";SV2+M0Q#%G:X@5)M/3X038W7ZM#I"0,VZX^XNFF"S209N!M^TJO@45>Q)
M;+X|?B!"/;KRY"1&;&L!/>M2E6VERALQ5V4;ET%5J_BF,IX2|H0S*%^'L3N?
M+N;'K;WS>ODX:X_(G|;?QST?N|,F'3?I#*VC>5JO1)O9OKSUJJO:-7T<-;E
M(1^O|_ 'ZCCY,|5,E.>+F3U3RYY&W M>>QE=;IUNB|SNE_H6: ^V-KM-CQ|2+ ^WAU0_-
R^O^/GMT|ME+!N<|NW!R'U/ M&.FB?/KG5^S5ER?_H+::6UN>OZC>7X@W?3RMW*->
Y"XL6&6@RD";8J!U)F|E MHLI%E8L>RT6_HMT^JRQ46:BRT&-9J.WC7%EHXXW#
RY%#K5Q%^%^|3_SRI; MB:P"0WEM/?;49DE;)XKG:BNVIRW#:
(R:*6L@<%H"UZ4#2YT'KOW-.BJ>4N>P M/AAJM-0:N,X)1"
(<;P\$C)=!1*7Q/|5/X/H7FX.U3G|X5YI-7_T%-ML2|,4T M^ZK M<-;6H&KSR@CZK0|);>,
(Z6=D|&(6E*5NJ9;=:LR.4(J!%2\$90 M\$):4:S@!Q:WB))LL;\$|9E!6X*G!5X*K
=0MP!6T4(9F#2R,12E.1>43E/!|*Y,*@P.*;L|H>.E
MTONS0MAND'E%M8IJ3|M\$E8A+@#-)=HW! F^|4)%C;&>&9)<)|8P,B.%B AC
MB986,IJ"(:6HA9*)^V@<):BVI91|7%NR'602W5# =LN0+%-|;|D./FW3N;J& M?
#"|547(M::Z,LJDBFI+E4S*#T"O=;,DO2PUR1/T|_ E63OD_+?W^U00/(1=|AT\$
M+1J//B8!SHGB#BW9XK*T0PC492D),|2C|46MLL^,@U>6HM;'24EL-) "RS3I*
M;97L=!:91"D0VLK!NX!=U0,/(1=[K_SL-"1EN,=JIA!15 K<\$)I4%HG1J63 MVH5-
)6KO"@9R;.3F|AZ?A|4>-?;S25SV^|*!5\$5'/>(DRI> M5KS.ZAK>A,=H.9#
|S\$R;P|R&1#*>|NY?U2>>B) MD%GC=I_H0EXZ@B||PW\$Q:_O27/1&&
XF:7|507S91*&Z19|*;U|OD++O4NU! M)6)>IMR|(PRXM+)4&A5Z+XJG6'.P3F0P2AJ;?
++\$=Z+B-N(I?I?N+A;_T/@. M7)O-"JC|%,C9=Y:I.%EQ|G!P4@1H2)04J\$@61(X;+
(&K\$QL*DH=A+5?9KQTU|3: Y7\$ M4|>BUY8|B^NX/_W2#+F|NQU1A&"<;Z&;H;
<2'W!YVV0F>-3-YF.8CYX.Y^M=4OT@/_L2-6F"Y.%Z6EV!;% MU'9*#MUG,?
948KD4N"_1(8%2|2*5KK3%22(TRR6W,\$AA.LJ^YT*3E(%3*T&4 M(U-
C'0.M(HTQ|.2)WTI9HJ%D&PZF^R*EO#QA5?&RXF7%RP E.E.\$ M;C@NI
)F=8Q4#*T8>BW0+GN5A='@I\$"=DRH!/F1\$4Q^(R#9D3|H!#(YFJA!# M"5>JZ)P>K-
<4E\$61NL)0X4: MTDV7.-LS#+WJ9<;7#J?
QE_4"OEO@'HT" AU" _RW_CKCBEL:187=+>ZV|J* MM69!!Q'
>8UDIQV:/QQ_A4B<9YP(0YX4(|FNLX#C5,W*K4H?DNSEH0F(?WJ M<2W;PBH_?
#Y+89XBCAV_|FO^ |JM|D)ZWI8^#^&X|?#?|X-4A(F6?X@/EL
MD>ZWRY1|98GZ=XH_8'_N;-"XD@90IZ?XW/-!;M>G&?TBP-SASR MGAN/S_'3TI-
Q*A>YIL2 /S*#HX<5Z9X>E-+2)4P|3|?CZ:<2M+X,6&|&W|2? M3|>-F|3FV^,KW+
<3#J|>EJ.#*VL4:4'D I66@RT#.W;+^72-GV4|N&!E^7K
M;';GT|4J4.WU|G'6'I\$ _K;^/6SQV9TTZ;A+2!A+1>AE.*;F|J;O;CLL^CIK1
M4L@^0@|E^HR+Z:D?Z%\$B^3_6'T=%|QG|O^1J(^3:%|@_ MNEHK.8-UPM77)6F9\$?
C+8L&<|^G7ZZ;/.(*+SN;-FUYL-.9&J,B|#'=G9Q) M|Y657 G^?
MB|UP\$BUQ<5FA1@|!E.1C&FR?&/?Y,Q))NEA1_6@K29+ L>2A4
MG9AT7";2HV5|+9+DVC|/6!)"+/6B\$R+WIPT3O/|RDCZHGLB|PXX@VQ|M?F
M3TJ;/'6@K*(@\$O=@C61_%'Y"LS*T6_#.19*D81HD"1*\$Y10,MPRTR,4|H;U3
MCW,E|7)&G)&|R|100;%ZEG.664\$2<%#)\$HCZ7L"1C\$/VA.OM9)|Y|EG+Q=
MSE7IL_=L6(7.M:-GGUDN9|V)1E=R0A/84DB<,I>TUEY3E|M-L4F,67%0U%H0
MHC1@2\$J|)MI9EXS4PFU3Z-@A(?M7W:4:5ST+^<|PK\$1S"%XJ-*Z\$|Z<-*EV2
M<8NZDZ99|"MT5!4Z5>A4H?;WJ9E-P65(3!6K)0BP1 K@.J#"QR6ERMT4.I88 M0XAO\$
RCI:\$Y(A.7\$8BU4L.D'=:QFT*'#Y6N'7FJ|,5H2.HY8H:|FCK7VD27\$5/36JN2D@",1J&)|HS*8
G756AH:9Y NQ+B|J|,|)T0"DTOYB,R|L9UPW><47W2H M;2TX5NVJ9|J?
C^=NW\$50C7XN08_IQ+|^&/4G%E0-*!H2E*I! T^\$B4% D- M)-|J.GI\$V.S2B2#(FG#9T>'\$
1|,?0S%R/NV7H,=!TOV<-L;HIV?2';KX!B|!ND1GW@*XU\$SAS1.IR6\$L#SU+,TN K#BJ#D;
MN_/C/\$Z?KRY5"2KZ^Z*9C_+Y^F'M=Z"9N|G|=3M-*+=OCKUKTG@T29T%O!RR
M.)O?|;)|HE3&CC0&%!S=LF4"IO.@LR9&IZM\$XAMGT_' MQV,W^?#G5VD"/'5D+
+R+3UB'EHTD8+R)>B_M|,O#+L')WBAKAO%E_&\$OP M=:>;|D)M\$1-
\$;5|1AY6Z6!K@^&^U<|/9J|^#M59!|6O93OVX*VL;E@#Y<(*KB5/(M|H|E?G2M(@>
M4WM%\$0/CTB3S=|J1*|J%|H|EE6/S1X+?%#&;I\$#+%TW!|?QO|,Y|MRC!N";3'
M6PX^I\$F:M2'T/JV>@=|P"2|.I=C6ERUCUI?M.INC"S:_0E/K#)#5|UNS0PXB M\$0(E|'2

.X\$TUK0Y(J,OY#N47>IN39OZ@'-(Z)'9>JT!'1-)\N KD((XJ0T
M+;5>)?:R9VN2=G/Z,1U=DV>X^*4IH|G"K01^V1>4:KNAW6\HX^"J*#IS'O),
MIC&MKWEU#4'!25X|O,Q\ -D/IK=H^7(5L;J M\HU;@3Q-XBUAKU>"[2_\$ _N=[ZDA?
E=R;"BQ^VH91>8U"+S&D;-S)A>V_&OU*M0+9B<)>G0+MA5XB@LYG|
MHGM%^R>C:DN=ZC?A+LJ5/EK-CHA&.3C6"LY9"DS|*\$E)6)?23\ 3R9HP->
MH0K_IFG2O/E^U(3QM%G,GIC\$9YZZG>TZ%&GZ-|%#E'\.R^!.C|
IQLN=W.PW,ZV%|Q|I-/URWXL%*5*+@.EI=>'TQD,51Z, MM#DH8ASAJ@_V^R.XO++.
M.F\$0-7-WN;B_ S=|JF)Z.0G.?BKIK42^ .96H"|0-6|8NDN(-K4=GTL6SZ4YI4
M)JW"LG+A5KGPWA%2E05KS-ZSQ.Q|Y|;MV>"R?MGW*.R*B-&VB!BOT7PO,+^C
M%G#H,0K/TI!X:0RH/.,@9 C@C; '@A?=:F)05"S=|TX8)RSQ+D"4MJ5#:@M.E
MJK/EF=CLLO*=UB%KCW1?00#E4-N:NE31:N>WM*)5KXV.(M6!\$F 2\49P2\#E
MR(!&PZUGWN%;-|J\$!\$.LR!0<+UU-I4&5*\$8.B6GJ28RE1]*&T8J1H:2VHE5% MJUW?
THI6/:(5*E R: *- 2LT0K8@ '*SP!JE0(TI2E|?WN3J M74EON1.,|A_ G,YP82>#L)C-
TB2<#^8S-VG&.5AME2@U;PF@#|VW4X2L:CD M\$))Q4/+KP 3"P&?+A\$O!&R|N"B-
%#&>N?-U05)V9R& 3RQ"R%KS8^LYWBF:M MA=&*D=^N^/C)1O_Y\$:37Z9-
TY=RO6%)M576I50M:A1+6K4RP%E< 0E\$@=A M22MZ EAF':#84<'GB%|HQ^6/YH%-P9?
1|J U2R5)|L|!"E!"D\$SEP:OS<|1O/&L/N:*C14,*S8>%#8J1VA.)@+7QH(@
M)H&GWH.7D7\$7/'&TTY+|,<4P-Q\$J(H5^_OBP?'6@I>WUW7KM0J)|X:%1(D
M4@YS"8M(8BB((Z5H8DB9K>V0V-.JD/PX0AI+OXP^IGBS,M#[,NVG%05ZD07M
M+HKKC"Z+Z|C+XCIMV<-14TK3K=J,7K:WKS5);HEQ>ADU21@|TH_N3G_\$U&-K
M4SSN,GN\$XL->^7GF AYUOG6^=;YUOKLXW|L.HFH-GEI6X-YE!2|K"AS.| |H
MPK5F5R6@'O&"DJ_@Q>\$5&GE<"\$,M*E(9JC+4K
M5N7|9M.F&;Q=E_)^TW9BJ1!56:JRU&-9ZDT(B|/%N.VOA?R\$B_*O>R=95ZZJ
M7%6YZK;5>Y>J6*H,5!FH:GJ5I2I+|09+54VOTPM@.%QS+(@AB+ 5GJ-
!%458U!H" LZ4X@: ^&T"9Z34B1%.@:!"!<0ZEQ+83+347#LO.M5L>T:X M=VG>%YJ9(>=|
|L#L6:6^W:#S"FL5UIY4/BHJQD)(P(GT:,|ZB8L;B!C9D8K MI:7S-V\$M4>IH
3.5\$,R\$E11*!RZ@1"=BE>..=W*TG\N>I7K(9;5G|X#4*|)5 M9-LE\$Y>RR\$CR#KPS&15
!L%J1T!\$ \$8CG4@K2J:G=,U)NVL250|N'V+D=\$WVJC49>5!!A5!^)S!:"K!41*BML+P;@^7G|
C9.WC; M|29C^WDX_G|F8FHNI GJFBX*AIB4EQOYL#\$Z% T:%)ZS"@@S-B0\$Y>*
M=*J|>4=U*,55C6&R|)%9PX(B58)/-(L"%-;|ARPH995.%3LJENZ5|CU/+X!
M)REAL;BLJ7Z;V@2|W_Y@!|0\$W7D7&:.-21X\$#)%,%D0B-H+YWGT(7<.|W*41'J6
M(7">0 CFP<5@-O\$ W4YNR#VJW!OK|J?5XRL&%DQ\HD/\$0W).5HF(3)'\$3|5 M
JNI@^P#%X(\$18W=,9N.,!8/VO?QIW!X'K06,&X@O&&P=-)9*-\$*,3)SC
M8)6B8%U.B>1D=>P<508,GGT>5DIM#A(J#!|I5D%SVW1P "*"Y"?=JA9 *(15"
M*H14"*D04B&D0DB%D)J5N=V#X#?AGX01+,7|Z,(T'|C6-A.)O>KGET=;#L6-M45'3^?
O,V90Q""L#&*,9B&@0,+QB8+11C/J4 ND<,3A'F54T 7':@>!XM<|"
M@0I&\$>VHL=ENJJ38\$-JQ=7&-O|+:TPML,GK|X3S|1U8'P0(O)(X-Q\$ \$1F M(DN^|
BIK\$4>N^ LIZL5L2LB'F?XG641;.DA6BU!Z&2 L\XHA6C MEG/'I!9DPPC7X_\$H'W*U?
V!6O8X5UBJL/2SJ0QIC=1)@!;<@'+/@G;? ",V9 M\$..IHS=A+3(CA8@**;!79*K+MCXG+##/;
M(^I%13*:N!X5P*05..LH-Y\$'ISMUWGM&REJ|^ .68N+O!515\$*X@^J7HQ)YFC M&0N29
-"60I62|06G11\$IV2-Z70EZQGT:07B39^3XVN'R_V7|=*16YRFV2C@ MWW'T|5X3H@S=?
MX3|!N#^>+#[UBA|H.Y&P<=%4DZ2)_/TJ1)@VD>S\$ _2X.WT M%\$=U_I_-P-UY,#
|XY)K!O|^F@CQ@B/V|JUQ,A#=-.2@!0AN#=AWA0&(.@KN M| -SIM<"IEHY"!Y;%
\$)&4LXVD8^#SDA+C\$CBUHP|=O|XJ|@|R:UZ'#MSDWSN9
M5UUC7OD5YB5'=_NKGHT!OCM<5EM-XF|M_FF=%B+V8'S"3?2!@&.M0G(TN7H
ME)2D6W,^RVR(S2!L:6,DD%9U9|H|=G1W,L<6-Q_ 'W,+ \$ M|H8R/YFE-
#C%OT^:09I\$!*@_TMD|G?HT&W R'##"1\$ND^()O;YS#P2PU9PEW M|F,:GQ|-
|AEZE=\$N)8JXZ;@\$81SRH1.)E:"4;HW|^)'<1>|;3>C55 F*6|YM?*EI=00K90:*L,HS"|FX
M3AUCJVD03G PM'@6E%|/K\$&I;TDU&K"@M_:YINCNST"!PV|D|'D12+O29JE MP:?
R:|=XQQ%+8V 6! D)@3.A)DA0(N3<>YD%-)T/&P/IN?B34OE MVZ/-+B4.!|G=I%:-
#_/"8'K\VV*0:03X_IY.AY//S6#;T839,3IHD%1 MVGQ|?)7@=R*\$K(?
5|'CJUGZYUBUWX>=;#K8,|@MYM-UWDX9#Z)5&7|Y.HS=
M^70QQT=|3O'U|G'6'I\$ _K;^/%#)V9TTZ;M*9F|EY6B|ZU%>WOK5;2DT'T?-
MR(-&H_GY|?H>=^7&M\$|U|,BP|MC/97W*\$%=3Q@7_/K5?WWA4OK(R|01-1M|
MXE>2B|P7GED_ (J|>NJ2W3* _#2|AY7G1,YS:Q(I)3|)\$%:H\$QEY@3Q+JD-YT7TC4; M?
E_3|:|Y*5_^')M3X?,FM)ZQ/P\$A*VIV)<(*P^3<"J\$7H703+UQDC)@DI*2 M>"+
\$(TX&JU4ADA|NW.2OWD(?8_ |C3^FO|8NJMH|HAFQ?Q&(54/= #GZJ MPR20F;^C)A+F-
QZ3L(A1UDA8?@L E!OMAZ/NFD'?/\$\$SID)G:DJ_JM|^%TR5E9X/4Q8Y8

M(:\X792@MRV"/'8".ZS&'N*U\H/'DMI-:)31NP-"APC\$6ADGB@J%*5A@WB\MC"
/^\816W>@MZOZ"B:U^DHI<-V5_)4K_U7:QTKZ.\$_IN=^FWO^R1JE7/A*:(('M"\$D8V!
I4*I,DMIPPE,O\?N+L\Q*ID6;OR=&[M)2'^_B9[B&[M8?OET:"L[U-B_GL>M\$6[UH-WKP?
=H\D;C:_WB\[%':CN9%X\57RZ..1TCKHW#GNKQUS:K=3-C-YN5M0_D
M4_GC.\$\$UD,^V9L? MG0XMO\OC4LU4J(A.\$:4BZE/K)% \$S2_A.\$\0'9,'2P(#PZ)%;
(Q6B4\6UV.)M\MM&5,F&PMH*J%MK4-ISEX\GBSC?PMR>)PGAQIE\$R2_8N5YN7AE!3*
00;E M7#&#X=Z#9XDH+PA1W7/%I_MZWTTG83&;XQ\?XSF,Y/TFR-8X35
M\'^:P7M7"^\D0MN=2-<;G?BV MB_(\<'V-1/T30C317'-_8ZT@"HEZC
WDBIO3Y!,,DO"8X#@***0E@H1)6GP MU\$JGHU2DW^9KI8GH3#Y?#OF\M\GQG<-Y?I
M12997FS\I&+M:C;E377_884<2@YR&*(^/.K_/_MS\? 7^=Q^@QQ-
\$NM\$"SYD803R>LX:L\I&\ORX?/KZS,6(>W#EA&6TG,7J4&+Y
MQM\7S7R4S\UI>3R#VIR5O/&US MZ?52Z\N-
7&_K';:K6H>Q)8=V@V\0@2=S>QWS^Q+%CBGFP M5T^K+'#+<.\K>&HJ\WZG-A_:?
&LJ= TU5K:FJ-96\ID?ECYK*O8/44R/?GA;Y M-
G,Q77&FU!3NEYC^5=,>^TQ%8582)P@D'S@(\PQ84>(I(K?2HKKB\I7\JV=R6
M\2I=OWW%0W YY+PF:E?\$VODMK8C59Z)VXAJA28#3Y:1<6D0?5DJ>LL\^20D_M^Z1,D
TB%K5#JUE%K"?HLC4?>QW_-#UWX_GY%6UV.%A%0%09<3!,5\$7#M<K
M:JUWB8(I\1^\$S>7)"!Q E0\5 MK>J6\C\;2>-07\I@WNJ8/436J4+AJE (5%+KO) L=
3!0@!'&#JGUB5A MM;/A:6W,UE&\Z\#2-Y/8,M\59\>
/_\7IZ7Z\MR12NL5OG9DRA6^>M!H?3& M%P
*R:).FS)X23)0%U6*T3,3>ZFBN4\XJDIN\=AN1,G\37-+<"5;(TV\0R)
M:I!6#4,'89;B:#X83YNF:K^U4ERM%'PF\;1/BE!83\2\(&%QI??44C5^Q9"/_L
M3+VY^QW\$?UOQM^)\OQ=+=P5_AHM&9,R#1\$!"&*;!<)HC%,LB9^NSU4\WDSXV_
MG&XX"F0_+=ZV9_\$7\>DDP\DU3C16HYNEJ.KA_O?4G0\,9""BBFA#<9K\$(+
M@"5"K58R9Y;Z*?:T.6\I":NF&PZKWK,R"(A."36):-<58P"#13*F764M-^*Y\=S&F%,,^=
M5.9LEW?_:71^L0RU2MEU?N^[\4)"UM4\0#M7-:,3YUCH!M0Y*K8-2ZP15_JC\I
M4>L\$\2#UU.(RI^56NT^#4U2D9R,WKL%X+S'
M5;2D7+@/D/_^NF:_OO*J\=#*FH92H6OGM\1"5Y\^IRY\)(
MYC@'83(-Y4#G01G2MM(#>GCG&F3T\$79D(H-GS.\&.BJ.2A/XI+_YW_"S
ML\DTI*:JMH?#.%4N7_LJUHCOV1*P%)52H:P_DXB'Z%,DS%ABN>M5I2V,/_D
MMR7;\248AE)N.(JCW\F\I(M;,>,>F>(A:7R3/#/'CA,@B?)'@?\$W"JC/=!,AMC MKYKL)A
+)U#QJGIHG\XC/XXFH^8DQ<&'Z316-:,FZ\5\O<<*&AVB4#*7:#F#
M@D5)"E9F%"Q.H3)L8Z:TDU_W)%5XS;L_%=;M2;#8(=FT:-G1E+JJ+E=DK,BX
M&97;4\B5R \3R_\$ZM">FN(N\$%)R+IA\6N;QLR"C&5)**S)6!/_S*:,OIW,W
M'HQNB_&O\F>/_N:V*(\$.*E'.N)A)_R\8>07&ZC!_KW\@HQKEZCJ&JJNH:<7I2-"V,
@9FE0+9<"O&4<M'+Y+22#6D4\IBH<6!;V95-
Y7)#0;*B&J1ZBJY!40*R#V%FBMO=79>,A)H&K-MM+'N%)?@\$@B":
IED\3Q#0+B\ROC+QPOJXN\+U47\WG82>^VX-K; UX+('UZY0:06N'H'+
MI:"M8(A4TMI2_HX"WLV!%-XKEY-WT??J&7\J<-6.6P^JEWDO\#;7XVCR83T& MNJY6U-
L;MHK^L)@N5Y<3O,CSOF?GEAH\ZO%#N^]>*6.9!B\!JD,GW@*XU\$S
MAS1.IZ6*67GJ69I=U-*)H^9L\ZASA\OKI4L:KHWO?-?)3/UP\KOP/-W,WF MK\MI0KEI
<^Q=D\;C2>HLX.60Q9'D^JLKM*D"C:NG7\&Z_I'2&0YD_'H_=&D MS #:5?C"M*^9!5?J=:
IJQA'RIQMW?*XIW@A_.DF#CVZ\2*7RY\$4C=MF;Y\NAK\VV.+FBXK7R\^GVM
MMNE?:E7<#>F\4;\$5R.,&AXN7+-H ER6K@)G\$P\4@DJ9#9 M)27EP;_?
YAUXP,CZ/WYGV4?K/\$25%8CL,QC*,F29;'+:."<\2@:G6CH>'5@6 M
RHFD0\J)*AS!)V1%!B1Q-VI9/SR\X^_IZ:-/N8?D-^F,:WI?K=J7&H:QJ' M_(J11(INCI%I?
GH9X+?'9:T+0>SGQ#1+:FR-71QS0^'^^XFZ=)(*\$M60F):@H@,25>6)BU6_M",65\I
(++/BJ#/Q\IJ.(R)\L@72W\^B=QDL6:/29)@C.* M1-%U)%I-@W""HU
E)2G/*7#6B!+G)DLK(<*WQ+1T=TBNMW!RPG:/(^\$RZ,' M:L\VAOBM\ID4#?
3Y>;M,/_QS,3HKAGNG25VOW2(DPQ\A(I<\$VJR1"%\BN+V MCX\$XFR)-G?
Z^CY\$)Z\G\AH;?,TD7DSO\I\$7-OF=&V;:^>(VCGBNF-IKSLI M'-A:^^>
(BX.F9SCRV\)\ULKX%ZM5.T=4_JC\43M'U,X1.Q#;^8M#&G'MJ4VQ M;?#AB^S"?
#\$K\LN%I5-CE%Y@!\$>-4>JSM(ZF5'/MP<700AGP#;,@_1+F:7& MRMS-G\HF>)XI"!L-
B!PM6\$'PE34^1"==)O'>3I<^LWFE'6HC:\A2Q;!=W** M87UB6
C2YR1!64)+;PD"5H4(S&1+|\7V>?*?-L.8J6,4E")8S", (T>"XBE!LY
MDI7SF.NRP8QN50JMH?YRE*<\$UP6BO!R37H!\VRP>CT;#;JV\$9?UB*JA\,=
M54Y<3R2RDKD@07LJRZE_NLZ.+53*|^WG\8I43S+Y#- MJT_W
'FGRHBK,B(90ZST'CPKJ;Y*)01@J'FJHT(.4K..ID@(1B90!0@C1>H MWAI17"<"#-!-,YYI.).

MH(O)F%(482@E<.TK&V*(WGE0.E%64D3N'7>0HT(%UT0+1ED&1"EI*>K(*3W+
MR5,M"E5=MOO1;G_->132("IF2)6+66H#=#9:RNL:I%:K@-<:X(1^+;0I9.LE
M9,TY",\$,^!PI2A)3XG.C4+:C*2>ME A\$@-.MN&&E)E!@H"0SWAK%<^C4!"J>
M@+BAJ!V%JS)=\$;(B9\(:95SJA17#9XD\$,YI<*:.\$2I2BTI0HPU6^B9#9,<:%
MHXBj'E&565)"ABG\$C+BI4:<7W=*LS^+&&KU_/WYLU M)\$F^X%=)TWNjTVW&
MX,1j2+MMIE)5S>A9=:FVI)ZO_:LM3C*[0("#!"2Q/_UZ1"8N@IIX "1(1MN,
M"@3RB,/jYT?X41&R>J4?2&^_KFC(22;I*15>C/E;73SK\$15Q90G5"7&3'.(N M@70002-
-4@':07C.^E2\# 2!8LCMF^M^ID3>L6N9j>ESQ2I)*54\$3#VL>"@ MV;
(DD,,X>ZNY)D:8Q.*6O^ NC0H>)@E8'3%>H:NZJ'?+K^48N#>S_ FHU(M
M/D2XQI=VMBAR:L\F,,= E2^J_'@Q?/52Y<>?IUC5j9:1'B&0(E&BSYDK*@6D M(U:
(8:EH#"K GK^O"EWZIXNP?UO@:/HjB_@ BZNT: ?UAKOG85.6B.)'U^J=|W
MJW50&QT^Q;VMZ'EXZ)DX9HH:A1(-(.6_@&+3(@'%ZT.E!%[KPI !Xj>3!QQ M_?R:++
X3/:NO^Y|IA>-N-IT74D)PS?ETO=^V(F|GBB'F%& M".).F0#Q@@:J37QWj>=jG^5-
8=|>Y/OM6V) 5R6N%OPj/%1Z_M%
jW'E9*YT9"/F"&NM(DR/SL*'EERCEZ4FHBI<5+RM>WJKH*"/.!NT0 M#E2!-
@^:N654(T^2U)\$+|A7>:VS-|O"2|B.B5<7+.VKT\#DW _SK8@&'|I?P M=V@_ 'PA 7GKW-
UjWXP4Y0!-B!/_|5NA0\$W|>A|'76R^V.|P&B%KKFD"IO N%
M8'7V,!#0QZ)'TBC%5!)>BNUJHD0)RX)%A@;0^T3(^8\$2(jK!!M.L|ZXW>^GIU.X|U;7S_>
M."|UW6Z>,)8:S%)0U"(I7\$#<,XYL| '99)SGP"0Z;6'I7;I6|Y^KS/'UOMj*
MI9=B;+10RFN/(E8ZMP6(&1>!'!)1P=&(/1&7=|THXKGE+-|Z/X^9N9%8^FX'=|
<2B!|VBVU7_TXO>/7FW; >8L'Z2_.K
M7KC^=P|+|TMK2I+S=K.L"9L|=>'G)DH/jM&@"90T#G48C:VVN M?
APETEXZ)!EHJ4\$G\$K=K7MP%AS_ZTQCFH_@A#;-;FIRG;-H@N?_)KX/UXU
M\$3CR'.Z=P74W,UGEXU#" 3AELN%:*)Z%I:NB'VP>V&L|GTT63I4|GMP2 M'H:?
+TS&9#P6^W@R|XS\$^QG|:W #D,|+G77S=Q7,|A>U8K\$-QG?7/?G75
M@>7GMFO+_EZ|7CSCNI/(EJAC@6|8|?|8WG7.^|XFSJ6Q*S|3SWLZY_U?+|S M
jZ_&:UZ%=-=?2j^S;XOjROYLY|@;N^7*UMK;7V7:|4?
ECY\$YCGV#NXCC"+37!Y/GF:M6NWC=RL0L,5\$S\$ M(>4CRTG@&CD=
(HK<6LNDH4IN.73N\$FCVT|GY:'(1X^|H|ZZY<|HUSHI=U53B M1|S4B0|5Q@Y^2RN;
|1#&N+'>@|@Y0C/M94XLEY:1#C//:2U""RKM|5=XK|> M#;H\$1:UO-
)|M.&:7;THKS3IBD=_UHY/XMA?Y%)+TSG0814;+X:%JK38B"LP M1%-M)
(HTIT8;BY&5H/Z*R)G3D3*AM^(*J/TCJ0IG;GNW8KIW@X|MZNDBB.Z
M|V+4SYVV*UP|NRU|HG 5'3!|4 J@QVE05 %U;*(2,>N5D,\$Ij;="2F^CW.X<
MKFHSJ^K8W:MC|XN=3NWXJ4%@"7"C0IJ|1S2#D&0B&YB#1/!E%L MI05EE<_.|H5A!W;
|HR6W|=C)<;35G@M7/'?BKGCU|+;TF>)5M)C2(!*1#/\$
M,0;5U#F%B%>.>"Q%|N=.VZKQ.X9K^B1,,^O<'#UR3ZB(CN-?7&H^10,KRH;
M7@S|5-FP<7HG"8DF&J04<8@3S 'G>4 I2J6UCP::>_EC%Z=WOZ|S&_P1IY_C
MSD4\$)U5\$5-Bj6_K|88MJK2O7 3'L 8*DH\$A| 7^j)"-3UBF|98+?)>A@_|"E
Mj:B@51VT|V>40X_!>=)ZXMjZV-|7F-L7Q#S5/&PT5|)8RZ-jP@+(Q\$7*B%G
MG4>">,|X5A">Q5@7_-XK-CN|X'K=NVI9:)Z:BMNU2U|;A%P?2F00DD+<;9
M4^N0=D0B;SU)S',5M^N6W=%3NW_<\$D16W*H>V_OSRH?9:9Q6F5_|M2.&W=-M-
:/6>,XQ2E\$'Q#D#N6(D11(|JCRU4JUEP1 MLB+D|K+8:/#>&&0E|X"0*2++#\$4\$|&FLG*
&;YV#W<6A_"(R8|PJUW;jN?Y
M@2,j1E=70:RRj+;7j.TU|M|L.H3\$E49!)E#=&FM4L*Q@6<'R5F 9HY<\$&Y0\$R|W;+
('E81H1XA-A1 9Z M/_Y0X\$E)4>87%^VO(+EMW7X^S,RQ,j4;N M1|8# CRW)Q&-
)R\$NGO5JHUCYOU |#O'K:|3>I%|BD(|C84"<|'C^=GX36B| MY&|>)U_?7-N0VC')VNV8-
N/>#"?"^B_>|E;I8O+#{_ZXO>KQ'B_C21j8Q,+F2XW|G1ID-ZC:|>C=@S#F-GI
M4*1Z|P=8UO|KLL^|56H33.ZU'7VQ%|U0D'A|RQ>;6+BY;-@:\$6QMYF|WS#Q9
M9EMGK;NG^:T7|5)LG5L7#;.*#DBD)@C"6&'&!*3(^\$!!C4D>A_,L_H/>;'%W
MC&0/PPX@0..TF4V6W3%LS^|BKQ_5=76RR|Q_P\$ZF9:5?SX&X
MIYE;=C'>7V%433|N'FC#/DIKD=Q2)+-QGH=->VXUS\$R7<'>;2|W+;!!WFN
M'3Q^S)0VC:'YCYRWUKP?^|E9O.7B/,F>%N_':^U>**,XJ'2;>#HO M3>&P!CZ7.A3J3=?
|L_';T(#R'\$=Q.A|F:GYL|(V45AAW;6->|^?-?|'Q\$Q#00S
MMKBR.V|^7L:7GP9Z,LH%:T=QUG?G*//7) 24_LY'F"K)J4B9Tj! 2/ BN\$^MBGQT
?|j\$)jF,V!%)MYH=QIB"TA)%YW,S&6=R2B@8/(8))@ (W,jCUH*\$<^FZG M_O3M./P8A?
1I1>?9N3/4|B_OAN6+1/D|_B-./SY-L>OH_F: MF?SL|4% M_V5|WBSUD|O?_WY>TXE?
GO|P=%'0.!%@T@3DGYNVI.GDK&>:|_j9"B'/ MNX,DHA
\$XU0@QXU"7|j"M/88!:jADQ@ (BF|5NI%*NT250|91#=#8V2TA'J9'F M@;#@ M,F|(B(W@%R

)#_E!OE@8";@S#;57LP>IB!%GLDRY/NVP,.LUZBVD<@ M+@L &1MXW#S90;
W!*GTI3EN/('@1;09'+S+\$1>6X3=HI-1FS\$|=7'6V!/: M K#A:O>,\$>'V9P0)X4-
Y@)AE23B)#>?CC&3H(L1<^PL<=I'I/LEWO;O=3 MW^1Q1V1[7=QI,B1W[7-! ZPS!U/#
(2!IK'-'LV3\$5BW6VW1 /=CEP%HQZ%L"|"DF"8Y&*.O"5KS(M;:KQ'2RG7;T"YC:I
&'(Z4>*E H!/: 8.W:1=ZL.M!CU4%
MGOVU'7V\81XW/^9G\|Z[F=6H^1B4+GM^/FJS47R%AK3LXCQT=H5/MNMR2\?S MD?
5]=\BJ^&%/=D MXK?>JSL2PQ7\O"M|@.#CZX.+Y&!#U(*0:U#|VFYDCZ%:KO>T[A7-
TJC73J<7V9;^ MG^U5W2 R5WA^F.@=!.B<7@-P.PP.*:6@D6H!RJ9)% Q=98"S'A&|?
YM.SN-T M=@&W_O0_|;:<^&N\F#BEJA-KM3#T!)#Q&U5;+1\$T#M \$",.-: Q889,\$NH
M3F#N\$T7NG65ZN)3"CZ|/WJTN.YQIH-
E;')W\&X3HFY|:OQ+"U>&#B|\$Q8H#=#UX0D,S^7N-""R-K/1,&^"C=A*ZXYM'
M""T@8PB9&A!#1Q9H5!QY2X"||&1";EU!_.\$@);GE-RJ('H;:_1C=|!,\ZH?1Q/_QJHG
Z>=PV6PZ'|1)&'P;:VY_S%T6 MK 0I? "-
&81|'WM=QDSR^EPZXX|DC5TGQOL\$SFQ1J2/LJXBHJ#),5QA9RS
M!B5J@F.:&RWY+JCTHS^83Z*U*ATQQJ>!VQ/M_X@4^3?#2UJ2KWJ.9F!73;
M;K80:2"11Z)EWS=G|L,V)-Y|YH|Y?
7MQ1H^Pl:WT>;_K7&7.,|2X'G9|9,^|+J+YW8*J+|8
MAA)QW3_ZU57);9_KBW1RQ>O%\^X+FNMO%6R8R;5G|8C_88Y|Z%^_Z->|FQ
MX>||XZW|6.E%|[H|Z|J?/=ONT|Z9+ZF|5,KF*ZJU,HM|GW9;6P?_83!;K(
MO_X_K^BK;T_VKGGY^UV.NZA0-W>6W9TT|HZ;_:3(I_+'R^&/:|W&E3UV7L_@
MYA+Z1A+YZ=4S>#
<9ESED;3V;|MWK7>/0DTK&O3\$,'492Z8.*F1X*B:0(\8C3X.07MHL(%|S;QV;
|:H"A=ES^8DG4UBBPM4!;VF%|JQW""%8M;49D\4BD(MQ+%+2+L<|B-Y3(I%8L)6#B
FQGH?"4J<;|B!'*2Y)TC);+V6-!HJ'@"NA*QP MM00?
3U5W;Z_NFE|=5H\$+55!4NLPUSK,=TWH98(R24 &N:@0=XP@YS%%"=1E
MHSCW&UEL%JE6, N(S:-N*,>^2LC"(%H!6)\$:U5<%M'S*(OE2RRY7S;H"
M8@7\$W07KX|5 7T\8I\$0ISP3:U!U&*?=%!|BJT4*V\C=Z6P"^9|R I68\$>>-
(L\$C:(%\$W%N)G% *1V@'|#-58H\$T
MF|'\$CH_6|T:K5'@Q_%.EPL:9I!""**R\1UBS7&\$T".84|\CH8*KV-8KO-HZ/;
M,1L|2L*RW.T45-X4'2(T.T D39BE;TF%7R=C?Y|V'B57#_TK3B=YKS7HL&^J M;*AP5;?
T^<-54BHDQA-BT7/\$'<('ZF 1QU)K:P.GVTIL#,:0"/CD72|<(W1 MVA&*E..)N<@<-7*?
<+5=5?N(D^MKI+PL|JXNV5U|LU63K8>|!3#P?N)%|!5>%G=1Y8;,%B8L7\$|_F-
M'=-VJNP#=#@Y4;A61<=8B3V3"5@5JU%8E|ONJW+OM|BF.8"DJ+!Z>A|F&.*_"
M*L*ERFU53M5&U;51|9T+IQMO,9,@=F+NV>848!)Q&H%Z;T(T00BN|E.L^8E'
M93RSWM05'RL^5GR|#3XZ8WW.>\$:@D"?\$4|PI=JBP\$P4A'-!+T:2^P1'R4|
M\$@^;|O+D|7%=H8?/N>|I7Q<+.)3X_>O0%/T&\$WJNK8K7RU)M%=AXKF6&WX^;
MGZ;:SNWTHLFE13;:|OK1)=-XAT&59L-?INT,|FO.@1%:GTNEQ|(3^6I4N>?
6715?;+^UHU "SSZ>EUOQR+*4,'8/AS,>CV'5-MM-
-1&Z>+Z/,8.8WG\ZD_M5W?!\IZ#QQ<2M\$OFRH#=#IM"R:O MAG+<_"=05)QV;
(KKV^G;:QL78:?' M96G6YB1+:3W3V!G1|&;WF9?HO3+(?MR6:#.5C+N)0GB-ZNRS'YAG?
H MX3GR3PL;:|:(8^_8RX ?H^ M6^X34FJ>7NZXO>*9@^NA\$@-G1'+6*
(LIU@)9*7BR&@MDU!,6KR5IZHBR?E7 M#\$EIO*EQDB!-N\$,^"0^:"O5>A>|1VW))?
H;|ORWKOK,6JMNMM#-1 M3.:S;F;|EMK?)|R7T2@%>.:?
7R>>^+FJN0|(#)/FW7S0^1W(RC2=V=C4^EW(5WU>#AI(6K_J6:).3F!LSK525%:/U)/=JZU
M@YH!&"8^QM U:3HY6|PI/+U0:-&!8&
'1Z;8>9,L|H(+.0.2DG#8,2XED("3DT9&B8A\$%"0%:E6(9BN|
MA6M/X0(D,,FIW\HARYE\$WCNLDA-*|N_H""^&|BP|13YR3-Z0GA9*P%7XMOVQ;
M:1%@&1\$2VY MU!QO51B\OS!|ZS(|#,'V>YLIH^S!YQ3 ^I\$^>?
Y<9%OZ_|S'L2&;C4Y)IKS2>_L"R&F+QBY%&:W'0TVT24/P|H9-%ES M.#3P=0;
(68;#WN(O+H6K7^CB1J(AD';1LL_77;:-7\$1%'<Z)/GDS;WKYMF MU:%_0^|>R5>
|>=>.:R""=GQ=A(<'V/B^418@|J-06U3U8>-4IEC^RI>6F;>S
MB|+OL|JK"P34+C/YLRQH:1 'QY'4""^&IBZ M&(FXS4!O*\$>9\$RU8 MC\$&+:+:/6A/JHT\$D
EOR:"DR,1?^U H#KU+)N;N*(|M%^C=@@I63/KOU */MOB|6-G@RJ|U+*)1/_M
8VC|BLZ;4.(X|<_T,H)ZBE!'F9 %85S940E4%2\$|7AMV2%?1P|H^3/L!H M,(DW_O,
(VW:M73(8(:WC%5@|>SI!|=,<>TF"<5P!#|YN\$)|ASL#6^ K'.(D#Q
MP>E_UD8J:03|SPH&^HPR'!OD"">"6W@QVWGY&T\$=>ZY^|Y?GA4J%(_DA_1Q
M5AH3KBM_|#&&(KJ|#^EM.6&Q/^8N<-.NX,92;.-UF*#?*QI;|*)LY<7T#B M+
|U@N2Q0@;:ZN?MGJ#V!A7_.NUF&SF9^/@BRB>_3%GH:P"QMH59G;.,4PMR

M+7Z&RXN(S9+PNM\735W7!W"%,!OGW\>Q)YMB;%L0CW_@H DCDV:CX/-P\L<
M<)K/*!U\%<I&RUD:2^PNZ/^-&0Y'-I_?PL*IF^6.R3S>?"DI^U\I.F'0^I
M&J=GA:\$RO_EIM'U#V=D5ZQ=BUC!\H?&97]MBOU277[#T/@PSO+#85K#X_H8
MN*SWG.0>NN/%-%9K0P 407@:B:5V M-@' R:TH*)P5*>^08ICFAJT&V:
(DD(G\3\$H76:C\$?EUIS70%NM>T/&_LH7X M4UDGH,*5-3-)E\#TIN;-IZ"2?
*,PVB->Z6Q)UF(B YG&E#),%BY;PS>85\95 M\%RNS\UK\ (C_ ^X40;3>_H-
#00KK!F\==@EFT\=HNKS-OS\$F'PKXPI MW54^M0*:&13!0LL1)N4Z.U\T'%\8?5L!?
R^!|HO8BD\|*|&\$-I?7?TTY:9(% MRWRXP7:#!P\3\$6\%9H^0:HMR*-LDKP>;G2Y:.*-(C)?
1-[XH FEXQ5BGI6X>O/AD#O>,"IV-I&B9F\LT9O&DP/A\2O# MA(9F\HT?V0\I
^!R0'(TG(2X>\FJC\ _B_2C3^U\>(O8&U_HI".^V5L-P8>7XV M?A:/GQD+U\G7\^B.
YOSB==6?_7 MA6EA6\<;
|B|CNK\>,'CK'C\$|JVO:>+|=)'IC"TMDUW+C3I<)'TX|E=5P,C"S0J4 ,M\95.:8E,L!A9Y@EA
MBCHEV3_(S1;W:0J3(6-QO9';R1=+4=ZR 9\421)V! EU\Z4'<8@7+)9^PN8
MHZ.&E5ML;W-T\;C7\FIX,&_ '@^6U:~?OE!_)O.J&-GO"71>GGX05UX\|YZ!9 MP
//P)0\$A1DLT&\N3\|L&^9;-;W;JPW/-;'-=CF%Y6Y3ZK>\3\5ENW\)\ 51+|WP8&*;VR|*+
|XF?,W9T<'&O\@D MK40Y"),)C+@6H2\1\0:KT4 JA(I2:O>-R&JX^L+& QT\$B\0@
E&H\SATXIO!;K>A0X^1@_*0=AAX),^OKZ(U>/M_.*(M>|WB'PX;KL&3_-);%:SWM%V:
3B?>*2IH"\S\TF+)7(BN21Q#(Q&3U.= LH M\IE*3YC%"4/A!";&U")0^Q2.!
()L5D;+|OM#3,D4CD\Z>C\VC93&W\!D2)?=8.4D34*BQH,FY*R-65@S\@^W:\N-Y
MMA@_C/_+3MML+69N)KMC7WRL#BJ"+*>|#+A?5(''+#;UPI9K;|+F
M);P.(0/+9G8ZNBB\,|F+579RX/7AMY5X@9OR8H/M VC1C@\$5AF\.-XTK\$)TH
M54!;0@%I:= Y'4D +4\+7 7>""TO\H\$".\22T?J#.7\NAZX>4+|"C46'P#5+|6P\#;|_?#C?
I02G./5*U M;Y,=:|A=T4I7)'G0*|7Z-C_9SX:\$*GV\$_5R=>G M?/*C*|(^>^_)P/TEF7E-
1.8C&@?;VL<:~?|D.>KYJ?Q?GJ0!UY9") E,8T\|MX|M'B>O'\$VLG'@^_%P\VK#,3N.5P/!@?@
I*Q%F7\N'_NEXHNOF9P<89D>,EYQS#|I*3A*BF"";NR11&3CV
MQ#"9MC)N;|/\$66%9Z"0\Y_X\|@8^H?'M./OBW02X>C*|^)@GL:&H\|=|2SG)
M_H:LH.0JC5T\|ZDFG7+PJJ;%G MWPQ6FE)O--(AT.S UARN&G;Q0-PR|
|>"7UTM/TWB4AF? M)6>R8,"'+EB;O>&;A|=|SQLB4^C6>+<\$N0\$L*EMI3X\7K=
M5XC/K_E|R.&KL\PDVTP5YM,E4SW"HJ<MY,5(G|
|9+KR\$9Q@%G#5"+X;#S'.MQ&S3H^)|@R@|P5Z@O'WHD>BG9%HRW)L0!T="10;D;/P^
MP;(91S!8>N-T&L\|L6_(=|K):U'5:./|Z;.'PW@\$AVEFI_ ^3B1L9*R3Q=IFGD
MZZ:3^&*%9%M.P%W9'1_*_#|~?OH*FQE> M\9S!HV8.IOS207.|J@0S#4AGZM""*&#-7Q?
4_OI:|O-8JDP<6F65W1M&&RM MAV>>6(9T>#R\9*G#\$UE\2--P&I
|NL5C"+ABQR>9WTOYE3UKF\RF@"5G8%SD M;|ZE\TD@!;4G&2X=<5\$(5\7-
/6J;GE#0&T%AH!BL.RX81X9FJ(A:F<2Q57*K M.;JNM,W?
>^&1E/RR7V3,W:WE,S\X!KH22FC\$;+4 M@?;#LDD4M<|U/KUCT1. N\UH3#"33 F?
|D'|==|G9C@BB.'M\|*C*|D+#+|_9 M6>>?E>X=H^6V+V\|>Q7A:%#_%
|G7*VW_%%3%2:X+,%J21DD-RXGN"Z/XBI3U M=>=H/EG+;~&3T6CRI6O^7/*^)_.'M3|Y?
5WT#ASX8X336Z\50=1=G\ASU\ MS?\$(WCS:ITJ"EY5\$-*4QY/SG""X>?
+T@&796P=O^M<1C(_QGQ8W^%Q! MXKR+K\|MX;G/@U6(=2M'X_MF0KNK<|
|GM6E=.ZUXOGO'FFC:9Y;4""S\|_4L MK&'.?1K6OW_C5G);Z1WOO-MMYIAHCE?_N^
C\G\;G6Z=[M.<|G?;?.7TK^L\ M\UX%J+=I_?7=KM4+&+|5.@=28JK,W3WU*+E-
BUH=C7\A^A W21?RW) |^< MZJT:.*#|:|M_%;KI>/9Q&4:RR\|EK?BJ9=1_C^6Q(=
<|)'=R>;F\0:/ (35K+Q4 M>6DWO/1KMHPK*^V\$UJK@KV"U0|"B%:PNK=
|&D7E%I,HOE5^&^QR^LDOEE\HO M5;Y4?
JG\4N7+85N(Y;QLVT3TL!3)WH:O\$FW9EBJ;|S 7M2WV\Q/VP>^I=S MX=J_-+Y-
F1^=|AZJ+_ES\3GNA""!F2\8H@'89&V.B)KO?.J.N+T5IH4(TI8 M%BPR-
'C\$12\7YG+8LE<)"(QB@>WE,)/-P+D<;|*CSN/TB.GK&\0\51K?+0=7 MV#J*5?
8VF7#J>"LY2PB LB#>&0*Z60LDH%|'A+*FX7:\$LB:6P2\$D0XQ#EF MR%
(64,*!:"D52XD^&&R1(V.N+SCQ5&FPE:%K0\;WR@;2\!D5QH EYB+_%J4< MF=R^\$DL?
H\0*:\G57_=O;JDH=S):LZ5M&44\!Q4:-8+A1FDELJ7AE7\$"\$Z,P\5O%\$O<&6_((
MX^NKT3U5&G\(-^(BTN3%NQ\$_GDZF,\27K:Q^Q)?'/E4R;'1X34\$YE@**3'BP MPY-
#QBB!3%1\$TABLPEN%.^|B/BQ*A1P%Y=AA:H#I>L*5<|N2Y\I M5&DN;)2.(25\I
|D'C";)|2)0XD4H\09*Z5^W*"E4'3M<5JH=ECY3J HN*1L, M13%*@"H.GZQ. #N)
<9&894IM&8!W<0U6J#L.OV-+QP6=|'-IWH%7R+S5*&P
M+A24(9\$K;I#B&@>:H\ZSB0BE JM>8R<;77'NXM7<,%SNP_.(5I7L5#!JFH MAP_@&
M;|S@LOYXU\UN\LY=|QMLQWYR%JM@N" |?+|FPI-AL#MN^JV\1CQ-X?+G.W:+
MN&4:M-!!!&I.C&)>\$@4F6-(LHEQ'+@(@>*Q#\$.&/'^0,#.W)58\3D%^B;E M-

AX=DZ_!K!4J*U06Z'V0*#6XIBX\$P3P*Q#\$24C(6HZ1=5XPX4W4VQ4G[A2'
MN0^H%=14H*U_6X&V_NW!_ZW4B:6@#.,+:M!:/!0"MYP'1I)(2BF,GY\$ZB2/HK5!;H:9"
!0Z@5FA/N8H4Z=)C3<6LTUJ#(F7>.T,YW0G4;#!_M<1\85:'V#E#!8!&S91KM.,!X^J?
>Q4T^K\$UI>%<>LOY4?+GQW@%ZT3!:=NI8
M)>!NV9(>T!R789)!YC%EX./4;KG)8COY<7BU^(I8!ZE40%IZ\$#\$:162\,T@:
MKA2UD22[92G/>E4CG?LJNRX-[ENCZ2_-KWK=SF_4_AM1T-ES^S<[FT_!61N!M!?
6\$M;EF8;[U!B7O_3H_B]/6+!Q9\$;A&!(DP9Q9Q@34R*AMB":?_1_P![\$@M_MZ;H8-
XL6_)Ux!;V<4PSXM/F1X^P8M^&\$W!Z^:"%OYGGWZTWf!&8D_\$CW<_M;_NN==?:
QJ:P0N/B:/*EF4;XS;W!9_Z7A!&E?VXOSN#>YFQ)_M(,UL4B!N?Q!-*YM_
0KO[R;G;'+OZM;R;:W;VZU^O4=1_ZR_X6=0N'%JC3_MK_05!SUV/ILL#:/!Q8H#S!?
CD;V8C(?*N*!Z5!]',#!&?UK<_)0RLN==?-W%_M"UXMG7)?
O45ZK!3%E_K_W:UZA/_AATK#D
M7!^!^O=OW\$N.#;_CG7>|31QKRO;XR@/L!^!U4#VE1HS/?JUS^CU!=OC^2R>
MN3AM&#YJ:I?>6A;L(8,6?HIG-L=83)M)NC'Q'?!2/+9!Y=%WO!;2N9=;A#MF
M8O(,12=+XSZ/-.*\$D<2"IEQ;%NUEV!Q:0HTD\$6&KP)
!+G09'!';O27_7!33'::/!SE7Y\$EZ2&KZ^*TY"<2&J&+C9;!*
ME18;M=D<5IQ\$X'_"/.KI*B5;XE2UY_)9IK3!(E!%\$!(X^90=PZCBP'
M"T52;Y.R((G)OY>,>RAN_C2A!T"?
5@2LL6\X!&3ZL%M&FVRQ0YZU\$V@N*N%&N/UFA4G%'_MA-
&8;4=VJ=%M"/!Q.41JR:0M44NC_C!T^!G.;J1OALI35TSC?"\$+HY+
M@E*;D2'NKGy9-9JIT?1_LT5DI/Q_M"0).KNOA'PVBWE8\K26EGRIH26E%
(K(R!;\$-42*N#48@_BUB1!,55<2.JCT*MPU!G8!J3>4CU\$>%
!3FYZ*34G5!40_UHK3GZZPPN1C+,=3KBCYQ,FG9F!>RP;!
M!H),H+18F(HJB:#\$Y*IU*W=,JM'4OATOYO#O29YN7VTH>1J",-&_9<0#XB\$2_M9
/'*#;',""QGDME)JN6F(V!/4&H?OIHP4!EQT_3&3#7X&ZZ%^!^?0BUX;<_M&5>+8!+3@B_?
%#_#JSX.W#B;W'J+SO.S^?3N/2<(HKN.O!^M4._O!ZL;,>/_SI#_=RC5^\$'BU#Y_=-4!_*=
!^%12F;C^R'1#7.=F&D!'"7#S_MU88?_%_E?/7K;|3>I%!\BD(!C87_LA=N?C9^R+F?
&007N=?WYS;\$(#^UPS9_MMI_%(,#!+_XY!V9MNEB!L-
R*XCB!_9!T;7EV="VG^_Z9VMI(W^!)(3G>PVE!_M/^!_!38WUPM?V!A^(Q<;=
H4B8;1M^-1.X9AS.QT)YN_@#+VG!|=JKG7BTJQ_MAM=V!,5>=
(.3<'W+%YM8V%*LV!H1;&WF;O?;I/:@X0\$9<+%%##W^!_!G_!W_M(<>KK#CMN
R<;F0CB%:>*\$;!MO'F!42CL.S<;>'! (FUL>\$!Z?<|TX/W#|!#1.FS6&O>7" M;/E3Y_?
CB.&YG!?-<9;#&#G!F-DP=G_%?(TAV!DG%_CP0R4/"CI":>|!1@
M_&W8R0!.B+;,\$)OPXC^'_^XO(#<"K,3WS\$1Y?'V!|<.31P-7CV(QX!XA-LB_M-7VBB
1_C'NSK?G2SDX+8!X?@?W6CFWS!F0:2YC,42,1'O3+Y*3U1P5YQ!O
MZSQ!U+2YB,'_S,\$&+-\$S<7R2O8S!(H,ELC5P'#F*4/8_-/69'IBQ^V_"H%G_MK&N*5=
_H"MIG1N7@!YF?3N!&Y@Y!A;&U9T1?H'>!ZX-#/H>3_M,CE>#:L(*&9\$1-H_\$
D&/41FYBVRN<3+!0)A"(L2"Z5&2DR!_R\$X\$XM*!!D_M.!|=RX"?CDWS(LD#
E9+PG73WVT\$>/_Z^LLOC(=Y1_V_P!UD"?L;.D\$W=QV8
M5B%SRE6,^!|=AL=\$KNEZA.45!+I8DQW1J/R&|_81I?*@4#|>2+95V4W5^=1F_34#_!U
M#E3D<7,^*L&(O7CI3;XG'Y.!T>9L<^BEF:0P\$CJ8QP;4_MR-
+%A6W7S=>NRL.83B!LJ+1XS_&WS7E_7)5#:#(>QW9T=K_=_S7!#I&3@7
M#X7K%M*!R8;72=!"OO!5<&ZA)H"2!7-?
6F*M2M,Z%G;K@:YF#XOY.1;BATL7BIEH!HY/&!Q,UP_C!P^W"P;@!%@_8^;=>H(\$UC/
M/*X!J3QF&7)ZQ1_6;X2'M"6DNNDW/Y!8S4=V6F3-K3GKN7H_WL-RGXW;U/JM
M/(J^!CL^U@H+!UG;XW39J=V5GZUF=R*CR3.+O)#E!74!KLBW_C%3J=VW"-!
MAK!TY';8@&*DS@N<=N;DNWP0?90"#J39?9H#B25T)D\$P#;+%|^/MH#"SA
M!3SC&"A)X!|3L-J!+;6G@V#/_7"T:%)!_TNMG&,@R@T?/!\$;S5K+!OB3&|_M@-(R8^
X4Z:"QX61CV!MNVU"X!&#VA*H!JWFM'HOYK?>|!\$;)
M1VVS8A)=@G"X!Q5S8_2T00NT=9)&65_M++!|RR%8_^DX7G0#IPU"_Y_S<#)
(J!21H@R!B!-9G!|SR+7RW)QS&!W4>AW_MG91:&"(H(-U"+@VT#<.#X?
L8!W"J<%H6/SD!+!QMN3_OPC7_!W1RUNM<6;>#_M_VZ#&_U;)'+"K0RB-
?/!K9#0P5@^Q<\$W7%_3LE;|I7&&G%U>(OR)J"K\$6_M?
3%'YYW/9P.UC^R7;MYNZH!9@QZ-8G!4_*!S7%V<=2<%0? ("H!_'M_@_
MTZMLA>^6!@!X,,S3?CV")Y^_F@8,>)\$QHIM-6Q_V!4ZRU#Q9:/8+B.A'LI2M_M/7Z
H>E!G'S6!%B_N!|YUN0YB_M5!#K?)*W*"N5P/Y@#.1/"Q%|W+Q/O=Z!O&@TZ4#
!S!NY%'69SR!O4Y;2L_P=M0%?&#/C!%=VQ9_N!B
M:88L;RD/>DBH&0)J#A9M/LXF_H!3>#SL_2!JRDkJ&J9!=!';S-+_#X"B#<(I-9Y6P^_NEQ

M*/=WZ9^3KUH\B^+KGI7Y 5 AGL0P NZT*_L;YI_+CV9'W\ZU" C?@43N%|A
M/JPO/-8N#4UX"*BLK6|H3^5)7H=>|CHTBL(L,?/8'4T'Q\$ _;MZN5(Z<.)@-8 M\$?3HU^F-
J6NZ29S(/K^\$. *?DV)A.-F@P18A&C^|O5R"6*_+=W0.MNVO|;46?"0(R:-/W M#
|X>GB/L:MU*>O4FC0|T#7@|GQ9?*W>: ?4,@3A>FT^J494.Y'93?|N6: IO M,)/<#|,B?
^"!/X.6"/(%GOCC?"91KG _;%FE1/CIO.K|U0|H|(E86#^@K)6X^ _;V/\$|C|/GHLP(0-7
'MDU==6BYUOFXP@7+_RK@Z%=H@RF M(C,P*+?*W|Q.0?PTQBVGg=_ZV
MY/2%I3\$Y7X0J#K?"-H9YW 2@|5=N3F7QF&D|S|(\$8EYYPF<-A%/#48J@7)QD MUP,
(J'E|JVS?%;, <3!RX<"42|Q/;<0;<|0S>,A|OZ'L83SZK|/63|21C_7Q: M/*<
BG8:%H0VF<|@MT\$V _/=I+!@(|^ ^@>*LVUJ67GN"JW9SG|M-I_DH8V4^
M/|HX+ULZ6@VOM _.+%0^#ZD"V%D-PG%TTW6S! ?3F&/) ^7VEZE7#I5LO(W|A7. M|.2-
P#53'|L%98/'/((= #G:|V%V'-J6%*W(HS)#-.=CR^72E4G|W"+J&.Q|V MN#/%=-SYR44":
|+674OF#,&X=NU(=Y2(IKGE(BLE@|PE8=HJG^VDUF:5|R?E5(#E>BN_XY^BFA1RV
MS|9|UVEV><3V8,%TA2T ECU?LO7)'J_ L"5"(4XW+* <3;H*!_N2E8^EPKEP M| #F9O?
3*.;SJT()#I";8Z:@1YCF224N/#(|.D:1Y\$MP\$;> /EX! =N)(F&*23 MIXASR9!6R2.L&>>
<&&:MW"B_U2_SA|72KE2YC>B0|A2,FFX|+.3|KS|_KS\$5
MI4>87|_ (1%B0_H+-3|561O/NLN7 W4T^ _),8C7/:G9.99C^R;C_L#CQ9SP
M_,WN@\$&WV;/_X,|B8QO|D% C28N M&8V1%A\$C+A1|VB6&F*64ADB\$9E>P8!8E'|+W^?
^45J'&#O=N|=|UAJX\$NS3 M18! ?J*=GT|G7XM; &DCLT
A\$!Q<%Z'7(&NX0EQ0^!;*1CH:YI*EA,5PF\$ \$8= MXU9QN\$<:Q
VER%GND=8I6F.387RC|>WOR_7XD-X5G"K>Z(|%RGZ>3%>4LB*E-M*
|/|2K+AWXNY|/;|\$.GF1DA>|,?^%&<-=VQOD@/>_A%GV4WDXT&&,ONDDV1<
M(H&51IPQAS3E##F&4XJ"\$1JVZF _>|GT6HT^|+?% M)6%_S)4+IUVYY7::
#W^1FW<1R"D|RR.|C2.AN,T;|MEP-E|T@, '3|63\$*3X32MG>0#|W\$^+1A<5%
<|Z2/(75B3'|*E ME6*)'2OCN+Q=#XI5#&|8IA|_O _|>Q|/#C^'B9_WP?
\$O@5;>#A&*;>QF\$:*T M.
(N=7XHP|,|FEF>QL\$&KH|@ANFKCN+G7A,0EP|82X#IQQOS^U|
M._/ +2YSW*MIE<0#:Q/|X,T;|VH'GT5J1^F%Z1VM|T^H:Q'JVO33Y=|@?E(,7QK/ MG%X2
|=PCFT1<1M#I?= MY.<^,.%SVZW",|T O.@@|T7=5BN*)?SG!GMY|*U8V%V|+%
|6Y*LU_KZ^ _-L M1%^ZU)<:Y%J?LQZQ5EDJZX*KB(W|M(&+BY|;@^ _;|LB@|)^TY8
GF54|;4).+8EMB.U?|RYMYA+,AU'\$1 MW;-|GT%+T?@9Y\$(V#"K> ^' E3K MV_,R-
<&1NIS7=;V="TX:E RKQ1>ZR_:KQ1KFI GT_S-44D*ZU81Y@MM8374 M(8OL:
'D^(|&|29|74|VB""Y14YIAU&O)9JEM,1XN6DLA*>_K7M@#-|7|W:
MGXS;64Y\$@+FM\$E 7:_2EV#S+XZGY>(@X?GO%KGYO='UHUV7%8J7AS(8HY@T;
M<*GQ7*G>K.EVR^BP|K+2| |^7F'+(;%KQS,!X6|!0XN7*CDV6_F605.O) CGW
M:9%&D+^(RX3%/ %\7EPE+AU+DYM|OA=UL1O)<7=F/&2^-P0\$E8ASBRDMD*/SC
MB6;")XR|WXEG|&?;3O _+CN9Q5<>ONVDAOYN,|>\$*^1U\$&3ISW.05; M|^*5MP
ZL^YOH\$P#NX0/X|C!AP0)#_8KKTO^|QDV,|Z|'X| |-*7|S0GR.B MSW((_*"
(7/8LKJ12NR*2K'.MAT6WXOSYTFLL4(\$).0/EKSH;-RE95RG3WN:>|
M<4F1'K8OVV=M' _>VD.6K2T|;\$'A3?WJ1|ZJOK/K7_+G<|I.M@)^S'ZGO^<\$^MI<
M|.Y|XZHXXK?A4VQO?#IX^Y6+!%70J2U266*S6_SN?Y%/(\$NM?RLRH;-=_U92 M(?
IZM.|#F2_Q6EZSVSSYU_BYSAJR%|J+U5>JKRT+ FVYB3OXU, ^N%SCI;AN
MWX_/YRO6H95U*NM4UKF2=?X^GES'-JRRS>Y;C7N8>O*WL1EO9",>;JOQ:XI?
M;W*FWBM KW>-6T^JP_B-
8>LP6F|_J%AZ@5.N%/VLM _<%3KE2|+|>WA6PP\$.QX|MX>!2;LOJ:*D\$HDI1%24B(OHD&9
A6&^V(7:.)1>|2- MBX@'Q9\$AQ"!%E?!4Q>0DO1P,GUGR|3CD _RT8LPKTDENK;""
FJLL_5W|'B MB%)U;9V5ITK|NV7MBF< _;.6*9|LL*>LHHDP1\$0"@%),(|,Q?(K.4H)EQ.QO
M-<<.TK)H""(B%|36S""CG\$..N|BCBYX05 _&LXEG%LXIG#XUGUF""&""(2&_0
MITHBY1%@D1JM;""RZUD12\$|Z2+EB%"+\$>>.09&@YBA0@:O,?
=;%1'WC&E"DP50 _=EQ|L&KQT@PIYQT|^ _L|4 M@C'M(@W"H.!-JGXFAXP*&&GB;:
(JA6BWG*7"FR08Q4AI%1!7+B++F\$56:PVJ MN:'|!|L2|.VB-M_/D^E'D\$@?
E^S|8W2SU5^|BT(<20UVZ|4NWNXXO-AG(J6 M%2U?#EHF)Z/|CUH#:
|A+BC(#N+C!&DB?E/1\$R8+;5S"%AFH*0B!*C,|("N,K(M\$/8*&R4QQT8 _+%H^N+I?@;
("907*EP247&5O;?#(,41US|!)R90_+ #30N8#
M=7(9*"6G3G\$%#UD'0*F%0|HHAB35AAAOC=2^JH45+2M:/M--?|%H2;2FOE/ M.ZW!H&;
<(L-SQTHPO@5).B@MM|S(A(44#44ZY+YBQH+|+:-"8+.GR P8|^ _!
MC?"J5CZ|_D.|1W<2P?ON>XU UL;% _|X.I2IU5\$|9;AZ#-'|A"WHJP|5-
Y|Q>!QC@^@D\$|D)2Z1"= /3TY5M*QH6='R5DYC MHZ51&B/' P.,I *YW/\$59
M|NRAT?|XG4K6E:TK&CY@M'22<|P#1'A(\$M!;B(FH."R3D-#ALB--R'|-& M;5".

(1^-0IQ(BHQ,V7^2M J":4T>7+=!|=Q1"@9?>_&Y|J7=064 A7"8|^ ^AJQ-
VD4OZ*^,SO07^Z9-#|,OPEM=SZR%Z_S MKV_.S=ITL7AAN17%<7AS/NE*_|?7I<5P^SFN
M-VQ9\$NC7&U+A/?J=W:J6Y/TVEY*-C>TWEUM M_@#+VG|=JKD_ ^K
))O?:CK|8BV|H?;.^Y8M-+.Q0-FR- "+8V<|=|9G;H^X! M&?!RM|U9IZWZ-?
Y#W*W%HTDVUO,<=7UPVW|AY|TKT'?XQ^:#U(2NM!5EL/ M7I4%=,06@P3CVGOP<-
JU>G6Z3Z;Z=9F20|2L?|93|'#V'JP3?\$(3K+T':.^! MVGOP*:
|PRYA@|7"S\HC4WH.5)2I+U-Z#E9EVKOP|!V :I=@&I?JTK1E:(K1;_0|7V!4ZX4_:RW|JE-
N?8>K+T'GP8L7?8 M0RN,7QM"|+(A!"/8):&1#4+DAA 1&
<,3BB0\$&Z41)*C+^5B*Y#821".GS0M|3"V0|A#&NCI3,6X: PXMHZ M@";!D62:I:B5Q-O=
2011"@AD3
RU\A..I<|(%1U'#ORO*07+CDDNU180U@GJ|@A86<#11ZRV7*52:"&E|0CKQ\$""*8=,X!0E
M+QTVEF|K|M%C&1'Q):#.^*#J|!4L*UCN"BR)\$80JSY!(WZNW= ! M&Q%TW&
|3*F04VCGD+.6(2PV?' N(2NOPJ4!9@?+E &5D M(F&C&
(HB.@"!):)\$C"B/#O(K.)&G%5BLM&DC,;5@1X:F)2;|@.^<.K5ICYH3E
MRLHMO TC5*I EWU2PK&#Y#Q%O5HP,! M&|MZ4#T% Q,||*Q5ZFR1.T=EI R3VG?
P"0%E|3M8^PX^+1%5NOV\U&X'6B6) M0Q8|N3DXY\0CT,|M2D\$*CJF@5*7+|BIAXA-E
26ELG+/6>X|F)TBCA*|H|-D MVV6|Y|XP1A))6O'@ZK/5|'L8+DGL&0>Q|021|)DX",|
(!N%0=HR'9WP4>DM
ML#0X1,TLR1YF@;C1#&EB%2(\$\$RHB8=BG!V_2^@"QNA4L*UA6L'S!8"D4%",2;
D@-8"F618SFNV')#)/\$VX*W(MX'V#Y=HP_@GL LTASNP9)B|!#4E,FYEA=6F@P<%E%-
V')LS>.UIU\1Q@|!_QO/9T,P+ MEV9>_ 'A|P>_3^&W5'W(12\$5<#),6AI%SDZEH.A)S)'A-
G=2U51SLQ4?0&7T M)B04P*8&|0|N<89PY#%VQCC.."&7L>NC/XUA/HH?TO6'7|I">
(|01VU9LT_Y MFD_PUA|&\$ _JR8"HWG^/SI/-X,(A3L;O+?>A6;>BZQBZ6#P&6H|
|F7Y>_B.=YIC(Q_ZG7?LJ:5@J'CM?P_=B:Q.MT|W24ZW M-L:IX=?K!.L\$.Z?_L\$G-
<':*7"|D'YN\KWM&*C|'6I+P,?FTSK|HXPL?|S
M|!#RZ**ZCBVBGW3V.QCR'W:YMAE92YRSWH/U7#,VI23>KLN;.) 47EC,WQOM_' MH
&,"G\AVW'-Z|H4|FC+XXY?)EUWL|)0E3TJ>|P,|OBIF|5G-G<2SM\$| MS7_=-"WNQ7)
(;=586S4^6 #H(1=:/0"|\Z2VM/;|JE.N%/U2MO<%3KE2|+/> MWA\$2.PV"J1S:T,CF-DDLW-
O0Q'EB>&K+XX%=8.74LKK.T0UBA/40M'40C,(6ZM M1#9ACX0A0;N E;);".M|@#7OYV?
S43|'^X_H.M6Y|TY&.2"- 5/|FO3R0Q MO|;N
7,>@XU*%\$5:RFRD4@K:G,PVJ^0TF>22L_N N3VW)ZG&:6W=6ENW/CM1
M=','7@OPGXMPYS#5ZQ:%-)L,XI=)8;:1*@V\$;JS@XHJRZ7E2,J4\$(|@M#F# M*9(FB\$29C
Y058-440H&V@NRPI'^?JYE0B*|C7*&89:H.12_NQ!'C#UH_?&G
MWE&HHF9%S8J:WT%-190*XXBKL\$&Y(0:Y+RQR&+.3=":1+G5>FT/J+E/M_YV
M)P>N*XO6&*TP6F%T5S":!*&T(BLM1E&M4>_6XTL%31RD83#^C%AI'D>&U04
MK2A:4?0EH:BF7F/I*4HR:<0!CP5V.:F88EK%JD5>T'1?9|*@.DN:MH>7BA M_7&4E-
J'ZJ6VH#(Q|<:,|+459+@+4-WS"46V\T'9KN!YWS;4|X&+E|H|S=?=
M=.J+B=9FK|79:VT'6J=;IUN;O=9>#76"=8*UV6N=X.=8&WV>KG9ZX_1#|U>
M2>GURFJ#F-KK|:9M\$|P*0-+|?5:6Y+57J_/_%"@J:|1>KP=#/)4|7B1WU%ZO
ME3TJ>|1>K|77: ^WU^C0BKUY@1MVSUW=+=:U.N5+T2|G>%SCE2M'/>GM?X)0K
M13_K|7UV4ZZ|7FNOUZ?|+-CUKKY|!Q*I+;1V6DZF"4^)(T85PQQ3Q0R
MAF(DA'2"TV"VJJ>3)5)4@B2N\(:N"=WT)\$JP3|\$T,1(|/10>KTR<<3TGDO. M/YE\KXIJ!
|RE%=5VB&I68L,#0)+C1B".+44Z2(*P)AI 2W/+MWH@|@'5:JO7 M"G,5YBK,
|00F(O"/))SK3'F,N\$H!>,LHH9';4TR3O/'A+FG6""EPER%N0IS
M!P5S,EE*L.6@PWD"VEP\$R(I6(>RMX-\$:9|I6=;U=P-R^2Y94V|1V>JV=7I^9
M)*J=7BLQU#8QM4W,-S6:@)66*9=1"X\$AG@)'CA@!ND&T8+;)%9S;:A.#4TR&
M(^DHW(,31T8P#7/4C@0?&,'Q0+SNDAT1:6JWF&K+5="LH+DKT#1&6-O6&|):
M=FR|NU!|!|T"+K|\$\$|5U04K2A:4?1YHRCV@A%!!+8 M!L2= D1402#AI0|1"L*I?TP4?
8IG!A5%*XI6%'U)*J(%\)'L-@E6/&<2HN< MB!Y%\$JT/3F,CJJ*+
|OE((AONAE2P/+RH_KN<4AS^,41M\UKC\ZN,|G_Z2FW|
MAE+;OAC/'9.YEU:0#O'H18Z(|4C1J%/2QI.T9?8%J@7G@2\$7"85|E\$\$.^X2H
M%)&YH"W! ^D!:'(P^\$H+7|B\50RN&5@S=\$X8F)D,PR2)*%4:<&8RF?1U10K:!:0?
5%:@J7B7+'C:"?LH H!4S""FO0E."*,C7JS|/1|/9"M?
MR8J=|^WQ.BS@K_.S.&T|!W:SP<"EI?>_LBYXAQPD&KC!I93PT*F"L. M_V<-VRH%
<)=^UY?TR4O ^8<_C..PJ?)HI'.NU|=;#_K&KZR"PB^-7?QU/KD7'AR>&<5N:D#-
ROYC9XSC0-CDEM0X&DV^V+/'?| ^;QM#.,N%|C*-1 M;^G\#(@0)TO'B^9#B#*@*/H9F-
@'*&XTR579Q/?<:-"XT+5S7->|K!FU?|31 M12:P6:'@!55|:>%F%YMIKBV7#ZNO?Z
K:JE,A|4<>*&=-G;9,,E/NEGC\CG(M|<&1JK6!AN04(BP:Q)6FR @)I,JP\$2(1S")I

..|DE3O19B_A)A-G8QP0)L MODRQ(!|<L5VA7Q (PW_AWM?
UMQ&DJ3YOK\B33.U4V6&0,=|4+-CIBJHOK36 M79*55-.V3V-QDCD% NA,0!+|UZ|')@
"!\$GQ F0#,TTBP3RB/!P_P(#_?A M+0T:HO=CT6SW%;;@1??
I+|ZN^UX+@K|5U|:C7')>GC%3 PS83;MXT|?BX%|!U
MH&Y>P<)>6PG*PFY>R@DV%";-8?S|-7/HXG_|U45P=.:PF-FS3S>S&O9%^?<3Y"RZD^3
M+\$QYR3M'IX+GMQT4U^,>\$*#Z63>9;V#ZO|6 |N<|U4&^!>"^!7,->NTQ#N!/|
MSKIGQ/5;3NK8V,:?+'5 |W\$ _FGH|G<, O|9J|JMI\$ _E|/ M3OX83UP;FR_94'W?6?
XYU#;V(+.=.!.|NNG%+3^>L>|9U00_|O9TS_#;9D|IR M0ZRR*@_>,"DBYRO(.D
M2!MF\$Z@Q0+6R:2M+;>|:|T?G|O'63F.L|_LQV>&+WY#OK?K_?5;D)># 'UO.:|
NP,53S+D+ZU_@ECBJZW)'MM7BW3;P60LT?Y|_|^@D34_L+C MLD!^Z;*&&AOZ?>-N,SG
C5UN6M-E! TV\$HL;*A"W40_@OO/8:6: F_"M')2 M2)W+BF=9A;&ULV:^R%>Z=
(';>4279RQH;HG1VB*OHT2<\$X,<#P+YY&T0C EJ MM|+#{Y6Q|*8K|/%F*Y/78 +?
IN,FPWL_* E3OGGZ\$ _&|3 _FL?VIZM<&\$1^W2"?H'WEYJT;<\$KN;|:0:3<#|:ZH
M|_6Y%/_S8QKB:A:U.FLO0_S*>S.)U=+|JVI=#DI|SHC|N. (7)3:C>AOW,>/? M8%
566&AW0?5?QJ C|G1^1JLLI6KQY/3&B!A9&> #;\$_ZG02 KQ|MU4|!6H O MO&U7^;?
UV\$|.:"FTV9B_0F|HW_;"-HD= MD# |U23B_IR(Y&J@YB%T-F- MO.L;"=Z=Y)7>S
#9L99ZO/,?*|E TJ6-6 N"
MU/U,%N&"_H/_F;>S.ITM7|C=BN(XO%YF;1|UL<|V7|_|/61F;WVYH4=YC0>=<
M"&\$""YS/T*|M;K^4RX4|605@%J.OQQG.P)*SS2(9:?,+(&O_<;?.?13&)IC< MD1U|J M6?
M(M5F?3|1 M>8D,A1^>:' P\$|>APZM|H-Q>E=PI;NPW%-/I-X2)F|8TK;D#|D,MLEMDA
MU6P/^7,+(=;7;F"65+J2?%7=,I7NKMNO#TN.NQQ(N+FK46/MA/@//:IS= MH;5-G6X39V-
C9@K?K*I4X/4|&O*=/1H%QNJSR|6|V1;G#R7|HD\$4QN|U^R=* M38Q54|*XGZ8
%:6Q@_J;-BC/(+\$91)E:AD1DO5"(>IT"5(+B M|X)4QN5Y"@D|H|U,(2*>8\$.?;(C.C1-
(E'FBR5//M/ 7,&>6@&5PD!'"&-)& M"Q024UH*#GZ'NPW>?P;IV2XG\$N;-6;3-|H25#;T-
MEM?#A=?F;AURVW19|Q+ M?&&/_Z%3\$!N0L2:(1FB0SR7_K\$)A\$@H3|D#H5)|JRGU;8|
(_"W^|Y|V7(_C MNW_,Z|G9DZQ3*/AY6*)4/5WND_2SX^%53R,U|,'+ #GT"28%;?ZY^
MCR'&TVY#|6,34VORB9A,V#BVU9H>I(U)S^_J|_E6C85T>M)82*I?P>ROWK|?5^|=?
AQV*7/+RVTS&|>FA9&VN4Q@_MOG!QU8^SR7&\$ 32#ZE5_|:N?
^G2|_ZK_S\$E0_SF:.#NJ/DRGDV:6?;N|ZN|'
MHQK>"6|;J^_V:>Z6+_CKQ^|_XFUCOX;)UW&^=G\Y?6O37ZQ/_^8%U?,L!GEC M>=R|
ELVXO;/V%UZXH|PJ5,L6(% MH)
(|AF<<9QZ8L.K'^J>#*Y=GK_-8:8XH8P)OB35R\$A0C%5H(G@A/8MM8-9XQ
MDH^6*^81S_TD.XUK!8G*#_ ^ M#+9LVP|M(SC1=E==5REO.RQ|J:HHC0^I7EX_C?
Z\$58_(B #ZC#N#|Q)0'E13 MNSRP|: ^QC34T>@\$6\$XZ2/!6=.3(LD"1E2)H+H)|-
B.:%'#N/9(:LX05|B M0R)%CCJL;2YL0-1%IEG1|"),P:.'YM,L-
SOHTK,_QJ9CH7"J&BR)M5O<|/|@0L,PAL'Y82N> H,I\$Y'0AHLPO;:8+N!T'T"@CJC;2E(=
<.:|G^|J|K MPW!;:3)7 EP3%X4SNZ,&H|'R%,'D|/"QVB0QLOS2?7;IHNAT: ^T=NA5!@K!E,
M%>*\$!*2ED,AX@PE31D>|=934Z01BH0V**L<8C4I|QD0#89AN\$,*MA5C|C2
MX^/;>3|=!Q?3T*/FSUVM#"J#VD-1Z|HGW\$7%#5T &;",\$.20#.F6C-A>PZ
M)*G7+1#|H'22AP24&^YQE)_779EZ_)4UV** MR|<<7IL\$KY+A@40D?+W)8
<.*I4|L4E+7@I|&M-ES&"&IC (6118!;G#5 M3*+6/|SY2|:/%^7@>XUK+B?"
|R=;H*3,>.:!+>N0O|48YS_=PYSOCS\$F>H|MP=-#JNVUE_#A7& M|P9.%|Z\$/WZ%-
:|^ (5;|_|^"M<6_TV&5;:,40U9I2_@07C|IWAH@=NJV)*?; M MW|F|CR>Q6O|5|1FJ4Z
P7+OE\$.THU+@T8&SR001V?<\$M|!;V 7>1#6%)W= M,ZXZPU7P*7_H5,9?6RY4Z#
(|BW;K9H|'V(O#I\$HMT MW-8A+OK1N)C=KGH_J;LN|L/->(_!U3!0-
M6^GE5AOE+Q>VS7ELV| MOL: "%06U^UC<1OVWZ6%E&Z8=-;CW'VZ63=<*DZ|P
@<;# "3(9-0"W03N3JYV|K=L5&I.&18K=-I\$8I: MYAO|^+87UY|*2DQ?UP(-80%ZO|?
I4BM_;"':C3W=0PK3S4?^1)*:|NW%_AI= M,|?>6240<63_7^J|JW_53-
5U+1>G|FW4/_M2>K3|Z/LV7'9QYZ!.Q*0*V|TO-T#:S7BN< M4W!!P#>KE7C3Q83(S:S#
H|O/A^F>0A|>.Z_U+/-O8>E>SN9@M4(DOYGG&7/ MNIKD_K9-|_W|/@='A6
G\$.GJGF5K;CJRXW:0+X&+Q_%X,JL|HV|VOCN>G:|F M,C|^66XC=&
(J>W_EG\$/;KA|=G^)|G\$W3SD%/|LNDZ?(0^T%U|JO+A;UBV|F\$ MH>|?T163@P>D>6?
5N;-<&^PDAYO_.0O|RY;BU77-S0U0)P|@*V_:K0M.SNGS M7>/3*O_9E1H#E5B-NS2-5 M|
(P,9PIQ#H!DO3*;;>6V84J"P|: @AS&+N% "62P4\$E@1L&|HY'CKX-T%-+HD MPG?_!X;2
S_ (^J0<.@|^+EL\$ _W@5%5D/DJE. J)@+X2+L%B X/((
_S#"3PH%)%EHKJ/(!VK054F@40V|7T MHM2#!Q JE|>-X>GX)CL--4A%K0O2(284
^,P1QET) @;+(6URAB|):5W:CZ_ M"BHL\$@-_SF">%5T\$PR>+TIM|X.ZX"
|.U/Y^=7|.0|S=?P3FX5T#B23IL;PZT MX.|Z*D"\$S\$*&KXOU97:7Y;+

f8'>@:F_>@U6\@=@\DS2S;H3>2\|/\$7H6VK'SM; M>S)OP3!M?SIZ.AM)I='R'NM#"C7D[*
/E&A_W-C(D\I%I.Y<)/GB"E#_D!\$MY MSU+>LY3WW"%YSV4"4/5Y4OT?8N-
K\%W^I"J#J,N8E:.*?Q;I
M*=)S(^GY/8ZB[84'O.L9.)NSRX[#%RDJ402RI:@_*=G+2<[XS/LC:Y+UYHNM
M1YT7\NLD%RSH/.CW"P^Z2%(H1OU09>(HIK1Z?Y\UMLAU>3_."Y>STC^..I+C4
MCWLQE;>>9/VX'&(8B9PGQP/2%GYXHZF.)#%OMTJ.:HLU47EC M2\AF/RJ*/GF?
SSQ(U+-TH76V%L8RN,?:^> M\8#1JY,VBG 40#N0*1>\V\')2J>-
Q2\$A&50N!P(-"/P&U5.8R,4=ULU+T4 MCN%\X,08?(P!,V2##R@&*W7
W,3@GQ#>:7/UT:XB&@7M#F3*!>UV4# I&"=Q M/J6J-
\$<\DH",P1QY\A@S+&D1MZP[^#R8X WRN6H2YSXA+9R%1T03E0!\8WT1
M\=-;RDWZOTYS_TXU\Z_-+M#,RYX0;-I Q E*#Y)5G("0\$APHZJ.H
MC_/SN\+*0/*I7>M\$+IU&YA)) 6MF\$ MN.%>8RLD4UMEEY17WB?'\$)<?)O!
<4LPIB@)A@O@DE:3;-5X.%^(\('2AJ,1L< MXA:P3N?R#L90*60.A\HM
V^/A0*!D*7\$,%I0@0EE>|1*#64PDZG5Q"!|"+ MAHH&V>AS;3@5T1,40E>Y(0GD:/)
(1Q=LD\$DHO5W# 0L2#(M(@N+(?:X5W*,Y M\$MJ"Z8QM%/0H:>)\$A\H8%>6\6
G2;2>9L4,I&"Z2!X\$W4DB*?#)C8W#)DM3((4RX5)3;@L%66^7# KCO\B/X9FTGF%\$T)?
5W MKH!=6=+G#W;!,;ZBL<@S&\&R\$^#G.|\>18X0PR:(08JMNHV\$R2\$4P2H"0B"L:
MD,4N(;A4!HU))%P>4FR@8-D\JP@(EYZ8Y#+FJ*).Y M:R35G;2#^>5(1@&
/9\>DSQ3L;H2GP126 +81>60\F,8L:!\#C%(KSK>RI3R) MA\BD1,)Y^Y\&NYA\,-
X&W4@.\$&%(U5_M1DM\N&;V=MR:#!Q#ERRX>V&=YR-C\5@+L+X<8-6,R\2X1)S)G*D
UKSU@)E\$ M)8\53GR06\G 45(FA):(& EN0#)@S>?#7\D:'(B.6L2MP\('/*Q*7-TUHZ;J
M0=6"J@55;YM&89D@!LQ5&C!'G*#3CTM0Q"A66FC,O=J\&Z=B8EUUV8;,-9<
MA\AZ%'@B;C\$C/-LJW\,XP5*CWJ^ZQ \I%R+;K1U^, @^J?>I?0RH(D7:N\$
M\B'K3\476S8<8.3E\POD8;.#QZK#QR6M/(JVZVPTB'-TAHF\USY\64JNMI M\ \$S5G5
T\$4(.BB\$DQ*7\$R.AHD*#&.28LUV*KOAIV(G>\$3@CCE.NK>8-L\ON> M!%5>80_?AB?D1'
|H/2\2ZQ=RV%/3RD6>"WP6N#U)@7=M"#1AUR?5P)4)@|F MH.(1*9D 1*-.&UMN_H@;:-
*>H 3(#)#, 5ZUHX@HI8CS-*9#SC'9WI;E \YD M@=<"KP5>"[SNN,VO-PJ QJ%HA\$"
<:H!7X1S2*C%CC9:2;^TM6DNHD20B;):7- M18,|\>1\$#3AXXK>69P>=ZR 9^STU,#@09+
|S\VM?= M?.H;K77A\U\N>)3(\$K7P=>:/;O,-|7'\$8TG(2Z?_VJCP>|N\#1MR/\$7J=1
M_(9"W<2.^W(3S/GI^'6HV^G(GAWE;U\;0CU^'@M\%?WLUA\$ROH/_F?>SNIT
MMGQA=RN*X_!Z.FGK\ME-'EXE&TL;+^0 MRX4\6<4>%Z.OOZ-
Z#,.8V6;10'3S"R\K_W&WSGT TB.8W)\$=?:5GL;+)X_J2 M+Q>Q\$X=NP=:88&LQ=
|MF9KGG;5;3D\|.5\>M;L;4#V>Q_!F=M-9 M_#>Y&2<_K>;U5W\$!HP5(!N G5*B?WWQ9+
M)1<5OWN*#^LWH^KK+_R\$P>5'8V T#/0CN.LTJD)WTJUFDVJZ?*P\WF>;V_A
M+PX#POW=|ZLNS)^@WF-CV/59(I, M\U_6L/X6Z|=SC\TGHBB7"7GM%.*\$&Z0-
Q\@SZH(C6#BYM=|P&V4QLNZHI>| M!2U^SZ38\,=@^>*/&T-TW1WCWPMF#T%KJQI!
M#D?SCJFSO"[T:O\|S^A/_F^3\J3T\;3)8"#,/NH78Z'0\$K9S\|S*>Y9E'L!
M\|9OCY08%^\#J8LI9:&|M>B\|"\$A\|^6-<|Z=@)\$ZX@X\C\U-!X=M)6X YD M&
(U34#2Y\R?#@ZR%^/|8=Q/HP;G,+D,>|*@;_+|>&GA9KG'2/*"@@T><\$X<,
M3Q\$)ES")*!-;&5*&UF&(*,)109);7&WEI&MRHTWL6=^N1/8IB/P)GZ+2N0 M;\$.<:-
|SNN"/;V\R60';?(YH_15SM1#OV3VX!7UE^97'>5X;^VO9-.+;<;K MCFZW5#E/-
B\|0QYPI%7Y)#EH7?EI\$@O)X "L\LM,V'K5Q:D%^XY(.W>9" ^Q7E^7F?:G;VM4CX-
JCY3.N.K\805;* MH=\$_K >O%G/NHU=_N>96, CE'>^|XVULR\|YC4-
)'_>%=*CONAPWN>T*9WZ MVHS.RT3K-FF>WSUUA03HHP" _?L3?M@)/L96-?!%_O;_O
(\MJIWB\J5?F^K M?Q=U>A7U^J22;&OUJM U?UE0%'Q%,*
(F\Q;L^:_GN\|/35+,#X&J1:.*3.U& MIO\>71,#>@,4L<>Q\$ZK_.;QX5KT%TZCZU=9-
15IV!|//%&00"UX1KU(QX\|. M:~?QL1SGOI;+ CM\$0 DRD"S"QDN;V8NK.E*)+&^EID@A-
3\$)2YTS>P"G2S#H4 M.:...!(B#EMG"85.Q\H"D\HU-87S2-.DD2&48T6<(83N+/NW;Y_|?
MS.FGD7 MG?|P.XG-YQ,| M#OEJU"0\U)M\NT-CDPC)5B304'#WU)-T\AJKG^:P'\$&J4"
M\@RSJ'0@H!;.(R.052I\K(W2F'.W?;AZL,\$Q*4\OC#'.TL&^+9#N_,\TM M&?
@U1\7A@O9#>M/%^W;_)ML^IRE%8SB=1BEWTL.'O('EGQ9\$"TU,2_E\IR^ M6639S\$Z
/L%QPM,3A=R"|"?'_&4+34BQ&8HJ4VB\J*&P*E-&.G@78XPP6\X2<2I MBU98';+9"KG?
1DL\?(2ID^#V_?@CZ;)+NMPX &5)>1><+ LZ00 0:(UXH'
M%*WVN1LL1R\|GU8K&Y.A%.REIX2#\V*FTZM/?[TL:2OA\GL)\7\U>TA%.|T8
M>7FIVNG'.QX?NYVVH\|K*1)#LNL28R1%UDG &,^LE-1@LMW\|+"T70\|N\|Z
M^0#CY\|F!K6_!U\U\$0SI4F5B*!4_."#6/^//#DE+D'X/UO^ODR;%NC@
_R\|=63KU/,M./8_C1%AK.0E, M(BYU;I\$|L#;(1.V2DQ-1A#HH3'I;27_.'*
^P>#-3C\JD@XF+9!Q=)2HDH&A0)F\|E)ATH M;AZ(OT#+QL2VO\|J_7-

Y@YR#0,V*,IYDYG1HUCA^DU?9?^@"EC/QJELI?S\$X M|TRLOEN5N.E;E>3*Q.N|.8+
+FJX<"/KW|_1\$?|ZJ>URNF+HME=/W?UNEV6 M?+ 0\$J'Z:MO#*Z-
M4M1&)8(\$U|DL#OSF'-8(&T)4U,0FLA4QN@O^OSN=CB9G M,7Z*S9?:Q|O5P0K*^T+:7?
Q|>|S6YG?)K/%V\$DRX7>4;5M:H97A|0?GYF7 MY;:'U7KGD|RZ?
M:US5AQ^J+7L_3N9M 9:NOR ITME>%N0I=/0D|Z\$'OZO(Z
MV=Q|Z04G2\$:C\$=>8Y\$X2&C\$2!-@4QO!PK|/9#V|?%#B'@ MVQ._QU-9C^/P7
M&'|FC+D=?S>N#A3HWVX|NR,\$QV, M\$BAHEMM'8HZL" 1YS(\$//0F!
|+@|^4,V)4:7OYNO4F-|HL-KVXRD9LVO"/ MJ^-5?VE^U?
=JN_<%W1=DO@|3H|@W5W5+>^|H6K+|I+R|P\$-RUU+HCWJ;&\$CM:|>4KDZ&
M%B)6K:)QU5HXKOIKG6*GR+J 4U%B19*H>M|7O M; <2^A|WW8VUYCH@-
E2K|GE/4|P-_)33 #.DI2 M60&Y@U_2DIF|2|3#5(44!:(Z\$,2OY,@:HA-6
DL?)%66'AC:72P%1ZGQ87XZ4 Q|Y=#|P"-<13Y+Q2 MB(MHD&74()^D2^ M>&?
N%1C9U>|I#3J). -99P1'W0FMCB(#W/ K"M;:>"N'T'8>A0E"#,2X?(XG,^'V#=#/QV*
M0!1&>)YT*!DK|S+27B|PS="6>G5=2NL45 M<"S@>\$V,F@1G52|<'9Q-W 6-7,(!6>*)
(=AIHK=ZYNPE@K,\$N0,*XI!RT.RE MHV3Q69\|MNZ?#D4@"B,|3S|43)I|V6Z_Y\$)
HU\$)XCQH5_/_%RCQWL^M6|>V> MJ_S.(\$@0KG#5C!D)
(ZY>XU"6GB|K.-88BD3EELGV/>1W|/63WM'23YLP-0# MGY2Z2;V|08-XB2>5>_*3-
O%VCHG@,0J:6*PZB#B M29> XKXC2FQH2D3H>-D<:"?#|KNGPY%(
HC/\$|ZE+2@7167OKJ!(1-XZRB.V-;M MNJW6\$FHDB0A;E?N_"H|SELX2*
|!"5FL,V|8L5|HK.Y=Q1;3 M_7ZFNXH|16F1\$S8BSFU"6F".@HJ""D\$X=5L-
6F|CNG=UU>HMO>8N/_@KBJ& M?H" LJ2'@XJ7!W=UL)%"U!,1B..04-:X>LP-
)Q'CGW_MZM(AX" TJX*WGX8 MQT<(WXHA*>';
G)/8TF+#+;C+0R#\$8T|1%1U1RL.=L9!G|"%AV@'W<:(*W=|V
M8P.^3YNXC\$8=KL+WYKG5T2I9.CN(7K|Q_A+'|^=|Q;XK@ECEOBN_0I\$%H
M:Q3@3XI@W"O,\$"@:BBB)BG(<\$|%;|8K'-NZO3-;82=(NH0-*'_C@80GGOE!T
MW;O.+:|;:YT'%6*H>,H@SQJ,\$LMU8B)9,RW\$DJMF,?CVW*,|+COL.Z;\$A*
M;85>T6I0H#2@R'))1WBMQKV-<#^HP/T"| ME^ 2|-T.^,+O%IS|M:%/;
<@KL!P#@>'O:C87;|6I5;&XY:6=:|PI-F2,_7 G MA#P?JUR._*K1W9QX%S5GJ+|Q|_#C|J|;
N|!^,X1;.ZG:\$XZOB^&|LTAWP6 M8PUU.QW9LZ,TBM_6"4AADAS;V=U.EL.H;L&@20TL|?
=Y%|^?'N4,P='|3AN MD?5|(GPHF/HNW6X-1=6_&9D7+Q|;40@SQBG,) #1Z^7TZW&>
>JH<,VT7_W' MCV15FR_3>;GBW7L(QC|<>.+%*=YB_#U^YD'4X|E=
U"P\$74P2J"@609#S)\$5 M@8-R;/1GH1 TG^31Z+M)HNNX+&JE_A8??ZS55Q@3@*6?
MCVR7YMY6LY-8A3JEV,1D-:<(8\$%<|I| MKY/8V1&.;P5?SE7P^H|^_9X2'EZS|?
KXO#FHP-SH&"LNPDI+QENPVV)+;U"= MSD>S>CJJ@7_=6??5N
OIYPLSDI|\$!P8SY9W#->=KG5LV>-DJ|68.O75_|R! M04+HIUZX|W6'LXWK4#?
7@<"M%\$:@@%&8/.)&"F2E5(A*:TC^\$^MT\$;=(MU\$IPKY%B*B*NO4 Z
Y|4.#)&X'I)=W;NXMT_YO7L|VXG37SKA#I|UC|YO.)
M'2^29M;)5'T*"P.*SHZ&U9N#LZ<&'4'MR@*&@NPG@N_!'VMA*7N|S:|D)N<.-
MQV(6UE#B1I+C6R8B'8-Z\$K)HWL/_7EV^YV"|3X(QA8S'F8LB088HAHBCW L1=?!; MP;.
|:Z^|!-"^J|UN7RJDW>%VQ XXAF;5>.W.Q1ZX.%/CW+C?IPU_55CJ?U75
M>F1J"@N.O10EPIYM1%0^2>J?;_2'VN@N_A+J)'52 TS*:GXY?;|2M+H0& M5#4_5
7J;+|IY?&=4#AOIZ":|INU-)H\$A>N|FW3!!XYM\$J-OCMAH'4|X;W
MK09'SLA>V#KS530O,+(&O_<;?.?0:N M33"Y(SOZ:L_:UZ_ ^LN*
(_' '=+GS;+=@:\$VPMYFI7S.S6DWRH;-HD KPN6CN, M,28=NBL<-
O+2|K|8(C&:#LJU^?/7QTQ_MJY^RM>5C,P,C(#MM?M|9
M|).4P(QMNCE|ZJR0;7ME!K%/=O>|+;,H)^O= MS^|_OWU3_5X=1W@GC*R|J7R-
HR|70*^WT2|)*C)8S&|M&MD&'#%|J6YAC,RKJM7,S^SYK3U!F9^3%-|G0|V+5
M|E;|PLX5AK(-\$9RSEPW;|D)(0RPDS_GM?H,|_QY!|SQJHK@4DWA>6|QQN"ZY,,@B|G
MO^;<;|. %|<"TBWS8++&CT>1K>W1+<'WXU)>"T.O+3?!N#_R"Z94'UMM6"S,G
MCR=;/3#|?#D" LW@R!_.V_A;#Z|7.Y|!#_L+S|YVV2;1N|VCBUC9W%S5WN|MFO
M+CMY|05-R-4C6+BCY3.N.E+5O5;*H=\$_K%MFBSGWIME?KKF5#(F|XYUWO(T-
MV2._<2CIX|Z0#O5=E^,FMWWGP)Z^|KS>9;)UFT-|SZOIY|>;MQM|GJ>TO0N
M: ^WU39N9S!4_ ^Z:O_ S'CW6V>"?S%BRK|D8|
M(N_>&_0""K\$J8C3;L1H&6I&BUAS)T|_F3W5ZFW>K/K5UDW5;:-VN3U9YHIX
ME4J|KCW56?ZV;UE;TH9P8>#S)T.6@P\$9|=. =9E,2BQ(5!7%B/#%4>12<)=IA)
M2K;:HZN@1;)>(L%\$KAZH,+*)1Q1<=\$X*)5A4C|?7N0H"77/.?K&)SC8VT=GW
MSHAB4|X,%!0|!"4MYZ9V"8QWDNEK>4^|*<_EKN>14V|&*\$IVFFC MSHM2A-D
)KH)%"- "#(B)!0U8|QB#+EE10"B5,JM>KQV'C09%(CP\$)\$5R@L0L1XJVK|;:3?00K|?%?

SK8'# MF04VW,D;:&\$)X;?0J;7GU|OG9N'>&^6M%,JL+4M@'M_@%3>AD""15KE(A#1
M8F2-P"A09,+ "4_506(D>P3(_\$42D2_1/1W%=%?'EHIZFJWQ?LO2S=,G*U
MD_X8WTFX?)HJ|W%|\#*N\HY(,1
6UB/.4SZ4JA7R2*1_F(L'6+TU%00*#XSFNf"6E5R+E&,D9P7\$Q_QAF# C',6(MI
MP%NI1X>,N@?BK3#I(A&|'WL|X1!:0)8F@"6)H |59".!&54PH@P*A&W'M!&
M8(THN",T8AT-WFH"&*W2GE&"(V@)75.%H"/D) ,/K5.N%S*|:D=5>BJ#J!_
MQF:2N4Q30E^7SH_E1^KE0.Y^SCR|8.PU1E*BM?7Q4Y>Y(5\$F|2|J^)^TTF32^75X_6*??
_6U14,^:|H|@+VMB^;B+| M9UGI<#(%-= \$723|OD%9M%HDH|=*>4+TT@8?
LSO72Z,,6\$S-#HCD^_W?7FF1E MNF6Z+VJZAU0E;SO?|CD4(WIIM;YDJ?
6UU6\$K=|;YVZ0KZ?QNNZ%.*>Q59*G(MT@W+4.;>5\$64=L)K1?;\$7L"l%/A|0K&Z:RE
0J\$9=^RDFKW!(|E|+!|TR1H|P) M| -#@L:\$.
<.64|Y\$DH+S)R(>/O\CHG8.N4P"lQ3N,D*EBJ7Z^ E(PVXEE(B)TA AEI%6.(\$&|Y7(!,YSE^
LX1R5)'
M|D)\$LNW/SK0E)/GB)*BHBW5U(,ES,A^W30);4!A>U06E#US(Y|DS>|&O9|>DSQ6_7\$B\$
MTXB(,Q+Q2#V@D@7K5|)%DE4PJ\$|*O42!!7CXC!D%YJXS8")|,)9)D#K28+#+=
M.G|H|C%5(&O_E|E29|_?)&8HM,FH\$!R2VWK#=#+,6X_"@Z7C'C|66|XZ"9HR
MRI',+COG@B"7-+|A1U'Z0ST#9B^0|A)6>>>0%B*E4@2*)<
M3|)%39+V("">F>2(V&4:V+#+),K).8(\$Q9+ADE |(*?K.!N|5B|:E_6X)T|+(MXCX!R)(2>2\$
V94?<9.^7\$QEQZ&:Y")D)1|YX@3J|6J/596|LNA%C@|JRD6.
MBOP7.2YR_++D^)|O3@1+;,%>B<-XDHKY")A")PXXR4G3I*M_4\$OM:6:<&2R
M#|>EA=^(\$2C2%&/CM%@| ^O-%5_NZ;-Z ;27L,J|!S0GHK?)YCG|H# #-)*2Y
MH4A3(:7D2;B(+P*:TSHIHB42*A_7D@|ND5P@\$D.PE!#&S)X3'@J@W2,X5;+C
M%L3|/;1-OZDBT>%^"6.)M.NMG'<+J)=K.!G+4E%::PK#&) M04XKAU0(42ANK3?
^HM+@QGLB*4="E:.(09D<<#(!Y)LE#\$ZO-|C;JHD51?| M*DOZ\$O+O/'
1#Z;1B1XY#HHI)6,"#/B>!!*8;MU3)=B|(A&GC.>+46N1H M,L@Z*FQT
BLG|HOF8@I^%?PJ2_K||4L01WS*@(5E/J40;*Y|0I%3+BJ.F6!Z M"
|D3C|JY!'C&.POX50N3>!02BS9P)T09K|9OGS -2X(5A"L+.GS1|H#\$J;0B
M2\$23T+G|ND?:2)|H7%/G2/)B"t+C#.)V'<(\$VVVJ)' +F".3.(>4^\$TU70>
M1OG04F'@7J'DA>W;,X61Z-Z?#RHCN,X-G;4A2!M@,OK=I:SY+|\$\$H5|F-Z? MEU4^?
3)BMY/VO-^|_?J<|):U)F6=@XRV,I>'D,A\$21%6"9-\$ R=T2P|ICV7B M7"\$)?
C_BD@FDG=\$(.^>2988DMN=(P\$ S|HCMA\$J&74V>,U1,+FB8Y(ZAXXU2DYR#)|Y2_5^
M\$XD&ZJ&WXT|54CY:EFHW^GH<8%#|4^|2.UZ0)\$^_?CZ4Q?4:C0|N?)S(|@
M.1|_)W)9\$D"^SD6A1)4?1D;ID&8A#9.Y&|5|*K;|5!>^"3&>J8XC"/%|-4':
MYOI\$5\$MD4H&8\$24L@|M-=ARX"!@Y)QER7B5@5(H%WN|6IQ@8 M^L!;G=>RS-
/3<@4X"W 6X+P5< H04P)O0/'L"@9D:.) (FYRCHA)S.\$MYR F MD30V"0DB'.
(<@R^1:R@E'(B64K&4|GLTC0V8?N"^8 4X"W 6X'S|P(EE|HHI MA8QT|G'-?4YO,(@
!E(AE+/:9WHIE=&;D%|@'B-N:4+.\$(X|QLX8QQDG^TT/ MIGQ Y0,?|W(69"S(<+1DZ?
D@-?W:&@4\$|.H64H>|,\$D'9H/4VXUH%?'<MMN2JL|N6|R&Q19B)")-\$D-M?
A=W*F_/1(9<8 |E\$DC@PEFP(_@NC(|WMAG7X^/V8VPZ(?H,C_L9I.K/5U4\$
M,9GF>|S7S0|(-6)XR3=>52_>|O7?F?\$349A%PM,V!"N MFE5_G;1M:|2L.H*N"|<-
:"W0XK|S?SS2:PR|KQ65>W3|UN*V=;8.:NY\$<|MF@-&5V.@S2C39@JT:3-MJKJM
3|?)1|O')G<.V7.@_GE||BO #'EPU,<33 M::=E)DU5C|/=<YLN8|#2MOMT7,U@O|
BF#4/UBC|M|+I%E_ ^ #FU.KGY:#|177#:QNV|D=^SBXF@!Y,7|HZ#6K MLTKY;3*#Z_(Z
!7:&E0/7 J#="S"|25|:VHY&9_WZY9,2RW'W+W;S674"-(3+ M8|H0|J-
Y@/M3,SGM9KUN5A#1@XIB M|%;7):CCT_GI:8<6^?-WWT RQB#|;B"8>8:0|
FZ_)ZI3!|6|/7-O='WH6 M&U?V^+B)Q_#|S++++)5@GS2WFO7.SVCAE6/
81D5XIYKI%UP2&'CI1-6+Y= M;R\$%8:72B+ D\$5=!(&-E1!&2#2E|-U6\$|Z.0.!3V)X.V^
BA|N>O46?O+ M"G_I#4P^10|7#H#6F^8VSU6K-O9|W_|H7N&-
AT8A@="7'WXXO&9=4TWK#D MOVV"^;#Z? +@-6LL>"#|RGVUF/RDPU-5G>+6H&H-
9=36E@OT;?MIH';NLK3Y"!?"-1GHA3Q\$F&E^PWL8,|R| ?68 MU4F1SU>J KX?
7V^BSO&V0ZVLT|'GRL1\$.6X,%7/-<<+@?KGO3/L%+28F1\$ MWJ8)@B K"\$-
>:|\$CQ9|(\$K0)2=W\$2/OD36*51_) NN@L_9ROOS3B|;7|Y|PW M-
W4A;C+ZF|H03U#|90B9SU;VT25VT=+6W!_JS4Z:&#O!A56/%0#)|*2MP.+ M:C1.9|&SG
&L.UW=70B_L\$|X?_39#2:?'&VK'SLHF|Q;N " (\$/6=+8VT6!G M|J>CER',5|<_MCY=!
@J|I(M;Xl."MH/ EQ^?Q7'30LI_#/+GONVQ%BK|,H M?
@/KN8D=L|X|K|Q/QZ!GJW:4OWT|M2;1VNYCW4_BT6Z8/_!_!S;69W.
MEB_L;D6P_*^GD|;NGMW\$47>,^K6;?,NT@F<>K<)>8WVX8HJ|'TWL>-GUZ:|B
M8V'|A5PNW,DJ 7,Q^GH|AE"H"N;V9&=SR:O-|L08?/^O<9V':.)|LJ.O

MHJOI_>HO*XY8/'FYB)TX= NVQ@1;BfG;-3.[#50\H@'NB];MK?K>.%^/5=XB
M8M>ILOV_IZ9J=!(F(>*PEZ7A=LRWX(.|)\$DM8-WRY0AP [PJH.VW&%/W="88
M#_\$/RQNZSD/3-AZU<6K!?(M+!NAV'/IGO|HL/?E+W=:N'M6SLZ/E,Z|(.^Y?
M*_ "0Z1_667>QV#WO_N6:6\F0TCO>>.;?;S)!HCL_W? \$Q=[VM3+=,|VE.|SMG M&?
2U1QDNTR27GV_8UDF7C?LVV_MZ1S;JY6;- ^WO/I\ F?D;_/*_GJ^LG> MI?
#99D\G'W8#>R_93\$>/+E+GZ\ MXU&,6Y;/L#1PA14RW)'>8|>+4I<@T>_?'G(:XGUFU?)
M:(&R\OW"@W)@6\$/7"_C8_7GIP**SW9M"RCN!11=B_)31Y%FN1.2)QB@SD:D
MB\$L*!R&,"BKO,6'GO,=SWEU3-2UUEO7C:'0N?
MKJID=06#BFYZ@B+VJ%6NG|Q*ZJHRTK+H18Y?)|(6.7Z|BU|D^-DMZ9.7X|?:
M8I6")!N1YTHBKFE")D6"M,F)_9A0%^PN F>KJK-=3=7SVJEM;XF?PAAOX3E> MZS!R.
<"\$%X>Q(.,36=N"C,7""*8NVC.,,;)2'/IE,JBG_J5/_M4*K*AL0!6Y0461L#H\A3YQ%G5"
(C>4329SN4VA#B|A/ZWGRQ|:BKQSWYI1/R
M3VLRWM7M+BE_Q0(ML%E@|U!ATRKIG4X"42,=XHJ#\$>>40HYS<-L-X(XS.T_Y MVP-
LEJ3_IO/<6T+;.X%-K%4.<4%8)-K;:"9#-+,Z|RWV@;K6-TJ_OJO9," M'Q|VB<
#30MN%MQ|;FM;<'ON)DB=RHXA7#(7KJ3&AE!.<+2)J.\$\S:2G:<-
M/CYNEL3"V\27GWOYJP.HK_>DYG>7:A%|!-U|U8MX*5,N'/VLE_<%3KEP|+->
MWAW5;E?1O'\$_CNGG5Y7Q**?+|T^+,3NMW4 W^!9"ER
M4>2BR\$61BR(712Z*7!2Y*)1CB_L_/C"WSLRQ8_L3,4>QZH|L0V,93?*M3,| M#O7XN
KS)O|G=A*K:6SJ22@9\$O?=QMT453JD65;#9)|/CES?).H_3Q#=<=EO
M0H/#@*N=)T0P|9CR-""CN4)<1(TT,1OYEKP6+JE+|F_ON'^;9|; M+|C^O1'#|HU(GZAW-
)WTB(Z('@CD=F+Y|V-XI\$HP+B,</:0@R..1<.,HE_M45*HZ!|PVEOSWDF2(#
<>DQC8?,"+E6C+|33^WY@\$G1(46'O"P=XH3' M*1* 4&I AQ
"\$*F51=XXBX5B7ONPBS,+DH_4_M1RYEXN(|_W0.D29
1&TJ)"B0HH**2KDHY'RQ#+D2\$;IH!AV@93BQCX&H0))JAE#SCM!W=#)9=
"TJY)&R#5_|MSM2JL-8T-OVNU\$U*; TJER6A_JFH0H-1<4_4Q6_GS._+T+7\ZY8.DLT=2
MZL3)@A*5X))1H&UV @_M5L;T|C TK^=C\$.V;N;5IH4KVM2>M/#P5?
4+|,\$&|"\$IJ#6TF#0HXHB@A+
M#CL<+=LV(W9!@4O./S_P_/ \$0%WOB5L!5"E\$4Q544UT\$JKD"TLX(QE+BGH+C
MH|.)T2|T=A99WR@N|B\$.ES%)<%GU=886/+L|CLBD).@B9*WDL3HE>(IV7T|
M!;5U:2FDHKB*XBj*JRBNI Z6X-%:@LGQ\$W&J#>+(::LU,B'&J%P@7N^D.A?A
M*JX@H_#::>2\$,CD1D2)'@0S&YB/2I*PK6|GNZ#_ /A07OZQI25%<17\$5Q544
MU|_27\$X)PH(C,B&!'LN|@D5\$D(1.-Y4DZ\$O!6Z=6|+<=KN)2 MPC)R3"QGI0
MW03FA1W00LD@G,!:2OP0%-B'XI*F**Z=**[U/4CX/6^<|93,|;CN5V0,M1? M_N/?
X<<5L|MN0BM^_6W><<(RRU;%|H|V|YB&&7Y0)Z2^3T^E|ULWY0|K(
MY|A'#^/O|/5U4\$|HW".V;-/YLS0G|I4>J\$K+S9;H*K;Y?!)!\$D>CR==|
MOF\ZR1_7=C0ZJY9T7&VQ|J<"O\8F5G%!T2H!2;M3@?Z|W8>*W&VUNX M(/AK!PG;W!;
|S6HO5"YZ.V|C58_SXQ<'#D^KKY/Y*%0G%L;B8AQ7%H:(5L|I ML1|)#99-
Y;|>A_6FC",U!6%X|6*0M(VTISOTV^#)%H1|L'MB1G<|F2T3+XP%:
MYN'GR|'(GDWF;WC%MOA>|Z\ S9HA_6%|O,XQ/VWC4QJEM_.&79.C,AO|1KR|+
M:OA2M|6K1_7L|&CYC*O2%;JW2CDT4N7W?LL\$RF-V_.=X*I(A+QW
MD8A|D&.7!=A^J|>Q^AO|>=)6|/99)W^*TUG_.8(5PX.'+27QO'FIP%&!HP.K
M6?/4X8ABR@OF%(DH\$K\$F\$:Q(1"G?|%)!|K|_ ^J,=5!^|GUT:?.#69=F&80=7\$
M=M;4/H=6%M&G;|/_M/'CXN_RV;7\$VS&|ZC'VI|WM0598B2#@Y3BJS*98BT
M9\$BSO*%\$ N,JZ(BUWD5H^OW8_-\$41F)'BPY4G=R|63O%|GFRW&.)X;|RQ>=
M:1H|N|N:W=WH\$OP@927I0,4<2@=(U|3+@BW@|WRD_1)"B#-"\$X8!A@'1/(M.FR"-
TDGL55?|BY|Q8>\$<\$0.M+JL4O4I-C6|^N?J8Q-3;)H<
M6.W6=5\$H+T:"7J|"^= _HBFA9=&+|+_H)7WR6/F@@TX(.&I+0JIS!
MGJ(0M,G5\$S436_G_#V88_C(9_';+AMKI6@|/;O#0B9B0(K?6X*MNO_I"MQ>
M_3:9G8=.KWYP'C?B0ZG-^C|!\$_M.GI@<*KAH.FGKS*A'31S9G.EV=?HU*:<6
M7HX\$%VVV\$X.IDR+RK4,|,EB)
(RDYXU0KD<|_W5.;O8UN=IZ"O,,81R|+)8LV*_!6EO3YPQLAGM%H*!())
MBUQC(2*3G\$=16:&P%|AHN54<*)BL&9(A0#WP)U@K#.)A./1428_*>^V3U7@
M|4D8ZR6\$>VZL|TUCO>B/9R|S17|L%'LP/FA.+"(X\$=?"B_A"@Y&K|= @'PMB
MNUUM12G|N:8|\$45CD- M."(N=4 &,XT8YCC21!.V6Y58'BQ_!<|&GWH<_I?
C_-2OG>H>%%R7.>R_ ^ ^CP!|5BP^G6;2Q=W!|I\$TN\$A,#
MF+3>Y&U#"R8MEQ8%G0C%5C#A=U*M|=)V9E?U<'L3_F?>SK(!O#MS5HL|N|2>
M^V)TM-34_5\$X@6\$+T|B"|"8U32(R|5@"B7!%FL-4I*,RFB3AYO|;?MK"?D_M8X(H(62
R;.&!9X|BEY:B?4@ /+"NZ|HW8VGGFO)^I%M@9W@E:=H5+V1LVT< MU>.X18_S?.A8.J?

=5=7;QJS5W[,18I#&3T>CGY>IQG@#H:7#/MC8SOM8JJ MBT*,&/IPX8F/-
<7MTK)^M3%6Y4JB5=U6[=S]3_2SW+S3KH"IFD\GXZXJL3I M>=/\$L8^YC*P'7+
U#P*P)/J&*KX)9\9JS5B/TR&\$M]H/SSJUWIK?^V>MZ@0/JQ RR_'G8;K)A)"=RX"
MR+8H:K/Y^G_?;#%|96?PF+/*9?:#90T+>LZZQV_3K:TN.JMQ"X'8N55A@@:I
M@1*DHP>[@ 2'G L>T1"RA<")%EM[W=82:B2)"%ME\$0?O#;G\$)9>2ZPLT>9|
MKWMDW=&RK?2;%7E[L.R)+0M94?V2:_0W(I?=_K8\JL?I6K\ZE9L6Y,?'^MU^=
M8TWP@>)DP-35H0>[X6W#6L?L_'TC+;+L=BjY,FS_5?QB#L_RVO!M>KRD1V
M&@@@F/VFZ@ME"3IV0+V#<6<\$JN1*\$=NIT"[7^%X3U'K<+W^'S!?'1" M?
O%SHZ#||M/G:RPIY,P6IL3^K(!#PU.K65)"!A1";KF;6Q&Z& CR01&BDP+<
MW,JJOTOGPNX@Z^JQ.FI P8-"?3MO0+=_[.K>?UK Y#V1DR@Q,->D!NT--V^B ME;M>
LTY?:K0\$;B\W\3F &Z@V4PZ4HJO^V2RM5Z11_7Z8]*UDMA09G.NK2UK7Y/E0H"SP-
R7@>09:QS=S;,,!>61,&4U5N1|SMF MQ\$U.XV?
H6W=>J#_)YMF_1^NC:M5X|>P9(3/JQZRE1 FLT#;S<@@GRJK:LN MAIS^,;?=
#SILVK:3'(- (M!3J0O&=;299=KD",JO@6#CN=@5* O^T8A&2T
M%N\ZOZV+D/4AJ1N|HX.8/D8)?P7@U2;F^&>.5>=8F#^I;+N(^I4Y(?%CGH!
MA5M'DZ|=<* JO.AEC+3M@Z2H!H^Z_N?"F4[I.X.)LWHS;_BO<33*_P67NXG_MF,-I,-
^J)J5OF(=0X(GIT/Y#S,UQGN:~/*CQ_9KJU8,@VZT&MW?9VW|>K3 M11^O_"FL-
#P.OEN|<7A+-GRZ+=06? @+X?>55CGG/AM&L=];/E?#\UZ_"U M5AN'O,P('O'-
GB/E%._L/.#0_)S1MA|L'6@*M"8<'E:6#7HI/YX.!6/'&B6!*
M"8W!,W>6(J.Q0T&11#050@FVHS*!#[KB5]<2V2I8/B'O?=. 'IHU@H/#&70*Y MVYRA|-
PP;F(=5;EN86Y'1F&)01W""*Q9,"7MHG=);TLV<3HILFD.)C\$,+9,@
MAW^!FLLM|KH9|7ZE.-W0QR5UJ;2SS5/|L79J.#7H=M47>&R;
H(I*;Y'B3MWA#XD4I*"MXQ^J/X:~MAM6"%O#N!3%6\$I>37@
PZMQO>QXS3%T:UBYE?;8UF, N|"L29\?9-LV9K|H M7 4@<3NK?1>87+1|RE*|>ETOSK%
H(NSKSD&FB_X Y:CJW#?H4"^;8G)?C(? MSW(I_!|WEX|N*8PC9R!|Q9<-
>370&@;6T>"R\$2|"#|MGNCBJXY<=<ICE&Tl MC*:U7^"SLG;A>-
J)EUUU_VJ*^@6;L+7-Y1S &2&(87XZ!;"07+*. @B37%J MCR,;3T)<+N&KC?RZ?
Z(:5.6W(1>=|EXH6|Z|*|<|GI^GZ|D<0XS?D/X^U
M(VIUSRB+4UW|Y>F^8%&OJ3|ZUIHY55B|+<;9K_>(!WOPYY|Y,?*C>6|#P=
M)"_J9NU|SLUM!XO%R6AJE@|"(P<9!005G8?&H0_!YTBEX
M8^560YL|H2|XQQM_ ;VS/&'A=K3/0)I)1H,85@L*52L2O;#AH6?TL?'#|T@ M5LJ0_
JQA2WBR0/2!1:03X1+!9;HF(78K+,%^V9(&>(+MAB%U1AUJ
MH|^&7=.034^-0J\$@84T1'Q)LM>;7OYD%@!=1E"B*I P/3%JB<2E
MJC+SR4ME98*MAP_-RU%1HK<*C\OFX"9?+.|O'IS8/D)+:CJ_J1/?8635_-:'
M@QM)93Z|!0^W#B969OJEL*:=W=ZJ<^J-OA| #0EUA-Z-YM407;P>F%SM)=D|P
MK@OG;|UT3CX\$6\$>XYNT/O|UWG4^_O?^NM6"+*>;+Z_6=I4%|H|#|LDSSJ^\$:S MI=C&-
MS:=[XPZ]|@|E|Z.857M^\$4"GKXDLE|Z-4:B^ZN,5B^_A%RN\$XV4" M?|O>ZZ;^XEA 54?
XFZL6<82-5P*?5_-T9D47/JW-Y#;|O79T0Y>5#0=-|53' MW-0M:XV:XJ8DIEK QZ-
R8D6IN;WA,O 5J^;PP/1/8U^SN,#&*MHG7CCO;U!) MU?NE+CP2B*2+YB|@FV2"
I)7K|>^!F; 9T|_R_S98F|C^|S;R5W JDTGI?6U M<')KLT7F1C<0WZHR/ (|;
I9VXN)^&X|9<J=5F*|PP9EEN|K*,78P#5?C9|; M1P%%5=U9SW6N04HQ!E>5\ZD|+&
(INV*,1(<_1B4|RiY,L7NYL!"UO.\$.=I-F M.%7CJM\$O|7;%S%S5;;KEF'&MUA-I'EPM>|Y-
%N\$|HK*X@BL 9+7CN*ZO'5@ MI#57F|JMA.>W:+K"L>>! 6M26,(MZ.#""S"F:??CK69JU
<>VOE9>:ZNC9FM M9=VWKC:N|.)1@,7-30|R0CR>@|&#Y;
(_"!DU1"S84&77F,N|&F95VH8.|V@
MYC2"_SV'7V'TP)Z^Z4JVUS\$|%AAUQ#VN6!Y+|RJ0+\$DBB,62Y.\$OI> 6:8/
MXK'H:Y/-1^9C?MJW^7E)V_-OFB|?YL7T78X6;)2BOEQE|U4AN%665|S|&Y6W
M8(I8>Z6<5P"!U7>7ISJW;I>?'M.N3%\UP(M.+ ZDM(\$-7 |&.. X>/E;*3N
MROD,70'59._JUR7)A?>M>SV0?:0FE;FL\$,L Y-MEL*?Tzt>_>:@B\$NXJ|<6H MF-
U=ML_85NK(OC7P+OSXV|4P3#/E.@|SET=NY1="I'GG?K,YPRHDU8/^|&O4W|;7+|Y,&V|
3J'+PQLLBB+!(|*F!DFM4A8DJ>: M)7\$<&2\T/I<;!Q%U%B>A,@'S_
CN\$5S|Y8EA//>B+XM3/I;Y>SW)I3PT|2| M^0 /PT\9S&|_C"O8.)F^N/7YOC-
>WNJP61_J*|;BPL|KP<6%@L.@^VP.I-M<^@)2?LL33DJDPB#+!(^ZE|CZP>5'N9S+;
MF0J2F\$FL5-*%Q.P\$;!UG:0\$;(K.X#6^C%OE"Q@LNQYH20.4N,R)G.(^G|N9>H
M=*,8|.L!6Q*|2;|J04^I8" C8"-@.T1BRV.E\$|D.4<^WU|K\$T-N!;Z|T
MCFQ|HY*9.'01(MPDW#P?W(QRFO?SYGFJ6"2ISY3J?99F)M\$PA<(G_=O,_5#
M)7P_9E&H0R9C8_N4QBQ6J=%"I,9/_|A)G?|("(<)-PDW"3V M8^89GTDI-
4LR85B6R@C@- OY^U|5"1YHC @|.NO ++TW@1X&NQJ781QV MR-

X4L1N%VQNC\$VX2;A)N\$FX^-Y3,M2^#4#'#L<<|NMM)SA4+TB#,4E_Z8;H1
MTY/'N4R37#(O %,3|#7%AID)&*HJ4\$I@*+I#H;ON7%PY%#RH'#S9#FV^T27
MNQ|^J.)\$PJDS'I*|T2&0(C&4\$9FD8<'#1_?H?YZ.!K%+@|\$P>@! M M
GJW3^2D%GJOQ"E5^H|@MQ-'\$T39DX>OCD/<I\$TR? MOQK|;>?MJ*RJ|^K>ZDT|H(G)
<4?5LPA6;_G'T.9#W#*=-,'#UH|HAE(FC!TW> MP4V9JF=3|>R.X,YSMSA?
W>^EDF4|\$O|MNR!'31R(4M^+L!'WQWG*9*9#IH0V M+
(BC/,N#7&7";.2QHx7AR9FH4@B)H613\$6185GN3BE[*J=D|J&!|X;>G"|D(?N2#O9T5G^|
(&@=+6X+&5X%&K-L=Z#QGH9=P M)KTD8|KX 3-A)DVH0A-
BNO|HG*HL4*G)F4E5S"3W\$Y9\$?LAX+DVJL|2\$9J,4 MP@F@,7*Y-[PJD(2,A(R\$C*^
C&'DQSJ3,=-^&@ RRIS%\$8">#KW(EQ|/O3S9 MR-KW0ZT2H5F: :1*\$6J6)%
I'XD!H+'\$8ON%&"Y<3(*,71D/KU<+02-!(T'C M;OB-@B<|X GC)M8
M9D)Y*HMTJ&.S<;S^%/YTZ(O_3|!XR\$P6BOU2\$?'ST50G/?W7>P6UY81LDD E//JZ!
%P% ^D4!|7(VXBAF=AT|E6@BN"J|V# MJ;G68AM#\$T8,9DN=?>IN'P^N?
(36!%8\$4F'#U9) M'J9!|D4LC_ '<>YXD3"DPM3A/(R\$OR"DV&AON4^SZ>& EW#
FN"*X(I*> 5Q) MXYL@37(FPD1@L:20J3C-F!_E'0Q!Q?;@.\$2-Z>!/E22L>DD4D3)
(HY2G#^5T
M4@)/&|=|G9AQ92B>>#ZR=JY*Y\$0)I%GB)=OP!IX|*"7M>4R%/&:ASOV<2^GI MW-
O(!4@#Y06>9GD>9J#(8H"S/%7;.:|E|,DS|1'JOL^E<7|P&HIR 0@1"1%/ MAXB<2|Z3U&-
I&\$. \$P),L,3EGB: ^Y"N(XA8|VS'1?FS"2'L,2IAB)X("B NS| M*,A2+: (H25XH3|R"!.\$)?
M#6T+|\$|B%BYN72)"9DH0D4DUOKEAH=LRCQO327
M:1A%F\7RDSB+0PRQ>E@L/P@-2T*P,'WE1R;A#3>;R:BD+B"4U(4(6)_: \$N(MV#U\$#"
(XY'PF9=Y@(@*S,/4X|8?|\$|AZ7L;E@=RP\$2-EQ,|/6) (J)JCB*41 MP"+7<1|IE,>AV:A|?
P)\$|+D;1X2(E";ZF@'>3Z::3>=Z-I"KSMJG#E3,U(S
MDSGZ&@9!|=Y>RB!IKNYIKE0F)H_CD 6>2)C,0 &I4\$H68T,L\$65)'F_8|OOU M#UR1Z
^U\$!|L:<(?X\$8DF? \$A 2\$IP"/)/54J_ '*?(<= !,>L#1(;<KP'0T) U?RX1W6?)5@+F7K|BEV
MH/S=(S6|)"ZPUV55CHKL-1O'GE2K;T'I'=VS7A+|B!)61P\$'L:\$ Y8(F;\$H
M"G/IQ9Y(U<9NYCXQX>_G53\$V5?6AO\$F+L06\$|_H?|Z(J!-=|/8|/A|*:'4X;
M>E%RRIZS:TSXFAUGR74@&"88|AD,AU\$<1SGX#|H3\$8B9&DN|;U8
M;M0>VR0H.>\$PX3#A;.'P(2HG*A%?'J*92B+%I-8^ MBT,%F,I#&6-@ DS?
0T3CR1SN"PR?+"E|G|!|#^+RY4R-'&PY?;_C_.F|PPJ< MN! H<5DY3T?F-37?Z|2:WV4Q2
GNI-1|)7D8A)KE?LQ1H7DL5CI@*O--E\$5> M+M5&?|=|00.G.6@4|2.G*\$|*>3W6?
3\$!_0\$Q*|ZXC.)=9)C_R,C (B3+&%I MEOE,)X&* Z55EFS4&MTG.'|"(;YGR(2LUB+D\$D=
M2Z;|W+ @|. (H"1NTHUDE7W"|Z&! M88G&.D^1D2P)<|T"|AG|3,A<^.\$A 02G* L5N(*?
=&MT.\$"|+2J_ /:/^ (=9| M3GB^&Y'X(|Z8-46;
%^ ^|M#D'=R47W;0=QANR0YNOGW;;;TF:3G*MJHV#P;NT45|=/?
U+H,R#O&4Z9.'K0Y#W#*1-'#YJ|@YLR5:\$ _Z0&)WZ?E
MS)0WA:8#\$7VL\$D8E|0Y0# #0+?66|D"6>")CD@6)QCB?O=*S"V\$M4EO/|>_HZ MBY-
0F8|Y?H0-|AB29P8QG,O|K(X|6.=W|_37XTLP_|C8X_ =C;|W*^&%PU5) MEM|@2N*=E-
D)OP9'TH'BE|QYYJ4|95G"-9-2)BP-|I@EF?'3T"11L%|_/*B MW,|DG#;5)'#\$7X5?G2?
HZ"9T#!3*P M|;10?)|9+K'#G(R8|B/.8J&\$#A)?FR2| #V2A%_M"Q0K;T'\$PQ&3.\$B-RIO-(
M^GX.UENZRDGB;)9@)<
M1)ET4FQ<8(|T;D%'V8L|/,\$@ "Q73"7@CYK82U44RL#+7M,B2|S\$/_+YR=X
M&=56/VF(|F|F3_ '*|Y(P4B=KZB0R?A;)D/EA'J(ZB5CL1: D(JUC/U*AU!M% M@+,D4H:EF?
0|*;-1-EK.OC1|)JXD55,Z\$7HM7EXG1NC MOU ^5|V81:\$&Q(M-! 9T%+-8I48+ MD1H?
Z|&^(GJ13T_H120|_3R L|(A,RE0=8C"X+<&&TJ|V/ERS
_7|VXBX7P^N710A%^\$7XM5E1.D^X MGQL#'|/*F91^"K^9G
DMTRP3H<|BC1IN/YEFN22>0\$87C*">| (T3)A*5:"4
M2&.C7M/ZBCRROEX2B*1\$DDX#\$6EL-LQ! M(WD<#;,4X_2'\$N\$2B_A&QHI#-*
<9|EB/%=8WCF-6>QG*3-@@*L8_N<|E4M MZN#8Z98=|6Y 5C?
A)_'D47#2YW\$J4Q,PZ6/1ST!G3'E>R+C)XCR*,Y7(CR)|,^+,'TT""\6OBY+%SH0@E"24))
<|);-0BR"0 M/O-|89A,/(%)D:|5*\$7)L(38J,T)<>AN%BTv6
MRRR1.1,J\$)B2&K#\$QX16E0)F1G\$JPM=,20W|DY:1|SE*GBQI=9_0SQXF"DH:AN/|7M/X2;
;GH*Z,E|)411Z+O\$BFH0F5YAOJ;|I> M@ "<|TQH'Y|H*D
Q|@DV"S1.4,O&2*!1>S\$(5I4SB9EFD98WSE27V(MCGTGA93W2>LDAYO@E\$
M:F2P45=S'ZOJDZEFT|F>S:??% ^ I0X9,9J9G)WH/D?BEFA:E^*"H|*JOYU/P!
M;_I^5.H_WS@&X&&"J>W3>5.+I1C/X:|9KD/_;|Z;A,9/+?93G&N7H|J|ET|QKB0
1PUSIR&!9P/U|"X9JURR X4"U|* ML?
T6XV5S_WGLO)|,BY\$C/'"%=4* C47EKUP/&@8<6KD PI^9+ 4J-CFVO_-7,DY=^_L'^%:-

IV"=Q^5\K.%VY=R6-MTS\!K6H#;\CFM8DP&<\$2O,4\WGQ>#."3*:=7:MSJ\.^<65G?
8IRR;7D+|Z\F ME;5C7NIYY<##1N7XBL'8;IRK;7D\NX:K)Z#|4>6#@\|XSM 'H%)A?
\$7E;'O; M^O#KMV9. !: #C^>4TFT_(K6,S,\HS'N+N9U#KX":7SN-,Y|RP*% IDR*1
M+,EER+2(P5/EB?8P6G+>>A8-)3BJF(PX|4F#@601P&&_E.6T#U M Y
&4#XUTX Y|V55X,BJ'T<%3*_AW@O|2?J);6++(O H._)&-BU2833YED MVY.A3B|FWZ)
(C_,|C:P@G-6?@!969 MJ(;+@=7^|QPX#.7UPOEQ<G8L%:C\$!O.%J:LP-W'_A?
f5Q4/*"J!Z=+&\$@|D_H;O&WY !#Q*;RHJ.S" M+\$>-\$ (K?:UF#LCDER*#1R ((+/A"-
JY7+P>/SCGH%L^C@V;P;4/+GY-86_Y
M|&HR!P2|FBN@+O#A^|!?"D|T\$4/>S0ZTOQR9<%"&:AMT|FQZ_%#/D-K,)) M68\$,
(Z8Y'U-88SNQZO68"4#DNAAM6>:YU7"@!TN+'O7'CIJ"J%Q9*7J"\$!.\$7
MW2(\$:F(SKNIL,N>W%:*"QXPNX2%|M/Z|R"\$_.#5(VMV@"G3.7+KE/N1ET'3S6<5AR|YBO:
|!E/5 MLMX8/&7G!KZX!MMXC(KVLYF J@*7R/'!U*G=;X"MB<\$ %(_3_E6'(T 3JWN(
M9KWD OUMU'/H3%L7?.ETXTT?'.%QG_K)(.58@R7J!G\$<5_3;-NMHMRJPE:
<|J*HNLN|-?6P=3,. M_G7T2%6PM!-U9=BX\$S\$P|?N_2_+I9L'_!CU?
+YG_+A^9KRP#|TN|R4LY?QF
M_"X#)WND|B|QVW<3E64PFY4#-46|2LT9E/J#_YE7LR*_:UIH;V4 ZN\F3;SQ MTBX4+-
J|M/R*M(|G7B|V5+_NN'"Z LWW)|!:_9A'1&LDK'=56|)=+T|U-*_O
MQB/0C."J^GL4LUGY;OU+V!9ZX|MG>NC/=8 N52C6W57O7OSEP5'-\$|NB6AW
M+2W!5IA@@YB'I5ER6&OE9)O ZZ+U? \$ROH;G9HU2K;L"E@-Y#5;:>VCG)%1U3V#_271?
GV'EKIUK.*YA-J=WE,SW6WJ8!U=EB-0>L*6E;\$-%JX48A
MXGA0A+P|7(&!E0Y!T.H^&JR=_7KDN3"^|:J'F|4I/*7#::75EF>?
A,9MJ_>YS6_Y7^GT+_^_.GL7VW> M#+-_-4:>_3W=>0<|!-J/3LR<'XQN8MA\9>
(2@@\NFN|5AZG?(-SWZ'|=A MI+3O,Q.&>
XMC9@*HHQFJ=9YDNC0"Q_HBYAH(U+!1)A'3&98=SO*4^8G?LX3 ME?
EJL^|V0WN*!SKJ'U,71(*M|L.48.N0>?D)G)C(Y"S,?<%DGAF6YEG(\$AV(M/-5I&B<;|0)DK-
*\$AXH9P#0FE6=8DB09PW17'OM&Y^+Q8QDO@BV|Z|O^::8E
M,G0LN'A'J\$6HU762\$FH=\$+6BW\$22<|V,"F,F902HY7N293(4/ KR(!4;J5Q)
MHF7F9QQ@"BZ7N5%,>;\$'5AKW>9*&6DM#J\$6H1:A%J'4\$R4L|G0.'F-@_#2+%?
3/STU\$D_4A=G(TJD)=:TA KR*/-|9O) (>)'+)8J9UF<29,F8;B MC2J!*C:1CB+!LB 'VQ:
|~^5*!GGG1|<+G;8G\$#80@/4%X120=
M/E|E,0|X6*G,BW3*9!1)IGPP4|'F<9X')@LV:|7'GHADX&QRO/) &!X)3&3.3;^|)*0Q;Z1S,M,C
MM0FM|D?2@:.*5'^8|BXS G0ZL+92D"%0 M<#?E(+Y(2#ZHJM9*%L#E4*\$QVSHW5"G-
X)UD&9%3^2-JU.QO-VS_,4SPP J MR|U0*18H 2Y|%.!&50ZV-?<#
(3(E0K61_|A/V/+W1OA_*J=K.NM0IK4;>R?M MKOEPYOVKH_(VXN|T:(=
ET"70/<\$H!L%W\$ _"/&,89<6YW#&|LL M1N_5WI9PC @S*6+)?_D%3_8AJJDL
J_3K6(N?;SC50XSDWHAV\$ |V0^7)FD M+ D59R8Q)L|33^A(GO" AW
#R4^IH>XQR&OJ*\$!|(9@DF#S%Z5T_R;Q0,ZZS MF,DT
^LLBGTFT@2>ZB6^SS<"*&F0:1-|SG0290"M/&.Q4#Z+ I%YB111;/P! MG=XEC"2,))
(P|8XQ4*LZ,'^0L2W0(9F'.6;J-SU+N1#:.2&>2J">_Q LS27(0MU' *R|CC)\$W*W.PR3JY%@
M^!W|074\$ >^|~|'7|3SUE=:C\,H;-BJJ&3-UVU|VHF9+DHCKS4779D|)%O1^
ML(NH|8/YSLZ3X>.KRU15!CMA;JS(W4U-B.CM.L;H"KM)|. MH7
*^LN>O"XS(PKVZAQ;+>#;*V-M-D7J*Z-F547SN=Y"FLSGA6PG-
@_ML%D\QT,=HIM_>SVFGW6K5D=_F0^K>;P9KSU M_>3!(VEX2!|S#Z3A8|/L|3&9T.7-
9%H@L|H&.L==AJM M4-!-?' +FZ*J0,W6;'A?B&H6?|H/<2|@V|J^72?SGL%?
IST#M#E"@77?@TD MF)38K+%&!E4U?4*K;?TQ3S|/9U4S#|;F.'1K3L.ZLW9G7:&-%V:
|F"F2|TY MCQ>./\N0R%U&=HPI;:&.+^6MH/YCYL=S*D!\$4D72=>^TO4;^- \$D7"?|HD6F
M (\$5-1Q)"5CMFBM.B\$021!*T18)VZ|1(\$D021!)\$H@DB"2(=%"W_ MV+'LW|'3M?
25R_TY;P!YKCNC4C?R-5|+"YW+E(FC!TW>,YPR>H^A7-6DPKM0U:?
ZMU;/NR@<_/HM)R9J;05(N^ MCRT% C\$ _"C*1FM"8*; O\$D|+PY-S\$*1 M1\$P*(YF*(L.RW.
<"&S(9<|2^E=23G5"KAR0EU#HD;GD|UEQPOB,AF>0-6"J
MQ|P37AK)W/=RL5&+)HFR0*4F9R95,=SC)RR)_)#Q7)I49XAUV2F|5W*?8(M@
MJ^LD)=@Z:.D#+|Z2Q&9IYF@GEJ2S2H8Z-J&Q%29'+M?2
M&|@Z62=+"C7B<_YFOA1H"/")(^6QJCPX:(.3P.6A^AUQR&JA\$ P7WO@K!LC
M=*PVJGUE@1;&&"R&Z("@"=_B))1:.)' RILPS8_8"9E,7@(K(NE9@I7(.Q%P
MQ9F0<<9D*&,6FYRS+(SR+(GSF&|NAB2Y#B(O,MA(#/QSKC6+=18Q993/DRB+
M4OUX)X# #6KJ11V!%8\$4D'3Y8!9%40L@4H%,*GF:D"8/|0|"L9,KB/%*9BGFN(D.656\XF|
@_.#1 M!BVK)\$M9J|7')G'<6G4C&>)0!6\$;8"#'.?!5X<)U'H;Z\$, M3AE#%
FAU0MBB)2NN*=\$?5B4V#1?)UC#E**)U.66NMSNJXK|2&L3))J%8::Q

MCY5A2F0)3*B\$GYHLYMQLJ*(T4%[@:9;G(08&0(>E.5C=1L08DV'J)I(I9>Z0
MZY^V T!G&M*2>4VX2+AX%%P,4I#-@RAG@0HPJIM+68P_-,87@M3CH=@(?G)?
MFS"28,>G:.*+G"68I)((46TH;EH2^8+|R(Q-F M0AKOI+@(!F,D"1@)&
D8"1@/!HS@\$>=9RIG(<_JDBE+@|1G\$8^%CJ3Q?9UN M&(R1,EI@)RQ(!#K24<32"-
"1ZSB/=,KCT!POM6<#&*7K)60P=C|I=)|-_*5@?X<>BR*PWZ66"4M-D#+-
%4|D&F0|X1LACCS(8R_) M6< QQ"\$|GRGA9RSW,K#BP\C(!)Y
H))\|P)6GS23H/4RNAH;A=VPK_N_M OXVOS'3 M0L/?6?&E_A0?
6XSGJEE7 !QNI@9DWGOWHZ_-;:UPI<6|U (?/#AOWI;:<^4 Y;:1
MA=,LE(.K5:P';N|B^;|L|C9+"OJ<'_MIA=,|KX_OJ (FGKO/CJ' ^J"HK
MOJZCG)NZ06J9VVL^E#.:WLSLA#ETX |G4Q M42.8+'#=-= 0W|9>CK@.
|WGP*GS!9YC2+^55H5WG5E5.455SH%I+KM5%2,8*
M'3X;ST^5SA,/"= '_0@C@9B2ISEB><-2KXP(-B+78>9G<2 5*%KX(?-0LS@U M
1.I.E.X:MX(R0#BWM3CC_C\$GTJG^UZK*G1RGZQJC|_NVG)Q2H|I9>
MM%6!GIY5G7H2R #:3KEF"|I=SA ||GWMAC(9)TC\$W("3F89,!%DL\$F7"/MXV5
WE_55%|/"(=:(=7XU7GF"|3)H^!9J&:1J)L&6^D4HO&R|Y>?SC5WV-S/8Q
M;T"H88X7|@N7TO7B|:'@5^"8LIZR999FTC@'Y|JH5G!IH9B<>CTKN6ZM5K00V;XDL756
T"D)X"C|-V0)V+4LYWDH00T) M3VY8OB8.O3#4 >-!&""GXEG2)&)9|E?<
>2)/O8UZ=,=2C9R|0H9N(+8|F*_
MHUV\$(S^188BU5;0'I)49X\$O,XPRLFDS((-2AXAO|4D&2A6F>1LP+-,A/H31+
MI)|#BRC)_2#221">BM+"C0",!-|<+A#AA!|.\$%+_HL9W;D;4 4ZOI@^"59@
M4E|7H.6;ZV|4'>A 6#(P*,X+_/8EQ;^"A:FSR0A>@+^<|G8,UZ1WSJ_3
MBP:C+ISW#;A%79,C|D;_ZG0> &U>VU&|DD??OWEL_/ @>\$/&KAR?O|9^>67
M#|Y;|".\$/Y^"1_8/ FI|_#1&*B!011C&"H^V8;+<-P-%KK.??%+BPIBI+BJ#
MZU#-8;JWS9N|9TUIJ#|QZ+Y?;YSQG,O4EV(B08#SR(B|M ZEV' CP@<"-#@ M<:SQ'J'@-
X5U1D3..<_R+-(Q7T8J;KZF#2JKGPY4I?NC'85+\$GNBEI#|FOJJ)7*^:&
(QV8<|E=|1OE\$6A: MP%8%|B9X*1R8BW2#I9(TC@%_P8N)-0 Y(#&+ =Q9GL9@(|HT
M|V*_;RP5N> ON|!HW62I-?:YC|8%H. VA(;UPOMKH'XQ0H,!.L.L5G?ET|VG
M7JL090UAG670.\$O|(\$TRYDLL6.EKP13@'GC5<1ADD9_P>*L4A3)#%QO|-0- M9K6G
)M)! "Y|+L(D,%F4"|%A75IJU';&#W8#HW;7:_L#YF>_>CD7"S T>0 & M9Z<S5%YVT|?1-
_NX>C&,W#K8=:4>.%K;.,JUG"9%V58&W MOAE^WKNQBW,(WGY-'2(&MH Q #|P!>-
(B#7Y7S636#YR-%U@GZ&=@?_OJ><7!-36ZF^+K;_U|8
M(QG23"B\$2+2#|0X;7+4H!4+!9VPI7Y.XA+ M?6\$%
(WRY.1;Z,@Q<&704=;8CR)KH|A|N>,VY8\$QX>0;E1K-K|^F:@KP|9E
M9MH|8%PK^YC_M(64OEXR_UT^,E|9;3D G2^!|O.;|NLJ"8C=7>)W|Z;8*QJ M?
+5R&*JH1|:<'ZH_^)|Y('9^U|H0WLK;_LW*2OK#5|;|S)@/;Q+RZX?^Q1
MO|A_|KCGGFXX&6R1JGYV(1KW%HO:'>|N7UXD16,_IB/"K&,(R9FLXNU7Q6 MOEO_
I:U_MC2N3Z6I7*8W*4.W;J|ZMV;O|S?NFZ):/?B+<%6F&"#F(>E6=)3 MH3IE@H-
5+S"OF_|6_WV3J6YLD|XW'\$!5@<8V"TFY*91M?OQHU%YBP9?MKZ|F5YR_G4
MR1=+K->6>+I%R;G?.Q F|!|_EDXIQ;:>TS|+KQB6:C'BO M
3.Q=C+@)C69&&6/9)I19:SM6CLD,+,P?|-%/P6S^923F=X7|>3_!@AWOL M_RQ3#UIT?
G@7KL+|>A|Q|SW_T<9AG3L8)UCD>-,/X\$;M_J?6R/>AW>/X//% MHBP#)?;|"
|,=8P)%38NW>-V;SS|^>||=RCYE|1/47S8AT|6AM7'3"PPTF:-H
M6ITOLH4JQO74|I#)N90!06V:&|X-1/WOUEV|BZMOM"C0Q;0Q|X-J")=)X>M4;
M"RI>W=DUQ:_2>05#K;KV<:|>|!7NLK%16?YI_949W%)O|,ZNU0PN_%*.OF"4 MN|JS?
N|K,'2ACGC>E|X|^'3AGMQ?6|0)|J536Y9=VY+<\$6;+U86HO&&F|7_M!&|Q?
JHO:M8>KJT=BD: UNCCVH_@^GE|Y-B*D+:BF14YN \$P'EC4.AJ33|N; M.N+=7
CSU|,BM;1SD3|I%S614V/'AV;9;%N<>W3?_0\$NCN|4|YASC,T7BTD MZH??WK=F>3N"
RCU^T4#HD75@/92NS5AA_&D7?K\$TCVI>|H|C.?1=U6V;|-' M(P'R|V-1PZB|H|Y8?
U)A/+;HC*XAP:"90_%JMW "X&ID>_/&|;|'+COB_*/MLAPMA'P% QJ7U6V_:CZ^-?
<_F5>+3U#.FD|!\$-I/4#Q|1NO=7X>ZXM%C*6: MIU61%0IC,Q?/IS4?
1GKGQR|F^J4PMV?"|I%MX A7X%#RX,<;BE(+ZTSFTPEJ M+VM" U_-04Y4=6W5FKT3
W%:FY&Q!8RM@SF|G|S|JVLK(M=S&(AS;=1H=GWA M_*>I=PK@ (U-
A"GE178;0;\$!'5*4J.A #&&4:%O-C+X>PX)<%;:1R I42S5S MT@ (LD@PS|E&?
&;1G;|TF,U_J)PX|CM4|H|S;8(;GMJ90#K<@@:1HJFW#4P M\$CZE',WKV-
TR|PV5)! "JWN&83,L0188*=%38_1MN8):5/A|3Z|+64G;:=K MKP"%".ME4*?:1:D-
V28RC1;+M)R |(|?@?Z&A|(WP&CF|G|B;??%T:YJ,Y MB*BNUA:DW8E74_N|?
(ZV*#YN9FQ#.GO|5=.=SK5|-&8T<6:8X8U&E%|I MF:7FVS>X'?
A9JS&H|4B^E6KP1=2.P"3CXX@,&GS,J;HK;|O,K#95:U^I\$2JX+9OK

M(BU&Q>SNPOD(+YEE.XI=PI%HOAG,-;I'1ADJMY/(@\!CPP!L1O<9O4)656L?MMQ(-S
_,"T(&0J?J7VU 6F%=:T0J K4-&8.ZK\$'-0.611 Y,:< ME\6&16
M6.XLJJCIG @US!N>!9*)82_KBL#;8&EN#/I@176#5ZB596GER3HG*FJ@9PV
M^V8&#L-^>ECTD=D!BP%Z9N""S'\$+Q)\B;XM8N+G==C9J=2HJMMTC;_5?%*;M7-
K6/!-I.E5O4OD&8=K?Q+.B.5+KDRMI+OFT4OQKRN(YU?6OWS@8"MDM6+=/_
O6ABF! MNV=J&6_B\$N7M&'W41E.WX-!Q-2K3>C2E#?#;
M@6#W!@4*3MU5#KKB5QOJ;Z'={O80@%Z"/9>(&O!;EE%:9N4&>O\$*P'2.U
M76=RK:8W\ZY/6CH(@PMU\NU@8J9XW+C#MW"+JY3X^*L367@+VPTT1H53V
M>Y3!N\$ @\E(W1*DJ^INR0J4MAA^.#8FJQT>M!Y&JF;J23?
8A\OJ#AM%;^(K(NJ&&-+)H(O_%#;L5;_ST02T#1M 0"U>EV E6K43:MR"PLV4V/:F!/
)V!&60<J+X'QP&.9&^?YKDCJUE3'=FQ
M#B8W8:EB@AMBJ!%!Q&\$UP6@19C"4M38&_JR_0%WP:0&,&LB6K4ZP'JGT/7EZI_A;G?
US+HPJ=OZW D8_1:T63BWQJJA M(S,SV4H^%/K:U1QQO\$YN62;>
(,^"/K=QX#9W*K,FCJHWI02LQ#T"V6P1K;T MFVLHP=OU!\,7RT>N
MSJ!V3Y=7@5D,OS8[%U8'H*>Y>E@3OUB.H9J#%63E&"<) G5[72ZS%!=Q*!5
M_MZF@H&Q==/X_/T?YH@2:D5YLS#X3?|R\0, #,?F' (*M-^UFQW !I+J_W M5'Y<7(+H
96P*@V_-Z1\$S\|9*(I_ (+SE8067(I M:2P=IY07'T%>'H:2B^2>
M\96W,@7&Y1S342T)5OBHR3Q\$U8K7HZGDKN6IU1F"-L@S!PM&56:W0UNKS\#4
M0PS)U#|L%WM"\$GV'^;C^_=Y)KNT3N3?Z)F/1GF2>-2\$K3)'3NIQF"B95BPVZ MX9;
I>|07!S:>FJTSYWV\H\$ 3-"I^-.I90@KU9^5>=E"-+&V(I=N.S89VF;
M!A+@7X/2JUNC=8ILW85.6PR\L:&/&QCBS%|Y\$X|WO;0WC|P:3Z?S0\$*)S;U
MN;K3#*S:5+O+(\$8 MOK&Z3\$':T2|<(.5R=>%E?O3M:J%67D2!X%\$T_C9G J\$:+
MM6CR0NR2/+(=&8->\$2|V|U82P.H7<|_JMY37X>?Y2VD@Q:.UD#U8U"7 1*M;#-
!AMG*TRVGC'.8!=SGE,*.>QQSF/>^X!(G(HJ|((@"R;WD M0#!>=A_%
IN^8%R,1FQUYQ?)5J=.3?|Q-RL!:D3T/PUX>Y-BC(A?|X<6SN=_
M?/QE<:ZW%D(P1*Z+B8U2PH1U\$^17>'3\$AH; %)FB;>ZN6CC@I=9GCF=X>J'9
MAK#A)9|0/5QHDF;VU=I,'SL-O77HCYW=._NY>?
M(RZDM>R7@ZEW R>R)OS\$XXKCCW,24|F\,7A6.,S;:<"C7ZT=
M=T&"0H+R8D\$QXVL;&&GV%|M\@.46?|/-V|Q3@E35>P9M|FIY_-I:U;==6\$V-T
M#D^9VKTO3(I:A A_4>D?US8|_O,O_Z\5H0)SA>LMA954CNJNPKT\$=&MNK !B
MNO)T7M>4>DAZ47Y(3\$A,|HD+-&<AV8S.R:Q&T7K4+7H>"LH ME">6H;S"
JHM8T|5H3=H=(G>DUTBO/6'^U9RUJ@.LR651;)'^(= (?0K-L|CQ53
MKACG4|56G3=D:1%|K5GW8*;M7O:U+CZ0, RNLBUK57M!-N>|<8;6/)M%B.K!_9/Z
MM,2TSON|W7(-/*DV%0X?W""#X(P,@O=+XW94WF+J|D7.GBZKG3;S"()@#?8
MRH;J%W&6>ZEE30;>Z'5)W)'V\@1G|6VK*9:%W9DU/B!HY9M;JCSN8|S-#T+ MT\$?
#4U;S APIFVL*OF>AZ|-6ZWD54P. :VIA(&N\$A&\$ _^Q@E89S5Z866G^H
M9M66+9ACEE#=KOSSQU_Q\$|L3;X35J8^|H'5Y7CSOX0++9K @|1F.YE 'UL9WO
LJZV7T|!*<1TMZF#?|N2Z+-&1^# 5_.|K|M; ME.@;6WK&#FG|76-S5|L9?UB&O:MU8*
J3M9>3O&4C.-IN:L\$;3"-UKM4H1_UE8JH6@DZAIXVQZB M;*PD(/0_X;8|>*)5*8N"-
W6^/H6MR4M|0;V,Y8X1.:0\$C7MPT\$>:/%-OO(*R
MQ^+HJ3:DDYD)UGH#*%O4M\$;C>3Y='OY*Y|E5L|MXIYLT&UMMK#T9U.:K9T*M7YX?
9K4|K7#@;:/%&#&8".BG9HWC0'R.DQ?8;751H.X(N6T\$ MK&
<\$K#_BAG:UDM&_2+IQVHD1WA+>|G<&ZIYGQ?E_+(IB../R=ED'LG6;:@"1
M&J2UT4"U2(NP/1-M9HGUCYS9W<2L)5IJ+(0_+:M)@8AN"S:YCOK'W&|VV?7|
MHRZSLQV(G6NRYL2|&-;UMYN/F(YF|%=A1|<_.|?#H)D)25ZD;V6|8,V<|M;|NN/CB--
ENM#J:L78^'8,NKNL0'BEM>3&-;ZD)VUVI9\63A/K;Y<'5EGKHJ MF'C';91>7@
57\$S\W4&%>B+439K.(7/\$V#JU#9:D+P3Q#-(WG,WXV;)U_5 M)X!7JWQA;DI5U4U':N|
1U?7&5O4*8)1(L#%0WES!&.O"!G#NRLPI8|;8|@ M3|0LYZLRKZ
084AQTT)J3='48#GC>N|Q*:5"R|G|LAM0MQPPC.2D""^J** M49L#UF;EM?
4J;&%T;@|@V_9N, \$(LC+1RQS)=M9I;N<\$Z<5^A;+%U@5N\K8O-M)RDA*3E-O9*FN)2)#
(LE(C;X-"4YO"4&?YBS8LU8+WGT=2Q;&-|S38\$5B^;3(L;F)!G
MK;3JTG+OVL3ZMKK7>>M^&ZJ|N3B&U1V;_WO|AV9:|I?*20)/%77(UT9-JQ"
MLS?;AR"0|L<.*Q!T91|45D."SJZ;=K=U<*>_4J&YX|&%Q++;-6@2*82W" M|?
*\$UDQ6X|8GQ?W*ALN\$2-#7MB/9FM(^/?6V%A>VO%78X.QE>!&&8%WVM5K,
M|DKQ|W6>|>R.:LB?\$(LE|N)>+X&G;:5.K5U!OGBS.L%-A|J_U@|H:CJB-V>
M+5K46+=/_;Y.-)X_/W7V0 0)A+CE_.*?5 P|U8NVSJ(&B'6
M1|#,Z9&CNHLCC.MW+KW89N3W'G'_8/&R0|RQCIYJ\$F*P!HOLZ9?BCV=O+6<
MU5E*YN<:J,|9,JOU)=B4S#7E^<1B7:(":ZWV:K/N1SVVIXN&78!&3_M/K:=LC|/;*/!

!JH:NG=8\3^6J2GG>LOK'(#&D+<-1SW%9SX_FR|<*N?*_8MS?/4DSN-U/_TH)V|(J:H&
MV^!L:W/C3LCH|*VZI&=ESZDM=L-VCK77"?WS|L:H/V.%>R:T=7E,".OU07".G
MJ_U5%JT3ZGSS%)Y>H#;"NLQMG8*F@K\$52H/I-4W4&_57*[WPEK%IDM!7NHK4
M/I>N#);8F5Q;?_AJ<>"COM>F.F8EMD)L!!U/L=9G0J!!&'ZKKN=(>9U8_7P
MHP1L\$DZ/T^??LOTExBWM".P.9*Z79X#_DY<\$<3A6BNV|A5!M-
E&9J5E;M.WT6A2DKY<=6;&T^_%8#FK99'6SQ)ZZZI1655U2ZUMKZI=PE';
M.JPVJV4VN(_2_NS3D!=Z?Z")6TTYAO,9\5HA:~J@U*KH6:AD\$URRQ:8"V/
MAZI6WF^#/_YFYL7YY8UFWK\$7QWX|C.H\HTU;IK|F):HBBWJ8:.\$+6"N\$N^D\$M
/_Y9':9=8/L2K5=>|P64C|*=:/&+AXJMNICVCKV.'->-E M+0)8H&G%?
_&*)>+>7Y67(>ZY\0J3-J?P568;K;#;8M>9K,,MU0J3%2=R&M<1807:0?
18|!#IU7_*=7IEO/VS:=-53>3=S^|^.XWN3(O|/Q6SW=Y.JH!NW4#
M>0NDK5JQM6O='@U?LRE7&C::N@HK"|Y>A&G%XFA#VXL(I|X/AM MG8_P60-M) MU-
L"!M6&ZIH\SUW MK4FU&J;8G6LLJ;DD|JT8MQ61K(;?LH-9%
(:Y@V52QL8NJ"!JO=8A|>O/=8 MFK1N|;\$:|=|8T|9<4;T;@>>%4|MD%2,5(_"%JLV.'_9-
CY295/AJ^!U3BE2=
M8M_Z/Y24U9^D+\$Y)6;W;1HR6NQSM3MIHWK_*T^LM|TZET_L_|VS>>_63!M?
S8&03OA/2V"UKE_H-BMN^PWM6("N\$T*->PL;JZ0#06)G094@I6+MI-7725X M\$=-
J^|S;>@-U"1AK4F+T6IMPOFT7XX;::TB76Y?+-6M?7%3%M?6%EBMD4>&
MAYKAW%3(;%W&3PWU/US;8VEG(B2;Z|"0@GH=-G>K;V<=XS';5FO5?.YSAVU
M78!MH0MD=M!D;-GR?"7BMA2U?%1BC|>V37MN|T'YBZV/:8>-;VN^=MMV-3CZC|
(2AO#'?7A(O);@MB6XTU|@?"IG6\$T-%OLGG\$51Z=*->6ZQ;:STO-M14H|;
VW#9;6|=2ZPYPMF;T(>**EVU1\$TQ@U;JI46Q>Z4G@DL_85RP!U<|!R
M^F>|2\$U#S<8.K5M7-SDI+?"LO=;:&OX;*.5G#9?U0A1KRJ.#99Y800,-,7|
M6WO|7H"TT+&=8J6W6-AX&6!K5J05M_|I/M;:;JZ?(<3|L2S;:;E?NYV9|%O_<
ML5%)9X(R|Y>B6%F*#>UL^Z^L|5?4%9_&M004>(WZ'_.BMH\$7>EO59>J+!U2B
MBOYE4=4;.\$O-N'2)5VKLW|.#ED|:'?5Z-<,.Q?O/4-"^AW"CZ=;?V|:W?X_-
MSD2RVKDOVO|:OZ:F*8E6'!10=C0Q-T85T^;D8:-05%5AKH:5)Y0U&WDMENT@
MVI;\$B|S-S4=8PY*02L,-64&DT"+L6TCWG2M3A^@4V5_?5/4JBZ0;QS<_+?OL+LJO
MGHE0KKOH9L2A?~*Q T, M+K"HD>8U6PF|_8PN!
!;E.=#BZ\$7WSG|3>UL)3S"CZKOKO?|C0J<@UN1XH M!& #>DUL#<>"H388.E|1NH.7
IX_%>305L<;_POFUOL+E^DI<5F:B,.N M78.IE3K|I#?X?AC
(MJ(62GUYMAE>W|S\$5R5K9^D%|&%GWR|&@9LYEG'?^R
MY39^DEN"BR@671W<'K>\$%Y'TNSHXH@_1I^/S(?IT>S|1A3@*?~|77V;3^TJN MV=="
(WC9_X4UAEIN_W084%LI35/OL.\$'#Y@2|<*CHP|XMU<51LA6W;*X@-9 M-0|O;3XXK6?
L?LVR,YD<<-^|J)+NU<|?I"G.CW|(P#IZB/'9:=FNT|L;=AYH_4?5"&CSAK MNX-
_0;Z7TDW"l;!R'|+K+<|WI,YMT@^EL2W(%1E)3NBj<2N'X8
MJ9CDI'0'(KND=\$GIDM(=+\$5)Z:Y(L(CN2UB6M.UB*
MDM9=KD44NSP0/28Y*=V!R"XI75*ZCRO=9^<3/S|K^659R!W=)V|K'33CBB3R<3J#R=
(#).JYS998>(!\$/:_9\$@L/D*CG-5MB MX0\$2|;QF2RP\0**>UVR)A0=(U/:+;'P (DZI-
D>^VS::D=*6|HSSQVY9GEL M;4|HG-4'>^|. (UL'B-%O;VQ,^Y?=WMBB_E|V3-#:(TB>Q@"-
EWD95!CZE,JL;D|DSEU0==+BF/GD3V MU6=+
(KLCI4788RJ3JB6Y/5.Y!54KHCI++JE:\$MGS\$EG9YR#4:YQ8H|WSO7;/
M*S/I4F@8!&V?|TW*" \$MW#>K|:N"3^4,B^<J5)9'=U6,YTP|I)+>=I"C)|:X1 M0C?F?
19=TK0DL>%RWN?4%U*U)++G);*BS^)*JL;D M|DSE-G*CN,;:<:1H26+/2V)
|'8,ZY>XYG3U_T>XY/&*DTG*J9D4Y=M0X<|K9 MM9G29OH+A6|?ULZ#-^G)|H|>#Z<-
:5_H^M!|K!L""8&#A<\$9;-U&!0B@\$ M#P0/>V#O_Y+++@X";N0Z4#8,"!2\$S8,
QO(@""0()#H1!NP;@(\$&0^\$"X0+ M%<@LX'@>@!"?(LN,@QA
V\$#84.OL*#|1PZ#3P08*P_RID:.7J|S&A,*\$P MH? #B?7^-#&+A^\$
T<(AT(&@@:'BVZ7"XHEK=A 4R M'0@??"!_VCTIRUSM@1^=N8@29#@0-! W/-
AT.UQ*OF|/0X?(FG<:<%_#4WZ9E M53F3:0D?
\$^[N*4T#1M6^8Z;P71'VN8XQF4HDLN;D^/
M5"W)+36CUP0H18?)+*O/EL2V5U5;9\MX|)&5>FNGR*@;HRZT,B(*P@?O/7-^+-
X|/L!#X<?MIML3"@R3J M>V9RJV,73|X7-.-
5.:1'8@A.R|R/I|E=2M22W9RJW/'\$|O!!*5*U)++G M);+B3&NQ'+L;,&V?UXO_V8Q&Q?
C*=L.V\$S5R&ZCJPPN+ZH9GG_!0DV\$^R-P M!*N|>C#2E1Z=WR>1??
79DLN2.GH3,_OD|QVDJ(DM|MZ,(529^+-Y.J)9\$| M+Y&-
;Y/S^12KON)&^M2,U,ODCKZ&09B M0+4WXD:@NFMXW_4E=5(EB7WUV9+\$|DCI,
I6"2&P|25\$2VUV#^VZ2|E?CA0M M2>QY26R?I944+8GMF8HM|YZ9R&|B2|SD<

M19J6)/:!) +:/&2]T'+WS6^A_3-6X4GI6E&.[@5] %U=X#!W^;MNP\$JSN*7\$I
M)Z9+H9Z\$4QF3E6.BLOI:35@X'UZ\GV'YL#UHL,5]WEDO6IL|_PALPLA R'#
M8)!"RY!IYNP0"\$4P@?"AQ>D%H3AX=K*=!,BR'(@9"!D>+UP3S=1@0P'@@>"MAQ?
TW""I U8H]29&D.5 T\$#0!&QH.%Q*1C=A@4P'P@?"!XHY=(%="!D(&0:# M#(>K%=I-
5.AP)8=.0|Y+TDK*F1HY<1@*LGXBE))"(@AI+)9%N0KDD! T\$ M#00-&Z?CR#ZCP X!!
'\$EB7SA>L+BNP0-! T\$#3?P#V<+4X MNXD+':YMTFG0>0%3_5)6E9-
/RYLVL:0<4T+)OE(U8'CM.WB^!;D;'1! 7UO(
MMIWS.O+>WE"4A'=7X8WZW)OG1\&ED\$A_2\$J2NZOD"NIRZ'#)5IV57A+>WE"4
MA'=7X8V'W];:U&Z/2\$J2NZODE[SVV2@F-4MB>ZYZ[M! MT&<3F30MB>R9B2RI6I+;
ILR6Y'9'2H?!X3J!#)C.)*\#(63?Y?5,U2R=-Z/ M73].KLVTV?
YVWC8MV;^CC7#J8T!|#+9MS074WX1P@7"!<.%>MO_48&"(0/ M!
!OJ8H8\$*\$HJKA!"\$ \$!C!/56M?A)@0!! '\$@PT-0C(AR(0@A""\$V.ID M\$#Z0"4\$
00"Q+4B9#U,29L7A N\$"_!%!0HJ'"ZUA(HKV,6TK=E3DY=3TR:8 MS-
170^W9^Y.015EWN_I=(G3C,RCW1H&7_E"4A'=7X0W/0' I(M(?DI+D]JOV
M/3>1ATO'I*STDO#VAJ(DO#009E*76)+<#LV6)'?G749/NL\$Y-'DFZ>T-14EZ
M2>^2WNTC24ER=Y7<0+HBI',!E*J)+SG*KQAGPN647?VU^A.T&Z:.TUA!L)%
MREZB!4'SU;&E,!\$EA,A!"\$G:VDN @!! '\$LV,KA!!D01! "\$\$0!4\$6! \$\$ M<2S
<+WZ/0UF1"\$\$(009\$*0"4\$ 00#Q_#UB+@DBR(0@A""\$H)/QT\TH4H- M=C5_,S-
G5%94F>\$PHB0N!,I25L]3D7E%V-U-E+XY&OX^O Z]1V 1NHE_K'23 M>VO6?2
FS!@49KR2J390J#A@88F>PP2%?(%\$V1!,>V\PD.59]L=Z!!F'& MH#"#;(M#0L4!3_'V";
(MA@63I!M<9S(L2?=F/N\$&F1<#! TR+@@XX*,\() M,BY>JS))%.TDVR+
(6(&V1:'A(J(8&*7)!;X5!\\$|*/#)HIX: >^!^!6' M"LR.DXN?
>M_!4V7LVV]KW*&T'&7/F7UI*,]JLIC!*/36]?ADOICOW#Q_0<+7 M69"74;^9K9/>.9-IF
^/"KYMA_9,5X\Q\O63^NWQDOK*LF!HJ*TI0'N5H?C-^EQ759*3N+O';
M=Q.59<7X:B4GL*A'UF31U1_!S]R:%?E=^T)]*S/C]-VDK KH*D9J5GQQ0! M?
+7YPS,0%UC]=0L@'Y#EXKQ!%SNK]O.0(OF)Q+N>I&7V(R^&(^*,0QC]S M2S6?
E>_6OX!EK3^V=*ZS\$U4.D]M4HUMU5]U|Y<%1S1;/HEH6=P2;(4)-HAY
M6)HEA!6EDPG5DD)6Z=XC\$@ZMID*S(#@B7!^8 %I.0(#*.0A"|=5D]^H706"8,
]S9M.-9\XY-]RO\X.E&@%|_ '\$-9_H(AK4 M?(';X0-_9G/L+ A00#%,=[TR,&:^-&#-0_9;P^?
MMFT!.^/43GQT?A GM|# MCL01(J3#G!QP W]SUS=6SSN6NP3*.JV5']<3XUQ?
H6_KROG1_# 'M,N>SF;'Q%PC!L82"50(8120%) 1E&) 5D&)%AM'<<[O&&
ML]O'X5X6=^MH'=#?FZS\|N?^|H! TY<3.S0#3"?.89U,>YS7;(F%TC4YHM ML?
B7I>LR46'B!1SVNVQ,(#).IYS998>(!\$/:_9\$@L/D*CG-5MBX0\$2];QF M2RP\0**>UVR)A0=
(U""-IM@=\$.TTL)C0>%97W]FSDN5J81W]G-4'>^|. (ULO MV"G] >5S-IO,;^..031,?&&]?
M^#W*N?XVIOEIZ@&W FT>0'G\ VX0ASVF^,EJ MN>XFS(>.*@GSZY"VES+,#U?=&OZN0?
7E6B2NY_59JDDM#U:8 M22W02&D_Z#&5NZJ6R5LF23Y]CPL_]C&97Z\$S%LER-
XE,)O.*UYRX29#TF.1D M8P]6FDD\$[RK\$?8Y=|7&)DDFO?QZ(BU"-^AU1)OT\F"EF?
3RKK&O)XO;=)C* M7=7+Y"^(3))|^]B6&'9^O'/KL|N.4/++=LSCL0SFNYC?8>
(^2[X]5>GOWLDF# M-VG)]HW6.;2];SH%-
SRBGVWSTM)\$UH06AS+'>, #1XJNNFS##;X08@P:,1(W M\|@ZW.=I-T*!
+6\$%8<4!K(O#94=U\$RBZ:ET,-WHQ8#SHN]1+VMHA22;=3]J_ M1H/]6-R%
(:D&P@M""V.Y2D<+EVSFTC15?N"8@N\$&/U\$#. [Z!SP)W4W4H\$ D M@06!Q0&<\$6_@0-
%5]V*XX8L!XT'OI7WXB:F'R4M]9E'(/=-0.Y]G^DRG\$M/%*DMQI&I,D[ZJ.8S?B
MATO)/@I*DO_/EK2]%.*(U#%YOUVE,4GRCIO^TS@B"7)/:.\$R"O".EP\#U99]+ MM9)=34)|
]D(<|+GV6U?5,4DR2?+D)3ER8]YG+YG4,0GQN0LQA;G(.^XTC4F2
M=]UUZG,"R"GSY=HZC@]M]JY)=-UFV0EP. +P MTVR)A0=)U/.;+;'P
(EZ7K,E%AX@4<]KML3" R3J>?+7]T.3^R)@^:&'H/KR1#M05
M5_3<*.ZS(B.1)9\$|+Y'UJ4@&R6UW9DMRNR.E@Y#".R2OKSY;DM==P|\$])C*I
M60K04'CG%;*HVOH1E\$7U+ K]5)A11GE4U..2>EP^5N/6Y5.-C]! T'#LZ&!
M;'ZR^0D?"!A>,1V\H>|HD.E T\$#0!.QPX=|A@4P" A>>.;BPS\<3]DC]F5 M\CH-
!2]@ES_*F1JU.9MMIS#"1;*;R&YZR&YR)45C"1H(&@@:]A+)9>*7"K" M\A'*K;F;01@.'"+
(IL<+HKQVIJ97!&2V].16Q&X(CK<+L6_*4TB.Q!"|EUDN7>F M9S])<#M)41+<'2D=#;=_
(EM?RA*W0;\$EN=|61(I>+^WR8AE0MB>QYB6QRILDL)+>=I"C)H8Z4#ONL9JF\$X,F3
MT#Z4HY%*RZF:%>78J*5LVLSI40T2N2G1/Y'S".J)\$BX0+A N'_|V;@J\$" > M%
<\$#P&PBSS0@2X)+>OW< M]IP8TEQ0D(&0@9"!HH3DN% |\$#PL-OA!-
>+AAX4(.!D(&0X=G(.!4(.! M0H5G&BKDO3Z-2 4\$7ZG].V5]E(B@N!BC
KY^G(O*+)M)LX?7,TV^GA=>@| MQ\$KD)N'A3K8\NF3D6A%2#(K8YP-0ARS#U%5T(!?
K'&&"#(JCL, \$KA|>JQ]4 M=R"##(HS0@HR*,B@((.B0S-Q8 CHNWCWNLHRR>TYJG=R!

(ZBYT7D10QPM6"!MJNO)\$S@CJ"!/@#P!LB@()LBB>W7(G9Y<*P||>Y
!AD49X049%"004\$&18=@M8L0T"?Q#OT>4_DV:#PKP+XL;|^,'KNG5HD||W|T=?
MRN0{3DX|};Z#YYP>
M8+)KZ:G.U11NB*)OG5GI?".#"^!AXVPZ&A>3IW9M8'3XUQ;N#^Z|HGX|QD
MSFT80K|>Q?11:0QB'\$Q MWF,,|SE7S@_P#(T-RC|CWE1%;;H:ID|GV\$A?
RFO"NTNUJL8ZZE1%3PJ07.^M\$>(B68P5I_)R""^"+4N(W^|VCZFI)D;/BB|F=+9A9_
M7)MJ.;S*N353W/(S/#H6:F_0+F|8U_X:\FXL5RL,SF^E63CXM;YQR/G5&
MYDKI.R>=5S"%JCKEW)XOF+R7DOFIX3\$@5V6N;N!#NZZJRZG%=P?
_7=Y?;7L+^P;;73PJH|XJ#NE3S6=D:MU#B68GR%0\?+V4C=E?,9//ZKR=[5KP(S_L+
|MKU!8SWF264N*PAJF:F70-KM7M3/?
G/_L,07@)*T&!6SN|OV_G|O_.CM0HA7,QQ_42,"|&=1|AL=OA_W|F<^PL"&^
M|,4QWO3(4<|XT38<#UEN#Y_OW+0!|X_U.4&0^\$#FZ#+\$=.30WC G!|R_W_SU
M#9=0'I_1004MCKL6N_IMM|4LI.4HVQXWL8|NK|5_^^.F?|L?A^Q?|J\$_7'0>
M(B*>D)"^|_|&35E)A!STY OKE4OV&<4S">9(OPODS(S2Y280-+|*%&
M|.R5)V|RD88D*3A|*7@R38BD8-A2)2=.'PI0\$O2^7"MQE=/EL\$C81BV,)!*M(.I("D@
PCD@ (RC,@PVCL.=|+*T|ZK WY XUG+^?NTG)GRIM 5U9X>Z,&<
M0Y|5|OLY+%^Z01CTF.1TPGH@LDM')W>D-%5E(I GMT&Q)YSZ|M(%T/>|PG7,'
M#-4DNP,A9-|%-NBSB4PZE^3V3.662S*627"!ULREIKP4GL)L'A*@(V/&*M)
M=@="R+Z++6H2&X|-%O2N<|N)!JY(NESNV;2N0.17=*Y.U(ZY#VF,NETAT7-.3ON;&5-
JVN\$KPN^>#L(S'QZ|OU'55=ZQVI7M|HP|X4P'T\$#0<-@H.'I@S,|AP5RI@@?"!_V-
QVXZP>|FZB1%D.A T\$#0|M>UOD<\$F W80%,ATH#GNF<=BW?<|WTUNOR(!)
<5.BOVAF\$#L1N&QVHUV1;F3 MS4_00-!X4*R^0D?"!|.5C_#
<^/@<*F2W<0(CAT(&@:@:G@T-0|H|(-.!PH7G M&BX<_A&GA|.5%-
P#V|Y8|7/,'A092@N!"H!;-RCHW*7|@.OWILEW6H>_X M*J6;A,>RG^XM&3E6A!2#(O8Y
3WCK5?TOUT(/_J'&%"#(JCL,.\$|O_?WKGI/NN7OVDZ.0"M"VD!@|;+_
M_F96Z04&&S#&DLB9F+\$_4E5EY3LK*/L|L|H*ZO(((/BB"0%&11D4)!!42(Q
M46,14'7VIII4Q+<54^_D"+R(GC=Z6D|_J;OAY='UY_D6 MC?R
11,|_P5"L"Fl.@F9|&QALVLQB|1T*)FMC1FM(RVQBQ_.N,!?!GY&|HF
M:H0|=C)G:Y#/Z3G>DU,^F'&#E|PF^QH',%0_%TV8X05WX(Z'S X|T?L&G;T-
W_L6!H#M%@3)NX!;SB/#V,61K+XC|= %UX4H89? MV+\$5A1+44
2WCB7"YO9TIE>8T,9+16R9+:Q|!#VKG|(2LNG|1V\$V'|D|@7 M#L L9W?Q-:
f'"^;E%"|H!;D@ (Y/&PY,QX)6RW9@<|4709(A\$AJ^8@CWXI#
M!N2)%UX8SGNU|O/;|B',%.HB |PP|?J6R>?#0)XS#BCH>BG,U|I/1;M=| M&<:2|!5-
I2OV!|;H*VGNY!O_W7(|T|=5!CZKKT-/M'<:HS!RC8L=92^<_MC!
SWQ=S_4NY5K8|WKI5E#HI3A)OHR%_#.*(G4J6#GR3T?2<"\$/_=&D;P?
A_!L^/|L.5A|'B@|H*RZYI:T*C-O1" T4%W7&X|A/'6%<"T@S
M7#H^WG#YW(|C&/Y>V.=J*G"_FZVWZ0N*)?/OG\$6"I#A(%K3/9!N@1K|9/F&MTRUH?
JG\$YV?I^<LV!|F@5_NF4=:5\$?+4COG|3_Z3<2EOR<=FL>S7CB.6\$_.@!KPFU|.NB>/
|HK)8V7W8I=+/VU MKK/T:S|K'_/RH8^Y&X'L7E>B.D1T'!QB/, \$A5:??V&TP0?
8&L>)Z% H#1W(^MVZDO&!,D,4|,0F+^R!|-3A+)AA>5#?57GG@X1QJ2N.#HN>#)C"3B
N*">G,!M6I+LPX1|XR>O M?*V;V)?8|S6O9NM:N_72|S>)?XE_2X7*RK/M.^EVW670%?
H%|W<2|HW|?L MD&=J>GM_E9/J++*)?XE_R|B_1F|_S6^)?XE_*X#*RK/MN_V5(RNMG-
ZZ>^6: MV'Z:9\$NQ?7^4%JRAV'X%V8;\$X|8Q05/KF&355_?7Q.EUQNYSEFKYI?;W2M@ZY
M)|2U1|>U9K_2(<&R5\$(FYB7F?07F-31=|Q"N*X-KXN0Z8_:9|=0SL"RMO?
,8OZ|H_.8#+4M|8%-F)B@6/|^_9L?J.H
M'@+U:>@K+W+W*"WOU|5#VHAT4"BH4ZBX:|_Z1NZ<1""(?E0?OFPXA;R,?DF
M7S|7SE-|8>U1;W8@=4GJ|D"-4DE5DFRH,;*/0#:0*4WR@4Q|J7W7|Z'4OS/
MT|;LUF*K1!(W^|)\$N1M-|6+|,78T?\$6#Y!|W'#?9B'+(G^?D&>M:K|6_B@2/
M|AD9)R0M2%I465KH;I(6)"U(6CQ%&U=:^VQEC!)BR.3%G5&9>69N|I%PNE:QJ/8_X6^<
(MS13@8Q*)M6,5*B-9/#XQ-:K5QGI9-(0_QXO_^JZIG>>|'|89J03_|&?|DE
MV3S;^EA|F+>2N.4E&_QC,'8ZQE#G24V|2_Q;^GXU^QIK4&EDP:(?VO#OV0|M;ZQVCZ
!&;50V'<|7|U'(K%"K\$(B<=>,C3KU9:3^\$ _@K\$OUVL|*M\$HA|
MB7N/EWM|S6/U1XAY2X|38MZ-56^?N)>XMUS@\$O=NS+V|9J7|G1#W\$O<>+?J
MS4HGKNTAD|_<=5|M=2L.72W(|.MRF=(W"V<|LLEX?
A+RA2G.G,B6(6U=C^<^S@2V=@)J MO;R?"2|4X?9|PS;XO5D7 ZX2 !G=R(0#+AJY+NN?
Q>R=V^0.:*)'X<@><+W
M9|MO376M8B5)%NTK7)0RH!);!M>"I@TL'1|O@.WKQV##.O?"E=3Z:U6L_4VM?
4%V\$YN%XBP4(/%X)-(|D/Z;&OMD.8WHU@F=H>,ZT?PL?7|5?I"DV|;Y9U<41|M-:>|HHO

!TB290_1',U5FF=UXN9#';:U\UV"9/T\J=/5,8P7B/[6\$[BLJG[W MY'%
=VW\,:):L8NUO;8@NG15/ROG[/*A<[8;@>S>=: (Z1'0<'&(P2%5I_|_M"1XT?
("M<9R(KC5P).>SG?J",3@2\|0@).:/#-'D))%L>% '94'_EB:=:!'&)& M"XZ>"YXLX\$!
<0%Q0;RY 2Y)IF'!O_&3?0&(&8H9Z,P,91L0%Q 5D&!\$7\$!>0 M8;1S'(XZ1*S?
T;|B|,*R)C);VA:WPO5G4_B*+NK5|OX6%_Q\FI7,WN5KC1%
f%L;|J5|ILWBZ#:CL2\|0*7=_ 67-SN:V:GTK6F
M2/D2_QXO_ ^H#K656NFL3|6|M^)>,YXW9MMK=\$:E;Q*%C^|?""=1UOK+&Q|\$3
M71GCYS8\|H11("L.D:BL\$>1J-P4UV9;:|>H'1:Q;1G);:=%->&H1D#@W!- M;%L"<(EM-
+7UT?HEQ+LEQ2GQ|L9!!0P&&G223GQ;|G");S?..?^EJ>K_2A^G\$
MML2V1|>V_4IKVH.&|"D|_URFYT=!:;\$6J1#C&|V6O &\$S:P*+6*B_3*R|/Q#
MW':W5VY_\$W;W^63T(AJ0# M28EV M\$@|D'HY0/) #E3|*A2@8A6?
X;GK_W1!XN!'+'|\$7>;/!!ZK>&,Z5MFS M/C2:|BI\$VX^'KGA-
^KP=1XWV8C*2|Q.6QN\|V""+TIZ1.472@J1%E:6%:6BF M\|5*N%TF+VDN+.J.R|LQ=
f7XJ=.f"FIXT_1|/8-M:KT>JGL0%B0L2%T|2SP < M@SWV=B)I<632HLZHK#QSZ|:Q|K
3PZR1_ZZP?)U|)A|V/,1.5NQC_C2ZAY;
MC7H4ISIS(EB%M5FWZ(AKNT5ON\$7=U|FAS39D+?A_Y=/9^?L3;?99S"QOR Z:W>6XV-
X+=H(N"_0 @VA;\$F(1.>#2|=BUDDID,1 M,+.E,:-EM#5F^=,9#^#+R_X-5-
+;A<55V,,FN;BR.AVP6.(!V&EFQR(=RX&AK8CY(_G79Q&,81#'DW^-G""V)\Q#T!<MXB-
J.8!7H#T8VHUQ|AS@D+LP/N 0|V\$H/ %X"S,TX8=AY%L_&T/Y-\$(%7RS< MPRJN##
|B\$KBOZP^YR^|X"?LFR781'#;|E,O:FYA;45"EF;F;|5VLQ|5M;RH?|BP<>18\$SC*6R)3FQ
M5|(WVOCO*QL/2|4LOR>U+#+|J&599RGQ9\$U/(#PO!-D)GR14/_)=U|_#Q|) MRO?C\$-
X+WY|MOV40|S+N88L>^&(G)(*J?>F%|HJ+.N-QY*D>2"|*C7VRG)AUZX3.
MT'&=: 'Z6OK|JXTL.9YK-?K>|JWCKN#B\$D!AF^_/3T|70*
QNW6"JOLJDN|. **WVM%;K|EJO\1,CZ2W|A|M(+)*PZQ.>7VHJY;7NDU(
MJK|GM9F'_%XXUEI/X(:)M?3KHGCP.ZZZV?E|V*79STM:G.TM/[K-RKRX?N
MU6X\$LOOUE^H0T7%PB/\$\$AU2=_O|E>-#P;:;&<2*ZUL"1G,IVZ@M&T4C,\$X.0
MF#|R1).31++A165#_96GL4'A\$-*0Q 6UYP*3N("XX+BY "U)/%OVQH*8@9CA MN)F!#"/B
N(",HR("X@+R#:#.0Y'M;C6;^BU !"X9ZE,6C^:B(!DN!QE4*; M)MS2-
;G:W9|:YX79ZM^7TSHZ-2|G|BT#N,2^6|O|V_LA?Q,2|4!EY7E6
M|U\$34H%+FG=K+AYHG6J7FB#=2^Q|O.RK;_T|L2^Q;QG)=-Y4URW6T^>
MB)49T=35_-!A_D_4Y^UW|"+RJJW0B0;J=;/N:5&.M3|J=I-)!Y(
MJSKI:9VG;R*0="#I4!)PR?+?V/+7H|=MV*6/IV;,>\$8A^"ILM D+_>C'JD7
MV;:;47D!;&AF>W_7+Z@5&0D+\$A:U%1;Z-ACT25B0L*B,@4Z>V.:70JJ,9|H3
M0HJ>%/T>FYAJ9N_) "DBDZ4E:D+0@:= '1VGJ'A 4)BJ8B^06;&X)',!\$5!; MF1OU;+.YV
^WE??+?K6>O+UFZ|\$;7JP3K|LP+D5'LY<.)&[4,1K5?DN;+X+
MV^P)2WY|YT03V%H|EG_*;|VMX7&I7GS7N)6SCZ@ZT.N=I(W.|K^&(-C
_Z,NW=|'B;M.XLH3Y\$H#1N)L (1/\$#F?G\$VV*)|@>RD< MK;"Y4PS557J"? "K83
2.CP)22LLF^P&B,)|66|Z';!8XL'H8E|FQ0+'GBC%W M0:S.MT|H!W/XS9*&
UH,EA|&H?:H+H@#%)|K|)&"M2%7\0%K3>7+UM@PL#4
M|G6&Q(RO<7=A\$CDWD|W6!10%8\$0*,EMR;|A*Z^:P.|X &,:D(M_'8F=LA+V
M9;:@TS3V8Q2PIQEK*TI*V?*"LL>2% M<,|#\$6.)*>|S">+:.5B!^#DQ>T|PZ)-@B(Z\$UQ?
X#_E+UK1V M|GU ^@\$WD)LQ.Q+|&|UH#M8X)OC|9H(MAQU%9A,|GPCL?"(=
D\$3UOFS3V M>K|+2K,BDGA+R%;PP(-|Q>\$-':@8"0Q-+\$=|/(:Q
>66P.L%R3DMU+,D_-2|>PQ|_Y8|7!*<) MQ,A5/@_|*D8C^#UE5U@!T""|-\$LLDS"WDF; D+
4L#M@&8@<'#4!;S&=7BRR MNPL35S+&_Q60H%
"Z)1XDZ)8D@:L=))H2#!Y'7@JR.U.0W_+FA>-|DG@5:E M"|OF41R!"YJ-
|E"KH\$6J#%".J22OAFCDZDI#A:RG924|Y+/Z580V<^Q? M3D+E=)NMP|KP=?3PEP-
^!SCT<|E/'_@,)|3S|+D+@5NMH(ND@OB<<^ \$E*9'
M4)2=BBAP@1+Z"QT|X|'_S;*0NWP+5LLM*Y|&ZK_R-FQ'&7HZIK>T8O&KK2?
M'|@HM\$*L^L^%U\$(?)6M!FP64 PSY82LYHH#K|>#QA M (2/21(^!!\$*N9912B
M+>S)TUA,G_#|E"N Y(KAU8/?S|XP+DTJ2"_0#: M7_0UW?Y_1OL
LQGBW/UDIQ3JB=G*|A:)?\$<^8BS7Q,GC MHDIZ_=.LVI+Z/V5<#(@<_"4RC|1"B1E+ '
MFG<;04^|ET|H2P_9N*KAX0 M;Y#B2IMLG^*)H.\$HI'YZ,S0%<@WHD#'H-91@6M*
MC2-/;ME\$:'5|1=E>;,N*A%,-JT?3'@OG@"LIV!NSVRVZQ=\$Z=_>-KK<+ M<4AX|*.PDN?
TW1W%NM+_V|!^1#^=.JH|3|29D"YCO%*C%J"71H\$V"94T9|4
M|&CO"#3|5XC UU*D%F|W")5L|P;'8%O% ^'5ZO!";35/PY&.!X(;*T/\$G4V
MEA'1(>Q#H@!@AAB8Z1.3KFTR% C M99RI9V\$?+)|X
I/9KV'Z0G'38*.==.APS9X@F&B9^6HRV!)@TMM|.CACOT MS|"\$P)4|-

H8W8*0H!*-7VHF8WC\$\$\$9"JH@ZP.HL#=#JB-"KU T75;QBX3JJ# MSQ?
2!T5"%NN.URCAJ,0)1OU*.*IWPE%EO1_NAGY162WH&LP\|P.PB\$&M#1\DO_M*U?
F*+CR# [?MT,\9_03P[%09(.%B>T'=IOKRO"2/#\$#\$&1?!
/R!+.1=NFAKB2VCP71GN2\$%!+CF: ML-
"G%8GH:K>2C)1"Y\$TJ\0*M%\$.FO.A/.POJ:HNJ#8C ?"51RI/?6U%G,-Y M?
LJL'OE@L:"1JD'/AT&CCT6&OLMLINHW#.# #0TV 01TOD81&:2WG:7\$SN&
MKV*,7JG@D1^,N>?AV?)^%+DJ0%"#\$XN/[@F\$"AL)-AK\6=\$5YQP7R#PLI
M\$UI/,6\&62LC&N*W(318:/@E2CXDH0Z&./CEPNP\$?+PD(;))\$WV\N3JXX^3
M\T#?/G/"#"1UVI40%.8"%0U.?AIX:[(+ =1Z7KBW;#.4SAG*>'<>YD;:G OD3L"
T/\$4CA!PW0EM:B- M^OCC:!\@1#UP12K M5[+|ZKWN3BUG7B6!;"00,D'JV-&0KR-
UEE58J/\$4AR#YO>=9:L_\$**KQ3C
M*Z!5/'^QUP7N[7%%%.S/YEN&\QE(BX/D)34D+U|HPC-CT/@U/#|V?;|_*W
MIU_"4T"@Y&W4)4<2%Z4|Q<1HP|6@#P=+Q|<;X.3|,3CKSKVPS|54>J05;+U-
M7|"X*Y^%XBP4,XYF2+H',J2BOCY9+E>*VDB=RIZE|Y^QJ\$,JI^N"<3 PWQ8= MS
10Y6&>KGE/;W:-'=[X16CV>^;K?R?7<8X=O@>*6K;7UG3-FT2N(J#-BUT
M^35^Y1G5\B%_H\$PNJ@TPN45=CF:OV^@'OIBA%"_C-+R?=D!?!W*K6_:MA M?
17#.#,;=J&63"OAEV,@|T1@))1)*SQ!*!@FEY;+1+>^/ MxG
D>8A'CIQ'GFQ90SSRK#X8>U3/Y>V#L3'!?'5B.FISM4R)5IOK,=#,P?
/!*+I<6|>^)E6N'4V+E(BL#)QM&M_Y87|G)U ;S>4:0 M3 JS52DU=?
V)#*!*\A'5I=^X);C9T|KM_36CJS.RB6|K@|H:|*UF=O;76:H2
MN*8XSW|B/\$G2,)DWQ\,ZQRHFW|7|6FMPK#XA,7!)<4H,O#\$\$=|1^ZUCYEV(Z
M.|,9580-2U:.*>ZM"=-;4\$401RY6/40+?'C2./J087":L%_Q_ZH,U6*U')*T MNW+?
T|EK=9;.%6^7N555:Z_L+)6V2O_?J@HGL,9(2)"6V/7/?HT=6/RE!8:Z=
MPUS%MBF/%\$Z4E6\=6?)#VGXDJO?"?-2?_M&-J+S9,5_6>1NXH21'ZA*@0M-
M9CPQEB57-X0CS,KFP2 |ZP^3= M5T4=@|KD-D9K?0YN|EB_1HQ-
B:1A3>.XMOKJ,2*L)7
MJ\$67;>,%@WRC4BYXAV8^E2P2^&FK)N&H#P,_CO#A3%T6S)MBD^Z,H>!YI9*Q
M6&JWD(O8I+^|!.P4AWEWDK0S@LT2@:I>-8M275:8QG;JR+F(O*[3O,.PLMEM&V
MIG!%T>M:.*K3BE;OK)I:T50AUKA=*YJZJN5/V46/XU7+CUUZ45JVW2^(-M^JV4|)O&
|C3|NXP"RGA|-TQIK/FRX|0:R,RA6A>KD+Y1,?RUPG4JAKLP5BM4 M(R+L<;
(0|(+ =B"VA^HW(L'8:QBZV=GL8\$=MF#|P'>|'"G+2B\$=EZ_N;U^6*&R MMAH>&C<6N%
7EH7HQ(W|YK08/E<90)=@.X_1=#2"Y3\WN&K_F|1#-V,&DD_M
AYPYZ&3'>#D/3JPB8>312Q40\$0|5N@"V#"5A1:29_WG7J)!.H'D.2Q;2D MGY<|^A@*
<*9G&+-C',.V ULV6Y<-@?ZHWG=9'^|N/BFS&CUJ JN9+W*5LZ; M-
*I2C9(2UA0IB:CMPOY/,P4L2!);J'Z-2F9@-VF1.O;JR;*D018KUP=-EX#42C@#7_J6"#9;IW-|
/!*CN5MP/_PX3,)AQ1U*YQ"(3A|Z MGNQ:D3=ULIS_BJ>A|!2/':I4'|J4M+!W|V,1O
P+COPY+E5&D-?! F6|>_8 M'B<'@PF|)SU @9+F;"+X+3D)L,7|:T@|H.NF/&V/NH!-
)U#XS.1OBGP-|TC^ M:0GG%B&2|<|@.|Q#B6448@U_U\$ 22ND
_.^9A#V^@"!_L81>,6QGWX|Y8JH*, M7F3|:(%J8_'^%!:,%|XN?LW?JE?=)6R@!&X4|K;JX-
MEW_#!N@(283T9)0.. MO%_JR9+6WK)1>-|'K;@A@1CS(&MZ;Z6BE.>B=%84I1DRCN:
"&1+(-HBR5LX M7V;JTDZ8|H@M?K5J#VT1PAX/DW#F,J*TA+N_H#T,_J'4=OU'FWH|HH-?
K:D7 MTU^YIU>"#\$0_6+>_%&P6@7-9H)+X2C<4-Q)5,LX\$*C&WV/PCV%CYBD7;>
M"3AE>JQQ^~L;7T8YC*_O @,?"Z87: WXW1+'U|S\DJ|17#L|O7_|\$@-I=401(MSP)\$K3*?'-
_"?*@Z+&O)31IN%?;S.7OC5AQ_81%5)AW0DZ>'@DT/?3N4SM_U9 MI
..929)8J>\$JHDE*@YYAQ"34=#>:+(/_%<>DN4|4|-.@MK2048@48T9-6KQ_M.412 2-
8:90'?!4AO)C*4%YIN.S<94Q|\$\$\$Q:F:OYMR:|HN8.@M;88|*YJT2 M|?UBH"PIC?
FS9_8_MN)9%SK!C8(W"30|O|LM)2_)|>|)SW"F?.\$OAN"D8YOVGT!EWYWPYY'(%U"KJ*S
BD|3|'6)O'TCN\KZ M;BCI6QX|V(B=\$I%WNPDBQ8M*1-ZX7Y*TOV7|51G:??
\$H|"4Z89GOGC.|1&*5 M=^|Y'3*G63!2WI<8|'"#8_JY,\NV#,W=#Q-'C-CEO;|B*3>_CL_1
7OAWOD-M7!E;G(N""P>F63YD6_P^|(|&JPI>+AU(G"-3!@_DJ CIR-UH<MMC+
<5%L0H#T|B;*IT).BH&1::VJJ):P8\FWUY??LB,L2!.CY(1O+!99-!U M6\$_"*6I&U-
FN,Y4*4/WZUXJT|Z"Z1Y/8Q6=5"FRTVGL@?Y-6J+|2|RI \$9S M',>=@5.).DRD?&C
C;|/+ =P?<5W*N|E'S@PU-8!_1FX=@%5Z(*XP_1V&2 MOY9&;+MR)FGR?(
L"2/L0>4D%KIWGPMPC6ZD M(PN|N*ML\$C#A95I"%OG#V&_@8YC/(19(F5M3N%8|2
M.E^Q^RY&ABD%K'!0E,3J@)"NU)T(-S4PV=-;0%~N"U7(!^CL2"P-%>64Q_5"
MP,HW*C,8/'4X)#?+Q|W*!5B0;I82;,XE#Q-)E41*EL)H%X^K!:OBX#!86C_M
"Z)'84.1K&#_K'/0:G\1,\$8^0|?T+9;>O,YKL(SPY64:56=3*L>95I|HE4E
MM=|OF0\$>IC;/Y;)+E|K;1Z+U4N4?SD-01:L-8#3=YPQ"\$,HZTC"3QG%FJTG-AR@IV,=)Z-

Y:6*2<=RJB)OL4!^BM MJBB]6DGJKBZ\, 6!GF8-RV='7/ZB)L0[LU*GAJ N+3E;& 7<|=+;?*
*JJS*Q M51Y7:IC*<8=B!2A?29GD:H43)-<0V* "XDFFA3Q3!BK^@42F.#N^12ZA5.
M%FWS; 5%)R3=W>4J+0XISRW"Y"LDH\@2S &/,.,B/TCK3"62^F"J#IL3D MN7>5
*"Q*4R;GSCB!6KT;H, SW, "-;=,@I!FDUP<\$@RZMNGI9!4QS!HDWU0
M; O@V9V5Y3D*!G!O'.=&!A00"O&MU6!<,>:N37+5!;BT'/LESYST)ONM1
=.N%'JR\$1NU+'8 M=%>%6+\$!+P'39B9-'Y]9(HC M&&2B%A.1"\$&?
+,\$!+6Y50TRYEKU7S_72B5P MI-FL'XK9K'E\$[3JW@=]D>8+O!?-@:RD%UI*H-
15R96>?.OE!SB-X\$3_D1+MV@_*=.ZM7S39=Z=\$4BC\R3ZI73H2^?-/D3J)TB%@,*QC
Q'+F*K,-"PD5B>G M6!>^BPZ?%T!%@#G6F#TG)556TP.I#?RH?
_DQ7N",7;R\!I(IQGAGZH"IDP!X MD"5TF:=RY6R6<-
E%>N:*.30IAM+#U=6IJ2HWWY*3/XBV+A0HTE;>)UB7OZ7. M@26
JH.7T!0RZ1Y\,KM;'H0@F\$+5;,AJ/>#!G2P!%4L_.I5.:G3E\$*KU3M%5
M4!>]ZLQ0YF#+!Q@>,C&=N?Y"N"4*S#9+\$L@>O!&3NPRGER*P\$O*,T"
M!Y%P)7WG_.*%_D&ZM-K2B*N3^/S5EU 4N84QW@I0D0Y,RYE07"BN!MXJS>
)6+6E8N= Y,@!N Q!0R'@!SH?V-+!_5(4%Z#WH'M5+K0G?{U)G&3>P%
M8NR\$<:.*2J0S#4R"S5=6(N7)KM,J>Y?RN@>[SND<?*?L/%9%*C/SJ:-@7CW47
M!5G737RN!^#ME\$;Z,G=X#-WH&(-7+0^#L>&?2O>MGU+T="&U_!T1+#{,;K
MRJUB0LM07408,15(1A.3Q!\$3S+-P#159PGIG65TL<|_%+M)
I_G3WY33R8FZ'NL0Q+&LNB1GUB>=T)J!<+H!4S=:E]J2)7D64H+ERG3BPA ML#L!&
R3R#5IBYK>%RM'_!0-4-&_N1H]+ "MIRW[J]<5NX07EA0&_10&;O!\$4E%3X3FS:W
M,Y7!%@A9(E"EO*D*9AX#I).+!J/;=JH8Q(?PCTA/Y(+*^D)05OI+V6I/U9
MZ'I@)D:V>TUVL3:U*2U.FD-E,JW4NBWX3^!JMOUYMMVC1' LJUAM7V+YI/X*+4 M
4QR%H)KP:,16#H^WG Y.!:1#'\O!_,U%=:4:JU-7!2RGP6BK-0W4X7Z1!(MV!-
JH)/E3BJW3NC(^!_SL_3!52U2Y'2FWFQUVF^+YS8)H.K@YG3->_IA7FDW
MS4!O,%,U3>,P\$YG-GGX@F A)\JU.LHJ&A!4XT4!MT>ZV7W9Y!M2&"O!9M?
3HR38R>5'SX6 MT_ ^2&9S7RH!)/2\BHMTVH.K \$8=D.W4!@/,QND,8XO!&
320KXF!/\$Y_LF!G
M<0AQ2+TY"Y"D=@F=XWY(CGF_QT'4L!*00/%67Q\$[C#,1'1!E'1\X!%WC#I%Y6
M!6(?.,P0L/^7EK1+^\$B>+G_F<_80\$;,%?18&O_L@B>(_PT!:=82W@FI%UY-UA M_R<&
(;4W3!4ZWJHK'25P?&5P#I;L_(M%V55 8.037Q;!G/WU>5&/CUL4X, M7!L&)L5+?
\$M!2]3!1F_G64#I<4K3!&C=DHOXC'>\R.WE 1FK>4:4?BV_*M2VXI,3
Q,*&2^):076N^K3MUOX!;2F>E,\$Y^70\$!TQ9YIB0S:RM"2\$2WY8'
M7!/,B8&)&@0F5Q+>\$[%KS;=VI>V!/%'!B7>>7J8>TF&ZM/TBV+FQ 4GAXARU8 MS-
+>Y<;XZ!;N70\$HO0ZEZ7S.!\
M##7#)JCR,E12LS.4M0\LG2=W!@T9=KN6_'5UUHUI3>R3A!@TL3MR\$?"2B
M^4W>=:M,I-MNLL^PR!*1+KN6^U7LQWO\$)\$M=&\$KW"/(5 YUF=Z?:M
K!*BLF%&ON5T0 07D\$RJ1GX(ZD9>!\$V\$115KROS"8] MCSH^!Y4M17&VG3P4U6-
3/O;LG:Q*/M4JM@/6U_H5(C&-*>
[S56%6_D!43)00AN352E;JE\VEE8E+*]6GUFXSMLWRLO+8&0;H+"=JU:WQ=1
8L!]&4SS!-=T3!XSVZT>Y;9Z/<[!@T9_8%N#GA!&I<|D14P@62_8W.-#S>F MWNMPT^:-
@6%;C7;:,C6&PZ!9&%J!\$6@)H!5!1/F!2FL4%CV&:(9L:P#DUW8 M/FR!_X/<-0:
M#J=5I?W1L!]=IB..ZSV\ 3#U<(R2;6P7RO^?CW"?AFR!;<&[5Z/ P7TATBV M?-
@8"AM(H)WJ=KM#P^A9O>?0@LN""=G^*@GALV_+?NNIT*W9-
X5NM7OM3F/0\$3K!9MC=4;?3/G2&SUUK1K?;+??P!#%-5E9ZRD7A^S*T:;9;IM'5
M!XWN4!<@Q_B@,>="(9 RMJN=D;#U!EY%[H]@ZD6[2=Q65S>&HM,0W")JP!Z MC6%
!*:H!T/1R/5T'FJE+1TF!:85-18*0Z@9%V
MBP(C)0Z,/,8*X^*=&_\$_<09.E&9@N+=)CB(:E7;^!H!QO_A:L3;0A4KH7%
MGB9VVL8@V0KV&WR:JN=2!>1#; ?EWZDNU8YG^<!,EWVKL19\(\$;8O-B2/0!D M-
P'A6!D8*;W@_"#9M?L!U*D?;#]2QVSV6_O!-Y.DQT2L\$'3!UN
MKO!@R:F>J'.13G!3*4278BP95A:%1-6_W6;A5:M*)6D^MF8^9KJ/255H_BM
*G%FT)CF3D%TG9%\5+/0#R:F7!VJ(!D/B:=0&*G\$B;X0 M,24Q906!JB!3'M;,>WF@R-
!#C'S\$>OP?!(W"!E(9!E!27Q"1E&>W#SIO(E M(LRF_A2%K=Z
K(M'G9FKI+CG;+!@L>\DBF;AV>GIW=U=,Q16<^S?GEX\$UL2Y M%>&IL,
<!.+5YQ\$!UO6OH@_8IK%K7!Z9N='2JU>NW=>/4%O>FWIQ\$T_4DM:H
MGUR8+2Q4_GC\)/O6XI'7^B #LN2\$74Q5*ACFK7T7822CXA!P-
T;_0AEGO8\$:9KN<1RWDR;!(W,=U8G MZY-&_!@*4?D0#J/J.\$A-9P:_5/4&IM:EOL.UAO-
'2K137;<\$2U02.450ZT MS<74ON L9?-!0B(AD9"X3TA?-
/!4@!B209'9:L:;#*,U,'OPD6VV6IU6UQ;W M!?

ZAPD0KXT_SEU^%ZZ.!%UYUD8AGR.CMJH9M>-/LF/6F&TW22,U@RCI_JH
MT3)6*GH*GI#13RBK.F@U<|D(B81\$0F(9D\$C!D|>#)R:9R04)GIB'"IXLY='(M6
I>BY75IO ZI#YS<#09>M'P?FN6C7,Q"QR7J3ZX!H5EZN?R45BF,AAMDZZI
M&T8I+\$.>!85E:HZR&CF#A\$1"(B&Q#\$BDL,SC89DG.^@>F:E|AZ\$6?86HI%Q&*
I>TM9GRBR&:Z'M>-+N5%L5XZ:3?V(LM02M9MX=(9&02\$@L Q(ISO*\$K6Q0G*5T
M<9:-XRN#3F?0E?\$5P^@:/5N_\$?=ZZW"Y,6B4LP^JHT_8A_@B!|W96SE6L#>
MRM9X&\$:1'WWCN-G.3%U-NA@'0K99I:A*[1PVBJK4#,:45:D=2ONG9HO"*N09
M4%BEUBBKD3-WG\$@DT BTPX-&@9-'<|EU,H=?-V|B|F\$#VR#=""S8D=-BP?#%
MMS@(8Z|N_WR/7<%TDS?T|CO^_E3OV.HWE3QB^S/,2F^<"TL.8C9,C|N@O>'
MKGDPY)X(&U_073%G%U:\$WQ@M|<2'B2-&|I>6+%,3?DZ@H6(@#)2ZN>6R89Y M;"("
<=>=\$\$Q(R!|O!5CY3B&(A|3>!"65U_HUB(35-(H%&H)7#_*!82"\$60BV#
MRA\$+,8XG%O+)|;AG.=RE6-C%0HX.N00;P58:4XAB(?4W@0EE=0*-8B\$U0"!
M1J"5PP"@6\$@6"S'RO)#U0^**&^UFMS|H_M-9MWL%^FCVX*&9'SK23P^\$RS\$=
M8.URWNGOC|U+0A|HD?SNOFAF85<=+/3>C(N,VAU*4>%XC(4
MER'8"+;2PD9QF>,TOPEE=0*.XC(U0"!1J"5PP"@N\$PA+F/4-RY3?(L!S4|
M",N4(&'F,&&9ET^7J3X14E2FGK@ET BT/_I6C&5=_J7 MOJ'KYQB@<-+O|O|^
66|/D1X|_9X \$(2,95ZCZN"731S|RB#-T:3\$2XD2A MFB;BXY#Q0#
Q'0H;&_F@KYN|G|GG8H(C&(_JSU_.F>7|!MB*D8 MU|9\$3#G|)SBD|/
(-2_SF>#^'|,SC(2&1 \$4BC@&Y!|O!5AI#A"(1|3="65U M HTB\$35-(H%&H)7#_*!(1!Z)6-
GIK|X68:WP|!\$-B,CP4;^<&41W@UA(<+M60-89A??
X/")C5D5E_<39^A\$3&|1OR**/QP%<@DV@NU5S0_XR8>ND+|>6K|
M<5%5SOWH=)M" _1K;2 M|Y4,=H3T+^PS|T#)RCQ%_!@3\$D/F!_#'"=:4%WA
MG+G>CQ\$C0O+LB,;=@)A17X@'Q%932Q?7;Y,4A@!4 <(!:|USCCR
M@C/CD6@N|;+MW#++Y6'XRPD /&VX3A@UA"MGE\$#/1"2;I'MA+"R^=G(%?=%
M/*#U_N|XC)S1/(55/M,(YCY7.YY X6OXG+6W' M2H8(-9G1:Q5"-
DH#CPGG"R8MB'#HHL*(*)_I2(L(&_H9S!8 AXWLA1LX!<3- M850G9+_'@'X1N/,".)
I@8SN?&|'.K.<5V9H#S,AL'M,\$">H=TE?|?/T1!G MLSB8^2&@.\$@#,KG#WT|O912";
|H&V; \$U(JI8,5#W"+ ^@SOF,-'PSD+Q A@ M0R)P/(0)H('X&+^<^?J+CA(FL)"%B.O
<=>/%B\$!N+(\$C-YF1R_\$WB."7|_-M>"3_#L08!\$R
U|W#F;#D0EW8J<|)J0GQPNK"D7&@!'R7_7Q)>Z+DT/_!6*6V? M+#=#=?
QH.0'%_UC#/)8LJ"8JWZX'+XJEWOB#:9MRV?),.#4|CN*@Q-|7'ZSD M?
>'9*THU#/_U|9%,8\$PR1+83AK|?T"GH/L79+^6|!\$&GMQ==PD7\$3;((2K+Z
M1*9*R7G&X|@_7_P"ME5|+/&L0BE|!,"=.S|SD|,(I*14R1*0T\$BK\$ \$ M#Y"Y7YP|*8U+;G?
E&#J\$M|H<^Y>3\$#|A\$0CM<\$G MB|D<;#D7/_|X?
GF|O6DL79K7LHYWAK98BT2IBS|CD-3*_ \$T+DN1*:\$"P|?Z MP&OKRWIFPD-
FQZ!C+!Z'J/Y01P=*,RM5B"0(7X!F184_%!/NCE#_X\$!2^24/ M1*C|8|2.G<"_L|LX";8
G+P!|N7P6BK-0@+<"9D"Z!X%D)SGVR7+X=8)P4ASG6A^ MEKZ_(K:NIC-|3;-
GOBV*|010)=/_U|S7;AJ#P?:OZ4W#V/ZM3J^IMYZ<|9 G
M\$96/FTC8@#KPFU|S),U<%808G_IX^++QX00'!FO5U|_?/WZVS6|^O*A^1JH
M*_6@\$*8"L1;41|DORSVSV.E09EGH3GW|Y0?@10QAG|(M_B|>V|;5F-\$R
MMCV.WEP!E&X#?IV?'1MW/('S&%/XS>SB(6^Z|@LW>"*HOHT/&6?'?|ZA,|N MQQ/?
G6KLZ3Y<6.13W;B\$>J2(X5MZMBV*RIFUA-W\$P<0;'7E|C5MK.2IX+=
MA(Z|JH0<3MQQ#'#5DEN?_B)8*L8;)5T MR(FQB?@)MAHRMHJK?YT)D)GHC1?
BZO):D3-=UZN09 #Q"<%6 QE0B+9?6)8? M>|E5P0<|_VCP_6AN6-/UN1)?GS,62/0@U^?
^ZW3HV/_C_=3J)INY_W|0 M2P,\$% @_)(IF6?E(XL|OM@\$ @N,:! !L86(M,C R-# Y,S
N>'_D M|+U|=^_VEB?Z_WP*W-Q9=Y)UY52Y|:V/+8JF3-9=YU%BY#\$ M\$XA4DY1MY=-
2;#Q(|_ \$^1)"@7.K5W7'9P 8V+|^=O_ |M_?U@2|X#R O|O
MWYQ^_ \$;A|UYX'K^|F_??'DZ.7NZN+GYK_ ^W_YM_KY 1=7M_" +
|UH3H)H&V+T|=/=^A_GS_>HJ?Y"J|=!=!G,MV0LO^@ \$K>)X|N'#Z^O MK|^|'^/K*-
Z7#1|_-@_0&=G CB%R%VX/?HTHDQ^N73QT|_.3D|/?GXT^ST MIU|^_?
#+CS|_ ^/'GW|X?S|^_.7C1Z5;L-F%WG(5HV_GWR'H1<0|"1'G.;?_X|.B,\$/4*W"#WB"
(\$WV+W%|BSD3LA\$LSXKA.ZSUI_&(&1/_|_U|U)XY#|WD;X^L@7%_BA,;E|=^^ MV?
K_N76(M_"P2|>88%B<3_/ESW13_.@7-PY/XMT&1YEQWYY#|GT0+C_0/W^
MA/(GTX^_G#RPZGLB>?N2;1|3OJQ/A&>?|,7CZ(|O)*QVTC3,-Z>)D9O/Z M YO+IX|?3S_|
HM;OOFR,?'|AKG3MO_|'^_.Q\$..\$7>^63H'_ (3H+^T8VS M;075'S_P/ZI-O8HYT.-
(|W&>S(\$XSPUW62R_HY-/W2?>? M|/"_?
O/O_P4A=LR|J28(8|1/^VTP9Q.L6"WXUXEB6>|W28AS|Y>DT@.WKZ3D*<,1O|1-
V|H6PT8J3|"N6W>P+_J|RW|&-O M/'B.W^JSW(#_FH^AW:(4OL/F,01_*MR68J?

UWYI(2\C^*Y/B17V)ZJH\Z MYU?IAG/F9MBOV-0\MRP?T>-OKNRQ\K M\#F.^CX#?
SP8>Z0^9:P9B>GWY?? M-U'NX!=Z*1-P?
#^(V1_@5_*7FXWG+P+^&_H\N*M^"0."9W3U\$/SPY?&FT1/U M(7;>C\8\SY KP\7
17SOD\$>?; YCW((.8B+J7#FL>F1-2PM%AE_Y
)5W/H<*L>^X0>/2>5AC'D=R#VG8U&W0*&_1\$EQLZS1\|@O+W'L>"3ZQ(-\4/(5G*5/I&-
/U;D3Q*(<#)TS, M" 4+E,R)_QFILO*_\$O-
"Z<30+!\$T:N+ORN30MV)Z5&T\^LON%\N#\$J)56>'8 MHWPVO66RG6J.R0\|
I73GHV\|P@WQWWNFZODR4NW;_DKU%R2\|"-B@MEQZXU^_Z7
MAON>DE=N"JK@^'WO^7VG"QHH^U7Q;6LZU.SOCQWW\|B\G7?W(EC3A5F\COR"
M;X.HZ287^I7L\4\|75F&_3C'/>\|YX_Q<\CU5_7!Q&5_^Y\|>+=)9WWW(L;_M\KV^?
+T9^)>|SH ZW\|?#?.\$"0X=B0QU?>X*NNW=@2\$<\XU9JS\|<>SLY10C3_
MGCC1ZIH\$KXW?D:1\|S?|_O_-|0@I\$G-OOY4W%!=!"E4COM4MT^/\^7\6TS;?L;:,G0V*V\|^
M%F*;Y'VKS6\|R^%W1&4V">6TD) [+A)S3^FST'@OGJ\$T/OQ;\$Y%V\|"-W0U
M_"6XM<^B",?1/8Y_R\|@3;05;_M?"|LJ";-IE:112AMQXA/DX_BXSW7\|K)K%_MA6."
IV39'VKVZN>2AT\QB2-!YK@IM1\|??A;6\$/93\|;+^+&P\|-#KN,IM79\|E_MOLFZU3\|MK#
IO=US_>FU^O?9BIB31\|E1\|GD7^ZFX7M6@9E<^%79%(<9>C@RY
MXV;5;=:UXX6_.F2+@T427GSC1W'((F7\$AM4UJMFT'PJ;!\|@01HP@:4AK7K!-I
M;EW=UMWA/_|T?*"JH<_DWZK\|+VNVYB^%K4D("OF<1^:OSHO:G:@J.SS_MSHCU/JY\|
I1V%ER_3/6*(\;:"K;B=|K^MV86B&B\|HH(3\$<2OJC9P@HH^*:G^&'E-
R!\$4D2!ZWK;F;)\NP0GC\$O\|1_M\|U6U6T\$.6\|OHT;=J_(-U6Q2T:I2=-H<
MMV=O#T+F6RK_6\|T&%>T@!6_"<7\N16RH_&+6OVKLP@4N-B..|EP";M>R>\$
M?/07G(G>|8EV\$7GI)_%|G0YD10\|Y7B^_EF\4\B=V0HS>U?SI@OI:XD^,UU
M4IOG"L2#6>CXT0*'(79UAZVW@6L.7K\|T/MHO*|
(XJWIK\|=&2\$"FDY_,ACTTXU+5Y/>'4YB_Y:V6WK)*_A+|&|48Z:G_MJ=6)'69&-4>
I:;%YK<+25F;-TZM4G.@|8%Z\$R(*S>J4\$<;FX5S\$IP&OWGQBC:|PU0."_>YH_T-
67.>B\|;)\NF?2,>CY*9XA>Z119#S\|XTDU?E*_^,|6\|2_.)@P_V\|M1C*_+^#E
MPV"4AORL@_@5=>F>Y#/&2,1@L1(-AG>F4G,&R@+R\|)\$>V4LA.S+|108\|I\|
MQZ3\|^V_%G^MSO/\|I3-*2VOE.>"PUU\|M_H\|85FH/3_M#>KKJ*X-?
0U=;V\|Z^IM@^SB&@_5V*_@="<5\|<-H'5=5\|X_M#;M7GZN?2TS1H5DL&3,#_Q-
F""%;P@S+H\43L%WM5V%P1@Q0\|XCFFBTL_/_&U\|
M58N^<-6>A;)+6G04Y!\$K'&Z\|H:V_|\FR'@?AKOF.%|K4;'19'GCY1B>4C\|O;_MZ:Y_"(-#N,=
I0_7Y;.:@R\|?L4\|/!)9G?F@V6@|_#K\|GFN-
OFIO%PB\|UB9/'"X\|7M.Z.5Z:Y.&-9M:%MAXX%;UV@Y9W/A\|
M_8_DTW:S(:Q^ED/8W^HCB? [|M/((=G+W1HP45""^3((?@)-
J=*8C5'N;.:D%0V%K4\|;H<3.HF3)SH+E\$|C>*|Z_M.%>IMZW_U9\|HUVQX!E5U7%%^Y-
20\$V-8)S&V\|UQR?HK6TV?\$YRF#W%&_P3K3W\|3;:4R0K#DL12MM
M^|M&CGZTN!@I:59^7=0UJMGGHA4W7RKL>/T\F%9\|P_T\|UBSRR5%8BIA+8H
MWMN>*S9/0#N,'NDRA2_800Y""FMZ\$T5;<%9_16E?WE5%KWP@CC9U;IA\|J\|:
M:5L(U;Q\|EDT0R1DBJBO)(%PY2<1F*0EEH#W91\|GMBLH:_G%U+!MS?EH=1Z_MO(4,
|BD#@_0@B)T241(96>LO=,Y1@|UN3J3F%!\|1-P16G(\V5&8G5+\$S6""|&1
MCT>DZQ%AOYUNX,>S.?WJV-2>R8J>M4<@A*T6?TAX#O-OT%RH..>&|GS\|_QO
M169+T\VOZU\|S#HK&U;IS<')>_)/,QCD>B3WDU1R<=YUF4M>\9L.+ELP2'/#C
MZV\|V3Y6(2_K9;/FR3!=JDV:\W8)0S3DHFB1+SX&J\|S3(>&?!-IN:-N(8\|V/XI6-=#\$.FJ\$/
_4\|O>*;07;W-R=;%|B(\ULJN1\|S\$B1^S#D;PT1\|SFF38M_Y3%<0'EXJMG#\|!"I#*_?0\|(9OR
9BO_MDIC"2GKHC\|=GVM2*7E=|^Q5-;TY0M75LH^/G9D*&!K#15VKFKUK4&/IN(%F
M-C""|_27.IVBABRGM0J\|ZVS^56#)+MEV\|H\|L4MGP&%K:0^\$4'>QDJSXU>U^&
M.5I73.5X\|?2PV0EV0YP<7G^=!\OF>TWIWT/15>=!\V2DFH-5AFL<|TN)4_M\|(O.KX0
FV)"YNA^|\^%5P'0_OG@B8;+D?G)5\$W%=<-K,FD\LM>M8B\|?GD'P?
A,L\GA\|<+WU\|!F@T/(-^B-45B%
M>)\$Y2\$FG3O\|_LA(N/\$)/S\|6^3^WTK/F\$|W;|H\$WGI#\|#=;!\V/+_|H#-D^IDS&^)DC=?/-
QWPF4T>IGMBA(-Y\|MG_M?)(LTIYSKJ#49>8P,(I6SO=X&P8;^_|\^0_|<18)%Z\|0-
^G\$|Q)Y\|IDT4D8_M)GV!^<(GX!^7F\|*GIZ"/B0_)).(0.B#^<^S\$B_&ZR\$!4_MW
+;6\|D^3TZ_YU,NIU0\|93G?LK57-_UG_M;Y4&&!RL;_VYPW<%;JHW@Q/Q\|
M\|@KC0+B05%'5X4_MBFJGVY3_"BA@C85B5_MH%9*;M)YP!LCZ^=N?.\$V4=SL0C6-0S6-
<&L@,<+!;,%Y'P9HVTHB19IU'IYFT_MW*1\|B-
K041\|Q5=MO\$'VEV0X4&@ZNN\|0\|*66=;&L"C5AH16,|G;+C6E(OY+L
MW8B9)EV'EL;3;RRS^!2;|.UKNQD60)N^#(W)W\$@4F4Q.V(-Z5(W\|%TI,U/%
MFDD\$0L0!0^,|J\$'?AGP8?";(G3\|:(%#*KVT7L"^9S"6U:1'A'AK^NMP=T9(M;!

<)X#HN6%F(&Q?281>>DPB#4DBDATS)4*!_HX\IY=S,L@ZU;L#YPJP2BP
MDQ/"4^&OK/7WIFZ'E@>PN:(N45<;8MTFIB'?<9T>YH?A0-
:=E3>J/TTSIO)WE,H380SK18""%Z-&/:%'EKZ\RD\N2 M&=0"R:9V5M@**0#-9%K@#?
W.^/1:J_!&&H\$ZZ.@L4V?
B\K,*>>JCLQ\FA%^1LWH#13YR%1\EM?.=4"C:'IY AIS/B==8UZGM!&XXI
MNI7;6T3H1GYTZY#N)(?:!2@J@-L6X-AYT5TD^_V?=-HX!&,CL;OH<\$8P!B
M/B\$HAOX'#\$TO#@\$#MY15.WH#FK)*BO6#=:CZ!/,9T@W:'VEJKV1.WR?./3
MAST.PIT!5G6T;)QGJHON@RN-^XJEIU*UIR/2&+O)DMV;SGNO0Q"8MK
MVJCF)Y+U8+VX"NPM192W=UF%'E+EO:@-.N\5=QM>\$^|SV!\$;YE@ZJAAA>O
M18@C6JW.M3-K:&A>8QG9?>^DO>D.O\FI4N-'UNZL<.:A^GY0EHV'L\8-|MG^W6%,?
K=G;:%U7JH_96(K<;'E,VA&QO%.+>EH;-N:NJ55J'H9M0?;|>1L MEE;)FE?
CAL2'O".K*T'U//V:TC"F=MJN+LQW/|S8..3|=3^Z5--+S-&OYX M-BM+D30\?0UH#)Y-
T/;|A|<#Y:5:=HQ>(>E"WG5|2.-N'F&4>314?Z+ R M9J=@>3U;@>9W6+0|QK&6ZUZ-
!K\7'GP3DN_\$'9I% ZQ3P-J)TU1Y5+TS+HU MZD1S/XX7303,|&WTKMQC
,)OO*W:S'>K1=58M05Z &# M'S")(_@-\$(I2R#H8IMGT"<#SWM*?1&L@L,4&_H\$S
0T3ZEX,'1(RV5\$Q<\$JE M5J720#)P.,|T99E+00F*><,5@-^D"R!^|8|D:^G<|W|,5EB-N._?
5/1(.U M28,<7U"8%>#!UW:1'S%9Z_TR^)F!>5R3.^&Z.R9/AC./-;QW^N8^RYEX4.F
MO_A'2?+, (YX'2|_|\$|LM,|ON Q||.,:YR|,A^|Y2J>+KY\$@E1N|2Q/QMKY MA
";U&|Q|N;|J|J2AM8F397&\$);Q\$O/_WOC%@\$H-&XVZ6F,,C.#WSAI?9HI\ MY% C(-;
(VV1E>4W60200|A"U"D&"X3Y2JFQ<@0X:
|RH>RNM>8'AL%^T6:*H.HH#/M0<#B|:K86'/ H87+ MM*2IM8FS=:/'7OC8ZW1_7/;
|UK=Q O-+&J7,=5 HOC!|=O|K)MOOM68S2)" MMDE2\?JW?11&'-/MEEJU9O@M/J?
C_M'19BOK;|YAAJR^-9|*680EZ0;_Q|I MX76PU4E>>Q*S+YN<|XIY+?
T.B\$5YJR&G>W9C1//3_\$SD|= _4?(I**ZVUZ ME+'8HK@L#1&GV&UF@LKTL'^D;_P-
5038.?Q4J2Y5|3@|IT>M9Z<|8:/O|_|S MX8=.21A@-
I'9RO&#%#T;1X%,|,;GU4)S:B0S8URJ&(TE#_OHIVIT0|2'2H^N M4;(\#3M:^Z1N
W)|M.G"8IQU4|<0+|DT^,'!OML MTOPCUHK)+?YAE(PICA07Z MKW3Z|!_> @#EYZR:?
B\$PQ>/RHU%15W;S&*H#)IG51W < M\$^PJ3J1;.E"IZI"V^1B-6N>|. ^>?0GFJ.IJ3|I-|@-
|1+)HVB'2L;)O;DP#A Y\N9B'S(>_86E<|C?KV1B|H|O&?
M+M(0V|3P"*QY/@|YP_|VRH@^""\$;V^|H"R07>B9Q1QF:OP6P5;'DZ D|
M>3'&_M5Z0X(=YEG@#^*80_1BZ8>_+Q6+CLTDBV6G7\$AU-LS;B,0*.EM^T)E
M7ZSF|C/#(,OEE|GN+5T,>Q&U&V/,4=74W%V9DLMF&5P-2V\$;:(8;C%15JH*M/^Y
U>XKE\|N |BW%R9;MY_4\$5D:BDOT|4-%7Y?/'?KE+D,|>ULOVX"6V@:
MLGR""H%8W|YV6,@URX'G% C" =;081C'5D|*Z|2X>W_N!5^HI^<|<.7"%*C
MZ5Q@=>\$^O|O*G"G|&/F4EVMXV\$?DO:N!">Q)\$ Z @A/R6M6Z9YHT-%NG!@S M^0
H^5D|F|S|MY6:3">2(TD,DNC!|+1NM3Z-RBZ&|?HU7W^XAMJ W-' /Y12
MVWU|*H.&F5Y@F|6AKPY^ ^Y\X';E;V=TK<'V2|H6;H\$K/^G:9O9.;R)8"#RR M*L|W|'
|USU"ID<91VR"<.O+NA6SX%=Z@:EQZ: + %Y3""ST_|N; &8P|VG<(X MPHL%|UC0,AU\$
(_32*-2WH=7@/"V#C%/R(#04Q'1%2,-**\U,0U>N%L/*KT MU01|MR!@+TNI&J8J.IB|
0FQ;D7Q\$% |\$^5|J%5;|6 M|FH0N*AK;70MV\4"GRUB'&JBB|M2&|'"!#BC>.YTJ,GIRL
>TI#RSH2&Y5 M|"LSWN4"^H><#CW(OQ-9P^1(&@|H)0L0F47>GC6\|0;1VB#))H?
PT|\$ MK%|H3|Q8(/6YJ/'|+MS|%%#N' MTJ,P8KO_I^1C1Z6|_21Q=\$%;J"
M8XX*RAR:11P=/0!#;Q*&%84\$MEL>N|9234L*H0U\$6L|'|17|H2B|C98-F_8 MD|_ ^J-
/&O4U&T40.BY.=|_LN2|TZ30Q5I=F(-B^"=6KK,9(6GM|(@B#261 M;EL,TH#-4**YJ^*"-
(U'XI91HL>NG3ENX9THSG&F\$|_|O&,C|Q% M%=F3FL7D"U\$&LD;2*K8S>OO)^V<.
(MM+=:B6OJU%F4V@#3PZKW=4G@@|A^@- M,F5M|>4OJW>D&AFDF;Z^_4!*XD5 Y1S-
;2W^W=X3YH2 AY545 # H+GNT2IM M.ZJ\$+"YRS@*&,JPS\$#?H:"|V7)8BO Y""
|AK=1^7^|WC)5X'-(|XO/CWF M!+3(SX|G<_6'*CZZB'\$CM.V|I,D-:XCTHV|OV/U?
C(Q(X::DDE|,?VG5=6Q6
M(A&4F6)8M4P>*^G_+JQ|S#611S8>P"A4/NZHG"/94(6<,2#!991?Q-8AH\$?G
MD|TM3L3PG4'H?P30W5E2|8-|^14!1+6=+'IHBS=9DL|>G>C?J*O9X+A@YQ".
MGZA9ZGR+04.NTVH=)^9*: T6+2RZ0A2).JC-ENF1#0B8D|8(XRN@";55?W3
M26/-EN,V\$|B%0\$J?Z&R|N.X|!#*1U85-WG8,\$8DB|K2F MJ'=|K&)#.C9%?*HCQ> H\$?
OTC2V-GF02J|@,R<)N7.R>|^C#XRK!PR*Y5I^7 MVH* ZW:=75;&(BW!_TI?
9X=G%:|"&ZX583|WP;WP?QWS\$#K"Z9=UL*A_<2
MU0)9*KD\$;1\$V1S8Y&V!.\$'SIT|^T&KV^K;UG.I5GV9K#OH5X!54=7W:E,5P
MORJ<#RVIC,JM! H3U'OWJWW/M1W?X9V@R),-;G&L8M|F>-(EAN:P*)=*W?
MA3N%7H;T:XIWH*+&4+-#%CT:P*6B'|M^ ^;SS|;%;?!&8T&+%=H-LVJZI7B3

M/0Q@,P6P_/#H81 KNXSJ,2S@%%JNZRIGM"9C+|@ #E.)5@?*"WS4)7I.D\$UW0
M0>/^X_35I4|D?=QU2N|#4/5K3\$Y|\$(+7'D=IY|")*Q%F|.WME_805>T\$!+HH M9-
>LQD=5UW% 'Z20T8W/8?/^8S"/CCA-&2W',__DL&"|090;4|P9%JAK7 M)2K/H;
H6.K^9#&'LJAZ=/WUWY|.C;+TV4BVIMC|#7I:8TMY6YCI8QJBYQ4 M=!BG|+&/Q/\$^%-
W|P4L,&)^#P'WU"!E X:V?@|4H5"\$T|X @D*/K'LW*+@.' MW^*E0U+4ZKIDR+
(>QCUB>+^U78;?0%F\$|H0 M@VL|8KK6XT(GE5#5:43^A4,
(Z|VB720:ML(P;4'58NP'2|;^C'VJ61& Z7?7 MGN_!QPJ94S)|OU+T:D=C4*" (TD>Z|&>+
|AW^*%3D!-89H5N1L/= @.P0B*)Y6 M&,M|^E3 JX5P;-;9 A,IY/. BNL^7+X5D5_5?6R
J8C_P&')A_Y7MOU|J&EI M=AP8LCVRC5N7FVU'S;J&+ #X)1;JLC@^|J|V>=):BO\$,
(WWTSES|4>P8'4U%&(MSG>90S0L>|:O M:ST^UV.= \$->@HU\$|CHX7XV#MS?
5I6(4F(SCY9U0<<=>\$1IDU\$ZT?8G^(A(0R|M!C|!%ZT!M(XS^C.N+
D)4'TQ;^;39\$C9+OV?..?"63^'GKO\$M|&KSY'3-QX1 MYK,FJ?*JRV C4WS|,2'9"M8\$Q|?
U&\$E(*WH5*QZ&V^3A"*\$! K9R_KK7-D*0T MPET?;:2TL1SP=|N_T6@>>AP7J0H
L**' 5#9VL^VK.4XX7943%6)GJJU1;0G M9//C+@GZ%;)!7>&PVH6XP-40
"JT%Y#84^!VE+CU: J.0)-&)Z)EE;MDBY& MY:OLR\7/O#<7:HETA4(#*GN7;./WH|\$WP.|>
(1WIE58-&=S_F+8A>J5KJU)N M*&|I:++
((ZC5I7=>_J|V(^1+LO<2=,%%\$ \$8.46Q69^X_MQP-6V;W/8_&/@M MX@_!M7>?;K=;
(@P%|JA.9L6|7'N_MB%A|HS0VR&0>A+?P&J0I)I.8X*CK914
M|.WM*85>Y(@J@FS80_.WZ6S2_",AG|3:(U&96!C1!F4E@:|TUU#Q: M/-'?
1@L>AE/U9ALB;MDM14I=24(/S8<*MNHZ3EN?MFK;7D#;%=0L(|MJDR%*
M&QZ>%WZ0^+&118F)PJVE!5NKHT*;|!SO&=#6K|=7XFY15W4K3;;R|70-I5|1@#%
_7_A3P,ST?^BYCC\$>|<_X9A.R3J8UE:4ME0.)%T(U94%3

2*L7?ZS9M'.AEU3.5* @*G,UF?M%^ MIS J|T> UT=/=V^ SC\$R8R-DSX-,! 357GR)L;-
|DU&F_*,<Y%>%+A! =; MCQ"J^WOG0|H"\C5=>E MAPG63*:/@7D)IUV38NO:IK;>;_YLJ
XEIHIKSHAXH.WGZ%R0AR1K|.B1.I! MH5Z|)%ZMYWS'*J+@.4"- 6|.28^!7HK+8;
|6Z7|MJ?R(0|+C%;A*|@E=2|.??@ (R-ETH-HE; M>C*79?%)S?
I8.|D2;|. =BBV.SRS5:TKA>O*&A?5".K-M)V?5<\$H5T UZ^1A
MF;+J+Y26%;+3_C0M^L+*86R:0|2VH3 *I+-; & &.O-YHIFUN^*|VO2!4"L/=
M!S\$&T|/W_XBUYN:|!K^ P-3=A*^C?+,CD|(\$&H)J; > Z%P!%1U&DH(-,|2E
M!Q0;VC.B,K\$YN>_3"T%G(=6VMXG.K%9MK%'JRMJ.XF:O20XO-+28;%U|O\$=P
MJM70ZSLG%KE5+%"+X_VR HZ\$1%28!@'IAH&Z5 (%=Z XRF29.I&A6=|QEO@1 M&
|1KQ.@^E.9G-6#B_(R.4IU|WKS_H.+)I1?B.26ES2'-1BCZ;RJO%EM-XM"
M=^31.XM>9!&8C)@0304J;^E|'V.F'KS.6"|0VPV^,2|^L3.3B3?H4D@&^\$| M/I-
V_G9>|5%#D": 4(UJAO_GAZ>V2LF+ @N|.5|@5OV-M>TO|B0>^XZ4+: M2B'A<.KW80?
I8R2;X%|!&B>HX TL!U4|H#H" ?RR5G;1T<&R-EFLIHUS|Q2
MM1^2+JB@BKE\$(ZJ,L1;!UU"9@ MN349&^50+NB/TW
6O.JK!Q5;6HPBGF_76_;>Z|":*BTJS?M;1A.K";3)-;)? M\$DA>@T|XN:X1A:O|&_NH6(+):
(7AFX56CV#E|YD99K|:.\$OSL#L?B?)@"I> MV2U'@6:0% G:1!56_UYD|!E:TJJ(F4=<9UG1-
>|!\$EW1\$,X#?QM!;CA+_"U3
M)JKU'XDB<>W,,;I6W\$B;4)J/0U#,,;HUDF^CKG9OT5J0@V|P P;3H;4;R_8 M&09A%5
M7OIC&Z^"\$"*M33_KVG\$|LHA)7OHX7LJV:03#FAK/Z("GXM!*YEC|VD|M01DCP
M"G%X|+7E!LOADH 4'V',!MP3X7O.!05UG#\$/&1Q'SE?
&=P?|INN4V421HMH#8;D+!^7)4C47*, M:D-S6E(Q"P@L C @
|OCH9&)P|5D:ZL:CPWIDKUN!@K=5-966FE.DV^KI<|M=@HUNVNDEXH./1.:22,S+P+?
91|J.Q?LA%R|02@R/S4BT3-8|,CV2#K+2|XH MTR-8COB9.6|X>G
|H|KJV05&HXLOJ9%Q<,&Z5-1085G<473ACNZ'U5%4';K.^H
MTA|KE'>>B3.EWQZ1(4'ND%'^OYU@=2Z"HA+W_%&40'-^MJW M1BD ?
K|Y|>J+'SR#VXC7;|EL60QGX(-*RCX3^"<5YNA'SY(5DG2?JNNGG|&\$ M?
L:006CN\$XJK^GO|N>YNJU-GZ*^9*;>F5C1Q|IO7?B09@\$53^\$8P9=%SPA8
MOD0EC1K?>VMRHZ(P%|'|2BX,FMQ036-1^!>E6@FS=&DBSTL.KN:EL-4_B;J
M,2F_Z>P#,S,+BXJHBQ?ZU+|S70K67)F.THZ*S:SJ#0|C'=A#(30#I !VJ5:E M/M9T&JFH-
WL-NN31)KVML:<(*4PH27(FZ&5;R5F#CO:K9H 6_K*86|I4G/F M*L(-
/7#L7X3K|/#V6=.UG#08=VS*4MO+0Z%J/X)TNRT(XW_&* &TSU;/Q^~Z?4
M5P1J90JU)BBE57>C\$|_#?_|H^%0:X-IB57BLMJEA!|0S9;.^#F59LS\$Y_FH#
M\$:O|V* XK(U9V&CY"F\$NF;%/RQTC|-=)5R=N/EKUJ0 +).D6K8A4+KZF(|,|I
MARA&8KA0HO(-59H#C0YA_:@WA@27Y7D%*CAE'GZHB&LU.8)%@TC'^IA<4-5| M7<;
(VQ, ML|T2STGW\$\$@H;|!>5J40:=M;S|F,P5=!%:@7>CC=|JV7"+1#CBQ%

M5_P,4,R;8"CO08SEDFPD9(=\$#8[U(.?H M"4^3##M7E#J D2JNGU;-
)F1S%Z!BHPJZW4#A83NQL#0:W/Y/)%EV(G;;J M6^4&5?6P&XB=ROG%*.JJP.O*?
F.\$%M5'N-9TLBG4A#SXF_WQB^&#J47?&U+
MQ:9YS\50C[?:35)H9M'207AN2?!6=4W3.OQU/>P^!?:A-E/=J1J7JJ;3
MB+X9"4#XX.PJ#)KU_6R@0(G_W'H^_E029*9O.X;4\$#"AMPV5;-OIX)_KA=
M^2ZD\$%:.\$^V7;CB&8!_6R9 M;J\$AD%USXXO2H\55^)P/.'S\$W!>)1;\$6?
MQ\$;!@TJ!+;>A_6)OQ5:~W1-M@TP(@3.[17.0SR\$O_GU,?MDJ2G>.P,%4?)BK5,5LOZ.?F
1?5TH2\;)AC2J_MM>E!>#!\$M9ESJ1^G5HD<>+!+V;KWU00%"Z?"(62R9F8" F4!W"S;L/;
!@8QZ" M5^';J+3;2>OOK?HUI;GZR_B5?W5V=59HVE_9VK0&*9%2;75+1P5Z07(E_M-
LD9RZOZU^S L/8RD^+&+WEW=4%TO8QE5ZO*^?0?G[Y4GMOJ/O9>SC0(*0N5
MQV/0;E3H4MV\UX;\$Q3TKKTQ;(U06=K-G"LL;K31_ZX8Z+~PV!%.MZ66/G5R=D
MZ5IU11^+J4800;1J^9OAGM9TM;.@3"34,)#J V9ZTL-Z08(>ES:5< D^D9R9L
M1L;.@=HCZ=SA\$5_3Z.X[3!\$*=+~;>(.&#+)YH\Y>OR6H;/65&VN:~R"+Z_1
MC@~YSPI+RK7G%OH&+9N\I@^T^-.8 FE\$X>I;/H%918L5-DV.;+U)IB_M;-(7:U0\;?;>
(-J8?,QQ_(75H!SCM4U/HI/I C/U@I=3(\S.& MBVNS\N8.T5UUVK;VS/8YI.
(QXX,'A"NQ98:SGD<=<)=IH"L8X761\/*>J)J_MJ\$US%&:"&GM.H:'M'?>VY+FNA>#/
M\$B=.;,1P!J1LL!B:~?W7RD;~>H_@_LA+VNE+EX7P;YEDN'"?90?6OU"*49'Y> M@'\$
AOMX.N\$ EJ(-M.MK/5Q%N85E985J3-7.?O81>42!QU?) U832MOQR8J!;>-
JZI4DZ+!A?:VKQ(5_MJ+3Z+LFTM!G#+\$V2;I80_9G@DG0A\2G2ASR;
(3^0S'^+EPX1^2W%XU?6PO;~M@^~3DP.;V#Y+R"%_*6RL\<\$^
)QS'157IJUW\0+>G.>?/6VW+ U.+?QY%. MQ&HFLJLRS71J#BVR%ZG1HNSI\BZ;F;21;:
(H+X'@)A8\PB@+~!K-W,AEJ= M8M0\$9?NZ+I O;&)KC=/\$EXK)WG1Y*M^93%,V8C.JLP'
MIT-91/3;:(@FX \$SVL2O"t%"^O@H!KVMA*?3L+6M67#U1G^A
M>+;T;1!@N!6\$^_R%XF>(/1 #@S"6,2)-P'4*^JAT3DO;U. +4B.@J897\YZ M4\$2@;X_@I
(*JD\I@S*ODNE9FSR\<#X4(0>'^)^1&C.]=[.;%+@6HHH\$U+JGSP*8RT)%:E M--
RHZT"7CI#7>/E*L'GKL;^T3>VK)N(T94Z14#7-"T=*R"O4HC%G<>|(3AC,EQ-1P
M\BQZJU98Z\$9U+~G7#TXX#9E\G\>U2R.9ANVFO4<&HU-E!U1N=>NV1E*/@85
M9NGJ\$WGS2H3?WL8;1?*"G9POE/_4A'JTH* J:3VLCJ*O'+B9RI#W.H+C;8@_M<+@P_?
1>"F.04"IWV^@@@ZJ*CWCL-+J6!;I7HL!)RI4&!;>%>;3QU%THC
MSMOJ#8._E6I!5%9PECA3F*_W%+J*P8TN&B *O,*'12\=.8<+*@JY,=PSI06R M;
I08NX\$AG?@A#/10F6H+>J9PX8J^Q&"6EJNA'NK/? M+~#NM*_W1,.3K(I?T\0=J P;
I6.%O"!9 P>(U7L.;KS=ZEK3_P9+Y*AM&H4;,\$614^#V,M:"7R\NW/"W\I MO?
7=ZB@&36-KD\^J?>G@'46W 2/.7,-3.QH6\$TB3N-&*~&M5/4; J*1-N*ML M;C\$@B\X/K-
X\$^):T<5>91O;MJBR/+~J%2^JT\LNNZG%XT8.U8,9GRV6(J6Z(MLU8/"@-
H.L"PXVQ&ZV*Z*~#AWRDW*6IC_\$4S(JOLIC2ZOB>?4-+:95#?V(V@
MQ"HK#\Z",O@K\X7JJF%2+A(BSDMEGK=&256K\$^7+VX\7A*U5 MH<1M\ADL5=&-
(-VL(W8F(&JB#PEB;A(0J)+T:ON--J7XHG*G3&<<1Z\$5V;_
M&&1(FRG=@#OID%0*J+!IZUH/*K6?19\SX,PA>\$U?U;W09DRAOUWE"-IR(<0; MQW-
%V!-MSROJ57VF=N9B3Y1))!- 4E.K425)5U%!,JH#3.Q(U*SAFY>A^LV! M)ZA:G-
4V'8N52TTJUJ>#-CR J5M!12NCTN4U> COL0@4K7"S-N\OW961FG0;3M+M-?)=5W;_
M2;LCSX=JACYI@+~#-%)>^J*QW;VJAW7;TH-PD; SX3\$%MSKHMZZ;72&@3?I M0LM-
I^>?"R&NM@;B+J_*/GY895Q%MI%~X*8E3\2 D!9YS^I X_Z^JL!KU'2\$~M70U?
#3I:U\H4N>C<"9>.YIO+!X)34U&IMJ:DYB\16FB.D"BLXP.X5N"TM: M'IZO-0.? @=15V
@9X=/(G:E*6'K\$'B?=(EY(YK@;#4:6?-(LLJZ^&ZQ@GK/
M>DRC*8S7N=4\7Z+*K00EDA?JU&G>?R*&<SI3D+FE,R/8L,)7-&2(U;=WN+S MJ^9T-
0RLJNED/^KGS\WGEKN\I@MAB;J/CBSK,WCB?&G9FJ(FHQ%&FZ;--NEI
M3W\QHA7\B1+PX\N22M%~@Q_8"AZZB^4EMSLEJ^A3/J-MBI#9N>%~@#_&JQ
MP%K%;N!)V,Z,@OB6TG(>=>6 F_4>33!J#3;YO;BBL4%",<-'E?UN0414!~* M7?-?
Z!AJ_<'I:O%=,G\>01O\$LL_L*N;LP3J+W\P#~7E0&3DM0^*M4-J7\#N
M(QC='VZ9HEJHY+D"(X6E9W+9X0:P17S,4A#AZ\W#X;)T'_@JWU0UEJ?
<5E+HP=+0JBP,#?Q&*18*R5'J*:#?9OI/8!>,^&HF?6T MT'Y00?5IA0FIRW7*~!K+J;L7^
GTJ\<.GJJ\IS^W.&I64620L0?>^9GS)LTA
M_I>PQZWD5\$0J*QPA.J+;0Q4=G<;NR*JCOF;.;S^(*>E!V=;55, M3ELJ-I%34Y\$C";0
\$*,D\$5_X3:OR(=M2L?^V53\K\!UI_%:UHC42LV5J5(UN M?'<IQU7X
(VZ\IX7:M\J7VG2L1K5FX0(MB=C%
MQ,N8;~6E\$94T3!_AJ*H5(W>LG+J,NUYVKQ9PQ)\YL553N(/M%>
MVW8@(?;RF+/+,44DO;~*9,O=2TM"O51#~L<0*8#~N%SN7KSJ,IQZ46;(')(MBC)/U1
U+CKB=XA6J.J*URQ.%O:J(!0HR!ZKI1YCJ*X&+86XK\5_M^C\+BX6_MR#3TXR+J=

HCC40(K=*&REK:3,74E[5-:F^JF:8ZG:\$](:.5")W(I2".XH6. MPR&5N-
0)T#RW#|K/LED_ZU^D6H1<+X+J6@^%O@VOOU1TN@C<4L1M|<^C|&:F
M:X|OX=DLD#!ZRF^=9S#YTYN.CGWG^%N [60/7A+QJCWIS?N.H894=74>@|@E
MY>M:QO9"05BD#7TCDU0:B+_)^M|/XFL,KFW"|,4P^4QC7=2(4MID(=5X.N#_0I-
1B+C%C!6P2(JKWLN?^HBN%"|4SZ MV:0I?_4&(7+8Y4:O-7W"!8O-
01L._JZ13V57>B38|REJ(A-6= MU|JF#UV^6-G+M29>J+K7:)+HL|GOPF3
06|8^=+=/VW)F*(S)|U9W"HU6X7! M=KE2E/\$RLV"C?KTK-|*2,*|LN0%+6T-
I|RG8;PA;OE+S4I4YV/V)/JP7B:5 MF61E;U&PWEF6(?GL3|M^J&56?ZS6CVLZ6<3Y9/!)|
(Q#!%M @N6.6U J;ZZZ M7H8_9(BI7'KS1TR9KV^E_4SV(#"^AU M2_EE
M(RM71GKS|3Z4+/KV8X<*4:Y4&2H_'DUCZQGA4"^57<;:W'V= /MF<@'6SO7',
M0TH%>TRR'AQN41UZ8)= M6M>?-DYIH:/F?8>-D8!;KE!@(.W@Y0@2>1R"-
CWMN1.J#/#R&KG<8C"_SUX# MG: ^A)941P%QU-#TUIRYD9!"SB@W|G
)=AEBS'.+F=/Y,=@Y!.:6WF!ENDWS
MSF:0%#R7F3Q58F9IL_\$B1|2:DDM0L#+7;&;U:Z<6P7;R/'=V2L|^SOP-M,9<7%-
+>.^UIO ^AFR>W*(DM0XC;Q4">|K|M;.:6/|@-4@P/G;EN7C0NG9 MQ,VP|IT_Q-
3&YI2K0&>J^YB5P0+X%J2;.:?@KAQ2AK.E:SD:/X0.C:?:J6 MBEE;N?!R1,Q>1_?|2X2?
@D5,3S|FP=1?(I:)&#IPOL\$3=X>INE9FZ|^;E,4O M0X(V1;- ^AQQ)H-O%L =2|^K%X_J*.
<|RA/|!'+=@TGKTL*|F,HBW=|L3I, MY7U2T<^L<8XB9_>\$PQC^EBYKR5
M8S/5'#D#A"UC32>0)A#1!;|1357TJCZCMRG=X|>8"LSD!=_1-
VZE31K@*054UFI\$;.:L@TMO M\$RW.|3X4|'D,TR/O|= *V437>@1F^20<78AC6IXA
M6ASK>O+|J%KW(\$6_2S.TDGI?;FM#6 MVF|VK)H0JSA=Y.KJ-
SWT+#S@;@V&LK4'8E: #K36H'J1 5J/&:0:=KTK:J M!_77S+R8OURN|^*Y6X>.:
<|JV!N77E;6<#02RTL0UL*|GP^0F!5YU8MJ53U ML/I\$*%'3.6/F&2'!XA6|
+7(7:JJO**>Y\$R&|LI)5*U4YFNJR^-/OT|+OX MA0|H-G%\$P%,E\$=FXI/&T??
XGA EJDPB1&2;BE=2,'&7(/M@J9U*AF5E4@A*- M5H@6J9>P9%N:|10K)>&
|_X&).PON',@OA|!S&6+_|!|-Q?3WOSE:T+>N|06+
M"G'D>AN#6E,42EHAD:&L%IJH0@CF5PVJ?:G^X ;|Q|H=EY+ ". \$1(S*6O"JR M3O2-
SZPS|""B,|I")|J:"DL-@(>50J4+*?P/%^Q@I_-8_!;#/MB&ZTRJ|)6Z/9):.?>Z:-
IDNGNAO(T#Q:9"| M;7" 41QH'D;G%WSH!^G|DVJ6@('>.)Y|#YKV4*RR
6HRM^02XO&E5E8/S=&6 MRA@2_4
WJ'4|Z|N/X/#F*Y|LKY3ORQ1>7Q5M3L!6>)2IAI&L4|CFLBZ;JZ MC"H
Y!;'|^)770VT1YZ'V&A4|90\$H'>-7QN0DEW|4-FYQM8|9"|&.:1A1\$+A>
MHQOOELSU2)6:ED;G0_4F=SN'+%IARM-.1|=RV.)#;X<0J?YIG;'95K:C=LIN
MZCKIK5'7D;B5F1'B:4,_"?J_ ^J\$+/L!<.:>94KNIM.Y<4LZ583F5#>QMH: M?
WF:A4S#W*6&T4K04D6',=F%|DZ6T7M"38|R3EQ\$Q0<#S5B""XL#O@|'!"?; MZKL7-&
(CNM;%2+I9+%) -25H+\$|6|S5L-(NP\$|!|0*UX\$I54)>GHF05"(0=<M
)BC/ZC|;\$%;:.*DMW\$;:5+6V36|'\$H'|(D1;JA8EKI(-W=T.AV-3>8M4.\$EYX|
M4&MS\$00%9D49G7V%1P\$>BFE\$3&B)(-B0&:=LF7Z_!Y4QH*8VM3 7-O-/H|;T'X
M:RLK.B^:\$&H:CSO)\$0&'U7+|4'IRY;JP-5^U<'0QN.;D'X_:%29*SJ,1*G M?^Y-
3AQW|(I@;|:94UJ3,1SQ%L600D<(!S7C\$*P1J-
W1PE7>VC\$K"K"BX'K2)4:.%@V:>B\$WM:\$ _N0O_8- MJD^/^/V3X8/*)L\$VU"M<22ZZ-
+G_@SPGPG88\$,RYIDR_OKY^SQ@'GCH_/C# M!_CSAQB'\$;X%JM_|>T(-
0IT\$"/X W;AW3DM0|"MM|#H6|'|. ^R\$T7=?U7K)DP,#GK_1D3HKI\$P+
M/>^0VDY,#;&Y39"8W02E|T/*!-'OCUZWN1-; MT|Y9@6|J^A|7I.E K0WLSUN?
*W4C'K&+,3//H(TLWH\$BB%Z8((GJ@.DUGPPK
MFL&XA|B|V,B\$-.*T)TBACAYZ9Q&DADOL!VMX=-,8J6X/4D+NEY%/FQ1FC"2I MD<|)S|
S<\$=#IE0IC0H0X2?2|^~|DZR"6KM.|9-:/TJ_|C7GO.IFK M@!HXR=2'5?
4|:|S>2K.TJ2Q9%4F?;ZUZ-|X2EK1)#^NDU*&@4)|8-DD\$C>Q!>5,JF0
M1RG|">)%^_IFEI<^3 IU|J":3F("X@6V|!G*2KL?5MX;RQ=Y2"X(1E&\$F+H
M=TZN=U&P% M AP20UK|HO6D|U47D)0(OO.^Q;)T9(P #X>>(GX8\$@9;8+\$ M/;"1+0?
N>SUR*%)96;4\$4XHVH")AF(68ZN)@/\$1FP_35CE5|KEJPZ#?V1B| MG?
I4888UZ2N(HMJN8 ;,-P9,BEDZ\$|0&P\$%(1*C#&1>,,HE&0V#%8J: @N@E M2GDR
JN8H|!"3D5%&LB\$)S.L0|AEKJA51%//@V3&2H+ "(O\$P-/DM8D2 MK8R!Q""
(C7*X_ *HWD|*SR2D>;D=9>0%V'K.|XPOZ)"YQQV^221\$H5.FRIQHP
MRY'D;S|\$|G5B+OL1SC*J29ZWA"L^QJCY*M6UW@%#I(R7B|.9ORJ)ES(Q08,(
MZ.PZ@|*GX@8RX4<&FB!SAUSQ|1)OVLKHW7^J M-
HBUGA@)MBZ>X=YCJ4N6.DTB22 S30_8R>| MIN2Z;.>GCY_^^CZXDK98-
M@)&PVEP_'K<8(D'#121YX@&!3!J(.9JL|WR8_

MX=&7/YRO=BQGOVL"1&J,1@EA;HL^~W6@=(^F"P8VZWQER(5%|Q^F[5OV)9
MI/E.*;=B*J 9/H28 ,HYA\$|#*2I>71K^DJE_A)0"2"@.4+S">|75O/-5)L4%
M+A&|X"9IMES" 3-D*%PI5 T'2306GR|<@)SJ 3'4--DBXOOY;!"6YLO_TWN> MRZ?
N406,#OIT0+,OW/L3Q(E.D&!FL("O7//;XW *|L|>>&6>;/Q2SS MP|
UV'NMB+L,9+Q!UDF4(SW7B)^.5IHCSH=K9R? \$CH(1"I6\$8-Z+(?"Y|
MA,4)0H6HY)OMM/ =SN=\$O"I* FS\$@W2ID.+X*4:"&NF5|@?9EYS#"2H\$K? X M3&
3I3?)<7-;FTN.F_P>-SF3 ZRLNY.N.X@^V|B%4%(N O4F <"9C&"I6R= M-
Q|T/,OJ(" #?)U8|+|4;| R"T!^OXE+.|YBH*7G;2*_AGY85\$|MGL_"%O8M M|P"&&IW0&A
<9K1#|V1|H@"!)!0G""@.EB"NQEVB,+)S!(G)=9C73WHTR|; MQ6U2|C-
J:6."5_T)SF@YRS;|XR:Y7N-JW|;(@/<"8^0 /I.U#5ZA? \$;A,2 M./Y@B3L&V-!
<(H(:\$B6S!|B=-+\$ERF=4S|! X4H&^,K%+PY_S)H4;>.I0B|4
M@|SVHKE#P.W3/<!*Y"HR|4H)CMD,DI MZCO5<0#.TX=-S2* &/RA>"NO;.,@N|
<&!0V|;#4,R|!\$"%CP+B8TE7>(^9HD(
MPC/^ZL6K%28|0CMVWD|K27*5WMLB24|7\$!0Q#X@/G#@EDCS@9-EX: ^|N.>+
M|SAO:V1JN(:7:B!M&&E#CW,YWQW09S(|/7)&7W>(49Z^-NR,V/J=S 17"1| M|XXE-
4%L<5-"GW-|:&|L-;,>5-BW|HD MS^AS11/D(?JZ), 'V.^:(?'8(>Z>B%>X?
2|H4IU7@2AD6#XPADN.%DT64;A9V M|;Z_K0*= _@G',<&N DIR2P?
NCJ8DZ*IH)RBE?"@0|GNSOGGT'(LK. ?Y5&0X12!5L+"E;#|/QWQ_K9+Q|~5?
D**0/D3U2Y&R"\$N),?#D|8FE /BJ@K!1=+/LS=DEH3Y#8R_ AXS9BR%"B<9-Q?*3MD
!;8_#1=S\$(&F|AC1Z2+B2BQ_M#4F*POB)0-
/@.)7315I1,4T8@|&_0)S"G?,'_FU%)_P0XK6W700OJ8D@ ">M
MY*ADD;\$TLP%NCZ%70.RW >=+M1"EDJ2(&.?C8M@X!,V,A)#)|K|H(H.05U
M_(LS>PUFJV;44GM"9"#8HS|J_6&!#N,V8?|(-X**+FUGY28E9 ^?3S|!%R1' M\$'>#'/!(
?.K?@LZ\$A(#H62L2H9|SVK<: 5R'T#7_%*9(\$W+)W|%%^,><@? MG#>#*:K?;I
N2V\$!.8+5-F67-KE@ M6B|74L|B./2>MS%;B^". @CEM(%H>-/@'3.?#P=+|:?.F:&(_O
7NDIO_PKH MP-R*PZ",BOBP4A14|X;H:@.I#V:Q|4"SV.!Z")F_ |B58/3"0UBD*"B*953
M(Y|("MMD.)CP#O_YI^/#D|&'%.BFO';+K.=! P/|8BGWX"G#_#>9W?WM)5YX MOPR
)CO_-BU<7VR@.UC@T""% M3L>/H_+?=K>L.,QPEIP!/RBDWR7G9"Q,@PZ2XME<4-
EC!ZD8K/;>B6HHMD"4B'!)7TC^92_O^'/;HUB,LR;%&8@G75/X4V
KD1/COL(5R)1E8AS2IV'WGSSL@K7Z0WS8\$)|"I/CWU9I-8/ MVR%9,4%C>_M&9-
L^>WC=M2^XP=-%:6%+86H!|@0@""=SLK4_/L5)D-= 7_Z3M@ M-
X47\$|,6.SU(0SF&+L16!2ESLL#I#KB<3"JW WN0GB3-Y!";8XA4L;+"JT\$
M1'L5RT""HM_N1?\$04,V.\$D141)SH#D^*=-/#,?Q 9GAH6\I%GI7&GH'WW, MP_E92-
*:L^|Y4-N;|E|4FN_<|Z|'A|:NQNC9@C)NHGSJ;(7LPS4W@ESXDCS
M\$9\$.,2,35".&16S<_BNI#KP@N;MWQ-NCET(?0KQO/%<,"|EE|5V&O|"RIDJH
M9BI&0)B3CE(\$R(&JK_3,="Q7"Z"W'=8 XYPT7^!G;|:ZJ,(I:K*W7UAL.Y
M%^&'T)MW,LYSZLQJX0+.1Q@-5\$9J?,MBW#@OUK90"TW.\$K%I?EV+;-K|I/+%
MSIBFGNL7_%FSX\$GJ66T=.1-V&3G(2665/G8A0-I;\$+#+TE.FBR^1%)|+
U/:9(DNSSR0N"?L-!8G@ES\$BQ.OD2)V,9*=K,7 M71GQ,/E6OSQ@>@Y,ARRPG?
*|C7#&.,IX)H?.,TG93??8YA8K4FFPOD_T\$+*O MU<1M*D!5\$YH#FGH-
<4.L,9)&5IZY+FT3L<&GX4,8O'A^-Q%71%D*PA/;%Z3>
M2>*PA2QS\$|3V'HM+D=_>/XVH3H&60I=_8>,(6_+L(FNGAX>+!1|?,3S8.E| M?
V+WQJ47AK?PG-3L(TK*PFN2WN_T;U0(<\$43 |>O?SS\$.%/(H@/I:Q&9CHG
M|XJ,8K)DL/L#4XGAL3,)K+AT\$|90/)3 C/W|/(2WA2J%"IC=ZL(29?VF8T,-G5X'UE%E;|H
M.;+2P;>0*A;13P1|+ _!5F*CERL="CAP,A0)UR1'#T5_(?JNP#D\$|R3+=S).4G5*
MCH32H60YU4/F.Z?\$(K70O9:N9U*L*#(V|PO&|(@C^)^5&&R7*_X&"Z."X;E M?
AG/R*72^"A7P*.IMU^V"X\$. (V(_B0|2579G@9|KGE9!&\$BXPVSL;\$ _&L#7
MEK)|Q&NMT3%.6/5N+QWEL%C-144)VH!O):@C1IZG1M_TSR6|
<2).N?PYAS'DATR+F7:&(7-J#,+ (V3X7\$T4N;L%EI4IF^AS,! (M&5EB;R5C"Y/&>UJ8W""%
(%FBN+) ^A GS!?'*2!>*12;W*2\$.04"9>,XG*KL8_MED1HP67|%*R=VV#IS?E?!*Y;WT|
YIP,?/ZV(R MIZP4*R/K9,,IRFH?! "4E9R)52'J@D9A;>1:F\$<>W,|7XH+ ^7U0|)%R3:A1|G<
M. 3J.6W|TU%|9%-L'4,>34E/,M5\$@#HZ&X3#=#A&!\$(LW6U\$ENAM0|:=->2=L
MBQP\$8V;.^7#OAO 8.BHQ6;T9F(:MZ#Q#G(AWT.UO\$70Q#R
MB;0GJ/9>+L\$8%Z2"@4'R,HQODA-'|7"4FO&A;D\$0|AZ=USN'A7/((=WJ7SFO
M:"T)'<3L\$ _>|H\$4?),I#0JYGM#7)2D: 52-%|H0+B5I?L1/&B;%"!"+\$B?>89
M+SW?!|E"ED0>,\$6X'W:O?%?#+.92U\$%R6FHX4MD|2'9(CA-9&)Z1|+N.'\$3 M7
!2JY\$|8@;Y.DPL4J=)DV'GFRCJ3@C73\$2_41G4|XA_|!)T?SBXID1A: M3@:JU'N+J+3YY)V-
1GQ_-Y MA,W,>>N&@B9)(J#9NZ!KA6'5|)0.-D')9\$XHX1.8S@0I4^"BAHMT41&\$-&)

MJ+U:R6\$7|AHC(8GIARR3+WO'.3'&!\FS(D.9)8I@T 6",EI3"-JL\$V4*G%% M(BIR>7QOO,
('9D!F8-G0H#:@@|9C'V(S">".1GH-9++H<2,WO<'X|XGG|5" M\$UM?
W<9(V4>VPU2|2S>|_VH2Y4'CHK19&CS5274M@|X80#1Z'TR*0UR5&,'
MF2!UF\$,.*">IZ1 IR^,\$|N(SIQ\$+-?=AZ0S3G*W/_1+8HX/#T%R_-E3N=X M
."67S/7,3@X;Z)('1)B|JK4,@!NSTJX0#IFMOY(76'RAP(2XSF3M2)I^*
M7J#3XX:48108RO9.MB:6\$,&CV9L+L&|!UQ2D& L0AHS429'H:Y@T Q2+<(T M8T3'\$W|
I' |3"D)T\P5"DM4,CD P%U11Y"/[ZY;TDIY#<=)|K9#:%J_F2H M,JE^?
1)J27YNDR%2CQZ#G4- 0.I^>R2D1CQ?DIOJ()|_OSGGBX-):KU|U5 : M&\$)L ^*Y;%
6W;E?"<7L|Z+0Y"&CO9?7;|D+L<=&HK"+&C'317D11!;V;;P:
MC;8ZXF&S2UIP.F#IF,0Y0.@P8'DO%\B%K;=3Y 2K#,F|PB<,KPDIM-=0/GZK"EI?
W4Y5@,E1!)27/YA|'^TH+BH?UK)BR.DA%3R.,R&21'G"7"3('07),L LPX27\$0[*]NU)
|V##E M:FO(Y\$#1=9"5<>^L|=F;U|GCR;(|@!#Z'4CU7VRGP|R)G2D_X:7(82<,7H
M(N1)T\$0)T0'CGTWQ0T; 2D<_F5*G|7Z|SX.U*:2UG-M,8QG)>J1Y+U?6|ERL
M+T6)|:K5S13)I7/JG?+\$(O,\$#8!(|DIF<":W@,|C#|UZ%&7;KX.0%VV7L*>=TC08P>)A@-
+%'B5!RLB1,V& M_)|7Y3\$V< R=V1"F*A/*!)Y&|L,?AP28&|;RA+Y@^N<|:MV_U.AB/P@
M:IM@SPY0L|R0(AM;3"C)IACG6C% *9=|)|OJ.+J*C4TS^:Q|I(?*+ZBB4#^
M%0/%WT;|EF01)|R0"RRD)N60N(#D\$O)+??N\$L?Z=D_Y\$USC/AV/^/6X)/ M/Y|_>\$J?
|KO |I8>062(L^Q>V \$!:73Z|'G'DU,0#) DCX!^K|A.!OF2&U?% MS^|
N.^""88RE>BR'&5B&|RC%X+QLF;+.P=8G|8,-S1|I|^>>DM%IC><'L_
M(>V>;^/|(|X|CA|IK2UEU^6K\$.(/_SOL M%31G
\$DPB1(^1'M3#E)S2,*,TV+A/49|T;E5G<|9^6AGJB.Z,VQ@0 ^092|M5H+J(
%|QI@A|OA(:\$*IVX8=(SB5(5|1@^F|X+20!%5 IHN.V>RJAX@^L_5
MP1B,QH&S2XJ<|H|S,P|*E,-@H48,R;3_E/6^=SL;\$+;?&EB\$Y("HC^E"!M9W
M:JR8(!9DPZHN<9*QO21_&AP1F:"PXN!..SO^5<<"@V3Q#HYFY,WV1%O6J3B|;Z-
65S@VWV1MK-)0|E X\$AM0VQ0^QS M8C*EG0J+|
Z.=Q#Y\$=,6<&@WZXZ^#DF4B:|840PJET44T)PQ*-IZP MEE=?|8*K0J.551|(X\$Q;|EP5??
8D_2&?\$Q?>D0/CVBMD+AD;P0SOA!*T M+O\$+)|@';9D4.D" S+'C X2((U|=!R%
|Z2'BT61:.R|TGG7S(PD&.%7KOEW.Q MU7(2|"M3H%-= \$H2J>, B;FPN
\$^FS2VX.JK6+I4NW!+6\$2TZH%O;|75/N MO'()99_4,Z,LU0I=|
<2R7(CWMC|\$|LC*ER5|2,|1) %ZBZWK*|&-274L5K(M7P^=GSK3C@)|I02^89|P<9*)" "
(S7.RXE7&,E,300""--@E=6P|ZKYJ.@G\$%| MC0?ZX,\$R1E2>RH*)"CR*"
9|R2A6@4I2X#.S6"4*,MV|B +=MS&+ACC&4KV,|1XA?
0,&6<|HH^F"BJ%QN)W'#"FSN|6B(*O(\$-V,\$^G,9; (M&+A)(A'N6(T.=I%#A7)Z#|!I=,|
3L,"F/V%DSU\$ID@%/P.FSRIGA,K;265Y M0Y=)|@R"Z"U&L'-|*
D(#TXX#9FHX;+5ER4=ND7FI^5#)FCCR-A%.P%)/3!+ M,GR*9
M*%'EGI,7X!Q).80>*W*L-R388:Q4C_-O<|S6BDGQ_@%W|!Q+;;8O M&|IW4@A^NI#.M|
|?">S>!*\$3|D0!6Q\$"R| SY0J-K.;D='H?41NQBOF25| M\$TH!EAWJ7|!_?
C|OX^GZ=G^5_0G#@/V97_Z|2>1582<;,P*0F88A|^ (JK), M*%,I3^I 785-
S+8+ _?!Q@JCR^A=A69J+WYZRW_XPH0)T!&BCW@LFNW|)%SG(9
MLB)>B'AT103&&)|MA +#^Y=,|+|^O"R8|_KS_@>_O=G3S>WT3SB\$|WV.
ME/U^2/;?5-'S|<4B>0X*"G3+((^5@3=)8K!
<7'Z|^%D:VV>NE%Q9^WC@|"|W/A(CXH'JM,/P?%2%,;ST\$QI;IM&EBO M!G&^|_")I<
_91_8_|CZ.)%|BFN(|^)!%|H\$S(1,MTH0S*D%ZZHH5*Y#8E#%3.^:O>@
%BMIKMPD#/1^ (KX|C/ MX#|SXN%
(|Z"9@SXSTD*A1!CDCMIGBZ.I;0\$K<4/EW9P(43J4W!-.*:1Z(G>DG
M\$28B/N\$Z"&_QTB%/(X)-^AWBID1\$?L0Y@0W|D_H15%"_8#X(AF6(L83HXD4
MHGVC0^#%UG?A90ZR68142!;SZ8H.\$29TT9831AM.N7< #T, MJ:ZPN"H%N8G|;%
|9.KW|L0998C8Y;58K\$<6!9#A3^=.Y,TAK|HC6RC\$VTM1 M,,"2V7(-!_X)8#)I\$-
@|X9T4V4X*,"2A8!/\$QN3Q-GQ4"|6*9,"8N,T5\$Z^9 M8F/A-E|>#O@-
Q=0Q3*6YA=>_6&Z>RRQ>TCOE4MY8@NZ)9\$BA!/A,<1+9B-' M@XHA)G0H04JI68WSO
Z|>1WYRVT92GD<*H8ZO6/%.7P FS:K1@?I(:P@7.80 M<.7M'4_--
XD10LH8XB8=;S&/6D0>!OT7W?@/+(BAF^6,T1)(D&,O9='SPLBG M>3 4HL_"0.,/\$9
MATG*=O=G4)(<#E#(\$L,D_-^\$W&!OG38_?V|+6AGP0&FJ_J|&-|ADK&P""X|
M.HL8!VMO;L PG|(|XQ)?K*#U-SL.NNH7=YR6|^ AAWXSH1%X@N=Q40@
MS;'+J908A/6CI0H+R&_Z3?VQ30KB:>*VVP4;B3AO@T:??5KZG @T;H470\$
MG|OBKLDJ6;T&^@%/O&(P>@B(-|)9N0=E/(!_"_:!X(5HVT.^<|% 7AG'6<@=2
M24#CAQ+.)P2P;#B;\$%(G8ED022?1>SQ3?U:*>RCC%M'7|.NNT3K,.AUT|=;^
MEVAPBUGJX%XP'92TQ= MR8@YM2*?%GXI9>.KQ0+/128!(?)

(P,'U^J'6JL/M1@2B,O3_9@1=A8@"/-WL- M.H(+_O0NF!+;7FG(G;#XNCG#JE\$&%CB#=-
^8S#.Z&%TX4!VK8B8\$&)%*D<[M93+D;\$
O"%DN_9|Y|)9/X>>N|2WL6L".\$;2/8RY9T*N|564D)T@2KA7::8R2D30^|,YAVF%DI>SMJG,
X^>6SX-0X*76N< M29+GKX@E/1Q;,: \$"2 =L>LP0T"7N1N+>BQM*
MH3I4S\$U2\$|?,HZ*4V!GP"3'!"G,?|@WPL0>*)|*#0^#@90\$|S|X@.HEOU.Y
ML9|9V|3@UD@"JS8/H(&GY5 V*P'_\$H>2XM9 M"6-N=QO6HUJ>RE7*4PV4&=X#>Z2\$,
f7PEB ^6 2H1-5BJ<^1QT|00QA>0P@|UV-#LZ4P';+/1<7>@P76A/7>@<*C\$3 M#A63/?
R=+|2?+G1ZP/L/-Q|>W2WXA75&OS7C W=I^|.!Z|3W(1A)%#E"20,_>?
MVR@6%7"GBYGS|L|?(<-%?|!>/E_!"H,).N'V""LPEG2A4&|S|JZYD,4X=T
M/,LD#@|V_|_ ^2V'IF3E|DR M!,HOJ4*T#0@NQ XL%0N3|!!^6H6-KE-
@!OL4/"XA3GSNT\$*-YEE*G.9JE23 M+UL0|MT6;7BS"O=6)7,#W3&SD\$DY.^9/X)'MW65
272@&G&F6"!ELY_(>/^A M|.?:T:I+% "UDRK|
'=P8HR=+E|7|YT9^!|@9,,D8L|P26@KWSFX3;|E>6\$00; M!AAF|)X!.*M42/V+0,^B%
(.L^;1TRP^%ZZK=>HZQWCX V-;^'E I8^GF-5_A< M>
(51B57A\$T9RQDA,&25S1LJD\$=#CKT|(C'(W M4-:\$SO?1B3%4:
|QZBT%UH7^Y|FG#D"V!*>>&'!3)41\$,,Q%E(M.AD3+V. Y MHNX<>V%Y0
./=.B&,Y,I13R1M89%<>\$!@QC,|4?RK F91"0?WO1:Y(P@!KO MA1Z8!^+,V>2I
"FDXZUWY!|#&,PQ M=B/ MS\$9%R;|E@X1CEY2!+:!|=<#G)+X1#K
KM&*8K49O|+Y|IL%0;;Y4J) MHLG)+0QG|I*>W6O""UGL22?
_+Q|5Q7Q8|E+CX|*GQ0T(<4(%N1OU|LR|E^55 M!/?*3YV92H&C7%
(=AEL%AD' LH>,M&8!5D1|8@ @X1L,C#EXY|VE|"%WN610// MAN!&2CM1N@LY?
&|QWUM/V=L@Q=@(Y-XZ^N|S@E|EWCIB;Y=L;UW8V|2B;Y| M.WL-9JM@&SD^A
I<\$3|3R&V;@|V/^!=|O/0U764W_T|?3T_2+\$,197M'!,B@M
MO7*=+WXW*N|3B&9F<\$L4|0<<+B".E6\$#6"SIW@>;),A#I#|;".*S-:DG(T.A!E+,\$
MJVS?D\$2NV/"AT*7(KF4#2OL)/>%)50C66 |+KM#^7>##+\$>CM+"M|P)>^-/#
MPQ"&,EX|VH|"XKGLKF&(UMT+7BL4.4CV("6O3?!!;+'0&:W/2!\$*=1L/J3;' MR"IP:&ML)-
%-UT&XP%X,@2_O>U'5<(NA5W:@V(V'\$&|U?UI;7JL5U'C6|=90IJU=/P6:9Y""SF;|S
M8V5/YONO?)7:6.&?H/"QZ56^-6'(+QO'Z W), 0A A-
%|H'TDFOI5+,"CEN:G9:W;R!\$4IAC3D M<;J-(WJ@H/Y(OVJH,4MI#&@I-
|GBRBC;F61M#\$1J37)',>(B+"8-"|V:|!HW|A;9|V|;5T|K(Y6R
MKX,0_F@&,&K;:W#IN):@|!^-,C'T.TP-B;GU&LE4@GL#SDC/%4DA,|I'Q),0 MDN!
R-;R+AP;B9AS.0J,3V\$6*'ZA,.7CA;HZR1DC^LF=+@\$&>C<"V9|0 "B M*9F5M(
P>TB\$G)QD1.6I\$P5(!T5|@ > 3_5G=B% C9B\$7FV^C|)?1N_DN66('X:4VS=02
M50ZF, @(<?+ ZFP.6%>V=X|(566!|G!D?F>33,Y'/#6F2H4=/^;QSZL:AI#X;
M8ET524PFUR;30|G|1P3T;M=.'!5I>GPL4|WX|ZA%TIXO?7=VX?N2>R<-
I+\$\$.>.@/P\$W7|_T&MQ3-, MD48|;09)K#+-6^|I%CON)(IKSN."|4@V VR;J;,WUIEF#|I-
P1|;@|>ASLH_! MSB'Q+L6%-A"P*V@J2-E|AZ^:Y(2!|R9RY|@.,RT,7-R4I2+4L,!1\$^).T2R;
M23C:P#C(B1'@<#);U1T.ESA|GPNSGU%5F\$XS8#||LG<8R>G6S@0I+9Q;_
MB1^X1+KN^8G?>#&'QWX%*C%5E;%2DNDBB\$P *F#(#E*IO(3&^<@V21M.!Q(
MN.B)U8+DD;(<29;50F5S&*I_JHS>.G!+OT26F-A?7 'Z'0;AZ8|V(PGV9I6,
MADL7>_ ^X|F,6P\$XW!+W7_"E\$SL&Y\$U.%RF\$ 2W'Z50\$,I:09*P@TKG;>6P"V9\$1HBP-
4LFPT|Q)=LI#H>: P "0+@2;\$ 0I,5"@-L.N M>V<>2';ZC-(@PMQ3L'9(L/3F-|HRBOT7
M2|A AS|B%Z^9KUU:50#KS5EV*P@!6.%I9BA|N0@W%9RH"P2A3L5"3T=@)O0
M6,U3,4.?UYZ(D;COK|YX^;3I0B0E,-4IYH_(D""BHA8\$%>!G1C|V*-9+FZ
M|9&D"S&E,NWBT+C*B0I-JRWYPQ4YTLQG_ ^U=4)ZF,CN\$4/=VDXWB2")\$H(M\$ST
/H@E%IA\$A..8%RB;+I2H_UOZV"SWJ@*1\$9 2XG"^U'PYDM_*.9(&5|J MLL3M8?*5UR4:
I%00|N|G(!?/4*Z6D-EG4\$MNOTA??|H1 UHD%F|^4=,,(L8 M'2G(TEC74-
X2W1.R&L+9B.CH*E2F09'D59,E_!^P|>(0F"6FX2J8|E?*""T| M5?
^#M'MFQ)QP4R9.Z9:9.M_70BB8_U_U0A2SVR|;+P2\$A3PGN?!@V63\$WN'Z MI"GR|58'
Q3CNUP7HBX'XXHQ\$"+S^\$AP0+E?JGVZ!_NB4_|P2|HE@X#(=& MC|
("PT;2N<0P+"C7ZQ^ZM4>N2)&A'5+4&HS#UJ:62U"?'10,N;S3\$9\$Z6W1:
M4AT(RLH40U*B@L!|J99<>SZE|='G|2\$019#D\$).DU':;')=S/>"|"+Pj: 5 M0VC%?
1#CZ'*+|WWX2_=?0R?/H^!3&2|!9\$HBH#9:20YMP@2AP|!6^|N;Y M*ZC,&C|=H?
@\$/(A'T"NZWACPE7E1|,WHZ4D|@Z 8|_W|G-F6>=T6!NB*@T M(C+OHZ> = (U\$1*|<%
/ZE#C|90+=*I@:"8)|N M6/RQO|P%8PW,J9L_1U!#S|;##M|X.2#YR3-\$Q: + MZC|K?
I6YH'7U7RK..%|B\$H?>J|X\$ R0|KD/ M6*@MU>DZ@:))U0WNW/O #|JZ6 0:/O?
N(5/?;C;MNLE.^#5JA8HOG/B;U'F=+%T"PF&_<#RIP=#'|S.(PH MW@N78I>U3%D 7;
I%5#| 65%0QKWMQ '<|;W.;\$1??%=*I@\$6U8"C/I*^N72 M+P\$ R^B)%W|7(O3>P4(E-

SV,-,FO3QJ/N)O *CS#IGCN1"!.SL+IT0;R,>_ \$ M;:5B;:**N<4IX(ERMB-
\$^6/D1:"/5,PR.H@5Z)(+13P.PNY2^A7Q4+I "MWG MFIS%G,A@PGA%TN'G,
(A:2P[9+X61H&L?ACNX.,[6<)T>&DMB: ^HPHQCM0^-- M54\$;,3B0.>O4O?
6WASQX_/_YNQIAEJU@%5)7UPC @\$; M%Z0!=61NU-
NNUTZX8_E!Z310.@!D)_*>UH;4+DOU6@SJ..TO5"Q;-,37<#NU
MZ.Q[BK;K>0FE[V>P;+MB^=5Q1-O)"MW39R)B="^W^,;_IY_A!63%WP7^/&J
MFV5\$#,%R!3RFYC,)UT+T(5^.)WV.D_3![@?5DF.RY1\5M\$!F\$PT!7O?T:O% M@LJ\$TX7,
GFD!VKJ6XNJY-.!OV 1A/3(*^DC(1SU!=G.XZW#0V@-'47Z&J#U#
!@M=^2B)R3(4KB9)2::3/ MP!%+!MF2#Y,;M"38&SI0*8,AX>?/=M<J2P-D\D?SX+@BXV"
(ZUVF_,?CG&W& M*!QG[->M-V=%8I5?=6+,Y9,IJ#@M!0PR=N.> L) M!I9" >8#D9FI/A
M_IE!U^,&<61-^*_PPT:<[!@C5;%7US+G,?DO-7!7M!7EH@S'S9H"9+9 Y%: MDBI;_>M?
9.)*\$J0HD00AUT2<,UU5(A.9 CD!4EJL.BDL*T#KV50** TN\$IW
M1JZ,&'6:Q.R/O#=#HUGO_25"3B!I<_3\!Q5,V1=X./4IT#L039,08QC!|!5 MF-
G3Q2(%Z\$;VO_MTEKOUPICB)-!DOUD\+!)FD M:IX;_9"2*-\$4>)DC'GJ4ELF!SI80<_E<7'
M"0=\$P5G5PQ&*^3RR?-5!.4I9J;+JEJU\$.C""4GM_1>-B.%9\$F\$SDC\$S"MR'
MO06B7SA9MNLXW9,5L.P2+[2%, "46XP37IRYQBZZ9\$|XHLV:M'4>5K\ (YX<5I
MG7H)AM!(UDF-6U_LBZU9J?Q\$4=R4ZS5D!=STT>&Q&.I M":12PU#C!>3ZDE4
MZIV4J&)CWDHW5R'2\$=DH(U9#'26):97PQ")>34_EMLP_2?)W;3=,?1;[BSB M?
2!8_C746V98A!|3?P1-,UHJGF3!|. %\$^XRI<9?BYLYHYOTZ"AP+#5C;+B
M1:8N=C>N.!KZJ?Q!@F;PGUXJ#H0)K+%7;+<((GY"3*=N^VX&YDGPZP;:: M_#5)H;|:-
!?!W(!V>2&R;?LI.-OZFH_ ^7&J<(SOJD*=, ^78MFEH"|C8%9"G MWNYT;4 G5903,W+^?
Y19:#"!FQLCZKZ(4WM?Q\$!;ZN,-ZDMK&S8;G)R(W-R
ML2A,IW8&6X%6^W>*+!SQSJQS/4I/T>1A3&04I2Z,LH31Y@UI)IO=SQGF4 M0_K
\$Z'TC\$ |,BP&,R-V70QA/?HD4.- 8M0_0?LWR0/Z(3C7& 6PR0 1MBM M
9P\$DI6/.6&%L,@UJ(|_!V'(-5B"E)'4U#\$02N!2UP(&# M0@'S(&'BL/SIU"45WT\$%
!*"T",B"PDIVU<)T*?S_D2A>Z1PDK+1GS@E M_&QSEW3!;OF MCY-+80C^%
|+_#^DR16XV@R/FV#F?BFD(D\IT)N, AJ DIH"N [M%A#Y,61N
MW%>,E0!Y*;H!)?)QLI1;BP09<%2H8!IE8=S;QB,\$>0W7-V?S-JK/L=*@EB
MD&AXP,H^V*=ESCDO)!?E!|V902;C!TPV#2&
!8^<@VJ"1_.7+R!BFYC)RG&THX0!/%::CPLGI!2M2T!6@ M0"98<' MLHIWJR2#R;U
/D@V3D_2!Y>S)W(QD'?-),25I4=)%Q8!|"')0Z(&.GT1:=& M!#[!@ P5\)(7+BX-- OZ(&"!0
!HU(%>U N2S=-HTPE>H;BE96\X:0U!G"- M|=6SC-00X;3C0/@2^G X2!>\$73!Z^E((E?
(!*"E(B=SXE^MZH9PG!0*U*OS< M|=._?(_RR3"5C>OW@O@^DD.V*DK6&!"T7:#_V
ZZ8&S83SX.)L88;SF(:B)G@H3*!F M:-C\$2P!FKZ3-G> D%&&79^\$!R0!<_8YT.UQY@4^TP
!|O-&6V L%6"H7XC0#B-5.!!&@@UBMOC),?(*-15P%=-SLXD"?%81M%K!O>=O/
M8ZNY"ZXC33@(%>4@!*"XR%PFY)S1OT@S&5-QJ\$KL!9?>E0Q6\N3B:24Q
M)N7:ZG^MC3!K4W2CU)PT#HX8N\$9\$[N;NRJ>7691WRS!' J#??OGZT!O/I-U
ML/S+/MBGHW"^IVM(+GM6'M6,K+B!/-,0.\KFL>|;4;)|2O-D""/=R!1),|=A M5M
PR0X1UEGK3PH\|=K(:KQTD6R#J.-)&RPQ*2-=D)<SGD*D*F)2E/?
N5\$PO9A,ON\NX!6!N^[_V!8D^_7S M)/CZ^>N?73AZKZ)L'E)^VE^Q?
^MV:4K7+ZQ+"E%W8#N4P)5(F,|! M1KH@WPE--L)=,F*LXY6NR2-
UM% "\$P_@LXCFPZ=,|2I;"1#+*ME)"40MLAA4 M T'VI&0R#?-
!@CDROB7>C\$ "CF26S!\WN!J"4V.\$/->96AV*)T%I\$ L.WJOF MF7F"87STS;+O,<^ITN,
(U!Q\$D_@F+QFR4XRS>;*B@\$X@EAX8XTSL8"S: ^SZX
MS9S\$*V@!|!^;271+/NS=H!NZQ:0;F3-W M&^8"ON\$T!#-/JD.D(LH|=T-
!6EZLI%0%/_%KRE\) GE?3VR\$&641SEY ::%E!S MV>-5I!;A;'<;_IZDYY0QW\|K\$?
YA.,\$>ARYC=TXAQ_29\$/2?>EHX N#(Y, MM!N^I4G6Z5"3E"9B20!"5:I@_9= _8I%BQ)-L-
"6XR5?:L&^G9Y@IEK61CI7 M1F200E:|U.U\$/2.K*
(ZYJQ4CHJ!0XN;HV^PMZ9YN;0FL;HG M*M@!L47_#7_%!6#\$
M#W#RZG.??K#L);H9(D/(DD+0#M"!/5T*_,@_4!L<# MK.EF>96D)%K%W_2?
!XS6'NPDPK!1GIFTAWO2'Z_G(7O#X#ER'XPFEF.\$M!*"MLA/L#&=((%|-=
!S!|V?"2+K!H>=+?"Z:;IB,A"U,S!>.:?/V(0,9U/R6V@C M U>!P;*1 XP%-V#(,|ZA^V_*?|?
V+?VA5!+4I/Q8#D>ZF@+^E T!>VC5KK!\$ M,T'S1(2@9?YU4U-
_!Y3VYA7ZNXBN+F<[J!J"M@%9WKN#L!A0QH\$+Q;,%L!F
M45PQ&/AM83A>\$>LT<8!6&P"RPR5:1G,P)'37^(1&<|8@_75&N5\&QDB%QO%B
MK*\$;,@0PM=GGE/H|\$=1T>_9#|EOSQ1B,V.85QE@NG)Z,(@X8.^F"=6KEV@J'8!_L5_M9#
(GD|^_M=7&[NKZ)TL /%H\70)" :W%_5JSCF-W\$IQ% @40&U.2IOR++*
MQ.BP81_&G.Z78H??IX_08\$""DB\$ZL=,_)H|Z0D!CS=5U,FUPQ?LN1#6BCO) M"WBY!H!

JLGGCG4BKJC).!8(*V.T!D:*\$X4RAW?T<8SF7IH)*5'U\>2+0W"
MZT+N+%,R\Y>J9LTH^09;*/[-U+T"t\$25U?7SKJKBOIP%ZL,\$6+(CSLXBQ;H M7!'-
ISDJOX0"8*O'K/*,HSJR>4-HRR-,H%);62;O3;)BRH5Y(,@^?Y@QNLVS M/.21,U%I\$,,,-T%?
QFVUL"#N2JU==KRK-HQ+OL1A"^K!H4TI0(3@<&%@=(LJSA6M\?AY8O^:+;F?F@<:
M.VH8IM^,*QF\@QRX\$X@,!?'&FKREW/ K&--3#%J+08'L\$<%-9*HX2?&Y"'!
MB%%L\!1)XG*^1'JBT@2GNHUJ&476L,/8IGBXZ@2R#5TH6H%IV>4-)!:-95%1?-
A86_#12DK^+G@2@=;R?TBJ4 M'.-588;OTZ""DW<)7F30ZH]=71'H87A8/;
<1%#3@U;8;!O='4@^>8V:\$!9H! MH3(A"QJ)FAU\$M2H-?+K67(/,21T^*LT63-
3&14;J\$P\WS(=@!U^JBP0ZB'8 M_RUF7XNGNE#(AI*--#^;,\$5+B'=KD6-
Q!/\$YFEEB*0>\$##*6#P_0V0Z:KY M>[U#\$\$%DS[T:!(I";J?Q KU7;>-[N4X-'?3TD&6F;?
Z*?M)#M#;44 W2\$+ MJ!^=W.-8-A:/MM0"1?WX240>C%V^@L\$.,
[5OJJO,,:YNP.D.Q.UU#F M\8>:SHXX48-?2X%\$YN #QG45=+S8?7ZFP,/C?
OE>D9*IZN8&8HS\$^F9\$=, M2SXS*I88FC-#.
>#ID(;B24\N!PU,:YIA5VW;@7N_)==BPZY+10 U@HO>E6
MJ865>L52GL,11476)*S!O0O@NB="V3^OOI&8I"%E"MMTP6[3"#P-H)?U
#;2VL*ZPWDD8D.WM(" <_& M0F\X\N'DPW. D783>)PC^+09DG<%;'":#K07&T\$?
M+)!_U)5W8(PQH9A*UM MS0?;!Z_7=3LV W5R./3+?L\$J0/ZD)A1\YWM0L*:5W)\
U+3/LSI.^()N4 MS'E\#E#]#=-/EWO:)#L)V-H4:@VYA@(P\I)D\56Y&\$[N>!
I%)IVDO>\$!"UV M\I)DN6%N<1DZ<9U,Y_-
T2TPHW//NX/%.7"CILE\p90FJ15CC#-.>|.9Z>G9\7-W?T\OKN\O@|O||7|^_DSO+H*GV?
WY_|:/3O\D??KJX MO+H^OYX-UL\Z#D02VPBX\$O,7R>M"lw>80_2=H:&?
[TT01,PMY?0[6C)H*] M"4"X7\89LH\3<+V\J<_%#5AJV\I\I\RO+5A*^N/7\4@*M52-
M3NJ8&,VKW3 ME=G\^+Q87AO(8W<'IO9-OKAQU?4GAO9("F?C"4E_933&
J9Y"OR7.O\5A7#D MUM
0P=DL84H<9@&"&]"&,V"EP'FXBQ@/6L;Z4&\H\I\$HYF13C(#.'WDI% '>%1,
MJEB;P32:3S@P!-K4R*Z\!;-C=CSTX?K\IWM\I R:!.J:@^A8Q91WF>/HV=>;G MUL?N?
HZAW!525>/@Z9A_-C:4 M0\$K>LDQ=3&U5FBFA\A.TH9P\^+;[2^2!
MSZ8O(<;RV'3G7X:-1.6)XT90H%E)//#S #9)R)QE*1W24ZRBRWY^OF7 M/W=/()+#!,8X
1\HP)&"Q98\$,-)"DO;RGDAY'12HC2@P"4;QR!U=<)KHS
MLB/%4/7/=OH1X>N80D:A+,U6Y5B8"S)C\MUC3\A,8P_UD_MYMX4)*>(+06CQ
MWL!!=@.OY/64B6_,=%&9;!:LN)>=W94%XQIXP;KBCN?IY(SC0+|T:O!_JB6
MZ(GCV3O.P5UOPBB5(#BEFE?,F\2U(Y6EQH\$Y*Q4MYZHC(4DZX*\$JR19O\$64
M3@*:Q*M/O*A75/*R8^NC3 "UR6\KS?S\I P<'UZQKSY<42L\|2#BP9Z!7\8C>N>JU/?
#U2GR@>15\ ?_DOKC>< MF!A%6!XFA*D/G:) \M+EJEQ%&J'6?
76CSPX@7\DIW^ARRI\C\O9RVH/AQ:CX MRRG53+K%"3
B2TS)F_>4Z&ZBN;F,O_4G\$C6E*83?-W!6S=9 #XE*[MRHO45 M'@?X//812R%-R^+!
I%:C(QT=>G\X>YU3A M/HP29K@IS_-A,KA+|K^37*2|=U1S>|!1-
DX5M6(!UR<02IT03SA&I"M"/4 M@<_!;3!O9E+J_?L*%G1(701_L6B!C1\LB"I>^_
BO%,G?>6\F< "K&3?LSCP MX0IMX9!GC<_'KOQ5&JZ\I M
#%1H,&DJ\$@Z2A4J%6B5EMD2FDRQS_ =+_7\|H@ M6)RL=YQ\7GAF2;QPA:
[JRP2U/7K\$O\!D'E'>97XD(S0)TW,HX4,PO'63A#&@
M):@"YT=L#CU0(SF!6Z+^' \$!2TWJ!)SR4. EP7-P4NK9=#SW"KKA EUNXVQ5UI
M'6^V>3AAJVIYP,G) \D9BG,[XVXWTB< MK*-Y#QB-DI*_W-(BHTXR1KIQ7-
HU0T\Q:K6R#^\$W LKGYC6:A\1K\IQ):^!C MN%<9J/V54GS\I"S"B< U?)2F\$EN#
P%YR'%=JSQ;%%@WS;VF29<_,AN>JW0W\ MVQE9)BDYI 5I:ZZIAP
:0>UW\$X%MUQ">C"F)DMF/C""GX"=26"P\$" /06F.
M)\\$+|N&B)2N&";J&|S@1H_U%O\!/,TEW-|=7\I)81=A%S*19=8HT(&12!E8A
M9'B0\|SFD#8J6WYQ3.-L\A,:S7?!A1_';6=.[IB1A29J(9^R:\DRXV" M'YI
T&E=I<JJ\$S43446*J&9%F0T?\$9XAEZ%POEE5)\Z?+I:N)PR*6UZ3 ?:@+DAXI9
M>")=R\9R9Q(4IZ=8<2I'=YG:U4<^I9'1Y3_KU,*ULUS);DUX3M#LP[_Y\:%HG*4J=7YQI
MK4 ^T/3=91RKD(A,N,DQV(QPD\<|=CB?KM>0U(Q^+R5P)N"<#G8#:@JF<2S=X_
M@-SR"JRI1=%1C"L\7>C2_E\5*,\$80\$E3.BM.PFC IVK,JV\H!Z@3_Z2HE MJ*V?
0_X.23=@Y\9=)&LPZA3(9Y)\$8^WX!^2J@Q::5@2XH3I8;%L MALM\$GF
G+ "/U2KS\#8\$&|O%*I\$UVZIS#<^L325+"" \Q=!5"+\$FBHY,(AV< M\I
I+CXS'_GG%UO\;OFB2Y8\A3GIP=##JGX\L.B@2\|P,M5\|=&,"64HZ"H
MIAP\<(V2!>12\.#34.F.D\1_\$=W_DTS F((C)*3\|@%&(3:S;&'U5RDL/(3
M\J41LQP"#=9(#S+X\$3>@B+0J'2,?&/35,>@D:W @,4ONJ#:+;A3BJ/^H96& MHDK#
!,:)+)QF\$/+1KF,#JF48ZPD"?WQBA#>KWJ \$#]=Y"94'WKAU@LSCUW2*

M\I\$=L2==H\!H09QO<#GR#P1&J%>HKQMG;W;7\5N"1CG3B 405>Z(!/M*1 M;"I+V
R"=LUT+@=!W53N\24)'5,(KBI\O@"E#|2FGA1'!S&P'H4H:8_XG: P M7(I\TAX-G)#I?
D\$U*YMP;QOY,B=!,INLDS;,-\JKCXIN'85N,'_7R+E>&+S@
MV1@:3'RX.:DT)E/S8(X_"10'."4F#Y,RX,JD>*+U"DKI:3K?=[<|1H<9?JJ
M\!_#3*)S*)%Q)U1#D0PSG6Y@32#@>L...:7H9Y\#1O@.%.%).!FWB@9,HKG)1L
MM"60959N^|L7%"|"%&1 "P34PDK(FD>P,_3L)T\HJ23ADC7S|_8^3%T@= M:C#.)-!%
'G9Z3fY\$GP0@+HO#P)8+P!QS2J7B>K-=)C";=(V\$_0JSM%9Q" M-
U\$>K?!\^>2)Y3LE1VE8AM@P#\0H:P(I20X%KC*K!@DR-=K)BTX+\$W%PV1V&G
M4*#"9Y.7^*2#JD?R2&_X#9\C|;;=?=K71#REE=:8-/9)8Y@U=MYCE4Q3!D6
M!1C3>1Y\Q\P9?57U^7SQD/(9J6*-T8X\2G0+I3\GRTS83R?!CL". MH-
I=>Z'(!H%!JX2\$H64Y3)+.O!V6=#B-XWR\8+Q\$2^S64LJFTU6E8"WR7GW&
MOW0WEF_5MAJ-'\$J0RUGT ME).-437&W6>R\N5:E:>IV?
C2Z\#\$HQ>+UC@#NO*&Z7R2ATF@)_ \$CSE3EN_@N
M8_)/@)H&T&IG43)+\$IH5U/X@XE!;S!IX80OH)EE%\X)!;'A"\$%X3Q\8J50YE
MV7^9%|1|S;S8W)S&X"5*DF5F)(&YBT"M"(XVSUG\$)R\1KA(<+2J<\$>7Q0!3
M#+T&&S\$.>%@B.480JD%.5URJ)47_P8,AZ4P"i/WYT-9,211L+MXZZJ._*&
M/W5R*%D%%#J5JL4\$X:%8_\$T12OW;\$A/HALTM_5@*O(1Y@\$;S^A-CM9H*
M=/D>93F)Y^1^R?VML^3RG?U#)Y>0S 5*BO&.24#D:'!%3<.ENVF@&JK\$F>
(F9*+J,Y9/OROCCP M'0"F,SLW;_J>U1UA?=-,*C!7JX0(IG!\$31A?
STQO6|)#%#LX13H5%D(2B1I M+OJ:|>*"U*2#C...D\A"2B%6\$V4#2=5(6WK-4I9W9(-
W@5>#:\$&6FH;Z* MNNT\98,#32?9!#V)04L27 L)%,\$3D<.TQ^J%&3C6 K4JO+|D*J(D/6?
J|D) M#T\9,|:6*%!=!>H\$DZ#G_ = 36\7H%M;_2+D#@6%QLR2QA-Q^A)!6=,GG#V4|Z
M55V;8H%I\$2RV&'L.C7%!^0QOY-.?"|/>:NB6RFPPG(9I:1JF'V0:RGI7IUTO M^
6(<\$,JK8!H*0!^ (G7CHXG,S>=.OEFL^HJKH2;BSSFZBW1#0NYQD,Y9AXE;
MP\X\$-2;AW)@\$-4ZA*R,?2C@MAOPD^@RS:H0 XS>)N2P@E\MM('G'):SD#&M?
9^DOEA1VR#UM"Y(K3DV?Y\X0|,^A14HG?EJ)>_F2J1Z)2)S)4H(R!C>I&9^
MOER)6*|)\$H6QA4?HPG%P:^KAZ) NR1@<:=ZMV#V\7NM3J(50JOJO@|Q"R4G_\$ M!"U?
Q-^NHFP>4J@)O8P7%TQ%|U2+*38J)\HK31G9X&) |L^9:'CB5')KQ"
M6N\$P\$SD7BWLX"!F30%"\$G6VI_"M3=*.CE.=.C"1-T8YFTER\$C"|5?"ULCX9@X|6DXO
#=#+@8P9\T.&|2ZK7N2A51C5|:N2&SQ*SO=N#|J' M1EPWN(X4OI6S0)'DI;
MW#F>KQF|?Y,T3'<|3^DA3.J31+GC0?|D\$GBW#(*ZKH83=E+(I*5QLO8'\$E|L
M"5=I*M-&S2-*#R'R_%12O).*K8H\J%L&Q3YOSVG()#UymKHP73K&34-(M
+H)>,'X,"A\$CHJS^C;ZM;H&'L=LP,WSJ(Y?ER="FI6D)%J) M%GIS+C#%=?
O&+J;).L4|1'41=KM?!?DFO|I2BC640XP":283;&'<:Z0G/H Z'/Y)5
M!_71<=ZU6Z\$(BFN"@WNWO%3)<+B MPY8|: ?N%8>R.VI'ZO!,-=?B-
\$@{(64R9(1.NR.4|2>=11K_|_8SI_Z + M8"#;L4'K|SR9:F6P1ZT\ \$VIE8%\$KI59I'),)
(G4\$DMM L|M(?GGC|1|SVLN9
M&1|R^J>4)F\PCS+-3?)UGD)%E.(>UJWX1;BWY0@!N|+1L8&RSW\$0A*\$8-L>V
M;PG%UZC(@LZKEY13#FY.3JS2;A\3/&6WI&R8AS191IWJ'9\$,U-K%<@KP/UO#H^6--
'V;M6;-(6MT"+J: MM3)Z42_HN%#X>X.'FJM036|B2-NU@L#D!-966^"7:Y*N& ?
L%0GL5PXGF8ICN8_H5L,2RZ@Q\SH-R\$G!%,3358*4;H M)#=@>PE^4,/E'.G&->6&-7?
#567Y,8LE_?|?L|EI-DW\H_I5;LOI(7I:)3^ MW28QV=V&Z3|)?K6-%SV4SB+%8(TD@R70/
T9J,D^IQ8@.6? ?25G51'\$UPC\ M0B\DO-O-((?Z% H/DZB;2?0HP8*#74 3X(T
O'B!D4|Z&@J6#)=YRR%G,.%F MB\9I?'0"+\$Z/RZ*C0:>*%K>*\$3H6X
MJACG1C)3M-8IWOJ52KE>LJ6&J=2-GM>J9FUEQ2Q'XZ%-&WHITE.H=SVQDN_A
M9T|L:EL!>/?Z|W-;A7>IP*OXX\!XKJ>W/BW*P|M7AUM+PY/Z\A)E;CN&|A'
MIOXLf#9;\$3KK4|/+1L,9A|,2=DD5VER1K_13#05UC=S_&"I\$P#AKWWG4"S
M06N<%=J_'QM|E|/CFXML,G|LO6=\$Y?OL_I%CU;J\39E4-KMV,-6^%KGR" MAV#)F
@NGQX>#!QS8&CP0N(D7LU(NH;MVTL3|(!=D= SXHA12<:Y!<>WA+,>*>U4
M\0180W+8'P(JK9R;W\G6-2AC%%QJ0Y'.R7?
4|Z!7&8LOG;*4)RXNFL9\WOJ8\ZO&UBRS+J/ M!SI*&C"0(ALFD6A0_A'*\$ECXL(E.Y#
M1NZ3H.Y%&-854UY6933K'I6D?"5R)\R3+LTH8 M*>NE";BMOL\$(!CET-3J=
XMA.H\XH#|Y_-T2Q:_A3|R?_YV039X4W3E23.8 MDM*G-/V\$5)H>BX"+7T)4;#F*^OA:>
|P!> U,C7*@(GOYN_4Y-3U|W%%_%_NV MG\3SPMP-C# M(5L\G?
DP;.)B\NW,6#Q)6L2%0VBWDN5_#;|Y^00_D9C;E?)E|^^J2PJ'1
MVB9'/T7PR^=)\7SUS_C8Q=D+O|U" |K+^ FS R(F*7SV EF+W-40EW5LZ+
M2!OG%">N,!?! 3?/^DQ?05R05IK7)\3XQ4_<3C'BJ\$IH% MBRW\$=%2?
6.UW8>CW=IOVIESO3^9J_B|-%0H57UM&\A|E.P0>ZB5_TX1\$ MDM0#3(?EFK9,5?

MXL|N:B)S|29Z=CCL4^P|^I^,(/Q>B.D\G>MHUC4#XEDIO*#*
8&*S5"C>2XEDP%MTX41^OMFNGH|3:D@1SBU\$02*Z7SL"7A M0%.>.&HF|60_1_!;P%
|/"T;5?T,D&79H_1U/,H_FOIR.46"K9Z*?<|^DA M3-
U&U<^3%'H/Y:1|H;4BY3G/M,2N1+ET5U0-;9U@Q.Z0E9*2,|3)3JS3L;CF
M" PH45I1(JWQ_ ^U'XQ.|2(UPDA+1&F\$F7(5G6IKXKT,U3<*4@5,W-|'*>M?4
M1X|P&TY(L922|_2=XGE1M!&4;HN+|2Q,5V\$42XT%6N=HK^-QZE#1F24&"!28
M#/SMQ_6U_LU1\$%MM70@8Q('+R5Q/X:D#1\$'0.'B(LL!)|S3E!|3E9(OLROO
MES=)&&/J9;>|*|T\$!|O&MS-E9(E&7Q1NPA2.FIE,V,F M *D)BW|#+"|<.Q
M5N#**707,;#?2M6>JC65S*IB=C.8G% ^Z60Z*%B|_OV;-8>/%7S4HDNI^D?-^
M+:6NC)4R6MVGS%S|V8_K2'N.4PHW=
<8F|I^(%R()MZ=PNZ0/O|K@:FV^_TEJX*06ZCMEW\$E)VWS(N
M,L#|/@<'OE^BA|A:X0L*0XBHH|QN4B^FS/&|2P\$NVV<)1E|)>!:5%&351L7;W
M2QZ9/1F!2F?V:(I#Q99DI3= +W#-BO*7B W|RLG+8OH&K^Y EX|7?R^Y>E>
M|TM1V|9)_SU_A3,7L'B6D&^E&D.(\$K?|I>->|1/+I3/'DT5A/IM8*%T5Z&K MB
IL^!YZ(P\$Q ?_N,^?4=-UL1:=!?\$Q8D<|R%,7.2IDC#B,,YR'V2O\A0Z MV)D#?
CFL\$8BP>2C|@1E.Q7|PGN1%,-?Q',HCR_7A_V5_YR"+E^|S/-0>PYQ<M+I?DB,0&
(ZT1:MG|+%)>@19_@TCX:)E/K3#^=?HGVR<|@E2G(ZOG%*3 MR<%SH;IR6S*
AYW;JC6!;L|;+)|DBWOPYV|35/1ERI|CY"4CZ7=P=&+C#G#W MQO.
(&=1((B1Q|XWBHV6T|3-G3J
M&GP?/\$GTW*PYG|&3,./.@NN8_1)#Z7\$2P_7(2|0|Y:,6Z|N#7_&V|C)X?AM
MN<8!3WT"2@?)CSL1!<_ \$;-P.^@L5!)0|Y<*S/\$AX1@%_22:R|S49!EHN\$@Y
MA,L:I@\$D|X)J4J".R#>&-8T=E|'Q5X4Z3JHLNI!+\$LNN|;*9I-#P(4,RXE M|X
H+-KY8!C|D+XT1\$!7MAY=^S2|@|_)BD'*R MFO@Y TSH5RY;\$@FI|H(L
MPA*,H",73*Z\$4,@?">=#=7)!8*>W|Q3|XS76(C%W">+O<@>8)LC+9BA#Y7
MC4@P0RKR>H8EQ+HQH_6=ZS%+UV:N1_#^VP_\$1_'K/P M76;104!=_@?
4|J/#U=SI|YE=,NO!):.S| MI6&6J52(^Q3|ZIV:=B-%XW@,DI1|ZYUU|0;_".+L'4%80G-
8XYC|<15_M,=BIBVV!%_!|Q*9:XH)K5H/0@=Q|L, <;8(!Q<&Z-%6LPV:C\$*W WLUAL^Y*
M!57#W\$!8A!!K6_ZR?H@YJ5C_\$ MT5&/(Z O%)/7=:U=ATOMG-R6"LI:QDW M)
|0PBTG8!F\$C\$K)&:3?%;/Z3DK@Q:=|H08 VWI|MI7,/:K^!EV|C|AK& M\$A)PQ8P#6-
WKf)WO,3O&N_J#|M2 MK-)P|QK-0WI<:*" VV50&SPDT*L4= 0:P,%\(:):KJ*,#?
EW\$J97|%|Z:422 M9,!H|D T0*HG(@=2P8=D4M'1Q@, 8@4L7L#&P_9ONRNVB-
FDX>4NYBD+NN2%WC'(OE-Q#-V4>-M0G&Z9N+\$>9)V^HP5D1|)"F&U1F=S6?
2Y=@X4E_!/?_AK|C|I_ ^OSY2|)!9S(M)/CR>?+Y,^_C^% ^3_ CSGRT0,4>W=/Q?
|&N4|"+>*Q/>2G3|Z2&T3V#N|>YM MU1*4|PL="/83Q5%.;M@*L,^)S?J.KX|=GQN|3*?
KB\$|X@_|0GIH\$VI0#DS2 M)ROL*4J% WW"D0(IE#A#H!N/VPF >_8|S-
A')!&W|FPW|+D+7_E#NNK+3M< M'WI(FL03G\$89!+<_.GAY\$2D|TBW<:
(Q#2)F25D2XFZ\$N"LNKF@' MLT1QZ9|>G"E*1G_DKJ\$*6X|S1T|^GJ0JR_N!
\$7PSGTY\$E)>)|XLJD:0"< M0@%0|I5CZI+9-O>1MX_IOT!/?
51J2\8|D1C6P+JD)C.S\$2^#>/M,A0N!=5# MH_O|H =!H=?F,'BRX3@G*2:M2
CHRX41S&XD#NZHP40MW5.>B*R"T=H@/#^R M%K82U+&T109?#+DCS7;_.Z?
CXK9C|R\$A|O:7NUER1A|".#%=LF.!^|_WG4Z4
MV2MA5P)0.VV9Y&+A0)6NZ\$9,%3**@S,2P(C,BH\$Q95!@>^)S4#I7>'<7R*FC
M./2_90%3>J,,P=4AS?""1BN>(+1,4M&??"/R@>!?RKW+P ZXZT B3F (.@*^?4=-
01P,9U,_0# M_(E)1S^J8!M^ .5AFK=?O DS-U=1'/J+B;)?/A.E4.(?1DO#A'ZD@>|'4D| MC?
-H\$=\$MJ\$GZ\$&8W%|TNR(*G|+W6VX;WR_+2-HW44P_4*I_ SZ#!^,F""07 M,J|?
+0&WAPV\$&|A!?*OAXSECS1L|X2E;+#!0Q2ZR, (AU7_3Y2'MM',4R6##
M:'|W@Y(|42\$H14Y@!P6.9R4*8WJ% X81Z@\$4"(>8<,@""-!M0C;|839?"33 MK5+ZJ+
T|N)P#.90A;8L|B"AI2=>BMV/^#GO=QF Z"@.SRD1YY(^A'F<\$;6
M@*V9|GAJ3A|GS2WYXX|P|A%X'LY?3T0&L9Z*FLR:|&XDIU"X IM&
M8E+PY/_9;YIL5Z|&0EXGPT:T|,XY55|6*_+|'1B'4S&@K-8\$%=|Y 5Y,ZGQ MY
0L%Q|Y(*@M@T*P@G^ ^?_J_64L?^Y4G/!!|_1EDGYRI%|_AI%BXE^#RY,5
MLYQ)Q|4MY:U, %/|_K*"BM=-Y&=|VJ)Z#NY4"DX 'MX19,W\$4<.5|VRD=4(
M@9'E@|U!EVP0;4N10D0HDN7DRQF,P8,C*G00W*421@T>/A84U%._))3\$AE3
M,F^|_P9/UZK)|@3LT3=,**@='P%|5\$EHY@|UA_FE/0EJ^|_MZH0:O|AY&.EH6
MK)JTZ0@|X)|Y3MF@6V'DAHLMKQRH+N9ILB'6C:)R9.T6E@\$ZA0"@B*!72> M.3\$I:8-
XHL\$S":A #BE6JVC^2|A_82PFM1|< 4D|2 O\$!SOZ>Q=(&6!2D"+1
M@%,|&7&*705K9'+ENP(GA4: 9-H+82_DD\$:(O0_7_!BKDBYF\$H(W')\$L3E|XDLS
MRHD1F81;-IZ1-S@|7&4>1C%9R%2)|J<2UOO_*;@@RV@>.>A'T?_8IDD,9TX

MXNHD%>BZV2P1-ME#"B9)OGM@%/-IO%#E?9T2"!D'KV)Y(DN@VR[69#(:H#
MH6UVI42QBWR[_@6VFG29.PAM!%CH*2#5!\$.O[9BV\H!8%G%\$(\$<8Q+@*!,4M^?
+T138#/X?+[2@?IT_@)V'AB<9%1)AT+];_N\$>=+*2[A!?'OXCV'!;DX".Y-JD\$#,ACG)
(452\CI!_+=+M[O?+C9\$P,=10[2O!TLK*6/#!"YM;K.YAG!L&(P6)A'XU0JK#37[B>*D0!
M7DG^I9M3_P+(J1HCV/!!)@7@/1SG!"65WBC,1=?
D@PWKXJ2Y\BF%LWRXP+"33@>!:;14@WV/B5QNI(R)SY)%WYP%&.2Z_M'4Q'4^7/I"
(25\$S?S5!)@I1J0,'%GFI\$|Y@DLZ\C.(-?DUCDHSF.4-:Y|>,MT_5VW?T*%
(2|Y946V'18E*0:7/=1AN0RI-^1<5KEV8F&,7M+9J)-@OCO>R-MG=\$|P'7\$L|OBA,JCRP|
[W,I4"?P.P^8LP)PL:H"N,DD!(>N\$(2;Z:M1=Y,I_G#I1&V_C6;YJ>_72/5Z)8K%\$4)P!Y
@V>,1)X4|)DT4(H4^CXR%U_M4K_JI7'3CR&!ZU1"!RF\WFZ#6DG|0!(0C=%23,(!=\$3D(,;
(ACD@NGIB%.M(K@6I0\0<<\$BS_0/130/;TF:~Z)_C*#/KW"EV.F1C|SP4PI#6.'R3?;XD
=L7T1K#9XS(*BX&1R,S(>IH]994\Q-P[9Z.G_M8.AG^!DM?,D4&\$_/?-Y_-
E(E=*!.81%P_MTOJH3:WV;|E""..IY_B<1.YGNE|PG4>RV;^GD)MY0?A_^[A*N+-
B;@|/OG|^%L)-M\C-V5!*H_?|2YI+OGF_SU^WAP%RJ>&3QB=-,
RF/@0I'*2R4E"3&U(%T#%GZ(NDTB8X&L%5DMXP#9UW?7PB>4Y)U^)S
M(^A>:@\EP#UY&3Y0E_M*QBGNI(@"&7.;LY.G%/"3/=|YW\$6|+K:&+4#7^+|M?
S+=L*.Y(RG95M@S5H_M'->J!2U79#00/OPXN.)U1WSH
_8.Y.#8M%\$.'^CQ17|LOY@6=3#|:SK*7ZI_MKM\$>3.XN.SV!R^:1+N%)-
JNM>%,0*OG,*T'1)IKRL854QM?>CTK.ZZMT.PU'EHLK\$1\K!3W*,GR\$,P"4UC*D/(7.Q
MI_FA@CM"TS%.8JZ3=O<2FX<[HWDB0M_Z_IV5!NCB;-4>7\$3JL0!Y1M|S,\H4
M^;YJQXV6|;E!*YC=M.'%%(?92-SCL*|'.%MTB+!|;_KHTEBD#0LHK7Z7G0+
|EI#Z)!SV^|I?"G1%=@0)|#2:|_C_MJJ(8X0@@W@-
C1=J8IRD6+4FDR4"3CKXA_BO0Y7HL.+K4PM!NI5.K!/Q5>6N_MPI\$79).2.>^9:G+U\$)
(*B?PYSMRL_)8;H"A!T%=,#1&.E\$);56T2;&I|PBj_M1L!,D!,5U?22"3OP_X20!>813DW6!?
1|VBQ#2FXQA&|"4JH7J/-+.'Z:J>H_M\$(Z" CXD_CK555!+NOE-F7KP
\$FR08'N"0E#F^1PV@'\$Z'Y;JAZ94|J|@9.*_M_?
T)8LHAZRP;F>IHHDAXCE2Q>SMCR"J:97L;?Y:F_@^9G#S02:B>.1VF0U'
M3FH7DU*M9NXZ-;H:6F3Y?9QITM7S72=)5-V/\$.4.D6)TAW148R|/+(ZJ&-"M5
53QAB|>.H\$!;/9')I0@XH9RFD;/B-H=)/&<|!A@L+.UA5@2V..<*&L\$S_Q_M-
2UH)N=,)XD6A,,<(08^;W^D8_C"Y3E:016('>C/FU??F=&X2P1Y02,!|"H_M;W\6-/3|1+B_[S
R3%^JQI:I9QD?;)C11T)N#|%_S_\$Y.T'@PD*C_4&9P8:-M
P#U: ^ZDBUSPOZYE62T2G/^0TUOZJM4TSXUIGA>F.3>F>=EE%P^>1&F\$78Z"
M&K'@QV%ZZ%^#_Y3Y|_?PDVH9!^\$OS|Y|^3SY|_2|'--@%P|V|R-(6"7SY/_M_@0^
S/VSTW07)"Y>.4+00++_PI^>:/D_||Q=|S|_F?SR|W^6KT;|5O|M4!5J\$U@M<'I%
|&3>.=K_|77R|=|%|<^3K|H|E;03(VIV|_ "^+S4MK+((I_W*_MEY;WQ!OR4+!E%(K8@8:
|ZI;VCE1D7"(5<0E\$O'!1ZC>|L67O^85L#R@?%4!%_M@YZ-
@TR#6EE;0JF*T&CZ)R=@M2!_RXNHQ-(AE+F\$3(MB1&S@ULG@!_>0RM>
M_(W0Q2RY#7-L+*#;S3_'FN=A71AX>_\$.G_+DDV0\$|F%4_WF3%Q|<&|/-6J&\$
MN3!3&|S_VW:|>NAYJ#LOH2X_C'?_EL\$IP#1(R.,R\$1C?(F:|IO/7P-?
>'@3<"6G|WP;TJZH@3^*W_W.H@D@_@7(M4F#P--\$MOJ#L%0"8|/W-
=|Y@+3!X0|/#/2<#9&|RZVUZGWZE=,<_9TDZ;);|
MUP+RGX8>0'5<.T\$A:XJ;6ZSHX&X(I?N<|80N_M_8Q>I4SM1CS8|ZB3J6S0#!31X!|
UUU:UYJH='RIC-Z7@*E+S"X#_1GV@K;+M*LKA!+.8W1;YQC"GD_4ZXE!^8'-C\$L=
(&3+^@MH*RSCV1WJX8J)F7*P3Z'HT&_8BZVJ<2UWH@V_M@PO.S(E/11\$3%N66-.)S|!
-8BN<8=5F)CS/(U>MCE>#7E2@\$)Z3>B"D553
MY*)PTM%TT>*644T|^#AXH%3J*2?!QW5?5%:O=K02-Y#)Q))U^C+CO#&IR0/+8GR:
(@2_M+G_WZQ/!^X\$|D@ZV=<,IV\$=G37V,!Q'TE,WD(*J/3=')QO)@"0_A.30^S:M6BA?
*=IL)-%L|_5==NIH6ZT/0?8MEA5WV3UVF(&GU"!FD.@IEZE:H&!9E!W_M=!
|V(Z&U"\$)|3PV;:KFFV=^8_0K1W>OHALY|J-B|O7D*),W@^CJXN3D_1%H_M/?
=..GWT)\$8IQ@14@U.4VX_VF#|BK1F/=;91B
\$F|;T(6L=HP*?!IP[27Q7W|:YABJ_A'IH=TPJ,S_M.@MCTT.2Y0A(=ZJRB46LP-
#QE\$H^!1;RD\$AVY8_&S&_O0).T#|U,1&ZP%_M5B|LTQ*W@23D-
==EG%GW_MOXOEIEF*FRDZ7S'37RH_|/2G(!>\$C<*7TY%&M;?*GIT!2-
JAG""S6/*"=:;|8)MG&B)1XK?Q-Q;*9Y&4DK4UZ3V!\$S"RWF_M4L\$RQ\$)YGGZ8@%\$-
_!|D1V|*>(*T9"4Q.9\$&#RC(6|5,*A+LN"EM@J_TK|B|_MP#@^;|+!Y5&F3P|_
GT+TP7V'KQ*TB6)(^XDRX'X_)>'.5B=UXN+)HMBHR#
MMRA_A3(Y=&KGX3MX;6#B\$H2R=QA%=SYC4B?\$3DIX("/+/JT2*#B20&8_1|'
M!E3#1H.)#S=+YMG4|U0Y|@|*B_X|FK_|@P|L9/V\$_'C3!QWO&WP/#"(1+<6_MX

S@DAGD!5#CP#\$^BMG?&8%2*":C@0\T35-&BPAX:U3<9HG(O&,"_EE=|&<MEQJS3\0
H!25FMVJC37I8&'BE(I.-8/'"#O@S)50&"SE#Z(\$RX:0.GB:Z1=8L MD4F2< KPS06U\I:
<%K!/?+W^H.:W4)?QK;KO/;3&F, RM FBK@A' M3KS-AD:@ M-
JH"* ,YRZP>.6I)0Q3>AHL2)"?C)'.YGF\U(D>H%F-.C(KVP?574%+#|/4A3;Y'"[(XVSUG
M4'X@"N_CU13 N+@#H0>_JB(A(KNZ4LHW; DYP@6<(T2+ ^?W77#7\$TQ*CXG@/-C-
AJQL"JSQJ?@6FI M8 I+8D!5OUPN >Y45LZ4\Y_!T_"S5D3\8A?:Y?N<;F&SRXZ
W3PV(A@0Z2K# M4.!Y.5#[AA!/+;L-LBW X2=\$/Y_"#\6#+&(AT\2UJ(Z@G.W;?
NE!:Y\$S\7+*,V%W#8_-#<@3 M;4;6FR0-TOT /->:JCHOY.0@\$(":@U?
MNE,Z^!2O6@BT(DPQNW4TJ<;9%#H\$% MKL!AJD#?4HLS3)\$-.-TQ&A6K@I/?DO2?
UX!... ^8: V\$/D7QIPTG=1H"*!U7 M=7X\/-@^5\I(H?@T;'CH"J\555#++_0_.K(?
K>./S1N(5O\20ZS-0-HCL;7B!6B8'P8 M-
A\$P4/#+X)=/C_*)Y35!F3G122"D<1;GZU&JHG)D"B>%XF.XQ30M^7@5_E;:N'<
<+W2=&U(:3/ T):EY0B02WO\^>9/\$*U"3;J#>B=U\B"J5S7LGB*-E#"EO- ECB4%/MU-
%>|_|-QA@& (D=1E:X5)&@'5 M?9;UVP\ (99'4T0'!:/F^ ^/\$!;Z#L=X;J5MG#W*:'#N'^BT!
JOEQP\$PG^)_L")Z33?Z),R->A\;N9F4C.)+A<+N1(!JHI*F MIW ^_N?8S'=.1M10';KEG,H-
ML\#D ...J74WGW\^_IS!3+,'RX!3H+KZG\Y MG E2YER/RXD7^H(Y0)-56R;L?J4%\Q;
HL2;JQ-G#;O>2'@_I M5\I(UX?E3 M-E&*3WC!="EX?
Q.Q_RQ\$*S\ (B#QW+HJ;=X;_>"Z('&RAG-"0J643Q3+(Z.S M?4O2%4DOW^>8LO;
(LUIFV_+(J&QK2#=#VE;&[*WM@ZDQ(_SO:G">+P@9J?M*+ M;)\RRS N:33?
V;Z\$^J=1%.: '*\X#<,+2=F@)%'_ UHO1#+6-TBC\$^\$0X;FJ
M'C:UCWJQ5UIUW(K0WY2NA\$A5;3: MST&%3G?Uuw/C*U\I
_L%8_1V+|4'LZ+76"143L=5<_IEB>FY4TOA*SOD)F9&!SB?/D\!=".K M9&O5
X^CY,=";/>F%T+JAFK5+Y5\I?N_TV(' M9;MW0\AO)@V:|\$.QY)LX>XS'="''%O"!-
=ZXZ\A<2_\$.3J>=-,8K>M,=71\ MX&@1^+
I581'N)JIAK\$(P1DN"VWH7L<<4+5D)Z/_YH+9!VH?E14)7_D6%YANY
%!5@)\$X69LI\HD/U)+X2P:'J07!LM'"<'S-C& MRK@O\TM+3;'V?
2!\$EGEAL!86YVW#8WZPWZ8Q(/?.+J A\!53VT,*RJH5RJ.I MC7Z|= #FO-W?
H_5V+1^P'NLJD_ =V\I2-^G#S&UX(!0MC=W#*!@AM&FG&\$Y
QK\IS:SU>1_PNA_BVL'W5T>_7)Y+GE"R;J.-XZT;&-[WK! ?KT^#:.JO=AK\G*7X)M4ZR\H
I(:X) M-|/ ^3(FHXS2-*_N>W/^>%P*2(D\(!OJ?T&3 S""F1U2\Q@ZD(078N.I_4@V
M6Z:8@CNAVHFF\J9K?,L+X?21P8\33#9/JM(=<|Z(0B>!?=+U:D-IK_V2JY\ M>/0+@*>
(W"JUOKKV\0.#SV 2WH;_) + ^,FH" T%S8/N4+H@NMT2=BI;L;7I-M M%D(88CO\$1)?
KC.\$>2\&(K"W/@(4SSG7\$F-OJ>|HWC MA6!:\$\Y+\$("?:S=K>BK?69W?
B;@VW>'A(Z.H>C%I+1"4C\HLZ;=U\$@+|GN
M&FG/_NA\$THMIP0\4VL@S'KG3_BI)24OG0NN71S? 9E\$.N_>:Z>_?H\4VK(2;
M:O_R8I7\$12J@->|3+ .NI4^AK' 9"%)%2=,7^43H1?XORU_-MEC-3,6W<;VW? M'?
U6+01Z8F'9G^W\$YXSH(^,?9A8>#JN"7Y:|*X9^<\$5UR; T='T/-BY9\I"
MY9R\ZB'0"14%6A\>VO^6%\I)KQIT3@%7*_L/G(G?&?_"K/_:|T%UX6>%O-2 M+|/9X?
1#KRPV,|+;H7/S_Z\SWX\$G7\,05,27^S55C+@>3"3I^IP NY1= MB^3J?Y-"LF'M0Z.O&?;
Z\$JY4RW=6\XP?WX\2H!A\^U(PLKH
M\$TJODA1\$JHW7ZE_00JRN:VD\$TF1&4Z\Y;/7#>#%|U4IW%6,_#S<1LY;:2@I:
MO^V%L(@<3A89W.OH\(-:033T;<+5/SW^ 0KG#=#M<9U&2)PFMN3+M3WFO\$ L(% M
X;"OC3@FD='7X/#DO2GRYRDMIS_CJ2\6.WJ.'?"0DDT8+61H67(N %RK"9?= M*(V^%
IK>#K^BE\I'6'?*LS^\$;W862C#RWXQ7VK\$5!|PO5G*>Z&6G'(Q^HZ&
M2K(P>RU#\$D&IB9F:67*V'_ :F%SN,9\TH4+\$\VH\ M44\L?P%M@NS=H@-N(2C
ML^J9+J:C*1NN-E!Y:%I=+2\$OIJ#/BE#Q2,.N'FXT+R93=V>1WKPHWK+= (P5 M=CJ?
D662\$17\1IAYS\A/4F;0A^D.(14 !0-^0&;|LE=EP7+|&3'(<*/?'3=, M*P#=:Y42/!%?
+T*C58#17/H^Z,+C,>#A\$OD._P@>VPU\WX7&2IQ2P1'J" M'\U&'09_M%K+;5XJ-5E)?
R\Z,S?;\$!5DRSCXZ>%Q:+N@YX7FY1S M9DM8NVG*!VKQFA?
BP>U1*/ZHS=FS/^F%\$,40H9'T>17.2=O(HO4U+|0\')A
MHLJN/9O(1Y+R8AH4)G63AEFY:/1351YM<|!NOS>D2\8^Z;7L*Y"7Q_#MEJE2
M:132&K>:Y4\$01"@S\IEF)D(A3V2R\A M-+=>F;8'O1#!5A#*=>U9PBPJ\$EN#"?O?
|D*XZ?M,PPE5N&3"T"||ZZ.B?2;+9 M.W6-4>5'M0TIMD<=-
F^H+1>C3_|\^IS5TZE5V\ZQ/U;:(I 1QH@6=J-_JJ M/2:|D'+H8-L2E7X>O>@#O%)%?
TLZ+#:5+K^PIWX<4;I6AX(70 M4\I8"25Z=^5X%"J751MM\;870AH^8:95-9P-
U@>|\$\$\$%O+:DOF-K3V<|X6\LM MVIZ.%Q-
@(FG9O:GZ\H&/_2\QR%|SLA3LLR9%E%SU\8^Z,6?(P+4IGWU.8@74\B&"D:(LT<^X-
\$ "4*BZLDO=I"KKU, MV\8K\0<2\41TUV((NS';N\%D;M@\$ FJ*GD;=_VMZ)?

X71(,DWIR^>SOWQAY\9MLD#X[BL:KLK7>,,CHXNATE,Y"!T8);SB\$ _Q
M(EI:F08=|M|H N)1QY2.B\$-\$Z/Y1V35WA"W.MOE=DO^=8)>*LIP'ON[%-S@<
M6K11ZG00AK5?G(WN\$:%X 9 X+;M>[1Z1V@>JV&>&ZH|+ 6N:DE>VK-%WHK,E
M\$=2R+FAU& DOQ+8%&L&VO%]*YV';|&3Q+2^\$&^X+-53FEN|Q?KL.#,&@%TM6
MS*NZ:4J3JWG4"S'ZC'2Q.YD45H;E_ZEZL<.W^JP\$(:GK>"X%:-0^XV#;VW#J4AA>"
MXSZS&+Y@'U_1Y\$W5JEF38MJ^[(6HC3%7G:JP<+A6O^J%F.V=&TVNN\I>"\$|
M=*0I=0*HQQJK?=@+490=*1KWBOXEHE=OBRYA#>|Y(6!-OX9V^|/URUZ(:GB*
M^|+T/L6#D1>2RKS8/0FNM>|\$*|0#,O-G/K|6?NP%Z*46@86@>F*4*|L26JN
MBX.)>"%ZN72D)2ILB|>|\$,|X#K%_8G,:L_JGO1"F42\$Y6(/Q0J0^|>/RGE0^
MF&|)LGB+*+5-D5,&O)ARI9_S7#%0V1LOW::G1_=VG\A2M(-8+7;4BKJGO%B
M):1YR"S_&|(*J6X%T5@J:7E|=&(*A'')+|6G=|DEY,RQ-!5(EO)&:&((6>.HMU%\$=P#D")
MHZR0J5F4>|!RIJ@KEW|Q8&WDK-90\$WS2Y|@|YWPNI!ST(*J35/KX1(
M.! "M@3;#UK1ZTPLAU<4K#(J\$V18.-+WCR10D(*? \$?V%5?|)^7Y4\$
M5D6E,5N+7,?'| \$M5.LSN?I M%EO3Q=^3.\$X66\$FWR6UZ2)OG1Q=
(6/^&3\$=1P"EO276(/LOA\$:WNZ=LZ1:P M?.7RD&M.K=K|DA>B%3.:
(714'SJN>|8+00IY,Z"YU\MI\Z@78MR17)=MV)@O M/. %RSPH
(9_SMD\C3AH7"TP: WC7HBC4KB;V_+8UZPWX@)9L)N2X!MNV?G M8"I>"&_/2!?
*2F.3TGV0>2&>#52\$6?I7T+|<0\$@UY7\TO.:%>-IRAYOFD-A" MJ?
G1|;SB999Z1/U09(^L\$|. *S*\$4Z MZ_4:ZX.CIR|@O^A>O:6?O)BINM*:!4T|(#))LY
:SL3IXO@8>U,N8/<@Q7_=|5@XBY|5T/*2B|VFKMK7U
M3X_ ^,3VD3//+H9G%/'>N=+/+715F;GO9D972GYM;6_JZ71E^GX8)=PAR8O;,) M=O5JF,P'
?:XRN/H"S=|2V:OR38+8S##+BG?G^H|(*XS@8. M_=(5%);"/H_6T YQ^<3^-5ORO+
:G:0?REY,\$H|Y4FO,49CL7VQ3T.8|+P1L MJ*:6-EP|O.5#/:G100!5;')|&9/M*3_6L*.:V
V|:YDZ)#O:4S?4.,=8O7 MO!!O|XIE>Y;:0-V3Z|:VB^I8/(RN08R@5GF@V7FQWS%P'H%"
56RS?'1NF>| M\$(0#I!@+5E=N9'W0"Q%\$O25>|?4A@>I37C#?/AN^90"P-1DOQ+?X^YM
/AL> MIT4;"|5_#";)&GMKG01"H83?=AK|G*7Y5S;E2|Y+P0NP>0?T?TJ98@\$_
M#J'JVD<:736QQ*//:SJ(*X\,1!,VTH'(|0.4M)1|S%1B@ZH,VX1#Q|T?"|V MK0T6C!<'-
-04'/SRZ'NKGS#+5(2Q(+:01FQKS/MU7;89S(M=TP(.H&0%/6=D
MN:4WT=+>KZL#/?2\FI|B4.03,K=V;HW| S_OA|P54|8D99W#S4 M-&K<|PG
C4Q|PFCO)_B3N=5U92MU3TWN@ 'W*O!|C5CFN@UL7T_5(>?9(\$
MI#.DWLEF:T8R|7F2U4516|_HQ3EY+/Z;H|@S&I8\$|PX@2/2=7(1Y:/E:|SWK
MQ4IAEU|Y+:-?;AOZ+1|W0AS1RZ0^YZKP@!6CTD^R)F>0T
M647SZWAN/|*J3W@QWWWFOYO_TH0U->R07DQK,3OKD2S(<<>?|"Z@%3Z/*O.
MA56|ICHJZ%1+^7AJOKAGT:JTH.8:L7O/B.)\$1LHY4><@+UH>+^%724WD
M=>RN<-(VJ2ZL7O1"QL6+/=?H&/(.% ^+6. M\$K0|9JH:
<#O:/WRZ.K/1922>9ZD|GKXXJ|>K\$M#V**V">J^=|P0#.#"V7" MSL,?"H|S/=+5K%T3*:
_#K? Y-5;#\$ E)!HCU%ZEW H>3\$AKL"W29R_VC6!=JJZ(>;EA-V=/?3333'
MVBNE.Q.N5(DVT'B)93I'YRZ):)YCB#AQ=H4X""!(N1?.DF_5QQ7+5|9?34-
MKRU&'GFF%8*ABP+AY(SP!6'79Z5"14@27JQFT3:HAWBI/N8%^ZYB.V/&E;R8 M:
M(XDU3G++I>2|\$*IQ)XC!JJ+EM>'STXPNWC SWF8?SDQ:S?D3?#T\$N3F/V1
MUU9DK8L2#J4Q>KK%I=G-|)S|3Z=)6|U/04KCWFQ;FS"M^LM*BAUD'SU_J26
M+WLAJBCR:4CJ*C|A!=/*+I'G|A-9K9L,@,871C_1((P'A((\$9VC/LFP_(P?
M:S&87B"P",922RK#C|H/5(6S"8)YPULF(-Z/@O*H9US# TOHG1#+J@G5C|
M6C7/CKZ"E@19PY0Z2^)M!L;B(Y0;,H.>MF+-2O:45?AG\$S7H,GLM|GTLUX(-MTF#2-
JH%;=[S0D\ (YMA9<8'?*DB/8AKG&?J(E"N.L+8N<|;-&%L349+|37
MB2R8:*TN/>%2PQJIRIW7* _J2-*+:3E:\$U!|Z7F7K VW^FJ10L-"KNE\$WB(|7
M4D/-1F/)1J5DL\4-UMM87NQ!N,0,<'8)V|T\$"AIFE*:O\$&"*?O|.1.LRJ%M MSQ.A|
R0W<%AFGPGJ;5'5C^4O9BD8CY**<@*)Q%<^Q!W\$R4QMNDXE(87@EM2
M\$1O+J9J>' _W+%U#'#"/+WSMEY MP(Z_>C>D|<'13XTB:/,33'Y.2'P=+|;
I%FENB092TX5\$O5J|&9!DOYJXM|J)>"&ZO3MCH=CSRM^ MB*5O1W%?-
FEA|4^/_I75I3J?)_ \$"SPC<6KC)+MAYY|O/%%GGBQY:4DFLSC* M7V;/Y+U8>QZ
FX7O)'L(H|4=J>GG67|*"^;M>6P-I4,-SX|>)Y;UIH"J6PX. MF|^-_I4-%V(RVC3H1FZV:->(:
(R^3X378_?EZ|LLRFEEKY1_|A+G>;G89KN MV#%9F|O>ZD4O1+052|=7
=8_|84PJN"O35&5|5\$OO&BN?:K+CMC_EA?"J20. M 6'^FM
%4R_V9|'T>M\$+\$6T(M+|%^>MSG+Q U) W@MML,6&:D6-Z*7Y)|%>F MFI+S 2N/5(U?
I3\$SR\$"C7Q52;B*LGE(^?:J8O^6U>D7E0>|V 6-
'PW^!399H(PAE6|:&RN.C*_|=I.M_U*AF_B3:0QK|TBXKVPH(7N^@Z7I!E?77P
MV4|W1J@O4SN(A!=B/Z30USG?@9,:|H%_#<'SNK:\$NOD-+X3:4W3_EAQ=KR|?

MJ4).0UM"[4B5.1%SNE]"_6|Y(5Q=MCJH4\$FT\$E5Y"M%;
M@_HN&?!CRF4:@|O^KH\$-8|Z(8: ^X&V%0V<|WC@+; >9V>D)K,J/K#T8282.Z
M@RT=ZI\W1Q?TEOSQ1Q@S186;S;4)YG7/C2|_P_.%S>>>'MZ69[SXPBSQW^:4
MW<87O!|)=*,3DWV?/D(.5Z&|I/HQ\$|HFULZ_1Q'R8@ID0P<-%(B-F: ^8%1#/#MHY
:/GLX^S+|3_5.US|H>S%A%E.IN4,&=B1@EXEHDL'F?Y0EQ'>(WDOHMS
M6W"N@UN_NKYH>S%13|L7ML1F.X@FU:XB6N+ ">L>|D(4IOI)"(C9C-_9OEV< M|9XS,
(PYB|;A"FTY|B+Y\X%2^\$+Q1^;22ZD82CSVOTSOUOC0X5-UVSKV4>
M6M26ZJ^C:UK7E&|9|OZJ/"Z|LE7SF!<;2.OF=PGN>6+@.^&6>(XC\,7A9|"-
MBK\$302^F1!SX@!K*+D7\YL'K?LY,,F:CIY?O<|H%_SNXWMC_+6KZUQY!Q@OO MC2
B|TI E+|JJV@9AVQ#P@NQ52942WCXIN>|S C31<@ "O(f6=(_CWZ.%I.=
M9V|LY^S8O^ED9ZF\$0L8=VSYMTZ8/H>3%FG76-?>?SST/,?K>:8!=O=KF;(M+
M6:9K|)' ^H>0KA9B|TAH|(@Q#MD8-*3_@Q99'7WC!:#=K@&JYYU@M!H B1B-
9PEM7D@C>_X850|-Y.><4%_ |U7,US>TPH908N) 37Z&V'D/!"
M|%D: +LA=N&YJ%*E^Q@O&+PC3^>>1Q 4WKTU|A+SV<2_\$P?MG.I^GVT+;Q@9|
MP>8WO!"J^D%(K-J'<%?G0-|TN@ID@78/?&?FR@F7TUQ&A_T8G7,S*=X<5@Z M<-
MW1U|KF:7*|I#>+&UR.5ULC|DQ1K5^)!%B,GT(1_@@::|86PMHP%NYU9 M?'.
(>.00OG;=2RZLF,\$^:6<5_M(>(B9B%YG?">*%\$9XH%9E
M"l/R;VD(O1SSL1S.3'+25?/I_|Y|\$+,V&9_G|8EC;1X;?03HJ%E|?-#NPQ_|>E\$N+R| MG-
8|B?2O7C"+G|RA C;7B=4_|84PMB" *ALM^TNN<"_A|+,Z3JVJ 2V>1AD
M(" ^FT)8H|OCT7+ ^?&U_P0B0C.%8#.RWB1F.ZXYM(&1'?/*UZ(|6N88LUE8YOH RD-
>L*Y3S6J5CA:8V,WO M>B&HK":V"2)_|X+1R_6&)CLBG55VXT
HF@'9+,D#ZGY.^POIEW|G>2Z.MBJ MS
PUV.A) L"B*CC"S';I*PW59XVY^THO|H+ ^R5HL%Z,YSU;-<+@=W>2(T>|O,
MTYX\VPJ9:0-+9";A%V7|-12X0(-%YRL@XFY|5TE\$N-FTS2NF='MT.+ %>&H MNO,V-
<)18L\$%/^"UT<7|1N)D', T% M27&>I+N;ZZM|\$4X5=Q6|W58U21K-
|W@AV#-4(%UF>;1FF|=Z?|>?&/U4.|KC MK9"/9>=@Z=|O|VS/(PAF,7M^XKC<=CAO-
@#3:#1&EOW?ED(R\BCIS8J=2Q! M+Z;\$=
(DT^;_*3WG|O"A4QU6X:0+1MC|HA0AEG1'+ZW|- '\%W*SM,7"L+WHA
MHC8!+!|@*V=G.^%L+-TH|&J.?W15V2G=);\$E3V?.H%^MGBP/P?E(,*U|P>81
M9\$;/#9%0R#)>#WG/Y101VS->K)O&|4),P|-0,AWT55O\$ M7#VDN/@XFJ-
:F=I5IXK|S'|0M(-W.&P1ZLH)P>|Z,7:6RX#V7:H 3E|WTM>
MB*:@R42ZG%6OJ3SD!>MEU>0QROYYQ697@KM &|GVBDW|VUX(:|0W-Z2A5H:
M74,IHO|!|*Y2L|"TQIW6\C4OUL:H-\$->&|%- %0QL!F:.5C3-[M|!+XYA1_1B
M4NOCF&S8^E.WQ6M>B*?P'Z+P0|?\$O6XXF|S'O&#?|V6:|7OL MSY18*O=J-
YC5R|P3|= \$ME!NR"JDH+2MM4LO/7JRK<1;| MH.D%+T3B->6*
|7^5.2Z|O"ZVY.|D3&>O3 ^S!S(.)#*Z|F-@D3TR(S<&4^ 5 MKN@;9A!P<)(GDN?
4VF'QH)='MP5OP_=HO;7 :5=^|&)%#@KZV%DK?, ^Z/+ \$E M<-(Q=+R8@'WEM-8/<,|
|7@A6LR*8&B5R3A|2X=*|I)A\$'\$*#DTM"|O@:P7
MTU,\A%6|W|YG'%CH='ZM|W@A4CV6M-J4/&E)JCX*Z;4%1.2K=K"./X,8';
MS8:*K!NHWKZBR9O1G|@1'*_=JUZ(>1FF@!\$&C1-Q|B|BNLUKLC'MCWHA!GZ'
M<.Y>KS=H|WLZ4#0|+@7XEC|\$4?WT:EIUS/P4%Y,XQ|1?6/7ULDN4__XMXC=M.>G|=5?
OZ3F(@!L|LYE62%AP0-8^,OIGP7*NDLXH8Y<66S!+V M*1 J^I#
<+WG95N4;.HJ%*0UL/0|TJ|54DH.(=IKX:H|S7JKT<1F'T%>_3A+!V M_:P0X+
(^V;|A5UR/|TNJ^|U66|CM'EQ|*_-/J+.|IS6\$+FH0 ^N>|V*%E"4A MMEUANPD+;7\$?JS;D|
&V^|)25_*&W.I>|!BRAJC6<_Q@JTSILOM+M_GD\$>V MAK|=':K(^3%%!C%?
B+8Q3\$%"GT_S0J'(O2V7<'I1-*+:2D!+3R\$Z7V*.2"|
MY\$/Z)&WBMWS5"S';MX|WN#%|UX(FHX2)Z>;LJ,JB>3U6^U"#>3&5=;@I9SOS
ME|HDJ?9O>R&L!+JP-4GF;9&_,>7DIJ:U>/NWO1"V>VBA#;UZL|HY|U-OP|R3%3\$9|?4
'J:A_V6M_Y&(-C.MC#>FK(0K4NB-6_\$A.|MY|\$D&J).W^++9Z2?9/F<*7)3#@4*8|
|>WQCEJG_9"&_.O>|KRNH^HQ8UI1V) M>S%5Y;R(QMRXVH<|N5\OUR1=0:NJ-
'G+7V%1PKC&|6Q|= /23\$% PV*.OTWAQ
MP10@FF"VN+&C9#7L+!\$*\$3L"\$7@TD|GF9HYJ9/2,"-XL8UODYCL;L/TGR2_
MVL: +ANP9^Y->"%&ZI(MY98:H|ZON4VV@PAX(;*1\$MT&L;+A|= 'SI>U8=_9R
MV:9G05B7IRV|H+!Q\$H05K==@X0DOF%8N92P S6|@?/M2?Q(T.Z%. \$=GI^|%
MKI^N5BEA)C0L.HUX.FNMG|H|*Z/?QWT&Y|XKD3F|A|>F&9\;KSX)B-J LP
MFO*8|4|Z(00|HN>\$++(K|J|0:D>GEKBEG^,%257_9RC*L!H94%%8U|^@%H>
M3)196|HMF% @?|*\$*\$XVUS<4!^ U=@=BU"W&T|2",|A5TF|6WU1XFMAEJ?N-#
MW4!|/3%7.X3/A^:@5|XZ+|;S8)0(^.*1;.:F+0|0|.KJU./<|;V|9^|J.PXL42:*4(

":-5HZJ_C&K*.-M>+3=*(Y^Q(I>C|^%<"LVJ-JUSXTN0>?
GHEB(:9LCQY#"W40/H\$S"Q@D4YRO-M(:!1T0N=5VH007+7H@J\$PMT:|=|*0C%)
/T0H@DOUUP&JP;<|ETO!)VEE/BX
M0Z:YLLV=ZCN62|\$*137@T%9G^=A>7#T\$[7GI.P#G"U#ZN.'<>+%/JK'T2P"
M_%LMNY;O^B%HI<*J2>.J?IH+8?:%R/'(D@Y@7A+9@FX.U40)D*Y4?*
(WO';3|@VKSHA8CUJ)Q-|NU_RPOA+"K769BN
MPBB6YQ7D8FLMK/Z<.XZ2%Y.@033W2^BYABX!K?L,+
MH71A|N+W+8|:WB^%TW|/);/E!4|RHP%EH|K S?:|%VM0UH1;8K>V>.T+|0-C-M"OX?
%.#O(04%"OV@\$5:RL!|0CM3|!^~)/K_&LFAV,%X0_E_V=|I=8\$L/WD|-(M^EU<+I?
\$;JZZY<" +21<5A9-8=6|K*=5@W+=|U0LQRS4:37+5/>N%/((\$A9T(MM|MYWX/N:A-
HWSNC*P"-10|DK-B1JX^0%FK>"SLM;M|U1;7#7?
FYW)C|ZNW.7'#HCL9I_I_O>|\$\$\$%R)HS RR/C;XQ)?H3YGG*>TS#1)6W8//3
M7JR%" +#"Y|@BG>0P"EX(7?4IVSA76*@U^7*D/!"|%Z#T\$Y* MGCRH9T(<#6|3?R.
G|%Y9?8/K0'BH|O>GD@<M):D
P(>2XKLD)|#.!.OGKW|6=HD|\$M#^32_6O|^#!4J%X|S4+6+0@;R8PJ**
M6V0061|S@OVKIF|UJF6V66IOM6P.IC+Z-|L|44\$B3G?&6L<2XZKSX M=O-@
M_|Q;O>3%NEIJ>L4Z9I'1|I?SR\$5GVF"Y|FBVH"!^,V+^6Z*7OMM|3,>FC|MN_S^Z-.3?
@"L1EV!#-V;|X"|C->.(KQ'#|H|Z12_6M|G7J?ZI=>GJ0W% M+#DC#V&TF"Z9|MN8X=2?
KQ?0T=EP|-_J?&&9# M8V) MFD>|\$.X HOG<5/N6>,K7HA5AL@H F;
(3PM|,*M9SVG#J0ONEU3P(G@SL#9 M:YIL5Z^&
|Z+BDFWSTNBBV0PNP:UH6|T!AV@;|WRVNCB28>N|@XR8QG=@DPW
MN%!M\$2\$)YHHE;TP% *S;<%7!-#N:D!=?;8U!W>!=:'|#"Z\$\$\$MAS|K" U,Z')
M:L==6/4G|)Y71M^N3SFD'J^B^2-AKX:O<%K7Q'R:'O9DA ZJPEI'\$&"\$?
21XR/7(AK:GZC|#^H="2' *M: +>.YWTM (G5|F|)MA?"|AD;+0#;BHD0F/#+9"N,>
|HOB:9?8'U6!&7\$1** MZI(TRL^-?A7)5D|X_V<T+I<1G.-J-
#!E*=-6&U#V/K%|7.!X%BM|-31X (<M7*>QW+ :UY|XXWQ%'E>76P)1%-
F;XDUSG08"2_\$UL!-'7V!+7KZ|3""Z%_ |M#?M" 7Q|E1+" 1\$P<^(QV844Q-
%':\42;AWFZ\$+>D;DL|ZM5JFW/^+&EN_-E MD!
WXW4&.8@#+R:|*,-(2"H22.4<,VL!EY|.NCPT;:DEV=\$OSULFPWJ|MK>2
M*/SHQ4H:A3Y-#MC20Z;?6>Q"G;TFVRR,%|,W|CGM(.7!W@00?IX=3,"+U>K5 M1.!U;D:-
V^!&265\$+R;U:/2TO>4|=PFVZR'E QU! 2Z8.J#B5\$?=*P|X|F*!
M:N*W|>=5XPNCGUU0:JGCM#M\$-@QH4^QYC\$_5J0E('R#(-U \$J.OF@R_9>AP
M95OK.2-/R3)G'QS!"HOG#(NBTQ ^J1MV:-X29OE6(D3'TO%CW14N7S;|_|E|
MMR7;611|)%=VS'X>>VR//>,39QY4MQ|)%J2|5KE*/8YV7#A8)2;0I4L-
+=6@ED2|C1";AT_GNP_5O)LS/!ZD MP(N:?,TU898R&. |1@"0U,B-SL?
HH_630Y(XYU<00T.5A' "RA C|@"_ANA) MC<\$!OJJ7@\$.:\$51#%-KNMT\$NS,="V?
ZK&@&E(H| ^H/2:'9X|?;U4(IX MA.Q^G_WPRV5WX("XCEW;-|8 MUY6T
P%UB8(R2AGX0VH)2!AB!+JU<_|O3|@R/G(=^ |3C3AN!8MR5D"7R2A# MC3C&U?
ERR4XIU">9GE#LN48W|(3S:CJ'|B%-5^L+^S>-<>66'LO#E&' R'(F|V MC49Z(EV:Q&8:
<4@YSY2()M%O12. 4FU*7-UST:X%X J:Y,1/P:G:O7E;AV? M1,|_|
|W,"9#LB5WYR(Y^|\$_;*>UY&(YDM.-N-52LJYNDR\$/.88;<9Q&\$D7#
MZKP*@N@;DN7@WV|CX/G4ILY=UM&N@92&Y4J|<6QC9C!GB6G:CT=P3MY2BKY?
M/%KH%2U+?>9"T6OV|CM 3=<+6R5T803\$5HI+HFFV.T8P+)-%|(
M2U=W=?,ZA289<2<)ZLHKUC0-8N=|QA7|=U6\$B(Q"=;,.11!="98KG3Z->
M,.'A>HZC|V3'6H?8G(5QM C!W<2(FI%BAH-YP*L//U!)SD01(BO<^5(P8DC) MMXP
,7S0W2BD(=J?RJO+QR K*N(2/R4.2CV!UP#E"EV>-XT(V|H0J.WYTJM MKH<8_#?
#H324PFL"TXPX7B7&OM455<;0RYMMQ&\$9|2UHD BEEN!"N9!1T4:8 MZ+^Z-"VCW#
(9O<*S5:I=EX=2_4K6X\$*JHFL>5TF4N2+/.|U#Y1BU\$1+)3 MY|P.)=J4"B:G#)+D\$D8
MW9R+'P59N=121H"A;/%|S8-Z BDK7I0QWH@#D4*#7D (ON4-XD6CB2I3C#T6
M*>*I3|24\$0=MOOR4CG#A((?*.UB_NT02/X=!8B#)VO_,7 I%93)P|10'ZJ;
M7N:BX@"%E92|?H(4|&W" _S@Q3F9"Q50\$8@|H<|73#Y3J *XI0(J"(0XPXFZ^O&YCK'J?
KQ9I MNN^1/MJ(PZC.G;XT15_P@BP.;OI5IQI!|C.=|A|0|10_,^,KO+E^@56=0(
MT)1",+P_-'%|9J>PB)CTS)VIG60> !R*/H5UW,EX|TV&VCPK*|RJB@|U3;
M6E1C2PJW2|N3.|R7C, 3JLQ\$'&#\$EB|A/U6O&(*)!?,?8|!T<^.224;BH+K M'58R
@B(%@E9;45/=|L.?E5C#A|YWSG(JNY8K-27L)#S:>- #-66|!\$G* (
MX|OX"J%3^!;EN;|7|NGK90SH2K#O58U!#AU1SXD|QB\$:S9.F:/%QD3O<|.PB@6G:I8?;
| (ER.>NH5=%%Y^*K%OWTK>L(?) +&'&KC8+?0FX MWAPC#G;)1?DMBO_
/=1=0(YB(H|TXA!"J<%(5\$|4ZK|ME A9FAV7|)(L%R(M#)?>3QZ1/X3761E##?

B.'4S=T,,N'AD\8 (N\$|T+|FNH9_G1DF*,FF#(*|A MF8?
P%RHF|D53S,Z"PPX8)AD1ZPHTT|2&*|JR|W|O>.:F|/:03VE@0(*A@B6_M
J:,^D@C#O\$"3H53:|~#|= 1C2+;~QKGA1 CMG@3#+B:&UG5SMZ2,Q)UIYG MQ
\$OM58P=T7|B:PH-DEOWZ?.1Q1&Q_/W^&2WT7N%)Z%THW_||?F)O|0 M"#Y2\$'K
^PL|X%\$=U@|\$JYA%=EC_\$8)?O,8&;Q)!..@/O=/GK_W@,^WB'ZPU_1
M'[[|2+S_C3N#H@TVK148.D7GT-KO)"P88%.7ZM)P1<*>:C^/O*7_DSEQ"N+@
M7*^+3=A=<^3(&|T-Z/>A=U?I%TC89GW?%J\$|U_A|DL_Q W3|HK,:~BBQV1^U;:9U MU=
|fV^A;R-MJ9:2.C6+BV<38XQ"Z=(JC#->OY6-U_N-CH37G;B<-
&I=="P;_\$E>'.T@F58BG#1Q9'H%SNX%|94.AU_M&L8,@AQ""#ZZ_!G?HKYI47QFBJ#74:-
ND|A+V=I@?=2H&|P_@GB/W"UQ|"T| M(-N\$|I(A21X|+D0/(AX^ZP-&I?
N!..|@N)D&@CM6PT-OZ(;4Z=EQ,|2A6+%B"OCX_P"=EIKCQI(C)_?D
M>|JTFPUU*&&K52NC\$B/M";LF_^H>..|2JN,:44^T(|:ZQ6%|7A1|(|77_|^
MZW=_^|O_.D&D0+,O_X"|;TL@1N)3GEO_/1;T4CR,0.15P
MM&R)!61^_IOMD&D8+TNX_&|7-KVTA(T|H*FK9|M@3)3W;#I&D7+L'R=|O!
MPK%%EU#ZV6XH40W>)7Q^L1L^1-MZ"9M_++|IF?) +V/QS@4W#2I!8*P@W'%XE/*P5
M>"|I+A5V:++|\$C^7R;L-O64+%V
MA(ZU,B|)'5P"Q5D|5|0)70+)6MFWX>HNX6&MX\$OULI>0L58\$9KCU2|C8+@>!*|2
MAF/TK*^=D|QAT!5I<7G@"0C2I/R7:P3*)6T3U|4HKI22#|8>JR1;<_HBBF2-|1 M-
E;DM?E\$+|/G1M|Y0^DHF'>"|?D79?K;N22,UPAZ^&DCLVNR*ZE|0|HKR M
!_N+0A,U4?R>3E+D6=\$_V8;E78XNZ:--F7|Y+
(WSU\$BNHO,!:91DX+ZAE/'Z9#1>@XBF7\$8=K_\$ (Y,:+K9TWAFG;
M!*60#|?:I)':Q456YPP*T\$BK5_XO-%=MP^7_VMI/ #:006=|E9LYPJN1B\$9 M)WBC#>
L@,|2@-YGH5"5I_0A:9J.|A=H<7D906WSD?EL:=?"F^63IY?%NT6_M*9U(?
P:D5M&HKD:0S:~GY\)47,4)"C"N?TJV_.T:EWGR"G+(JKER4":_9!
MNA|G:F4|9:X_PEE1!1%#.ELES7:-(&"*|I|QYVD|T@M(3|\$7MEOME:|?^>| M/NU, A,-N:
<75"5TL_N2Y+6GA>ZH.4>S(8@6WT|X_%
M.5H4BVBV@\$HJ"J7699H#9"N#)|@8L8RF(G,2C86J4V0@VL0)8Y B;-ECL)#E. M2
^CSY9(^ (P5(!06*:2#<0KP_3|K|\$D+%|0(|N@)2U?,\$*+K("=++2:44R6_M *F;:"&.F%:
D2|U\$(./+(*-A"9)#G_K8/7CK&\$E|SKR_NEL_YGT\$TD,WK,"
M:G)PHD8+6@\$K.G/GABU:!!!?E4/CRQ@|J.L82/'T,7",FT#G#1;YP:|6@%!
M218O&VEJ|0SY_|-2X\$10,S4).'(J "E:>Q_P
MF89#|5T=8M'B5D|2#G;T4'2EP/HU!U8(|N@1V9H&,P\$^3XYXMP*CI*T8Q_#| MLLBM+:
29F,B20:6_\$_2>D|(5AT\$3*9)%"+>1H&D|BMP2HYW,2)_C%KG,JE_M8S.2-@8!GFDXQB?
(%M'-&R"*XJ(OT/KGK&E/-&;5\$G#TTP0963D%|Y=2\$|L MYK<=Q#7OT-Y>H20"(7#SCO-
2Q|,I66@E#-6&4A!9GZF%L_,P^P-(??=J6L:
M5;1G6|"UP3'A%6UBO&,/&|&>08S|;U#.)CK;E./EO41667J|!/@G|,2.U9IE
MUG'629+):'688=8Q;AU>Q,|2G6;*@1Y|^!|A|(|ZP_@CJ0-GDE&'87(&Q@2C#L'G"
|Q9)E06EB0=D9DF'\$N0:%@SS#D&DUQH_MHAW9/H|0F%-
_JB66|X|V8E+'FZ%'=DU)\$Q;%K4A35@3%-H.R(F=-*?1*OFA%
M,HA2R)&Z5LX|EEH1^"@:E!7|B%U!*"JK61'QHP:(U-=CWB\$*'H'7>#SF|396
M"3C2VZ'6;SH7Z_FIV5;X3A5-D"XP+_J&\$.:#&_F3E-E8".Q.|7.TKG_CF\$P_M*0\$W@|DAD)?
Y_L@DVA7I3/#7B7J8X=|&OZ190XB#-38Y0|'>?:.@K:&:32: M)CBPJDCAY6V<.ESK 38|%
(V) TU_..Z|('F-KK=FC|!-|H|0&Y(RGRZ1|JC
MJ\$'X/X->&;K+2FJ/G<1HY#C,"9GW4!^CK|H""4)Q(D=M0M;=81.(DUC
MB+99#._|%FHX>Z|/F#A4:9.CVRB_XERW:(L_5*(|0|YRD#;HW60(5B"2!_M"N0;U#
|Q#MW_9GZN?|X_7"P#"|_4F\$LLH/^INE: XCU2E9'ZMUV^F*(OJU'H M=-/)\$ J%SQE|_)T\$?
()_?@%NM_ ^173&OPRZ.6B*+Z>S!|6+(@G+B"Y_X!"1!1#_M1=&)S|BD@C)
D3X989FCO#"F-C',%S6#\$6ZVN-;*'21Y07::&W;?P(IE^77
MQQ@2|)H7GT@0UJQ#*+3G=DVAR%?*5#/NX-)-8AM5;/|%DM2-D_BNR" T)K*+M
MN&6ML=+GR#H4>:PQ6|_S@RREAL+21FO;_F|_52V#8@!\$?VDBJ9?
^:_HDK(B7Y7DVZLY7NA!|"F#1_%8\$ M/)S4LP:>CQ_!H(>QY4P:_@(^B+J6?
=UN|5|. 'Z#^IDR+34SQI@0GZY1C'O_MJB|@UL|AN|X:O*C!K^P"#%-U9D+4K1GHSC
MW_KH2>)8U2|S2\$+GI#D|P?5O!9#\$D*AKE,\$0.:|&-AH2_R(U6L&NY%8VM^*\$_M1-
B5SLI!IP\$#+JPH&"P#9T)\$AM+4UGJ?D^E!J1'X,4SRZC012"S01&W>ZJS0
M222&9<0ZO|8#CQ(1,V*2ZN1=(F|*8%D2:T;)I_DXWM*T%E2X:8+Z.CQ0B7P_M1E
"#,T@KW6.KH:/3BR1?+/+7R|<1Z+5#%N|:KG0*F8\$F9H=Z"O2EQR^_WZ\$
M&K^C&@_@#N3_Y258|E_8.*|0(W1WX=Y\$ROWO(V=,(\$;S-8OQ#FL;^6Y;F|EK>>T_2?
L/LP3A07|1.J*4G3@|P"|>|E|6_P%7U_M59T%>)MG*O=+

05KAG%846,>RFY==%7#9"RYMY1OCYAWY)&ZAZYEDAWOL;#B
MIA0@N(K+MB+P95RJ4:H6W\$W"NB*0/8\$<\$T*H(+RR?CP=Y0@T:I'=T=V/GN M-
9EW8H:-EL'+X IY34Q?A^W,>(F" HQW^!54TXDNXK^E;YGA#91B""0D+=M,
I\$Y^G)BZ/LA%D-CCS6A-0RS"%%[G'I\$V1#8E;BMDC%7_I&F4-MM-EV%5HG MYV_IL^
#@>/6.?GPS6;2 WN.1@1JMY.E(%%KH#IXNVYVS' L+\$V"8]^%V/OY M-
JX:J1:"EJX)5N::54 ;KI8N\W/H=3H3(E8LCY7>?\$-JBNE=Q_@-CU\$VHEIPX+F79H?
\$<*"SLQ81Z,,4UKJDUV\$ M44[P7;TYV/QW1"A3IZ%EB>D@2)-
_CICD1>#!N#C4M6@@@3^K%X=>P*F@8@+2 MLY"&/='(0I&NF3I/<0'EBYG@!<#!"%0;
&+4(2;/4:25Y"F;:"-+8L/I)T M-
E6TU;KFB79ZAVOS33LBQIGN)VQ/7V(*9Q2I,TGSY=_KCW\SRA+1 MS2SVI<;%TOM)B
MQ^@#Z4:=2J%XR@7>U(E3DV I4=*+S.FLP#AA!L;OSUH1=:B /\$E"XA"PFSY1
M/EI69T^<\$L4I|4.\$4AI81D.5>T_OOJ,+7@WB=4<3AQ;U M0#C(_&#('#N\|@' *
(*NS/5(CJ*6!S<=%S*MF00KZ*2C8Y/SR U'<16 IH+V5M
M1HNSN4IT1#K8K3&M'<<I@'Q!F(0H |+8: 1F^;DZ;<&ZB|^LM1UT5K7I8H3
ME0J9R8T4'7D(D>)D&,'L,J I,%6F-%^+;:@8FBYSULG.3P\$T;>)I2UIJ|27SI2%
MNY\$C+DHL8% YT)7KHA:ER0MP@? .D"2%INL,F49X|QQ'I\$HIOSEP2Y?RXW
ML((<I#T0/V^Q0X++7GB4GK8A3^(JU_M*:8AVCA!XD*1&,ML_<C>*75/P
MK4)-5BMN*IK)A3%#Q)FIU/N G:"\$J76X2Z*CIE\$P<%P=E*JY:4H>)A I\$D M;V>+);)
<;EB\)<08.GL-S|I?;QOF66Z;R.&76'4.!.Z/H!J'&R;:2&W0_R M*6V
N^G8GIP(FHZ+F<;9'^#>X:7VYRLA33:U4I.N?!. /\$;A?@OB(I)#X%|O
M(67|M#/RYQDDHZ(W,80?HI?99,_1=I3G L;;J'@+7P|1G")8Y\|T?*8>"2Q
MN1IO*6^1C@ (R(<%0[Z4^2M_37_3_K8>*TEYZ\F#M:(1(U8%O=<)%FNI(@PCY
M.89LO_?N"K-'T4A^%>.)OZLD=23=5S,M->((#;T5D0U(F8IU
GW*/N1286<2=HYY\$,47X,J45+GQ;O&89B,B0;QS|+B!G?=R5)7SM/7 MU&:W@VKF9G?_
0\$=|L&+DX)-B/(@<^C^DI;X|< VQ3*1\$5L20J_ ^#Y61%", M\27MZ'V1!2&A.I
>D;Y<"G<,IKEB5"XM,, "2LT73Q\$&^0MJ_K_9P1*IRY)Q/ZS(VI"-&6!X
OH|4Q0R|Q1WZ!?"K./35009%ME4 X MHX;(WDV6/D7I_P!L B P>=D5=#:4RAER70: ^|Y-
4GJ4,+)V7,XC\WT8AMOV B?=-JF20H5N(CDW+1*
MR;*K3)/|#!,!O%+L1A9V(WH\F=ME!&2F\$R|\$?X|@VCJ8MRJ"?CBUS\$2;O!1 M.?
+K+SKO.W?)G!_7#QNX0Q"%\49;B&WWJ/-&9QIHHEM!\$=A;T^C452*##|7 M4NN@Z-
!7T;:,!>AQ3L2T3_9O>;\$|<.G1+9<_3VY"#X"58XO/- M"-
&5C|OD=TT@A40J#7.NIT.:E';0/8R2GXX_IZ)'(B&.#2A)PIJ*W)?N(9:U MS"I6S*
(M*"D7\%A6T^D6=&@%;@X9FEC%WJZ1?':_4P*Q?O4)V|PW(#PG\$-
MKGYR5"UL3VE&U.004Y+ZA^\$R5K2=4"2%,84-*P"1I@H3C(=D#L8QV8I"&57
M'ML(NK4"\$|>2N6@NK"&,*"RH\$;F(L8J6_+XJO:@Q,*E!^SG8Q)PE9FFA.R
MA^@VE480"TP"JR)YBT-&G M)9.)8@6"CB43"&?(6-+|4Y%XH"PQQPID'T|Z:"7Y6-\$J5%:
&#N-:)!+,,UF
MHT:VD\$DZL@*L'24+Z1PH*QC%:";'CFE92B_!7&E9K3%"/OUK0##/WD3!R3"S
MHE_VJ/+&,#-&PC!@|2I29 =FD%3|^RLP%OU6AZ|I?"H:F:LU+S# MHSKOA
MXJ@|I>LOPT#5R+9L8PFI_\$Q**Q!9#9.5R>(I*ZO%Z:| M='E=NKQV@?
G4>|Y,MM/HTEMWZ>DZB"3?XJ|+>KH:)|M(:SL6-RQ=&M\RP;/T M1>
(\$,B'OT*&CCVH%:T=7|6I M;C*70%SO*GC OWQM|9JFT'&*ZTG^I(%X(>_W?S|
_S\$Y|CS=S|P'@)GW|@2 MV*-UDNU8C=>NIOI1RXIH_N?
S2/UE(,3\$SM*4/T|JCTF'Y0<%@0
M)1F.6/*3S>ZY>E.A|YH=CTY\WNQ>_7T(0>_B7(L\7PA"|CD*?+=2|7(:J#V
M_GF=,>D3|/6W)%\7ZY:V\$/ (W ;T!4*|ES1!I^%=:JRS6"X;CZ2#:64.I MNT M*)YP !|
_Z>8U-7V>DU<^A;,:8EBUP9ITH@\$3)SIH7\I"#,"OGT"TCYW3
MP7=7,7"F1;#%*5"P'RGTTET.|HK,UFHN9&^01LO!T,TA9\ C+KYAI10,V=KJ_, M|%,4>=_|
(,!9HWE1WV9YB2>0_C0M@J|A>9*89 M)-_IAOE_?A FCO-WS@!2F9^/0"0WH'4|8.):=K5
Q3V|>M%3#: ^ZT?0?>TFD1,|JQ|%M,&;R-6,N:YFA? M/*HDCS6#_-
B74"4WRHEG3U<7X."\$IHD|F/F>,:35&*2/I@_4S4_I@8S|Y'\$F MF4%EY&NH41?
G|,G,Q38Y>=AVG_1TLTA%\$ X/6=0Y2"KQD&\$'SNY;-3&\$'.W MR:-?
R47,H.=.E|R,8Y0!W=S)_Y(A%.V*Y\$ G6(<0?IGFJ)E>_0I%=5/F%/V- M&R544/8<_A7Y(*
(^6MVJH:~P9|_J\$?@KQYV;2(=|SA_P:@Y3&BS6@1Z,? MYE SR(8,RC+RB7|N=/'E2O@Q
14N0GN+@?#'=CYKC|QR|R8-*,@@ZH)|Z("J|A|TZFP T3&:-
:I*Q<5'O2M73UM2O1XO3ICCL!X70H?,ZR MHAS/HMIO46WT+KSOF^J^>5R@|ZIF|
8UB%(K,=T7VG-_)I BFH(/(.3N.T M&,N|T.);7_9/>_)IPW7Q@R:.;^*1.7V|&03,NY!;
PGZV>=.)5N0|BN,O& MA6W!K!D:0XY:F^+'&C&FF\$%|

I=#;'EEI<7V%>S14_1"3J@V=+B?%ATV=|K M'4(KD_K;>Q(0M\5F&D&/?
(NJ::SBL!C[C2)*X5F+FIM&.X=5#DT%)QX^Z'H|?Q<0SIT/7_]=*4(Q MN4@*6FD-
+N%SIAE7U\$F&S,57,(6ZQ2Y1I*.*Y,3<)Z%^2:S7G5C?V-HY_ ^" M*?2|R=H.JP4USKU/4O|
(*996BZXQ2&.16I(FJR2)4,M\$X*'\$O_L//W\$D,9. M4>(\$5[%A\$]+Q=B\$AOR,C--
S4<6PRW)193>35&)5=4?
%ZAVD+#L:#!/("FD\$Q3JH>CR(P4Y>9UA|AU|F+496A.:841JVLY96&..IXQRZRZRE,4MF=>7
MCMH7@/TY(648Q)@8H3J|>00|?~?W'R?@IO!U8|PR&.W"O\UV>5!64) 4/T5
MC1\$D!/Q\$|T3E-3X+@:3+2F9P_A|5MP4)R0K9L\1DK?-F:|M@,|O=-)O>GX.4.I>
MZ"%4Q.%WO*,)3#3@UB"JQ1FH.JLD|XV|@!G/=8]&-DS"X#Y22)\$1IM-%&=3>|. |
_R@34C!VH,M* M:BL77_B_VH,3|Z,:S,4Z2^=ES&"2(@W=*-AJA?;6K>\$=EQRLT,
|HL.M.>W,W MWG/ZATWQ;9Y?%|+)-|V7U8T!%0^ ^-!E)KZ3|ZD4Y0R|H@|!L.>(K"
MN'8,-+|(CWJ;E6J)*#/B|E<7-N->9:~8,7 M+=,*3<57S&;+;)RJ%K:W/%*?
*|I<4B48&%+^\$|2.1><;T^'R44X3O_\$OHH M-QK7|Q,S6O=;TP!0D%D"WOGFE.<=X-
'YX4-,KE+BLY:/@H2A!\$9M'E4>|H M*(^-,?'4Q"= =04XWW)_*^PD0T*|^T-CA2UE%
(27>LZ&, +O0Y/Q9_7XHC6O>\$9-#\$H#R-WGN@9>- M|MI35'TGWP2|@KZ-
O2'CK;L*O3L_R%+IBI!RJQEP_%68^A|:G/|>|_ @<@,G64_\$')|!L|#!/=PG_<-
T<_,O7>|A*TC,1H*V?%3?\$/3|!M/?==>@2P4(9 MI\$|@\$"P4VZ;SX"*DI\$8A-
K;2"8H|1|M1&KMADA-YK,:BS,=CX1|C\$E-|W*@/_MQPMR9!
WV/QUU&U|=C|8W:D;JS^ ^_@0HP@"U|^&RFQER5=8)2,Q)YGIYA6<
MRF5N!O,2F6G>L=#6F Q-9*9)O8B**LOLO_'GJ:6<0K^Y|,TBH*\$_H"3!RK=
MS*US|E,G0&Y)6EM3ZO|SY^K@/%!= VLH0#0IM-,29HGP|Q|@=OT\$/,=04;K|
MF!2_)C_("/?|0|A9D@/?N\EAS@@2-9A"N+0";XDH)2@ ML-
A\$V1#|8/)+>|D3QFB3^3*0"Y-I-|5;DS:6|288)985FIT&IAOZP0!|&|. M3:E*1D"36-
4\$P|*\$S\$V|B;+KS<"YQ&7K"-S519^KUX/%|+LA1QW%W#.&*PR*
M9>*Z2FHMHEA.B;E"2L@?UJAZ6_5YS#HDCN9*N13R(G@|9@T0*:|)%6LHOHFY
M4I602Z;>G|E_)DU(E&|*>63U?|HV_\$*TMM=@|)%8..V\$?S>7QIWA+9LVL.CCJ2GA).1F#
<(^GB*NNL)WP(Q9T48C M@O)|-(1JO (OS|S9H\$!D7@DXLK=IUK0KZ+JDIJG
NS)7G)*V+31|::NA<#3 M@.I^NUF#HH_13S>"#@\$R\$ZBJK_S0V34|:QSL\OYQ',.SAE=?
FJU8/(:HO6(" MH3*| |@*;>-R"8CO9B<)C,"SF!\$%LZZJK,)|QC'H#U&49RYXV3|H9-
8ECU1@ M)U7=&J(TTQ^7C"2;+5D:5D-;M9X!U1DBR@ MJ K!5|)%0A6'
**AM3,*F0^"Y91?|X8 MX3YI?Y7KH%AL!5!.72=)!KQ5Z*\$_\$+)|VA_B"26#B992I75A0T6R?
>ME7|")#Q>N3 M59K&_EN&K1G;Z|F9UZ|GS%W2_7!&S1;,. "E"0DF@-?L|7?@IMNHV"-
L#7|(@|XM-TAE?@=6U>*7GV8HBT;U75!TTR-G8^TZV3'(KL|W|G"?A9_GYL#?
@9_"UI/41QBC*MU^\$|5#%)A69'^:2Q +K-8J2(M5G|8G#K#O>/P\$E Y8=BZ,#@Z|
A|=2M|-SY2+@*@')WM9_ID+(^|=S FSE MA|O"J|\$D.X|'8<8>9@%JQ/%"N,7S""|)?
LM8WOH\$96%Q;C8P7Y7,:<8^YY9?H| 3I^;JK|D8| MR<- NOHO&
|HKYG,TPI:H)M@QOGF!\$"4#Z|KD+BNQV;W)0%\$54'S9F9;MI@U M-P|^ @&3OSL+D*
|U GW_F4P/NKVX(2?HLC|Y@?!* 8MWAYF>K1T)6.GV;D MB"D.JN*\$ BJ-/K(J46C@J"-
&W.S_\$3Q6W>*@4;1J04B,HC4 A\$MZJV'Y8\$MZ
MZY+>NJ2WFO+&T|6R<8*:9MT)809'69=(*ZONM(>(IHQHK0#XDIYN\$AL:69VG
MAAE:E00_PONA*9;1JF04|600K|TJ\$^/_ZU4"%*PJ1S%!,5DV;-:J^|3|HW 0
M|2!0GH"A4F1Y|8|0W6U5_M:2|LC|1K05RDL?X&8J#WK!MWS<1'/UY%L)I>E@=A(K|D(
MY?5F'@7*.(!|"X.:|O?GJ_0S^# M>_B2?:Z??|#/P6/_GN;HF_.GYW?HQCW|&84V9-
905O*\$F.3URT^_4=V&3|9 M5;0=M15QH9;IO/&6:66T'RQ
6EWY0%HI4J%IFH|V!UX!T%T MX6N(!,;LU@SM"/94LW!!%WA-X"\$2'BT=Q|>_E
;LL>/1WM*>NUY)F6'4Z_MZ,55,XVTOCGWU,HN&FD;H#Q%SXJ0*\$9VT+5O
N50|4\$#4HARRK999_3V.H/6_M69\$=K1R)Y>YL"!BW,-CH.*HOH9-Y\$%
(H4>|ABH.!|)P3NKX3K,=^CL:/LEH MJ=DXN F*1E+>EE@?/-9,(X_U|
)U")\$;/\$;)A+>2,M|,5B=K:1.Z=JL,'2H@_MU" L|;0C_U^!)Y3+F|(G4CM_3X#|W3YZ_|X#?
LXZX|^N'/^Y>L|5!+2,S&* MI?6SVF_5N&80|7T7H@T|4*4|2%|1%+PQ@#+L4;H>H;W?
8I"^%=6L!Y|CK:C M-';#C&\$BC|47VQ\$=CU#.2B/W#W9\$1VNIYATD-<#%-Z>8|^5T\$
J<|0?9?*Z8==ZP-1X9|)%EM_<1"-: MEPCM@>D!|"Y_2<0@M@)4/<<|PAE!42F2-
\$I"NNQ@VSEUAA7+G(^V')1|7?M M6"|0B2<7V|7@#SLXX11| WYUG^^(B7HR
M,Z=P|H0|JDEE!R4;UEX!'LGR.T'A)>\$, *D&RCM6A5K?6\$B4/(I-C,R"@T.NP^>&
|BE;X3XW49A!=K/. MJWPTLVODYYMT|Q7@XF@9X-
U&B4Q/2|H"2N_G6KZ@|)%PFM|DQ"W)CK9_@%H%Y M?|>'(KV#&(7&6KWI%
|:W=Y0TO\$5,UQM%K>*'\$C6_%A%4|H|Q%?.|)3L),3|K;
M8P7V#4C?/PR3;60<"%40,%/GG6O.%L.3AV#3-KN6@/ANMN*, G+LZUVT+(=

MGF8;EKI1\M%FAY)=O+=6=&'L@YE\$ACH\$U*:(GOVY@R'\$. \$4, M!'+C,\$3?.,+f@0<8I
('ZL:NXFBHU#HOGC\NO0D718B,AS\^43[V#D=?'<5-M-Z?
DCM\$.8L:SW\>HT3#\9+0K9FC/PQ2-0X9"F)>Y*;Q?\$_+BT?BCALU(#I
M8@?)*O2*/23\$. 'OV6+7!74GBG,L/4*.:2:/T-;BHH>NF1%=61@ESRJ@H<#&\$
M7(G1"2@ (2Q\|H\!OKD)*M;2QVI#E^*N^!+! MD17\,@0MF5X)
TPCU=;C+4:NUVFF(M\|AQMD^M3^46T?^#\JOZWQT0RSB2DHY_M_SJ\$J)LA:GW-
3J3QR8ZXDR\U^TQVG^J\$:*9.%4?HQ1:Q=)7 M\$94*;H(Q9<7P/!\$N;L.?
@I78RSX+.,VN9/TAVZP-)S2<.,|0+F8?VL)5K^X6-M%I*Z,VOPR&A-#51JH-
NLP22DFY7P86A\$LP921Y6JUC^\$B8:SAIZ0+EVB6%/% MFS5D9-
7%*D)UTLAF#4VI!Y&K!5H1*R;S.#)>B5G#2IAJD;3RV4-&B. HI@ K
M8@E%24S\+9@UV.2\$A.;M9N9M!SJ^<@-#@="=|2|5\JD9?L
MXGZRJZAUMP1!=O1#9P6E+/Q!NM.%,G(I#CV9(HAF!\U('&0+UJ|L*H3#*+A*
M^KL4Z)YGRPGJFF^Z\|R1T\$+:%6.T\GY#CZ@ Y#,\$:/P.FF8OJBH^!+)-BID
M\$JBOGT^R11)-%)P-MYE#5Q7&-M003104FW!1XV^BFW)(''=N/2.5|NZRBD=4EP(G=
+2!.PCR(),8 M4-37H+(XUARE-(X0<70>CH<;=!:0Y& DZG^3D,3:|:?
92&=\$6N>8*BjXN88@J:>R\$|H@6L MUGU:EB|G^KFE G'G
ITLRYL53&F)=5U*G)H<-|HQ|5F!93T%T)8Y8)BB|AO^WZ:.,M/BHM+)"MUS:C\$)-U"|K-
AX"?0:&<7;4_7I%|H:&O\$R=+MNL-CUD'478B3ZXRO&6+|H_7G&7'=F33)_C4K8-
7EQ93Q|("U)' V80_CK', MND*OD\SU@D#_<1?IB_5DOJ@LC@HX^*UHHBH(@
RW,WC50B=(QBK3N\^DK\ MJIKI27-!Y7F#*,EB4\$!NU2JXFV/3GS>|+8'<'M
9J1U>%>^G|+:7WB?-ZJ1=8_55UM16;-|X6WT^L,!(X:EF4D,7 MK|Z=
|.U@J7S|;"^4J5@,M#H.:F@*M/1;(FGFG@|U0E;BE|3)TY-(M+!?(+
MP(Q\$=*VE81_=.;2|HF%%H)(TCM9T&YN#^ZBF<\$U;(%=5|AA07#QYW?AAE"3
M',27G|LL|Z'7@IZ|A=B=&4R28^+4.#H)2;|AQ+&?K-|A?^:|/+H!9901M'B MNDWUW?
>!/7'AA)5=VD37!6^\$AT3_)9(*V)P5ADI30 WX6> MW/,<9-260N-
J8=%95U45@O5%*M55=5.V!1?GS%E@-EZQF>J6Q@ (8EO4"MTR MU*.:?(\$TE?W+PL
)4DC&0=HC|<7R&4E-J'"\$JPD%M#V<%|Z,9:>|>+&\$H;Y MGCU^VU%*K..)
<^UQVK?,V:E&J^CHEY4!4Q^C-.|Y.8Y2\$!UJEUX\NS5\$^V5" M'MHD\BNCY0C:=WB
MDW-DE^60746?A<4&*V-1H0QX6^>PBB(|N<7?W|V?V=>;-.1%&>|5%HJHD'
M^Q33K3G<:=H.M(8<>|>;|JN8NIQ)?AGEY7T=;6.'0^@C;#Y26N8=NN>!:9B
M!F|8N6YVS/+="=|;\$9QD MAH|509:N:F#2,JH5 #EY?X|QK++?&R|
)^9NSQ_@Y:%J34IA^6L. MRQ#5TD#2@V%HJHAQ,04T.|Q00|GLCRV_HQ+|PQ
Z=7"/6J!%Z5.,%'GWA-J M3H"<\$W2AV>1X;_"Y6
M&MI:%0;HGF|"R*O@1#;/8;&^GX:65DCWO:\$G3!>6U_L#% 9BAU/?IJ&%"1
M6;4SBK3*OP+!JAT<\$*UYFD!&%%O(B-18\$|WS4R^QH|M*7"?X'^#0'(@J
M5M8N*UH@%LO=TQ/D-|MO(' @GZ,P/71>I%%)P(A*//;Y\$2&)1K3>GH,LT
MIMYUM0D=_R^*U/^RV)*U2^Y:QV4 "CG*KO:F,=BRMR9V+OYP9(O^(%M-Y M*Z-
#^\$:\$92@K(+RX1Z>)|LVVISPI?U#C_04B1BUM*+4QS|=2*1A/C0367#X?H
M03%YH/:6N@NH_KQ_51RJ D)_ =9?YNJQOG\$"5"CN|0 N)N2B.7VTNW62 UP\$ M_>?
^OYG_|@2H6,4D#T*IU3ZNT5LB.EJHA M-%=C*50(7!|19Y| #RJZB|28;>VOMO?
X/E9&.&^Z^IB\$W_Q2%+BXN02_J2QEN MQL,EQWJ|47UB>&|)C'1W.\$IS\$BNTU^YXV8-
56:&OJL+6*O<;3R75'3|!\$\$\$U7 MKAME&--<'\$)"O*+*I8&B4Z3G!..SA7HI,"
|UA"E&WB)SDZ0GJ_KWQ*E>90
M.;).B;60(^.NA4H/8&4?!*YN6IC+X,@^H90|"&*2|WX%K(2'P<7\$B^?.T6C
M&"D.:V'83N(H(=.M%8Z;L"B|YA%%&0**X+|;1'YJ^C'9|E6>"+ZR,LLF%/K M:C#
(>LL4EM?A_Q4%)|7&=DTB^WE:EZ<;Y_A|F+?"6CV.)8_5O_+8K_6(?/
M<>0".B849;#^S2.G4'(' @HJX6Z^/EC_YEG5ZQJ#E^H&E|7IRE=KB^YH<4W^MI)%3?
PI#&.:1_L6@UN!MB_PO!K8&5UT\$?C&PU|R)S|7I_RN+G-T|^BX/GYJX)|#
M@\$6*L|9|2@4_W46H9GEM^H\$3@(.4>"MCZL<|TM@5IEDS|\$7012%|3C/<
ML1EKCWOXQ#)|#;|F:#S&|91!X8Y->|S1Y0\$|>I5OYA3%)C0(*BAK?TG_!|+
MOT\$|@,K9Z&.UP7:SV_DN\$\$.|MBL:U?B|JH5MC9QZ;8*1)|X:#?HVF*G\$.RJ M8IT5
)15'86@6_6^%5"44!-.*YR\$N&XW")E,4)U6.&"M9)/ /B|/P|;T74Z MN\$HF=R\$-S6|
,8F:8U8X198U4FQ.48_90J|!|2 <65/*L4%'A7T#| M3LD?\$YDQ!%R_A|X'D^<ZN%
|E/*AR|HBC|K,\$K^:/-J@YDW0Z|;3.(76\$ M29F!|3BF%6:>;J%K5\$9NA=;<,1V^<MI8H?
WU+!M>^FLT&9Z(1SC&;B:%UW MQ_|_594I^N50GOWV-" /MQ!|?TV6WT#.)=%!|?
HA@3?/+9^?"V;\$<0*K!-L073#G^K7/R(27A8I&>CVD)MDA1TQ1_0GU^WN^|8%,(%W+?
>;<')H30K2YT|0=J.IV;7A;*6=AS3-%:M| MI/1D7.|D0L"8^PXY
M12Q+D/J8+Z86)@"9PL-B:AF"SHF2S6*8&0+47#EJ.>@,7:JI#:\$%8A6WEEW

M8,4=>*MTQ:U59=[LT(^3-L)1N\$>(O@1'8";@4D9K#.S#6)+ZN."NV^|A##2
M6(U*_ENZOD&8(DG7M-'Z4B,A)FP+3.!6,J(-@3V3|Z1C?74X4H5Z5<00@Y: MP=*G*
7)709^_-M/?ZA/#6\$5G2V(<=;'#V+HV<>CAXBT>\$H M.>%#"\$<:>B@)HJ5,-?
1@6_@5F&'(07&L-).F+DX+7%,732NH^MS
6T'C)'IP02<(%8P+MN^_7@P%TCF@#>#XR#2BQBR(U6J.BZ^1=DO6&=4VR^MXLK|?
NH|P?4C6'G>|[%|3R/V#P";8XY5NC?82P&|/OH#_B8.@(;,"W)82-=7
MM(JVC3T2#J/Z"R9(8WPYS!0:N7\$2/WD|Q<#Q-N%_G-A'VCCB8&(DPIANR '+M356Y,Y+
<|Y&U-D&T?1-"@3\$|M;K|B@-2XSIT8YRTX03/SAG|H:++I719PZX MW5QX|
WBBT|9\$F,V.S3 "0)HW_ZLGN4UM**DE"BSE_)B M6@@Y036;K&U:"")
:SI3QZB7)FANJ&"Z/OY5W7KC%1LW|X59=HD82<3,C!\$ MO;5@NJ 3#\$ 8I'C^!+%.("B
-4_%E-\$):1 />?M@.7&,91.?7!3BRP2.E MBKXHGRK"4DIH*K5X3.R-E0J
0%FO9;5,0ZGA-^B4,@\$|Y10LZ#%|" .AT^N MM7#QWV^C9(5<,O=H|)OTX2!
MVC9=OM6|/;?'Z8-S!O!*Q.>.MSO-&91ZSI((\$|I M@A-\$H\$/B U8X|82@0V X5C@-
Q%"GP=J46KY_S2\$3@CUN)STUV+011JTD:E!O M3KHD6N>|7T|(CD3B.3PD^H="|?
GLH\$|S\$)WI-MH>|D4J/4ZG*|7RVG@V!FE|MI9,\$@/IEE1=P+BXI>0'(</>TA_?0!7J,3_
JP:\$G+/18T&PAW&7B"N+7|!H)W M#D*TP.U/\$'7Y8P' +JF|;>HY|G+5:9Q7!0BK>+
>)U)'DARGI1=W49I9EL
MS*|OHQOXJOC>:@.'7SPM1FGDX0P1B=!#36VLH:DMJ)ONCM?L=J**+C'W#&&
M^G;C#T_7BS'E6)S?@+|_0#I;011R|B#77ADS#WQ7O(THH5< MD:SS,@8Q+;D
\$!&;T0MV1/0:SY!A!O^?>*<+;%SCD|R!Q(U!?\$_LGA&L M&6JY8!*GE2/
OUVW#_R|07E11,JQ=-&W|+Q)K2S5|'W=9GY, _9D?JQNJ_ M:W8\$-3'KD=/%AS=+J?
>Q#-'/?|A@G_<^2Y8A8B/13%:Y?QZ|-729(=BQ"M^X^3#Q|H01K
MSC)%|.9*74@(;T@Y0V@E)F0>4B2G\$@(-Z676NAE1KJVAPI!@, \$9)(7!TB\$E M(9C-
&H%DW2H4'F0G=M\$K"/*0<0BCAPGPXK'FNCAN20R+,&.240<6V+69NK!V
M8DD0D!+\$: ^H(EH0!*8\$=0|6R)"A("1AK:MQX84%Z_6WT?'HISBJ!XY#!^" M
>*0/W77P0IN'IX\$GPS*V4_PHJ|_LH5_2N##|K>>,IMYW^ ^C|>P_X^|A'Z|A7^!+&#O
M!/?PZ^F9X*XAC1A|8_D7B?VL6S^K;7,+UPRBO>^N0Y?>U;8|2!NVH8)8FUV%
M5AF=F2U7C==2N*NYW!H: MFYTC\$;B|D^NVV2ENO&E*.17A*^4+2&!9K-
&*^X2G:1YJ|R7O+,6B&)(N_!1 M:Q(_Y'+93A^G@&X;:1<\$?C%;3A&LN:0;PE-2
F##!#Y^VHYEP**M-4 M##O<\$SPM!<&(J"#,U?U
4SHNK9T(>H\$5>,+4+ZKF)&EJG"LJ|3#)":L05J!>
M)XVCWEZ,S.,LZ:7)9_\$<(I^K|H2/T9RK&MKA+A1&+5\$'O5(/H8G\$*.=@96KW
MLW;J,NS2I51:%|2&Z>\$W43XE:()97,MML'4S"RW>98HHR|(W65)PH@/5TJQ@
M5G3"ZB*/4X%=;.*('AODV_ ^>G!#|>'Z_1_ ^R"&UW,X3S(PY*,FW/H1(_@'00, M|I'@9&T&
L,NE/D-RR/*F1PGAXDA!!=W6T';4%P QUW=3X-TZR0\$91^!_!O^;
M^>|_@'9,_E=FM\$^O);4!XG,4@O-G)_X#I |9Z+&/2!FLSZ-!"F# AD3|%/= ME=?
RTE294_0?9 6?5(39F %XF|(^)'P)H|<\$Q.|Y8|H3EL*?(_B#!.DG\$VI:HF4--A8\$?.BPK)3
MA3'-0&(%./D&EBJH^H">"H"*&N(%*|!"IF(%A(!9P>L!@/01?0'1 CU,A3IP8T%
33HC8HG3M2E.MVDOJ5M)5L(3"4:N<9=9PB6MSVO@X(SK9LP!+.;+"O|A\$QNE 1|KG
M8-G6'-SE;75H\1(#-V7K-<<3O@!7L2> 2|OT>Z^MW-R|5'#EG+^N:(^)_FQTN-OWD'\$.?
*|U2F.<3F*BXY=Q;X+N_ MX;XN%,|E=9A^1)IZR--K|H;XGN|=75Z|PP*IX_7?
Q<3+R>GX.UH24<#O\$^/
M^F,|2"P8555NR8Y)77A,7AHGR<|^QFM)L/O^WU++06/_'8K|SX'CYMOC|E+V
M!|WWJK5H%A'&MP?4Q6@=5L3I FH5"J|2.0'P758QZC8F6|HK|LSBZX|F:O#1 MM:
<>B3:S;AE5SSPH@|=P! MMA33,N*E9EK;!Q*JAKB<\$X!+>:^I\$Z=SNR*J,,7@.7-
00|KAV>>HSW8YLI=* M.|8QW<|V!Z5@K|N7YP9XT1",OKQWJ-
OKLI&C(^38/W(+7AH*V MW&@?EF%;E%.K6|H4\$ 5!|V%W,*_WT*|J7\$KW%
<0!'D@&^(1|R_ ^X./Z.*3 M HY"4)CV)@G:|Q52G5T&&S7P%299NQ2S 8\$|C|!##
|HN.AS#2HM;2D5"7;.: MXM 2.+H\$CLX|<+2R.ZP\$HBPXYKD8\$XPYQ'/LN^
_ \$9(QD,;*KE|E-%<_*DY= M;R/A#8-%4(?K0XF9!\$@M@:<|4)7B#-
S>B|_|L,D&WB(2GG#GBSI^4B AM80Q MM/GB)W|I|Q
#B+93N09*^."F08J*,!8R|390BW^\$&|31C;NW^XP3|/C6/P,_OS3"2&&H*JZZ7G:D5/(>WSU
(,H|31^@I"H,CY=9)DP+O+ M\$/D^Y_D3|XCWR6T40B\$S@8#?|/(_I_Y,M3FZNLR%#A)
M4F1R,/V/A('Z-GW%W^>2'>.-L;LC<69I#7Z|!D5LC_5U& 5 MM:&.UW:\$ _"7D^'4;@|06O'
2*#Y32XC4?M8&I3JU/#OQ)L9WZ6%Q%3XR^(6A M0\$|PLE*H_L?_QLF*%"M_6Q\$Z;
_07^!;_4^0N^#BLI=32*DEE"7_|W<#Q% ML1.?
>4NK,S;|1.!4E*\$M,+M1)\$+>S+%+0#JLTRI5&K,"J M99;G.-
K'SI'BFV,,UFS0)T&S19!\$*S|YKAW@;|=!F^6'B O^!-XJR,2)!@

M78S@3"O<+@KI@.KG90Y7;J;>?HNVARA+()=?HAI_P093'YU3WA_P:>L,D
MKKLB6*%9H1#LB?K<:(Q"O'&:*XT_T0Q1B/OZE58!UGLS MHRABB?:J B/1)\\$*:QW?XLO
PIEBEY@4QZ:_N>>>B+[PI\$GXC\$-??H;P&3R[6@5(Y4+P#5*04>!--M#EL*9R+J.
M:G)I">'2E#!I*KUN5KPS\MW7H97FY!|S: M:PC|\$!G%T%Y\$%#S9Q?1I>E?
<0^AYDQ,YRV3&FJ'M&*MOD:(Y)7;J8_2IH04Z
M,W9:&V*QM:AC/#W/Y\$@>JX|\$=\$=_0?)%E:FO4-+?'K.-F_-U2/&D8ERNNV"O MZBB-
<)>5_9T!6?!"^=Q|VY|Z|^1HS*"|["SZUS|E,GX#SZU*P*V74&O*U7!:_P4
M@/#ZUF',D;@P@27,I=" \$1CK7-R?TA(2=03XUU,U?|NS^>JB,|A%W.=2-1>|
M?.%5|+V\$U8UML%+"S'BBCU=Z\$Z_P=A^CO>|B!8 *:N(P;,"\$ _"F-?90#C*'S M)?
33Y.7U"Q.>|EFJ,ADZB:8LJ3U#"ML6@)Z2-6RT)#WK0_127&H65L:&&@%
M4/C. ""9F60\$CIFY4_Y5Z3<0*,OP?JYB,X1!V<"P/4F&7V=^5AC=A|3Z\$#41Z:?
XZZK8^~Z%_S,@I&NW?QX<8)>/K^IL)<4*= MGW7;J**>ZR|Q2
*5#R|!B3@:_|P+E%Q"@6AJW49(F&,90%1CS^K#U7%3IJ_9 MQ'L0WW|
!1!BS00:|X'EDT:-RX^<#S8_JOVN5YAH"9CM-^M29&E8'3IG;D
M#R#>0G#GRF*RVN|CL(?HL0ZA#!|FOHO3L?|!#17IV').&W9@KR|TT_\$1=W:({
MWWT7D_WA.J=H00.:|IME#I!|7?\$MYZB|'| ^G+IW|6QDU2FK^X7J#
M"BPJ2&S|^GYBCC'6|R7*4R7_HKH\$;(WOO#)TN\$@5.A?V/LG SSD&+AKLNKQ(
M9B|1\$#Q\$,9HTNF^2N(GH;LT3|-X*3|!==(J|T?|ZS_ZHT;&3.&,Z%@CZ|
MYV|MSA>39X_K@W|Q_26V=HFM76)K^;&UPU'D*DG@#|HV\$\$\$?9_K!RX?C\$1|_(
MLFYCMMSGUBS_#SG-|3&R).LPKRYMGJPBN|_97Y'F&S_8P#,-1Q^9|U=,BOO
M|RO)T:BN_,'HK2|!|4;AECFH8S"/ZWS@/#+"W'=>=G_SRQ&8%X9I1J_Y_O@A MBG?
1P75\$O/H5VIS|TK\$J7'7/GJ8P|A77G)EF^YU2:=;TNGF=0.& MY>GT>/?L2:O2)E
8ZXZVZ/*UB!7:O/1VW.M\$4CEF?@LSU|6D_S.69,*)JVK-M. |+^GXL:.*D3(CU4GJG"S5/
M)\$KBZR^7F_1%O3_|/O2,N_:94G0|=FSD>S6IPDNEJ^,*3?UW>'2|2KJ4?B|/_M|_
|OL8|!|*FA_WF9&N3Y,(O:D/_<0+(1K2-T#_)E|?Z8:".)0HW.+W0WG:Q ML0&K|K_-@?
@#1/_3/W.4G%"0<4)D_"GP6GN/T#L^@EXCGT7(%K9C468HAN9
M.|#U0GJ"KW|7\MU#%2;KO9|Y8'C|;/_C=-.|9J2HU|0|09%N\$RHM:|!U"^K;
M5W>INB,T;WH-A23FH+-HV >3RE>8POFHM+U*"D0AA)0J,PAU, PO'>RVD MMZ
/3Y\$0L(:O/_#N,KBC?7|;N<12E1#*"Z?R-?F%IDN8 ME?"@9|6TI>,XFO\$K9(KY@_47-
QBT=#A"O706:-3Y(|HZ);4A@ALL.>RYY*I-UWF0I M:66416.,
E7&78|ZT6*4^!DK|F0BU@R5_3SVW.L<)!3Y"-|HG>H#!-A51_"QV7-/ M50K!=6%MNO&K
*|+/(ABONF"%OPLK;#K4.(|N_58B2^AD?T\$70SE08UC1.Q
M9I|AVC'K|>;&#%'/TI:*H|KG6)\$5EZR_E^\$PHQX.XQ95W|\$,?D5;JOX-BEVS|
MEE0##+E*\$0
M>HSK5WGH"4#H):C_*F;|3TZ<0V22MO3;P\$D2R(F1DX!HAR0,U*B(QSY(;IY+
M9,*;XJC=|!G:CG'OQ"C-ZH))'-,?=@!1N!5F/J>'V2(#EZ!FT'ZA_"^W"# M#&+W
^1\$2'K*SKNDM:@@7)WCO^9|3 M'U|G|:0T|.FWJ\$9@%
|UE>|R_%WT|7KO|P6<,BA_(>6H#7_6G;\$GFB%3T1/_MNB#%>*VL4-
!Y#QW92J3F31D"P(%!L%7|K @G;0EP9"N0>Q@AJ'X-U+=@P>Z> MV,UYGZRP2
V/P>JN<8@+,0GAN7)?S>!/D#|*.^!WP_(\$PXPP5Q2N(5)UB |S M##'TXP|
_DA&DW1^&FCM(GRC5#=>A6M2DK_C9/X+D6JEUO#6J,.\$64@L"#0 MV-C3'J_-AI
X24PVWJ*MJ.6U="KR)|L@Z|MS,U=D0S"DTUAFQ9G(@|U@QJ6;W#1PJ)4=L(OF3'(GS_\$
7P54|8AY)=Q9B; M*HA\$|*|*T7JE-^BE;-)W:N=H#^ MA\$9_R2TI?
BQ*:D0PS|K^(4OL8E*34EB95X)%@A0IPM@0(4H&\$5PWWBTB|,TZ
MMJL'7EU\$QR\$BN,S*|:78NZ+=@;=T"|_##&ZB#-:8+7?QIZ\$M<3+F2&/U93W"
M/5PK'3PY1S;DJY2,%1\$ MQUK<6RW%:%VF+%)0P?7\$M2EJP_K8*7Z:~F MRS1/3Z- Y-
17*!|I3IFUKW0" M&3?SOA#|)\$ \$QJ5E1FV9(Z>VY_U2T": "2#!WR/|!9U/D_R M|3I"EX-
J%4TPSNX5P;3(L?4;"R&2Q/ %/;E6)&&&)*5L27\$HP
M<#QE55.C%K'|,L8+.\$5QBIK539KU-T_#X?O4X?H2|_IA)=^2@XN8|%FA-8P) M9A
M|T|T>B,TX|G1C:##\$|AU3=9_F7;)"E&K,-=%!_SBIG&T&@2IQ7TAG^|
MHC;|W):)U'@>WA/6\$HG1N(RAVJ,@(Y/J.M>
(+ZZN0P|VY^%&PFX_P2FJ/+4TKA*!#QD#|=0(:#(NT?|SYNNF%F2Y0'Z,T
M/NHYCE(0'7V7WA:H-40WK\$ADU++))0HQ_S-3P^W69)" M#2'.+5.
(.R8)1%S@09V!@QH: M_3#CEMSAC12OX0C)M?HAO(+0!Y3-
+5%|FX/3KRG!C|3AVK;>/G(W4;-'Y1B MBK0P|H^9GV##=+6=#>4X\$@MH3)B
_HCK%PK**0!XEZ&W.B(F_R?
^=VH*AE*@|6!\$;)J/^=A/Q90Y&O#R#XL7%RU@"2TCWJE;!K\$KX=0.JN M1!-K)-A;0;-
IHM>6+ M4+->L/?=%P /XX0%LZ,7+F*.-P.RB! Q_B0@?N<6"!::LC!)N148S#).|HP

M.0^|"%M5^#EO;7@_W%U,??>?-#_ {O1@2 M)F)
(J%.5J\$F!.,N,XQ0|>HF"X"&*OT\$J\$#D.8991QY\$X@|Z-HW)##;QGVD#H
MX_5E4!|/070&X!6@>A&ARX|.I8TV W4L,+,MOB #C\$\$/#DKM3L^W 92HPCV3 M8LAC|?
5#S>M2)I#GUV!*V3UUN+|DAUSXJNR%G3E"&VX&ULL_=E|_.D11&4|;
MLRC"4U"0HP+N@C|0.N\$EJ-@|36S96\$^|=.&NBBX?HRKG?|7S7|Z%
|QL_IXL'06?.5'8U6_6KQP)CF@9E^/3+|Y1J'JF\$U/3.'S:4B M5"?QSQ-*BSU|*1BT%
PR%\$CFQZ*;6 AA*0VD2HRPMC2+^BJ#|X23\$,W96<)>F
M1/_D"/5&=#?'*H#VL.18%KVT\$C.R&8.4F>%RKO,V=L(\$2MBD&A8MDP-GFD;M-M'|
"WNGC9Z5#OA%F'*9K<./:CJ>)D34,R\$Y'%ZMXH*|6%D0,E+ M!_^TC>Y#B/EGJO%
<=@4EQTN ^|T^>O_> WY^_.OB'Z'|@7|XR=MWZ6:E9Z-9) M/#|SA!1"QO?922#_>|A"
|_&9:BCB3M'O |K,;X;"#J+C*0I%?4#\$.?J2+^|J M8=K"R6,-Z)5"8=)S;GVBZ#K47PM;4=?
(-|F!@(%Q)C D/%<<|W1RGT2=| M1@&N>XXS;=0G|,Z/@0N7(@*=,\$?
&2.|Y,9)D*A^1/T>=" 4A1NFOV)UO@XI M0I+4YHWNVI;L(F>3/400(8)/^_.E1X.5G|CX%+
MAQUEY\$BBVR/8.T\$NH!&X/FF\$N22=T(CJ^FB%'BI<|>0<=L_A2G|V6@9,D
MFUW1BWX3OZ!&ZF7QA&NS<-2Y'G@WY|)G?3&0)@GT755M?30(XB#;^XZI);:
M89#>" 7?1;WKD7#R)?33Y.7U"U.88<-1J+? S>2J_UU>&R;/K)|L|0E|PS_1
M%1BAR1H%\$S?=O*G_AIO;YY:XEL7C"U1=|H&)3VW/TV4E,ZRAHF;NNDV=8DF:
MN1^+;Y(J/3/2QJ"Y5EFB&9!*|P3?QF.'\$U#\$.E3+\$"7;8.:*1DKL-U7X-;PA
MQ6\$:"H_8866B6|C'/%M1Y.D/+9;|J@;|8\$H@_VG@%LYBU;!.43 MGM',NKB)3H|O0WR>?
X%,<2(7LH#.N|-ERH!MA90T49'1)-PT. S@0*9-C! M2U@05?.\$?
OYN=A,9T!4N)%YV,|?;,"=:6E_|_1#Y|1.2T\$C.@2%,K|G0-#X M-0P32+:(3V/K;AANE.H|!+
-|F@0(??2=P6|4.-UAYL#X?-08@AXFD3|W9Q? M'9R&!2!_-B8=P,|/_0;R0"-
R/OB7|NF",#S>Y"=(KY:INL@2!6/31+MBK1> M^N^"C3E=EI73HO%?=0?
R'_9"S,|M3Y(8RP\$;F'/CX1L#-,8%)! T2?T|C^0 M,,#=. '6XU@-
L=I^BR\$/|>@7QN^_^"Y#4*Z*D>U FZT>8!LFO(/C!\$D2_A-D02 MZ CB^P|WR)#|9Y5
F\$,>LW4^V)@EM=*H8;?/<>1E+E3|"LA39TP<@(+9_4+W#E)D\$)VPRIGOCQX3
MOYBCKQU!CBC,<+|Z&(WUJ@*XW/X3""")!B;MG>\$I ME'D/|3':MOHICI(\$XL3.IY%L=
<126@M|>:(_B?5835I8,9?LWI\$??|2=J@
M6|93N8V.;ZB3'=JA^|_,SOO<59/|*3"76\$#_4|4.H6X('B%6|OZIRDC|VRY? M3-
&7U2ATNH%D" 66YPP^FDX"/L\$ _OP WVH?^G|!;.,,VM"YXV+;#K|.4Q!#
M%I3CSN56**>CC=;,\$.@I"J,Z#;#?8|XDC7=1TF^I9/EA!K=WM>_<@%T4@WP< MU*|
RT7J681ECO+ "J/4% MVFAMVW|"*9?EU=H%."K=MNKG399AU!HS|V35+E>8*H9=
|Z=_P &?^V426L M|Q %'MSRC9/XKL@M".RBKQ*!\$X7DPFG/MXG;R MP_1|SS|>?
&M.\$'!261|9#MVZ"X/A%>L,B;^U(+%S@JMP)7Q4#QL!_WJLJ9Q=
M#MUVAA4S|V#Q72=UM2O=*3|P,-!<7X>|E_!E&P|6'^ (XDG|JZ-8/Z-
1F\$Y=%LZTBP3T)_0B1|?BO)%W503A8DT"VAXMH8X
MJH^F44+-13;Q\$|L^>P2GVT0A((SJHAZ^(>#PDVFXS|"7B9|?BA)D*1#P.7O MQN)%U;
(^|9-+803!+30\$|7|V|>*|G:','XOI@&'ZOL=XO3_..WT/-?Q\$#\$X MIVE &-3E/_0\$?
S43@@|O|R ZEG&V^(:W>I!#&V=L\$/-|P(+X|1-.5?Y(& Q M3A.AN-
0';QQXC;5*3_(8T3.B6=^H, Q3AA4|K|+P:6(DVSGH9I8D)FE1/F
M!0+NX*Y<*EH3W|LW=N2LZDL\$C\$&4,>|_E_UV\$;"UZ@U/P0Q:@\$ N4TLJ0H MOYNE-
X_&00:|MZX_36^"C6M:I;SYH6S,*?KZ&UT:#SX|OK<;YV3GSH!AQ|8
M<_36W*^Q22H3:@W4!W_7S8X9MM!C"Q4BSA@<4%#>V&&8=^%|'QM1|RB9RR+
MSX7V3&U(PQ^O,<\$OA9P2>*6FPVE)01QL9B^*JS4#E;=I_<8(,*+Y.P35-
T6.A8W*8;CLV!-(SLH.>^ GV9T%M1_7=- M@F|2/43\$ES4-(E=WAI/070&_J?
82H*%TGS&"L9MKQ|<51|HL!">AKF7;T M_*|PCT6|Z/L/\$+M^0LTCZK"0:8?
&=Z3@S(QU-.HPOV=)B@UOVXBBG."|>FN6 MJWP!>9@,*N|C,6|0%H #XN50T.^+
Z<>@%G HJ)B |"VG8\$XT|%.N:~?,4 ME^XFE> !R,,.6
6DL|0LS88_1Y!6F:)Z(UMBP_WS0VE2-
)7JMTSM|H9;=.44QB2NDZSC;!=85%UZWP|1S'VLZ50F'W+TMRO_8R+H5(-MUW?
5)5O5F)0Y\$G#A(% " *MPQTYA:0Q87RAN3,G?GY57*2'KW3B26;"&,1PHTXD-3H9@3
M<^(9?0-CH3X8CI@7.#0BLGS'\$|F'|C|&'|GB2<1#HUS%_NU),/|A:W;.\$V M+:UY>-?YU-
_B5:\$FOYT^|33)@<\$T)#)-0|GH\$|LP|?3+H1_3NA-^ZGF9|^A
M(P!K6KK!&*40IB7R|PZRF%8.,4SQ4D&WM"3@?.#'T#JN_",VA,Y'Y?,X)'2
M!7,F2|DU;3&|*=KOV=F@BEAH!&YN1KM08:L6EZ:W)&@K7\$ D8<4A*=6,G*
M2^BGXWO=*OF5T8?7"@V4)ZAT6_RHRA!U4"91KR@PJ_P
M&0#.5:FX=9+#0Q!|2PQ3(BH|X|3;9DY9%(O9JFZ+-K1H0U/0AB:F4#_8|Z):
M+*K%HEL,6K4P6GHV-K&@,W.L<)-I*1!W?H*@FN4UB*&>|RY'3Q0V2SF-3L> MG?

B\|V;WZ^|]#?09TA3%>NB_H@(!TE6M(*:XO|H'
MX&4!X.R!)M)V6D)ICK|@UTD*A/1TM<)>7\$J<5P00^|2IT\;HO%>@#M.Q47J0
MI/9N"6/U:4"!DT#2_U1&>1-|0LJELR08^GCS3H"4QUBS9C',?274FTTP20>
MH#Y&R583X'ZWC|Z_|X"?|Q+^X;HY^)>O|Y"U4=3EUL|J>35<,XCVOKL.72)8 M*
(TFW26LLHZ^8(A-8DY|'^'+\$^|)!6*;OXZZK<_AW_,CM2-U7|?'V(4N>;Z MFYF7:,3| M70|
(R2-5+4?Q=2+6XW?7/>PL\R6)3(3/..A;:&9%LB,^=Y+/W(M>%-T^ZN\$IN(_QH!|/X|M1)
(H;C?^%\$:10&Y>#1CH-KRT@CSI%W|9\$14:,HTJ><8ZLN7'Y/B
MU^0'&>6(NY92#'_W@+?+3|'16;B,*-8&?TMI8TV:OM*,+%^ZFCTE">K7|4Q-MXTK:?
LB6M&N_*R6THN-XV4D4F=1_|/|/9;DT1'\$6Q ?D?G9:./7(<|D(=!A MEU74HO8?
X?:Y1T|E:.,?|!GC FC"\$|=E%|=+\$+(5R\$|RU/ NH*:M9C20ZV. M* GD3|S^)^BS,43?GX@|?
(\$O8O|+=H|0;H;D#^B|Y|' M! ENCALZP9<\$E!(3%L,H&Z(?3'XI?55ABU9_+^ \$M^|@XB;
|HD&%_7RU6B>62F@.@L6-'OJH QC;AW M1|"*D".
|WHB|YMV;Z+%|!H(+9R1X|(P^ZE(D>ZD(S2%S@HNG?/@:OC*C#|E| MZ50>M?*4-
0|Y(RD1TSTD--XG+A!|5VCW1JO%M|G:.*4Q!B\A&M4"#15'|U\$
MH,2^H8#SS1(3>!M%+:B7R0EBF=QXG"0<%M?*F,)NS6-!@Z3TS!!_0U*?
5TYDX4:A)10"6G(+N'C3Z_D/C|!2!7<43@G9D(%@" MATJ #,M>1LB'DC8U-
=S>\$SXV2_6N.|/-N2@FAK=1F|R2_9|33N'-TP47EW> M44|8A,F-
A@8GIHJ%R&0XZ*4@90"*R:V(1K&::>A|-T*Y>*/8N|(|-/>1R#X3|)3?GRM^8|21EE|&>
MZE/!11J2Y9H+%J<E)_RDFNKT\$-_8,! "Y1>T@VE)Z)IC:NT0\,50%/:0B<.V
M,DB^|HX#5JI\$8X)2|!|6+:T?0JLB1@E,%| ^JWM+|0^47ZH.4(M*UE:%S949"NHTY7&
|WS#N(UNTFAMA(P'UW/FOI5^.*-F" T8 |*%&|NFKW| M#MQT&Q5|1"70RX9CR@
F_\$F32(|V,@D2HR|QN?0K&26B9E*7EM6-#H/H%%#(
M!)!2V=YDV(D7T^VHWFD\$SMB_AJDOPE>8@.@JY|?MO,"W&@?HLP U200LAK!|H WXP5D
\$76%*5(,WYV 4:5JX(, M IC5?QD/+4E?'=JZW9V&|K"6Y-DYXQDA^IQK=|+A, 2 M(3!
(-4^55/QZB.(4)2&MPW>H"Ts*+(|R26,!)=)O%,6|D=OEA<|,(-P _B3"9_5_+MT;
(%DW#WQHGW4+MYSF+W #G2 M)_CGZ^%71Z21BR.?R&(F'|S-5-+@8U
J/103XLPBURQ41|DH5V8#,: "2|/D MOC&^, L")N("N3&D%_H'|>(>|PMOT1G)TC/5UVU-
^))FX66\$?G=4_ S62> M5M "W00SSC)!2L M.)/Z'|C-8R@R.5.C&(M|-
#+F51VF99=E|C1N=R\$3E,\$*S)T)@5|3*,1V|BU^4NU;,G#N)%FVC8T,CJ"26*=Y+F:@7
M>FQ#.#<&>)+F:A;MS+D2./B95A1+4ZB|*+J,!B P|+N*Q1 %X(7#00-0B& M0S^#>
|BW5W*R@T^("1_ ^|34LMRUHC|EMJ"0J,/+W>W/^|/P>Q;AAH5A1
MOBYK:@,%XZ*JNV24ZD)9P<1C7K?XY!S9Q;QD5|'KN%|A(W:R0&,J?K|A@+3A MDBAI1?
2\$IFH|V!UX!T%T MX6N(EP)BNRRDIW"UL^,A"/M|:P8V1N^V|CQ +IP-A-L#3,*(294 ?
5*A.Q7DDO" M|-G:CG>,)6ET!/\$+ "+ *EQS|\$QNS6#.T(|F23&V"NOP;0/(6/-H|B)T| ^)*
M718|^CN:\$MEKRQ.Y 3ICNI|/9.N@Q%?A)ZTM3@1BA01H, @NTJC9
MH,;GON2JIB&/G\$@=;2^5.'\$5?B-!|S0T^IH!*"A"J9.&.1'(L9B7'M#-AHG9 MD0//AT,/
TT5E=J*N-%PF4EM (U5-7HXS;25V!@QO > GY|5_N%Z1/B7K >0GZ=GHG.V|;-:RQ<
M,XCVOKL.7;K_M3U(R*D3EIH Z)|A2%J|@6PZ)GJ/M*(W=,%WSY+'Z7);1
M1B%KVGDL%V5+;&J=UR\$J>5|<*_7;<*_+U!;X|@+C!YJ^C;NLS?)R.V9&Z ML?
KOXT.,0\$KUWS1&-L G&5SH^;H-|U:+/..T8G\$@DUISY',7(1*G7@Q.# MY|AW>9T>R7-
..LJ4 G^60#:50N8CV#M!+DH2D(T0I^4|P*XW/X3"*&.&!*R
MVMX1/HHH40BI546Y'W:0E-P:XPH S@=; *C|KIWA! IX|_(IU/9!#)(T62=) MAJU1Z |,?
4SE%Y22-/ZP@Q.ET#?@5_?YCIBH)S-S"K=*2UF06L*D@S|'T4,4
M'YUUNS/_RWS\$<9/=. '\$+..FFSB MORA)!H=F|0UM MZ?UB1Z<8@M%A"
<98HP_)Q'2B^;8|90T TSVCA|VX M|LAG&BDG @|V7*XZ@,PYVI8I G
_OR9#8^E0MD1GJV"P##LQ.G1;=ISN4>T+
MN!8*S!=PY|74)CE+O^,E:S%G#)JO"848+S,32%)@/C==VD)\$L1A.C::0#6YV\$-"#)1FCU4;
MG9,DSKG| #5JDC1J5,A=U,\$KHW "RCW3QXZ|Y3QDIKH)ZF73QTYORP-EB""V
MOCJ"&.Z|C,\$\$ =HX;<\$F'Z LLL|IBE,N'^-T)?L^?E^Q4Q7J S0F':!@<5)JZB.
M&9<\$ \$|Y=EQ_Y Y-SE4;?7BV?YVKNUP.LB2-PN2#"QN'193D!A(T\$,5D,/1GZN\$
ME8=GZ!\$3@0 IF%,-""8?OBFD*)9@:*IE\$SUSG^>PD|(WT?@1J8>"JSZ:.(1!
M'@T&=S\$9%Bj8!4D1-SDD1@414/3Z"1|,_%UHVPL,#DQ1S_(&97(CQ)|('9M@
M\$YEH7(0T;3?L*Q,->I"Z;:L-9Z)A#9*HSK<@S<-);TP5U<49/ZHS7N(@*X@A
MX1Y+M(ARGB"*7_ ^E\$AO&KA0ENXI:CT(09\$<_=%80N/B#=#+|'9>124G,R%;6V M<.W-
KH)OC&HY+%VD9H>5|_A15-G4A6Q9%>WSO\$M|KT|>\$P|+F|C##8*SA,J MGDFF|9;-((
1%81ZAB!@%+P3B-,SVATR':"TVA,|M|T64,L72V)P 51|"S;S*7.@;)0"
MX)5,D<00!6<.52@5ETFY,&V4F^NFP-M&-^66/\$C8?D0JD=AE%8VL+@%|.I!X@ M#A3-
4G&:=IZ+3&5QK#E*,^01P@|N>M\$2B|R?"TAS,!)4?+TG,IG M;U%R%Y\$?

2B^AYP"0;2LX0V65)?1K&J%? OVWNJG8%I\VS9(T4;#H+|IB;-8
MOYYD.BS\$BC(Q#66UGG.R-#,1V+*"0T%G(E\$CME0!7. 8G4L>YS1L%BJN(T1
M1<@Q%TXT/\$R1:-4R5DX4/IK(1L='CEPU1Z]-?S8KP/9Z#QQ*/2(IN89LDV.
MH1Q,W1BU\.((\$:4|J(7N/I@X+&1HANNTF&C(:?>"T\$17R<2AT(6+RKA?)AJ@
MW)5@A!T\XU@|@|J73IZDB88|IQ-0F.ZGB<9=|4.&6_7Q.NY*0(-PZZ?
6:03X%:HFUE9,FAL|C^?67I"3KQ:-JL|ZAVQTU@)?Q'2JZ1E^;X5WS|^><(NEQ)JV3"8'
TT^=STZ6XFH9 M^X2UIX1S% _|D.!J?-T/E|,P>,BY#/#6J.?)RN"\$|C|=>QF7#W,U
9>LHW# MW|AO NO-N_06OR)>6I+VU&LND.A.Y2/-P\$\$.ME\NG'(-LU_#|&"N"34H'
M'R=2ZAP/21E354L9=|QX4Z>6ID;ZB6)29LKOW/Q|W/R%U+9+3RO+XA3X"8F(
MV*XVK^2OZ:8(\$:FX)61T:ZB/ M &C:>?L6 ZUV/JG4.A+??Z'JT)_5>CGK-"/K:-
>5;#/H8*Y(<=<%59?DB3X M"*.(2*O^@|OTX8\$L_8JR^O'K4I)9NHSIOSV.CP0KI|+'9U:9:
|>98|ONV|:ZJ M-J024OUQ|MYR.^'Z@9(!>J1IT|TSDQ5Z%85):C8(W\79Q\$R?:X\$FYW
M@E?O=6=|/+TO6&S2*J=9 V@9EZ+FK)MGN@I4< UNX)"5| #T7A+T T8W(KUUO
M&,1|MO#|?)\7|?;!&?A;|* WH"%|%5BGO*)"RTZW84'^8')9D \NWY5H.8D
M9WUM)CKI'-UO>NZ6 ;I? \$UG&.A5DC%W(86F\$42Z.3+(H8P=#6'P'|
(AG\$8PFFQ49,2S?:PV&0("Z Z=|5+ M@:54+LS@4B|W|2V|ZENV8S=J:QF.&Y*7P5U?
%:D:ER9*B^/HERZ(K4+/)/(:Q'9 M=G\$)'TE2.;@T)@)P;PEWJ>?<4DRW|J|P7|+40L4D>,#
<|.FSTY)D0IV9),"B M6Y,F#.K,'-7&?O3>:-OH!!_)UYZ|. *?
M!7(:3>@C/<+@CW76A:FOJ/(=F'I-T'WY3#TJ/1(MT\$C1RL@S4"ZU\$-
-4WB|C9T|VF9ZMI(6E)G(A8^FP9\$Q:)|@&&FVQ64%S0|)7 ME#DC@6Q;XEGG#
2R:66YO7"XZP"!1W:BO* |94X 5EKXF&4KOO.!H%K#22|&^50J,7M|@;
<%12TLU7+82|64<7 .U,*K|=|3P4 MS*:?JERP==Q_/-7.(%(09P5!OA5Z-KJ*&1<:.\$?
K)'X'.6|P(-ZG)1ID M*GKW-O 8AR,8D(F&|U PK6BX8.!,7S1P# O'81|H%FZGE
G6P!AD\$WHV\$624 MC"T: ^!S\$|1CIP#OA7'R'JG<>QEX6OJ-K!<:P;E&
<)>SQL5X# 'V<3S@L*T/Y0 MI(2%/GHFNM7D0=R)0H SXdV#J7 &S'RN2|Y(5 M|RN>C-
"=#T;,>!.|,=#".UR:'|A|'BWV2"X-YPN&7B^@-^"7!PG/OVGTDYUS: MTVR;96|^0D'Z0
S399KF|)GMC21@*9DP*BG=?_?9L|<-LBCH1\$LO,9D-A+2J M;\$>#:JR9
@00EJ2+TNS%RQ|!8S\$P5'FE"U@%LB GZLPJ"8MV!*FV_ ;KSR*|H MG4#!#Q)
#18!5'^\$V4RKS6N6^+|RV(1| M_*A;\$TD"|NV N=_8-UFJ,V%>A,.2>UV3?;+I|)\$#S-A?@*"-
J?4P*'?DQDO# MJ/6
D1>LXI|'%'&^5@>E=\$,AT(@-6FFMR9:N|WU\$N5|=P0|^BG*8Z)G-NG+)G\$8?
22UPAN@,>1L2NG0-O_@\$(;-U@|B2;O@H-=%OV>!"DN6/R&\$?-)|3+SC\$*O4^"#UC:
M|,#8_B28<4&_%:0".%8.>6IWR3HBIV!*(Q|1FJ)B4WO*^
MA_M|+|Q8^=1D|(JWESLENR*^@0&PR=> Q2H+RA&'UY\$;X0!<,U9 MSN96:NH^|?
B5BZ M^J'C8>B1L")1H|V/2(^\$H);|98O|S;9|N:7)>,HF"5#DK,.K6W.Z)BMI
MVD*TU*)'VQM\PM"\$V0KC&"(9O65T'7|ES7Y5^JQU_#DSWB;KC)NC7D4Y?LP M|A9;C-
@'Q2|Q'T: @OT4^7<)>N|_ "E!8()|H8W^0|P5LONB=GGQTYKF3> MB
MMK|@BMZ53|^=QV|.0-:D&_K+V!=WH^D/LG9=:+1XM6F0NZ2C\$G^LO<8R
M9:|N|1:%V^*AU!PMXZ|J|JP_4/2.G@A;VHF T9UM_6F/:J.U(36)RNGC4KO
MG*|4K(A#^++1(W>)RK+"D4V/0 :-5*RD1C=
M%3|HWR'((981&:'B.D'&PD1.8*7Q^+G"3%(H?.\$EC1MX||351HNB7^P)+4
M>'>|OG'0'1(Y"QPO:QPB;H1^!|>K&P?@HNG"<"O46I>-/'@A9K68|T#L: ^)
MTN5%=8U, ^IKO|QX^KC8OM#01\$_)GU7F_A-DNC->|>OH_0H0)MG='VQ':TXX6
MY#PS8B1Y%,Q@%::&&P<06=AX MS" 81|/-L4_RC^@=19)HFN9D^|'59U/(-O|-
EKV;8|;&YP'5_EM|+XAP|I#| M4'#KI;M%S|G_C|Y^Y%=..?
|OTIS)LY:TAHBGI(8'9|_ "O*O(XD(H&&SQ
M!3LN2B5,1S+A2HK%DO;O)G/G;A"FCMY7(OQ"GXA#OB9&'5XI_RUUC1FW/;
(>&40|1G*ZD\$RP+WR8?I,RR?^%# K9#M@|E#IOP(1E_OG-XG M|I#;I|@L|D69M2QI)
(MY|^S?SYMA0ZAXP^D^8I^7|F@RTSY8O*T9Z|C=F?,\$ MR_Y|X|H7)V-
93U|(H|,^4EP1F-5R_B=J&U|I7(GF6#_=!HB^4=C(?ZC;3-6
M|UX849_*OX)?=H7M=*2;)><^K|\$,&E!W5./QF?TT_6SXDYS?2%K7B|LTET
M\$WETFY|4;V@|B:=#/-V7AU!%NRBW@Y=,WF+D|A"FDB6>:U"B%W
M\$K92.4>E0D=0)U4H|. #.#:FG4L|069#ZU5;B;B|C#|3WC:=P67@4P:-3%-S
M2N5=5MD'/3>G(|C1M*!&1H|;'&V@MB'P>"LMS)XGV?&B:B.F56)G7VG'43;+ \$
M_N@ "2>:_%+Y|QX|QKJ;:MT|4^P5GX&PIN MD|1X^U(SYTZYS#71|).7G"AHQO?S?
1|1M|V_X"0E>A !(*)\$|4P|QNJ8*.U M|WT8/6JN|1QJ:|>#J5#37AL;BZ8"Q-
2;VFI|(PKC*"FJB3J>J.8\$(6+QT' M%;.)C:H-,W7B@1-Y5_9#H?/-M;VFJT%V?
%|R2#JO/"MST|QP+.9-)AQ;L?< MW*/1_84^, M"(TPF'VL)N_I6\$0>L3VJ-

\$EN1CB\7,D\$/OI7-I=,?A-;3S=4_12\N:7OK2 MD;R%\$#JRM0SXVOG?&I=5X/'=Z/K/D>
<7VU,R#?D\$^>=JM843%|>W. J>S3)N M.;LEUAJJ3/O(.8@?L@JHTQBU49.3(>5QI
A)0/D<[1NRWWVH?^]V2Z7'W0 MD;-KKR@M)Y*^PE>_9,53S4&C08MBE-
H*T*C@39'4"+Z1@9)[-]IOC\$;7.; M_=(3J@SC&D"0 UPPU
<).X",O&G\$H,+L=|PAG|<'@TT.-|C6GDO,V&(O 8=C MDQ7O:1#(-?YXC3|>XX_7^".L^&-
C=XQ1TQ0_*5R2"6" 8\$^M_IQ\$Q.:@UH2|MA%5K+AC0*+HE-TLX'!0
PD,9KS2P;P7QM/:CVI56"H_&"QHD6^:CT7QE2FBAT!|.RT-|X MJ+A&_\$;T4.)'SE3:@ID)
3FZ \$,A\$%|NR+B;7*|D)##;'6/UBA9VH>,QJO-(MBV=5NA67>D*_>;%A
1H@Y+L^)>=Q:^(JN1)EJ)6\$?%5#&CT6AK|H?VAF1Q M'-Y(>X4B-
%5BF:8Y"NYRRB&>\$:'FX'7G\$<9YF|3O"%/9MMH4_||"MV;UJ #"
M,O<=%QDISAJ((/15(X'Q|INDYQ*B8.'Z5W8|ISDPF\$7W>@+.N1\$-.?52M-@2
MV49H|LIK H?<.;|A0++O_|^-O#0MLY*D00S.0'N;KJ_F,UD18:)7L(W)V_@J
M9EGD#VK1Q*MGT'4E^9T*^0_F'0OI/XR;N1=BFZ8R1+V M.H"C_2'!CX6VG*QPX9))
!..6U4DCD9A067HOT'.3Z2SY0/H6P(\$:/8|U*Y MT51G0V *NZ)H'U>,=|>@;@GVL+@;:4-
&Z@, @0HE@P55D>0P0L=C(Z-V40/ MQ)H0JPFL2G6&C
5MQI;\$X=%F*D+%&S(:).0PR'(1506T%'0&-"KME395:V+ MP;D^CJ!
6EUY'@ZFY8X7C\$T8J|JZ5AEDC(S%*<7B%C+T4S'(MOGK>*S)1/DV MLJ@=;WEI@!>U
3X%+OX""A=F-KY;X-'C%64,N99YQLL;<7Q.|D@R^| M:8JL_C|R;\$?N|&H6.RIE/R!!X'F3
!G(S;28>|NO&S8QQ|\$G|UCDER:XWB%UG^|W M2XZ|V'H'GV; M0>6FX(^U9Q34^*
<|NBG(5N::D,VP9P80,A#FL@H&365++BH10/ZVC(.+:!7
MD.Z24'),_6QT+SI&I>EB|EZ<_B#\0-\$I3W&.K%(=MH:8GVC!E1M/QN4|?&;
M*MJ;?'!2YZV12WHS;\$>4PH|1ADU><2!%NB3?,H: XN|WAR@YHD)6KIA8ER:" MB|?
#/701>;3C<;5M.??3@C;|&#%V6PK|ODGEGRO?L(O:-XN !5S;=VID39S7!(-M:QW9'?
Y&U/"TY?6;|+;YUBL93E9*;?>(&;8\$|&DM,!<#ITRU!!5PY(S1AT%YE5#!>"7-
Y3+:AS^P|X3ZYPYQUVTO- MR)8/16:T.>IPD^N|'#>;L9D%&3';.0P->|WU*FW;*H., KUD6)
|MUG*B=;^\$8MQ\$G|3L/'""-|1XU:: CNYMRZ!/5,2,5@|HW&ZL:(HCZ#R%@9+2,TL
MAS/7=REZ/*X3UR1B,WYTAN|79@ID|S!IQ\DX175\$WJZ%7BDD;WUXMNZXD(GGW.K_W|
(+N6<\$|_*IS:P2U M>/5OGR AC,OIGQ#>(GS_W6=OA+Y00N6P<=ZHR_(8|N\$|M
MWL(@EEX2T6B|++*GX?ASXK%?
R9L0IZ|9&\$W|C/;\$'X/2YKH29&OM*43W6>A*JV3S(N:O|F:78U MR?Z),OI4^3:6I(=-
|SVX0EXD>)4TTVCT\ NB|>@)1MZ)WDK8(:+RF?S|-B'D MY/E9|D6T*?
OH|N0D>W0V#60|>U^0.W*NP0PZ1'6N0|O1|)(Q0@E&='6.-0T: MD9|O#4719JIOG%
<5H|T#V5\$@/T&H|7)5U#VC|-3)M\$E&|L)XS0X9-9X_CN_<
MPAF/D,+_QC*;ZQ=Q%\$L|=3VK3@*Y*7%D|5_QE_,'C|D)E'%TP,F<@,M>6)
M@WP:|=JFWH|8YGL S#=#E.Z,%T/#UH0C8!OI4XBWRFVNPDBS2%_D(O28Z71.=
M7\$QTFHY9G#CZ2Q)%#PFFDRX>_.!NPKU0:A>:#O?|0H|\$OB/J6_W|EO*V/#8
M4=3A&YDSA2N08(NU5N#>S#7W"LW#2R_ UESR;#|")-R0 ! M>H>3?
+M;^&1|RHP#4W8,=IN?-&4-"AW!(,Y,F=&Z^DR+EK7PE.?3/I/ N@-'FYGLX%BI ?P?
7Q/MKXOTL0L7|Z,|<#L%*_.;"AZ8AK.9P ME->\$=5M\$"YC"19R%01CE="^O
MR,);D.4WG_ WHYS_T#.EHK)/"L|YM|H'F'.D.|&A|K.-MCP ;|N9L.BYW\$;Y MB#U'2.-
=8ZDCAS/0HN6+"8IOGLEJ"..RJ\$!AYXIGV.CXKE-W\$J<@N+Q%D\$@ M6Z
O6:/@CE!^O"T"+46BY"V-.&4D7WQ|RPDQ%Y?&B<9RUJ%QDOZ%"^X,S9 MO
Q@^41G72|CBRN^ V8<3N^XY2?FY6WU3<(A06- RY6B9*HMTY>#.= H4!|! MI/?
M3&X/&;4#'%-CJH=M-M)V""S.3\$J9"^;MFB'0NT(KQD|YR0#V0AZPV_
M3^("N@J+FS86TV3366>193A|RS,49\$FY \$7=+HD(.50MO*|6|M7*G8^5>X?>
MLC|13&)B<08"V;2RNZ|PN#4 'I-XFR&|ISNCY7;2|0L&6|P0.:DP=\$N*+!'> MV'&;PZ&8B*
|&A|X2&9#>Y8B.%.9FZ,P"0QZ2:|D=C;/'C|K"V*|E*6=TZ
MZ4%%6UQG'P"XT+G7FE!2M:0T.G|*%H_7)'M;|R%Z?Y!E)=7"9 P=#51F5E
MQ5>)'AL\$86'Q%9^FW@QZ"-^(P8:~O%_1+|0.0N1Z|L+7S|_R.%Q9RUW|>5<
M=E^NEB=3;+0T|2:V\$D!C0.TKDEL|00FKJKN./PJ|^|40:QC&8#&A=9MD%D+
M36(0D0UH#-CUG(YAST!&+R#7/H^G.^|3'X%/_30IGYD)?.-LRQ4R;@%=4;Z@ M<3P?
&!1A=GT(CF<5V|>MP""A>&+RE'@=|. %PO-W#%#&@|W|WB5EC^M7"KO*!#
M0A29>%O'Y6_RE" H3:5RP4YPU0";_58-+_H.Z.=(D"@.V\$89V;D!5.M1B.!4?:&T1T?KC
M\$H6*D*IHO&6<;6 MF%%# 'L^8&-C)/O3%C25Z0RSV:&"%AH4&\$K.N7|^\$V>Z6*%
|)'N%"0Z&Z6)J2 M|T7!VOLNP.B0E:R!O2)FK|>4B))BI4Q1-'I4LOF"8CG1=
;8QUU1P4A3'%5X M:XRT+PGUY)|M++G6W(-8|FTMT2IWPk#_MRAUC9>R0)BT+R%
<5'57#<#?T\$1 M|2Q!2Y|X!@L8#%|
("1'Y8VQB% "9?'V8D|5U|_8WX7Y@AI3G0U5FQ@|@IXN

M^08\$Y."Q"F@HS.VXZQ"1XT!J3Q1;663US@1Y4CT)>J_MQ\Q)(&AR##Q8C@>[Q^*(CT?B%LOYM8=(#J@RYN YA>9.VK2JAP0;>:(ORN MK,#6F@H@K-S:YZ(^"7KE[,+)ZA5@.'?I4YB2(!M_+)RM2_-LHM'CEDO2#HAH M&_HOB #CQ270\$1=*2L?#P*Q+'O]12,) ^!%S"+ZHTJ^>DD/_I?13NJ5J @J+1 M"? G_OK@2;XR5G8T(F,@J?D1_0Q1_1O_,L-VUA9]0?Z^%"F34:&BG"N9RJG*0 MRX Y(<'@#EW.I+MLO\$ "J/TGOA L1 T7H:"PD3!M NJ"W:Y3;,53@S\F^?P\?DTVV0^1/,? E3&*JRW)U5MJAG4Q]#[RV,6#K]U2J^6L43G9^N?<-SEEX"!F@0+'9]f&Z? %A\VZEQJHXO'60+C?'Z+DB- KHG53L2_/812- M=O|\$@#D)7'+2/'@^%='6Z*-D? U("8@_UMK6R8']%WA%DX%NQ<.MYA+ MC;W(T\U%PZ\^H*L/R,'Q%.A(")U- 03ZU1"E)ST%L?QH)2H30P(M0?02#!W M!(E-AB8V)*AS!!_3J\$S\$>)(AO&%'\$0;C,GQ]D :CJH1_F">##BI@)%VO&D ML0&D(%;+'<>%\$3F(=?LY>8:Y'N#[S2;T0Q3]1Z:47MV_5_? OG#L0S+E-B-UZ M^!FT"#&A\XNUIW#6V^E^7PW]f? 7>F:C)Q]3A>/8ZS+S<%751X+=="_5J:[Y#ES M('0B=ISB_7\$1M)AAG7\$P+NVN%U)# <4+=A>F%'TY1B5Y/WN8IC;6_74!-9=M M;/_&XQEZ<>CZW;+- GJ2FF@7!T8WAQ;OVBZO/37LF@OGAX\$KCLX(U&2H&CT M11TPZS"CZ%W&0? @>!KD7"?PO_%"VMTJ]H;#3IX2P"P_KY#[.]<2NNQ,5Y@W M>./FX:7(^,V>?I3@. ("20*/&D#R' ^2] + [WZC^DELO#<*8,H@8X?3)2S.\$ M' (X>'P6>E"44^P[V_ DL 9K(_)+&N@YT[QUY";LW4E]J?ZRUK2]H/+5^ MX(2[Y?88"\$))X;SLCK-'XZ?GLNB!\$|NF:- W1>#/KYMA_4HNBNI9Y'- B*>7# MWY-|RJZK/_2S\MFb;T313E|>OTG/73[G0K+A\$6V]J) G!O%&W%1V7P78N23 ML;B(Y R>W- \$U%SPU_HILIOE!ZQW7EP^CO,S(1,4+..B;|@&H%7ZA;QQ5%;3U:S_TN2@4W!RKAZ+*@2(MX-Q5QVVQ0J13E&Q#?QF+#X8SR**N2P12817?%77/I/87E/L5?;"?Q\$JOUF2+ M>MGL_OYRT3Q8_.7E..1CB&\$8\$GJP0.-" M&0*5>KFJ4(>Q +81G(@ZET^!%;>K#42JBHRHO8E@0;<+ %PNDO78^=XML8@J^=BOD!'D:NIZZG| M@I"AOYR:((\$H'*|D-+E|6CY:1_&AO"XBYR|D>"/W0;A:C^,/,PQR,9WK:'<4 M9ZKKP_/.0P;U|A:TPB_A^L>@U0|S0#)%*CY*VS4#_JO_AS|H62&)(0"09_MNJ?S4@K1? 4P4;?CK=WI1V&Z9+_2\$D-U'@_ \$A3E'\$O:?'+'4XN)XT1UAZ&#T2%/_&#_OAG M#89U<8@8(JD179CJG_8>'I^3YG6N;=H@V.7)Y"/.ELB; MBJ+FF*H#|.A1|/#>9L5.0=|WCNU*'_T*|>73R!S^"Q|&)?^|H=(=/4/R/_2| MW|V(G6IVZV%|)*?:UB7@_ZS'F,F-Q7GK)8HN-X8/J80;TPA*|3.'|'\$#YD> M\$VH;VFTZA0_C\$+;|1GM:'XZ/I4NJ0**+?9+'V2++X\$. "7PDGKAW4=^@M:[BKG0- =CRTS"*D2]9:Y|Z*8 M'R_CS(NWU)56,F64W7_WHYP&K|XD2?_1T0SCVF,_'% /J9M50BMGEI0YTC';4 MI_B.ZL?B"2Y6F|7WW2'XA|!NWBAG %;S+=^G(BA|03XB*B0A=*LW1L,'TYM MH|IR|?,851-,B\$#*V%3EBND+U| ATJ3)YUZLCQ|8;";|U#F'D1%TKP)*I! MFPX>D)+7\$+7_0_|O_CM_-J-IB UKIWL7G3I|/#? |Z|!TI1FK;|V@#S#T#/_4,%Z2MW|,8FW:X3W ME/UP#Q\$|<)>Q|*()RH@5)IOBZ? ^,DP;1'4>:U4U|_E)B/E_7;S;P|U_@_510 MJ<3CYQ1L\$F'1CL4(PTWPP173:L|H_F_PP"CHLN(NA6%,|.&FKZMQ_9T'5\$=" M'\$WU;Z:@7J@94XLJNUV8BA|M;Z| #' + A|K;8;;?_59QXK17: R&TMRKU-^Z6 M>|.L;5C75|4|0#D- D#JO5OMMZ&7R2.@'TW9UL!K9^UP86@-@4 N.1@:\$VU_V80/TV("Y%|CL7F=^H<("X|&A.MBC=A7H|0THEFC-L.2I61T|H= MQ@1|_-9+N.%C6VNN/>U3G%7#UT2%X^UQ*|J#)|S<=<=:+ #3@Y,-P-X;:6W; M Y):N\$ "9KV.7R 3)+&)*XT^P=|E-8\$E|W9*X|'2: 8H9I#JUP+6B\$.E>=Z=2MC|NDZO1K>M*AR*|@-""B M6->>YE,T9)TT4LC*S*L;+PU|GAQH+>&N!|A'8+ ^=)PS_M\$8<#L="YM*:KP !7!Q@HX701<6G\$UP530;)>1!?=,&MP3//D<8CZUPB11(W>1K&1-X2@^6- ((GMSO|/J8L%Z7LR\$|O?^H,W|B+^3? +|A/MG'X&PHZP0'H;4\$NC\$V69D.&)VUFW16|_.O|+XTWGG"# M7<_KD\$OB_H? 92V2<|HOV7>-=B21RA9_&6:PVDQKGW.W+Y|A+GNDK^=W|F<8(MBQ@?X" <0G(Y2O;OAI(G|D9:YHP'D4:MZ! T/Q\$;.?24:JG3^U>8Q|>)V)/; MAIFU4\$"G!YFJ*8 UW: (N XP"ZL1MN ^<2;:F;'2ZAC\$W5>A3|T?15:S|A|; (MXIGW_D4H_=;WW_V=%V_9Z|7WFPWRN7JIR2UTQK_YC|6<&:(W36B'@AW-:U=Q MG'527CYA8;M+V5|@+R+W5)PQ|,<1;D2%>T&'NZM-HWJ"5YZ&E02._/X<1' M*&#Q_KJ0G/6A.9I:?'I11"NIJ"9<+-LNM8&?PP?V&G(IUAFTCG,-RZ#;..B&V M\$8V4T| (E,IEV"-P1J^C&8Y;'GKKZO986|M/L+V=7)K|NB.U(N^?PKJ\$#Z+!_ M#XM? 5IOFZ%5|UKX<>O'P/_66**0X"W|C'UEMNATCG!+MS.OC\$X|%- MNZ1W=E)P&J:1&|:Q_F^Y3'WO_+4?M/\$SMWZ("1'WI=|-\$ \$ MPIQ;KV,-!Z? 83;)|BL&6WGI_V |3%' QX1 >% '1!>_31#HUD)FM-

T^&9\5DW*VF^"E1Y+9QU6PQ'BJHCU(^SOB1\A/2\8->X M<, |&AL=TM>!:LS ?T\X
CKIO\$128P/Z"\3GX>+!"S%K&5S'I5>;7SQ.N^ V
MD#:/G4), \$&7C\HE*K_=M?./7\DS_7\T5DWM2;8;SU7>-E&G&AX8V\$=C:2P(\>V?
6L/MVH2@5 MB@N5;(95,"X?=>.)@YH*;N!;WV61F.DE,4AZGL8!U(&7L,U+@)!-MOKPR/
^& M#^T9*UH_6_<#.F)&R\G'0&*E N\|N=:PVT25(?N(B8XDOVVCU39#UP,:"8 M!(+-
G9>|H.1Y9RUOL?&#,E^!"|EZGM5GNH?D'?>|AB%I_&TDPKX\$*K.QO\$ M?
19D"2@O*G_>J\$ _S<0\YK8V)1MGKT6.BYT#38HSBYYHN,?\$*D, T>FY(?SX@
M\$'DQ;DWH.%,!:: (5FO"*%!\%\$+B\&+3^:7:G6@-, \$5#F0B2? ^B.L+"FJ>F
MM1@@X'LA7T,N4\VS_X", '0K@\$@Q\=H81+-U@U\4E N&_GR0+1/J-UTY+NSZ M@=?
U#C4B)+2OPHDU4K\HG(9!V7B7=90H&\$?YH"N\$7@LZ+D77P<;"#Q&F47TB@TF0*?
9GJS#,:|A'_M*9ST*7%\6KWM1D\|Y+|M%X B\&7<6YY#?5G.@,:=Z#,JN"O>NB-
#MR\|NJ6 MQ9\YQ=4\KFDS\@.KWW:|#\$ _O9>@UB\|ZLT5T\0-L\|P@MZG:1JN1\X28Y>
ME!TYS:,@-YN#AF9=DBX&MZW2%XKGU>9;VNTK^S^?^A"F^\$KUK&;K-&I/Y<*<
MOT-S,+:FTX0"ZA1_ '/+U\|P_)KI0 |M**'A&Y3 M-/DDB,"4Q&D*3C\$-
(D!"@C,%4;30S+CO0YZ16=3+XW<@+3T_8H9-U@'_LZEJ
M*3E&)7RF#*V_P@O:>R%MC4VP2<|B_Z)/ R^TMP^WKX2ZE\ _H.@=/25QMH-? MHVP?
992RUA\)^*I+()@BX@:|K\|F#@;N'),?@2\O&1)5B+
<|LQ29#N(HHX@XR121\!!M99+H\K!90)RU>N!M+LO?\$B^C\1ZPZ=3-%7JCI@8*A M*
<=>W'V\$ "H#!6M'7*,|V-96^P'BE8A#=#2\$:0==+=7"M":02RFI@18E5SJ1@(G 7GM'ATK\|
M'_1&/B2X\AL4CR;2-TR&-R>|%(N5@-ACI+RQHRK\|3\0T^1\0T;=@/BJ\|C8B
M'&KSK4R=V\<|7+VYH^):?7-Z.%=<4\XGW(G /\$ ^GCQB M+8=>Y(|4-
H#OEP3_2E\ 2WR4P@_3#0"0>D;2'0IH\|SXHR\|J\$0/H%E.U!#< M\$/F>6V/M;
|U#_/*|MP?;WWR'L.6;;P\&*44XLJ.J ?\$;Y1^ O(BP1\$603"<< M\UH>H2G@C82KYJ/=Y-
|1\5QYW I%JCLUFN<6@L<1?3,GP|E/EV5L9HL)GVE3 MQH\PO94ZH'88DW0*/\$|D
EDQR::U--*E\$QE4XRQOS\|LNW%|?)D\|DB9JG*K M=GI' 9*M_)<_10+?UF-
)D%LMX10TU:"3\$1,;,%\8P)DP_'T"GD@/:5!,%X;R\|HR HN.IYHSJ/ MA?
R\|YS,6C1S7ERWDPGT?MFBHW3B\B*F*8^J"&5/@5<("1?@53\|&&9Q5GXZ):
M,0FX6GV'WAH55ZU\$B\|6&_@A(I7Y,XBWM_D>WQ1,S=_KHG""W%(F,I2% "Y
M5G@@=2Y0;PB(C3:)1\GEQF 0FY=S*|Y(X"R*|SV_-B@ (RD*6K\$*#)_>/:-
#SRY%\$CE%I\$ZV2\|0\TNO:|D>)HBQ\G M?"RA2>|R;E&SUEPWFS%<##UDKG-
M%RZ)'%<: +%P<)TZT4K@T5IQHFG .4ICK M6#9OG=P0(10&E^N-,
(+6;X:'GE*L.1TV@":M\$/P.!T.D2S^Z;X(<#OPP0MQ&2!Z"&,O\|D,O
M6K*,G8<99>#U>8%4;|X@?G&2\TES#;A3&Q \$ _3_Q\$2G&! !ZFPIFPR5&VQ M\|H;?%
Q.MDW\|#@|)?O4B\|H!+|JW:MZS^+XS0H3C M\|8&@38MB'2G VNCH\|F^O-GPGY/1\|D<-
HY4CC\MD-W;6HK\Z\10-VC3(I M%C8\ 5HZ:|39\RS\^UN,D1?
11;|04^F&\$@U:>|J=*EBQB32;P\|9'&M\|REZ&(- M4L@,Y3)@
)Z=^3F/V:WG_WHYQ\|E3)D\O=#GK'=I+/_LG N??O<,AC#
<_) 5/YASA."C65_8W^"47L@|I+ M@R)VX3P%F&BW.\|H7E\|HX-
_+O;VY!"X/Q7G\$V3X#_1?Z=|"/MD02618FOR MA\ _+LW?
TBS,P!%XIE'!;Z>D5TSSCTT6I3DG\$!CV(0!S)V9&>
M%L941F3G0%93#34Z4)R6"LB)=&Z.?<+Z(,8\|0!GQX;7\|2R8<6PBP<0USL"
MR7;'7IE*P_(@&+ZL?+HXA0*5*;M%EDEK,!9*6*L6@>OD9Y1F3;5AN\5H2TSG
M94S81)R&?ME!^\$SL#_YN\$ _6\$AQ\$+%1\O0?SEW+>B^P4Y-?069I(3>2%&^@|_
MOOGK#P093TD0;D(4/\$3>ML*<^/ M6=%Z;K\|RA*CR60%G,*+T(*\$I@A-###
|;|EMHKQ6FP'I#0;M8?R7J7Y"FY
M;^207A'M\X90O(R#W\$>G>TJH+3/UGP>Q",NC*6RABU\2,@_-T3.TM=W3\3\|
M>O#|\$Z\$-9K@BLF^|0Y@5@8'7 M9).1DT5WA+U%"1-8-'S6N3\&\$R#>K,IH*FR-C#
|T\XKB,,%?DPS1;+X? _S3
M7\|H0&TV!"#.YAN^\$4(EX*H15Y0UJ@ZD:1\$RVER\$90\$1B=0@P@;WHJU=Z\$KK
MY!GA38+W5(A1FR<5=. KWWA*3^)BPB\|X1\$^ZY\$N0?,=BI-|&%-YORC7JO##
M_:FE|U%39FN;3(C"EI?O J"G, |W^?Y+|E'Z1C4#K\|<<_C(|ZBO\9AR^>?)
M+0\|P;WG_@;QMA-U%&\$>\$7)^@\$.:"MPF=F\3KU,\|H,\$+K"%B-D1\|Y\QG6-O8
MSUL# "C\5W<;^_R;EE=G\|NRL0C6-%3.QW4WS\$%5Q3%7NU>47XG9@C7>6<^QM\$
M;G&3IV&,: ^|_1M5\AJA/*3;4P-BV5-LWPVK*U"^0PG=2L1-86Z'NKZ_ =+U M5+82:OS
KWA=E,K\&5\|U!H3JD\|CHFHN<5AP=>X\$-0D*X4\$|73\>1QK\|H M,@?LF.?
GH1\8K8G@/:.'XYZYK1FLP1#B)ZD/D.6L-SYR&)Y\:'2R\|J0RR
MX)E\|NZ\$UF4\|M\|H\J^XZ&D\|E1Q4NX?DV^",%3 0\$+>4TKV*|RR"
("S2!8LTF261H_1#WVC\|@B?O5_3++HG(D:)|F.^? MO._4+|*-%0U;8\1(X1BWD3EX&QY?

L7M8:RA\$GCNRJF6@_TZD!GM (H6J+R<MXN;A!1+%OSL#XL_AK^2,VM>J_3>
(IZ>A>!"*7-.*@-VYY^#L;J>YPB+"6U-6X M0<I)%/K'-?J>W42-5#Z-
@5WXLNHGRPD#7Y%_F^!#Z7EM'QI_-X@G=7JTL,,F M^G^'PAZ4SL53T!?
7D(B&3>C31["%XD)BV#T13L\|D/U9G,&! N"!^!(TVQ MS=^8\$NN&C/9!\$K)_7Z?
UQ"@^#84FU5*9 OV"LK!(+U^|1>&V*#M<%J &-WE& M-,%_HHSVV#D):!-
HA@18I)+|=XXL3K9C#CHOW\$Q:9WJ?=<9(BT-|65NF
M88"*I9FM5U36524W&2)L,V/N,|1(Z,-P'7?T@^F*ELK\$.|J/NN)W&;?#!-8^
M#TYXEF\$B#V9Q-024< H6I M*N|3F1+VP+J>%#FHM,WE+2' 9\$|
(E&@:Z6I3PM6^"X.FCAPR&Z7\$XQ3*/6FL M-+A=J*T/"7XD
K0PKUY1EA63:QP,F0ON,BN.LL&;:EO3B!BD*P"DB;NRHOT+ M|2V4L'5<8=
(ASMQ_I@K\$700M154A1IM_2P9_9-P|!>.,Z+1KMP1#H!R<2ANN M| E.G!^>Z@*
(QI_>.,YN_*N*_A)#!:KC(YD_E/EG&C3VK? MS=GN37U"R9"18!"C9%?./
ER/V/ELRP|M5M|)/@9(LD+"@ \$K|Z&,A0V:Z@IK
M:V;EKS:5.Z.:R7 RA6N.!D/C*O"%KXZ71R_Z&4X*T7 MEWRQDVHF'P3Q\FD&XA_)_:
:/5T9\WD#@OB30MX7:.EM40|,E/JTW.5-)WT M(4H^GHMV781@Z\2NP0MPB!Q +
|!#)&B<5N:23Y#5S/(@/."<3SV|1%S*6<^8H: MUI?
N>#"ZEUHW8:5O)F6VNN,ALE4:.)\$S8W\$SG09XZBA!S=|X1!>+D8; <&|/8'U1M|?(-&
\$:43^C%%CU9*U#.,@5&^F|8,2.;HW<-|(7WA.R|X#1 MUR\$3U,D)QD&A0B7(O*=|2P6-
_9LH#|1Y= H^Z YOL5#:)L(!SQI M7P61^O/#1;HZ2+X.4/72CK4/C=&#DQHJW879F.V;U?
H3Q.MT4F98J(^|HHSQ MD=|@^73RAN@|**|U)/WQ8/0;@PI88G5&I>^3|?|ES/QK3
%DRERW('O8W"XA M0*G19F?:XVZEH^0N)
|HLN:5D\$JZR2IBVVP H6#YCM#*%4;.:UH>EW(?*TG)G9* MM)(-<86/:06PC*)=@
Y9;>TT\$Z?B,G/NYEC^XOLO\$|/.*24G74 |\$ K:MM9 MW(+LOI^49ZG=M*PW
R*/*7R9(O_GDGI&8\1Z+5&I7|R7V*ZO,)WKC GH@>I9% MT+%)>SA4FV"H8YPF"?JG9X-?
I=_(QJ1+44L6:)H9"C+XAWY.^|0V!D1|K+G M8S6@E;LP^K)06+C2H-
E'Z3^2B\$J@=|D^1HW^",*(?)FXZ8&=-:0%+L|>+;*7V%11GZ MI4.Z:B9+!WA1Q+*1^+F
6A:.(Q.&'|01B+| M%"N|@M4J;GYR_+ #ZKV?
(;*51M*J*%|M,NLS=F+!RO(W^KWA0UE@|D*\$#'R MA'|S8L)VR_VW;.:Q;|!#-5.E+A<#
|PSD4SN#GY;ORC))1=39'(_R|B=W56<4 MA,)'&6CX,45CFJ""*%4K'|"HR1L^
M5TG.9?!UVNIXV7>AJ&@:.#^|V;=T7%*#|H?1^%\$Y#EM' ?%WWWWWV\$Z/6OZX"3
M32%"TK!\&HE00H^P+,>I J'LCERJ1WKQJ++332CD_F;U6O|OGR@OJ;|!#>^=
M_7|02P,\$% @)(IF6>G*1|LX"0 @CX X !L86(M97@S.5\Q+FAF
M; >U;ZV_.:!+ _OG\%+T47*6 YMA,WC9P6QR 8A M>Y5/6E)D\$ Q!#
(8V9/76GN,2B|LCL(XL"H:/|6FR%I_!2*+81(&AZU49+.Q
M_EFNC+!"9:\$&R:T80:NO)H\$1?Q&_OM(QZ #O()O3?,8A49DE\$@CKM=RVO-">
M7|L|2W@JY#3LB10,NX QNU8ISV:\$?66M2I'6PL0&7(I:%DI(+/&@X3,VXZ&P
M\$)B<1Q#F&H*QYGEKA?=GV2&OL8CM,\$R\$#2*DA(R8_/JL_K+6.CV@L6|. #W+|
MC^9S9OP|5=1D|=8>\$ _K/0,1&V^HG&DI+ALYK|U|I?_|%?P;Z2\6,8I#,9
MBKZPS'OHW"P;&J3>^!+;^VT2H0"@5Q?
^YGAk'/=Z|HKGK5|W|O'21"^L|UPXWVU5|TI"QV|>'Z MYD,;:=[9#=#HD^MNK|NY0?
N;7"(M!6)%-FAJR&*^:@ MB!A);LSK/10K#:0P-@)*=|JHF@YZ+W;
<3<@'<.C:K/QZGDK%B:7?!HF\$B;+ M-GR)6ORO,,1W)J.C"8SEVK:2S|A@|TV|.EN-
MI<3\$|ZS7:L|7)OQ.;L6&? 1.PTC &&)T(F'8GP4J %L\3YE7TQE|)W2*:O7 M@O|RE;
;3,ABKF/V5JB>4M*P;A95%|D\$91*+?&+GA_1"1M;X(10<75B*4%ERSA M\$=
|23*68UEGEZ>X09!"!,5Q/B23EGP#Y+LUR%Z,PB!+2<&/>!!)'14I\$B6
MX7"4!\$L\$AO:)ALP4|&,Q?@P:RDE(@508B44/5A9L+.P0%30Y)L+\$G>9%+ @5
MHYHC'!:S_G39# #N\$ /4&\$'6XSPH E(D,?)C@L?+:."|)\$R?*R7GHLLP2# J6;# MOR-
9Q#@GXF+)02N(*4&| X4WA\$A"J|0+R)7>;E98HZ2QJ| K1%()\$"<*71;
MQ\XX>2)NABR1:FQF(-0P0\$ _7!'EQNNGE1BDK2U@R,V'N2+N#TQ.\$T|)\$6P*EW MR_=^?
39IU.HG+5,BIDS(:8=722+PTKEEFW\$-#@#HT*(O@1R5>K=1P<;\$CF1 MI1C=*,+1-
>H:264*\$?-65:1)-K%4&,MPW;1|>/ 9'DO;LSP1HA&P!K8TBY
M+B12N*JSN0|OW%!7==*5OQ14#F8>@30_H|BS!\$P/%)E8T;)+48).B(|5^&*
M%)1YAH\|P9-J|67S9X'@R:N3QO&K6K-YW#RJUTX>"8%|Q!X#@;-C:|HLJTO
MXZ1"B6#\$"|Y\$,K(^H ^7W+R.9XJ-\$Z WC<2QL4KI(+,S4,%^"+2+4=+WU9&
M\$)5)W@((E3*2TD.!40|E,4J*F%LG:-^(6' M2 'A4U\$7OS.:J3"4'KH|Q|A< MTD4W90
%LAA-.5".2RJB0G(*RJB6\$V*19N((G|0NY|KX5Q^(\$!<,QT|AZ'%R
M!|D)O!FE_ZT"Z<:BY@|7-@|3&D\$68CT1,2.1&99RB,?IQH:F<(WAR'<^@|N 5
MO"^DL%/*.|>QI8W#HB"_J14*"|TCH U+D^.(G0,)X K#>0 M8?HK\$;?

X!'+:\$(@\$BUZ/3=PX1(YQ=X?.IX?.: 00V1EQ6;@X0ZX+24*OXT;H M=&9-?;7(<3<(G/YR?
@97]GU56'O%V&3T,IGU\$!E: +E1@KKSPIB MM\& -P7*TZ+)=X!Z-
R[M'BV#50648:"WC(0%P&'D/2 S/A.;F0C6,5:94V\VS4W< YTU18" "Y MH-
Y7]#8/"6*!\$KI9\A&O" -#,1I_4S\$[VV;@ST*@ FY'*3)WB,>|V'5RGE\4
MW(9.3EMB>80&%P@DZ@Q2CS\$2@)Y?9I+SCLH8C4&IH2^77'+H"CWWCF_VJN!!
M>"J:|XONR8N\1@'&IB'I?NQ5]:.;Q@TM7\0FJP>S4%"GZ'=K(:5.F!&O?
MJNR2SZ<)HVWHM;0QQTPT;OD5=&IP80IAX5XXE BI^/Q,9",E1T!)6L8'Y7MS
M748V2'.HH!/QT/EPQF_A4Y\$T^,DL=5|/R'/5_KCD&|1M,:D-)1YU9YT)AD
MH7/'*#J1!^A96""C]!:(6W.OJZ+?E0/0P23/#83&=Y_F'6';?W<[H T"J!G
MW*D7YC>M<#:^)\$*J^+:3-YO/EP]\$ETK.3D0?V/B>|Z]52PZ4,C8!0(W M\2-
V7U98H\8XNG52?,T: B\LP_3W\$!=S#?>S2-VF7#;%%NNU?^5?|6#W?
4>G%Y\8R_\$T%Y(I? M5B_UQG(^@"!3,"UE+MMPKMGFFQ6W'Z_I_6VWMC|.|\@15
M"KD<|ZEQ!?:T@+X@?_/+Z8'H\OS_4\$L#!!0 ("2*9ED)%TE /D (!! M-
;:&%B+65X,S%?,BYH=&WM7.E3X\|@2_[Y_A98IMJ_J#DD@' Y+50;" MF\2;@GF0J9KH-
ARHD6VO)*<8_ZURW9N0@SX5@@.Z\$*\$MLM\]>'^J0_+G/9-
M+,Y^(:=|1D/X)*>&&|.6M^|_6JY=KKG#H%@+Z\US<^J3:V+)>0#XHY&6-
\$S\$U=J/V#YLA0_\$8.J=F.&|==-I7|/FYWV\16Y MOB2=3RUR_JG=NB27|:OFU7F\^1E.
T7KY0%F>K*GO"L;??EZ<_NU>=4AG6MR
MVSK_>M/NM%NWI/7M_%/SZC\MTCSOD)NOG^%4=9|ZU8,=NDN:5Q>D6@_=4>EG
MM5SSEC00KK\T6A=DP8C6W?8KM<+E;ILW'YM7K500^MOGUA_6I'"E5JF\CB7
MK<*K&N\YMFJ7R">: "EE0IJ"C5PB 5.&1V-B^M3X"Y; @!<(JO7O6R!1 M\I
FNC<<\$BQG>2) J96IK\JOZJ)Y_4*|7CK<;(=>IH&_FZSYCL\$!?!L-/ (M
MQ+,TGC94F8:UDX<J1|>'!R>U_.;# MHU\HNS&\$D.YU%:-W_AUC*4@E)K;@B8?
C6:U4MA&\$J8*9&&X"C*\$T*3,ISY8_7D_.E\7,=9Y\$\$_0HUL'P/1!9"" "+F8< MM_28XA@X0'B-
B\$2D"C&%7.|M>H\$U2!K: KN\$%)D_L"9!+>U\+25)Z"Z3R(A MA\H H6(|'0%Q3^A>-
+)|#5*69K"D"V'N2;N\TSN\$T\$;P*DSYWN_?1C5*M63 MALX1DR?DN,++*)P:-
VR3:AB%#@#@T+PK&#HJ8:|W%QRLC^1(%D-TPPB'QZ!K
M(*3.8!PR5YAI(4VJ9,!"*W)#CA^R!)SKM;HZ!|DQXC30@I-YD "EMPUG?8 MKAUJ"TX\I
15+|I#Q8@\$|CW6RT=%UC_%&>Y\$V\4,HC_M*5|D\$/5
%BT%#ZFQ@G8U#SE5'!7@+A6U\3O:F3*-Z:%=<|3-)6UTDYJ!0 :B
M*0Y*X9;R(!,4@S*H9868HDPPB6ML\DV?.LR)(0;|N-9^.)Q<@/29X.TNW8@
M73G4W,/JZD%J9<@"S<|1"12+1.*T1C|.%-8SB\$J0H+J!X.>URP5B\$54(|G5
S+%NC'S=22+T&|*_%I'A"\$ M""2TL^P_7@&\$&F,T?&(Q6RPS[*^,@P)V1=G/<7-
=>AD\,44!Z! MP3D_"3N#V&,... //SS/)24=E";, U-"52S8YM(6>?<97/"IX%)[RYH?KRRZ)
M2S2\$@9I-PM+#V,OK0Q@#^(%;5W()JH;L5&,% "SY)7|J9L,4P,(<^<,
|Q4W+Y&4&4@P8)FD)|>7/S54>V5B<"CEF M<'78ERZ)HDM/^#GK|U\HE%WY^2)-
X=05|?GMWWG.M7;'S>,^\$#XZI/&|;_M&\$*|&#+VK1 M%OF6;^MO2SUA9C6Q?
ST\<1< TP0H73*_<|YXEM\#E_!NO^L9L&!?'(%^ (V\ M_.'#\$JE5:@=S^|&7W((%S4&A-
5;_.LU_#CVGZ#CY"4)U^YGH(L^*2*%\$*L MEQ7V\|Z\O;3+S)SK!;.,MV2-T-
^|\$,;W3:ZO1JX-|#^&1QDH\|MZZO8,8)_W
M.8O(M6OV)#UR/=M^Q=*3O\317\$Y*SIQFLP;|&WUIH\|MZZO;,-6#GB\OZ M\N M3O?#X
IP#_.|WP,|?&)Y4VZ3J_VTO9"ZSBE/>8E,F3%F*VYGN;,* _"V>J> M\N%
|HW"_LCB9|R(7K)|:T*>W'JU?FEGE27A>WFG?OG+L*_|5OVT_!F?|!)*<
MYKQ+;701KH^LB\$HU_)9^*(1UK&YE_|_#_)YS\U: M:7/;.!#^WE^AHY;.,H_-AI_7FV:&\$F?
*3"^D@=ST/@I+QKK*EBN)/WUMY(Q M_0JM->[M\$DRDQ!;N\K5\O/(JS7M1*?|I
5J)Q03^\$1MS32G9^\$|HEPO7:M MN_2!VD*B/1)DCI2><_JZDF(Y9IFA\$2+WUB:"ZEQIH,
<\$|*RL8|.|EG_64:=MA+)|QHGWD!15KA;#;>D?UH%TSNF?M6@Z_\$#X;QO\RB=)\$
M/:@@1EY7%(U,T+V-%4>""^F_K-N?8/?ZIT4&1X*3'O&0<):P\$=.H0.@R+|<, MB-?X)|.
|8Q*! U1N)OZ\PM -KX>|BUZW,^SU+U'_G7?|L(+%'X(NS?#WAI A
MW(+1\K;0_3=F\FIXG-UK&2OS=%H_>JJ1_4H/WX9HT+E^T\ID,!T\|PIOP3|3I
M#@W9&_5Z8U=@|(+,,S33_J';C;W-MWY0?OAML?@?8/U\|V+3JZ+?691@RE\$X
M3@1/J^@J<=<_*M()1=V\$T1B%,QI-3(V^G',(BJ1B-\$*A2")4%OF!@*P17J
M99&+|HW;JY>S1MV+@JY(64C&EU_P6FM(HX5NIU!4*?.IPH5!.4VH0"N'J:RL M%W".R:-
!2N-D+R!,Y1S/_9C3V2I.CB!3?TV4"4.9!ROC*(VE#BP@'&-1^2.L MJ"G\OH#.738-+
(_W'@I+A^YQJ^\$=GQP=GC::QX?^C=9>,(7BT1E)BC_Z'RG- MP2N^C
7+;|5K0_*5&%3./+?,QDJ%6|CTZO6|C0D?ACJ6(*L/(PT4>C^!|5#) MY^B:FC(>
4(OA\$R15W?>+V'_J9!""%/86_D@&<***-PX)WJ?4P0,#U)3U,T7Q7.C_3Y%ITOA%;,
(R0'Z*+1K-"_9O M"-RU0%P0)<;,T

9,*P/(@JAF&H"!0HY)A#O!6.2!:%8^FF&4XB\QJF)#8LZQ! MJ9&:| +
J!G::H2\PNZNCNP_ &A/NK8A@4><;B.B:3H\$BR. |<5T,!U(^X M>,0\$0,=FL
LL@>4"M!8*@"&.ZNMB<4BRJY\$39,=>LWO5#NJCO\ (S<7M6BOV*1M3>P* MX^U?
QIS8LNY;4R-%F""^ 4X#I(1HQH|@?=B'P')#@ (W0I;HL'VU'Q7%MKOFS) MP6-
8^INY WW+7;="A?=5@|N",X(*OWXM0)14|7M9XMMX7D:C/JF^&WI5SY2
MRJ"GL,AG*CO3X9D*14<9BG1FNFJV8M_19JFQC,UGAXUJ\|D@V-M#N?:+QAO
M\#5*P*:&^<7+ _Q*_:ZCDBRWZ87/B|:6;6 5W8'U 0AE M<=OFMMBO<0Q+|C&?
XKFR^W:/9KX\LG(MRU**Y83R_&9%G_0-
!-28Z|##,|,W;;J&HH('DC"LZ34)QV+A*/K5^!L+ M&1/IP!-
PT\H*#XG@VIB0P*MF.LR#SOV%MBW!*67+8\$13HE"?S-&52#\$0#," M:Y&"K28+
|6!&)SQ@)-'&A^E>N)E/J2:RG!\$@DP29RYQ%NIX_J8|\#6GL9X& M"=5.!):\$&R M?;@:?
FCW1V@T0%X3?7"";L=%PV|XN75&M5R_/ %1F0|A-%PW;5Z:._>
|0&7Q|V_T+M3LC(W:_6CVX^=D)F3.4 MZZ#N-HG1|OA_*3|<-
|O>=%>P_ATVO3)Z@_DG(3AJ,D_?|*TC/24H,Z4D@1= M4HYY1#%#@R2A\$9%
()&@(R4F,98Q>43\$2@BG4XY&+CDVW%||7?M6+PHY(|R7
M^<P8&2)VI\$V+69QS72P+IM^QG!;E&U*E^@S%W-&X@DI M|Q#_9%41PTJ|+
'JJ<.HT@YA)"6&G(|1F1H.W=SS!:(DOC-HS"F*F-X&22 MZ"9%3F&1/LV4@:%8 FOC*
(VE#BT7:-1!6.LB,GX;K'F9B'!60T8>4TJKMGM#=#|:Y|6S_W:6?W;;QR%<|@;G;\$D^'/PF9
,HF)K+"BW":R%Y|L8E"X|MUB- MC>0V|^E5JT<| |Z/:JQ -AE^'BKT?@83()
(MT14Q&3P"AEX*F2*OZKQ?T_Y+
M;H4("LQ;!G(G8|AXS@^68N%1#,)Z3^,T%U\$4PGI%",=UZKY|I+;80A JVO
MY6'RY9NL^4DFJR@3_S>1">7_!1;-IH6#-'\$|-02<264!%;C&W"M#('+IAE
M0="2'/X0\$,&C%;YT92L#R48,+;76,-28S5C.?!%4,_Z5_7G5W)U#W#YP5YR
M;2T"CQG9)T13;PA7MWT3B|G|0^C&W 'RB!F0CBY@%U@3RP5JK3H AQC.% D4
MR3"@O1:AO?'F8|LJ|00@"^_75,&=DU&|(#(K^*R.PBK=YW&BZ?OUHLS"QFF=1
MF:CH^\$#7V@|V:|HGIW?I"G_(W:FMZBMVZ38D;G|ZYL%^G=V>;7)E"+,5O3) M*74?
E9@|!|*"/>|@: ^! @U!/?7^?%VFI|N6|67/1 M03B"T1@50%14Y=;E8A|RCT-,WP7=GEKE
U4+>@R3?%+!DPJ>5)"7E 9Y M:LXGZY*2R=U|HEY(TT-EIR?!/ GF\0GF^)\VD(|,=-".
(C'C5C9&+K<\$U+UOARLL'VPT 9?|8 MKFV^I^,\$IA1@-L=+9;?
Q5L7|8|7%LU;_%_DO&WU!+ 0(4 Q0 ("2*9EG0 M4QB266<" \$ _(@ 2 " 0 !I;6'-D4\$L! A0#%
M @) (IF6>G*1|LX"0 @CX X (!*^X& &QA8BUE>#,Q M7S\$N:'1M4\$L! A0#% @)
(IF60D724|"0 @\$ \$ X M (!C_<& &QA8BUE>#,Q7S(N:'1M4\$L! A0#% @) (IF68|MC*23!0
M?2\$ X (!|P' &QA8BUE>#,R7S\$N:'1M4\$L! A0#% M @) (IF6?!0 F2\$ X (!M@8'
&QA8BUE>#,R <7S(N:'1M4\$L!@ ' < K \$ (\$,!P \$! end XML 109 lab-20240930_htm.xml
IDEA: XBRL DOCUMENT 0001162194 us-gaap:FacilityClosingMember 2024-01-
012024-09-30 0001162194 lab:InstrumentSupportServicesMember 2024-07-012024-
09-30 0001162194 lab:ProteomicsMember 2023-12-31 0001162194 2024-01-062024-
09-30 0001162194 us-gaap:CommonStockMember 2023-01-012023-03-31 0001162194
us-gaap:LeaseholdImprovementsMember 2024-09-30 0001162194
lab:IlluminaCambridgeLtdMemberlab:IlluminaAgreementMember 2021-12-31
0001162194 us-gaap:ComputerEquipmentMember 2023-12-31 0001162194 us-
gaap:CommonStockMember 2024-03-31 0001162194 us-
gaap:EmployeeStockOptionMemberlab:TwoThousandAndTwentyTwoInducementEquityI
2024-09-30 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-07-012024-09-30 0001162194 us-gaap:RetainedEarningsMember 2024-03-31
0001162194 lab:CapitalizedSoftwareDevelopmentCostsMember 2024-01-012024-09-30
0001162194 lab:NewEnglandBiolabsIncMember 2024-09-30 0001162194
lab:NecCorporationMember 2024-04-012024-04-30 0001162194 2024-02-012024-02-29
0001162194 lab:CollaborationAndOtherRevenueMember 2024-01-012024-09-30
0001162194 us-gaap:ServiceMember 2024-01-012024-09-30 0001162194 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember
2024-09-30 0001162194 2026-01-01 2024-09-30 0001162194 us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001162194 us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2024-09-30 0001162194 us-gaap:CommonStockMember 2023-07-012023-09-30
0001162194 us-gaap:ProductMembersrt:MinimumMember 2024-01-012024-09-30
0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30

0001162194 lab:TwoThousandAndSeventeenInducementAwardPlanMember 2024-09-30
0001162194 lab:SeniorConvertibleNotesDue2034Memberus-
gaap:ConvertibleDebtMember 2023-01-012023-09-30 0001162194 us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001162194 us-
gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember
2024-09-30 0001162194 2023-01-012023-09-30 0001162194 us-
gaap:OperatingSegmentsMemberlab:ProteomicsMember 2023-07-012023-09-30
0001162194 2024-05-31 0001162194 srt:MaximumMember 2024-09-30 0001162194
lab:StandardBiotooolsMember 2024-01-052024-01-05 0001162194 us-
gaap:ConvertiblePreferredStockMember 2024-09-30 0001162194
lab:ProductAndServiceMember 2024-01-012024-09-30 0001162194
lab:InstrumentsMember 2023-07-012023-09-30 0001162194 lab:GenomicsMember
2024-01-012024-09-30 0001162194 us-gaap:EmployeeSeveranceMember 2023-12-31
0001162194 srt:DirectorMemberus-
gaap:CommonStockMemberlab:CmlsHoldingsLiLleMember 2024-01-05 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30
0001162194 lab:ProteomicsMember 2023-01-012023-09-30 0001162194 us-
gaap:CommonStockMember 2023-04-012023-06-30 0001162194 us-
gaap:OtherRestructuringMember 2023-12-31 0001162194 us-
gaap:CostOfSalesMember 2024-07-012024-09-30 0001162194 us-
gaap:OperatingSegmentsMemberlab:GenomicsMember 2023-07-012023-09-30
0001162194 2025-01-01 2024-09-30 0001162194 lab:IlluminaCambridgeLtdMember
2023-12-31 0001162194 lab:SeniorConvertibleNotesDue2024Memberus-
gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMember
2019-11-012019-11-30 0001162194 us-gaap:TreasuryStockCommonMember 2023-12-
31 0001162194 us-gaap:TreasuryStockCommonMember 2024-09-30 0001162194
lab:SomaLogicPlansMember 2022-09-012022-09-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001162194 us-
gaap:RetainedEarningsMember 2024-01-012024-03-31 0001162194 us-
gaap:RetainedEarningsMember 2023-01-012023-03-31 0001162194 us-
gaap:OperatingSegmentsMemberlab:GenomicsMember 2024-01-012024-09-30
0001162194 lab:SeniorConvertibleNotesDue2024CurrentMemberus-
gaap:ConvertibleDebtMember 2024-09-30 0001162194 srt:MinimumMember 2024-09-
30 0001162194 srt:MaximumMemberlab:IlluminaCambridgeLtdMember 2024-03-31
0001162194 us-gaap:EmployeeSeveranceMember 2024-01-012024-09-30 0001162194
us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001162194 2024-09-30
0001162194 lab:TwoThousandAndElevenEquityIncentivePlanMember 2024-09-30
0001162194 us-gaap:RelatedPartyMember 2024-09-30 0001162194 2024-07-01 2024-
09-30 0001162194 us-gaap:OperatingSegmentsMemberlab:GenomicsMember 2024-07-
012024-09-30 0001162194 us-gaap:AdditionalPaidInCapitalMember 2024-06-30
0001162194 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001162194 lab:LaboratoryAndManufacturingEquipmentMember 2024-09-
30 0001162194 lab:IlluminaCambridgeLtdMember 2024-03-31 0001162194 us-
gaap:EMFAMember 2023-07-012023-09-30 0001162194 us-gaap:SecuredDebtMember
2024-09-30 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31 0001162194 lab:GenomicsMember 2023-07-012023-09-30 0001162194
lab:IlluminaCambridgeLtdMember 2024-01-012024-09-30 0001162194 us-
gaap:ServiceMember 2024-07-012024-09-30 0001162194 us-
gaap:FacilityClosingMember 2024-09-30 0001162194
srt:DirectorMemberlab:SomaLogicIncMember 2024-01-052024-01-05 0001162194
lab:TwoThousandSeventeenEmployeeStockPurchasePlanMember 2024-09-30
0001162194 lab:StandardBiotooolsMemberus-gaap:CommonStockMember 2024-01-
052024-01-05 0001162194 lab:CostOfCollaborationAndOtherRevenueMember 2023-01-
012023-09-30 0001162194 srt:MinimumMember 2024-01-012024-09-30 0001162194
us-gaap:ConvertiblePreferredStockMember 2024-03-182024-03-18 0001162194 us-

gaap:TradeNamesMember 2024-09-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001162194 us-
gaap:RetainedEarningsMember 2023-06-30 0001162194 us-
gaap:TreasuryStockCommonMember 2023-09-30 0001162194 us-
gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001162194
lab:GenomicsMember 2023-12-31 0001162194 us-
gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandSeventeenEmployeeStockPurch
2024-09-30 0001162194 2023-09-30 0001162194 2024-03-18 0001162194
lab:ConsumablesMember 2023-07-012023-09-30 0001162194
lab:IlluminaCambridgeLtdMemberlab:RoyaltiesMember 2024-03-31 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001162194 us-
gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandAndTwentyTwoInducementEqu
2024-09-30 0001162194 lab:CostOfCollaborationAndOtherRevenueMember 2024-01-
012024-09-30 0001162194 2024-01-012024-03-31 0001162194
lab:NecCorporationMember 2023-12-31 0001162194 us-gaap:ProductMember 2024-01-
012024-09-30 0001162194 us-
gaap:EmployeeStockOptionMemberlab:TwoThousandSeventeenEmployeeStockPurchase
2024-09-30 0001162194 lab:SeniorConvertibleNotesDue2024CurrentMemberus-
gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-gaap:ServiceMember 2023-
07-012023-09-30 0001162194 us-gaap:ComputerEquipmentMember 2024-09-30
0001162194 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001162194
lab:ProteomicsMember 2024-07-012024-09-30 0001162194
lab:CollaborationAndOtherRevenueMember 2023-07-012023-09-30 0001162194 us-
gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandAndSeventeenInducementAwar
2024-09-30 0001162194 lab:ProductAndServiceMember 2023-07-012023-09-30
0001162194 lab:TransactionAndIntegrationExpensesMember 2024-01-012024-09-30
0001162194 srt:AmericasMember 2024-01-012024-09-30 0001162194 us-
gaap:EmployeeStockOptionMemberlab:TwoThousandAndSeventeenInducementAwardPl
2024-09-30 0001162194 us-gaap:ProductMember 2023-01-012023-09-30 0001162194
us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2023-12-31 0001162194 us-gaap:CommonStockMember 2023-09-30 0001162194
lab:CostOfServicesMember 2024-01-012024-09-30 0001162194
lab:TwoThousandTwentyFourShareRepurchaseProgramMember 2024-02-06
0001162194 lab:IlluminaCambridgeLtdMemberlab:IlluminaAgreementMember 2024-
03-31 0001162194 2023-12-31 0001162194 lab:InstrumentsMember 2024-07-012024-
09-30 0001162194 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30
0001162194 us-gaap:TreasuryStockCommonMember 2024-04-012024-06-30
0001162194 lab:OtherMember 2024-01-012024-09-30 0001162194
lab:ExchangeConvertibleSeniorNotesDue2034Memberus-gaap:ConvertibleDebtMember
2019-11-012019-11-30 0001162194 us-gaap:CostOfSalesMember 2023-01-012023-09-
30 0001162194 lab:NecCorporationMember 2024-09-30 0001162194
lab:StandardBiotoolsMemberus-gaap:CustomerRelationshipsMember 2024-01-012024-
09-30 0001162194 us-gaap:PerformanceSharesMember 2024-01-012024-09-30
0001162194 lab:SeniorConvertibleNotesDue2024Memberus-
gaap:ConvertibleDebtMember 2019-11-30 0001162194 us-
gaap:RetainedEarningsMember 2024-07-012024-09-30 0001162194
lab:ConsumablesMember 2024-07-012024-09-30 0001162194
lab:CostOfServicesMember 2023-01-012023-09-30 0001162194 us-
gaap:RetainedEarningsMember 2024-09-30 0001162194 us-
gaap:CommonStockMember 2022-12-31 0001162194 us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember
2024-09-30 0001162194 us-gaap:DevelopedTechnologyRightsMember 2023-12-31
0001162194 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31
0001162194 lab:InstrumentSupportServicesMember 2023-07-012023-09-30
0001162194 us-gaap:EmployeeStockOptionMemberlab:SomaLogicPlansMember 2024-
09-30 0001162194 us-
gaap:RestrictedStockUnitsRSUMemberlab:SomaLogicPlansMember 2024-09-30

0001162194 lab:InstrumentsMember 2023-01-012023-09-30 0001162194 us-
gaap:OfficeEquipmentMember 2024-09-30 0001162194
srt:DirectorMemberlab:CasdinPartnersMasterFundLPMember 2024-01-05 0001162194
us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001162194 us-
gaap:CorporateNonSegmentMember 2024-01-012024-09-30 0001162194 us-
gaap:PerformanceSharesMember 2024-09-30 0001162194 lab:CostOfServicesMember
2023-07-012023-09-30 0001162194 us-
gaap:OperatingSegmentsMemberlab:ProteomicsMember 2024-07-012024-09-30
0001162194 2023-04-012023-06-30 0001162194 us-gaap:SecuredDebtMember 2023-
12-31 0001162194 us-gaap:CorporateMember 2023-01-012023-09-30 0001162194
lab:StrategicReorganizationMember 2024-01-012024-09-30 0001162194 2023-07-
012023-09-30 0001162194 us-gaap:FairValueMeasurementsRecurringMember 2023-
12-31 0001162194 lab:SeniorConvertibleNotesDue2034Memberus-
gaap:DebtInstrumentRedemptionPeriodThreeMemberus-gaap:ConvertibleDebtMember
2014-02-012014-02-28 0001162194 lab:ProductAndServiceMember 2024-07-012024-
09-30 0001162194 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001162194
us-gaap:TreasuryStockCommonMember 2023-03-31 0001162194 2023-01-012023-03-
31 0001162194 us-gaap:CorporateMember 2024-01-012024-09-30 0001162194 us-
gaap:ServiceMembersrt:MinimumMember 2024-01-012024-09-30 0001162194 us-
gaap:RetainedEarningsMember 2023-12-31 0001162194
lab:SeniorConvertibleNotesDue2034Memberus-gaap:ConvertibleDebtMember 2024-09-
30 0001162194 us-gaap:SecuredDebtMember 2024-01-012024-09-30 0001162194 us-
gaap:DevelopedTechnologyRightsMember 2024-09-30 0001162194
lab:EquityIncentivePlanMember 2024-09-30 0001162194 us-
gaap:OfficeEquipmentMember 2023-12-31 0001162194 us-
gaap:CustomerRelationshipsMember 2024-09-30 0001162194
lab:IlluminaCambridgeLtdMemberlab:IlluminaAgreementMember 2024-09-30
0001162194 us-gaap:ProductMember 2024-07-012024-09-30 0001162194
lab:SeniorConvertibleNotesDue2034Memberus-gaap:ConvertibleDebtMember 2023-12-
31 0001162194 lab:TwoThousandTwentyFourShareRepurchaseProgramMember 2024-
01-012024-09-30 0001162194 us-
gaap:EmployeeStockOptionMemberlab:TwoThousandAndElevenEquityIncentivePlanMen
2024-09-30 0001162194 lab:GenomicsMember 2024-09-30 0001162194
lab:IlluminaCambridgeLtdMember 2024-09-30 0001162194 us-
gaap:AdditionalPaidInCapitalMember 2024-09-30 0001162194 us-
gaap:RetainedEarningsMember 2024-06-30 0001162194 2023-01-012023-12-31
0001162194 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001162194
lab:ProteomicsMember 2023-07-012023-09-30 0001162194 us-
gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0001162194 us-
gaap:EmployeeStockOptionMember 2024-09-30 0001162194
lab:CollaborationAndOtherRevenueMember 2024-07-012024-09-30 0001162194 us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001162194 us-
gaap:ConvertibleDebtMember 2024-09-30 0001162194 lab:OtherMember 2023-12-31
0001162194 us-gaap:OtherRestructuringMember 2024-01-012024-09-30 0001162194
lab:CostOfServicesMember 2024-07-012024-09-30 0001162194
lab:SomalogicIncMember 2024-01-012024-09-30 0001162194 srt:AsiaPacificMember
2024-07-012024-09-30 0001162194 us-gaap:EmployeeSeveranceMember 2024-09-30
0001162194 us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001162194
lab:ProductAndServiceMember 2023-01-012023-09-30 0001162194 us-
gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0001162194
lab:IlluminaCambridgeLtdMember 2022-01-31 0001162194 us-
gaap:CommonStockMember 2023-03-31 0001162194
lab:SeniorConvertibleNotesDue2034Memberus-gaap:ConvertibleDebtMember 2019-11-
30 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-
012024-03-31 0001162194 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001162194 us-gaap:CorporateNonSegmentMember 2023-01-012023-09-

30 0001162194 lab:GenomicsMember 2023-01-012023-09-30 0001162194 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30
0001162194 lab:VikingMemberus-gaap:ConvertiblePreferredStockMember 2024-03-18
0001162194 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30
0001162194 us-gaap:EMEAMember 2024-01-012024-09-30 0001162194 us-
gaap:ProductMembersrt:MaximumMember 2024-01-012024-09-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001162194 us-
gaap:ConvertibleDebtMember 2023-12-31 0001162194 us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001162194 us-
gaap:CostOfSalesMember 2023-07-012023-09-30 0001162194
lab:EquityIncentivePlanMember 2024-01-012024-09-30 0001162194 2024-04-012024-
06-30 0001162194 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0001162194
lab:VikingMemberus-gaap:ConvertiblePreferredStockMember 2024-03-182024-03-18
0001162194 2023-03-31 0001162194 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001162194
us-gaap:FairValueInputsLevel3Memberus-
gaap:MeasurementInputExpectedTermMember 2024-09-30 0001162194 us-
gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001162194
lab:CasdinMemberus-gaap:ConvertiblePreferredStockMember 2024-03-18 0001162194
lab:IlluminaCambridgeLtdMember 2021-12-012021-12-31 0001162194 us-
gaap:FairValueInputsLevel3Memberus-
gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001162194 us-
gaap:EMEAMember 2024-07-012024-09-30 0001162194 2024-01-012024-09-30
0001162194 2024-03-31 0001162194 us-
gaap:OperatingSegmentsMemberlab:ProteomicsMember 2024-01-012024-09-30
0001162194 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30
0001162194 srt:AmericasMember 2024-07-012024-09-30 0001162194 2024-11-01
0001162194 us-gaap:CommonStockMember 2024-06-30 0001162194
srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-052024-01-05
0001162194 lab:ConsumablesMember 2023-01-012023-09-30 0001162194 us-
gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2023-12-
31 0001162194 us-gaap:OperatingSegmentsMemberlab:GenomicsMember 2023-01-
012023-09-30 0001162194 srt:AsiaPacificMember 2024-01-012024-09-30 0001162194
us-gaap:CommonStockMember 2024-01-05 0001162194 lab:CasdinMemberus-
gaap:ConvertiblePreferredStockMember 2024-03-182024-03-18 0001162194
lab:IlluminaAgreementMember 2024-09-30 0001162194 us-
gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001162194
srt:AmericasMember 2023-07-012023-09-30 0001162194 us-
gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0001162194
lab:StandardBiotoolsMember 2024-09-30 0001162194 us-
gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2023-12-31 0001162194 srt:AsiaPacificMember 2023-07-012023-09-30 0001162194 us-
gaap:SeriesBPreferredStockMember 2024-03-182024-03-18 0001162194
lab:NecCorporationMember 2020-03-31 0001162194 2024-07-012024-09-30
0001162194 2024-05-012024-05-31 0001162194 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30
0001162194 us-gaap:TreasuryStockCommonMember 2022-12-31 0001162194 us-
gaap:TreasuryStockCommonMember 2023-06-30 0001162194 us-
gaap:RetainedEarningsMember 2023-04-012023-06-30 0001162194 us-
gaap:CommonStockMember 2023-12-31 0001162194 us-
gaap:ServiceMembersrt:MaximumMember 2024-01-012024-09-30 0001162194 us-
gaap:CommonStockMember 2024-09-30 0001162194 lab:StandardBiotoolsMemberus-
gaap:TradeNamesMember 2024-01-012024-09-30 0001162194 us-
gaap:CommonStockMember 2023-06-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30
0001162194 us-gaap:ServiceMember 2023-01-012023-09-30 0001162194

lab:InstrumentSupportServicesMember 2023-01-012023-09-30 0001162194
lab:StandardBiotooolsMemberlab:PrivatePlacementWarrantsMemberus-
gaap:CommonStockMember 2024-09-30 0001162194
lab:TwoThousandAndTwentyTwoInducementEquityIncentivePlanMember 2024-09-30
0001162194 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001162194
srt:AsiaPacificMember 2023-01-012023-09-30 0001162194
lab:StandardBiotooolsMemberus-gaap:DevelopedTechnologyRightsMember 2024-01-
012024-09-30 0001162194 lab:GenomicsMember 2024-07-012024-09-30 0001162194
lab:SeniorConvertibleNotesDue2024Memberus-gaap:ConvertibleDebtMember 2023-01-
012023-09-30 0001162194 2020-09-30 0001162194 us-
gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2024-09-30 0001162194 us-gaap:OtherRestructuringMember 2024-09-30 0001162194
us-gaap:RelatedPartyMember 2024-03-31 0001162194 us-
gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001162194
lab:ConsumablesMember 2024-01-012024-09-30 0001162194
lab:StandardBiotooolsMemberlab:PublicWarrantsMemberus-
gaap:CommonStockMember 2024-09-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31
0001162194 us-gaap:FacilityClosingMember 2023-12-31 0001162194 us-
gaap:CommonStockMember 2024-04-012024-06-30 0001162194 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001162194
lab:StandardBiotooolsMemberlab:PublicWarrantsMember 2024-09-30 0001162194
lab:SomaLogicPlansMember 2024-09-30 0001162194 us-
gaap:OperatingSegmentsMemberlab:ProteomicsMember 2023-01-012023-09-30
0001162194 2022-12-31 0001162194 us-
gaap:CommonStockMemberlab:SomallogicIncMember 2024-01-05 0001162194 us-
gaap:TreasuryStockCommonMember 2024-06-30 0001162194 us-
gaap:CorporateMember 2023-07-012023-09-30 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001162194 us-
gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember 2024-09-
30 0001162194 lab:InternalUseSoftwareMember 2023-12-31 0001162194
lab:CollaborationAndOtherRevenueMember 2023-01-012023-09-30 0001162194 us-
gaap:EMEAMember 2023-01-012023-09-30 0001162194 us-
gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2023-12-31 0001162194 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2024-09-30 0001162194 us-gaap:RetainedEarningsMember 2024-04-012024-06-30
0001162194 lab:SeniorConvertibleNotesDue2034Memberus-
gaap:ConvertibleDebtMember 2019-11-012019-11-30 0001162194
srt:DirectorMemberlab:CasdinPrivateGrowthEquityFundLPMember 2024-01-05
0001162194 us-gaap:CommonStockMember 2024-01-012024-03-31 0001162194 us-
gaap:TreasuryStockCommonMember 2023-01-012023-03-31 0001162194 us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2024-09-30 0001162194
lab:StandardBiotooolsMemberlab:PrivatePlacementWarrantsMember 2024-09-30
0001162194 us-gaap:ProductMember 2023-07-012023-09-30 0001162194
lab:InternalUseSoftwareMember 2024-09-30 0001162194 us-
gaap:ConvertiblePreferredStockMember 2024-01-012024-09-30 0001162194
srt:MinimumMemberlab:IlluminaCambridgeLtdMember 2024-03-31 0001162194
lab:ProteomicsMember 2024-01-012024-09-30 0001162194 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001162194
lab:StandardBiotooolsMemberus-gaap:CommonStockMember 2024-01-05 0001162194
us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194
lab:AssayServicesMember 2024-01-012024-09-30 0001162194
lab:PublicWarrantsMemberus-gaap:CommonStockMemberlab:SomallogicIncMember

2024-09-30 0001162194 us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2024-09-30 0001162194 2023-06-30 0001162194 us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember
2023-12-31 0001162194 us-gaap:CorporateMember 2024-07-012024-09-30
0001162194 srt:DirectorMemberlab:CmlsHoldingsLtdMember 2024-01-05
0001162194 us-gaap:RetainedEarningsMember 2023-09-30 0001162194 2020-09-
012020-09-30 0001162194 us-gaap:FairValueMeasurementsRecurringMember 2024-
09-30 0001162194 us-gaap:RetainedEarningsMember 2023-03-31 0001162194 us-
gaap:CommonStockMember 2024-07-012024-09-30 0001162194 us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001162194 us-gaap:TreasuryStockCommonMember 2023-04-012023-06-
30 0001162194 lab:AssayServicesMember 2023-01-012023-09-30 0001162194 us-
gaap:RetainedEarningsMember 2023-07-012023-09-30 0001162194
srt:DirectorMember 2024-01-05 0001162194
lab:SeniorConvertibleNotesDue2024Memberus-gaap:ConvertibleDebtMember 2024-01-
012024-09-30 0001162194 us-gaap:RetainedEarningsMember 2022-12-31 0001162194
us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001162194
lab:InstrumentSupportServicesMember 2024-01-012024-09-30 0001162194 us-
gaap:TreasuryStockCommonMember 2024-03-31 0001162194 srt:MaximumMember
2024-01-012024-09-30 0001162194 lab:ProteomicsMember 2024-09-30 0001162194
us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001162194 2024-06-30
0001162194 lab:AssayServicesMember 2023-07-012023-09-30 0001162194
lab:IlluminaCambridgeLtdMember 2021-12-31 0001162194
lab:SeniorConvertibleNotesDue2034Memberus-gaap:ConvertibleDebtMember 2024-01-
012024-09-30 0001162194 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31 0001162194 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001162194 us-
gaap:ConvertiblePreferredStockMember 2024-06-182024-06-18 0001162194 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001162194
lab:LaboratoryAndManufacturingEquipmentMember 2023-12-31 0001162194
srt:AmericasMember 2023-01-012023-09-30 0001162194 us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember
2023-12-31 0001162194 lab:AssayServicesMember 2024-07-012024-09-30 0001162194
lab:NewEnglandBiolabsIncMember 2022-09-012022-09-30 0001162194 2027-01-01
2024-09-30 0001162194 srt:DirectorMember 2024-01-052024-01-05 0001162194 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30
0001162194 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-
012024-09-30 0001162194 lab:InstrumentsMember 2024-01-012024-09-30
0001162194 us-gaap:SecuredDebtMember 2021-08-02 0001162194 lab:OtherMember
2024-09-30 0001162194 lab:StandardBiotoolsMember 2024-01-05 0001162194 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30
0001162194 us-gaap:TreasuryStockCommonMember 2024-01-012024-03-31
0001162194 us-
gaap:RestrictedStockUnitsRSUMemberlab:TwoThousandAndElevenEquityIncentivePlan
2024-09-30 0001162194 us-gaap:PerformanceSharesMember 2023-12-31 0001162194
us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember 2023-
12-31 0001162194 lab:SeniorConvertibleNotesDue2024Memberus-
gaap:ConvertibleDebtMember 2024-03-31 0001162194 us-
gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember 2024-09-30
0001162194 lab:NecCorporationMember 2024-01-012024-09-30 pure shares
iso4217:USD shares lab:MonthlyInstallment lab:Office lab:Segment iso4217:USD--12-
31falseQ30001162194 P1YP6MP1YP1Y0.3448276http://fasb.org/us-
gaap/2024#PrimeRateMemberP3YP3Y10-Qtrue2024-09-302024false001-
34180STANDARD BIOTOOLS INC.DE77-05131902 Tower PlaceSuite 2000South San
FranciscoCA94080650266-6000Common Stock, \$0.001 par value per
shareLABNASDAQYesYesNon-accelerated
Filertruefalsefalse37225879821064700051704000155683000631910003531700019660

1409000-2221000-1151579000-
1000752000185800003132000464670005977000489333000-
14805100068153900032306700019593000187110006534800057814000244380006566-
31718000-21172000-142419000-
5521400000252130000394100034000013559000656000957000-115000-
865000292000-26820000-20947000-104512000-
5426600011800050000301000614000-26938000-20997000-104813000-
5488000000460140000-26938000-20997000-150827000-54880000-0.07-0.07-0.27-
0.27-0.44-0.44-0.69-
0.6937153800037153800079152000791520003460930003460930007896700078967000-
26938000-20997000-104813000-54880000-304000-403000540000-
560000395000500027200050700091000-398000812000-53000-26847000-21395000-
104001000-549330008336400083000860816000-2221000-10007520003132000-
5977000-1480510009293100093000357174000-4601400031125300017330002000-
20000-
18000470007200072000116110001161100041190001105100011051000100900010090-
32157000-321570004290004290003876520003870001674672000-1792000-
10789230007251000-1702800057731600013840001000-327000-
32600020200042500042500046500010009800009810006730000673000011329000294-
45718000-457180002920002920003897030003890001682480000-1500000-
112464100018580000-4646700051026100011020001000-71000-
7000036680006800059210005921000-26938000-
2693800091000910003908410003900001688398000-1409000-115157900018580000-
46467000489333000263677990400080000847008000-1896000-926096000422000-
563000-81467000420000-93000-9300031480003148000125000024660002466000-
16843000-168430005680005680008032400080000850063000-1328000-
9429390001672000-3029000-9715300014100001000-37000-
3600026800032600032600031140003114000120900023750002375000-17040000-
17040000-223000-2230008200200081000853466000-1551000-9599790002881000-
5404000-1133870004820001000-12000-
1100043860008600033860003386000176000399000399000-20997000-20997000-
398000-3980008252700082000856926000-1949000-9809760003057000-5803000-
131720000-104813000-
54880000252130002426200096480003533000840000093750002874000630300032100-
4740001111000611000-2272000-6770001491000032580002718000-749000-
12887000-48400034500005448000-3572000218000-4414000-2802000-443300046000-
129395000-
292260002800330002266120005585700028900000009196400049730002753000337448-
48096000-5806000-518000-196000159439000-
18740005249900082324000211938000804500004442190001644000217100040700062-

id="note_1" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. Basis of Presentation and Summary of Significant Accounting Policies</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Description of the Business</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Standard BioTools Inc. ("Standard BioTools" or the "Company") is a Delaware corporation headquartered in South San Francisco, California. The Company has an established portfolio of essential technologies that assist biomedical researchers develop medicines faster and better. The Company has

created high resolution instruments designed to provide reliable and repeatable insights in health and disease, through the use of proprietary mass cytometry and microfluidics technologies, which are useful in proteomics and genomics, to help transform scientific discoveries into better patient outcomes. Additionally, the Company has an integrated proteomics platform ("SomaScan® Platform"), capable of robust, high throughput proteomics analysis with broad proteome coverage, low limits of detection, and high reproducibility.

The Company works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding financial reporting. All intercompany transactions and balances have been eliminated in consolidation. These interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying financial statements contain all adjustments of a normal and recurring nature, necessary for a fair statement of the Company's financial position as of September 30, 2024, results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Certain prior period amounts have been reclassified to conform to the current period presentation.

Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 ("2023 Financial Statements") included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 1, 2024.

Interim results are not necessarily indicative of the results to be expected for the full year ending December 31, 2024.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.

Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.

Restructuring and Related Charges

Restructuring and related charges include employee separation costs, contract termination costs, and other costs associated with implementing restructuring plans. Employee separation costs principally consist of one-time termination benefits and contractual

termination benefits for severance, other termination benefit costs, and stock-based compensation expense for the acceleration of equity awards.

The Company records restructuring charges based on whether the termination benefits are provided under an ongoing benefit arrangement or under a one-time benefit arrangement. The Company accounts for ongoing benefit arrangements, such as those documented by employment agreements, in accordance with ASC 712,

Compensation – Nonretirement Postemployment Benefits

(“ASC 712”). Under ASC 712, liabilities for post-employment benefits are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with

ASC 420, Exit or Disposal Cost Obligations. One-time termination benefits expenses are recorded at the date the entity notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.

Level 3 – Unobservable inputs that reflect the Company’s own assumptions incorporated into valuation techniques. These valuations require significant judgment.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. When there is more than one input at different levels within the hierarchy, the fair value is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assessment of the significance of a particular input to the fair value measurement in its entirety requires substantial judgment and consideration of factors specific to the asset or liability. Level 3 inputs are inherently difficult to estimate. Changes to these inputs can have significant impact on fair value measurements.

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting in accordance with ASC 805.

Business Combinations

size:10pt;font-family:Times New Roman;min-width:fit-content;">("ASC 805").
Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. When the fair value of net assets acquired and liabilities assumed exceeds the purchase price, the Company records a gain on bargain purchase in earnings in the period of acquisition. Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Transaction costs, including legal, accounting, and integration expenses, are expensed as incurred and are included in operating expenses in the Company's condensed consolidated statements of operations.

Software Development Costs

Internal-Use Software

The Company capitalizes certain internal and external costs related to the acquisition and development of internal-use software or cloud computing arrangements during the application development stages of projects. The costs incurred for development of software intended for internal use and cloud computing arrangements are capitalized in accordance with authoritative accounting guidance.

These costs are included in property and equipment, net of accumulated depreciation and amortization in the condensed consolidated balance sheets.

When the software is ready for its intended use, the Company amortizes these costs using the straight-line method over the estimated useful life of the asset, typically

three years

, or, for cloud computing service arrangements, over the term of the hosting arrangement. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred.

Software Developed for Sale

The costs incurred for the development of computer software to be sold, leased, or otherwise marketed are capitalized in accordance with authoritative accounting guidance, when technological feasibility has been established. Technological feasibility generally occurs when all planning, design, coding and testing activities are completed that are necessary to establish that the product can be produced

size:10pt;font-family:Times New Roman;min-width:fit-content;"> </p></div>
<div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">to meet its design specifications, including functions, features and technical performance requirements. The establishment of technological feasibility is an ongoing assessment of judgment by management with respect to certain external factors, including, but not limited to, anticipated future revenues, estimated economic life and changes in technology.

</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Capitalized software costs include direct labor and related expenses for software development for new products. Capitalized software costs are included in other long-term assets in the condensed consolidated balance sheets. Amortization of capitalized software development costs begins when the product is available for general release. Amortization is provided on a product-by-product basis using the straight-line method over periods of
three years. Unamortized capitalized software development costs determined to be in excess of the net realizable value of the product are expensed immediately. Capitalized software costs are subject to an ongoing assessment of recoverability based on anticipated future revenues and changes in software technologies at each balance sheet date. In the event of impairment, unamortized capitalized software costs are compared to the net realizable value of the related product and the carrying value of the related assets are written down to the net realizable value to the extent the unamortized capitalized costs exceed such value. The net realizable value is the estimated future gross revenues from the related product reduced by the estimated future costs of completing and disposing of such product, including the costs of providing related maintenance and customer support.</p></div>

<div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenue Recognition</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Revenues are recognized when the Company's customers obtain control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the products or services (the "transaction price"). Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's contracts with customers typically include multiple distinct products and services, and the Company allocates transaction price to these performance obligations based on their relative standalone selling prices ("SSP"). The SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. SSPs are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product's SSP using a cost plus a margin approach.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payment terms may vary by customer, are based on customary commercial terms, and are generally less than one year. The Company does not adjust revenue for the effects of a

significant financing component for contracts where the period between the transfer of the good or service and collection is one year or less. The Company expenses incremental costs to obtain a contract when incurred since the amortization period of the asset that would otherwise be recognized is one year or less.

Product Revenue

The Company generates product revenue from the sale of instruments and consumables, including Integrated Fluidic Circuits and reagents. The Company generally recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer's facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in

30

to

60

days.

Revenue from the sales of certain instruments that involve significant customization, which primarily includes sales of the SomaScan® equipment bundle, is recognized over time as the Company's performance creates an asset that the customer simultaneously controls (the instrument installation and customization occurs at the customer site). Revenue is recognized based on the progress made toward achieving the performance obligation utilizing an input method of costs incurred relative to total estimated costs.

Services Revenue

The Company sometimes perform shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

The Company generates services revenue from the sale of lab services and field services. Lab services revenue is generated by performing the SomaScan® assay on customer samples to generate data on protein biomarkers. Lab services revenue is recognized at a point in time when the analysis data or report is delivered to the customer. SomaScan® services are sold at a fixed price per sample without any volume discounts, rebates, or refunds. The delivery of each assay data report is a separate performance obligation.

Field services revenue includes revenue from instrument service and support contracts. Revenue associated with these arrangements is recognized over time using a time-elapsed measure of progress, resulting in straight-line revenue recognition over the term of the agreement, which is generally

one

to

four years

. The Company measures progress using a time-elapsed measure of progress as the Company stands ready to provide service on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments collected in advance of service are reported on the Company's condensed consolidated balance sheets as deferred revenue.

Collaboration and Other Revenue

From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808,

Collaborative Arrangements

. With such collaborations, the Company determines if any obligations are an output of the Company's ordinary activities in exchange for consideration, and if so, the Company applies ASC 606,

Revenue from Contracts with Customers

("ASC 606"), to such activities.

For other payments received from collaborative partners for other collaboration activities, which primarily include research and development activities, the Company analogizes to ASC 606. Revenue from such activities is recognized as the Company satisfies its obligations.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when

the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC 606, as the grant agreement is not with a customer. As there is no authoritative GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC 958,

Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

Warrant Liabilities

In connection with the merger described in

Note 2, Business Combination, the Company assumed warrant liabilities for the warrants issued in connection with the initial public offering CM Life Sciences II Inc ("CMLS II"), the predecessor company of SomaLogic, Inc. ("SomaLogic"). CMLS II issued

5,519,991 warrants (the "Public Warrants") to purchase shares of SomaLogic common stock, par value \$

0.0001 per share ("SomaLogic Common Stock"), at \$

11.50 per share. Simultaneously, with the consummation of the CMLS II initial public offering, CMLS II issued

5,013,333 warrants through a private placement (the "Private Placement Warrants", and together with the Public Warrants, the "Warrants") to purchase shares of SomaLogic Common Stock at \$

11.50 per share. As of January 5, 2024 (the "Closing Date"), the Warrants converted into the right to receive, upon exercise of such Warrant,

1.11 shares of the Company's common stock for each share of SomaLogic Common Stock previously underlying the Warrants. The Public Warrants are no longer publicly traded and are now identical to the Private Placement Warrants.

The Warrants are classified as liabilities on the condensed consolidated balance sheet as of September 30, 2024 as these instruments are precluded from being indexed to the Company's own stock given that the terms allow for a settlement adjustment that does not meet the scope for the fixed-for-fixed exception in ASC 815, *Derivatives and Hedging*.

Since the Warrants meet the definition of a derivative under ASC 815-40, the Company recorded these warrants as long-term liabilities at fair value as of the Closing Date, with subsequent changes in fair value recognized within other income (expense), net in the condensed consolidated statement of operations for the three and nine months ended September 30, 2024.

Segment Reporting

The Company manages its business through **two** reportable operating segments: proteomics and genomics. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses performance. The Company's chief operating decision maker ("CODM"), its chief executive officer, assesses performance of operating segments and determines the allocation of resources based primarily on segment operating loss.

Recent Accounting Changes and Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting - Improvements to Reportable Segment Disclosures*, which requires disclosure of more detailed

information about a reportable segment's expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company expects to adopt ASU 2023-07 in its Annual Report on Form 10-K for the year ended December 31, 2024, and expects to include additional segment disclosures as a result of adoption.

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the impact of adoption on its income tax disclosures; however, adoption will not impact the Company's results of operations.

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses. The new standard requires additional disclosure of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories.

ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted, and may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement disclosures.

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding financial reporting. All intercompany transactions and balances have been eliminated in consolidation. These interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying financial statements contain all adjustments of a normal and recurring nature, necessary for a fair statement of the Company's financial position as of September 30, 2024, results of operations for the three and nine months ended September 30, 2024 and 2023, and cash flows for the nine months ended September 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Certain prior period amounts have been reclassified to conform to the current period presentation.

Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements as of and for the year ended December 31, 2023 ("2023 Financial Statements") included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 1, 2024.

Interim results are not necessarily indicative of the results to be expected for the full year ending December 31, 2024.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosed in the accompanying notes. Actual results could differ materially from these estimates.

Significant estimates and assumptions which form the basis of amounts reported in the condensed consolidated financial statements include, but are not limited to, the identification of performance obligations in contracts with customers; standalone selling prices of the Company's performance obligations; timing of revenue recognition; fair value measurements; net realizable value of inventory; income taxes; and the fair value of intangible assets acquired in business combinations. The Company bases its estimates on current facts and circumstances, historical experience, forecasted results, and various other assumptions that it believes to be reasonable. The Company obtains reports from third-party valuation experts to inform and support estimates related to certain fair value measurements.

Restructuring and Related Charges

Restructuring and related charges include employee separation costs, contract termination costs, and other costs associated with implementing restructuring plans. Employee separation costs principally consist of one-time termination benefits and contractual

termination benefits for severance, other termination benefit costs, and stock-based compensation expense for the acceleration of equity awards.

The Company records restructuring charges based on whether the termination benefits are provided under an ongoing benefit arrangement or under a one-time benefit arrangement. The Company accounts for ongoing benefit arrangements, such as those documented by employment agreements, in accordance with ASC 712, *Compensation – Nonretirement Postemployment Benefits* (“ASC 712”). Under ASC 712, liabilities for post-employment benefits are recorded at the time the obligations are probable of being incurred and can be reasonably estimated. The Company accounts for one-time employment benefit arrangements in accordance with ASC 420, *Exit or Disposal Cost Obligations*. One-time termination benefits expenses are recorded at the date the entity notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period. Other associated costs are recognized in the period in which the liability is incurred.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs, other than quoted prices in active markets, that are observable either directly or indirectly.

Level 3 – Unobservable inputs that reflect the Company’s own assumptions incorporated into valuation techniques. These valuations require significant judgment.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value

hierarchy. When there is more than one input at different levels within the hierarchy, the fair value is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assessment of the significance of a particular input to the fair value measurement in its entirety requires substantial judgment and consideration of factors specific to the asset or liability. Level 3 inputs are inherently difficult to estimate. Changes to these inputs can have significant impact on fair value measurements.

Business Combinations

The Company accounts for business combinations using the acquisition method of accounting in accordance with ASC 805, **Business Combinations** ("ASC 805"). Application of this method of accounting requires that (i) identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii) the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill. When the fair value of net assets acquired and liabilities assumed exceeds the purchase price, the Company records a gain on bargain purchase in earnings in the period of acquisition. Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Transaction costs, including legal, accounting, and integration expenses, are expensed as incurred and are included in operating expenses in the Company's condensed consolidated statements of operations.

Software Development Costs

Internal-Use Software

The Company capitalizes certain internal and external costs related to the acquisition and development of internal-use software or cloud computing arrangements during the application development stages of projects. The costs incurred for development of software intended for internal use and cloud computing arrangements are capitalized in accordance with authoritative accounting guidance.

These costs are included in property and equipment, net of accumulated depreciation and amortization in the condensed consolidated balance sheets.

When the software is ready for its intended use, the Company amortizes these costs using the straight-line method over the estimated

useful life of the asset, typically three years, or, for cloud computing service arrangements, over the term of the hosting arrangement. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred.

Software Developed for Sale

The costs incurred for the development of computer software to be sold, leased, or otherwise marketed are capitalized in accordance with authoritative accounting guidance, when technological feasibility has been established. Technological feasibility generally occurs when all planning, design, coding and testing activities are completed that are necessary to establish that the product can be produced

to meet its design specifications, including functions, features and technical performance requirements. The establishment of technological feasibility is an ongoing assessment of judgment by management with respect to certain external factors, including, but not limited to, anticipated future revenues, estimated economic life and changes in technology.

Capitalized software costs include direct labor and related expenses for software development for new products. Capitalized software costs are included in other long-term assets in the condensed consolidated balance sheets. Amortization of capitalized software development costs begins when the product is available for general release. Amortization is provided on a product-by-product basis using the straight-line method over periods of

three years

Unamortized capitalized software development costs determined to be in excess of the net realizable value of the product are expensed immediately. Capitalized software costs are subject to an ongoing assessment of recoverability based on anticipated future revenues and changes in software technologies at each balance sheet date. In the event of impairment, unamortized capitalized software costs are compared to the net realizable value of the related product and the carrying value of the related assets are written down to the net realizable value to the extent the unamortized capitalized costs exceed such value. The net realizable value is the estimated future gross revenues from the related product reduced by the estimated future costs of completing and disposing of such product, including the costs of providing related maintenance and customer support.

P3YP3Y

Revenue Recognition

Revenues are recognized when the Company's customers obtain control of promised goods or services, in an amount that

reflects the consideration the Company expects to receive in exchange for the products or services (the "transaction price"). Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

The Company's contracts with customers typically include multiple distinct products and services, and the Company allocates transaction price to these performance obligations based on their relative standalone selling prices ("SSP"). The SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. SSPs are generally determined using observable data from recent transactions. In cases where sufficient data is not available, the Company estimates a product's SSP using a cost plus a margin approach.

Payment terms may vary by customer, are based on customary commercial terms, and are generally less than one year. The Company does not adjust revenue for the effects of a significant financing component for contracts where the period between the transfer of the good or service and collection is one year or less. The Company expenses incremental costs to obtain a contract when incurred since the amortization period of the asset that would otherwise be recognized is one year or less.

Product Revenue

The Company generates product revenue from the sale of instruments and consumables, including Integrated Fluidic Circuits and reagents. The Company generally recognizes product revenue at the point in time when control of the goods passes to the customer, and the Company has an enforceable right to payment. This generally occurs either when the product is shipped from one of the Company's facilities or when it arrives at the customer's facility, based on the contractual terms. Customers do not have a unilateral right to return products after delivery. Invoices are generally issued at shipment or in advance of service and become due in

30 to 60 days.

Revenue from the sales of certain instruments that involve significant customization, which primarily includes sales of the SomaScan® equipment bundle, is recognized over time as the Company's performance creates an asset that the customer simultaneously controls (the instrument installation and customization occurs at the customer site). Revenue is recognized based on the progress made toward achieving the performance obligation utilizing an input method of costs incurred relative to total estimated costs.

The Company sometimes perform

shipping and handling activities after control of the product passes to the customer. The Company has made an accounting policy election to account for these activities as product fulfillment activities rather than as separate performance obligations.

Services Revenue

The Company generates services revenue from the sale of lab services and field services. Lab services revenue is generated by performing the SomaScan® assay on customer samples to generate data on protein biomarkers. Lab services revenue is recognized at a point in time when the analysis data or report is delivered to the customer. SomaScan® services are sold at a fixed price per sample without any volume discounts, rebates, or refunds. The delivery of each assay data report is a separate performance obligation.

Field services revenue includes revenue from instrument service and support contracts. Revenue associated with these arrangements is recognized over time using a time-elapsd measure of progress, resulting in straight-line revenue recognition over the term of the agreement, which is generally

one to four years

. The Company measures progress using a time-elapsd measure of progress as the Company stands ready to provide service on demand throughout the term of the agreement. Invoices are generally issued in advance of service on a monthly, quarterly, annual or multi-year basis. Payments collected in advance of service are reported on the Company's condensed consolidated balance sheets as deferred revenue.

Collaboration and Other Revenue

From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808,

Collaborative Arrangements

. With such collaborations, the Company determines if any obligations are an output of the Company's ordinary activities in exchange for consideration, and if so, the Company applies ASC 606,

Revenue from Contracts with Customers ("ASC 606"), to such activities.

For other payments received from collaborative partners for other collaboration activities, which primarily include research and development activities, the Company analogizes to ASC 606. Revenue from such activities is recognized as the Company satisfies its obligations.

Other revenue consists of license and royalty revenue and grant revenue. The Company recognizes revenue from license agreements when the license is transferred to the customer and the customer is able to use and benefit from the license. For contracts that include sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied.

The Company receives grants from various entities to perform research and development activities over contractually defined periods. Grant revenue is not accounted for under ASC 606, as the grant agreement is not with a customer. As there is no authoritative GAAP guidance for grants awarded to for-profit entities, the Company has applied the guidance in ASC 958,

Not-for-Profit Entities by analogy. Revenue is generally recognized provided that the conditions under which the grants were provided have been met and any remaining performance obligations are perfunctory.

P30DP60DP4Y

Warrant Liabilities

In connection with the merger described in *Note 2, Business Combination*, the Company assumed warrant liabilities for the warrants issued in connection with the initial public offering CM Life Sciences II Inc ("CMLS II"), the predecessor company of SomaLogic, Inc. ("SomaLogic"). CMLS II issued 5,519,991 warrants (the "Public Warrants") to purchase shares of SomaLogic common stock, par value \$0.0001

New Roman;min-width:fit-content;"> per share ("SomaLogic Common Stock"), at \$
Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;min-width:fit-content;"> per share. Simultaneously, with the
consummation of the CMLS II initial public offering, CMLS II issued
style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-
wrap;min-width:fit-content;">5,013,333<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">
warrants through a private placement (the "Private Placement Warrants", and together
with the Public Warrants, the "Warrants") to purchase shares of SomaLogic Common
Stock at \$
<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.50
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;min-width:fit-content;"> per share. As of January 5, 2024 (the "Closing
Date"), the Warrants converted into the right to receive, upon exercise of such
Warrant,
<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.11
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;min-width:fit-content;"> shares of the Company's common stock for each
share of SomaLogic Common Stock previously underlying the Warrants. The Public
Warrants are no longer publicly traded and are now identical to the Private Placement
Warrants.
<span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;">
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;">The Warrants are
classified as liabilities on the condensed consolidated balance sheet as of September
30, 2024 as these instruments are precluded from being indexed to the Company's own
stock given that the terms allow for a settlement adjustment that does not meet the
scope for the fixed-for-fixed exception in ASC 815,
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;min-width:fit-content;">. Since the Warrants meet the definition of a derivative
under ASC 815-40, the Company recorded these warrants as long-term liabilities at fair
value as of the Closing Date, with subsequent changes in fair value recognized within
other income (expense), net in the condensed consolidated statement of operations for
the three and nine months ended September 30, 2024
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;min-width:fit-content;">.
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;min-width:fit-content;">55199910.000111.5501333311.51.11
style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-
weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-
content;">Segment Reporting
<p style="font-size:10pt;margin-
top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;min-width:fit-content;">The Company manages its business through
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times
New Roman;min-width:fit-content;">
<span style="font-size:10pt;font-
family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-
content;">two<span style="color:#000000;white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable operating
segments: proteomics and genomics. Segment information is consistent with how
management reviews the business, makes investing and resource allocation decisions
and assesses performance. The Company's chief operating decision maker ("CODM"),
its chief executive officer, assesses performance of operating segments and determines
the allocation of resources based primarily on segment operating loss.

<p>2
<p>

Recent Accounting Changes and Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the FASB issued **ASU 2023-07, Segment Reporting – Improvements to Reportable Segment Disclosures**, which requires disclosure of more detailed information about a reportable segment’s expenses. The new standard is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The amendments must be applied retrospectively, and early adoption is permitted. The Company expects to adopt ASU 2023-07 in its Annual Report on Form 10-K for the year ended December 31, 2024, and expects to include additional segment disclosures as a result of adoption.

In December 2023, the FASB issued **ASU 2023-09, Improvements to Income Tax Disclosures**, which requires disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The new standard is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the impact of adoption on its income tax disclosures; however, adoption will not impact the Company’s results of operations.

In November 2024, the FASB issued **ASU No. 2024-03, Disaggregation of Income Statement Expenses**. The new standard requires additional disclosure of the nature of the expenses included in the income statement, including disaggregation of the expense captions presented on the face of the income statement into specific categories.

ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted, and may be applied retrospectively or prospectively. The Company is currently evaluating the impact of this standard on its financial statement disclosures.

2. Business Combination

bottom:0;text-align:left;">On the Closing Date, the Company completed the merger (the "Merger") with SomaLogic. As a result, SomaLogic and its subsidiaries became wholly owned subsidiaries of Standard BioTools. Upon completion of the Merger, each share of SomaLogic common stock, par value \$0.0001 per share (the "SomaLogic Common Stock"), was exchanged for 1.11 shares of the Company's common stock, par value \$0.001 per share. The fair value of the Company's common stock provided in exchange for SomaLogic Common Stock was approximately \$419.2 million. </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Purchase consideration also included replacement of equity awards attributable to pre-combination services. The acquisition-date fair value of consideration transferred in the Merger totaled approximately \$444.2 million, comprising the following:</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.54%;box-sizing:content-box;"></td><td style="width:1.9%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.56%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New

[illegible]

[illegible]

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,858</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total consideration transferred</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">444,219</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company accounted for the Merger as a business combination, using the acquisition method of accounting in accordance with ASC 805. The identifiable assets acquired and liabilities assumed of SomaLogic were recorded at their estimated fair values as of the acquisition date and consolidated with those of the Company. The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date: </p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:80.236%;box-sizing:content-box;"></td><td style="width:1.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.823%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times

Total consideration	\$444,219
Assets acquired	Cash and cash equivalents

wrap;vertical-align:bottom;"/> 	white-space:nowrap;vertical-align:bottom;"/> 	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 278,857
white-space:nowrap;vertical-align:bottom;"/> 	height:10pt;background-color:#cfff0f;word-break:break-word;"/> Short-term investments	white-space:pre-wrap;vertical-align:bottom;"/>
white-space:nowrap;vertical-align:bottom;"/> 	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 148,305	white-space:nowrap;vertical-align:bottom;"/>
height:10pt;background-color:#ffffff;word-break:break-word;"/> Accounts receivable	white-space:pre-wrap;vertical-align:bottom;"/> 	white-space:nowrap;vertical-align:bottom;"/>
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 16,430	white-space:nowrap;vertical-align:bottom;"/> 	height:10pt;background-color:#cfff0f;word-break:break-word;"/> Inventory
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 		

[illegible]

Royalty receivable	4,669	
Operating lease right-of-use assets	3,796	
Other non-current assets	1,590	
Intangible Assets		

[illegible]

Operating lease liabilities, current	1,601	Deferred revenue, current	3,522
Operating lease liabilities, non-current	2,193	Deferred revenue, non-current	

	30,667
Warrant liabilities	
	906
Other non-current liabilities	
Total Liabilities	

63,855	Total fair value of net assets acquired	469,432	Gain on bargain purchase	25,213

The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration transferred, resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, management reassessed the methods used in the acquisition accounting and verified that management had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. Management also reassessed the procedures used to measure amounts recognized at the Closing Date to ensure that the measurements reflected all consideration transferred based on available information as of the Closing Date.

Management determined that the bargain purchase gain was primarily attributable to a rapid decline in the price of the Company's common stock in the days following the announcement of the Merger, which persisted through the close of the Merger. The bargain purchase gain is separately stated below income from operations in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2024.

The preliminary fair value estimates of the net assets acquired are based upon preliminary calculations and valuations and are subject to change as the Company obtains additional information during the measurement period (up to one year from the Closing Date).

The identifiable intangible assets acquired consisted of developed technology, customer relationships, and tradename. The fair values of the developed technology and customer relationships were estimated using variations of the multi-period excess earnings method, which isolates the net earnings attributable to the asset being measured. The fair value of the SomaLogic trade name was estimated using the relief-from-royalty method, which determines the present value of license fees avoided by owning the trade name. The useful lives of acquired intangibles was estimated based on the contractual terms or period over which approximately 85% to 90% of the cumulative discounted cash flows would be realized, depending on the nature of the asset.

The valuation of the intangible assets acquired in connection with the Merger, along with their estimated useful lives, is as follows (in thousands):

	Developed technology and customer relationships	SomaLogic trade name
Estimated useful life (in years)	8.5	9.0

	Fair Value	Useful Life
Developed technology	\$	20,000
		9 years
Trade name		2,750

7 years	Customer relationships	2,750	11 years	Total fair value of intangible assets acquired	\$25,500

**align:right;">
</p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As a result of the Merger, the Company incurred \$1.9 million of transaction bonuses recorded in selling, general, and administrative expenses on the condensed consolidated statement of operations. Additionally, the Company incurred \$12.3 million of acquisition-related transaction costs reflected in transaction and integration expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2024.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unaudited Pro Forma Results</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and SomaLogic, as if the companies were combined as of January 1, 2023.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The unaudited pro forma financial information for the nine months ended September 30, 2024 combines the Company's financial results for the nine months ended September 30, 2024 and the historical results of SomaLogic for the 5-day period ended on the Closing Date. The unaudited pro forma financial information for the three and nine months ended September 30, 2023 combines the historical results of the Company and SomaLogic for their respective three and nine-month periods ended September 30, 2023. The pro forma financial information for the three and nine months ended September 30, 2023 has been adjusted to include certain nonrecurring impacts associated with the Merger, including the bargain purchase gain and transaction costs. These same impacts have been eliminated from the pro forma financial information for the nine months ended September 30, 2024.</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from the Merger, mainly including adjustments to reflect additional amortization expense from acquired intangible**

The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023.

Three Months Ended September 30,											
Nine Months Ended September 30,											
2024											

[illegible]

		\$	128,359	
		\$	141,047	
		Net loss	(26,938)	
		\$	41,204	

134,607

\$

109,000

\$

The results of SomaLogic have been consolidated with the Company's results since the Closing Date. For the period of January 6, 2024 to September 30, 2024, SomaLogic contributed revenue and loss of **61.5** million and **30.6** million, respectively. For the three months ended September 30, 2024, SomaLogic contributed revenue and loss of **22.9** million and **1.6** million, respectively.

0.00011.110.001419200000

The acquisition-date fair value of consideration transferred in the Merger totaled approximately **444.2**

New Roman;min-width:fit-content;"> million, comprising the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.54%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> SomaLogic Common Stock issued and outstanding as of January 5, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 188,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Fixed exchange ratio </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1.11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td

Shares of Standard BioTools common stock issued to SomaLogic stockholders	209,577	Standard BioTools common stock price at close of Merger	\$	2.00
Fair value of Standard BioTools common stock issued to SomaLogic stockholders	\$	Fair value of Standard BioTools replacement equity awards attributable to pre-combination service	\$	419,154
Fair value of Standard BioTools replacement equity awards attributable to pre-combination service	\$	Fair value of Standard BioTools common stock issued to SomaLogic stockholders	\$	2.00

26,923	Less: Fair value of restricted shares subject to service conditions
1,858	Total consideration transferred
\$	444,219
444,219	444,219

The following table reflects the preliminary allocation of consideration transferred to the identifiable assets acquired and liabilities assumed based on the estimated fair values as of the Closing Date:

			
			
Total consideration		\$	
444,219			
			
			
			
			
			
Assets acquired			
			

Cash and cash equivalents	278,857
Short-term investments	148,305
Accounts receivable	16,430

Inventory	14,642	
Prepaid expenses and other current assets	4,835	
Property and equipment	22,455	
Non-current inventory		

	12,208
Royalty receivable	
	4,669
Operating lease right-of-use assets	
	3,796
Other non-current assets	
	1,590

Intangible Assets	25,500	Total assets acquired	533,287
Liabilities assumed		Accounts payable and accrued liabilities	

20,660	Operating lease liabilities, current
1,601	Deferred revenue, current
3,522	Operating lease liabilities, non-current
2,193	

Deferred revenue, non-current	30,667
Warrant liabilities	906
Other non-current liabilities	4,306

[illegible]

[illegible]

Trade name	2,750	7 years
Customer relationships	2,750	11 years
Total fair value of intangible assets acquired		

#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td></tr></table>20000000P9Y2750000P7Y2750000P11Y25500000190000012300000The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2023.<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:37.2%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr></table>

[illegible]

[illegible]

[illegible]

The following tables present the Company's revenue for the									
three and nine months ended September 30, 2024 and 2023, respectively, based on product type and the geographic location of customers' facilities (in thousands):									

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

6,191			
6,452			
18,738			
18,704			
Total service revenue			

[illegible]

[illegible]

[illegible]

align:left;"> </p>
</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt
double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-
content;">\$</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">25,367</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="min-width:fit-content;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">\$</p></td>

<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">127,714</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td>

<td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p>
</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt
double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-
content;">\$</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">78,152</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="min-width:fit-content;"> </p></td> </tr> </table><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New
Roman;min-width:fit-content;"> </p> <table style="margin-left:auto;border-
spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-
right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-
sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td
style="width:9.184000000000001%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:9.184000000000001%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:9.184000000000001%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-
sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:9.184000000000001%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> </tr> <tr
style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-

[illegible]

[illegible]

	32,975
Europe, Middle East and Africa (EMEA)	
	16,057
	8,162
	39,108
	27,435

Asia-Pacific	5,161	6,340
20,365	17,742	

total revenue	\$44,969	25,367	127,714	78,152

bottom:0;text-align:left;">Illumina Cambridge, Ltd.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In connection with the Merger, the Company assumed a multi-year arrangement with Illumina Cambridge, Ltd. ("Illumina"), originally entered into by SomaLogic and Illumina in December 2021 (the "Illumina Agreement"), to jointly develop and commercialize co-branded kits that will combine Illumina's Next Generation Sequencing ("NGS") technology with SomaScan@ technology (the "Co-Branded Kits"). Pursuant to the Illumina Agreement, SomaLogic received a non-refundable upfront payment of \$30.0 million in January 2022. Subsequent to executing the Illumina Agreement, Illumina paid an additional \$0.5 million to purchase the equipment, supplies and training necessary to run the SomaScan @ assay at their facilities, representing a modification to the Illumina Agreement. As of the Closing Date, the Company determined that the transaction price of the Illumina Agreement was \$30.5 million. Subsequent to commercialization of the Co-Branded Kits, the Company is entitled to receive \$124.5 million of minimum guaranteed royalties through the term of the Illumina Agreement. No royalties were included in the Illumina transaction price as probability of commercialization had not been achieved as of the Closing Date.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Subsequent to commercialization of the Co-Branded Kits, Illumina has the right to purchase SOMAmer reagents below SSP through the remaining term of the Illumina Agreement, which will continue for approximately8 years following commercialization. Illumina's option to purchase SOMAmer reagents below SSP for this period represents a significant material right (the "Material Right"). As of the Closing Date, the Company allocated \$30.4 million of the Illumina transaction price to the Material Right, which will be recognized as revenue as Illumina purchases SOMAmer reagents post commercialization.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-

bottom:0;text-align:left;">During the first quarter of 2024, the Company determined that commercialization of the Co-Branded Kits is probable due to the launch of an early-access program, and adjusted the transaction price to include \$127.9 million of royalties expected to be received from 2025 through 2032. The Company allocated \$0.4 million of the adjusted transaction price to satisfy performance obligations, and recognized that amount as revenue on a cumulative catch-up basis. The total transaction price of the Illumina Agreement as adjusted is \$158.4 million. Substantially all of the transaction price is allocated to the Material Right, which the Company expects to recognize as revenue over an 8-year period from 2025 through 2032. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">NEC Corporation</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Additionally, in connection with the Merger, the Company assumed a joint development and commercialization agreement (the "JDCA") with NEC Solution Innovators, Ltd. ("NEC"), originally entered into by SomaLogic and NEC in March 2020, to develop and commercialize SomaScan® services in Japan. The JDCA is within the scope of ASC 808 as both companies are active participants and are exposed to significant rewards and risks dependent on commercial failure or success, and is accounted for by analogy to ASC 606. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In connection with the

Merger, the Company assumed certain contract liabilities and recorded \$1.8 million of deferred revenue as of the Closing Date. Under the JDCA, the Company was entitled to receive \$2.0 million in exchange for research and development services, which was received in April 2024. As of September 30, 2024, deferred revenue related to the JDCA was \$1.5 million, which is expected to be fully recognized by March 31, 2025.

New England Biolabs, Inc.

Also in connection with the Merger, the Company assumed a non-exclusive licensing agreement with New England Biolabs, Inc. ("NEB"), originally entered into by SomaLogic and NEB in September 2022 (the "License Agreement"), whereby the Company provides a license to use certain proprietary information and know-how relating to SomaLogic's aptamer technology. Under the License Agreement, the Company is guaranteed fixed minimum royalties of \$8.7 million to be received through September 2025. No revenue related to the guaranteed fixed minimum royalties will be recognized, as all revenue related to the receivable was recognized by SomaLogic prior to the Merger. Any revenue above the guaranteed fixed minimum royalties will be recognized in the period in which the subsequent sale or usage has occurred. As of September 30, 2024, royalties receivable related to this agreement were \$8.2 million, including a current and non-current portion of \$4.8 million and \$3.4 million, respectively.

[illegible]

		Total
Deferred revenue at December 31, 2023		\$
		\$
		\$
		\$
		15,127

[illegible]

[illegible]

12,552	Revenue deferred during the period, net of revenue recognized
1,000	8,354

[illegible]

Roman; margin-bottom: 0; text-align: left; ">\$</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">46,118</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> </tr> </table></div><div style="font-size: 10pt; font-family: Times New Roman; "><p style="font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">The Company expects to recognize revenue from unfulfilled performance obligations associated with service contracts that were partially completed as of September 30, 2024 in the following periods (in thousands):</p><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p> <table style="margin-left: auto; border-spacing: 0; table-layout: fixed; width: 99.0%; border-collapse: separate; margin-right: auto; "> <tr style="visibility: collapse; "> <td style="width: 80.236%; box-sizing: content-box; "></td> <td style="width: 1.94%; box-sizing: content-box; "></td> <td style="width: 1%; box-sizing: content-box; "></td> <td style="width: 15.823%; box-sizing: content-box; "></td> <td style="width: 1%; box-sizing: content-box; "></td> </tr> <tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word; "> <td style="vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">Fiscal Year</p></td> <td style="vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; text-align: left; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center; "></p></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: left; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center; ">Expected Revenue(1)</p></td> <td style="vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; text-align: left; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center; "></p></td> </tr> <tr style="height: 10pt; background-color: #cfff0f; word-break: break-word; "> <td style="white-space: pre-wrap; vertical-align: top; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">2024remainder of the year</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: nowrap; vertical-align: bottom; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">\$</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; "></p></td> </tr> </table></div>

content;">4,321</p></td>	<td style="white-space: nowrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
	<td style="white-space: pre-wrap; vertical-align: top;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">2025</p></td>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<td style="white-space: nowrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
<td style="white-space: pre-wrap; vertical-align: bottom; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">9,002</p></td>	<td style="white-space: nowrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
	<td style="white-space: pre-wrap; vertical-align: top;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">2026</p></td>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<td style="white-space: nowrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
<td style="white-space: pre-wrap; vertical-align: bottom; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">3,678</p></td>	<td style="white-space: nowrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
	<td style="white-space: pre-wrap; vertical-align: top;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Thereafter</p></td>
<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>
<td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">1,790</p></td>	<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"><span

Total

\$

18,791

(1)

Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

The Company also has unsatisfied performance obligations for service contracts with an expected term of one year or less not included in the amounts above.

The following tables present the Company's revenue for the

three and nine months ended September 30, 2024 and 2023, respectively, based on product type and the geographic location of customers' facilities (in thousands):

[illegible]

[illegible]

Instruments	
\$	
5,586	
\$	
9,002	
\$	
19,959	
\$	
26,512	
Consumables	

[illegible]

[illegible]

[illegible]

[illegible]

New Roman									
18,738									
18,704									
<tr><td>Total service revenue</td><td></td></tr> <tr><td>24,438</td><td></td></tr> <tr><td>6,566</td><td></td></tr> <tr><td></td><td></td></tr>		Total service revenue		24,438		6,566			
Total service revenue									
24,438									
6,566									

[illegible]

[illegible]

2,848	
1,070	
Total revenue	
\$	44,969
\$	
25,367	\$

#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">127,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-

[illegible]

23,751	10,865	68,241	32,975	Europe, Middle East and Africa (EMEA)	16,057

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

	406
	10,899
	12,552
	Revenue deferred during the period, net of revenue recognized
	1,000

[illegible]

[illegible]

[illegible]

2026	
3,678	
Thereafter	
1,790	
Total	
\$	
18,791	

content;"></p><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.</div></div>432100090020003678000179000018791000<p id="note_4" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">4. Goodwill and Acquired Intangible Assets, net</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The changes in the carrying value of goodwill by segment are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.2%;box-sizing:content-box;"></td><td style="width:8.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.9%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.9%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Proteomics</p></td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td>

Genomics		Total	
Balance as of December 31, 2023		85,798	
\$		20,519	
\$		\$	

content;">106,317</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-

[illegible]

[illegible]

[illegible]

wrap;vertical-align:bottom;"/> 	white-space:nowrap;vertical-align:bottom;"/> \$	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 137,414
white-space:nowrap;vertical-align:bottom;"/> 	white-space:pre-wrap;vertical-align:bottom;"/> 	white-space:nowrap;vertical-align:bottom;"/> \$
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> (	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 119,081	white-space:nowrap;vertical-align:bottom;"/>)
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 	white-space:nowrap;vertical-align:bottom;"/> \$	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 18,333
white-space:nowrap;vertical-align:bottom;"/> 	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 	white-space:nowrap;vertical-align:bottom;"/> \$
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 	white-space:nowrap;vertical-align:bottom;"/> \$	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 117,354
white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 	white-space:nowrap;vertical-align:bottom;"/> 	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>
white-space:nowrap;vertical-align:bottom;"/> \$	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> 	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>

[illegible]

[illegible]

172	2,578
—	—

[illegible]

	\$
117,354	
	\$
115,954	
	\$
1,400	

Total amortization expense of the Company's acquired intangible assets was \$0.7 million and \$2.8 million for the three months ended September 30, 2024 and 2023, respectively. Total amortization expense of the Company's acquired intangible assets was \$3.5 million and \$8.4 million for the

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine months ended September 30, 2024 and 2023, respectively. There were no indicators of impairment of goodwill, long-lived assets or intangible assets during the nine months ended September 30, 2024.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, future expected amortization expense of acquired intangible assets, net was as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:81.82%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.18%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal Period</p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 remainder of the year</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$ </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">711</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">711</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div></div>

align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,844</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,844</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,844</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,844</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,280</p></td></tr></table>

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,367</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The changes in the carrying value of goodwill by segment are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.2%;box-sizing:content-box;"></td><td style="width:8.12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.9%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.9%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Proteomics</p></td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="border-top:0.5pt solid #000000;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-

Genomics	Total	Balance as of December 31, 2023	\$	85,798	\$	20,519	\$	106,317	\$

Foreign currency translation	27	2
Balance as of September 30, 2024		\$

New Roman85,825

Acquired intangible assets, net consisted of the following (in thousands):	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2433	2434	2435	2436	2437	2438	2439	2440	2441	2442	2443	2444	2445	2446	2447	2448	2449	2450	2451	2452	2453	2454	2455	2456	2457	2458	2459	2460	2461	2462	2463	2464	2465	2466	2467	2468	2469	2470	2471	2472	2473	2474	2475	2476	2477	2478	2479	2480	2481	2482	2483	2484	2485	2486	2487	2488	2489	2490	2491	2492	2493	2494	2495	2496	2497	2498	2499	2500	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515	2516	2517	2518	2519	2520	2521	2522	2523	2524	2525	2526	2527	2528	2529	2530	2531	2532	2533	2534	2535	2536	2537	2538	2539	2540	2541	2542	2543	2544	2545	2546	2547	2548	2549	2550	2551	2552	2553	2554	2555	2556	2557	2558	2559	2560	2561	2562	2563	2564	2565	2566	2567	2568	2569	2570	2571	2572	2573	2574	2575	2576	2577	2578	2579	2580	2581	2582	2583	2584	2585	2586	2587	2588	2589	2590	2591	2592	2593	2594	2595	2596	2597	2598	2599	2600	2601	2602	2603	2604	2605	2606	2607	2608	2609	2610	2611	2612	2613	2614	2615	2616	2617	2618	2619	2620	2621	2622	2623	2624	2625	2626	2627	2628	2629	2630	2631	2632	2633	2634	2635	2636	2637	2638	2639	2640	2641	2642	2643	2644	2645	2646	2647	2648	2649	2650	2651	2652	2653	2654	2655	2656	2657	2658	2659	2660	2661	2662	2663	2664	2665	2666	2667	2668	2669	2670	2671	2672	2673	2674	2675	2676	2677	2678	2679	2680	2681	2682	2683	2684	2685	2686	2687	2688	2689	2690	2691	2692	2693	2694	2695	2696	2697	2698	2699	2700	2701	2702	2703	2704	2705	2706	2707	2708	2709	2710	2711	2712	2713	2714	2715	2716	2717	2718	2719	2720	2721	2722	2723	2724	2725	2726	2727	2728	2729	2730	2731	2732	2733	2734	2735	2736	2737	2738	2739	2740	2741	2742	2743	2744	2745	2746	2747	2748	2749	2750	2751	2752	2753	2754	2755	2756	2757	2758	2759	2760	2761	2762	2763	2764	2765	2766	2767	2768	2769	2770	2771	2772	2773	2774	2775	2776	2777	2778	2779	2780	2781	2782	2783	2784	2785	2786	2787	2788	2789	2790	2791	2792	2793	2794	2795	2796	2797	2798	2799	2800	2801	2802	2803	2804	2805	2806	2807	2808	2809	2810	2811	2812	2813	2814	2815	2816	2817	2818	2819	2820	2821	2822	2823	2824	2825	2826	2827	2828	2829	2830	2831	2832	2833	2834	2835	2836	2837	2838	2839	2840	2841	2842	2843	2844	2845	2846	2847	2848	2849	2850	2851	2852	2853	2854	2855	2856	2857	2858	2859	2860	2861	2862	2863	2864	2865	2866	2867	2868	2869	2870	2871	2872	2873	2874	2875	2876	2877	2878	2879	2880	2881	2882	2883	2884	2885	2886	2887	2888	2889	2890	2891	2892	2893	2894	2895	2896	2897	2898	2899	2900	2901	2902	2903	2904	2905	2906	2907	2908	2909	2910	2911	2912	2913	2914	2915	2916	2917	2918	2919	2920	2921	2922	2923	2924	2925	2926	2927	2928	2929	2930	2931	2932	2933	2934	2935	2936	2937	2938	2939	2940	2941	2942	2943	2944	2945	29

[illegible]

Accumulated Amortization	
Net	
Gross Carrying Amount	
Accumulated Amortization	
Net	
Developed technology	
Developed technology	

Roman
137,414
119,081
18,333
117,354
115,954

[illegible]

[illegible]

[illegible]

—	Acquired intangible assets, net	\$	142,914	119,547	23,367	\$
119,547	23,367	\$	\$	\$	\$	\$

bottom:0;text-align:right;">117,354</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(115,954</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr>
</table>1374140001190810001833300011735400011595400014000002750000294000.
style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As ofSeptember 30, 2024, future expected amortization expense of acquired intangible assets, net was as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p>
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fiscal Period</p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-

2024 remainder of the year	
\$	
711	
2025	
2,844	
2026	
2,844	
2027	
2,844	

[illegible]

bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"> </td> <td style="width:1.62%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:17.619999999999997%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:1.62%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> <td style="width:17.619999999999997%;box-sizing:content-box;"> </td> <td style="width:1%;box-sizing:content-box;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">210,647</p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-

space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">51,704</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,291</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">795</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash, cash equivalents and restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">211,938</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

52,499

Restricted cash of \$1.3 million and \$0.8 million is included in other non-current assets on the condensed consolidated balance sheets as of September 30, 2024, and December 31, 2023, respectively.

Accounts Receivable

Accounts receivable consisted of the following (in thousands):

September 30, 2024		December 31, 2023	
Trade receivables		35,337	
\$		19,972	
Royalty receivable, current			

[illegible]

628

312	Accounts receivable, net	\$35,317	19,660

19,660

Inventory

Inventory consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Raw materials	49,953	

[illegible]

[illegible]

wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,644</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory, non-current(1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,949</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"></p> <div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

(1)

The value of inventory that is not expected to be used within 12 months of the balance sheet date is classified as non-current inventory on the condensed consolidated balance sheets.

The Company recorded charges for excess and obsolete inventory of \$0.1 million and \$0.4 million for the three months ended September 30, 2024 and 2023, respectively, and \$2.0 million and \$1.0 million for the nine months ended September 30, 2024 and 2023, respectively.

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

[illegible]

[illegible]

[illegible]

	105,382
	57,342
Less accumulated depreciation and amortization	
	69,623
(Construction-in-progress)	
	35,489

[illegible]

Depreciation and amortization expense was \$3.2 million and \$1.2 million for the three months ended September 30, 2024 and 2023, respectively. Depreciation and amortization expense was \$9.4 million and \$2.9 million for the nine months ended September 30, 2024 and 2023, respectively.

Accrued Liabilities

Accrued liabilities, which are included in current liabilities on the condensed consolidated balance sheets consisted of the following (in thousands):

[illegible]

[illegible]

[illegible]

7,265

Accrued liabilities	31,686
	\$
	21,019

Refer to [note 16](#note_16)

Note 16 for additional information on restructuring.

Deferred Grant Income

In September 2020, the Company executed a contract with the National Institutes of Health ("NIH") under NIH's Rapid Acceleration of Diagnostics program to support the expansion of the Company's production capacity for its COVID-19 test products. Under the now-completed contract, the Company received \$34.0 million of funding from the NIH and used \$22.2 million on capital expenditures for its Singapore manufacturing facility. The amortization of the deferred income, which is offset against depreciation, was \$0.9 million for each of the three months ended September 30, 2024 and 2023, and \$2.7 million for each of the nine months ended September 30, 2024 and 2023. Cumulative amounts applied against depreciation expense for these assets placed in service were \$10.5 million and \$7.8 million as of September 30, 2024 and December 31, 2023, respectively, and the carrying values of these assets were \$11.7 million and \$14.4 million as of these same dates, respectively.

The current portion of deferred grant income on the Company's condensed consolidated balance sheets represents amounts expected to be offset against depreciation expense over the next twelve months. The non-current portion of deferred grant income includes amounts expected to be offset against depreciation expense in later periods.

Cash, cash equivalents and restricted cash consisted of the following (in thousands):

	September 30, 2024	September 30, 2023	December 31, 2023
Cash and cash equivalents	\$210,647		

	\$
	51,704
Restricted cash	
Total cash, cash equivalents and restricted cash	\$

[illegible]

weight:bold;min-width:fit-content;">December 31, 2023	
Trade receivables	35,337
Trade receivables	19,972
Royalty receivable, current	435

Other receivables	173	Less: allowance for expected credit losses	628	

[illegible]

[illegible]

[illegible]

Inventory	60,593	20,533
Inventory, current	42,644	20,533

Inventory, non-current

(1)	\$	17,949	—

The value of inventory that is not expected to be used within 12 months of the balance sheet date is classified as non-current inventory on the condensed consolidated balance sheets.

Property and equipment, net consisted of the following (in thousands):			

[illegible]

[illegible]

Internal-use software	16,870	—
Office furniture and fixtures	3,482	1,762

Property and equipment, gross	105,382
Less accumulated depreciation and amortization	(57,342)
Total	\$69,623

content;">(35,489</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Construction-in-progress</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,223</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property and equipment, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,982</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:10pt;background-color:#ff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr>

double #000000;"/>\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,187</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>5978500035563000174000001378500078450006232000168700000348200017<td colspan="2" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued liabilities, which are included in current liabilities on the condensed consolidated balance sheets consisted of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued compensation and related benefits</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-

[illegible]

[illegible]

1,354	1,516
Other	7,265
4,033	

[illegible]

September 30, 2024	December 31, 2023
Convertible notes:	
2014 Notes	\$
299	

[illegible]

align:bottom;"/> 	align:bottom;"/> 	align:bottom;"/> 	align:bottom;"/> 	align:bottom;text-align:center;"/> 55,099	align:left;"/>
height:10pt;background-color:#cfff0f;word-break:break-word;"/>					
align:bottom;"/> Term loan, non-current	align:bottom;"/> 	align:bottom;"/> 	align:bottom;text-align:center;"/> —	align:bottom;"/> 	align:bottom;"/>
align:bottom;"/> 	align:bottom;"/> 	align:bottom;"/> 	align:bottom;text-align:center;"/> 3,414	align:bottom;"/> Term loan, current	align:bottom;"/>
align:bottom;border-bottom:0.5pt solid #000000;"/> 	align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"/> 				

5,000	Total debt	\$
55,212	\$	63,513
Convertible Notes		

In February 2014, the Company closed an underwritten public offering of 2014 Senior Convertible Notes (the "2014 Notes"), which will mature on February 1, 2034, unless earlier converted, redeemed or repurchased in accordance

with the terms of the 2014 Notes. Holders may require the Company to repurchase all or a portion of their 2014 Notes beginning on February 6, 2029 at a repurchase price in cash equal to 100% of the principal amount of the 2014 Notes plus accrued and unpaid interest. In March 2024, the Company repurchased \$0.3 million of the outstanding principal amount of the 2014 Notes.

In November 2019, the Company issued \$55.0 million aggregate principal amount of 2019 Senior Convertible Notes (the "2019 Notes" and together with the 2014 Notes, the "Convertible Notes"). Net proceeds from the 2019 Notes issuance of \$52.7 million, after deductions for commissions and other debt issuance costs, were used to retire all but \$1.1 million of the aggregate principal value of the 2014 Notes then outstanding. The 2019 Notes bear interest at 5.25% per annum, payable semiannually on June 1 and December 1 of each year. The 2019 Notes will mature on December 1, 2024, unless earlier repurchased or converted pursuant to their terms. The 2019 Notes will be convertible at the option of the holder at any point prior to the close of business on the second scheduled trading day preceding the maturity date. The initial conversion rate of the 2019 Notes is 344.8276 shares of the Company's common stock per $\$1,000$ principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately \$2.90 per share). The conversion rate is subject to adjustment upon the occurrence of certain specified events. Those certain specified events include conversion of the 2019 Notes in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined by reference to a make-whole table set forth in the indenture governing the 2019 Notes. The conversion rate will not be adjusted for any accrued and unpaid interest. The 2019 Notes are convertible at the Company's option in whole but not in part into shares of the Company's common stock upon certain

conditions if the volume-weighted average price of the Company's common stock has equaled or exceeded 130% of the conversion price then in effect for a specified number of days.

Offering-related costs related to the Convertible Notes were capitalized as debt issuance costs and are recorded as an offset to the carrying value of the 2019 Notes.

The carrying values of the Convertible Notes approximate fair values as the interest rate and terms are reflective of the rate the Company could obtain on debt with similar terms and conditions. The Convertible Notes are not regularly traded and there is no public market for the Convertible Notes. The estimated fair values for the Convertible Notes represent Level 3 valuations since the fair values for the Convertible Notes cannot be determined by using readily observable inputs or measures, such as market prices.

Term Loan Facility.

On August 2, 2021, the Company amended its revolving credit facility to, amongst other things, provide for a new \$10.0 million term loan facility (the "Term Loan Facility"). As of December 31, 2023, the Term Loan Facility was fully drawn with an outstanding principal balance of \$7.9 million and a carrying value of \$8.4 million. The interest rate on the Term Loan Facility was the greater of 4.0% per annum or a floating per annum rate equal to the prime rate plus 0.75

size:10pt;font-family:Times New Roman;min-width:fit-content;">%. Interest on any outstanding term loan advances was due and payable monthly. In addition to the monthly interest payments, a final payment equal to 6.5% of the original principal amount of each advance was due the earlier of the maturity date or the date the advance is repaid. Principal balances were required to be repaid in 24 equal installments which began on August 1, 2023. The stated maturity of the Term Loan Facility was July 1, 2025. </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On March 4, 2024, the Company fully repaid all outstanding indebtedness owed pursuant to the Term Loan Facility and terminated the agreement.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total carrying value of debt consists of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:63.367%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.777000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.54%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.777000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr></table>

[illegible]

[illegible]

[illegible]

Total debt

\$55,212	\$63,513

7. Leases

In connection with the Merger, the Company assumed three leases for office and laboratory space, with lease terms of three to five years. One of the assumed leases expired on June 30, 2024.

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

9,789	
2026	
8,800	
2027	
7,428	
2028	
7,362	

content;">Thereafter</p></td>	white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,225</p></td>
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td>
text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,023</p></td>	white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: amount of lease payments representing interest</p></td>	white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(11,761</p></td>
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td>	height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td>
text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td>	text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td>

34,262	Less: current operating lease liabilities
6,122	Long-term operating lease liabilities
\$	Supplemental Lease Information
28,140	Supplemental information related to the Company's operating leases was as follows:

[illegible]

[illegible]

2024		2023		2024		2023	
Operating lease cost		2,386		\$		\$	

[illegible]

[illegible]

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="width: 40%; vertical-align: bottom; border-left: 1px solid black; padding-left: 10px;"> (3,228</p> </td>	(3,228</p>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;text-align:center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">(1,978</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr><tr><tr style="height: 10pt;background-color: #cff0fc;word-break: break-word;"><td style="text-indent: 10pt; white-space: pre-wrap; vertical-align: top;"><p style="margin-left: 10pt; text-indent: 0; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Total lease cost</p></td><td style="white-space: pre-wrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;text-align:center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">2,498</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;text-align:center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">2,295</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td></tr></table>	

[illegible]

[illegible]

7,428	
2028	7,362
Thereafter	
10,225	
Total	
46,023	

[illegible]

[illegible]

Weighted average discount rate	11.9%
8. Commitments and Contingencies	

Other Commitments

In the normal course of business, the Company enters into various contractual and legally binding purchase commitments. As of September 30, 2024, the Company's open commitments totaled \$16.2 million.

In connection with the Illumina Agreement, SomaLogic, and now the Company, is required to engage with two contract manufacturing organizations in order to ensure manufacturing capacity. In 2023, SomaLogic contracted with Integrated DNA Technologies, Inc. ("IDT") to manufacture custom products. Under the contract manufacturing agreement with IDT, SomaLogic committed to minimum annual purchases of \$2.3 million, which

obligation the Company subsumed in connection with the Merger. As the minimum contract term is three years, the total purchase commitment related to the Illumina Agreement is \$6.9 million. As of September 30, 2024, the Company had not yet began placing orders under the Illumina Agreement.

The Company has entered into several license and patent agreements. Under these agreements, the Company pays annual license maintenance fees, non-refundable license issuance fees, and royalties as a percentage of net sales for the sale or sublicense of products using the licensed technology. Future payments related to these license agreements have not been included in the open commitments above, as the period of time over which the future license payments will be required to be made, and the amount of such payments, are indeterminable. The Company does not expect the license payments to be material in any particular year.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In addition, the Company has entered into indemnification agreements with its officers, directors and certain other employees. With certain exceptions, these agreements provide for indemnification for related expenses including, among others, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding.

Legal Proceedings

From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. These include disputes and lawsuits related to intellectual property, mergers and acquisitions, licensing, contract law, tax, regulatory, distribution arrangements, employee relations and other matters. Periodically, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and a range of possible loss can be estimated, the Company accrues a liability for the estimated loss.

content;">Stockholder Litigation</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On December 12, 2023 two separate stockholder complaints were filed in the District of Delaware. The complaints asserted claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and Section 20(a) of the Exchange Act for allegedly causing the filing with the SEC on November 14, 2023 of a materially deficient registration statement on Form S-4. Among other remedies, the plaintiffs sought to enjoin a stockholder vote on the proposed Merger. These complaints were voluntarily dismissed. On December 13, 2023, a complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty. This complaint also sought an injunction postponing the proposed business combination between SomaLogic and the Company, which was denied by the Court on January 4, 2024. An amended complaint was filed on June 20, 2024, containing primarily the same allegations, while removing some of the defendants. The remaining defendants filed a motion to dismiss on July 5, 2024, and served an opening brief on August 19, 2024. The Plaintiffs' opposition brief is due on November 1, 2024, and the defendants' reply brief is due on December 13, 2024. No date for oral argument has been set. Litigation is inherently uncertain and there can be no assurance regarding the outcome. Whether or not any plaintiffs' claim is successful, this type of litigation may result in significant costs and divert management's attention and resources, which could adversely affect the operation of our business.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Between October 24, 2023 and January 3, 2024, SomaLogic received 18 letters from purported stockholders demanding that SomaLogic allow the inspection of its books and records and/or make corrective disclosures to its registration statement. The Company has resolved fee disputes with all but two stockholder's counsel.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In February 2024, the Company settled previously outstanding litigation with a former stockholder of SomaLogic, whereby the Company relinquished 422,048 shares of the Company's common stock that were subject to vesting conditions.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In May 2024, the Company settled previously outstanding litigation with former stockholders of SomaLogic for \$6.2 million consisting of the repurchase of approximately 1.84 million shares of the Company's common stock from the stockholders at the market price of \$2.40<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;"> per share, and a cash payment of \$1.8 million. The Company recognized a litigation loss of \$0.6 million during the nine months ended September 30, 2024.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On June 4, 2024, the Company received a demand pursuant to Section 220 of the Delaware General Corporation Law from a stockholder to inspect the Company's books and records relating to the prior conversion of the Company's Series B preferred stock. The Company has responded to the demand and has produced documents.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Additional lawsuits against us and certain of our officers or directors may be filed in the future. If additional similar complaints are filed, absent new or different allegations that are material, we will not necessarily announce such additional filings.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In the normal course of business, the Company is from time to time involved in legal proceedings or potential legal proceedings, including matters involving employment, intellectual property, or others. Although the results of litigation and claims cannot be predicted with certainty, management currently believes that the final outcome of any currently pending matters would not have a material adverse effect on our business, operating results, financial condition, or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based only on the best information available at the time. As additional information becomes available, the Company continues to reassess the potential liability related to pending claims and litigation and may revise estimates.</p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other Contingencies</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Following the Merger, the Company is responsible for SomaLogic's liabilities and obligations, including with respect to legal, financial, regulatory, and compliance matters. These liabilities and obligations will result in additional cost and expense by the Company and, if the Company has underestimated the amount of these costs and expenses or if the Company fails to satisfy any such liabilities or obligations, the Company may not realize the anticipated benefits of the Merger and there may be an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. Further, it is possible that there may be unknown, contingent or other liabilities, obligations or other problems that may arise in the future, the existence and/or magnitude of which the Company was previously unaware. Any such liabilities, obligations or other

[illegible]

	Total	
	Quoted Prices in Active Markets for Identical Assets (Level 1)	
	Significant Other Observable Inputs (Level 2)	
	Significant Unobservable Inputs (Level 3)	
	Assets:	

 	 	 		 	 	 		 	 	 		 	 	 		 	 															
 Cash equivalents—money market funds 																		 	 	 \$ 		 185,227 	 	 		 	 		 \$ 	 185,227 		

[illegible]

[illegible]

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

Investment Category	Level 1	Level 2	Level 3	Total
U.S. Government Securities	\$155,683	\$—	\$—	\$155,683
U.S. Corporate Bonds	\$—	\$—	\$—	\$—
U.S. Municipal Bonds	\$—	\$—	\$—	\$—
U.S. Structured Securities	\$—	\$—	\$—	\$—
U.S. Equity Securities	\$—	\$—	\$—	\$—
U.S. Private Equity	\$—	\$—	\$—	\$—
U.S. Real Estate	\$—	\$—	\$—	\$—
U.S. Infrastructure	\$—	\$—	\$—	\$—
U.S. Other	\$—	\$—	\$—	\$—
Non-U.S. Government Securities	\$—	\$—	\$—	\$—
Non-U.S. Corporate Bonds	\$—	\$—	\$—	\$—
Non-U.S. Municipal Bonds	\$—	\$—	\$—	\$—
Non-U.S. Structured Securities	\$—	\$—	\$—	\$—
Non-U.S. Equity Securities	\$—	\$—	\$—	\$—
Non-U.S. Private Equity	\$—	\$—	\$—	\$—
Non-U.S. Real Estate	\$—	\$—	\$—	\$—
Non-U.S. Infrastructure	\$—	\$—	\$—	\$—
Non-U.S. Other	\$—	\$—	\$—	\$—

	Fair Value Measurements At Reporting Date Using	
	Fair Value Measurements At Reporting Date Using	
Total	Total	
Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	

\$	35,385	\$
\$	35,385	—
Short-term investments—U.S. treasury securities		

63,191	
Total assets measured at fair value	
\$	

New Roman;
margin-bottom:0;text-align:right;">98,576</p></td> <td style="white-space nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

<td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,385</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,191</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">There were no transfers within the hierarchy and no changes in the valuation techniques used during the nine months ended September 30, 2024.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes available-for-sale securities (in thousands):</p><p

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

content;">340,562</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">348</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">340,910</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:9.96%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.9600000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.9600000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-

[illegible]

[illegible]

[illegible]

—		
Short-term investments—U.S. treasury securities	35,385	
1 or less		
63,169		
22		

[illegible]

\$	—
98,576	

As of September 30, 2024, no

no

t intend to sell these investments and it is not likely that the Company will be required to sell these investments before recovery of their amortized cost basis.

No

allowance for credit losses was recorded.

Liabilities measured at fair value on a recurring basis

The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs we utilized to determine such fair value:

	Fair Value Measurements Using	Level in Fair Value Hierarchy
Fair value of warrant liabilities as of Closing Date	\$906	1
Change in fair value of warrant liabilities	474	1

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of warrant liabilities as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">432</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liabilities</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Warrants were valued using Level 2 inputs as of the Closing Date as the Public Warrants were actively traded at that date. Therefore, the Company had directly observable prices for identical instruments as of the Closing Date. Following the Closing Date, and as of September 30, 2024, the Public Warrants were no longer publicly traded (see Note 1), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:</p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p

September 30, 2024	
Volatility	70.2
Warrant term	1.9

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of September 30, 2024 (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value Measurements At Reporting Date Using</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span

[illegible]

[illegible]

[illegible]

[illegible]

The following tables summarize the Company's financial instruments by significant investment category measured at fair value on a recurring basis within the fair value hierarchy as of December 31, 2023 (in thousands):

	Level 1	Level 2	Level 3	Total
Fixed income securities	\$1,234,567	\$2,345,678	\$3,456,789	\$7,037,034
Equity securities	\$4,567,890	\$5,678,901	\$6,789,012	\$16,935,803
Real estate	\$1,234,567	\$2,345,678	\$3,456,789	\$7,037,034
Other	\$1,234,567	\$2,345,678	\$3,456,789	\$7,037,034
Total	\$8,271,591	\$13,316,235	\$16,935,803	\$38,523,629

Fair Value Measurements At

	Total	
	Quoted Prices in Active Markets for Identical Assets (Level 1)	
	Significant Other Observable Inputs (Level 2)	
	Significant Unobservable Inputs (Level 3)	
	Assets:	

[illegible]

[illegible]

[illegible]

align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,191</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>1852270001852270000015568300001556830000340910000185227000155683

**style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes available-for-sale securities (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.8%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:9.96%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.960000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.960000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.960000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.960000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> **

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

content;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">340,910</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:44.8%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:9.96%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.960000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.960000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.960000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.960000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr></table>

[illegible]

[illegible]

[illegible]

[illegible]

Total assets measured at fair value	98,554	\$	22	\$	—

The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation inputs we utilized to determine such fair value:				
Fair value of warrant liabilities as of Closing Date	\$	906		Change in fair value of warrant liabilities

<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(474</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of warrant liabilities as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">432</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table>906474432Following the Closing Date, and as ofSeptember 30, 2024, the Public Warrants were no longer publicly traded (seeNote 1), so the Warrants were valued using a binomial lattice model (a special case of the income approach), using the following Level 3 inputs:<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.283%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td>

September 30, 2024	
Volatility	70.2
%	%
Risk-free rate	3.65
Warrant term	1.9
	1.9
70.23.65P1Y10M24D	

family:Times New Roman;margin-bottom:0;text-align:left;">10. Mezzanine Equity</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Series B Redeemable Preferred Stock</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On March 18, 2024, the Company entered into an exchange agreement (the "Exchange Agreement") with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, "Casdin"), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP(together, "Viking" and, collectively with Casdin, the "Investors"). Pursuant to the Exchange Agreement, the Investors exchanged (the "Exchange") an aggregate of (i)127,780 shares of Series B-1 Convertible Preferred Stock, par value \$0.001 per share (the "Series B-1 Preferred Stock"), and (ii)127,779 shares of Series B-2 Convertible Preferred Stock, par value \$0.001 per share (the "Series B-2 Preferred Stock" and, together with the Series B-1 Preferred Stock, the "Series B Preferred Stock"), representing all of the outstanding shares of Series B Preferred Stock, for an aggregate of92,930,553 shares of the Company's common stock. The Exchange was completed on March 18, 2024. Following the closing of the Exchange,no shares of Series B Preferred Stock remained outstanding, and the Company hadno amounts recorded in mezzanine equity.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On June 18, 2024, the Company filed a registration statement on Form S-3 (File No. 333-280321), which

became effective on June 27, 2024, registering the resale of 105,116,628 shares of common stock, including the shares of common stock which were issued upon conversion of the Series B Preferred Stock in the Exchange.

The Exchange was considered to be an induced conversion of preferred stock as the Investors received a lower conversion price, and were issued more shares of common stock than provided under the original terms of the Series B Convertible Preferred Stock Purchase Agreement entered into with the Investors. The \$46.0 million difference between the fair value of the inducement and the carrying value of the Series B Preferred Stock was recognized to the Company's accumulated deficit during the nine months ended September 30, 2024.

1277800.001277790.001929305530010511662846000000

11. Stockholders' Equity (Deficit)

2024 Stock Repurchase Program

On February 6, 2024, the Company's board of directors authorized a share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company may repurchase up to \$50.0 million of shares of its common stock in the open market, in one or more Rule 10b5-1 trading plans, or in negotiated transactions through March 1, 2026. The repurchases are contingent upon favorable market and business conditions and are funded by cash on hand. The program does not obligate the Company to acquire any specific number of shares. During the nine months ended September 30, 2024, the Company repurchased 13,603,617 shares of its common stock for an aggregate of \$36.1 million under the 2024 Share Repurchase

Common Shares Reserved

As of September 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

Plan Name	Number of Shares Reserved
Securities To Be Issued Upon Exercise Of Options	11,162
Securities To Be Issued Upon Release Of Restricted Stock	11,242

space:pre-wrap;font-weight:bold;min-width:fit-content;">Number Of Remaining Securities Available For Future Issuance	
2022 Inducement Equity Incentive Plan	7,320
2021 Equity Incentive Plan	454

family:Times New Roman;margin-bottom:0;text-align:right;">7,929	
7,929	7,929
12,781	12,781
23,584	23,584
2017 Inducement Award Plan	2017 Inducement Award Plan
59	59
—	—

2	2017 Employee Stock Purchase Plan
—	—
1,379	1,379
SomaLogic Plans	SomaLogic Plans

24,920	757	—	Total common stock reserved for future issuance	40,228

wrap;vertical-align:bottom;"/>

 | 14,436 | | | | 25,419 | |

500000001360361736100000

As ofSeptember 30, 2024, the Company had reserved shares of common stock for future issuance under equity compensation plans as follows (in thousands):

										

[illegible]

454	2011 Equity Incentive Plan	7,929	12,781	23,584
2017 Inducement Award Plan				

[illegible]

—	1,379
SomaLogic Plans	24,920
757	

bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#fffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total common stock reserved for future issuance</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,228</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,436</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,419</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p>732000089800045400079290001278100023584000590000200000137900024920012.

[illegible]

[illegible]

2.00	Granted	10,263	2.21	Vested	4,002

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

>2.50

Exercised	573
2.12	2.12

[illegible]

[illegible]

bottom:0;text-align:right;">196</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested at September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,006</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.76</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.1</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">93</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

[illegible]

bottom:0.75pt solid;margin-right:73.333%;text-align:left;"> </p></div><div class="item-list-element-wrapper" style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">Aggregate intrinsic value as of September 30, 2024 was calculated as the difference between the closing price per share of the Company's common stock on The Nasdaq Global Select Market on September 30, 2024, which was \$1.93, and the exercise price of the options, multiplied by the number of in-the-money options. </div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The total intrinsic value of options exercised during the three and nine months ended September 30, 2024 was nil and \$0.6 million, respectively. The total intrinsic value of options exercised during each of the three and nine months ended September 30, 2023 was immaterial. As of September 30, 2024, the aggregate unrecognized compensation costs related to outstanding unvested options under the Company's equity incentive plans were \$22.5 million. The Company expects to recognize those costs over a weighted-average period of 2.6 years. </p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Performance-based Awards</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In July 2023, the Company granted performance-based restricted stock units ("PSUs") to certain executive officers that vest based upon the achievement of specified revenue and EBITDA targets for the twelve months ended December 31, 2023, and the executive's continued employment with the Company. Stock-based compensation expense is being recognized over the requisite service

period, as it is deemed probable the Company will satisfy the performance measures. Certain of the specified revenue and EBITDA targets were met and the PSUs vested and were released from restriction in April 2024.

Activity under the performance-based awards was as follows:

</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.98%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.88%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of Units
(in thousands)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted-Average
Grant Date Fair Value per Unit</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">309</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

[illegible]

[illegible]

[illegible]

[illegible]

	2023	
	Cost of product revenue	
	\$	
		136
	\$	
		151
	\$	
		441
	\$	
		524

[illegible]

[illegible]

[illegible]

[illegible]

5,921

3,386

24,262

9,648

0.01116200000

Restricted Stock Units

[illegible]

Assumed through acquisition	
2,970	
2.00	
Granted	
10,263	
2.21	

Vested	
4,002	
2.34	
Forfeited	
1,728	
2.30	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested at September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,006</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.76</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.1</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">93</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

[illegible]

[illegible]

309	
2.42	
PSU granted	
100	
2.25	
Performance adjustment	

width:fit-content;">	white-space:nowrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">	white-space:pre-wrap;vertical-align:bottom;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> 26
white-space:nowrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;min-width:fit-content;">	white-space:pre-wrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> white-space:pre-wrap;min-width:fit-content;">	
white-space:nowrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">	white-space:pre-wrap;vertical-align:bottom;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> 2.42	white-space:nowrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">

height:10pt;background-color:#ffffff;word-break:break-word;">		
white-space:pre-wrap;vertical-align:top;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> PSU released	white-space:pre-wrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> white-space:pre-wrap;min-width:fit-content;">	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">
white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> 383	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> color:#000000;min-width:fit-content;">	white-space:pre-wrap;vertical-align:bottom;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> white-space:pre-wrap;min-width:fit-content;">
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> color:#000000;white-space:pre-wrap;min-width:fit-content;"> 2.38	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> min-width:fit-content;">
height:10pt;background-color:#cfff0c;word-break:break-word;">		
white-space:pre-wrap;vertical-align:top;"> font-size:10pt;margin-		

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p>3090002.421000002.25-260002.423830002.3800<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-based compensation expense is reported in the Company's condensed consolidated statement of operations as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-

[illegible]

2023	Cost of product revenue	\$	136	\$	151	\$	441	\$

524	
Cost of services revenue	
228	
37	
455	
122	

[illegible]

[illegible]

4,833		
2,739		
18,885		
7,759		
Total stock-based compensation expense		

[illegible]

Three Months Ended September 30,					
Nine Months Ended September 30,					
2024					
2023					
2024					
2023					

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

 	
 Weighted-average shares outstanding during the period 	
 	 371,538
 	
 	 79,152
 	
 	
 346,093 	
 	

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

85,327	111,012

(1)

The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes prior to the Company's exercise of the Issuer's Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company's common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of the Company's common stock that may be issued under the make-whole premium is

4,741,374

shares.

Note 6

for additional information on the 2019 Notes.

The

175,910

shares of the Company's common stock that were repurchased during the

three months ended September 30, 2023

shares of the Company's common stock that were repurchased during the

Roman;min-width:fit-content;",>, and the 15,448,533 and 2,634,594 shares repurchased during the nine months ended September 30, 2024 and 2023, respectively, have also been excluded from the Company's net loss per share and diluted net loss per share calculations. </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;",>Computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows (in thousands, except per share data):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;",> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;",><tr style="visibility:collapse;",><td style="width:50.38%;box-sizing:content-box;",></td><td style="width:1.22%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:9.184000000000001%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:1.22%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:9.184000000000001%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:1.22%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:9.184000000000001%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:1.22%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td><td style="width:9.184000000000001%;box-sizing:content-box;",></td><td style="width:1%;box-sizing:content-box;",></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;",><td style="vertical-align:bottom;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",> </p></td><td style="vertical-align:bottom;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",>Three Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",> </p></td><td style="vertical-align:bottom;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;",><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;",> </p></td></tr></table></div>

[illegible]

[illegible]

[illegible]

[illegible]

)	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
\$	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;
(	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
150,827	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
)	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
\$	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;
(	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
54,880	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
)	

	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	
	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	

[illegible]

period	371,538	79,152	346,093	78,967
371,538	79,152	346,093	78,967	371,538

	Net loss per share attributable to common stockholders, basic and diluted	
	\$	(0.07)
	\$	(0.27)
	\$	(0.44)

content;">0.69</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>-26938000-20997000-104813000-5488000046014000-26938000-20997000-150827000-54880000371538000371538000791520007915200034609300034609300078967000789670000.07-0.07-0.27-0.27-0.44-0.44-0.69-0.69<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.967%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.357%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.357%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-

content;">2023</p></td>																	
<tr><td ><p="" ><span="" ><td="" >rsus,="" and="" espp="" options,="" p><="" psus,="" restricted="" shares="" shares<="" span><="" stock="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>	
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>		
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>			
<tr><td ><p="" ><span="" >54,664<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>				
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>					
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>						
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>							
<tr><td ><p="" ><span="" >16,872<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>								
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>									
<tr><td ><p="" ><span="" ><td="" >series="" b="" p><="" preferred="" span><="" stock<="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>										
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>											
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>												
<tr><td ><p="" ><span="" >—<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>													
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>														
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><="" tr=""><tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr></td></tr>	<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>															
<tr><td ><="" ><p="" ><span="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr></td></tr>	<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>																
<tr><td ><p="" ><span<="" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" td=""></td></tr>																	

75,164	
2019 Notes	(1)
18,966	
18,966	
2014 Notes	
5	

[illegible]

align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,012</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">(1)<div style="width:100%;display:inline;">The conversion rate is subject to adjustment upon the occurrence of certain specified events, including voluntary conversion of the 2019 Notes prior to the Company's exercise of the Issuer's Conversion Option (as defined in the 2019 Notes) or in connection with a make-whole fundamental change, entitling the holders, under certain circumstances, to a make-whole premium in the form of an increase in the conversion rate determined based on the effective date and current price of the Company's common stock, subject to a minimum and maximum price per share. The maximum number of additional shares of the Company's common stock that may be issued under the make-whole premium is 4,741,374 shares. Refer to Note 6 for additional information on the 2019 Notes.</div></div>546640001687200075164000189660001896600050001000011692000853270001 style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">14. Income Taxes</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's quarterly provision for income taxes is based on an estimated annual effective income tax rate. The quarterly provision for income taxes also includes discrete items, such as changes in valuation allowances or adjustments upon finalization of tax returns as well as infrequently occurring items, if any, such as the effects of changes in tax laws or rates, in the interim period in which they occur.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recorded income tax expense of \$0.1 million in each of the three months ended September 30, 2024 and 2023<span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;">>, and income tax expense of \$0.3 million and \$0.6 million in thenine months ended September 30, 2024 and 2023, respectively. The decrease in the Company's tax provision reflects the effect of the Company's foreign operations, which reported lower pre-tax income in the first nine months of 2024 compared to the same period in 2023.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's effective tax rates for both periods differ from the21% U.S. Federal statutory tax rate primarily due to valuation allowances recorded against deferred tax assets on domestic losses and the tax rate differences between the United States and foreign countries. The Company maintains a valuation allowance against its U.S. deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized.</p>10000010000030000006000000.210.21<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">15. Segment Reporting</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company operates intwo reportable segments: proteomics and genomics. Each segment is identified by its unique portfolio of products. Proteomics includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. Genomics includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">During the first quarter of 2024, the CODM began using operating income to measure the operating performance of the segments. The Company determines each segment's operating income by subtracting direct expenses, including cost of revenues, research and development expense, and sales and marketing expense, from revenues. Amortization, depreciation, and restructuring charges are included in each segment's operating expenses. Corporate costs, including general and administrative expenses for functions shared by both operating segments such as executive management, human resources, and finance, along with interest and taxes, and transaction and integration expenses are excluded from each segment's results, which is consistent with how our CODM evaluates segment performance.</p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company does not prepare or report segmented balance sheet information as the CODM does not use the information to assess segment operating performance. The segments adhere to the same accounting policies

as the Company as a whole.

The Company's business segment information was as follows (in thousands):

Segment	Three Months Ended September 30,	Nine Months Ended September 30,
Operating Profit	\$1,184,000	\$3,456,000
Operating Loss	\$1,234,000	\$3,567,000
Operating Income	\$2,418,000	\$7,023,000
Operating Expense	\$1,234,000	\$3,567,000
Operating Profit	\$1,184,000	\$3,456,000
Operating Loss	\$1,234,000	\$3,567,000
Operating Income	\$2,418,000	\$7,023,000
Operating Expense	\$1,234,000	\$3,567,000

Three Months Ended September 30,

Nine Months Ended September 30,

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<p>top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >301<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >2,681<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >41<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td colspan="12"><p >="" ><p="" ><span="" ><td="" >(<="" >)<="" >16,013<="" >corporate="" <="" expenses<="" p><="" span><="" span><span="" style="white-space:pre-wrap;min-width:fit-content;" td><td="" td><tr="" td><="" tr=""></p></td></tr></p></p></p></p></p></p></p></p></p></p></p></td></p>	<p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >301<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >2,681<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><td=""><p ><p="" ><span="" >41<="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><td=""><p >="" ><span="" <="" p><="" span><="" style="min-width:fit-content;" td><="" tr=""><tr><td colspan="12"><p >="" ><p="" ><span="" ><td="" >(<="" >)<="" >16,013<="" >corporate="" <="" expenses<="" p><="" span><="" span><span="" style="white-space:pre-wrap;min-width:fit-content;" td><td="" td><tr="" td><="" tr=""></p></td></tr></p></p></p></p></p></p></p></p></p></p></p>	<p >="" ><p="" ><span="" ><td="" >(<="" >)<="" >16,013<="" >corporate="" <="" expenses<="" p><="" span><="" span><span="" style="white-space:pre-wrap;min-width:fit-content;" td><td="" td><tr="" td><="" tr=""></p>											
<p >="" ><p="" ><span="" ><td="" >(<="" >)<="" >16,013<="" >corporate="" <="" expenses<="" p><="" span><="" span><span="" style="white-space:pre-wrap;min-width:fit-content;" td><td="" td><tr="" td><="" tr=""></p>													

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

\$	9,932
Genomics	378
373	1,125

703	
Corporate	
1,540	
193	
4,590	
639	

[illegible]

content;">11,274</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table></div>2<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's business segment information was as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr></table></div>

[illegible]

 	 	 		 	 	 		 	 	 		 	
 Proteomics 		 		 \$ 		 34,565 		 		 		 	
 14,008 		 		 		 		 \$ 		 			

[illegible]

[illegible]

[illegible]

	Income (loss) from operations	
	Proteomics	\$10,210

content;">)</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(7,106</p></td>
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(48,485</p></td>
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(16,297</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Genomics</p></td>			
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,925</p></td>	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>

[illegible]

[illegible]

1,998	12,374
Transaction and integration expenses	5,079

1,666	25,024	Total loss from operations	\$
1,666	25,024	Total loss from operations	\$

space<pre>wrap</pre>;min-width:fit-content;">31,718</p>	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
</p>	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> (="" >21,172="" <="" p><="" span><="" span><span="" style="color:#000000:white-space:pre-wrap,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
	<td style="white-space:pre-wrap;vertical-align:bottom;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> ="" <="" p><="" span><="" style="white-space:pre-wrap,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> \$="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
	<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> (="" >142,419="" <="" p><="" span><="" span><span="" style="color:#000000:white-space:pre-wrap,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
	<td style="white-space:pre-wrap;vertical-align:bottom;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> ="" <="" p><="" span><="" style="white-space:pre-wrap,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> \$="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
	<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> (="" >55,214="" <="" p><="" span><="" span><span="" style="color:#000000:white-space:pre-wrap,min-width:fit-content;" td="">
	<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> <pre>p</pre> style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)="" <="" p><="" span><="" style="color:#000000,min-width:fit-content;" td="">
</tr>	
p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> ="" <="" p><="" span><="" style="white-space:pre-wrap,min-width:fit-content;" td="">	
p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> ="" <="" p><="" span><="" style="white-space:pre-wrap,min-width:fit-content;" td="">	
p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> ="" <="" p><="" span><="" style="white-space:pre-wrap,min-width:fit-content;" td="">	

[illegible]

[illegible]

[illegible]

[illegible]

639	
Total depreciation & amortization	
\$	
3,858	
\$	
3,986	
\$	
12,908	
\$	
\$	

11,274	

34565000-14008000-98954000-47296000-10404000-11359000-28760000-30856000-10210000-7106000-48485000-16297000-1925000-301000-2681000-41000-16013000-10703000-59217000-31877000-2341000-1998000-12374000-5415000-5079000-1666000-25024000-1666000-31718000-21172000-142419000-55214000-1940000-3420000-7193000-9932000-378000-373000-1125000-703000-1540000-193

16. Restructuring and Related Charges

In April 2024, following a strategic review of the combined business after completion of the Merger, the Company announced a workforce reduction plan (the "Strategic Reorganization") to reduce operating costs and focus on long-term growth opportunities. Under this Strategic Reorganization, the Company reduced its workforce by approximately 10% of its total workforce, with the majority of these employees separating by July 2024. Employees who were impacted by the Strategic Reorganization were eligible to receive severance and other benefits contingent upon an impacted employee's execution of a separation agreement. Certain impacted employees were covered by employment agreements or existing severance plans that provided termination benefits.

One-time termination benefits were recorded pursuant to ASC 420, *Exit or Disposal Cost Obligations*, while termination benefits under ongoing benefit arrangement were recorded pursuant to ASC 712, *Compensation - Nonretirement Postemployment Benefits*.

The Company recognized restructuring charges of approximately \$2.3 million and \$12.4

[illegible]

Severance and other employee-related benefits (1)	Facility Costs	Other	(2)	Total
Balance at December 31, 2023				
825				

[illegible]

[illegible]

[illegible]

\$	—
	
	
\$	—
2,541	(1)
Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.	(2)
Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed	

[illegible]

[illegible]

Proteomics	213
\$	\$

[illegible]

[illegible]

[illegible]

The following table summarizes the change in the Company's restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

	September 30, 2024	September 30, 2023	Change	% Change
Severance and other employee-related benefits	\$ 5,415	\$ 102,300	\$ -96,885	(-93.7%)
Employee stock-based compensation	\$ 1,220	\$ 1,220	\$ 0	0%
Deferred compensation	\$ 1,220	\$ 1,220	\$ 0	0%
Other long-term liabilities	\$ 1,220	\$ 1,220	\$ 0	0%
Total	\$ 7,855	\$ 104,740	\$ -96,885	(-92.4%)

The decrease in severance and other employee-related benefits is primarily due to the completion of the restructuring activities during the period.

[illegible]

 \$ 	 —
 \$ 	 825
 Restructuring and related charges 	
 9,522 	
 2,108 	

[illegible]

[illegible]

\$ —

\$

2,541

(1)

Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.

(2)

Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets.

The Company's restructuring and related charges by segment and corporate were as follows (in thousands):

[illegible]

[illegible]

[illegible]

691	
Genomics	
—	
70	
—	
629	

Corporate expenses	2,341
	1,715
	12,374
	4,095

Total restructuring and related charges		\$	2,341		\$	1,998		\$	12,374		\$	5,415

8250000082500095220002108000744000123740007806000210800074400010

17. Related Parties

In connection with the Merger, Eli Casdin, a member of the Company's board of directors and the Company's principal stockholder, and the former principal stockholder of SomaLogic, was issued 3,807 shares of common stock, 3,807 RSUs vesting in equal annual installments beginning on March 17, 2024, and 144,088 options in exchange for his shares of SomaLogic Common Stock and SomaLogic equity awards. In addition, Casdin Partners Master Fund, L.P. and Casdin Private Growth Equity Fund, L.P. received 11,246,525 and 2,744,219 shares of common stock, respectively, in exchange for their shares of SomaLogic Common Stock, which shares may be deemed to be indirectly beneficially owned by Mr. Casdin. Additionally, in connection with the Merger, Warrants held by CMLS Holdings II LLC ("CMLS LLC") converted into the right to receive, upon exercise of such warrants, 4,824,802 shares of the Company's common stock and CMLS LLC also received 7,548,000 shares of common stock in exchange for its SomaLogic Common Stock, all of which may be deemed to be indirectly beneficially owned by Mr. Casdin. In total, Mr. Casdin may be deemed to have beneficially received 26,515,248 shares of common stock in the Merger, including the shares of the Company's common stock issuable upon the vesting of RSUs and exercise of options and warrants.

On March 18, 2024, Casdin and its affiliates entered into the Exchange Agreement with the Company whereby all of the outstanding shares of the Series B-1 Preferred Stock held by Casdin and its affiliates were converted into an aggregate of 46,465,458

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock.

</p>38073807144088112465252744219482480275480002651524846465458falsefalsef

Merger consideration included 26,367 shares of common stock that were issued to a related party. Equity consideration transferred in connection with the Merger included 26,367 shares of common stock that were issued to a related party. See Note 17.

Related Parties Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's condensed consolidated financial statements and are subject

to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.

% (P;+AA@P/EHA:53CS\$X3,.BS.TTY6;F\$DID(EV@H M\$DRIO(ODVBT:RNEQ-CZ-S3F =17RA"5X-/U@9N+SL65+I%K&>+I/O.0<0; M<~AQ3344M@Q+I+ _29I.7CF 37+DQ4 ^B.G(7I>X5(=E6087302>PDM-EP6.%EIV-K%>I>1 M*(T:BG&DWA?I(S*%&.9@P19(W6^C-.MBFP QTRYPQ8IT. MGDTU)0*/- ID_ L\$R^A1.C847ZFCJYU>:QXT4E.8%455X6N5ZI>? EM<=51V M+CC%Y: W0J2737\$XQK%TW:~+FXB\$1K" JQ0ZJP(2I?B@)1^KE@IU:~06> M-T%UCWZ^&LGIV<7+NIJ2CY\$IL7^ J.L:4-SVHY.~W/Y>OIDU. G4TAVHBJ<="+IWAJ. 1SPNJK M&UU+DZGMW:LJG@.KJSD?7ARO<@>O?5(12%5MZ+&C%I 44_IY/>IW1019Q M0E8BA1\$K&I&A2)C"E.1I/E7IA&9WI.DIL^44A).IB2B?4H%ZV?3Y\$Z3RUJ# MQ_H 9I) UY(X@I@U"1.57&2I+Q9\$9'>QA@.#1+H^=O2^=8NM5\$&2J.2I M@/2)I*E#,0VYU. %&VN^~*#I5#PUU)UC8F+K+DN.M.#7GN=2HKM^UXDS1 MHT4IXQ06QW.1%*%:G575HY?F\$~GNN;L>WD7\$GW)6:@>> C'E'CYA=1CJZ MB^HC7=M0.WI%K20%6E((2&B?I).BJ U%8C1L8>T JXLE^O6POZ+*?IZ2_IJF@E.M19N9WUW.JE@I(GL:@OKAS#:(@LA M%KP%)& K\$SL:N8.NV6^ M4#AV50I@4.A(KE3+).I.J.\$&\$=? MIL^AY8U<X.M95Q:3^P+2*8B"ZH8CC MHSI.D.HI'X\$H6K/S\$%\$<J.EO.J0N1Y60IBI.&C- ENLC5AE0C:X2XHS" M?9AD:~<=HNB&+^IUIXM^O /ZHOVAUO%:HRS\$G^EW8J. MAM_K9.IJ^&C/(I41<740DX#I? .69\$LI>V/MFNT0A.4I3XIMUB97R3.*? MB66ODIWE6XM IO79X+./SN%8CA6^OKI5^* _RI.GW@2I^I)FPGA@I?SI MX/+(TF^O\$N)0%HL.CSG49.3.8OB>#JXK:1Q:RAHAU(O7^IUDKYIAQIX4.P ME81#F21^ISEDYA-HGF+H-XLFEO^NP-HS=MNN B>&7-2^7B(W^I^QUTA-TX4_MAU:YIY^2^= (#3X2^Y^AN1+2Z+70^23T5Y\$Q9I-MJ>5DC7XU)NTD1>(7W>KYIUV69VR4;/DBT+HJC(N=4M30G.D=R.DNQA JG MPAHSQJ(80\$PM5A7K\$80MOY3@_WUW/HGFLPIC2Q.> MU1V7K9<ZQ8#_Q3+NIJVL~.9%\$&I.6UM16L.R1YX\$U1L7E^DCL1%35=:4(I.MGN+&5.1DL582DTC@:2BLR^A^U38^@.3^SV+@P<#DE.:NVP^GI.CWGTRA5_I M#H5H^I&ULM5IMV9B0K.MRO\$X_EU1Z_0#>@23L^I <<~*87IIG=P<^46Y3.CB 80% MOC\$IIZ?WWI.L.R.B>BNW:CPX@5X^:X^~OK(CI?~NJ.+Y.S=N^BN>IBBYUYUZK0K=>ZW5V9OFI?)T> MY2 >V^4JTA?%||W>FEN3/QUZ|?I=1%2FW7Q@7KG6K-XL7IY-D/3>TGA2I MPYIM&Q6=).YIY_ICJPUZB.34L@TIHHD0>.26_I2-T)A@I^Y\$YACR.LR<MI_BN^N-1R-MI\$C.BMK^I^M 5%-6%Z<=I.S186R? _ZKMDAI&R.G7:QMAIYB4=K\$ZZVTF:FE=94UX2AQO!"TKI^X^M^Q\$W>T#<4 4E 9E^>AJAX_W.T.UHMLZW.Y9WIFPNJ.QNJOH>N>I?E_ 06P3-OPY900XY/WP0=(8_KI^<(FI). M>VN.+KIYZQ3QR.O7.&I2.I2I+ N.N^*ZPLD^F2HY1#YXJEI@R3IKJMHIM2*~<4)ANC^M^UP2B.4/NX.@00P8S:1I2VF#8HZZJ7MIJUO@O8XICD?3 MB8U9ZJ.9J;EU-4Y6FZZM5DAI+^S3M5EHQ.0^&LYI UXL?>@7K 2#>I J.MZ~N3^5J>I>S.D5I .?9T\$ZCB\$GIL5ROI=>TR\$M.I@JI=T48 L1O9W M3>3C2I%CN9Q (L12)^PMWIEAS7/UHL%_KGR_5I.M MGC&^PU.1#KUTU7V JYJLGLIG)I2? C3Z->O2C^3I.026U>ZW<5>?7QZPN MSS-7TMEF280K#V.ER2M1C Q.YW6WADS=14+V.KOY:SE:GF53=1V9.N5IO& M+ME8HQ +WIRUICU+M87^>~>W2M)Q I&~<@MEP.HF1855%=(HJ14QPQWAZ(I MOFYTN17AB"%Y7ZO^TZ=JM^T4O^~.166?K@:UUIHC+YS.^ ZITM-F=05#J. M:=H^C\$0%23VI\$50.MY.TN%CC^2X74C@XYOIMAMZ&-4KX2JIGINY=E4I M^P2IJC%I\$S^GW:H05-SQI2%~H1NL(K4;U-Y\$ I7IKM3\$MED:~(=C.MP18&I&P4V FK07_I(3Z+3K5Q2^~X@#=#Y9N@5.16W/8IX=L71%\$VLJYINEL^C8^YICII16S.ARIUC?2ZEE2.8#F#CIH4T0IT M<=KDOXM:6T0.CALIRYS.7ILOSFW6;I_1?Q =LC+FI\$ (H&GAJCOO+ICZ.C MIK G7I "OES^+P-&XKSF^CK;I&MPYM!\$>U63NLI)5DYYO\$D12MI10- I1J.7)0334IP3*Q1T?_P.4.3P1&:>~6MZUY\$D14Y^M.7A1\$%AXR2P MBYW#R#I\$A?Z??PMD^.\$W<+DH#30W&>4 P=#5J CZ\$RNUO?W+PJM%YV91? MZUUV^R3@&B&S)!^2:)A EM95VKM\$&I@SL76I3K4>PEH_~2WIR2AXNE^K-D^5 F8^"R/LX6I+& M-L7.W.3UP^ZDE_@L2& KY&#&O16I@3? M<6IYICM06GI&N T511J9WUJJBK- ^DUNI1^PR#;5X6^KEI?E^I^>4 J2.M4I83PM&AE+H1>CFS18D.STY^ZNIE2N3XV1\$K\$DR.C90=&06V15DE2F.G3NT MLX6^P.R045SDYNI JWA A4^~ T&I:DS&#&P/O^2)ICM@:GQXA+M^P^I|W^X@/E)HA)K&^DSBK98@9;Q.&P(O5&CAO:@I8K)IHI>ALV@IU+4 M4_8R2^X B+M&F8ND:"EOBX\$F_PIV.7>~*P.@G%/ 3>IY?7P#F194>2@8I#(M3PXR IIE+IS\$<23 D<25811 KJI>L2E +&ITCNV8VMNJ125&= ZY&S& UD MEIUV\$#<K 11V^DIX(3" I45?I44009IY"5:AI4509I6I6="^OIIN@) UF M" AHHB0F^Y^_57YDK+I19+NTDMM\$@LHS! C87PW755MILOQZ#I?2<B^R MI9Z7+2QHJFEZBKSOZ?\$.8^P8>2JSO^Z>N327TZ73&I.E^74PJ\$G8Z^U&U&6^MP9TLY\$JN_2LT? <6^9B=6CS+7 F\$4@F08B/8I:F M1HMS)29\$S&IRJA>> JCP25I/X->B(D.X4I@5I9W\$P5+&9I&(15/^#>=PDJF+=+9N1I^Q44:~\$I(5M6K.TFGHZH&K\$26I#+=+M3_LN3JY^Y8 MM10>SPERNBNC7?7I2I#F54%#QX^I^J8I09%: CDSI? 54169JXG77=SQD00 M>~<O2YP^I+VTO&W^*Y3L H7YVJ2>Z>EJL\$B@P?7=QXEV.@.#)OEI^RT>Q;E: MJOKCZXT:5&A9+&."M%QO:PK9SZ.IHITE."B->(SD64\$LI93^TCF@Q:FI.M2.R.L6I+6U F\$H4U^X+E&^*7RX-M7~BRVZWE>=>LW7IC?PE#I/ ME=EO8^XKON.M<=&E7\$>#H1<ZR6+& 8^E>~>A/U AQ8 .?CE5I\$8T&R.LY9.MHD.<I (ID/M0%3I^750^K76#B.@V\$J^E>I8? V.M.+@R# 0XGF@F=F/PWC^I)5I>B>).DODXN1<@%"GQXW88IUBY\$Z M&\$&BFWXUPZHQE5^FU@IV3^6092.B/GPUGV:II<AC^:LGZ?&G&AT=234FM^5;> 3^\$(+ YRV\$IO M? V7F+>OJF JA#^."LI1\$>I\$3XIC\$S&E<0>@_B04RG@P=U+I86F^U2@B:DNA7.K MTR4E2^P^%QUU/IM-3I2J?I#&I19.XISAM>JL IP@#N\$Z-2T1I^H#N<="32 M^KO\$S_X:WKI? &V0.YIY2I^F2>Q>_sI7 8SD8175_VIPQWS^AQ^GUR7K^~MSS:@T4I.E4I^E2_H QC^C^Y6@QUR/LY/-(APB)^F8ZE^FSK(B_5#LPIA: ME47V_IX(K/>C)I^?YXOR1IYPS(6T ^OY^0PGI_RL.@003^&O6TE= MG:~2V M=I%T2Y^I027\$QWA6=&0%OYNP3@/WBL^OH7A7I#U).C18I^U/LM2Z^Z+& MU^XIE67I_&I^>N(=G>F4AU>^VT0&I44CM^YU&I:1QQ- ID3<~^C^V.L^A?>U MB_K3@.I1:~BAGMB(2&~IRPS^EGW2^S+&^DOD:U3GJX\$J^I>_j2 M.E.~&XNRW:"H^P^XY3XCXW0=>9&K^X^YM _DGOQS&GAC^IHYD2I96W M%@ITP<0>=>~7 7S9Q130SP0>5X;7H ?I>D6VH2\$4I8:V^R(2F.^Q2I6/ M19AUS_ \$A@9B=I7LBDB5W-NC(N687N19M^M.#XBRREC:)S+Y)CB0053D1JBS1-T^#))I ^N^>5-DIR8HUO^_37IIO%MMQHIS^."O!^ WXL1BPQ0983C3.^I=952?RDZX#F^HJGLSSK^G&\$P&J1 ME4=0-#I:|LPTEL^KD83I^U^Y2CKIR1- 1R&9^I^IR^I3^F(2^>~GI:ZS MGGE3REXKOEQ+3.YIOPZ4_P2_@D8*~242^~(= BE M9>G&~XUMXI(3^8FK^I^I^AG/^+U3.P.U) OME/DISU^&I^A^?I^IZ@.ECI M>).CAI? <F80BB>I@&3\$-4&ALKNV5XJCF^QD4#WPZZ52I23J8I.# M_L I^ _PK=&8F\$?KQC^R C:YI>3?2Q0BR9A24^.#3:9I0#905-1#PXIT& M#6W: _MI^N+=@8T.K:2DR8.1LKX7EJCI^ZVLHBWSBI^Y<~<@G/I2M^Q O^*~YHOTVIOQ+>=C3A8>5L2&L2.S+R2I6H\$~9E?W4(I\$9_8+RB3 MX&LX4J7WJGG82E^8IBI. ICLW9=@_58^>OV%2U)YI^=" M9S<8JYIUV=H^*5N3:Y-MP80=" &SS^+&.@\$N~#A=FNK^2\$S?M^G.O.^DR\$Q:/=79>)BXI M:4_&D.I_8/7F%BG5G_%Y9AIFW^2AKBT3N? 589(I@ERK)OQK^AH^MIOT=I2J.3E#A=Y^9I)ITZ/C\$3X=V\$0@.OJCI-LPQ6Q1KERA8E8G7.GSX4T^M^YID8>PW.IA(JER.^%6LZ4Q+Z\$QSU.^_V7ER/@V@TOI0QICORJ46?E) M1OGI@R+I+63T^*732\$1^RRZ_OJW^LHWQAC760XW_++6S2Z_VU+@Q:~ M^ONIUNOH7VW3.4^ MD-RIS90L1XTI:HL&ANL_WZZ.^@TGIRCV^C6N#1?<C M:29I0>+>2-B%KICLI_12I^E^J18XV3I1PRXCASO_R\$X&CY7>D^M^#AZ.1 MX_?A7D~I M1Q58N5I+R+E^A^W=H6I+&PN-FI3D2^MES^PL&~9.LJL> M4^Z(2V-8IHU22^67^7J5OI^Q- 95HA(G3%QO^I.L^EZH-XSL1I>I>6AJVYFAFOULI>D^7AH9\$QI\$>8SSUPL^M8P6^KAI.O^I(=#+&R I>V87I^>~I|HW=M:MY7>M2LXPH7?Z4ATLY22.&M&Q&V) IE62#I1&6%>@P\$ _3<2>~#C9& MU?IUF65\$A6^9J8I:W+?>JRXXX^DC.LID-\$\$& IDRFPQKOSG=>I@CT MI##_00B.^I^W@7I3U@I+>+M_VU.285PYZL IZOI_1IWKJ_-Q9S@=> P2^FJM.MATW\$X^&V_S12B<IG^&I.Y.F=I7.AH^&A?7_49H\$&05IDQO+U>2^6EO.QI3XIK>M37W2D+&DIBIALR5LEF8ORSM^QO(WQW<+TPWIKJ&S^+H3@I_0^2.1S2I MH@WIJHC^Y=K0X2A4OG?BJ+I.L 8^+&.SD@9=>X9HN)P%>K^>~4OEHHMD^I^N^DK M^M^V-~%GLVCF(IH_<5L5.D@TO7.N(4I^HOY.TZ59Q@9+>+I^XFD2?S2O2.M 5LOMFEM6I.DI^="B&5.3(O\$56.L 9D12.IBW2^8)-I^OHO:YF+V-51\$N.^YI M^+&@HM>OYC@I.L-2.R2RB1&4I77?IOAQOF@:EQJ:7ID12:~>~YM^I^INA&+^='S8" (I542LGS8T<=&QUL.S1HH=EQ9.MNTO-KG&@/I.E.V=I:O^QBRK<_0KX3^1^11L>Z>WBGD62^-B1K#2^:LI.MR^TL^YA^I7-N@3A2^MN^I(B2D^ +=#WOK&P=9^3^M8Y45L41HLXI3L^CML(MO^K-JVOWU-K2[IS3=I^IP@H.^MT(FJFIEO:ZI=RO H8M.^O.QCI1ZSF^.@RZ MAI#MAWBOI72HUGX(R)^Z=4+CRCU+U@I(I19>M9:PI06-07-I@D9CBGJ_WN MP@~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~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~LN.B:E#V#>4IMF=' MRMN^MBA^*~L^:ZHANEI#_5KO^WJA_Y44NWUWA)ITI.K:HN7I@E^='=)I9P+ MZN\$4_\$H_" <\$\$S<2V7W>=>#JKMIJ08-X3>+I^QEWVX(IH8^%QAOAEG.I^H4B1 M.F8VB#I^*~I/M62I4H6T=KJIB3YE2C\$;O6X)I\$YA39^I\$>OAWGZ^I^N^B^OQ.MFZHI^E.W-+WREIO(FKXHW=6I_\$I^C255=AR7^LIO1)KMGEO@/I^UOY6I2 MMMS^5I2I_HUQ2^AGV7W^2XL:~#5+OXDK4HU&I)T9^RT+H.9: 4YUW.CK1ZOL25+&2^=VRU1>O>I1I>D&~YQ0R:393<@++2A&8^SE6G3>2XL\$E9&6DGI3^&_EDVIC+D6E M^U+UKYI>9Q>X9HGWQ^O_H9L6.E.LL.II^CQIWAC^&K&R3J (7K=QN.OPNA_@I5S1>I2I1E^~>COZBISZ\$ MI9-S7:\$SIP\$U@D:UA.LRZ=H\$%X<(<=AK^):H?^CIS%>YIM+7AT-"73ZX M&EZI>>BIB7A^JM:3FU "RASIOKX4I_#Y43>T_Y^#6I@+4#I/I5 @22>9-X2^2_EG3: M4 SC89S)I>~3^Y3YR/82N^ROVY^2A.ZIN^Q@I.L^I>Q?;S3<=&EF6M^Z=UUPX M0\$^SIIZI_L+U+OFH)26EYU@I^%J_YOS15 I5QD4I5.ZI85(I32<6^?7 MIH5FID32I^QDG>?P@Q\$ B^P^IUVXR_C0=&B&PEU>=>SB.SI7&I&GJIB^S+L M20\$3C^QJ32K(FI_&Y&G& M2%#DB+&I^HJ/K-376^"J4I U.4^U4L8VW5^QI&JRRR(\$3I^?0GH&#%#&W0.M^ZZZ555\$X^H^4:OLM:47IUV7K+&\$^M^E2D^I>~<N@9/VGK9+K9UO) M^2_NUGI7^8(XJGJ^U7SINZ243RQ1>OI_P^P 9I=EKNW.X@_P^I^CA(MNBIA MOGMXN_/PA&I\$PZSUZP1+6I2I@.~6IH2IY5%CL^PUBU&I&(U.T.O2W2^~\$A0<MOX.XM9P\$&~>253QOQ&~&10>~&I^P9PU0I&R^NZZK JY1=SYMFCJP(KO M9???)I-4=CD^6LF2_RXPJ2N&2OLD?SMA?I@7/F0AA6OTIV4PWWYX6M.IYI MU&OUN@.(^ZU>~G^WII#_POU^HLK<I9V02V.O^R^U>:I^/RMIZ7AACDIIU9 I=I2YGV\$VN@>4#_@-0 M2.2% @IIE65I\$&N^F^ RQ4 ID.I\$^I^W^K&LU5C:5I+>~O LI1E^V MR18>25N^~67+U@<4^N:L84LNP=IO3T^IY7O.UNI7FKKYI^NI^OU6K^ M^I)7.9<646T^I^<~954+K18+2>I3I>~.%E^~85NWF<7PX_IH5^I#6G@<~N^ M:US4I AF2^U+UOLM2^PNM/I^I-4=OBRRY^M&R^C^I^/S.B.V.INR3^QX4YA: M^T9DJI4Y^MK^LIU:FI1#EC:R+I:(GA&5E7KE_2M_&X4I^@APIB^IJR-KM-QJ6 MONE&67YXNK6^5D:75A7K32.RRM^RJIU>I^M^SES>&IE^>4U^9^O:ELBUYA2N MIY&I=EH\$2EM-5TY3=>333^VOE=EHJII^1/98?2M^M.BSK2KZ\$6\$M^W+V6IQX M^+JBY 5I>I^J7^I2^Q I.MN^I^OKRZK_PIR#I^H12LOUL>I^ VNUX\$OJ^I^SGEG M.WE>~Y7.F:Y^*BZ&J TMU%8.+W_~9P\$>UZP.DM3UI2_D_)>E^3W:GD<^N M:<~<X1JP^LMN&~G^9:9AI@P7J@E78J M-GFX8(LY^B9I54QO^I>= MJGPID:QBLE&4VICIDE>I2G>P IN:~#~TS^Y^I^A:ZY8H9V)I^I+50GKWN MI:(G^FEMI+D_YE^K/U@O^YI2\$S=>~.IMEIS&6Y:318IPI8H71AE=97JY9 MK.FY9D.RNE\$UI5G:I.1^3MIL@DKB#~%2=&NSN=FRJW&AR^W4I_9KOEY MFJZ.^#~:MA.\$S3^YNOEG.HI\$42N1M05&49^XN^4I\$D 9RD7(^<^Q^I M>=70I19I MIGI^IBF^D^L<I@<~P^G=5W X66QI4IYEW7)I6L_72K@ZIVIS:D6I>~>I^O M8SVFIV8^C7:~E4F^E^QV\$1^I^P^%I^I^A74=I@I#%DE4BEHI557E@=KIC\$C^P M16&AV: C^R^I>I(N4_4FINE^LPIGD2I\$~V%I:~I^I_V6>PO2.L\$XVUEI8^_9^I83BNSU.OI 8QI=M.C&OBA5F&Q15I&Y0<I4_I90#&I.CYD^FTA(I2R68_4NI:6WBPR)M/ RP+ M@L&O&(VR@RI!+&C6I0.2A<6Y2Z>^I=Y&~WITRP^IVT5ZA/Z(IMO-AP8NI^E3YCPB=#\$N^I>S>CY8E MG.54X8R\$5IJJ4_I.O.EIB@2I/M@I& I>Z^27%N4C^>Q4@&B^~YI1Z^PCAQ.OGB9\$S^ZOS2^#O@28I^I_3SMHLEFJIT MI7^Z1Z>2@I^QJAMA:83-D907I^I>+CKH&~UB-XC&I.E9^1IHC&E+8.8A0^M78CZB OC9K? @I^LP8_AFF^I1\$Y^I1J2XTO2.5A3^7I)M^Y^+2\$JID^I7KW&@I^Z+P^&6^VZ\$ MLZ=D6^V@LQI&A&G_IY@OJ^PAXIUBTIU=>^CNT#-ZX2P.2NC_?=&I^>E MW3JIX6-6U.WDQ? 2GXNM&OJHHH#>2^I^W^VU^X3@>XO+M^Z_GM@AE.GF.SO-Q4O@I^M^N^&6&K&U^I^I^GNVANO:IN^FPPOY7_M^%FOIRS^X^I.FCCBM^R^9^C^8D@XHRD005?@&AH7#S.R TX8I=7CAD.4I^* MP76\$S^CLNHUI-Q#_F3A:~I@LRY^E\$K@IR^V06HUE^N=7RE9I@_I^I= G06 M^I^I_155\$S.W=2\$M-JQCVCJ74R:4>ONITV2YK17\$WUKTO NI^I_YK-HO^@ M#~M^"~).I^&ER#I1@8\$EKT\$1^<~\$SCVN\$U^_4D23T.X22ZGQ:~IH7H^FSEKGD M18DS^27K4AC&#E(I1QI(O>I^<C^K\$N^I^I^R^I@S@>I^&F^KYWF&A86I:BZ@S^I1 M0AKI:8BGLP^S>92\$ W3I BZML6H\$S\$W7 ^E6Y\$5.7V0L077RB32>2^RIO&< MA3-O-ANSJ3<S=2P>3^I@R.4^CSB\$~D6YF9_P\$IP@:GN>~I^I)FQVIL7C_X MLJ52I&I^I^B(I2C+I&N6UO_M I2N7^2^Z+I+&W6=C.5K5K&Q6B1\$5 WZ^C+&EAVZ M&R-K^IEN^O^W1R9SBIJ@/ 4I^TMI^OOWWVO_5I+ P04^I DBF99 MC^G^GO\$%&^&S^&Q @I+&W=ORSRTEP.MN96Y2.12>B&X:H^E^B92ZU MP2I>I69D^BUXHYB^?I2^X7I4<D.KBIW<I^OORAC^%>H^K_E6ER+&C2I&BAM^%QI^O\$1I^@QVJRKMKU#; M.A/9<_HI1^2@XA:4>?PJPWM1#>DX%#@8WI M-WKD5I2^\$4:C^PLO<~9I^JB^*BI>OWPW3R.9FI-Q:E,&2ISELF(MB)C)OAS MJOQ:~IRA-"SE>5KGG ZLGG^V06:P_LYP+O /C/&I^>F2@IEX=>UFE@OJ:5I4I M0KZU^I&D^NAI3^LFBVIG\$~#C-U:E7XAIK2_A&AP+UMF>RYR7I1P>I<~&I^L^BM#I@TIN9 M^TA+&CIBIGW^A16:G^I:M3N#7# I^BD9F@P@_GK8^KIWD>2ID_80>O^I^V@E>U M9508S=>R@C=1CFM^I@7:6JGI:MKYUKEF^M@>7<S^43^S7I+04%1\$^WW2^R>B M^TA@=I20I@>V3N^FI2+52^S52I0>

[illegible]

[illegible]

M.1WZV=IKXB ^<I 8Z1OWZ^,34GA<..I(1CN74P")I:~>C-P.BR.)J:~::@EUXJ9 M202ALAMH?2>E>IK8OMQJ5L7_ E!+ P04 " DBF99\$<G.DRP_ I+& M&O ^AL+W=O/_ X'-IO M5%<CNCS? T7MYR3J7W8W06I,DI8J3ELF89BTBS<7DTCX3CAE0G0?75IEP6I4 MW.H=YI^+<O>H8F(55)02%IH^026_ JI9B25^0I^7I]^*32POMY(LN Z+& ^UYJ@.I>^IW6P MOH(TSIJK I&==S_ R' J0.<S8.X=8I!_<O>0^>S>#>7 7Y9 MIESA6206IHHNSP5_1^XG1^<Z5>9:ONX@<KGJ0>2316>IY54N1XIT8I6G M=W%&2IE/T^*U^<GJ_188AOT(U@2:03ZPO_ M-5.T3N0I?2IU?I? HJ9NMWZ V=8(M526.D=36<I^N(a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~.1M ML^*EK4I 2B-0>^ZC8&38);M2>T>2RH1?BOD:~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

Q62 Q85U2/2X8YV1 M, PRN1UKNCL17%W>3V1KSW7SC, M/Z, Q3-E, Q4RIULM8561S9: ?>X>=176S/OCV:Y+Y- 7S_U 1_9M+GI<%=>1=Z9O(P:WY9:/IZ M=T99QIM>S3?>Z17=GX+I+V2K0Q>[M>M+V+I] FW74L1< "(2P?PW0% MZ J1HDZ J1H4.H 71PI?=@=DI@/UD/RW0&Y7:7LR %|HJBZ E1HJR
MZITG=VQ1.9HTDZO+>I HQ6G>E6UKW81LOVZ:~%Z671% M:MKI\NM.JXVHY M4.QGD:MIU/JM.FO+Y+Z:IKXW19A.M.MIOF?O2E.S:~W> &J.V:7L<:JZ~SZQ=1J-V?>
OH ^>V6T= O5<@>R7Z~QHVAIV=BZN17Y M~%0:2IOWZ125DESEQV.A V.258MW=>IIMJSD> / 4? 93J==+>19YIYFLRFY+T1 M2S(OYQY3KO?>
RNDWZ J915F4F4JG?>V "444212?>="ID.F MSPV9>AOR:~?+=1?M&1&7%U15ZGNAUQ2-D:"I1(FD3?5.O19>=0^Z3U.U.M 45&Z6=" M "L1C800DTB8 L&4J?>
ORGW=C.H.38A/VZE?=>IKZZZ&7L M3^ M-3GM.C^FSU=U=9I&15M3US&U&1U2(HO9)+UD MWG<=,B)OXH6?F<+O^K&>=>S55^UPIA@42C2^5.@>
MFI\$Y7.S7&L CH8RB+M7P4GO+@/41H3NO7A.6Z16XW-L-D#4" M\$S^U:6UR1XV^K^GD XMD V9W1W+U-O^W6^W=X:SB(OIAW^#3+13.W)=16 ML^I-
&E8R8MHE163>J188 YE.TGL^I9. KNYV8XF0=ODL ^>70>?0Y^YI M8B.1IIXQ6612QV3^"815-8:~@2E^F^A^"/M6+^J+=>6&UR\$H 31/LE^" M+MQ+>IVCIVB\$5 "&2?7\$*A=^>
^5\$VA:69I:~&2^95(^C&SQ000A=54%RYS^ M^J^U= E6V3ZNYI:~&6G3)=RY="FJLQ**KLG=NMVGL21.G(^U6H=IRHXCKL: M^R@PIV4-HB2A-
OFH32U(YFW=Z+X(^NTY(^LVMR+Q1JLQ(^#A7&:CLRW U:M^Z^T:4I^T\$.S:VZ: L^M@VPL: ^I&E^I.5F^:VO70DMQ4< U 1^DJ34J1^TV6ICKM^UGS
MANZO1/PB8^PL^EXVIRU1J^TN:~T\$>LTO<=D^NP&A17%2STXQ.O/MC&2^C^M^SVH1@>E22A-H6AF&E-A-CX=J>=OTO0=IKK.#. 800L:CM:SK4RIM7.MID31: M1996)ZEB51E7A?>
V^2-3M^OC/R:7(MZ^"GJL^"1ICV1^I(R^436+D^2P&A^P-?)U.TSIL^UJL^IJEY:~T-5/2AM**4" M\$S^U:8HJ3JYVW(1K68^L^S^H:~<E>#>T(24)J\$T^*9I.Z.TK?X9:R^T^W
MUR.TVA)74V0I(1+LH68^E":A-(6BF8&D1<+&#P^*^K)I0N2K179N9N(JC.R.M.HIHC3^* XD&OFH3J^HILUR5K28^Y^S^H)QM# +I&N83C3J^M3A^T^T GVR:N.M:LCRSD@&H(^?E":A-
(6BFI^R#~6+ 4-B1^R^Q1+K^EEY?>=CQA3^I2D MOPD^I3.IK46IQ:~G3^KQ&G5.180Q>QC0:SC8ST-L^JA~4I%.UTM^833J^L^M^>K(KOQIOTJKB
MQJO 1ZO7OT B**2^GQC=R>IECR.2S;IY4H301F24DS5SM1N^J156=>D M>V.B)=+I&S2NTLL123M3VYH^4MU1^P.DN<+<B^JIE^DQY2Q1EJL@IIL(>HYWF6
M0G61^TVU.LZU:~P&S^ZG^MD^2B.H.ORE^2A-OFD1=1\$7LZ1U@UH6V+ A M2\$^U=R^M^&4J^T^4I%.T^*W.L<5N5=>Z2^7(SC:7)DN+8E^ZAS.5) M^SVA:&8^:P&Z^>
21766@1Z4RDCL^&FS3GQ^O2^VPV4.T/2E.HFENEDK?FE M2LUO ^*J>7^>9ITG16IUXWFFI&Z+RKY;UT9:1L89:~%":A-(4BE&A^I M4K 8=S0FR^M@>4OCL1R.O^B7+>
FT10FD^13.IJU6^>U^ RG3^WI MGN-FJ.27NK^":U. 4HH3:~%HIJ.UX)Z2: 3AW-2^6K.M^R^IFB3^&+I1^KV M06D22E-T^?^WR>UW1>ND(>Z>C^54&2IK^# WX@I\$E^A-
~77N:RRUJR MR R2W:IAFHR:BOM7E:W1^6V^N^A9^SU^":@CB8912GVK M1+70 +4(IJCM4^AQTIA)I42%HIM>U@E)CY1^U^".23P1J&A=664
M1J\$TA~9I:SUO208HN^V^P^ VFZ F3A(G&8F3&K&Z7E1HX292D1Q2OGP.Y1U^6^8512QTVNM@EQ-Y6BBM MBW0A>D04+&WU.Z4KIAD3@I.Y>Y@>44I6ZVPI:6UY^Z83^>
1J4H8=>0.1^JA^":4I%.WTKLH2^*M:8SE3AZBWVW^PGP-9^5^C&D13^KIZH/M8D^=C=K:P6-W@7(FM4^I1DJ34 M^M^2S09>SX1.5+8 M3G R5R78^4-L^JA~4I%.UT05:U^: T
@>2VB49>9-IVIEKWCE2D^5W5+N7.M0N?2Q0FEBR E(J\$F^C^MHID^U12OT2@=1#-B41M1?P^?N=+I.V(C12P^>D&E^90=" M.17J\$A^WUDU MZ:I(G:MO^Y^6V(DVZ^X>T31%NL^>
M^X:R9Y70>T20:9.4B71U^F 18="O7:H8^2%HIGNUX)1<@>8FF74I(1E3) M^12P^M80PDI=>9(H1Z5.4L7HUSGJ+ZG3A9: 2I>=>9J8NKV)^8ETJ2:~L\$J
M+@07^DJ34H:HL.TLJE&A^K^C+W2^I^J^H81VA- &E22A-H6A&2Y:~%MIEH4 M-7B=&6J^K+3^X2S&0X."2A-OFH32^IEH7H32T^2G:ZL&M)2&L2L.R2Y58 M^M^I4J^ TB24IE
T.S.T.E:ZU:=IVFKUQ323Y1YR9P@>@I4J^ TB24IE T.M.PBT^2Y:~%J1E4 L-8.5L7LUKY^I<~1^I3(34H1^TB4S@ M1^6K^2^4YID1=6)S^MB.B3F6?>
K1QI:~8^E^90~16C4L1>L9J^TY@ISV^ M.9U16E^":I3@EFO=3N:2+K&R195D(01<I9@:~2K(8RUCFK^5.1.1\$S=^M B10:F&M1 MKI4I9R:FA%:9J6IUIK(7I^@A@JQ4%\$SDI3@YK8C
~MLY:6A.M.ENH8S^WKB70+>MOT9R8.^%E^A-(4BE&A-B2I1NV+NW+OT7Y:L~*~M.R16\$NEOX^849 :5^+>D0-B1/5I^VEEMI^2:~8B.W15L^1%1:6.H34I
MSDI3I9NPYO13J1215L5O1^A6T1U7H:0QE^":@- FE^13~"DMSE7 3V:(^NL1 M^W&S^FD) 9LH68^E":A-(6BF&DE:SI^W^&S:7: 7W ZOYIT^V3O1 M^DIUV,U0K0Y%I4VLM^KJO?>
NW108ST^2YRVDX1364^K(KDJ34)^2.T3G162I^B<+L M^#~KRH6BFT1006.W=Z4 ^3WVPIZ^M^S(=TUH315I.M1E.UKNQ&6&6CD/KX1V8/1=Z&=>QI^S^B>+M^HJ^ MV:6IS
Z1.JONP&4^7IF&A^":X>Z>J^G:~%SD&B^C23C10L^I2L&I^Q^ MFIQ^O+L&Z^WNSW.^L/9< M^P^F^M0(=0^TB^B.N1O5.ESEMD4).ERC=YRIO^FMO&KPI^PH+^TH&G1
M4MC1NWH^7:~D>C3J^LQ98&B^):GK1 GP16P9>DIWA0>~&BONH+&L3B1^MO4DL31^P5PECEIZ^E^"?>:~WIR^A4>=>?Q(1S^V8PP^+DUB=>N&L^&H.LHO M^+IJP.^>N)E
8RN.^U^I^29(FV:MGIIQLN+ARBS.9SFI^"V7SP1^M&16J(I^H+>=>EB88R^YEB3B7M-LJ^N^Q6B34^X^VBH+9M.QI^D^R5UX&:S^V^SS^O<+A.W2O M^+~99Y3P&B.W8\$H^"/&J7+>
G7. JKC01RPY(L>V2^94^UPWT+S=C^XAO.M9T7I^53) ^%+E^"L.M1C^>F99407>J56^GFMOE:OF6I+ER-F69%&?^LP.Q#R& M7^EN0+30R MY>V>^/XP:1^X>?Y^D4=I<~>
5.WVGNVOAYK^2MG725=>6B+ZMHTBUS(^D^S6FO) MN0F^ZBTN:G=UW&P&S:3J3J1^I&AQ M(Q19U^BIP=SN^R12^3^VNZ.R^F5^R MJ^6="WZ6DR^T18&^AV#H-
~I14(ZRIG0.8K^C2 72^C^S207:2.KM+>+>L9:ABP8FE1-SV8^FADNWV+AI^Z M^<H.O^>D^T4D^<~?^I^I^>X^W6R6G^AUR&R^F^CURX&S^V^F1Y-VI^VIM MGZAKY)PFSU6I
(F05LEH+6214^YD@OEVET73<42>^%NUJH8X^P:~+B1M^V MDD.E^XFGI&0F^76@+>OZ1I18K^F9M9I K=KSHJIG>5A=I&8.W1F+PX1L^J^D^J^WQZ^

[illegible]